Dietary deprivation of non-essential amino acids improves anti-PD-1 immunotherapy in murine colon cancer

Zhehui Li, PhD, Grace Yang, PhD, Shuang Zhou, PhD, Xin Wang, MD, PhD, Xiyan Li, PhD
Filtricine, Inc., Santa Clara, CA, United States

Background

Cancer cells require outside supply of some non-essential amino acids (NEAAs) to survive. Dietary deprivation of select (NEAAs) can slow down the growth of multiple solid tumors in mice, creating a new non-drug strategy in cancer treatment. However, deprivation of NEAAs could negatively impact the immune activation, an essential process for immunotherapy, because fast cell proliferation poses a higher demand for building blocks such as NEAAs. It is not clear whether dietary NEAA deprivation could be combined with immunotherapy for better safety-efficacy profiles.

Methods

In this study, we tested the effects of NEAA-deprived diets and checkpoint inhibitor anti-PD-1 and anti-PD-L1 in colon cancer using syngeneic mouse model (Balb/c) bearing tumors of mouse colorectal cell line CT-26. Three diets were tested, including a natural rodent diet Teklad ENVIGO Global 16% Protein Rodent Diet (control 1), a formulated NEAA-complete diet COMPLETE (control 2, using amino acid mix in place of protein), and a formulated NEAA-deprived diet FTN203 (treatment, using amino acid mix in place of protein). Both COMPLETE and FTN203 have the same nutritional structures, contain 17% w/w protein equivalent, and are isocaloric. After tumor size-based randomization, these diets were provided to mice ad libitum throughout the whole test. Each of these diets was used alone or combined with anti-PD-1 antibody (i.p., twice per week for 2 weeks) or anti-PD-L1 antibody (i.v., twice per week for 2 weeks).

Results

We found 1) On day 24 post tumor implantation, NEAA-deprived diet FTN203 significantly reduced tumor growth when used alone, compared to the group fed with Teklad ENVIGO (by 81%, P=0.0054, unpaired t-test after Welch correction) and COMPLETE (by 81%, P=0.013), respectively; 2) The efficacy of FTN203 is comparable with that of anti-PD-1 or anti-PD-L1 in tumor growth and median survival; 3) FTN203 did not negate the efficacy of anti-PD-1 or anti-PD-L1 immunotherapy antibody when combined; 4) FTN203 significantly improved the efficacy of anti-PD-1 by further reducing the tumor growth (by 80% on day 26, P=0.046) and increasing the median survival (by 5 days or 14%, Log-rank test P=0.031), against the combo of COMPLETE and anti-PD-1; 5) None of the mono or combo treatments caused body weight loss.

Conclusions

Our data supports the use of dietary NEAA deprivation to improve the efficacy of anti-PD-1 or anti-PD-L1 immunotherapy for colorectal cancer without noticeable side effects. With further development, dietary NEAA deprivation may become the promising foundation for a broad spectrum of cancer therapies.

Ethics Approval

The study CA-XLI-6 was approved by the CRO’s Ethics Board under IACUC approval number 19-015.9.

Poster Presentations

Biomarkers, Immune Monitoring, and Novel Technologies

P501
Dietary deprivation of non-essential amino acids improves anti-PD-1 immunotherapy in murine colon cancer

Zhehui Li, PhD, Grace Yang, PhD, Shuang Zhou, PhD, Xin Wang, MD, PhD, Xiyan Li, PhD
Filtricine, Inc., Santa Clara, CA, United States

Correspondence: Xin Wang (jimmyxinwang@filtricine.com), Xiyan Li (xiyanli@filtricine.com)

In vitro and in vivo RRx-001 synergy with regorafenib and in vivo attenuation of regorafenib-induced toxicity

Bryan Oronsky, MD PhD, Tony Reid, MD PhD, Corey Carter, MD, Pedro Cabrales, PhD
1EpicentRx Inc, La Jolla, CA, United States; 2EpicentRx, Inc., La Jolla, CA, United States; 3University of California San Diego (UCSD), La Jolla, CA, United States

Correspondence: Christopher Larson (clarson@epicentrx.com)

Background

In the Phase 3 CORRECT study, which led to the approval of the multi-kinase inhibitor, Regorafenib, in 3rd/4th line metastatic colorectal cancer, the OS was 6.4 months and the PFS was 1.9 months compared to an OS of 5.0 months and a PFS of 1.7 months for placebo. However, Regorafenib is very poorly tolerated with a Grade 3/4 drug related adverse event rate of 54%, mostly due to hand-foot skin reactions, fatigue and diarrhea, resulting in frequent dose reductions and discontinuations and a general reluctance among GI oncologists to administer it. RRx-001 is a minimally toxic macrophage repolarizing agent in Phase 3 clinical trials that is associated with a reduced side effect profile from these chemotherapy agents. Recent studies have demonstrated the inhibitory impact of M2 macrophages on the activity of tyrosine kinases suggesting that the repolarization of macrophages by RRx-001 may enhance the activity of TKIs.

© The Author(s). 2019 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Methods
These experiments determined whether combination therapy with RRx-001 and regorafenib not only enhanced anticancer activity in vitro with HCT-116 and HCT-15 colorectal cell lines and in vivo with HCT 116 and HCT 15 xenografts but also attenuated the toxicity of regorafenib in these two xenografts.

Results
The results from these experiments demonstrate that 1) RRx-001 + regorafenib is more effective than either agent alone both in vitro and in vivo and that 2) the addition of RRx-001 to regorafenib attenuates the toxicity of regorafenib in vivo.

Conclusions
A clinical trial is planned to investigate the translational potential of the RRx-001 + regorafenib combination. Future experiments will determine whether RRx-001 also enhances the activity and decreases the toxicity of other tyrosine kinase inhibitors such as sorafenib, sunitinib, dasatinib, imatinib, lapatinib, and cabozantinib, all of which possess similar efficacy and safety profiles, not only in colorectal cancer but also other tumor types.

P503
Local treatment with adenovirus expressing TNF-α and IL-2 proteins promotes abscopal effect in mice receiving anti-PD-1 immunotherapy
Dafne Quixabarea, MSc, Victor Cervera-Carrasco, MS, Joao Santos, MS, Riikka Havuven, Akseli Hemminki, MD, PhD
University of Helsinki, Helsinki, Finland
Correspondence: Akseli Hemminki (akseli.hemminki@helsinki.fi)

Background
Treatment of metastatic solid tumors remains a challenge in oncology, especially in the context of locally given therapies. Some responses in non-treated metastases were described in the middle of the last century after using local radiotherapy in breast cancer patients. This phenomenon was named abscopal effect[1]. Nowadays, this effect is known to be elicited by systemic adaptive immune responses against tumor cells, following local treatment. Of note, abscopal effect remains somewhat limited in the clinic mainly due to the depressive microenvironment surrounding cancer cells. The systemic use of immune checkpoint inhibitors, such as anti-CTLA-4 (anti-cytotoxic T-lymphocyte-associated protein 4) and anti-PD-1 (anti-programmed cell-death protein 1), has shown promise in the treatment of various tumor types but only a minority of patients respond[2]. Oncolytic virotherapy is an interesting strategy that has re-emerged in the last few decades. It is able to prime the host immune system against tumor epitopes, generating anti-tumor immunity and thus theoretically complementing anti-PD-1 and anti-PDL-1 therapy in an appealing manner[3,4]. The challenge with oncolytic immunotherapy is that not all metastases can usually be injected. Therefore, it is of importance to study if local treatment can induce distant responses. While our previous work has shown synergy between oncolytic adenovirus and anti-PD-1, here we sought to establish if local adenovirus injection can impact also non-injected tumors in pre-clinical models in the context of systemic anti-PD-1 therapy.

Methods
We utilized a murine melanoma model (B16.OVA) where each mouse had bilateral tumors. All mice received anti-PD-1 systemically, but only one tumor received local virotherapy with the non-replicative adenovirus. Both tumors were then studied and compared for possible systemic effects following local treatment, including immune responses and anti-tumor efficacy.

Results
Improvement in the overall survival was seen in the group receiving both therapies (anti-PD-1 plus virus) compared to the monotherapy groups. In particular, treatment with anti-PD-1 plus virus was the only group that presented a complete tumor regression of both tumors. Likewise, this therapeutic group presented significantly better tumors control in non-injected tumors than the other treatment groups. Further information, including full tumor growth and immunological mechanism-of-action data will be presented.

P504
Arginase therapy combines effectively with checkpoint blockade or agonist anti-OX40 immunotherapy to control tumor growth
Anna Rold, Ph.D.,1 Scott Rowlinson, PhD,2 Melissa Kasiewicz, BS,1 Mark Badeau, PhD,2 William Redmond, PhD,1 Giulia Agnello, PhD,2 Leslie Priddy, BS,2 Danlee Enzler, BS,2 Jason Wiggins, BS,2 Christopher Daigle, Jessica Van Cleef
1Aeglea Biotherapeutics, Inc., Austin, TX, United States
2Aeglea Biotherapeutics, Inc., Portland, OR, United States;
Correspondence: William Redmond (William.Redmond@providence.org)

Background
Metabolic dysregulation is a hallmark of cancer; as such, many tumors exhibit hypoxia for various nutrients as they are unable to meet the demand for these metabolites through endogenous production. Arginine auxotrophic tumors, for instance, are highly sensitive to depletion of systemic arginine. Pegylarginase, a human arginase 1 enzyme engineered to have superior stability and enzymatic activity relative to the native human arginase 1 enzyme, depletes systemic arginine by converting it to ornithine and urea. Therapeutic administration of pegylarginase in the setting of arginine auxotrophic tumors exerts direct anti-tumor activity by starving the tumor of exogenous arginine. Pegylarginase monotherapy has shown significant anti-tumor activity in various arginine auxotrophic human and murine tumor models [1]. We hypothesized that in addition to direct effects, pegylarginase treatment indirectly augments anti-tumor immunity through increased antigen presentation, thus making pegylarginase a prime
candidate for combination therapy with immuno-oncology (I-O) agents.

Methods

Tumor-bearing mice (CT26; MC38; MCA-205) received pegylarginase (3 mg/kg, 1x/wk; iv) in combination with aPD-L1 (10mg/kg; 2x/wk; ip), aCTLA-4 (10mg/kg; 2x/wk; ip), or agonist aOX40 mAb (250ug, 2x; ip). The activation status of CD4+, CD8+, and NK cells in the tumor (7, 10, and 17 days post-treatment) was evaluated by flow cytometry. Effects on immune subsets were evaluated by flow cytometry and single cell RNA sequencing of sorted CD45+ cells from tumors 3 days post-treatment. Data represents the result of 2-3 independent experiments (n=9-18/group). Statistical significance was determined using a 1-way ANOVA with a p-value cut-off of 0.05.

Results

Pegylarginase monotherapy increased MHC expression on antigen presenting cells (APCs) and the frequency of intratumoral CD8+ T cells relative to controls (p<0.01). Further, administration of pegylarginase in combination with I-O agents, including aPD-L1 (p<0.01) and aOX40 (p<0.05), resulted in increased therapeutic benefit compared to I-O agents alone, including an increase in complete tumor regression. Combination therapy evinced the greatest number of activated intratumoral CD8+ T cells and elevated systemic levels of IFN-gamma.

Conclusions

Combination pegylarginase/immunotherapy induces robust anti-tumor immunity characterized by increased intratumoral CD8+ T cells and M1-polarized macrophages. Our data suggests two potential mechanisms of synergy between pegylarginase and I-O agents: 1) Increased intratumoral MHC expression on APCs and tumor antigen presentation; and 2) Increased presence of M1-like anti-tumor macrophages. These data support the clinical evaluation of T cell agonists and/or checkpoint inhibitors in conjunction with pegylarginase for the treatment of patients with cancer.

Ethics Approval

All mice were maintained under specific pathogen-free conditions in the Providence Portland Medical Center animal facility. Experimental procedures were performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and in accordance with the Earle A. Chiles Research Institute Institutional Animal Care and Use Committee (Animal Welfare Assurance No. A3913-01).

References

1. Agnello G et al. Depleting blood arginine with AEB1102 (Pegzilarginase) exerts additive anti-tumor and synergistic survival benefits when combined with immunomodulators of the PD-1 pathway. SITC Annual Meeting, 2017, #275.

PS050

Abscopal immunity achieved via in situ vaccination using a novel combination of cryoablation and Interleukin-12

Maura Vrabel, Francis Gillam, PhD, Jared Hopkins, Khue Nguyen, PhD, David Zaharoff, PhD

NC State University, Raleigh, NC, United States

Correspondence: David Zaharoff (dazaharo@ncsu.edu)

Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):PS050

Background

Clinically, cryoablation is used to treat various types of cancers including certain prostate, liver and kidney tumors. Because it liberates massive amounts of tumor antigen, cryoablation can potentially serve as an in situ vaccine that is patient- and tumor-specific. However, numerous studies report that cryoablation alone rarely provides abscopal immunity [1]. Therefore, we hypothesized that direct injection of an immunomodulator (IM) following cryoablation (cryo) can induce tumor-specific immunity, controlling both treated and untreated tumors.

Methods

MB49 cells were purchased from ATCC. Female C57BL/6 mice were purchased from Jackson Laboratory. Primary tumor implantation, 3x105 cells were injected subcutaneously (s.c.) in the right flank. Rechallenge, 3x105 cells (s.c.) were implanted in the left flank of cured mice. Bilateral model, 3x105 and 1.5x105 cells were s.c. injected in the right and left flanks respectively on the same day. Tumor volume calculation, 0.5*a*b2 given perpendicular long (a) and short (b) dimensions. Tumors, 200-500 mm3, were cryoablated with three cycles of freeze/thaw using Visual-ICE Cryoablation System (Galil Medical/BTG). Unless noted otherwise, an IM was directly injected into the tumor bed two days post cryo. R848 (Resiquimod) 10 μg/mouse, DMXAA 500 μg/mouse, and Interleukin-12 (IL-12) 1 μg/mouse in 1.5% (w/v) chitosan acetate (CS) dissolved in dPBS.

Results

Cryoablation of a single primary tumor resulted in a tumor-free survival rate of 40%. The addition of R848 or DMXAA did not significantly enhance survival, while adding CS/IL-12 resulted in a 90% survival rate (Figure 1). Cured mice were rechallenged with live MB49 cells and then given no further treatment. As of day 70 post rechallenge, the number of tumor free mice out of total survivors were cryo alone (3/4), cryo + CS/IL-12 (5/7), cryo + R848 (2/5), and cryo + DMXAA (1/4). In the bilateral model, the median survival of the cryo + CS/IL-12 group was significantly longer (p = 0.0016) at 49.5 days compared to 26 days for cryo alone (Figure 2). Furthermore, one mouse treated with cryo + CS/IL-12 experienced a complete response up to 90 days post tumor implantation.

Conclusions

IL-12 formulated with chitosan and delivered after cryoablation is superior in treating not only a primary tumor, but also in inducing an abscopal effect on a distant, untreated tumor. Of note, neither DMXAA nor R848 was formulated in a delivery vehicle, as we have yet to optimize these agonists. This work supports further study of cryoablation and IL-12 for in situ vaccination and cancer immunotherapy.

Acknowledgements

This work is supported by BTG, the NC State University Provost’s Fellowship, and startup funds provided by the College of Engineering at NC State University.

Ethics Approval

The study was approved by the NC State University’s Ethics Board, approval number 17-052.

References


Fig. 1 (abstract PS050). Survival of single primary tumor model
Targeting inflammation in the tumor micro-environment to improve radiation and immunotherapy

Debashree Basudhar, PhD, Veena Somasundaram, PhD, Robert Cheng, David Scheiblin, Erika Palmieri, William Heinz, Noemi Kedei, Jinqui Chen, Daniel McKear, PhD, Stephen Lockett, David Wink, Lisa Ridnour, PhD National Cancer Institute, Frederick, MD, United States

Correspondence: Lisa Ridnour (ridnourl@mail.nih.gov)

Background
The presence of tumor infiltrating lymphocytes in breast cancer (BC) is associated with improved survival. More recently a study found that increased CD8 cells and Th17 cells are specifically associated with triple negative breast cancer (TNBC) patients, a highly aggressive subclass of breast cancer. However, they undergo functional reprogramming in the tumor micro-environment (TME) evident from decreased IFN-γ and granzyme B. These immune escape mechanisms contribute to inability of the immune system to control tumor progression. Thus modulation of TME is necessary to effectively target the tumor.

Radiation therapy (RT) is commonly used in cancer patients including BC. Focal radiation limits systemic side effects and acts as immune modulator. Currently there is no approved immunotherapy available for BC patients, early data from several ongoing clinical trials show activity in various subclasses of BC including TNBC. It is reported that PD-L1 is high in 20% of TNBCs and COX2 may be involved in its regulation in tumor-infiltrating myeloid cells. This led us to hypothesize that modulation of inflammation associated biomarkers in the TME would increase the efficacy of RT and immunotherapy by amplifying anti-tumor immunity.

Methods
We investigated the effect of nitric oxide synthase (NOS2) or cyclooxygenase2 (COX2) inhibition using commercially available inhibitor on radiation and qPD-L1 induced tumor growth delay and lung metastases in murine model of TNBC using 4T1 cell line implanted in flank of Balbc mice. Change in immune cell populations in the TME was investigated using confocal microscopy, CO-Detection by indEXing (CODEX) technology and flow-cytometry. TME associated metabolic changes was investigated using Seahorse bioanalyzer and LC-MS/MS. We also measured the levels of inflammation associated cytokines in serum using LEGENDplex.

Results
We found that RT induced inflammation associated biomarkers NOS2 and COX2 in the TME, specifically in the tumor cells. We have shown that co-expression of pro-inflammatory enzymes NOS2 and COX2 is a powerful prognostic indicator of poor outcome (HR=21) among ER-negative breast cancer (TNBC) patients, a highly aggressive subclass of BC. More recently a study found that inflammation in the TME would increase the efficacy of RT and immunotherapy by amplifying Trex1 expression in irradiated cancer cells.

Methods
The mouse mammary carcinoma TSA cells were irradiated in vitro with 8 or 20 Gy, followed by chromatin immunoprecipitation (ChiP) assay to determine if the transcription factor cFos was bound to Trex1 promoter region 4 hours after irradiation. A doxycycline-inducible shRNA was used to knockdown cFos expression in TSA cells.

Results
The transcription factor c-Fos was found to be phosphorylated in TSA cells treated with a radiation dose that induces TREX1 upregulation (20Gy), but not in 8Gy-treated cells. c-Fos has been previously implicated in the induction of Trex1 in response to UV irradiation [4]. Therefore, it was a good candidate as a regulator of Trex1 in 20 Gy-treated TSA cells. Consistently, a ChiP assay demonstrated that 20 Gy but not 8 Gy irradiation induced cFos binding to Trex1 promoter. shRNA-mediated c-Fos knockdown abrogated Trex1 upregulation induced by after 20 Gy and restored cytosolic DNA accumulation and type I interferon pathway activation.

Conclusions
Overall, these data identify cFos as the transcription factor that regulates Trex1 gene expression in response to UV irradiation (20Gy), but not in 8Gy-treated cells. c-Fos has been previously implicated in the induction of Trex1 in response to UV irradiation [4]. Therefore, it was a good candidate as a regulator of Trex1 in 20 Gy-treated TSA cells. Consistently, a ChiP assay demonstrated that 20 Gy but not 8 Gy irradiation induced cFos binding to Trex1 promoter. shRNA-mediated c-Fos knockdown abrogated Trex1 upregulation induced by after 20 Gy and restored cytosolic DNA accumulation and type I interferon pathway activation.
Correspondence: Marcin Kortylewski (mkortylewski@coh.org)

Background
Radiotherapy has been routinely used to treat lung cancer alone or in combination with chemotherapy or surgery. Despite the tremendous benefits of radiotherapy in localized tumor control, it is not very effective for treating metastasized lung cancers. In addition, the application of radiotherapy is limited by its damage to the surrounding healthy tissues.

Methods
In this study, we combined radiotherapy with checkpoint inhibitor immunotherapy and a radio-enhancing nanoparticle NBTXR3 (R3) to extend the application of radiotherapy to treating metastasized lung cancer in mice.

Results
In both the 344SQ-anti-PD-1 sensitive and 344SQ-anti-PD-1 resistant lung cancer models, we found that the combination of anti-PD1 and radiotherapy-induced robust immune responses, which resulted in significantly better control of both the local tumor (implanted on the right leg of the mice) and the metastasis (implanted on the left leg of the mice) than either immunotherapy or radiotherapy alone. In addition, we found that R3 significantly enhanced the efficacy of combined radiotherapy and immunotherapy in the two lung tumor models to control the local tumor and metastasis. The results also showed that with the supplement of R3, radiation plus anti-PD-1 achieved similar control of the metastasis under 3x8Gy compared to 3x12Gy, indicating that the treatment benefits acquired at a high dosage of radiation can now be achieved at lower dosages with the presence of R3. We also found that the triple combination of R3, radiotherapy, and anti-PD-1 significantly reduced the number of metastases in lungs compared to other combinations of these therapies. The immunoprofiling of the tumors after treatment showed that triple combination therapy reduced the population of regulatory T cells and M2 macrophages, resulting in favorable conditions for immune-mediated cancer cell killing.

Conclusions
In conclusion, R3 considerably enhances the ability of the combination of radiotherapy and immunotherapy to control both the local tumor and the metastasis in both the 344SQ-anti-PD-1 sensitive and 344SQ-anti-PD-1 resistant lung cancer models. In addition, R3 allows a lower dosage of radiation to achieve similar treatment outcome compared to a higher dosage of radiation.

Myeloid cell-selective STAT3 inhibition sensitizes head and neck cancers to radiation therapy and stimulates T-cell-dependent tumor regression

Dayson Moreira, PhD1, Marcin Kortylewski, PhD2, Sagus Sampath2, Hae Jung Won2, Chongkai Wang2, Peter Lee, MD2, Ellie Maghami2, Erminia Massarelli, MD, PhD, MS2, William Spanos, MD, MS2, Seek White2

1Beckman Research Institute at City of Hope, Duarte, CA, United States
2Sanford Health, Sioux Falls, SD, United States

Correspondence: Marcin Kortylewski (mkortylewski@coh.org)


Background
Therapeutic and immunogenic effects of radiation therapy (RT) are often constrained by tolerogenic activity of the tumor microenvironment. We recently found that combined modality therapy (CMT), using RT with concurrent cisplatin or cetuximab treatment, triggers potentially tolerogenic STAT3 signaling in circulating myeloid immune cells in patients with stage II-IV head and neck squamous cell carcinoma (HNSCC). Here, we extended these studies to tumor-containing lymph node biopsies collected from the same patients before and after two-week CMT. The clinical observations were later verified in feasibility studies testing the effect of STAT3 targeting on sensitivity to radiation therapy in HPV-positive and HPV-negative HNSCC tumor models in mice.

Methods
The STAT3 activity in immune populations infiltrating HNSCC tumors was analyzed in patients' derived fixed or frozen fine-needle biopsies. We used the multicolor immunofluorescent analysis and also gene expression analysis using Nanostar assay. To assess the effect of targeting STAT3 in the identified tolerogenic myeloid cell populations, we used TLR9-targeted STAT3 antisense oligonucleotides (CpG-STAT3ASO) in combination with local tumor irradiation.

Results
Using the multicolor immunofluorescent analysis, we found a significant increase in the percentage of CD163+ M2 macrophages with activated STAT3 and a concurrent reduction in a number of CD8+ T-cells in tumors post-treatment. Similarly, the Nanostar analysis of frozen tumor-containing lymph node biopsies detected significant increase in the percentage M2 macrophages (CD163, CD206), with the upregulation of Th2 (IL4, IL5) and immunosuppressive regulators (ARG1, IL10, LIF, TGFB1). These results suggested that STAT3 activation in tumor-associated myeloid cells can dampen immunogenic effects of CMT. To test this hypothesis, we combined single-dose localized RT with intratumoral injections of myeloid cell-specific STAT3 antisense oligonucleotide (CpG-STAT3ASO) against three mouse models of HPV-positive (mEERL) or HPV-negative (MOC2 and mEERL/sh) head and neck cancers. The combination of both strategies resulted in a strong synergistic effect with frequent eradication of mEERL and MOC2 tumors in at least half of treated mice. Regardless of the HPV status, effects of RT/CpG-STAT3ASO therapy were associated with reduced numbers of tumor-associated M2 macrophages and increased percentage of CD8+ T-cells and/or CD8:Treg ratio in MOC2 and mEERL tumors. In addition, we observed recruitment of M1 macrophages with enhanced expression of MHC class II and costimulatory molecules in tumor-draining lymph nodes after RT/CpG-STAT3ASO treatments.

Conclusions
Our clinical observations and animal study results suggest that myeloid cell-targeted inhibition of STAT3 together with CpG-mediated immunostimulation dramatically augment the outcome of radiation therapy against HPV-positive and HPV-negative HNSCC.

Ethics Approval
The clinical protocol including the relevant informed consent form was approved by the institutional review board at City of Hope (IRB-14255) and the study was conducted in accordance with the amended Declaration of Helsinki and the International Conference on Harmonization Guidelines.

Treatment of murine mammary carcinoma with focal radiation and immune checkpoint inhibition results in reduced immune suppression and enhanced cytotoxic immune cell activity

Philip Lapinski, PhD, Maryland Franklin, PhD, David Draper, PhD, Scott Wise, BS

MBioresearch, Ann Arbor, MI, United States

Correspondence: Maryland Franklin (mfranklin@mbioresearch.com)


Background
Despite the success of immune checkpoint blockade in treating many types of cancers, there remain many that are insensitive to these treatments. We have previously shown that focal radiation can sensitize the immunologically ‘cold’ 4T1 tumor model to immune checkpoint inhibition. Combination treatment with radiation and anti-CTLA4 antibody resulted in decreased numbers of infiltrating regulatory T cells as well as B cells in the tumors. While numbers of CD8+ T cells were not increased in tumors that received combination treatment, the cells displayed a more activated phenotype. We hypothesized that combination treatment decreased numbers of regulatory cell types and led to increased cytotoxic activity of CD8+ T cells, Natural Killer (NK) cells, and Natural Killer T (NKT) cells in the tumor microenvironment.
Methods
We orthotopically implanted 4T1 mammary carcinoma cells into BALB/c mice and treated with anti-mCTLA4 antibody, focal radiation, or both. Tumors were analyzed by flow cytometry, utilizing the Mi-CompLeukocyte™ panels with absolute cell counting, as well as the Mi-T Effector/Memory™ panel and a custom intracellular cytokine panel.

Results
The 4T1 tumor model is typically unresponsive to immune checkpoint inhibition. As expected, we saw a synergistic effect of combination treatment on tumor burden compared with radiation alone (77.1% vs. 42.3% TGI, respectively), suggesting that radiation primes the tumors to be more responsive to checkpoint inhibition. Our analysis showed that there was a 2.4-fold increase in the percentage of CD8+ T effector memory cells with a corresponding 9.4-fold decrease in CD8+ T central memory cells. The percentage of T effector memory cells was inversely correlated with tumor volume in the combination group, suggesting that this cell type could be directly responsible for the decreased tumor burden. Consistent with the increased effector memory phenotype, the percentage of CD8+ T cells secreting Granzyme B was increased 2-fold with combination treatment compared to radiation alone. Combination treatment also increased the percentage of NKT cells that secreted Interferon-γ, suggesting that the increased inflammatory cell phenotype is a broader phenomenon and not specific to CD8+ T cells.

Conclusions
Taken together, these data suggest that synergistic treatment with anti-mCTLA4 and focal radiation can induce the tumor immune microenvironment to change to a more inflammatory, and less suppressive, state than either treatment alone. Reduction in numbers of regulatory T cells and B cells resulted in increased percentages CD8+ T cells and NKT cells with a phenotype consistent with improved anti-tumor activity.

Ethics Approval
This study was approved by the IACUC at MBI Research under Protocol M05 - Subcutaneous Tumor Models for Evaluation of Test Agents.

References

Acknowledgements
Research material support for this work was provided by Bristol Myers Squibb. This work was supported by the National Institute of Health under the following awards U01CA233102, the University of Wisconsin Carbone Cancer Center Support Grant P30 CA014520, RSNA Fellow Award, ASCO YIA, and the Benson Translational Research Fellowship.

PS11
Mechanistic insights into combination low dose targeted radionuclide and checkpoint blockade treatment to turn a “cold” tumor “hot”
Ravi Patel, MD, PhD, Reinier Hernandez, PhD, Peter Carlson, BS, Ryan Brown, Luke Zangl, Amber Bates, Ian Arthur, Justin Jagodinsky, Joseph Grudinski, Amy Erbe, PhD, Jamey Weichert, Paul Sondel, MD, PhD, Zachary Morris, MD, PhD, Ravi Patel, MD, PhD
University of Wisconsin, Madison, WI, United States
Correspondence: Zachary Morris (zmorris@humonc.wisc.edu)

Background
Radiation therapy (RT) to enhances the efficacy of immune checkpoint inhibition (ICI) in multiple immunologically “cold” preclinical tumor models[1,2]. However, the optimal approach to delivering immunostimulatory RT has not been established. We have developed a novel strategy to deliver immunostimulatory low dose (LD) RT to all tumor sites in the setting of metastatic disease by using targeted radionuclide therapy (TRT), with a tumor-selective alkyl-phosphocholine (90Y-MM600). Here we evaluate the mechanistic basis for an observed co-operative interaction between LDTRT and ICI in an immunologically cold murine melanoma model that does not respond to ICI alone.

Methods
Mice were engrafted with B78 melanoma tumors, 80-90 mm^3, and were randomized to the following treatment groups: vehicle only (VO), anti-CTLA4 (C4), 90Y-MM600 TRT (2.5 Gy tumor dose), external beam RT (EBRT, 2.5 or 12 Gy), or combination TRT+C4. To compare LDRT delivered via EBRT or TRT to or high dose EBRT, tumors were harvested 1, 7, and 14 days after RT. We performed flow cytometry (FC) and qPCR on these specimens to evaluate immune cell infiltrates and gene expression. To determine treatment effects, tumors treated with VO, C4, TRT, or TRT+C4 were harvested on Day 25 after initiation of therapy. Immune infiltrates were quantified by FC in these samples, cytokine levels via multiplex ELISA, and T cell clonal analysis via T cell receptor (TCR) sequencing.

Results
Comparison of RT dose effects demonstrated increased ratios of CD8+ T cells to CD4+FoxP3+ regulatory T cells in the TRT group, compared to the EBRT groups at Day 1, as well as increased myeloid cell (CD11b+) and NK cell infiltrate with TRT. Gene expression analysis showed peak apoptosis markers on Day 1, peak type I interferon signaling (ISG) and chemokine expression on Day 7. High dose EBRT had significantly greater ISG expression than LD-RT (p < 0.05). Following combined treatment with TRT + C4, tumors showed significantly greater CD8+ T cells and γδ T cells, compared to single agent or untreated control groups. Multiplex ELISA showed increased concentrations of multiple cytokines with the notable exception of IL-10 in tumors from mice receiving TRT+C4 (Figure 1). In contrast to prior studies with high dose EBRT, LDTRT stimulated increased TCR clonal expansion but did not increase TCR diversity when combined with C4 ICI.

Conclusions
Our results demonstrate a cooperative therapeutic interaction between TRT+ICI in a murine tumor model that is functionally immunologically cold and does not respond to ICI alone.

Acknowledgements
We acknowledge the support of the Wisconsin Carbone Cancer Center, as well as the NCI (R01CA188409), the James S. McDonnell Foundation (220020214), the National Cancer Institute (R01CA096129), the National Institute of General Medical Sciences (R01GM102062), the National Institute of Neurological Disorders and Stroke (R01NS095321), the Robert M. Warner Foundation, the University of Wisconsin Brackenridge Foundation, the Pediatric Brain Tumor Foundation (S9112: Development of a Novel Diagnostic for Pediatric Brain Tumor), and the Wisconsin Alumni Research Foundation.

Ethics Approval
This study was approved by the University of Wisconsin institutional animal care and use committee protocol 005670.
Information on clinical efficacy of immune checkpoint inhibitors (ICI) combined with radiotherapy (RT) is available from numerous retrospective analyses, mainly focused on the treatment of brain metastases. The interpretation of retrospective clinical meta data, however, may be complicated due to variability in the design of studies and confounding factors. The aim of the present research was to systematically review and perform a meta-analysis comparing efficacy profiles of mono-RT vs ICI-RT combination in the treatment of brain metastases. The analysis also aimed at identifying factors affecting treatment outcomes.

Methods

The meta-analysis was performed using the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guideline. Studies with at least one ICI-RT arm and including patients with brain metastases were curated via a systematic literature search. Information on 1-year overall survival (OS) and 1-year local control (LC) was extracted and analyzed; additionally, if studies included mono-RT arms, risk ratios (RR) for the aforementioned endpoints were calculated. Random effects meta-regression models were tested to evaluate the impact of different factors, such as combination treatment sequencing or type of ICI and RT on outcomes.

Results

In total, information on OS and LC was reported in, respectively, 26 and 6 studies, with 50 and 13 arms, featuring 2528 and 525 patients. The corresponding information for mono-RT arms was available from, respectively, 12 and 4 studies with 2021 and 463 patients enrolled. Higher 1-year was observed in ICI-RT treatments vs mono-RT, with corresponding incidence rates were 59% [95% CI: 54-64%] vs 32% [95% CI: 25-40%] (P=0.039); efficacy of ICI-RT treatment was not affected by ICI and RT type.

Conclusions

RT and ICI combinations were associated with improved 1-year OS vs mono-RT. The highest benefit in outcomes was determined for co-acting concurrent ICI-RT treatment regimen.

Methods

The synergy between RT and palbociclib (a highly selective CDK4/ CDK6 inhibitor approved for the treatment of BC in humans) was tested: (1) in vitro, in 2 human BC cell lines with differential sensitivity to palbociclib and RT (MCF7 and MBA-MD-231 cells), to evaluate the effects on cell cycle distribution, cell death, cell senescence and IFN secretion; (2) in vivo, in a unique endogenous model of mammary carcinogenesis that recapitulate multiple immunobiological features of human HR+HER2- BC.

Results

We identified the lowest doses of RT and palbociclib that mediate robust short-term cytostatic/cytotoxic effects in MDA-MB-231 and MCF7. Optimized dose combinations and sequencing experiments pointed to RT followed by palbociclib as the approach with superior therapeutic potential. This largely reflect the ability of palbociclib to block in G1 cells escaping the G2/M arrest mediated by RT. Both RT and palbociclib were active in endogenous carcinomas driven in mice by slow-release progesterone pellets combined with an oral carcinoma, but failed to mediate disease eradication. Ongoing experiments are elucidating the impact of combination and sequencing in vivo.

Conclusions

Our preliminary results suggest that RT should precede CDK4/6 inhibition to achieve superior disease control. Altogether, these experiments will determine an optimal approach to combine CDK4/CDK6 inhibitors with RT in the context of endocrine therapy that has an elevated potential for clinical translation.

Acknowledgements

GP is supported by Fondazione Umberto Veronesi. ABM supported by a Breakthrough Level 2 grant from the US Department of Defense (DoD), Breast Cancer Research Program (BCRP) [BC180476P1]. LG is supported by a Breakthrough Level 2 grant from the US Department of Defense (DoD), Breast Cancer Research Program (BCRP) [BC180476P1], by a startup grant from the Dept. of Radiation Oncology at Weill Cornell Medicine (New York, US), by industrial collaborations with Lytix (Oslo, Norway) and Phosplatin (New York, US), and by donations from Phosplatin (New York, US), the Luke Heller TECPR2 Foundation (Boston, US) and Soto a.s. (Prague, Czech Republic).

References


Ethics Approval

The animal study was approved by Weill Cornell Medicine's IACUC; approval number 2019-0022.
PS14 
Molecularly targeted radionuclide therapy modulates the composition of the murine prostate cancer microenvironment
Hermann Potluri, BA, Reiner Hernandez, PhD, Christopher Zahm, PhD, Joseph Grudzinski, PhD, Christopher Massey, Jamar Weichert, PhD, Douglas McNeil, MD, PhD
UW-Madison, Madison, WI, United States
Correspondence: Douglas McNeil (dm3@medicine.wisc.edu)

Background 
Prostate cancer responds poorly to checkpoint blockade due to its immunologically "cold" microenvironment with low CD8+ T cell infiltration along with relatively high numbers of myeloid-derived suppressor cells (MDSCs) and regulatory CD4+ T cells (Tregs) [1]. Our lab has studied DNA vaccines as a simple method of increasing antigen-specific CD8+ T cell infiltration [4, 5]. To further increase CD8+ T cell infiltration and deplete suppressive populations, external beam radiation (EBRT) can be used [6]. However, it is often infeasible to irradiate all metastases using EBRT. Molecularly targeted radionucleic therapy (MTRT) is a method of delivering radioisotopes radiation selectively to all sites of disease [7]. The effects of MTRT’s effects on the tumor immune microenvironment are not yet well described. In this study, we examined the effect of 90Y-NM600 MTRT on immune populations within murine prostate tumors and assessed whether MTRT combined with antigen-specific vaccination can improve anti-tumor response.

Methods 
6-week-old male FVB mice (n=3 per group) were implanted with subcutaneous (s.c.) Mcy-CaP murine prostate tumors then given a single intravenous injection of either 50 (3.1 Gy) or 250 (15.5 Gy) μCi of 90Y-NM600. Mice were euthanized at day 0, 1, 4, 7, 14, and 21 post MTRT administration. Tumors were harvested and examined by multi-parametric flow cytometry and immunohistochemistry for effects on immune populations. In a second study, mice (n=5 per group) were implanted with s.c. Myc-CaP tumors then given five weekly treatments of either DNA vaccine or vehicle as well as a single administration of 125 μCi of 90Y-NM600. These mice were followed for tumor growth.

Results 
CD8+ T cell tumor infiltration increased by 13% at Day 14 compared to Day 0 (p<0.039) following MTRT administration in both dose groups while GR-1+ cells (including MDSCs) transiently decreased by 31% at Day 4 (p=0.007). Recovering CD8+ T cells showed high expression of the checkpoints PD-1, CTLA-4, and LAG-3. CD4+ T cells were depleted following MTRT administration and did not recover by Day 21. MTRT combined with vaccination resulted in decreased tumor growth compared to MTRT alone.

Conclusions 
Our data indicates that MTRT disrupts the suppressive tumor microenvironment of prostate tumors by depleting suppressive populations and increasing CD8+ T cell infiltration. High expression of exhaustion markers on CD8+ T cells suggests that combination of MTRT and vaccination with checkpoint blockade may further improve anti-tumor response.

Acknowledgements 
UW-Madison Medical Scientist Training Program: GM009692
UW-Madison Institute for Clinical and Translational Research Predoctoral TL1 Program: TR02375
University of Wisconsin Carbone Cancer Center Support Grant P30 CA014520
Archeus Technologies for kindly providing the NM600

References 

PS15 
Defining the TCR repertoire and functional differentiation of tumor-infiltrating T cells in mice responding to radiotherapy and CTLA-4 blockade
Nils-Petter Rudqvist, PhD1, Claire Luhliier, PhD1, Erik Werenerberg, PhD1, Jennifer Sims, PhD2, Sandra Demaria, MD1
1Weill Cornell Medicine, New York, NY, United States; 2Memorial Sloan Kettering Cancer Center, New York, NY, United States
Correspondence: Sandra Demaria (srd3050@med.cornell.edu)

Background 
Focal radiotherapy (RT) in combination with CTLA-4 blockade activates T-cells that reject tumors in both mice and patients unresponsive to CTLA-4 blockade alone [1, 2]. In metastatic non-small cell lung cancer patients dynamic changes in the blood TCR repertoire were strongly associated with response [1]. In the 4T1 mouse model of triple negative breast cancer we found higher intratumoral CD8+ CD4+ ratio and CD8+ T cell clonality in tumors of mice treated with RT+CTLA-4 blockade compared to each treatment alone [3]. However, the functional state of expanded intratumoral T cells remained unknown. The purpose of this study was to identify the intratumoral T cell landscape associated with response to RT+CTLA-4 blockade [4].

Methods 
For single cell sequencing (SC-seq) and bulk TCR sequencing (TCR-seq) experiments, mice were inoculated in one or both flanks with 50,000 4T1 cells, respectively. To obtain pre-treatment samples in each individual mouse, when applicable, one tumor was removed 2 days before treatment with RT (4x8 Gy) and/or anti-CTLA-4 antibody (9H10 Ab, 3x200 μg i.p.), and the treated tumor was resected 1 day after last antibody administration. TCR-seq was performed using the IRepertoire platform, and 5' gene expression, VDJ, and feature barcoding SC-seq was performed on sorted CD3+CD4+ and CD3+CD8+ T cells using the 10X Genomics chromium system.

Results 
In tumors treated with RT alone or in combination with anti-CTLA-4, both the TCRα and TCRβ repertoires increased in clonality, whereas a smaller increase in TCRβ clonality was found after anti-CTLA-4 monotherapy. Increased divergence between pre- and post-treatment samples was found after RT alone or in combination with anti-CTLA-4 but only correlated with treatment effect in mice treated with the combination (Pearson correlation coefficients: TCRα = 0.85, TCRβ = 0.92). Compared to untreated tumors, tumors treated with RT+anti-CTLA-4 were enriched with an oligoclonal population of Ifng+CD69+Tnf+Cd8+ and Ifng+Cd4+ T cells, and had decreased proportions of both Foxp3+Ox40+Cd25+Cd4+ (Tregs) and Pdl1+Gzm+b+Cd8+ (likely terminally differentiated/ exhausted) T cells. In contrast, tumors treated with RT alone were enriched with T cells exhibiting the terminally differentiated/ exhausted phenotype, which may explain why the TCR repertoire

Acknowledgements

References

dissimilarity between baseline and post-treatment tumors correlated with treatment effect only for mice treated with RT+anti-CTLA-4.

Conclusions

Overall, these results suggest that RT promotes the differentiation of the intratumoral TCR repertoire but in the absence of CTLA-4 blockade it does not drive the expansion and functional differentiation of T cell phenotypes necessary for immune-mediated tumor rejection.

Acknowledgements

Grant support: R01CA198533

References


PS16

Radiation-driven changes in immunomodulatory DNA cargo of exosomes produced by cancer cells

Sheila Spada, PhD, Sandra Demaria, MD, Nils-Petter Rudqvist, PhD, Tuo Zhang, PhD
Welli Cornell Medicine, New York, NY, United States

Correspondence: Sandra Demaria (sd3305@med.cornell.edu)


Background

Radiation therapy (RT) used at immunogenic doses (8GyX3) leads to cytosolic DNA accumulation which activates interferon type I (IFN-I) production via cGAS/STING pathway in cancer cells [1-3]. RT-induced IFN-I is critical for activation of systemically effective anti-tumor immune responses in combination with immune-checkpoint blockade therapy [1]. We have recently demonstrated that tumor-derived exosomes (TEX) produced by irradiated (8GyX3) TSA murine carcinoma cells (RT-TEX) contain more dsDNA compared to TEX derived from untreated cancer cells (UT-TEX). Interestingly, the dsDNA transferred by RT-TEX but not UT-TEX induces upregulation of costimulatory molecules CD40, CD80 and CD86, and STING-dependent IFN-I pathway activation in recipient dendritic cells. Furthermore, in vivo, RT-TEX elicit tumor-specific CD8+T-cell responses and protect mice from tumor development [4]. Here, we tested the hypothesis that not only quantitative but also qualitative differences may exist between the dsDNA cargo of RT-TEX and UT-TEX.

Methods

TEX were isolated 48 hours after last dose of radiation or mock treatment using ultracentrifugation. Internal DNA from TEX and from the parent TSA cells cytosolic fraction was analyzed by (1) semi-quantitative PCR using primers for mitochondrial 12S and 16S ribosomal subunits, NADH dehydrogenase subunit 1 (ND1) and genomic 18S ribosomal subunit genes; (2) DNA length was determined using Agilent Bioanalyzer; (3) DNA sequencing was performed using the Illumina HiSeq4000 system (paired end 50).

Results

Genomic and mitochondrial DNA were identified in both TEX and TSA cytosolic fraction regardless of RT. DNA length analysis demonstrated an enrichment of DNA fragments between 60 and 250 bp in RT-TEX compared to UT-TEX, and in the cytosolic fraction of irradiated TSA cells. These results are especially intriguing in light of the recent report that cGAS is optimally activated by dsDNA in this length range [3]. Whole-genome sequencing is ongoing to determine the genomic versus mitochondrial origin of the differentially represented DNA fragments.

Conclusions

Our data suggest that the immunostimulatory DNA cargo of RT-TEX has unique features that reflect molecular changes occurring in radiation-treated cells. The impact of these differences on the DNA-mediated activation of IFN-I pathway in innate immune cells that uptake TEX is under investigation. Identification of a "DNA signature" associated with TEX ability to activate cGAS could provide a blood-based biomarker for the immunogenic tumor response to radiotherapy.

Acknowledgements

Supported by American-Italian Cancer Foundation Fellowship, The Chemotherapy Foundation, R01CA201246 and Cornell University Seed Grants for Intercampus Collaborative Projects

References

Nanoparticles were given intravenously as multiple doses in combination with fractionated radiotherapy of the tumor region. The optimal formulation and dosing schedule were based on in vivo efficacy studies. Tolerability of the treatment was evaluated based on body weight, hematology, and blood biochemistry as well as cytokine levels in plasma measured 2h and 6h post injection. Antibody responses against the nanoparticles were also investigated. The effect on the tumor microenvironment was evaluated by flow cytometry.

Results
Nanoparticles containing 1V270 displayed a synergistic effect with local radiotherapy and all (8/8) mice carrying CT26 tumors displayed complete tumor regression. In the MC38 model, tumor growth delay was observed and 3/9 mice demonstrated complete tumor regression. No anti-tumor effect was observed in the poorly immunogenic B16-F10 model. Immunologic memory against tumor antigens was confirmed by tumor-rechallenge with 80-100% tumor-rejection rate in both CT26 and MC38. Improved tolerability, compared to other lipid nanoparticles, was demonstrated. The tumor microenvironment analysis demonstrated that the TLR7 agonist formulation induced infiltration of a large number of innate immune cells and supported the formation of activated tumor-specific CD8+ T cells.

Conclusions
The novel immunotherapeutic nanoparticle formulation induced a potent anti-tumor immune response; resulting in very potent efficacy in vivo against immunogenic tumors. Furthermore, we demonstrated improved tolerability in mice, which will be further investigated in larger animals. These results are highly encouraging for advancing potent immune stimulating therapy into the clinic.

Ethics Approval
The study was approved by the Danish Animal Experiments Inspectorate.

PS18
Testing a new platform for precision use of radiation therapy to induce in situ vaccination in breast cancer
Samantha Van Nest, PhD, Tasnim Anika, Adriana Irizarry, Laura Martin, Giorgio Inghirami, Silvia Formenti, MD, Sandra Demaria, MD, , Samantha Van Nest, PhD
Well Cornell Medicine, New York, NY, United States
Correspondence: Sandra Demaria (szd3005@med.cornell.edu)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):PS18

Background
Immune checkpoint inhibition targeting PD-1/PD-L1 has shown promise in breast cancer but is largely limited to triple negative breast cancer (TNBC).[1] This limitation is primarily due to inherently low levels of tumour infiltrating lymphocytes (TILs), particularly in HR+ disease.[2] Focal radiation therapy (RT) has been shown to generate anti-tumour T cells and increase TILs using mouse models of breast cancer (BC).[3,4] Mechanistically, radiation-induced increase in cytosolic DNA leads to activation of cGAS/STING pathway and production of IFN-β, which is essential for priming of anti-tumour CD8+ T cells.[5] This process is under the control of TREG1, and dependent on RT dose and fractionation.[5] Inter-tumor variability in optimal RT doses for activating the IFN-I pathway and heterogeneity in immunological response amongst BC subtypes highlight the importance of precision use of RT.[6] We are testing the hypothesis that improved in vitro and in vivo assays allow testing of the pro-immunogenic response to radiation in individual BC patients.

Methods
Spheroids were established from human adenocarcinoma cell lines MCF-7 (ER+;PR+;HER2-) and MDA-MB-231 (TNBC) by seeding 1,000 cells in a mixture of 2% Matrigel in DMEM. Patient-derived tumour xenograft (PDTX) was dissociated and organoids formed using 66% Matrigel in media. Single radiation doses between 2Gy and 20Gy as well as fractionated doses of 8Gy×3 were delivered, samples harvested at 24 hours post-treatment and RNA extracted. RT-qPCR was used to interrogate expression of key IFN-I response genes (IFNB1, MX1, CXCL10, IFNAR1) as well as TREG1.

Results
Spheroids and organoids were successfully established using human cell lines and PDTX, respectively (Figure 1). IFN-I pathway activation by single radiation doses ranging from 6 to 10Gy was detected in MCF-7, MDA-MB-231 and in PDTX, whereas single doses of 15 to 20Gy enhanced the expression of TREG1 and dampened IFN-I activation. Similar results were obtained in an in vivo irradiated PDTX and in vitro-irradiated organoids. We are currently establishing and testing additional pairs of organoids and PDTX from the same BC tumor to determine the most time and cost-efficient platform.

Conclusions
Developing a platform that utilizes pre-treatment tumor tissue from a patient to determine the functional response to different RT doses and aid in the selection of the best combination treatment with anti-PD-1/PD-L1 is a critical step towards precision use of RT to enhance responses to immunotherapy. Our data suggest that organoids and PDTX could both be used to test the functional response of an individual patient tumor to various RT doses.

Acknowledgements
The authors which to acknowledge financial support from the Breast Cancer Research Foundation (award BCRF-18-053).

References

Ethics Approval
All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Weill Cornell Medicine.
 Immunogel - an intratumoral multi-drug sustained release technology that polarizes the tumor microenvironment towards a proinflammatory and immunosupportive state

Trine Engel, PhD1, Jennifer Jørgensen, PhD1, Lars Ringgaard, PhD1, Fredrik Melander, PhD1, Sophie Jensen, MSc1, Linda Bruun, PhD1, Camilla Stavnsbjerg, MSc1, Andreas Tue Jensen, PhD1, Juliana Thuróczy, DVM, PhD, Dipl ECA1, Lajos Balogh, DVM, PhD2, Frederikke Friedner, MSc2, Martin Bak, PhD1, Andreas Kjer, MD, PhD1, Jonas Henriksen, PhD1, Anders Hansen, DVM, PhD1, Thomas Andreason, PhD1

1Technical University of Denmark, Kgs. Lyngby, Denmark;
2Animal Health Center Budafok, Budapest, Hungary;
3Righospital & University of Copenhagen, Copenhagen, Denmark

Correspondence: Thomas Andreason (tlan@dtu.dk)


Background

Polarizing the tumor microenvironment (TME) towards an inflamed and immunosupportive type is highly attractive for anti-cancer therapies. However, critical challenges are recognized for optimally modulating the TME. Firstly, immune activating drugs are poorly tolerated and secondly, the plastic and reactive TME must be stimulated to recruit and activate immune cells. Here we present a well-tolerated multi-drug intratumoral delivery technology (Immunogel), which has the potential to transform the TME and support immunological anti-cancer activity by ensuring a local sustained drug release. The Immunogel can easily be injected with small gauge needle technology, which has been demonstrated in clinical cancer patients using advanced high-precision image-guided technologies.

Methods

The Immunogel was formulated to provide sustained release of a TLR7/8 agonist and TGF-β agonist and TLR7/8 agonist (NT03-gel) and combined sustained release of a TLR7/8 agonist and TGF-β-inhibitor (NT04C-gel). Therapeutic efficacy and immune-modulating properties were evaluated in syngeneic cancer models. Drug release kinetics and tolerability was demonstrated in preclinical rodents and laboratory canines.

Results

The NT03-gel demonstrated a sustained intratumoral drug release of 31% after 24 hours and 81% after 7 days. Combination of NT03-gel and immunogenic cell death inducing chemo- or radiotherapy in the CT26 cancer model induced tumor rejection in >60% compared to 0% of treatment controls. TME analysis demonstrated that NT03-gel in combination with chemotherapy reduced intratumoral levels of immunosuppressive myeloid subsets and improved the cytotoxic T cell (cT) to regulatory T cell ratio more than nine-fold compared to controls. Additionally, a high increase of strongly activated CD137+ cTs and intratumoral infiltration of central memory cTs was identified. NT03-gel and radiotherapy increased intratumoral levels of T cell attracting chemokines and chemoattractants. Encouragingly, NT03-gel significantly enhanced anti-PD-1 therapy, indicating that the immune modulating properties of NT03-gel are attractive for improving immune-checkpoint therapy. The potential of multitarget therapy was demonstrated for NT04C-gel, which in combination with radiotherapy induced 100% tumor rejection. Furthermore, 18FDG PET/CT and lung metastasis scoring demonstrated that NT04C-gel in combination with low-dose radiotherapy of the primary tumor significantly reduced lung metastasis in the metastatic 4T1 cancer model. Importantly, the NT03-gel and NT04C-gel were well tolerated in laboratory beagles during a three-week evaluation period.

Conclusions

By enabling intratumoral sustained drug release, the Immunogel has the ability to polarize the TME towards an inflamed immunosupportive state, which is key for improving anti-cancer immunotherapies.

Ethics Approval

All experimental procedures involving animals were approved by The Danish Animal Experiments Inspectorate.

Matching-adjusted indirect comparison of pembrolizumab plus axitinib versus nivolumab plus ipilimumab for the first-line treatment of advanced/ metastatic renal cell carcinoma

Yufei Wang, Yichen Zhong, PhD, Shahruel Mt-Isa, Rodolfo Perini, MD, Oluwakayode Adejoro, MD, MPH

Merck, Kenilworth, NJ, United States

Correspondence: Oluwakayode Adejoro (oluwakayode.adejoro@merck.com)


Background

To date, pembrolizumab plus axitinib (P+A) and nivolumab plus ipilimumab (N+I) are the only immunotherapy combination therapies demonstrating superior overall survival (OS) compared to sunitinib in Phase III clinical trials in subjects diagnosed with advanced/meta-static renal cell carcinoma (mRCC). No head-to-head trial has compared the efficacy of P+A versus N+I in mRCC.

Methods

An anchored matching-adjusted indirect comparison (MAIC) was conducted using individual patient-level data (IPD) from KEYNOTE-426 and pseudo-IPD (digitized KM curves) in the published data from CHECKMATE-214. To adjust for differences in baseline potential effect modifiers between these trials, data for subjects from the KEYNOTE-426 were re-weighted to match the baseline characteristics reported in CHECKMATE-214. Progression-free survival (PFS) and OS were compared. The analyses were conducted in the intention-to-treat (ITT) populations and repeated in subjects with intermediate and poor risk disease (by International Metastatic Renal Cell Carcinoma Database Consortium [IMDC] criteria).

Results

After matching, P+A resulted in a lower hazard of disease progression or death than N+I (HR=0.81; 95% CI 0.63, 1.03; p-value = 0.090), and a lower hazard of death (HR=0.71; 95% CI 0.49, 1.03; p-value = 0.069) than N+I in the ITT populations. In the intermediate and poor risk populations, P+A resulted in a lower hazard of disease progression or death (HR=0.84; 95% CI 0.63, 1.12; p-value = 0.238) and a lower hazard of death (HR=0.75; 95% CI 0.50, 1.11; p-value = 0.148) than N+I.

Conclusions

Following the adjustment of cross-trial differences, P+A demonstrated lower hazards in the PFS and OS compared to N+I in both the ITT, and intermediate and poor risk populations. In the absence of direct comparison and sufficiently powered studies, these analyses provide valuable insights on the relative efficacy of P+A versus N+I for patients, physicians, and payers.

MEK inhibition enhances oncolytic herpes virus immunotherapy

Praveen Bommareddy, MS, PhD1, Andrew Zloza, MD, PhD2, Samuel Rabkin, PhD3, Howard Kaufman, MD, FACS3

1Rutgers University, Woburn, MA, United States; 2Rush University, Chicago, IL, United States; 3Massachusetts General Hospital, Boston, MA, United States

Correspondence: Howard Kaufman (Howard.Kaufman@replimune.com)


Background

Talimogene laherparepvec (T-VEC) is an oncolytic HSV-1 approved for the treatment of melanoma. We previously showed MEK inhibition enhances T-VEC-mediated immunogenic cell death in human melanoma cell lines in a BRAF mutation-independent manner. In this study we sought to understand how MEK inhibition and T-VEC promote host anti-tumor immunity.

Methods

Immunocompetent C57BL6 mice bearing D4M3A melanoma tumors were treated with an adapted T-VEC encoding murine GM-CSF (mT-VEC)106 PFU) given by intra-tumoral administration biweekly or without MEK inhibitor trametinib (0.1 mg/kg) by oral gavage for 2
weeks. Tumor growth was measured by calipers and, in some experiments, animals were monitored for survival or collection of tumor specimens for biomarker assessment. In independent experiments, treatment was evaluated in mice following depletion of specific immune cell subsets (CD8+ T cells, CD4+ T cells, macrophages and Batf3+ DCs). Flow cytometry analysis was performed on tumor-infiltrating lymphocytes using various markers of immune activation and analyzed by FlowJo software (v 10.4). RNA was collected from tumors and subjected to Nanostring gene expression analysis. Statistical comparisons between groups were determined using Student’s t test and Kaplan-Meier method was used to estimate survival. 

Results

In an immunocompetent murine HSV-1-sensitive D4M3A melanoma model we observed a significant decrease in tumor growth and increased survival following the addition of trametinib to T-VEC therapy. Therapeutic activity was associated with recruitment of CD8+ T cells into the tumor microenvironment and was dependent on both CD8+ T cells and Batf3+ DCs, as anti-tumor activity was lost when CD8+ T cells, but not CD4+ T cells, were depleted, and in treated Batf3-/- mice. Characterization of the CD8+ T cells revealed early recruitment of HSV-specific CD8+ T cells followed by melanoma antigen-specific (gp100 and TRP2) CD8+ T cell responses. Gene expression analysis demonstrated that combination therapy induced an immune-inflamed signature supportive of lymphocyte recruitment and activation within the local tumor microenvironment. Combination therapy enhanced PD-L1 expression providing rationale for addition of PD-1 blockade in vivo. In this murine model, triple combination therapy with trametinib, T-VEC and anti-PD-1 was associated with significant improvement in therapeutic effectiveness and resulted in 80% overall survival. Finally, re-challenge with D4M3A in surviving mice demonstrated complete protection suggesting development of long-term anti-tumor memory.

Conclusions

Oncolytic virus immunotherapy is improved by MEK inhibition and appears to sensitize tumors to immune checkpoint blockade. These studies support clinical translation of this combination approach into the clinic.

Ethics Approval

The study was approved by Rutgers University IACUC.

Methods

One-way, mixed lymphocyte reaction (MLR) assays were performed on human peripheral blood mononuclear cells and mature dendritic cells treated with different concentrations of M4112 in combination with avelumab, a fully human anti–PD-L1 IgG1 antibody, to measure interferon-gamma (IFN-gamma) levels [1]. Naïve mice or CT26-KSA and MC38 colon carcinoma mouse models were used for pharmacokinetic and pharmacodynamic and antitumor activity studies. Measurements of M4112, Kyn, and Trp levels in the plasma, liver, and tumor were performed after treatment with M4112 alone or in combination with avelumab. The CANScript tumor explant platform, which predicts potential antitumor effects using an M score [2], was used on 20 fresh human head and neck squamous cell carcinoma (HNSCC) tumor samples. Supernatants were measured for Kyn, Trp, and cytokine levels after 72 hours of M4112 or avelumab treatment alone and in combination.

Results

In combination with avelumab, M4112 treatment increased IFN-gamma production, indicating enhanced T-cell activation. Kyn levels and the Kyn/Trp ratio were also reduced in mouse and human tumor explant models. Treatment with M4112 in combination with avelumab led to reduced tumor volumes in syngeneic tumor models. In addition, M4112 exhibited antitumor effects in 4 (20%) and 7 (33%) of 20 HNSCC tumor explants as a single agent and in combination with avelumab, respectively.

Conclusions

The dual-selective IDO1/TDO2 inhibitor, M4112, in combination with avelumab enhanced antitumor activity in mouse and human tumor models and normalized systemic Kyn/Trp levels. Thus, M4112 represents a promising therapeutic agent targeting both the IDO1 and TDO2 immunosuppressive pathways.

References

in syngeneic mice. We examined a number of biological markers of immune responses and monitored expression of immune-relevant genes after mice bearing glioblastomas were treated with SGT-53 or anti-PD-1 or the combination of these therapeutic agents.

Results
Adding SGT-53 to anti-PD-1 immunotherapy resulted in increased intratumoral infiltration of immune effector cells and altered expression of a number of genes related to immune responses. SGT-53 triggered changes in both innate and adaptive immune responses and caused immunomodulatory changes that included elevated tumor expression of CRT, FAS, PD-L1, ICAM1 and MHC I. SGT-53 also markedly modified the previously immunosuppressive microenvironment of tumors. Importantly, the combination treatment restored T-cell effector function and increased CTLs within tumor (Figure 1), which was correlated with inhibition of subcutaneous and intracranial tumor growth (Figures 2 & 3, respectively) as well as a survival benefit in mice bearing intracranial glioblastomas.

Conclusions
Tumor-targeted p53 gene therapy via SGT-53 was able to augment anti-PD-1 immune checkpoint blockade and convert mouse syngeneic glioblastoma tumors that were unresponsive (immunologically “cold”) tumors into tumors that were more responsive to anti-PD-1 immunotherapy. These findings suggest that SGT-53 has potential to enhance the efficacy of checkpoint blockade and thereby provide for improved outcomes for patients with glioblastomas. Our observations provide compelling motivation to test the combination of SGT-53 and a checkpoint inhibitor in the context of a clinical trial for glioblastoma.

Acknowledgements
This work was supported by the NCI grant (R01CA132012-02 to EHC); and a research grant from SynerGene Therapeutics, Inc. This study was conducted at the Lombardi Cancer Center Shared Resource facilities that are partially supported by NCI (P30-CA051008). Some of the data to be presented at SITC have recently been published [11].

References

Ethics Approval
All animal studies was performed under an IACUC-approved protocol in compliance with the Animal Welfare Act, PHS Policy, and other Federal statutes and regulations relating to animals in the AAALAC-accredited animal facility at Georgetown University, which adheres to principles stated in the Guide for the Care and Use of Laboratory Animals; National Research Council.
PS24
CRISPR CA9 mediated BRCA1 knockout modulates the tumor infiltrating lymphocytes landscape and cytokine profile in a murine breast cancer model
Julia Schuler1, Anya Avrutskaya1, Kanstantsin Lashuk1, Mariette Heins, PharmD1, Cordula Tschuch1, Astrid Jensen1, Gerhard Kelter1, Anne-Lise Perille1, Maycee Robinson1, William Durham1, Armin Mayer1, Anne-Marie Zuurmond1
1Charles River Discovery, Freiburg, Baden-Wurttemberg, Germany; 2Charles River Den Bosch, Discovery, Groningen, Netherlands
Correspondence: Julia Schuler (julia.schueler@crl.com)

Background
Around 10% of breast cancer cases are attributed to genetic disorders like mutations in BRCA1-1/2 genes. Targeted therapy of BRCA-deficient cancers has been achieved using poly(ADP-ribose) polymerase (PARP) inhibitors, which block BRCA-dependent DNA repair.

Methods
To study the effect of this common mutation on tumor biology in general and specifically the immunological landscape of the tumor microenvironment, we knocked out the BRCA1 gene in the murine EMT6 breast cancer cell line. Subsequently, we analyzed the tumor infiltrating lymphocyte (TIL) population and the cytokine profiles in serum of tumor bearing animals.

Results
The percentage of TILs (=CD45+ cells) was similar in both lines (33.0% vs 29.6%, BRCA1-/- vs BRCA1wt). Nevertheless, a more detailed analysis of the TIL subpopulations revealed higher percentages for gMDSC and M2 macrophages in the EMT6/BRCA1-/- line. The analysis of 23 cytokines showed a significant down regulation of 22 cytokines in the EMT6/BRCA1-/- bearing animals. Solely, G-CSF was significantly upregulated in the mutated cell line (multiple t-test, p<0.001). With the objective to elucidate more in detail the biology behind the differences in cytokine levels and TIL distribution, we investigated the influence of different PARP and checkpoint (CP) inhibitors on both parameters. Both lines showed distinct TIL and cytokine profiles under treatment. In the EMT6/BRCA1-/- the TIL population decreased under PARP inhibitor monotherapy (Talazoparib) but increased significantly under treatment with CP inhibitors anti CTLA-4 and anti PD-1 in monotherapy as well as in combination with Talazoparib (Kruskall-Wallis test, p<0.005). In contrast, the TIL frequency in the EMT6/BRCA1wt model was similar in all treatment arms. Differences in the TIL composition were mainly detected in the NK and gMDSC cell fraction which were upregulated under treatment including Talazoparib specifically in the EMT6/BRCA1-/- model. The TIL analysis in the EMT6/BRCA1wt tumors showed no differences in the individual subpopulations although the observed antitumoral activity of anti CTLA-4 as well as anti PD-1 in this model (tumor reduction of >60% as compared to untreated control). In line with the enhanced NK cell numbers under therapy was the fact that serum levels of RANTES and IL-2 were enhanced under treatment in EMT6/BRCA1-/- bearing animals.

Conclusions
Further studies using microdialysis as read-out will give additional information on the influence of the BRCA1 gene knockout and the resulting modulation of the tumor microenvironment and will help to elucidate the tumor biology and clinical relevance behind these findings.

PS25
Dose-dependent sensitization of combined anti-angiogenic and PD-1 blockade in breast cancer
Wen Jiang, MD, PhD1, Yifan Wang, PhD1, Betty Kim2, Jiejiong Liu, MD, PhD1
1The University of Texas Southwestern Medical Center, Dallas, TX, United States; 2MD Anderson Cancer Center, Houston, TX, United States; 3Sun Yat-sen Memorial Hospital, Guangzhou, China
Correspondence: Jiejiong Liu (liujiejiong@163.com)

Background
Cancer immunotherapy using immune checkpoint inhibitors has significantly improved the clinical outcomes of patients with multiple aggressive and advanced-stage cancers. Despite its enormous successes, the overall response rates of immune checkpoint inhibitor as a monotherapy remain suboptimal, especially in treating breast cancers. In order to improve the efficacy of cancer immunotherapies, there is an increased interest in combining immune checkpoint inhibitors with targeted agents to enhance antitumor effects. Previous studies have shown that anti-angiogenic drugs that suppress tumor vasculatures can improve the therapeutic effect of immune checkpoint blockades in preclinical models of human cancer. However, the exact mechanism of action of such synergism is unclear and how the two treatment modalities should be administered in terms of dosing and sequencing to produce the optimal response remains unknown. In the present study, we investigate the antitumor effect of combined blockade of vascular endothelial growth factor receptors 2 (anti-VEGFR2) and programmed death (PD-1) in murine breast cancer models as well as in a phase II trial.

Methods
We tested the combination of anti-PD-1 with different dose of VEGFR2-targeting antibody in syngeneic breast cancer mouse models. Tumor infiltrated immune cell subsets were profiled by flow cytometry. A cytokine array was carried out to identify mechanism of the synergy between the two modalities. The efficacy of this combination was further evaluated in advanced triple-negative breast cancer (TNBC) patients.

Results
Antibody targeting VEGFR2 sensitizes breast tumors to PD-1 blockade in a dose-dependent manner. Although both conventional and low-dose anti-VEGFR2 antibody treatments normalize tumor vessels, low-dose VEGFR2 blockade results in more robust immune cells infiltration and activation, and promotes the secretion of osteopontin (OPN) by CD8+ T cells. OPN subsequently induces tumor cell production of TGF-β, which in turn upregulates PD-1 expression on immune cells. In advanced TNBC patients, combined low-dose anti-VEGFR2 and anti-PD-1 treatmtns demonstrated excellent tolerability and efficacy with a doubling of progression free survival as compared to historical anti-PD-1 trials. Tissue analyses further revealed that higher OPN and TGF-β expressions were correlated with improved clinical responses in patients.

Conclusions
Taken together, these results demonstrate that a dose-dependent synergism exists between anti-angiogenic therapy and immune checkpoint blockade, thus providing important insights into identifying the optimal strategies to combine immunotherapy with molecular targeted agents.

Trial Registration
NCT03394287

Ethics Approval
All patient-related procedures were performed with the approval of the Internal Review and the Ethics Boards of the Sun Yat-sen Memorial Hospital. All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of UT Southwestern Medical Center and Sun Yat-sen University.
Combination cabozantinib and nivolumab treatment in patients with refractory metastatic renal cell carcinoma (mRCC)

Emily Kinsey, MD, Landon Brown, MD, Chester Kao, MD, Patrick Healy, Michael Harrison, MD, Megan McNamara, MD, Andrew Armstrong, MD, Sundhar Ramalingham, MD, Daniel George, MD, Tian Zhang, MD, Duke University Medical Center, Durham, NC, United States

Correspondence: Emily Kinsey (enkinsey@gmail.com)

Background

The treatment landscape has drastically changed in mRCC, moving from anti-VEGF therapies to an immunotherapeutic approach in the first line setting for IMDC intermediate or poor risk mRCC. Combining anti-VEGF and anti-PD-1 or anti-PDL-1 therapies have shown survival improvements in mRCC, leading to approvals for first-line axitinib-pembrolizumab and axitinib-avelumab [1,2]. Cabozantinib and nivolumab (cabo/nivo) is also a safe option in phase 1 trials with some durable responses [3]. We evaluated the outcomes of patients who received cabo/nivo for mRCC refractory to immunotherapy alone.

Methods

A retrospective analysis was performed of patients with mRCC treated with ipilimumab and nivolumab (ipi/nivo) and subsequently with cabo/nivo at Duke Cancer Center between September 2017 and February 2019. Patient outcomes were collected including demographic information, treatment details, responses, and frequency of adverse events. The cohort of patients treated with the cabo/nivo combination is presented here.

Results

Eighty-six patients were treated with ipi/nivo for mRCC and of these patients, 34 patients also received cabozantinib, either alone or in combination with nivolumab. Nine patients received cabozantinib prior to ipi/nivo, and 14 patients received cabozantinib after ipi/nivo, and 10 patients received combination therapy with cabo/nivo. Of the ten patients who received combination cabo/nivo, 2 were favorable risk, 6 were intermediate risk, and 2 were poor risk. One patient had progressive disease, 2 patients had stable disease, 3 patients had a partial response (50% responses), and 4 patients were un evaluable due to insufficient follow up. Eight of 10 patients had treatment ongoing at the time of data collection.

Conclusions

Progression on immunotherapy alone did not appear to confer resistance to cabo/nivo treatment for five of the six patients who had a disease response assessment. Phase III studies COSMIC-313 and Alliance A031704 (PDIGGREE) are ongoing to evaluate cabozantinib in combination or in sequence to ipilimumab immunotherapy.

IgE-based therapeutic strategy against pancreatic cancer

Kamiya Mehta, PhD1, Kamiya Mehta2, Ragupathy Madiyalakan, PhD, Christopher Nicodermus, MD3, Thomas Cafrey4, Michael Hollingsworth, PhD5, Kelly O’connell6

1University of Nebraska Medical Centre, Omaha, NE, United States; 2unmc, Omaha, NE, United States; 3Oncoquest Inc., Edmonton, AB, Canada; 4AIT strategies, Charleston, MA, United States

Correspondence: Michael Hollingsworth (mahollin@unmc.edu)

Background

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, accounting for 338,000 new cases worldwide with a 5-year survival rate of less than 10%. Despite progress with new treatments, PDAC remains indomitable. New therapeutic strategies that are tumor-specific, relieve tumor-associated immunosuppression and modulate tumor stroma for the efficient delivery of chemotherapeutics are urgently required. Abundant evidence suggests a reciprocal relationship between allergies and pancreatic cancer. Distinct immune surveillance in allergic individuals might enhance immune protection against cancer [1-2]. We investigated a novel immunotherapeutic strategy to trigger a tumor antigen-specific allergic phenotype in a preclinical model of pancreatic cancer.

Methods

Using a combination of humanized anti-MUC1.IgE, anti-PD-L1, and PolyICLC, we investigated the efficacy of this unique triple combination in a preclinical model of pancreatic cancer using transgenic mice expressing human MUC1 and FcRRI (hMUC1/FcRRI). IgE antibody against prostate-specific antigen (anti-PSA.IgE) and anti-MUC1.IgG was employed as controls. In parallel, transgenic mice for only hMUC1 or hFcRRI were utilized as additional controls. We also performed immuno-depletion studies and analysis of tumor-infiltrating lymphocyte (TIL) from treated mice to investigate the role of innate (NK cells) and adaptive immune players (CD8 T cells) in providing protective benefits of derived from the combination therapy. In parallel, we performed a phospho-proteomic screen to elucidate the mechanism through which our proposed therapy harnesses NK cell-mediated anti-tumor immune response against pancreatic tumors.

Results

We noted that combined immunotherapy with a humanized IgE directed towards a tumor antigen expressed on pancreatic adenocarcinoma (MUC1), PolyICLC, and anti-PD-L1 induces antigen-specific cellular immune responses that mediate rejection of tumor cells in a pre-clinical model of pancreatic cancer. Our initial mechanistic studies suggest that effector mechanisms for anti-MUC1.IgE includes induction of ADCC by NK cells and activation of antigen-specific CD8 cytotoxic T lymphocytes (CTLs). Furthermore, we noted that the anti-MUC1. IgE-combination treatment promotes intra-tumoral NK cell activation and increased CD103+ DCs proportions inside the tumor, which were reversed upon NK cell depletion. Also, we noted the activation of SMAD1, but not SMAD3, pathways in NK cells post-treatment with anti-MUC1.IgE-based combination.

Conclusions

Taken together, this is the first study to show that specific stimulation of the IgE/FcRRI axis in combination with PolyICLC and anti-PD-L1 can activate CD8 T cell and NK cell effector pathways and provide long-lasting tumor-protective benefits against pancreatic cancer. Our study provides preliminary evidence for the clinical applicability and rapid translation of an anti-MUC1.IgE based combination therapy against pancreatic cancer.
Combination antibody treatment targeting PD-L1 and 4-1BB leads to reduced anti-tumor immunity against CT26 tumors in B-cell deficient JH-/ mice
Zhengming Yan, Heather Llewellyn, Kerry Kelleher, Bernadette Pascual, Angela Stauffer, Ying Ding, Xiaorong Li, Mark Ozeck, Jeffrey Toste, Han Yang, Haikuo Zhang, Sripad Ram, PhD, Cathy Zhang Pfizer, Inc., San Diego, CA, United States
Correspondence: Sripad Ram (sripad.ram@gmail.com), Cathy Zhang (Cathy.Zhang@pfizer.com)

Background
The role of B cells in tumor immunity is poorly understood due to their conflicting roles that augment and suppress anti-tumor responses. For example, B cells can augment T-cell responses against tumor challenge as antigen presenting cells, while B cells can also blunt anti-tumor responses by developing neutralizing antibodies against therapeutic antibodies. In the context of targeted immunotherapy using antibody-based therapeutics, an important question arises as to whether B cells are necessary for eliciting an anti-tumor immune response.

Methods
We use two different clones of anti-PD-L1 antibody, 10F9G2 and MIH5, which are rat IgG2b and rat IgG2a, respectively, in conjunction with a mouse anti-mouse 4-1BB antibody. CT26 tumors were implanted subcutaneously in BALB/c mice or genetically B-cell deficient JH-/ mice. Binding affinity measurements were performed on BIA-Core. For flow cytometry, tumor, spleen and lymph nodes were harvested at different times after the last dose, dissociated and assayed for different immune cell markers. For single-cell RNA-seq, mouse PBMCs were isolated and analyzed using the 10x Genomics platform.

Results
In vivo and in vitro pharmacokinetic studies revealed that MIH5 clone had better bioavailability than the 10F9G2 clone which is attributed to its higher binding affinity to FcRn. Combination treatment with the MIH5 clone resulted in superior antitumor efficacy when compared to using the 10F9G2 clone in wild type and JH-/ mice. However, for a given combination, JH-/ mice showed consistently poorer efficacy than wild type mice. More specifically, in the absence of B cells CDB+ T-cell expansion in the tumor was diminished and memory T-cell development was systemically impaired. We also report that B cells are required for reciprocal crosstalk activation between 4-1BB and PD-L1 signaling pathways which could augment the synergistic response of combination therapy. Results from single cell RNA-seq suggest that B cells promote T-cell mediated tumor immunity through the production of cytokines that increase antigen processing and presentation, and support T-cell activation, proliferation and differentiation.

Conclusions
Our results reveal an underappreciated role of B cells in T-cell targeted cancer immunotherapy. They also underscore the importance of serum persistence of therapeutic antibodies in mediating anti-tumor immunity.

Ethics Approval
All experimental animal procedures complied with the Guide for the Care and Use of Laboratory Animals (Institute for Laboratory Animal Research, 2011) and were approved by the Pfizer Global Research and Development Institutional Animal Care and Use Committee (IAUC).
Methods
Here by using pre-clinical models of melanoma and analysis of clinical samples we sought to characterize the mechanisms of immune suppression associated with the AHR pathway and to evaluate its potential as therapeutic target.

Results
RNaseq analysis of human cancers revealed an up-regulation of Kyn-degrading enzymes in patients responsive to PD-1 blockade. Also, we observed a correlation between the expressions of Kyn-AHR pathways with a TGβ-immune signature and markers associated with immunotherapy resistance (PD-1, FOXP3, CD206). We found that the overexpression of IDO or TDO in a pre-clinical model of melanoma (B16-F10) promoted CD8+ T cell dysfunction and accumulation of M2-TAMs and Tregs with an activation of the AHR pathway and enhanced suppressive function. Moreover, IDO-Kyn-AHR-mediated tumor progression was dependent on an interplay between Tregs and TAMs, which could be reversed by selective inhibition of the AHR. Treatment of IDO/TDO-expressing but not wild-type tumor models with a selective AHR antagonist delayed tumor growth, and its efficacy was further improved with PD-1 blockade RNaseq analysis of human cancers revealed an up-regulation of Kyn-degrading enzymes in patients responsive to PD-1 blockade. Also, we observed a correlation between the expressions of Kyn-AHR pathway genes with a TGβ-immune signature and markers associated with immunotherapy resistance (PD-1, FOXP3, CD206). We found that the overexpression of IDO or TDO in a pre-clinical model of melanoma (B16-F10) promoted CD8+ T cell dysfunction and accumulation of M2-TAMs and Tregs with an activation of the AHR pathway and enhanced suppressive function. Moreover, IDO-Kyn-AHR-mediated tumor progression was dependent on an interplay between Tregs and TAMs, which could be reversed by selective inhibition of the AHR. Treatment of IDO/TDO-expressing but not wild-type tumor models with a selective AHR antagonist delayed tumor growth, and its efficacy was further improved with PD-1 blockade.

Conclusions
In summary, our findings demonstrate that targeting the Kyn pathway through AHR inhibition could overcome key suppressive mechanisms and sensitize otherwise immune resistant tumors to PD-1 blockade.

Ethics Approval
All mice were maintained in microisolator cages and treated in accordance with the NIH and American Association of Laboratory Animal Care regulations. All mouse procedures and experiments for this study were approved by the MSKCC Institutional Animal Care and Use Committee.

P531
A tumor PD-L1-NLRP3 inflammasome signaling axis drives adaptive resistance to anti-PD-1 immunotherapy
Balamayooran Theivendran Galaxy, PhD1, Kathy Evans, BS1, Nicholas DeVito, MD1, Michael Plebanek, PhD1, Michael Sturdivant, BS1, Alisha Holtzhausen, PhD2, Luke Wachsmuth, BS1, April Salama, MD1, Yubin Kang, MD1, David Hsu, MD, PhD1, Justin Balko, PhD, PharmD2, Douglas Johnson, MD, MSCG1, Mark Starr, BS1, Andrew Nixon, PhD1, Brent Hanks, MD, PhD1
1Duke University Medical Center, Durham, NC, United States; 2University of North Carolina, Chapel Hill, NC, United States; 3Vanderbilt University Medical Center, Nashville, TN, United States
Correspondence: Brent Hanks (brent.hanks@duke.edu)
Journal for Immunotherapy of Cancer 2019, 7(Suppl 1):P531

Background
An in-depth understanding of immune escape mechanisms in cancer are likely to lead to innovative advances in immunotherapeutic strategies. However, our understanding of these mechanisms driving both primary and secondary immunotherapy resistance remains incomplete. While many groups have described the role of NOX-, LRR- and pyrin domain-containing protein-3 (NLPR3) as a sensor for pathogen-derived danger signals by antigen-presenting cells in the innate immune system, relatively little is known about the contribution of NLRP3 to tumorigenesis and its role in modulating tumor responses to immunotherapy has not been explored.

Methods
Several pre-clinical syngeneic and transgenic tumor models, an autologous humanized mouse tumor model, and clinical plasma and tumor specimens derived from advanced melanoma patients were utilized to investigate the genetic and cellular alterations of tumors escaping anti-PD-1 antibody immunotherapy.

Results
Using several pre-clinical tumor models, we have determined that granulocytic myeloid-derived suppressor cells (PMN-MDSCs) accumulate within progressing tumors undergoing treatment with anti-PD-1 antibody (ab) immunotherapy. This PMN-MDSC recruitment effect was found to be due to an autocrine Wnt5a-dependent upregulation of CXCRII chemokines in tumor tissues. After additional study, we determined that this pathway was induced by HSP70-TLR4 stimulation and occurred in response to cytolytic CD8+ T cell activation. Using genetic and pharmacologic approaches we have found that this tumor-intrinsic signaling cascade is triggered by a PD-L1-dependent activation of the NLRP3 inflammasome via a STAT3-PKR signaling axis. This mechanism requires CD8+ T cell activation and IFN-gamma expression. However, treatment with chemotheraphy or anti-CTLA-4 ab immunotherapy failed to induce a similar effect. Genetic ablation and pharmacologic inhibition of NLRP3 suppressed PMN-MDSC recruitment and enhances the efficacy of anti-PD-1 ab immunotherapy in an autochthonous model of BRAF(V600E) melanoma. We then sought to validate this pathway in clinical specimens where we found elevations in various myeloid markers and CXCRII chemokines in tumor tissues as well as an increase in plasma HSP70 levels in non-responding melanoma patients progressing through anti-PD-1 ab immunotherapy.

Conclusions
This work reveals a tumor-intrinsic PD-L1-NLRP3 inflammasome signaling pathway triggered by CD8+ T cell activation that ultimately drives adaptive resistance to anti-PD-1 immunotherapy by promoting the recruitment of PMN-MDSCs to the tumor bed. The identification of the key PD-L1-STAT3-PKR-NLRP3 signaling axis responsible for this mechanism provides insight into promising strategies for augmenting the efficacy of checkpoint inhibitor immunotherapy as well as for monitoring the management of cancer patients undergoing these therapies. NLRP3 inhibitors represent promising agents for future anti-PD-1 combination clinical trials.

Ethics Approval
This study utilized clinical specimens derived from ongoing tissue acquisition protocols approved by the Institutional Review Boards at Duke University Medical Center (IRB approval number Pro00059349) and Vanderbilt University Medical Center (IRB approval number 100178).

P532
Increased adiposity reduces the response rate to a combinatorial CTLA-4 based therapy in diet-matched, renal tumor-bearing mice without substantially altering intra-tumoral T cell profiles
Brian Turbutt, PhD1, Shannon Bo1, Rachael Orlandella, BS1, Justin Gibson, BS1, Lyse Norian, PhD1
1The University of Alabama at Birmingham, Birmingham, AL, United States; 2St. Jude Children’s Research Hospital, Memphis, TN, United States
Correspondence: Lyse Norian (lorrian@uab.edu)

Background
Associations between modifiable factors (e.g., adiposity) and immunotherapeutic efficacy remain uncertain. Preclinical studies suggest increased adiposity improves response rates to immune checkpoint blockade; however, few studies control for diet effects between chow-fed lean and high-fat diet-induced obese (DIO) mice. We found previously that DIO reduces the efficacy of an immunotherapy
Consisting of replication-deficient adenovirus (Ad) encoding tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL) (AdTRAIL) plus Class B oligonucleotides (CpG1826) in renal tumor-bearing mice [1]. To eliminate the confounding effects of diet and explore if therapy response can be improved in DIO mice, the current study evaluated response rates to AdTRAIL/CpG combined with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in diet-matched obese-resistant (OBR) versus DIO mice.

**Methods**

BALB/c mice were administered a high-fat diet for 20 weeks. Following diet administration, mice were characterized as either OBR or DIO, as previously described [2]. DIO mice possess hallmarks of obesity, including increases in systemic glucose, insulin, and leptin; whereas, OBR mice display phenotypic characteristics similar to chow-fed, lean controls. Mice were injected orthotopically with Renca-Luc renal cancer cells into the left kidney. At day seven post-tumor challenge, mice were randomized to receive saline or AdTRAIL/CpG injected intra-tumorally, followed by isotype control (n=7-9/group) or anti-CTLA-4 therapy (n=12/group). At day 21 post-tumor challenge, immunogenetic profiling of whole-tumors was performed via nanoString and tumor-infiltrating lymphocytes were characterized by flow cytometry.

**Results**

Both OBR and DIO therapy-treated mice had significant reductions in tumor weight compared to therapy-free controls (66% reduction for OBR; p<0.001 versus 55% reduction for DIO; p=0.007). However, therapy was effective in 75% of OBR mice compared to 50% of DIO mice. Over 30 differentially expressed genes were shared between OBR and DIO therapy-treated responders compared to therapy-free controls. A third of these “responder” genes were related to T-cell function or migration (e.g., Ccl2, Cxcl10, Il16, Il18). Cellular analyses demonstrated that OBR therapy-treated responder mice had a greater percentage of tumor-infiltrating activated (CD44+) CD8+ T cells compared to DIO therapy-treated responder mice (p=0.004); however, CD8+ T cell IFNγ production and PD-1 expression were comparable between these groups.

**Conclusions**

When controlling for diet, increased adiposity reduced the response rate to combinatorial anti-CTLA-4 based therapy. However, both OBR and DIO therapy-treated responder mice shared immunogenetic and T-cell profiles independent of weight status. To improve treatment strategies, future studies are needed to understand the mechanistic drivers of the differential response rates to immunotherapy observed with obesity.

**Acknowledgements**

Research reported in this abstract was supported by The National Institutes of Health (NHLBI) Grant #5R01CA181088 to LAN. WJT is supported by The Research Training Program in Basic and Translational Oncology (T32CA183926), The University of Alabama at Birmingham School of Medicine Department of Medicine, Division of Hematology and Oncology, Birmingham, AL. RMO is supported by The Cancer Prevention and Control Program (T32CA047888), The University of Alabama at Birmingham, Birmingham, AL. JTG is supported by The Training Program in Cell, Molecular, and Developmental Biology (T32GM08111), The University of Alabama at Birmingham, Birmingham, AL.

**References**


**Ethics Approval**

All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Alabama at Birmingham, approval number 20233.

**Combination Treatments**

**P53**

The genomic architecture of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immunotherapies.

Sonia Iyer, PhD1, Shuang Zhang2, Anniina Farkkila3, David Pepin3, Raghav Mohan4, Sean Smith5, Tian Xia6, Ferenc Reinhard7, Tony Chavarría8, Esme Hoefsmit9, Shalija Pathania10, Yunlan Zhou11, Kevin Elias12, Benjamin Neel2, Robert Weinberg, PhD1

1Whitehead Institute for Biomedical Research, Cambridge, MA, United States; 2NYU-Langone Medical Center, New York, NY, United States; 3Dana-Farber Cancer Institute, Boston, MA, United States; 4Massachusetts General Hospital, Boston, MA, United States; 5Massachusetts Institute of Technology, Cambridge, MA, United States; 6Whitehead Institute for Biomedical Research, Cambridge, MA, United States; 7University of Massachusetts, Boston, MA, United States; 8Brigham and Women’s Hospital, Boston, MA, United States

**Correspondence:** Sonia Iyer (iyers@wi.mit.edu), Robert Weinberg (weinberg@wi.mit.edu)


**Background**

The cornerstone of the existing treatment of high-grade serous ovarian cancer (HGSOC) is DNA-damaging chemotherapy; however, practically all patients eventually develop the progressive disease and the 5-year survival is only 40%. Immunotherapy would seem to be an attractive alternative treatment to chemotherapy, yet existing immunotherapies perform poorly in ovarian cancer, with only ~10% of patients responding to checkpoint-blockade. Why this is the case remains poorly understood and there is a pressing need to understand the underlying biology of immune evasion in ovarian cancer. Unfortunately, the preclinical tools required to explore the relationship between the types of DNA damage repair deficiencies and immune evasion have been lacking. Hence, we have modeled the biology of ovarian cancer using patient-relevant mutational landscapes in an immune-proficient, syngeneic-mouse model to help us identify the contribution of common driver mutations to the immune repertoire in the tumor microenvironment, and thus to responses of HGSOC tumors to immunotherapy.

**Methods**

We hypothesize that the immune composition and gene expression signatures of the resulting tumors will vary based on the combination of genetic alterations and the DNA repair proficiency of the transformed cells. To this end, we have engineered novel syngeneic mouse models from murine fallopian tube epithelium using CRISPR/Cas9 technology. These tumors capture the most common combinations of occurring mutations observed in patients. These models can identify the contribution of common driver mutations to the heterotypic interactions between cancer and stromal/immune compartments and examine how DNA repair proficiency contributes to immuneignorance.

**Results**

To validate the DNA repair proficiency of the transformed cells, we measured Rad51 nuclear focus formation after ionizing radiation (IR) and PARP-inhibition in comparison to HR-proficient cells. Initial immune/stromal analysis using flow cytometry, scRNAseq transcriptomic and immunofluorescence analysis revealed substantial differences in the myeloid and T-cell regulatory compartments between HR-proficient and -deficient primary and metastatic tumors and within the ascitic fluid. Preliminary results also suggest that inhibition of the DNA damage response, checkpoint kinase 1 in combination with immune checkpoint inhibitors, potentiates antitumor effects and augments cytotoxic T-cell infiltration.

**Conclusions**

These results reveal how common mutational drivers determine the microenvironment of the tumor and its response to treatment. Understanding
the genetic basis of these complex cellular interactions will be critical to better tailor combinations of existing targeted treatments and immunotherapies in ovarian cancer to fight this devastating disease.

Data Sharing, Handling, and Access

P535
The automated subset assignment pipeline (ASAP) for data-driven clustering and automated analysis of flow cytometry immunophenotyping
Isabelle Solman, MS, Ann Mongan, PhD, Lisa Blum, PhD Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, United States
Correspondence: Lisa Blum (lblum@pcyc.com)

Background
Characterization of heme malignancies, particularly in response to therapies, requires detailed monitoring and analysis of changes to patient immune subsets. New high-dimensional cytometry technologies have expanded the depth of data that can be collected, and several clustering algorithms have been described to improve the consistency and efficiency of associated data analysis. However, few studies have described a pipeline that is user friendly to immunologists and compared such results to validated data generated with manual gating by experts in the field. Here, we detail a flow analysis pipeline, ASAP, and demonstrate its precision and accuracy on data from a published study of over 200 clinical samples [1].

Methods
ASAP was built on several existing R packages (flowCore, flowPeaks, ggcyto, uwot) and makes use of marker enrichment modeling (MEM) scores for cell subset classification [2]. The pipeline performs data formatting and manages intermediate inputs and outputs to provide a seamless user experience. Starting with 3 input files defining panel information, preprocessing settings, and fcs files, ASAP performs preprocessing which includes data transformation, applying compensation, and removal of debris, doublets, and dead cells. Processed files are then clustered by cell markers and assigned to subsets based on MEM scores. ASAP automates the tabulation and visualization of user-defined and novel cell types. Results produced by ASAP were benchmarked with results from manual gating of a 16-color panel [1].

Results
Results produced by ASAP are highly concordant with those produced by expert manual gating, r²=0.98 (Figure 1). This high correlation is observed for major immune subsets with strong marker expression, nearly independent of cell frequency, ranging from 1%-90%. Analytical variability from 14 repeated acquisitions of the same human peripheral blood mononuclear cell sample on multiple days was low (interquartile range <10% median frequencies) and within the expected interexperiment variability (Figure 2). The typical runtime of ASAP is less than 30 minutes for a study of 20 samples at 200,000 events/sample, and less than 5 hours for a large study of 150 samples at 3 million events/sample. In comparison, the manual analysis and quality control of the same dataset would require approximately 500 hours.

Conclusions
ASAP enables the automated analysis of flow cytometry data from large studies with precision, accuracy, and reproducibility comparable to the gold standard of expert manual gating. The automation of such a pipeline allows high consistency of gating and immune cell classification, which facilitates objective evaluation of patient response over time.

Acknowledgements
Funding source: Pharmacyclics LLC, an AbbVie Company

References

Education and Treatment Management

P536
Orbital tumor board: life saver or time waster?
Irfan Jeeva, MBBS, MRCPophth (UK), FRCPophth (UK), FFBO (EU), CCT, Ayesha Butt, Medical Student
Aga Khan University Hospital, Karachi, Pakistan
Correspondence: Ayesha Butt (ayeshabutt21@outlook.com)
Background
Orbital tumour board is a multidisciplinary approach towards ophthalmic cancer management, where relevant experts collaborate to manage patients holistically. Studies corroborate the notion that tumor boards positively affect patient outcomes. However, there is a scarcity of literature on the influence of orbital tumor boards globally and about tumor boards in general in Pakistan. There is no existing literature about orbital tumor boards in Pakistan. This study aims to assess the impact of tumor boards in managing ophthalmic cancers.

Methods
A retrospective review of data was carried out on cases that were presented in the orbital tumor board of Aga Khan Hospital, the first orbital tumor board in Pakistan, from its commencement in August 2017 to May 2018.

Results
Out of a total of 80 patients in the study, 40%(n=32)were female and 60%(n=48) were male. The age of the patients ranged from 4 months to 78 years, with mean of 30 years. For analysis we divided the patients in three groups according to the nature of the diagnosis. Group 1 included those who had malignant tumours 40%(n=32), group 2 were those with benign tumours 30%(n=24) and group 3 was the non tumour group who were eventually diagnosed with other conditions 30%(n=24). Overall, 31.25% (n= 25) patients had a change in management plan, which was recorded, which included 10 patients in the malignant group, 9 in the benign group and 6 in the non tumour group.

Conclusions
A systematic review of literature has concluded that 54% of studies stated a change in management plans of at least 10% of patients post tumor board meetings. In our cohort, 31.25% of the patients had their treatment modified after tumor board discussion. The study shows that the management of ophthalmic cancers is influenced positively by tumor board discussions.

References

Consent
Consent was obtained from the patient for publication of this abstract.
Outcomes of a newly formed multidisciplinary retinoblastoma service

Ayesha Butt, Medical Student, Irfan Jeeva, MBBS, MRCOphth (UK), FRCOphth (UK), FEBO (EU), CCT
Aga Khan University Hospital, Karachi, Pakistan

Correspondence: Ayesha Butt (ayeshabutt21@outlook.com)

Background
Retinoblastoma is the most common intraocular malignancy of childhood, accounting for 3 - 4% of all pediatric neoplasms. Mortality associated with retinoblastoma in the developed world is 3% to 5% whereas in the developing world it is 40%–70%. There is scarcity of research about retinoblastoma in Pakistan. We aim to study the presentation of retinoblastoma and impact of multidisciplinary management and tumor board discussions on its treatment at a tertiary care hospital in Pakistan.

Methods
Retrospective review of retinoblastoma cases from May 2016 to April 2018 at Aga Khan University Hospital.

Results
A total of 35 eyes of 26 patients were studied with 9 presenting with bilateral retinoblastoma. 57.7% (n=15) of the population were males. The age range was 1 - 84 months (median: 14.5 months). The children presented from 3 different countries with most (76.9%, n=20) belonging to medium, upper medium or upper socioeconomic class. The most prevalent symptom was leucocoria (38.5%, n=10) followed by decreased visual response (15.4%, n=4), squint (15.4%, n=4) and positive family history (15.4%, n=4). Most of the eyes (57.1%, n=20) were Group E on presentation, followed by Group D (20%, n=7) and 17.1% (n=6) Group B. One eye each presented with Group C and A. All the eyes that presented with Group A or B were of patients who had bilateral disease with advanced stage in the other eye. 54.3% (n=19) of the eyes were treated with a combination therapy including enucleation, focal lasers and systemic chemotherapy, 20% (n=7) with only focal lasers and 17% (n=6) with only enucleation. 42.3% (n=11) of the children presented with heritable traits. One patient (3.8%) did not survive.

Conclusions
At our center we see Retinoblastoma in children with diverse background and majority presented with advanced disease. Multimodal therapy improved outcome. Awareness needs to be created for early detection and referral especially in the developing world.

Management of melanoma: education improving clinical decisions of oncologists

Haleh Kadkhoda, MS1, Jeffrey Weber, MD, PhD2, Charlotte Warren1, KINJAL PARIKH, PharmD1, Ann Carothers, MEd1
1Medscape Oncology, Houston, TX, United States; 2NYU Langone, New York, NY, United States

Correspondence: KINJAL PARIKH (kparikh@medscape.net)

Background
The evolving melanoma treatment algorithm has highlighted the role of immune checkpoint inhibitors in treating patients with this cancer. From the first drug approval in 2011 through today, many changes have occurred in treatment approaches. Selecting the most appropriate therapy with implementation of monitoring strategies for managing adverse events is vital. The goal of this study was to determine if participation in an educational activity can improve the proficiency of oncologists on the application of checkpoint inhibitors in adjuvant and metastatic melanoma.

Methods
An online continuing medical education (CME)-certified interactive, text-based activity developed by Medscape Education Oncology and the Society for Immunotherapy of Cancer included 2 patient cases, which served as the foundation for interactive questions. Educational design included a "test, then teach" approach to elicit cognitive dissonance, with evidence-based feedback provided following each learner response. A repeated pairs pre-/post-assessment study design with 3 case-based questions and 1 confidence question was used. A chi-square test assessed differences from pre- to post-assessment. P values .26 is extensive. The activity was launched online 2/25/19 and data were collected through 5/8/19.
Results
Participation in education resulted in statistically significant improvements and an extensive educational effect for oncologists (n=62; P < .001; V = .342). An average of 41% correctly responded to pre-assessment questions, increasing to 75% post-assessment. 40% of oncologists reported greater confidence prescribing immunotherapy in melanoma. Significant improvements in competency were observed in the following areas:

- Selection of an evidence-based regimen for patients with melanoma in the adjuvant setting (24% vs 73%, P < .001, V = .484, Figure 1)
- Identification of the most appropriate regimen for patients with metastatic melanoma following molecular testing (47% vs 74%, P < .01, V = .269, Figure 3)
- Implementing team-based strategies for monitoring and managing irAEs (52% vs 77%, P < .01, V = .280, Figure 2)

Conclusions
This online interactive, case-based, CME-certified educational activity resulted in significant gains in oncologist competency in identifying and selecting appropriate treatments for patients with melanoma in the adjuvant and metastatic setting, and in implementing monitoring and management strategies (Figure 4). These results demonstrate the effectiveness of on-demand education in improving the translation of clinical knowledge into practice scenarios while improving clinician confidence.

Acknowledgements
Supported by an educational grant from: Bristol-Myers Squibb Company.

References


P540
Understanding oncologist preferences for chemotherapy and immunotherapy monotherapy and combinations for first-line treatment of metastatic non-small cell lung cancer: a discrete choice experiment
Candice Yong, PhD1, Brian Seal, RPh, MBA, PhD1, Kathleen Beusterien, MS2, M. Janelle Cambron-Mellott, PhD2, Martine Maculaitis, PhD2, Kelly Clapp2, Emily Mulvihill, MEA2, Ion Cotarla, MD, PhD1, Ranee Mehra, MD3
1AstraZeneca, Gaithersburg, MD, United States; 2Kantar, New York, NY, United States; 3University of Maryland, Baltimore, MD, United States
Correspondence: Candice Yong (candice.yong@astrazeneca.com), Brian Seal (brian.seal@astrazeneca.com)

Background
While platinum-based chemotherapy doublets were the first-line (1L) standard of care for metastatic non-small cell lung cancer (mNSCLC), the treatment landscape has recently shifted with the approval of immune checkpoint inhibitors. With the availability of these newer treatment options, it is important to elucidate the risk/benefit decision-making with regards to efficacy and toxicities that underlies oncologists’ real-world practice in mNSCLC. This study aimed to quantify preferences for attributes associated with immunotherapy and chemotherapy for mNSCLC among US oncologists.

Methods
Oncologists were recruited via a healthcare research panel to complete a cross-sectional online survey. Preferences were assessed in two separate discrete choice experiments (DCEs) where oncologists chose their preferred option in a series of tasks showing two alternative treatment profiles. The profiles varied based on six attributes identified in qualitative interviews with oncologists (Table 1). In both DCEs, the attributes were based on 1L treatment of patients with PD-L1 tumor cell (TC) >=1% and PD-L1 TC >=50% expression, respectively. A Hierarchical Bayes model was applied to estimate preference weights for each level of the treatment profile attributes.

Results
Oncologists (N=216) with an average of 16 years in practice participated; 69% were in community settings, and 31% were in academic settings. Attribute preferences were similar for patients with PD-L1 TC >=1% and PD-L1 TC >=50% (Figures 1a-1b). Improvements in OS were more important relative to improvements in any other attributes evaluated. Reducing the risk of neutropenia was second most important. Preference data showed a willingness to make trade-offs between efficacy and toxicity. For example, for both PD-L1 patient groups, oncologists chose their preferred option in a series of tasks showing two alternative treatment profiles. The profiles varied based on six attributes identified in qualitative interviews with oncologists (Table 1). In both DCEs, the attributes were based on 1L treatment of patients with PD-L1 tumor cell (TC) >=1% and PD-L1 TC >=50% expression, respectively. A Hierarchical Bayes model was applied to estimate preference weights for each level of the treatment profile attributes.

Conclusions
This study provides key insights into the trade-offs that oncologists are willing to make between efficacy and toxicities when selecting 1L treatment for patients with mNSCLC. Results suggest that improvements in OS were highly valued by oncologists and required to offset increases in the risk of toxicities, particularly neutropenia and pneumonitis. These findings were observed irrespective of patient PD-L1 status, which
supports the consistency of oncologist preferences despite the differences in OS that have been observed for patients with PD-L1 TC $>=1\%$ or PD-L1 TC $>=50\%$ treated with immunotherapy regimens.

Acknowledgements
The authors acknowledge Oliver Will, PhD, and Bernadette Hallissey, PhD, for their assistance with data analysis.

Ethics Approval
This study was reviewed by the Pearl Institutional Review Board (Indianapolis, IN, US) and determined to be exempt.

Table 1 (abstract P540). Attributes and levels used for each DCE

<table>
<thead>
<tr>
<th>Attribute</th>
<th>PD-L1 TC $&gt;=1%$</th>
<th>PD-L1 TC $&gt;=50%$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median overall survival</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median progression-free survival</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 months</td>
<td>12 months</td>
<td></td>
</tr>
<tr>
<td>17 months</td>
<td>24 months</td>
<td></td>
</tr>
<tr>
<td>21 months</td>
<td>30 months</td>
<td></td>
</tr>
<tr>
<td>Risk of grade 3/4 fatigue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12%</td>
<td>12%</td>
<td></td>
</tr>
<tr>
<td>6%</td>
<td>6%</td>
<td></td>
</tr>
<tr>
<td>1%</td>
<td>1%</td>
<td></td>
</tr>
<tr>
<td>Risk of grade 3/4 diarrhea/coilis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td></td>
</tr>
<tr>
<td>Risk of pneumonitis all grades; grade 3/4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8% 3%</td>
<td>8% 3%</td>
<td></td>
</tr>
<tr>
<td>5% 3%</td>
<td>5% 3%</td>
<td></td>
</tr>
<tr>
<td>Risk of grade 3/4 neutropenia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25%</td>
<td>25%</td>
<td></td>
</tr>
<tr>
<td>24%</td>
<td>24%</td>
<td></td>
</tr>
<tr>
<td>1%</td>
<td>1%</td>
<td></td>
</tr>
</tbody>
</table>

Fig. 1 (abstract P540). See text for description

PS41
Informing and empowering cancer caregivers about immunotherapy: results from a psychoeducational workshop on immunotherapy
Maria Gonzalo1, Claire Saxton, MBA1, Alex Swales, MSW1, Alexandra Zaleta, PhD2
1Cancer Support Community, Washington DC, United States; 2Cancer Support Community, Philadelphia, PA, United States

Correspondence: Claire Saxton
(csaxton@cancersupportcommunity.org)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):PS41

Background
Providing education and support for caregivers of cancer patients improves physical, psychosocial, and quality of life outcomes for both caregivers and patients.[1-4] As the use of immunotherapy continues to expand, it is important that caregivers have access to education and community resources to support their loved ones in making informed decisions, recognizing side effects, and getting optimal care. This analysis explores gains from Cancer Support Community’s Frankly Speaking About Cancer (FSAC): Immunotherapy program, a national evidence-based educational program created for cancer patients and caregivers.

Methods
One thousand two hundred thirty-two adults attending FSAC: Immunotherapy psychoeducational workshops nationwide from 2014-2018 completed a post-workshop survey. Participants rated their pre and post-workshop immunotherapy knowledge (“How knowledgeable were/are you about immunotherapy before/after this workshop?” 1 = Not at all, 5 = Very much) as well as their level of confidence speaking to their doctor (“Before/After this workshop I spoke with/feel more confident in speaking with my doctor about immunotherapy: 1 = Strongly disagree, 5 = Strongly agree). 23% of respondents were non-professional caregivers; the remainder included cancer patients (66%), health care professionals (8%), and others (3%). This analysis focuses on 282 non-professional caregivers who self-reported background characteristics and workshop-specific outcomes (81% response rate). Descriptive analyses and paired samples t-tests were conducted to assess workshop outcomes.

Results
Of the 282 caregivers, 54% were spouses/partners, 31% family, and 15% friends. Caregivers were primarily White (72%) and female (70%); average age was 55 (s.d.= 17.6 years; range: 19-85 years). 56% of caregivers reported this was their first informational workshop. While 46% reported that immunotherapy treatment was an option for their loved one, only 9% reported speaking with their doctor about immunotherapy and its potential side effects. Post-workshop, 47% caregivers reported ‘high’ or ‘very high’ immunotherapy knowledge vs. pre-workshop (11%), a statistically significant difference in perceived knowledge (t(210)=24.05, p<.01). Caregivers also reported an increase in confidence in discussing immunotherapy and its side effects with their doctors, with 71% reporting confidence (agree/strongly agree) in speaking to their doctor about immunotherapy post-workshop vs. 24% pre-workshop (t(83)=5.8, p<.01), and 64% feeling more confident in talking with their doctor about immunotherapy’s side effects post-workshop vs. 32% pre-workshop (t(98)=8.9, p<.01). The workshop was well-received, with 87% recommending the workshop to others.

Conclusions
Results suggest that the FSAC: Immunotherapy program increases caregivers’ perceived knowledge about immunotherapy and their perceived confidence in talking to their doctor about immunotherapy. Our results highlight the potential benefits of immunotherapy education and support for cancer caregivers.

Acknowledgements
These workshops and analysis were funded in part by generous support from AstraZeneca, Bristol-Myers Squibb, and Merck.

References

Ethics Approval
This study was conducted under IRB-exempt protocols [category 45 CFR 46.101(b) 2].
**Immune Cell Biology**

**P542**

Case of an outstanding anti-cancer immune response in a microsatellite stable metastatic colon cancer

Thomas Duhnen, PhD,1 Carmen Sallesteros Merino, PhD,1 Venkatesh Rajamaricikam,2 Brady Bernard, PhD,2 Bernard Fox, PhD,2 Eric Anderson, MD, PhD,2 Philippa Newell, MD,2

1Providence Cancer Institute, Portland, OR, United States; 2Knight Cancer Institute, OHSU, Portland, OR, United States

**Correspondence:** Thomas Duhnen (thomas.duhnen@providence.org)

**Background**

Microsatellite stable colorectal cancers are known to harbor low mutation burden, a limited immune infiltration of the tumor and thereby respond poorly to immunotherapy.

**Methods**

Here we describe a case of microsatellite stable metastatic colon cancer with an outstanding anti-cancer response. Briefly, the patient was a 53-year-old man with a T4bN2aM1 metastatic colon cancer diagnosed in 2012. The primary tumor was resected at time of diagnosis and the patient underwent several cycles of chemotherapy from 2012 to 2017 in an effort to treat the multiple lesions present in the liver considered unresectable at time of surgery. In 2018, the patient’s CEA levels began to rise and he underwent a left hepatectomy to remove a slow growing mass.

**Results**

Analysis of the liver resection by flow cytometry revealed a large number of immune cells infiltrating the tumor, a phenotype distinct from the other colorectal metastases (CRLMs) we analyzed to date. Most importantly, more than 60% of the infiltrating immune cells were CD8+ T cells, one third of which co-expressed the markers CD39 and CD103, a phenotype characteristic of tumor-reactive T cells. Those CD39+CD103+ CD8 T cells expressed high levels of PD-1 and CTLA-4 and were highly proliferative in vivo as demonstrated by Ki-67 staining. Using multiplex IHC, we confirmed that this pattern was unique to the recurring CRLM and he underwent a left hepatectomy to remove a slow growing mass.

**Conclusions**

This case shows that even cancers with low tumor mutation burden can lead to strong immune responses overtime and this knowledge should be considered to establish patient’s treatment plans in the future.

**Ethics Approval**

All subjects signed written informed consent approved by the Providence Portland Medical Center Institutional Review Board (IRB protocol no. 06-108A).

**Consent**

Consent was obtained for publication of this abstract.

---

**P543**

A transcriptional signature of exhausted CD8+ T cells predicts relapse-free outcome in ER+ breast cancer patients

Colt Eggleton, PhD,1 Weihua Guo1, Christian Avolos,2 Min Hui Lim,2 Diana Simons3, Peter Lee, MD2

1Beckman Research Institute, City of Hope, Duarte, CA, United States; 2City of Hope, Duarte, CA, United States

**Correspondence:** Peter Lee (plee@choc.org)

**Background**

Estrogen receptor positive (ER+) breast cancer tumors are generally poorly immune infiltrated tumors as compared to triple negative breast cancer (TNBC). In TNBC the presence of tumor infiltrating lymphocytes (TILs) is predictive of response to chemotherapy and associates favorably with patient survival. However, in ER+ breast cancer the relationship between T cell infiltration and disease is less clear. Exhausted CD8+ T cells has been described in murine models of chronic disease and recently several human carcinomas. Here we profile human breast tumors for the functional, phenotypic, and transcriptional profile of exhausted CD8+ T cells and their correlation with survival in patients.

**Methods**

Fresh surgical tumor specimens were obtained from consented patients. Single cell suspensions were analyzed by flow cytometry for immune phenotyping and functional assessment of cytokine production by T cells. Single cell sorted T cells were subjected for whole transcriptome RNA sequencing and bulk sorted T cells were submitted for T cell receptor repertoire sequencing by Adaptive Biotechnologies. Transcriptional profiles generated from single cell sequencing were utilized for signature score analysis of outcomes in public TGCA and Metabric data sets.

**Results**

Exhausted CD8+ T cells were identified in both ER+ and TNBC. Functional and phenotypic analysis identified T cells to have a reduced capacity for IFNγ, TNFα, and IL-2 production. Further phenotyping of exhausted CD8+ T cells revealed a loss of expression of both the IL-7 receptor alpha (CD127) and KLRG1, suggesting terminal differentiation of these cells. Single cell and T cell receptor sequencing revealed distinct transcriptional and clonal signatures of exhausted CD8+ T cells. T cell receptor analysis demonstrated increased oligoclonality of exhausted CD8+ T cells as compared to other CD8+ TILs. Finally we demonstrate that a transcriptional signature of exhausted CD8+ denotes relapse-free survival in ER+ breast cancer patients.

**Conclusions**

This work is the first to demonstrate a T cell subset beneficial to survival outcomes of ER+ breast cancer patients. Immunotherapeutic interventions to expand exhausted CD8+ T cell populations may offer improved overall survival in breast cancer patients.

**Ethics Approval**

Fresh tissues were obtained from patients who gave institutional review board (IRB)-approved written informed consent prior to inclusion in the study (City of Hope IRB 05091, IRB 07047, and IRB 14346).

---

**P544**

The generation of memory CD8 T cells is regulated by intracellular Galectin-3

William Redmond, PhD, Mohammad Farhad, MS Earle A. Chiles Research Institute, Portland, OR, United States

**Correspondence:** Mohammad Farhad (farhad@ohsu.edu)

**Background**

CD8 T cells are a critical component of anti-tumor immunity and enhancing their function can promote tumor elimination. The levels of extracellular galectin-3 (Gal-3), a carbohydrate binding protein, are increased during tumor progression in many cancers and higher levels of Gal-3 are associated with a poor prognosis. Interestingly, intracellularly, Gal-3 functions through protein-protein interactions and is upregulated in T cells following T cell receptor (TCR) stimulation in the presence of IL-2. However, the function and mechanisms by which intracellular Gal-3 regulates CD8 T cell responses are poorly understood.

**Methods**

Wild type (WT) or Gal-3-deficient OT-I CD8 T cells were adoptively transferred into WT mice and then stimulated with soluble ovalbumin protein along with an agonist anti-OX40 mAb or IL-2/IL-2 mAb complexes (IL-2c). The frequency, phenotype, and effector/memory status of the adoptively transferred CD8 T cells was determined in the peripheral blood (days 7 and 14) and spleen (day 29) by flow cytometry.

**Results**

In the current study, we demonstrate that Gal-3-deficient CD8 T cells exhibited no defects in early (36 hrs) activation or proliferation. In
Expression of retention integrins by human CD4+ T cells

Kevin Lynch, MD, Marit Melssen, MSc, Walter Olson, PhD, Craig Slingluff

Journal for ImmunoTherapy of Cancer 2019; 7(Suppl 1):P545

Background

T-cell retention in epithelial tumors is mediated by transmembrane proteins (CD49a, CD49b, CD103) known as retention integrins (RI)[1]. Expression of RI correlates with cytotoxicity of CD8+ T-cells in human epithelial tumors [2-3] and with immunosuppression by regulatory T-cells in murine models [4]. Recently, we reported that RI expression by CD4+ cells was modified by exposure to IL2, IL4, IL10, and TGF-β as well as by T-cell receptor (TCR) stimulation [5]. TGFβ has also been shown to upregulate CD103 in human CD4+ memory cells [6] but investigation into RI expression by CD4+ cells has otherwise been sparse. We hypothesized that expression of RI by human CD4+ cells would be modulated by cytokines and TGFβ in a pattern similar to CD8+ cells.

Methods

Peripheral blood mononuclear cells isolated from five human donors were stimulated with mouse anti-CD3 and anti-CD28 for 24 hours. Cells were then cultured with TGFβ (5 ng/mL), IL2 (1000 CU/mL), IL4 (20 ng/mL), or IL10 (100 ng/ml) for six days. Integrin expression was quantified by flow cytometry. Data generated by flow cytometry was analyzed using FlowJo software (Tree Star), and results were compared using Student’s two-tailed t test.

Results

As shown in Table 1, TGFβ upregulated expression of CD49a and CD103 in TCR stimulated (TCR+) CD4+ cells relative to TCR+ controls (p = 0.02).

Conclusions

When comparing the expression of RI by CD4+ cells to our prior findings in CD8+ cells [5], we noted both common themes and significant differences. TGFβ upregulates CD49a and CD103 on both TCR+CD8+ and TCR+CD4+ cells. In contrast, the effects of IL2 and IL4 differ based on cell type. IL2 upregulated CD49a in TCRnegCD8+ cells but downregulated CD49a in TCR+CD4+ cells. IL4 decreased CD49a expression by TCR+ CD8+ cells, but decreased CD49a expression only in TCRnegCD4+. This heterogenous response to cytokine stimulation emphasizes the complexity of RI regulation and raises the question of whether regulation of RI expression is CD4+ subtype specific. This data supports the need for further investigation into the regulation of RI expression by CD4+Th1, CD4+Th2, and CD4+T regulatory cell populations.

Table 1 (abstract P545). Expression of Integrins by CD4+ T cells

<table>
<thead>
<tr>
<th>TCR</th>
<th>CD49a</th>
<th>CD103</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCR+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>TCR-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>IL2</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>IL4</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>TGFβ</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

Table adapted from original research. 

P546

Immunoprofiling myeloid-derived suppressor cells in non-small cell lung carcinomas using multiplex immunofluorescence and image analysis approaches

Edwin Parra, MD, PhD; Mei Jiang, Cara Haymaker, PhD, Jieying Zhang, PhD, Tong Li, Carmen Behrens, MD, Chantale Bernatchez, Auriole Tamegnon, Renganayaki Pandurenga, Jack Lee, PhD, John Heymach, Cesar Moran, MD, Ignacio Wistuba, MD

Correspondence: Edwin Parra (eparra@mdanderson.org)


Background

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that consists of myeloid progenitor cells and immature granulocytes or polymorphonucleares (PMN), immature macrophages (M), and immature dendritic cells (DCs). MDSCs play a critical role in tumor-associated immunosuppressive function, which is important in the effective immunotherapies for cancer. The aim of this study was to analyze full range of MDSCs to investigate their role in the microenvironment of non-small cell lung carcinomas (NSCLCs).

Methods

TMAs containing 247 patients with stage II/III NSCLCs (adenocarcinomas, ADC=162; squamous cell carcinomas, SCC=85) were analyzed using a multiplex immunofluorescence panel contained CD68, CD163, CD11b, CD14, HLA-DR, CD3, CD8, and CD4.
CD11b, Arg-1, CD66b, CD33, CD14, and a pancytokeratin (Figure 1). Densities of different phenotypes and neighbor distances were correlated with clinicopathologic features and outcomes.

**Results**

Using the median density of MDSCs we identified overall higher densities of those cells in SCC than ADC, with significant P value of total granulocytic (CD66b+CD11b+, P=0.016) cells, PMN-MDSCs (CD11b+CD66b+CD33+, P=0.021), and M-MDSCs (CD11b+Arg1+CD14+CD33+, P=0.009, Figure 1 and Table 1). In ADCs the densities of M2 macrophages (CD68+Arg1+CD11b+) were higher in solid pattern than other histologic patterns (acinar, lepidic, papillary, P=0.038); and the total macrophages CD68+ were higher in solid pattern than other histologic patterns (acinar, lepidic, papillary, P=0.038) and the total macrophages CD68+ were higher in stage III than in stage I and II (P=0.075), Figure 2. Current smokers was showed higher densities of PMN-MDSC than never-smokers (P=0.031). In addition, EGFR mutant tumors had fewer M2 macrophages, total granulocytic and M-MDSCs than WT patients tumors (P=0.009, P=0.009 and, P=0.043; respectively, Figure 2). A 10μm distant radius from malignant cells compared with the other distant showed analyzed higher densities of CD66b+ and CD68+CD11b+ myeloid cells in smaller and EGFR mutant tumors than in larger (P=0.024 and P=0.028; respectively) and WT (P=0.039 and P=0.034; respectively) tumors in ADC. Similarly, higher densities of PMN-MDSCs were observed in stage II tumors than stage I and III in SCC (P=0.029) at this distance. Patients with ADC and a high number of total granulocytic cells (P=0.081) showed worse prognosis than patients with lower total granulocytic cells.

**Conclusions**

While SCCs showed the highest densities of MDSCs as compared to ADCs, our data suggest MDSCs are related with clinicopathologic characteristics that can increase the risk of tumor progression, such as solid pattern, advanced stage, smoking status and prognosis. Additional studies need to be done to understand better the role of MDSCs in lung cancer.

**Ethics Approval**

The study received approval from the MD Anderson Cancer Center Institutional Ethics Review Board. The Lung Cancer Moon Shot projects through the National Cancer Institute’s Cancer Center Support Grant (P30CA016672), and a grant from the Cancer Prevention and Research Institute of Texas (MIRA-RP160688).

**Table 1 (abstract P546).** See text for description

<table>
<thead>
<tr>
<th>Phenoype/Markers</th>
<th>ADC (N=162)</th>
<th>SCC (N=45)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median Cell Density (cells/mm³)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignant cells, Pancytokeratin+</td>
<td>3137.00</td>
<td>3918.67</td>
<td>0.192</td>
</tr>
<tr>
<td>Macrophages, CD68+</td>
<td>423.50</td>
<td>485.33</td>
<td>0.692</td>
</tr>
<tr>
<td>Dendritic cell macrophages, CD68+CD11b+</td>
<td>231.80</td>
<td>188.50</td>
<td>0.297</td>
</tr>
<tr>
<td>M2 macrophages, CD68+Arg1+</td>
<td>0.42</td>
<td>0.88</td>
<td>0.122</td>
</tr>
<tr>
<td>Total granulocytic cells, CD68+CD11b+</td>
<td>0.33</td>
<td>12.33</td>
<td>0.016</td>
</tr>
<tr>
<td>PMN-MDSC, CD11b+CD66b+CD33+</td>
<td>1.82</td>
<td>3.50</td>
<td>0.021</td>
</tr>
<tr>
<td>M-MDSCs, CD11b+Arg1+CD14+CD135+</td>
<td>0.01</td>
<td>1.00</td>
<td>0.009</td>
</tr>
</tbody>
</table>

Note: Adenocarcinoma, SCC, Squamous cell carcinoma, SSC, Polymorphonuclears, PMN, Monocytes, M
* Mann Whitney U test

**Fig. 1 (abstract P546).** See text for description

**Fig. 2 (abstract P546).** See text for description

**Conclusion**

Distinct B cell signatures and tertiary lymphoid structures are driven by two etiologies in head and neck cancer.

Ayana Ruffin, MS, Anthony Cillo, PhD, Sayali Onkar, Sheryl Kunning, Robert Ferris, MD, PhD, Dario Vignali, PhD, Tullia Bruno, PhD University of Pittsburgh, Pittsburgh, PA, United States

**Correspondence:** Tullia Bruno (tbruno@pitt.edu)

**Journal for ImmunoTherapy of Cancer** 2019, 7(Suppl 1): P547

**Background**

Current FDA-approved immunotherapies aim to reinvigorate CD8+ T cells, but the contribution of the humoral arm of the immune response in human cancer remains poorly understood [1,2]. B cells can mediate anti-tumor immunity by presenting antigen , producing tumor-specific antibodies and immunomodulatory cytokines [3-5]. Head and neck squamous cell carcinoma (HNSCC) can be induced by human papillomavirus (HPV+) and carcinogens (HPV-), and the immune infiltrate in the two etiologies has been reported to be distinct, in particular, more B cells in HPV+ HNSCC patients [6]. Further, the presence of B cells in HNSCC correlates with increased patient survival [6]. Our study seeks to differentiate B cell phenotype and function in HPV+ and HPV- HNSCC and identify putative immunotherapeutic targets.

**Methods**

We utilized a multi-level approach to categorize B cells in HNSCC patients. Single cell RNA sequencing (scRNAseq) was performed on CD45+ tumor infiltrating lymphocytes (TIL) and peripheral blood leukocytes (PBL) from HPV+ and HPV- HNSCC patients. Data was analyzed using the Seurat R toolkit in R studio. HNSCC TIL and PBL were stained via multiparameter flow cytometry panel using the Cytek Aurora to allow for unbiased analysis of B cell subsets via computational spectral unmixing. Paraffin embedded slides from HNSCC primary tumors were utilized for single parameter immunohistochemistry of CD20 (n=25 each for HPV+ and HPV- disease), and multispectral immunofluorescence was performed on matched tumors from scRNAseq for CD20, CD4, CD8, CD68, PanCK, DAPI and Foxp3.

**Results**

We demonstrated distinct trajectories for B cells in HPV+ and HPV- disease. B cell signatures in HPV- HNSCC patients were predominantly memory B cells and plasma cells, while the signatures in HPV+ HNSCC were naive and germinal center B cells. We quantified B cells and CD4 T cells in tertiary lymphoid structures (TLS), and the presence of germinal center-rich TLS was associated with HPV+ disease. GC-rich TLS within the tumor bed of HPV+ patients correlated with increased overall survival. Independent of HPV status, we have identified an atypical B cell signature increased in the HNSCC TME compared to healthy and inflamed tonsil tissue with no cancer. This atypical B cell subpopulation is also elevated in the periphery of patients with advanced, metastatic disease.

**Conclusions**

Characterization of B cell phenotype and function in HNSCC is important for devising new therapeutic options for patients.
Development of therapeutics to enhance B cell responses in the TME should be prioritized as a compliment to T-cell mediated therapies.

References

Ethics Approval
This study was approved by the local Institutional Review Board under protocol UFCI 99-069, and patients provided informed consent.

P548
Beyond a cell metabolite: glutamate receptor signaling improves antitumor T cell immunity
Anil Shanker, PhD , Maria Teresa De Aquino, PhD2, Thomas Hodo, MS2, Roman Uzhamchenko, PhD MD2
Meharry Medical College School of Medicine, Nashville, TN, United States
2Meharry Medical College Medical School, Nashville, TN, United States
Correspondence: Anil Shanker (ashanker@mmc.edu)

Background
The interaction between the central nervous system and immune system underscores an intricate neuro-immune network.

Methods
We were intrigued by the expression of glutamate receptors (GluRs), particularly ionotropic GluR3 (AMPAR subtype 3, GluA3) and metabotropic GluR1 on T-lymphocytes, which were upregulated following TCR activation. We blocked group I metabotropic Glur and AMPA by specific antagonists during T-cell stimulation and analyzed various parameters of T-cell functions in vitro and tumor-bearing mice.

Results
We found a delayed CD8+T-cell activation exhibited by downregulated CD25, CD69 and CD44 molecules, resulting in impaired proliferation and cytolytic activity against orthotopic mammary tumors expressing a cognate low-avidity antigen in vivo or specific peptide-loaded target cells in vitro. While Glur+CD8+T-cell frequency ranges about 30% of total CD8+T-cells, treatment with glutamate receptor antagonists profoundly affects T-cell functions. These effects are mediated by transient reduction in phosphorylation of molecules such as Lck/Akt as well as calcium, indicating interaction between TCR and Glur.

Conclusions
Data suggest a costimulatory effect of Glur on T-cell function. Therefore, optimized glutamate agonists may overcome immunosuppression in tumor microenvironment and boost antitumor T-cell therapy.

P549
Identifying the host immune response in adult undifferentiated pleomorphic sarcoma
Rosanna Wustrack, MD, Evans Shao, Ross Okimoto, Lawrence Fong, MD
University of California San Francisco, San Francisco, CA, United States
Correspondence: Rosanna Wustrack (rwustrack@gmail.com)

Background
Undifferentiated Pleomorphic Sarcoma (UPS) is the most common STS subtype in older adults. Despite advancements in systemic treatment for other solid tumors, 5- and 10-survival has remained stagnant for advanced stage UPS. With the development of immune-based therapeutic strategies, it is becoming increasingly clear that the microenvironment plays a critical role in the surveillance and potential elimination of nascent tumor cells [1]. In STS for example, subtype specific effects of checkpoint inhibition were observed in patients with UPS, suggesting that UPS derived antigens modulate tumor-specific adaptive immune responses [2]. While lymphocyte subtypes have been quantified in large panels of STS patients, these studies are hampered by the diverse heterogeneity and relatively small numbers of UPS patients analyzed [3]. We aimed to identify tumor infiltrating immune cell subset and tumor specific antigens in UPS using a robust and well-validated multi-parameter flow cytometry platform and determine if there was any correlation between the immune phenotype and other recognized prognostic factors such as tumor size and depth.

Methods
All patients undergoing resection of grade 2 or 3 UPS were eligible for inclusion. We performed single cell multi-parameter flow cytometry using 15 immune-based markers. tSNE plots were used to demonstrate the relative immune landscape within UPS tumors. The relative frequency of tumor infiltrating lymphocytes were then correlated with clinical outcomes data.

Results
From January 1, 2017, to July 31, 2019, 20 resected UPS specimens were collected and successfully immunoprofiled using well-validated multi-parameter flow based cytometry. We identified an increased frequency of CD8+ tumor infiltrating lymphocytes in smaller tumors (8cm) representing 25.82% and 15.01% respectively (Figure 2).

Conclusions
We were able to successfully identify the tumor infiltrating immune cell subsets in 20 freshly resected extremity undifferentiated pleomorphic sarcoma specimens. Lymphocytes represented a greater proportion of the immune cell population in smaller tumors compared to larger tumors; specifically, CD8+ T cells were seen at a lower frequency in the tumors greater than 8cm compared to those less than 8cm. As patients with high grade tumors greater than 8cm historically have had worse outcomes, this data shows that the host immune environment may play a role in these clinical outcomes and could be a future target for sarcoma immunotherapy (Figure 3).

References
Background

Although immunotherapy with PD-1/PD-L1 antagonists has significantly advanced patient care, the majority of cancer patients currently do not benefit from checkpoint inhibitor therapies. To identify novel targets for the treatment of PD-1 insensitive cancers, we developed a novel Immune-CRISPRomics platform that enabled genome-wide CRISPR/Cas9 screens in primary T cells in an in vivo setting.

Methods

In vivo genome-wide CRISPR/Cas9 screens were conducted by introducing sgRNA libraries into Cas9-expressing TCR-Tg T cells, followed by adoptive transfer into tumor-bearing hosts. Targets enabling enhanced TCR-Tg T cell function in the context of the tumor microenvironment were identified and validated by follow-on efficacy studies.

Results

Our CRISPRomics platform identified clinically active molecules, such as PD-1, and also predicted recent clinical failures. In addition, we identified multiple targets that enhanced anti-tumor T-cell function similar to or better than PD-1 as a monotherapy. The anti-tumor activity of targets was assessed across a collection of PD-1 sensitive and PD-1 refractory syngeneic tumor models. One of the targets identified, IO-7, was found to possess robust activity across multiple PD-1 refractory models. We found that inhibition of IO-7 leads to long-term T-cell memory and prevents tumor growth upon re-challenge. Moreover, mechanistic follow-up studies demonstrate that IO-7 inhibition leads to an expansion of central memory T-cell subsets, which have been implicated in driving the durable clinical response of checkpoint inhibitors. We then extended these findings further with an in-vivo double CRISPR screen to examine more than 2,000 pairwise combinations of active sgRNAs in vivo. These combination studies identified CD8 T-cell gene pairs that when inactivated gave anti-tumor activity that exceeded any single gene inactivation from the primary screen and greatly exceeded the efficacy of PD-1 monotherapy.

Conclusions

We describe an Immune-CRISPRomics platform which 1) identified multiple functional targets with therapeutic promise and 2) functionally screened combinations of these targets to reveal the most potent T-cell target combinations for the treatment of PD-1 resistant solid tumors.
compared to their peripheral blood counterparts. Despite the recent identification of a core signature for tissue resident memory T cells (TRM), a definitive bone marrow-resident T cell phenotype has yet to be identified.

**Methods**

Here, we used multiparametric flow cytometry to perform single-cell analysis on CD8+ T cells from MM patients to identify those subsets that are enriched in the bone marrow (BM) compared to peripheral blood (PB).

**Results**

The activation and tissue retention marker CD69 identified a population of CD8+ MILs that is virtually absent in PB and displays peculiar phenotypic and functional features compared to its CD69-negative counterpart. Despite the virtual absence of CD103 expression, CD69+ MILs displayed increased levels of CXCR6 and variable levels of CD101, thereby sharing resemblance with the canonical TRM phenotype. Interestingly, CD101 has been associated with both tissue residency and exhaustion. As such, its variable expression may depend on MM burden. CD69+ MILs consistently displayed high levels of the bone marrow homing chemokine receptor, CXCR4 and low/absent expression of the follicular marker, CXCR5. The expression pattern of these extracellular markers further characterizes the BM-resident phenotype and suggests a unique role for the BM microenvironment in anti-tumor immunity. Analysis of exhaustion and senescence markers clearly separated the CD69+ MILs population from both PBL and CD69- T cells because of intermediate expression of exhaustion markers such as TIGIT, TIM3, and PD1, increased CD27, and markedly reduced CD57 levels. This unique phenotype is associated with preserved cytotoxic activity and proliferative capacity. In human T cells, TCF1 and T-bet have a reciprocal gradient of expression. Stem-like features are associated with increased TCF1 and reduced T-bet levels. Interestingly, CD69+ MILs were enriched for TCF1+ and T-bet low T cells suggesting the presence of a stem-like subset in the BM of MM patients. As a whole, CD69+ MILs are distinct from their PB and CD69- counterparts as they uniformly displayed higher levels of TCF1, CD27, CXCR6 and high CXCR4 levels and reduced expression of both CD57 and T-bet.

**Conclusions**

In conclusion, we identified a subset of MILs that appears to display a stem-like/resident phenotype. Studies are ongoing to determine whether this population can be exploited and/or enriched to improve the efficacy of adoptive T cell therapy with MM, especially in the post-transplant setting where activated MILs therapy has already been proven feasible.

---

**P552**

A translational platform to assess immunomodulation of the tumor microenvironment

Louise Brackenbury, PhD1, Robert Nunan2, Anna Willox2, Michelle Yap2, Laura McMillan3, Louise Brackenbury2, S. Rhiannon Jenkinson, PhD2

1Charles River Portishead, Bristol, United Kingdom; 2CRL Portishead, Bristol, United Kingdom

**Correspondence:** S. Rhiannon Jenkinson (rhiannon.jenkinson@crl.com)

*Journal for ImmunoTherapy of Cancer* 2019, 7(Suppl 1):P552

**Background**

The tumor microenvironment (TME) is a complex network, consisting of the tumor, blood vessels, stromal and immune cells, and soluble factors. The immune system plays an important role in combating tumor growth and various tractable immuno-oncology targets have been identified. We have developed a range of primary human assays to model the TME in vitro, this provides a multi-cellular platform in which to study the mode of action of novel immune-modulators and to identify biomarkers before moving into the clinic. This platform models multiple aspects of anti-tumor immune responses and has been validated with standard of care therapeutics. The assays include: T cell or NK cell-mediated tumor killing, myeloid/macrophage assays, exhausted T cells, Th1/Th17/iTreg differentiation and regulatory T cell suppression assays.

**Methods**

The ability of therapeutics to reverse or inhibit T cell exhaustion was performed using primary human cells. T cell-mediated tumor killing using Pembrolizumab and Ipilimumab (P/I) as controls, or 3D tumour cell spheroid ADCC assays (Trastuzumab control) were performed using an IncuCyte. Myeloid/macrophage cells were differentiated from monocytes in tumor-conditioned media (TCM), phenotyped and tested for their phagocytic capability using anti-CD47 as a control. The TME is associated with increased Treg numbers and low frequency of Th1 or Th17 cells. Many therapeutics aim to shift the balance away from Treg, towards Th1 or Th17 cells. Naïve CD4+ T cells were therefore differentiated into iTreg, in the presence or absence of a USP7 inhibitor to examine if iTreg differentiation altered.

**Results**

PI enhanced tumour cell killing in a 2D co-culture assay. Trastuzumab drove enhanced ADCC-mediated killing in a 3D spheroid format. TCM drove the generation of macrophage similar to tumour associated macrophage, CD25lo, CD127lo, CD184hi, CD80lo, CD163hi, CD68lo and MHCIIlo, produced IL-10 and VEGF and were suppressive. Reduced iTreg generation, without significant alteration in Th1/Th17 frequencies was observed in the presence of the benchmark compound and resulting iTreg were less suppressive compared to non-treated cells. nTreg suppression assays were performed and the USP7 inhibitor had a partial effect.

**Conclusions**

We present an immuno-oncology platform to model the TME in human cells which enables a rapid assessment of the immunomodulatory capacity of therapeutics. The 3D assays represent a more complex system in which to support translational drug discovery, sitting alongside T cell mediated tumor killing, myeloid/macrophage assays, Th1/Th17/ iTreg differentiation and nTreg assays. Together these assays help to define diverse aspects of the immune response in the TME.

**Ethics Approval**

The study was approved by HRA NRES South West, Bristol (UK), approval number 15/SW/0029.

---

**P553**

Platelets as immune suppressors in anti-cancer immune responses

Ana Micaela Carnaz Simoes, MSc, Morten Holmström, PhD, Madis Andersen, PhD, Per Thor Straten, PhD

Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Copenhagen, Denmark

**Correspondence:** Ana Micaela Carnaz Simoes (ana.micaela.carnaz.simoes@regionh.dk)

*Journal for ImmunoTherapy of Cancer* 2019, 7(Suppl 1):P553

**Background**

Platelets (PLTs) are well-known players during cancer progression. For several cancers, an increased number of circulating PLTs correlates with poor prognosis. Not only can these cells modulate angiogenesis and directly bind cancer cells to facilitate the metastatic process, but they can also of macrophages from inflammatory attack by mechanisms that are poorly understood [1,2]. Studies in the auto-immunity field, have shown that PLTs form aggregates with T cells, downregulating T cell activation, proliferation and interferon-γ production [3,4]. Nevertheless, no similar studies have been conducted in the context of cancer.

**Methods**

We investigated the presence of circulating PLT-lymphocytes aggregates in solid and haematological cancers. Furthermore, we assessed the effect of PLT binding on T cell proliferation and phenotype. To that purpose, cryopreserved peripheral blood mononuclear cells were analyzed by multicolor flow cytometry and fluorescent microscopy for PLT-T cell aggregates, as well as CD4 and CD8
subpopulations. Lastly, to evaluate the effect PLT binding on T cell anti-tumor reactivity, in vitro cytotoxic response was continuously monitored for 40 hours, using the xCELLigence technology.

Results

Our preliminary results show that, compared to healthy donors, cancer patients have an increased number of PLT-lymphocyte aggregates, specifically CD8+ T cells. Furthermore, PLTs seem to bind preferentially to a specific T cell phenotype and modulate T cell tumor reactivity. Data will be further discussed in detail at the meeting.

Conclusions

These results suggest that binding of PLTs have an impact on T cell activity, which could greatly influence the immune response against tumors. However, further studies are needed to confirm our preliminary results.

References


P554

Divergent fates of antigen-specific CD8+ T cell clones in mice with acute myeloid leukemia

Xuifen Chen, PhD1, Blake Flood, BS2, Brendan MacNabbi1, Bruce Blazar, MD2, Justin Kline, MD3
1The University of Chicago, Chicago, IL, United States; 2University of Minnesota, Minneapolis, MN

Correspondence: Justin Kline (jkline@medicine.bsd.uchicago.edu)

Background

We have previously demonstrated that high-affinity, leukemia-specific CD8+ T cells are efficiently deleted in leukemia-bearing hosts in a manner that depends on cross-presentation of the antigen by splenic Baf3-lineage dendritic cells [1,2].

Methods

Here, we generated a T cell receptor transgenic mouse strain (Tg101) that expresses TCR-α and -β chains from a CD8+ T cell clone specific for a native H-2Kb-restricted antigen on C1498 leukemia cells.

Results

In naïve mice, Tg101 thymocytes predominantly develop along the CD8+ lineage, and exist as naïve CD8+ T cells in peripheral lymphoid organs. Tg101 T cells do not recognize other H-2Kb tumor lines in vitro, suggesting that their cognate antigen may indeed be leukemia-specific. In leukemia-bearing mice, high-affinity 2C CD8+ T cells specific for the H-2Kb-restricted model antigen, SIYRYYGL, rapidly encounter antigen naïve 3-4 M H-2Kb-luciferase antigen presenting cells. Cross-presentation by splenic CD8α+ DCs, proliferate briefly, and are largely deleted by day 14. Conversely, antigen encounter by Tg101 CD8+ T cells in mice with C1498 leukemia is delayed (day 7-8), and primarily occurs in the liver - a prominent site of leukemia progression. Subsequently, Tg101 T cells expand, upregulate expression of co-inhibitory receptors (PD-1, LAG-3, TIM-3 and TIGIT), adopt a transcriptional program enriched for upregulation of known genes associated with T cell anergy/exhaustion (Cibl, Egfr2, Cldn4, Pdcd1, Tox) and produce effector cytokines poorly, all consistent with the acquisition of a dysfunctional state. Antigen-experienced Tg101 T cells isolated from leukemia bearing mice fail to expand upon transfer into secondary C1498 cell-challenged mice, suggesting that the dysfunctional state induced in Tg101 T cells becomes irreversible at some point. Surprisingly, antigen encounter by Tg101 T cells in leukemia-bearing mice occurs independently of CD11c+ cells, suggesting that cross-presentation of the Tg101 antigen is not required for in vivo proliferation. Ex vivo cross-presentation assays also fail to demonstrate detectable cross-presentation of the Tg101 antigen by DCs subsets isolated from leukemia-bearing mice. Rather, in vivo Tg101 T cell proliferation is strikingly blunted in mice harboring H-2Kb-/- C1498 AML cells, suggesting that the antigen is directly presented to Tg101 T cells.

Conclusions

Collectively, our results reveal that CD8+ T cell tolerance is effectively generated in leukemia-bearing animals. However, the nature of the leukemia antigen and the context in which it is presented are critical factors in dictating the underlying mechanism of tolerance that ensues. A search for the Tg101 antigen and investigation of the epigenetic landscape of naïve versus tolerized Tg101 T cells are ongoing.
upregulate a module of functional receptors that mark highly suppressive intratumoral Tregs, including TIGIT, ICOS, and CCR8, as well as a network of TNFRSF members. Correspondingly, NRP1+ Tregs suppress cytotoxic T cell proliferation to a greater degree than their NRP1- counterparts, which can be inhibited using blocking antibodies. NRP1+ Tregs are enriched in vitro in low interleukin-2 (IL-2) conditions as well as upon T cell activation. Proinflammatory cytokine exposure, such as IFNγ, increases NRP1 expression in a subset of cancer patient samples.

**Conclusions**

NRP1+ Tregs constitute a more suppressive human Treg subset based on their enhanced regulatory phenotype and function. Given the increased expression of proliferation and survival markers, especially under destabilizing conditions, NRP1 confers a survival advantage to these Tregs, allowing them to persist and function amidst such signals. Therefore, destabilizing intratumoral Tregs with NRP1 blockade may complement other T cell therapies such as anti-PD1 blockade.

---

**References**


---

**P556**

**Sex-based differences of the intratumoral immune-infiltrate**

Fabio Conforti1, Laura Pala1, Vincenzo Bagnardi2, Eleonora Pagan3, Giuseppe Viale1, Tommaso De Pas, MD, Elisabetta Fenacchi1, Paola Queirolo1, Emilia Cocococchio1, Pier Francesco Ferrucci, MD1, Filippo de Marinis1, Adriana Albini1, Richard Gelber4, Aron Goldhirsch1, Fabio Conforti, MD1

1European Institute of Oncology, Milan, Italy; 2University of Milan-Bicocca, Milan, Italy; 3Multimedica, Milan, Italy

**Correspondence:** Fabio Conforti (fabio.conforti@ieeo.it)


**Background**

We previously demonstrated that patients’ sex is a variable that influences the response to anticancer immunotherapy: in RCTs comparing immunotherapy-containing regimens to standard treatments in several solid tumors, men obtained larger survival benefit than women when treated with anti-CTLA4 or anti-PD-1 drugs as monotherapy, whereas women experienced larger benefit from anti-PD-1 or anti-PD-L1 combined with chemotherapy.[1,2]

We hypothesized that such heterogeneity of response is due to differences in the molecular mechanisms that govern anticancer immune-response in men and women.

**Methods**

We analyzed 7 public datasets containing data on genome-wide RNA expression analysis of NSCLC samples.[3-9] We used gene-expression data to estimate the abundance of 64 different cell-types in the microenvironment of each tumor sample, using single sample gene-set enrichment analysis (ssGSEA) according to a previously validated computational algorithm.[10,11]

**Results**

We found relevant sex-based differences in the cell-type composition of the immune-infiltrate of NSCLC. The higher levels of immune-suppressive cells, such as GMP, Macrophage-M2 and Regulatory T-cells observed in tumors of women may explain lower efficacy of anti-CTLA4 or anti-PD1 given as monotherapy, and the need to add chemotherapy to counteract their inhibitory effects.

**References**

P557

A2R contributes to adenosine-mediated immunosuppression, which is relieved by the dual A2AR/A2bR antagonist AB928

Daniel DiRenzo, PhD, Kristen Zhang, BS, Sean Cho, PhD, Sachie Marubayashi, Dana Piovesan, MSC, Jesus Banuelos, Joanne Tan, PhD, Alksha Udayavar, PhD, Jenna Jeffrey, PhD, Mannochan Leleti, PhD, Jay Powers, PhD, Matthew Walters, PhD

Arcus Biosciences, Inc., Hayward, CA, United States

Correspondence: Matthew Walters (mwalters@arcusbio.com)


Background

The tumor microenvironment (TME) generates high levels of adenosine which binds to A2aR and A2bR receptors on immune cells to inhibit their activity. We have previously shown that AB928, a dual A2aR/A2bR antagonist, blocks the immunosuppressive effects of adenosine in human cultured cells and mouse syngeneic tumors. Herein, we describe studies to assess the contribution of A2bR to adenosine-mediated immunosuppression.

Methods

CD14+ monocytes were differentiated with IL-4/GM-CSF for 6 days to generate monocyte-derived dendritic cells (moDC). Cells were taken for NanoString analysis or placed in a mixed lymphocyte reaction (MLR) with CD4+ T cells. PBMCs were activated with CD2/3/28 beads +/- NECA or CGS-21680 for 24 hours and supernatants run on a CXCL5 ELISA.

Results

Using publicly-available gene expression databases, we identified that T cells and other non-myeloid cells predominantly express the A2a adenosine receptor. In contrast, most myeloid cells express both A2aR and A2bR with cross-presenting CLEC9A+ dendritic cells (DCs) having the highest levels of A2bR. This pattern of adenosine receptor expression makes DCs a prime target for dual adenosine receptor antagonism in the TME. Experiments in vitro showed that moDC have the highest levels of A2bR expression compared to other cultured cells such as monocytes and macrophages. As expected, adenosine-differentiated moDC showed a decreased ability to stimulate IFN-γ secretion in a MLR. Notably, AB928 attenuated IFN-γ suppression by adenosine and showed significantly greater rescue than a comparable A2aR-specific antagonist. NanoString gene expression profiling identified 39 genes (>2.0 fold change, p <0.05) regulated by adenosine in moDC. These gene expression changes were largely rescued with AB928 but not significantly changed with the A2aR-specific antagonist. Importantly, stimulation of primary human DCs with the dual A2aR/A2bR agonist NECA reproduced several of the adenosine-driven gene expression changes observed in moDC.

To further highlight the importance of A2bR, NECA or the A2aR-specific agonist CGS-21680 were added to human PBMC cultures. Both agonists significantly upregulated the ligand CXCL5 with equivalent rescue by AB928 and the A2aR-specific antagonist when stimulated by CGS-21680. However, upon NECA stimulation, AB928 showed significantly greater inhibition of CXCL5 compared to the A2aR-specific antagonist (86% vs 72% of control, p<0.01), demonstrating that A2bR signaling in PBMCs significantly contributes to gene expression changes.

Conclusions

Collectively, these studies demonstrate an important role for A2bR in adenosine-mediated immunosuppression and provide a mechanistic rationale for stimulation of anti-tumor immune responses with the dual adenosine receptor antagonist AB928, which is currently undergoing evaluation in several Phase 1/1b trials.

P558

Novel expression programs of immune-tumor-stroma identified in inflamed head and neck cancer microenvironment profiling using single cell RNA sequencing (scRNaseq)

Corinellus Kürten, MD, 1 Adeel Kulkarni, PhD, 2 Lazar Vujanovic, PhD, 3 Xueer Chen, 3 Anthony Cillo, PhD, 3 Xinghua Lu, 3 Robert Ferris, MD, PhD 2, 3

1University of Essen, Essen, Germany; 2UPMC Hillman Cancer Center, Pittsburgh, United States; 3University of Pittsburgh, Pittsburgh, United States

Correspondence: Robert Ferris (ferrisrl@upmc.edu)


Background

The tumor microenvironment (TME) generates high levels of adenosine which binds to A2aR and A2bR receptors on immune cells to inhibit their activity. We have previously shown that AB928, a dual A2aR/A2bR antagonist, blocks the immunosuppressive effects of adenosine in human cultured cells and mouse syngeneic tumors. Herein, we describe studies to assess the contribution of A2bR to adenosine-mediated immunosuppression.

Methods

CD14+ monocytes were differentiated with IL-4/GM-CSF for 6 days to generate monocyte-derived dendritic cells (moDC). Cells were taken for NanoString analysis or placed in a mixed lymphocyte reaction (MLR) with CD4+ T cells. PBMCs were activated with CD2/3/28 beads +/- NECA or CGS-21680 for 24 hours and supernatants run on a CXCL5 ELISA.

Results

Using publicly-available gene expression databases, we identified that T cells and other non-myeloid cells predominantly express the A2a adenosine receptor. In contrast, most myeloid cells express both A2aR and A2bR with cross-presenting CLEC9A+ dendritic cells (DCs) having the highest levels of A2bR. This pattern of adenosine receptor expression makes DCs a prime target for dual adenosine receptor antagonism in the TME. Experiments in vitro showed that moDC have the highest levels of A2bR expression compared to other cultured cells such as monocytes and macrophages. As expected, adenosine-differentiated moDC showed a decreased ability to stimulate IFN-γ secretion in a MLR. Notably, AB928 attenuated IFN-γ suppression by adenosine and showed significantly greater rescue than a comparable A2aR-specific antagonist. NanoString gene expression profiling identified 39 genes (>2.0 fold change, p <0.05) regulated by adenosine in moDC. These gene expression changes were largely rescued with AB928 but not significantly changed with the A2aR-specific antagonist. Importantly, stimulation of primary human DCs with the dual A2aR/A2bR agonist NECA reproduced several of the adenosine-driven gene expression changes observed in moDC.

To further highlight the importance of A2bR, NECA or the A2aR-specific agonist CGS-21680 were added to human PBMC cultures. Both agonists significantly upregulated the ligand CXCL5 with equivalent rescue by AB928 and the A2aR-specific antagonist when stimulated by CGS-21680. However, upon NECA stimulation, AB928 showed significantly greater inhibition of CXCL5 compared to the A2aR-specific antagonist (86% vs 72% of control, p<0.01), demonstrating that A2bR signaling in PBMCs significantly contributes to gene expression changes.

Conclusions

Collectively, these studies demonstrate an important role for A2bR in adenosine-mediated immunosuppression and provide a mechanistic rationale for stimulation of anti-tumor immune responses with the dual adenosine receptor antagonist AB928, which is currently undergoing evaluation in several Phase 1/1b trials.

Fig. 1 (abstract P556). See text for description
Metastatic osteosarcoma utilizes multiple inhibitory checkpoint molecules and immunosuppressive myeloid cells to inhibit the cytotoxic effect of tumor-infiltrating lymphocytes

John Ligon, MD, Teniola Oke, Woonyoung Choi, Gady Cojocaru, Compugen, Holon, Israel
Correspondence: John Ligon (jligon1@jhmi.edu)

Background
Patients with metastatic osteosarcoma (OS) have 5 year overall survival <25% [1]. We aim to understand the immune architecture of the tumor microenvironment (TME) of OS, with the goal of harnessing the immune system as a major therapeutic strategy for the treatment of patients with OS.

Methods
Immunohistochemistry (IHC) slides from 66 formalin-fixed paraffin-embedded OS tissue blocks were digitally analyzed. Laser capture microdissection and RNA extraction was performed on 13 OS specimens, and gene expression profiles were obtained utilizing RNA seq and analyzed. Tumor infiltrating lymphocytes (TILs) were isolated from 25 freshly obtained OS specimens and analyzed by multiparameter flow cytometry (MFC).

Results
Digital image analysis of IHC demonstrated significantly higher infiltrating immune infiltrating cells in the pulmonary metastases compared to primary bone tumors, particularly at the tumor-normal lung interface. There is increased expression of multiple immune checkpoint molecules at the interface, including programmed cell death 1 (PD-1), T cell immunoglobulin mucin-3 (TIM-3) and lymphocyte activation gene 3 (LAG-3) (Figure 1). Gene expression profiling revealed increased CD8 T cell and resting CD4 memory T cell signature at the interface compared to the tumor interior, and a strong M2 macrophage signature in both regions. Genes related to neutrophil and myeloid cell chemotaxis and known to be associated with polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) were shown to be highly expressed in the interface region (Figure 2). MFC revealed that TILs isolated from pulmonary metastases had higher expression of PD-1 and other immune checkpoint molecules, and these TILs were more capable of producing the effector molecules IFN-gamma and granzyme B (Figure 3).

Conclusions
Pulmonary metastatic OS lesions are more highly infiltrated with immune cells than primary bone lesions, particularly at the interface. These immune cells are capable of producing cytotoxic cytokines and proteases by MFC, suggesting that these TILs may be tumor-specific and capable of acting against the tumor. The inability of these immune cells to penetrate further into the tumor interior may represent an adaptive immune response by the tumor through a combination of repulsive cytokines and inhibition of TILs via upregulation of multiple immune checkpoint molecules and recruitment of PMN-MDSCs. Treatment with a combination of therapies targeting both inhibitory immune checkpoint molecules and the immunosuppressive myeloid compartment may unleash these immune cells and allow them to destroy metastatic OS tumor cells.

References

Ethics Approval
This study was approved by Johns Hopkins University’s Ethics Board, approval number FWA00005752.

Fig. 1 (abstract P559). Pulmonary metastases have high infiltration of immune cells.
equal proportion of CD4+ and CD8+ T-cells (except for UC and HNSCC with a CD4/CD8 ratio > 2). Unsupervised analysis of immunophenotyping data could not cluster patients by histological type or by the expression of TIM-3, LAG-3, MHC-I or MHC-II on T cells. More surprisingly, we found that cancer patients could be grouped by clusters with mutually exclusive patterns of PD-1 and PD-L1 expression on T-cells. Indeed, patients were either PD-1POS/PD-L1NEG (18% of patients), PD-1NEG/PD-L1POS (45% of patients), or PD-1NEG/PD-L1NEG (30% of patients) on their tumor-infiltrating T-cells with an identical phenotype between CD4+ and CD8+ T-cells.

Conclusions
Patients’ TIL are either PD-1POS or PD-L1POS or PD-1NEG/PD-L1NEG. This pattern is uniform across all TILs and mutually exclusive across patients, independently from their tumor histology. This result could have a major implication in terms of anti-tumor activity of anti-PD(L)1 therapies and patient selection for clinical trials and routine practice.

References

Ethics Approval
All samples were collected in accordance with French Law (MR-004).

P560
Cancer patients can be categorized by a uniform and mutually exclusive pattern of expression of PD-1 or PD-L1 on their tumor infiltrating T lymphocytes
Aurelien Marabelle, MD, PhD; Séverine Mouraud
Gustave Roussy, Villejuif, France
Correspondence: Séverine Mouraud
(severine.mouraud@gustaveroussy.fr)

Background
We reported that PDL-1 expression on circulating CD8+ T cells was a predictor of bad prognosis and of resistance to CTLA4 blockade in melanoma [1]. PD-L1 expression is currently assessed by IHC stainings and implemented into clinical practice for selecting cancer patients eligible to anti-PD(L)1 immunotherapies. However, PD-L1 IHC stainings have a low sensitivity compared to flow cytometry and fall short in identifying the very nature of PD-L1 expressing cells in the TME. We aimed at better defining the PD-1/PD-L1 expression in the Tumor Micro Environment (TME) by using flow cytometry.

Methods
We analyzed 132 fresh tumors by flow cytometry: primitive tumor samples of Urothelial Carcinoma (UC; n=45), liposarcoma (n=19), Ovarian Cancers (OC; n=24), Kidney carcinoma (n=17), Head and Neck Squamous Cell Carcinoma (HNSCC; n=11), Thyroid (n=8) and liver metastases of Colorectal Cancers (CRC; n=8). We evaluated membrane expression of PD-1, PD-L1, TIM-3, LAG-3, MHC-I and MHC-II in the TME using a BD Fortessa X20 and analyzed the data with the Kaluza software.

Results
We found a high variability of tumor infiltrating leukocytes across individuals (from 0% to 90% of CD45+ cells) and across tumor types (median range from 4% for CRC metastasis to 20% for OC and NSCLC primitive tumor samples). However, the level of T-cell infiltrates (CD3+) (TILs) was consistently around 60% across histologies with an

P561
Formation and function of and CD49b+ CD8 T cells CD49a+ in a murine breast cancer model
Marit Melssen, MSc 1, Robin Lindsay 1, Amanda Briegel 1, Anthony Rodriguez 2, Salvador Cyranowski 1, Cornelis Melief, MD, PhD 3, Spoor van der Burg 2, Craig Singluff, Jr. 1, Victor Engelhard 1
1. University of Virginia, Charlottesville, VA, United States; 2 Leiden University, Leiden, Netherlands
Correspondence: Victor Engelhard (vhe@virginia.edu)

Background
Integrins CD49a and CD49b can mediate retention of lymphocytes in peripheral tissues by binding to collagens type IV and type I, respectively. Their expression is upregulated on CD8+ tumor infiltrating lymphocytes (TIL) compared to circulating lymphocytes and density of CD49a+/TIL is associated with improved patient outcome. Little is known about how expression of these integrins is regulated in vivo and the functional capacity of the cells expressing them. We hypothesized that CD49a and CD49b expression evolves over time as T cells differentiate in the tumor microenvironment (TME) and that integrin expression is associated with T cell function, by directly supporting effector function or localization.

Methods
To address these hypotheses, CD8 TIL from an implantable breast carcinoma model, BRPKp110, were for expression of CD49a, CD49b and functional markers. Where indicated, mice were treated daily with 5ug/mouse FTY720. For transfer experiments, OT1 cells were activated in vivo with ovalbumin, polyIC and anti-CD40 vaccination. After 5d, CD49b+ cells were purified and transferred into tumor-bearing mice.

Results
In early stage tumors (d14), T cells were predominantly CD49b single positive (SP) or CD49aCD49b double positive (DP). Later (d23), CD49b SP cells largely disappeared, and CD49a SP cells appeared, while DP cells remained unchanged. After treatment with FTY720, to block further T cell infiltration, the switch from CD49b SP to CD49a SP cells was even more pronounced, suggesting the change is not due to newly infiltrating CD49a SP cells. Regardless of timepoint, CD49b SP cells were antigen-responsive, whereas DP and CD49a SP cells had features of exhaustion. To test whether the switch in integrin expression depends on antigen engagement or environmental factors, we transfected activated CD49b SP OT1 cells into OVA-negative BRPKp110 tumor-bearing mice. In these tumors, CD49b SP cells upregulated CD49a, followed by downregulation of CD49b (Figure 1).
Preliminary in vitro experiments showed that restimulation of T cells in presence of CD49a/CD49b ligands, collagen type I or IV, strongly inhibit IFNγ expression, suggesting a potentially direct negative role for CD49a or CD49b in anti-tumor immunity.

Conclusions
Together, our data suggest that in CD49b SP CD8 TIL evolve over time to upregulate CD49a, followed by downregulation of CD49b, as TIL gain an exhausted phenotype. Furthermore, the switch in expression is dependent on the microenvironment, not antigen-specific differentiation. Future experiments will assess which environmental factors play a role in CD49a upregulation, and how processes of integrin expression relate to the antigen-dependent generation of exhaustion.

Fig. 1 (abstract P561). CD49a and CD49b expression on transferred OT1 cells

P562
BTN2A, a new immune-checkpoint targeting Vgamma9Delta2 T cell cytotoxicity
Carla Cano, PhD1, Christine Pasero1, Aude de Gassart1, Sophie Agaugué1, René Hoët1, Emmanuel Scotet1, Erwan Mortier1, Agnès Quenemueur1, Chirine Rafia1, Antoine Briantais2, Anne-Charlotte Le Floch3, Daniel Olive, MD, PhD4,5
1IMCHECK THERAPEUTICS, Marseille, France; 2INSERM UMR1232 & CNRS ERL6001 CRCINA IR, Nantes, France; 3Centre de Recherche en Cancérologie de Marseille, Marseille, France; 4Centre de Recherche en Cancérologie de Marseille- Institut Paoli Calmettes, Marseille, France
Correspondence: Daniel Olive (daniel.olive@imcheck.fr)

Background
Anti-tumoral response of Vγ9Vδ2 T cells requires sensing of phosphoantigens accumulated in malignant cells through binding of butyrophilin 3A (BTN3A). Moreover, an unknown partner located in human Chr6 was shown to be mandatory to BTN3A-mediated Vγ9Vδ2 T cell activation in murine models. Here, we identified butyrophilin 2A (BTN2A), which is located to Chr6, as a requirement for human Chr6 was shown to be mandatory to BTN3A-mediated phosphoantigens accumulated in malignant cells through binding of BTN2A, a new immune-checkpoint targeting Vγ9Vδ2 T cell cytotoxicity.

Methods
CRISPR-Cas9-mediated inactivation of BTN2A1/2A2 isoforms was performed in Daud1, KS62 and HEK-293T cells. Vγ9Vδ2 T cells expanded from healthy PBMCs were co-cultured with wild-type or BTN2AKO cells +/- BrHPP(1 μM), HMBPP(0.1 μM) or zoledronate(45 μM), or anti-BTN2A mAb, and Vγ9Vδ2 T cell degranulation (%CD106αβ+ cells), and intracellular TNFα and IFNγ assessed after 4h. Mouse T cell hybridoma S3/4 expressing TCRVγ9Vδ2-MOP were co-cultured overnight with NIH3T3 murine fibroblasts transfected with BTN3A- and/or BTN2A-encoding plasmids +/-HMBPP(10 μM), or increasing doses of HMBPP or anti-BTN3 20.1 mAb. BTN2A transcript expression in normal vs. tumoral tissue was analyzed using GEPIA tool. Anti-BTN2A mAb staining was performed on human samples of primary AML, cervical and pancreatic carcinoma and assessed by flow cytometry.

Results
Degranulation and intracellular IFNγ/TNFα (n=6) were abolished in Vγ9Vδ2 T cells co-cultured with BTN2AKO Daudi, KS62 and HEK-293T cells compared to wild-type, in all conditions tested including anti-BTN3 20.1. Murine cells do not express no BTN2A1 or BTN3A orthologs and are unable to activate human Vγ9Vδ2 T cells. Ectopic expression of BTN2A and BTN3A combination but neither BTN2A or BTN3A alone in murine NIH3T3 cells, allows triggering of IL-2 secretion in mouse S3/4-TCRγδVδ2-MOP reporter cells in presence of HMBPP or 20.1 mAb in dose-dependent manner. Anti-BTN2A mAb was able to suppress Vγ9Vδ2 T cell degranulation/cytokine secretion against cancer cell lines and activation of mouse S3/4-TCRγδVδ2-MOP reporter by BTN2A/BTN3A-expressing NIH3T3 in a dose-dependent manner. BTN2A transcript was significantly up-regulated in pancreatic, ovarian and cervical carcinoma vs. normal tissue. Extracellular BTN2A protein was detected in primary hematological and solid tumors.

Conclusions
Here, we show that BTN2A is mandatory for BTN3A-mediated function in human Vγ9Vδ2 T cells. Moreover, concomitant BTN2A and BTN3A expression empowers murine T cells with activation through Vγ9Vδ2 TCR, opening new roads for mouse models of Vγ9Vδ2 T cell anti-tumoral responses. We describe an anti-BTN2A able to suppress Vγ9Vδ2 T cell function, and we show BTN2A expression in primary tumors. These results are relevant for understanding Vγ9Vδ2 T cell antitumoral immunity triggered by phosphoantigens and amino-bisphosphonates.

P563
Profiling regulatory and cytotoxic T cell relationships in the tumor microenvironment of non-small cell lung cancer FFPE samples
Bonnie Phillips, PhD, Mark Burton, HTL, ASCP, Katir Patel, PhD, Mael Manesse, PhD, Sean Downing, PhD
Ultivue, Cambridge, MA, United States
Correspondence: Sean Downing (sean.downing@ultivue.com)

Background
Immune cell infiltration and exhaustion has been a key question within the field of immunotherapy research. In particular, regulatory T cells (T-regs) has been identified as one of the cell types responsible for modulation of the immune response. Spatial resolution through multiplex immunofluorescence allows researchers to identify cell types only identifiable through multiple-marker expression and their behavior and relationships with other cells. In this work, we set out to identify three main cell types and their interactions in the tumor microenvironment of non-small cell lung cancer samples: cytotoxic T cells, T-regs, and tumor cells. We used the UltiMapper I/O T-reg panel (CD4, CD8, FoxP3, pan-Cytokeratin) for characterization of cell phenotypes and additional testing to assess the reproducibility of the assay for downstream studies.

Methods
Two sets of 5 serial sections from four different tissue sets (one human tonsil and three different NSCLCs) were stained with the UltiMapper I/O T-reg panel (CD4, CD8, FoxP3, pan-Cytokeratin) on the Leica Biosystems BOND RX autostainer. Whole-slide images were acquired using the ZEISS AxioScan.Z1, without the need for linear unmixing. Analysis was performed using Indica Labs HALO® software Indica Labs. Samples were analyzed for immunophenotyping and spatial mapping. Coefficients of variation (CVs) were calculated based on resulting data. All image acquisition and analysis was performed using the same analysis template for each sample type.
Results
Detection of single-marker and multi-marker phenotypes were identified. T-regs were identified by CD4+/FoxP3+. Cytotoxic T cells were identified by CD8+. Tumor regions were mapped with pan-Cytokeratin+. Cell population comparisons and proximity analysis was used to compare T-helpercytotoxic T cell, T-regcytotoxic T cell, and cytotoxic T cell:tumor cell ratios. Overall CVs were less than 15% across all markers across serial sections. This included the total cell counts and average signal intensity.

Conclusions
The results presented here indicate that the UltiMapper I/O T-reg panel offers robust and reproducible multiplex immunofluorescence data for the detection and characterization of immune cell infiltration and T-cell regulation. Histological standards for coefficients of variation in H&E based assays are typically

References

P564
How tumor-specific CD8 T cell activation in draining lymph nodes supports the anti-tumor CD8 T cell response
Nataliya Prokhnevska, BS, Rajesh Valanparambil, Caroline Jansen, BS, Viraj Master, MD, PhD, Martin Sanda, Haydn Kissick
Emory University, Atlanta, GA, United States
Correspondence: Haydn Kissick (haydn.kissick@emory.edu )

Background
CD8 T cells are a critical part of the immune response to tumors. With the increased use of immunotherapies to treat many cancers understanding what leads to highly CD8 T cell infiltrated tumors is crucial in the improvement of these therapies. Especially since the number of CD8 T cells within the tumor has been shown to predict the response to anti-PD1 blockade and survival. Recent work in CD8 T cell immunology described how CD8 T cells respond to chronic diseases, finding two subsets of CD8 T cells within tumors. One is a stem-like CD8 T cell and the other is an effector CD8 T cell with cytotoxic capabilities [1]. Understanding how tumor-specific CD8 T cells activate and differentiate to produce an effective CD8 T cell response with both stem-like CD8 T cells and effector CD8 T cells is crucial to determining why certain tumors are highly infiltrated by CD8 T cells while others are not.

Methods
To understand how tumor-specific CD8 T cells respond to prostate cancer we have made a prostate cancer model which expresses the viral LCMV glycoprotein (GP) which acts a tumor-specific antigen. Using this model, we have used this model to study tumor-specific CD8 T cell activation by adoptively transferring LCMV GP specific TCR transgenic P14 CD8 T cells into TRAMPc1-LCMV-GP bearing mice.

Results
We have data showing that to have a highly infiltrated there must be a population of stem-like CD8 T cells which are capable to differentiating into effector CD8 T cells and supporting the CD8 T cell response against the tumor. We have found when tumor-specific CD8 T cells are activated they acquire an undifferentiated but activated program, upregulating CD44, PD1 but retaining high TCF1 and CD62L expression (Fig 1, C,E). They also upregulate effector molecules such as CD43 slower and completely fail to upregulate CX3CR1 (Fig 1, C). These undifferentiated activated CD8 T cells do not acquire a typical effector program that is seen in acute viral infection such as LCMV Armstrong (Fig 1, A,B), and proliferate slower than P14 CD8 T cells activated in LCMV Armstrong (Fig 1, D).

Conclusions
Tumor-specific CD8 T cells do not acquire an effector program after activation and instead gain an undifferentiated but activated phenotype. Based on this we hypothesize that tumor-specific CD8 T cells are activated in the TDLN and differentiate to become the stem-like CD8 T cells within the tumor, promoting the anti-tumor CD8 T cell response.

References

Fig. 1 (abstract P564). CD8 T cell activation in viral infection and tumor model
P566
Does loss of BAP-1 influences the activation of non-canonical NFκB pathway in uveal melanoma with inflammation?
Mithalesh Singh,1 Lata Singh, PhD,2 Seema Kashyap,1 Neelam Pushker, MD,3 Seema Seri, MD,4 Rachna Meel, MD
1All India Institute of Medical Sciences, New Delhi, India; 2University of California, Irvine, CA, United States; 3Dr.R.P.Centre for ophthalmic Sciences, New Delhi, India; 4University of California, Irvine, CA, United States
Correspondence: Seema Kashyap (dr_skashyap@hotmail.com)

Background
Inflammation in Uveal Melanoma (UM) is linked to a bad prognosis. Infiltration with an inflammatory infiltrate increases with disease progression but does not seem to inhibit metastasis. Genetic predictors for metastatic tumor behavior is the loss of BRCA1-associated protein 1 (BAP1) expression. NFκB is a principal coordinator of innate immunity and inflammation and has emerged as an essential endogenous tumor promoter. We hypothesize that genetic changes not only influence the immunological microenvironment but also drive metastasis in UM and that NC-NFκB proteins are the consequence of a highly-inflammatory profile.

Methods
In our study, seventy-five patients are recruited for a period of 4 years (2013-2017). Based on the expression of CD3 (infiltrating lymphocytes) and CD68 (infiltrating macrophages), we divided our study cohort into two categories: UM with inflammation and UM without inflammation. Expression of BAP-1 and NC-NFκB proteins (RelB & p52/NFκB2) was evaluated using immunohistochemistry and western blotting. Real-time PCR was performed on 60 frozen tumor samples. To detect the presence of p52/RelB heterodimer by Co-immunoprecipitation was performed on five each case of the inflammation and non-inflammation group of UM. BAP-1 sequencing was performed on 10 cases.

Results
In the inflammation group, activation of NC-NFκB proteins found in 82% and 64% of cases while the loss of BAP-1 was observed in 82% of cases. Loss of BAP-1 protein along with activation of NC-NFκB proteins was seen in the 70% of cases of the inflammation group. Loss of BAP-1 along with activation of C-NFκB proteins was statically significant with inflammatory factors such as CD34+ (p=0.036), IL-6 (p=0.012), LBD>15mm (p=0.031) and epithelioid cell type (p=0.027). Our western blotting results supporting the immunohistochemistry results. In the inflammation group fold-change value of RelB(5.21) & NFκB2 (4.65) genes was reduced to 2.85 (RelB) & 2.34 (NFκB2) gene in the non-inflammation group. Mutation of BAP-1 was more frequently seen in the 70% of cases. Loss of BAP-1 protein along with activation of NC-NFκB proteins found in 82% and 64% of cases while the loss of BAP-1 was observed in 82% of cases. Loss of BAP-1 protein along with activation of NC-NFκB proteins was seen in the 70% of cases of the inflammation group. Loss of BAP-1 along with activation of C-NFκB proteins was statically significant with inflammatory factors such as CD34+ (p=0.036), IL-6 (p=0.012), LBD>15mm (p=0.031) and epithelioid cell type (p=0.027). Our western blotting results supporting the immunohistochemistry results. In the inflammation group fold-change value of RelB(5.21) & NFκB2 (4.65) genes was reduced to 2.85 (RelB) & 2.34 (NFκB2) gene in the non-inflammation group. Mutation of BAP-1 was more frequently seen in the 70% of cases. Loss of BAP-1 protein along with activation of NC-NFκB proteins, was associated with reduced metastasis-free survival and overall survival (p

Conclusions
Our study showed that in an inflammation group loss of BAP-1 showed the synergistic role with the activation of NC-NFκB proteins and are the poor prognostic indicator of overall and metastasis-free survival. By predicting those patients who have a poor prognosis might help to differentiate which patients require more aggressive local treatments and which of those systemic treatments.

Ethics Approval
The study was approved by the institutional ethics committee, All India Institute of Medical Sciences (IESC/T-417/2015).

Consent
Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal

P567
Characterizing myeloid-derived suppressor cells in the tumor microenvironment of colorectal cancer FFPE samples
Angela Vasaturo, PhD, Katir Patel, PhD, Mael Manesse, PhD, Sean Downing, PhD
Ultivue, Milan, Italy
Correspondence: Sean Downing (sean.downing@ultivue.com)

Background
Myeloid-derived suppressor cells (MDSCs) are developed to protect the host, and in the context of immunooncology these cells protect tumor cells through suppression of immune cell activity. MDSCs are not present in healthy environments, and only rise during pathological conditions associated with inflammation. Two main types of MDSCs have been studied in depth: monocyte MDSCs (M-MDSCs) and polymorphonuclear MDSCs (PMN-MDSCs). M-MDSCs are an intermediate stage along the path of differentiation from myeloid cells to monocytes. PMN-MDSCs are an intermediate stage along the path of differentiation from myeloid cells to neutrophils. Much of the research into MDSCs has been collected through flow cytometry because of the ability to immunophenotype single cells with multiple markers. Within tissue, research has been limited because of the current multiplex immunohistochemistry technologies’ inability to detect co-expression of multiple markers on single cells and measure a range of expression for dynamic markers. Here we assess the Ulti-Mapper I/O MDSC panel (CD11b, CD14, CD15, HLA-DR) for characterization in a colorectal cancer cohort and for reproducibility studies.

Methods
A set of tissue microarrays (TMAs) containing multiple colorectal carcinoma samples was stained with the UltiMapper I/O MDSC kit. Staining was conducted on the Leica Biotexys Bond RX autostainer. Multiplexed images were acquired with the Ulti-Mapper I/O digital scanner. TMAs were analyzed for cell phenotyping and spatial distribution using Indica Labs HALO software. Coefficients of variation (CVs) were calculated based on resulting data.

Results
Detected co-expression of multiple markers in the panel and range of expression for HLA-DR was identified. M-MDSCs were identified by CD11b+/CD14+/CD15−/HLA-DR− cells, PMN-MDSCs were CD11b+/CD14−/CD15+/HLA-DR−/low. Overall CVs were less than 15% across all markers across serial sections. This included total cell counts and average signal intensity. Differences in densities of MDSCs were measured in various colorectal carcinoma samples.

Conclusions
Given the robustness and high reproducibility of the Ulti-Mapper I/O MDSC panel, the identification and assessment of MDSC cell types in tissue is reliably attainable. This allows researchers to apply this technology to cohorts of colorectal cancer to assess the utility of measuring MDSCs in the context of immunotherapy-related studies and the overall immunosuppressive landscape.

P568
Terminally exhausted CD8+ T cells potentiate the tolerogenic tumor microenvironment as functional suppressors
Paolo Vignali, BA, McLane Watson, BS, Ashley Menk, MS, Nicole Schärphing, PhD, Kristin DePeaux, BS, Greg Delgoffe, PhD
The University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
Correspondence: Greg Delgoffe (delgoffeg@upmc.edu)

Background
Blockade of co-inhibitory ‘checkpoint’ molecules, PD-1 and CTLA-4, has induced impressive clinical responses in advanced tumors; yet only in a subset of patients. Limited success with checkpoint blockade therapy suggests other cell extrinsic or intrinsic mechanisms may be dampening an effective immune response. Cytotoxic CD8+ T cells (CTL) encountering chronic antigen and metabolic restriction can differentiate to a terminally exhausted state (Texh), marked by hyporesponsiveness and metabolic, epigenetic, and transcriptional dysfunction. While enrichment of this population in tumor is a negative prognostic factor, it remains unclear whether Texh are simply non-functional or instead possess tolerogenic or suppressive properties. Transcriptional profiling of tumor-infiltrating CD8+PD-1 hi/TIM-3+ terminally differentiated Texh reveals that exhausted cells express a pattern of genes associated with immune suppression. We hypothesize that
Textx potentiate the suppressive microenvironment of solid tumor by autoregulation and inhibition of local immune responses.

**Methods**

Textx and were isolated from B16 melanoma by expression of inhibitory receptors (IR) and assayed in tandem in microsuppression assay with progenitor exhausted and CD4+Foxp3+ regulatory T cells. Murine melanoma clones with inhibited oxidative metabolism were generated by CRISPR-Cas9 and validated for ablated mitochondrial respiration by extracellular flux analysis. Enforced expression of CD39 in effector T cells was attained by murine retroviral vector delivery. Deletion of CD39 was accomplished through tamoxifen-inducible Cre recombinase expression in CD8+ T cells (E8icre-ERT2Entpd1flox/flox).

**Results**

When sorted directly from tumor, terminally exhausted (PD-1hiTim3+) Textx, but not PD-1 intermediate, progenitor exhausted CD8+ T cells, induce marked suppression of T cell effector responses, comparable to suppression from Foxp3+ Tregs cells sorted from the same environment. Suppressive activity correlated with exposure to hypoxia, and exhausted T cells sorted from tumors engineered to be less hypoxic had significantly less suppressive capacity. Our data suggest hypoxia induces HIF1α-dependent expression of the cell surface ectonucleotidase, CD39, which depletes extracellular ATP, contributes to generation of immunosuppressive adenosine, and has been previously associated with terminal exhaustion. CD39 overexpression on effector T cells can confer a diminished phenotype, and preliminary data using CD8-specific CD39 deletion suggests it confers the regulatory phenotype in tumor-infiltrating exhausted T cells.

**Conclusions**

Our data support a model that as CTL progress to terminal exhaustion, hypoxic exposure upregulates CD39, providing Textx a mechanism to suppress proinflammatory processes. These findings suggest Textx are not solely dysfunctional but are rather deleterious to antitumor immunity and may need to be drastically reprogrammed or deleted in order to alleviate immunosuppressive functions.
Background
Colorectal cancers (CRCs) have very low response rates to current immunotherapeutic approaches with the exception of the microsatellite instability high (MSI-H) phenotype. To investigate the basis for such poor responsiveness, we evaluated expression levels of 6 well-known immune checkpoint genes (ICPs), as well as potential novel immune checkpoint related genes (ICPRGs).

Methods
The biological connectivity of 6 known ICPs with IFNγ and its downstream genes was examined by NGS in 79 stringently procured and processed CRC and their normal, patient matched intestinal epithelium pairs. Identification of novel IFNγ-induced molecules with potential ICPRG activity was sought.

Results
In our study, the 6 “classical” ICPs were statistically upregulated and correlated with IFNγ and 183 additional immune related genes in IFNγ positive (FPKM>1) tumors (Figure 1). By ICP coexpression analysis, we identified 3 IFNγ-induced genes (IFI30, GBP1 and GBP4) as potential novel ICPRGs. These 3 genes were statistically upregulated compared to normal tissue, expressed at relatively high abundance (average FPKM = 115) across 79 CRC pairs compared to the abundance of the 6 ICPs (average FPK = 12; Table 1) and correlated with expression of IFNγ and 172 immune-related genes in IFNγ positive tumors (Figure 2). Further evaluation of the TCGA database revealed commonality of IFNγ dependent expression of 6 ICPs and the 3 potential ICPRGs in 638 CRCs, 103 skin cutaneous melanomas (SKCMs), 1105 breast cancers (BCs), 184 esophageal cancers (ESCs), 416 stomach cancers (STCs) and 501 lung squamous carcinomas (LUSC).

Conclusions
The expression of higher abundance and novel ICPRG genes, including IFI30, GBP1 and GBP4 requires further evaluation of protein expression levels in tumors because these genes have the potential to be druggable targets for immunotherapy of CRC as well as other tumors.

Table 1 (abstract P571). FPKM of 6 ICPs and 3 ICPRGs in 79 CRC pairs

<table>
<thead>
<tr>
<th>6 ICPs</th>
<th>average FPKM in tumor</th>
<th>average FPKM in normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFNγ</td>
<td>115</td>
<td>115</td>
</tr>
<tr>
<td>ICOS</td>
<td>115</td>
<td>115</td>
</tr>
<tr>
<td>LAG3</td>
<td>115</td>
<td>115</td>
</tr>
<tr>
<td>PDL1</td>
<td>115</td>
<td>115</td>
</tr>
<tr>
<td>CTLA4</td>
<td>115</td>
<td>115</td>
</tr>
<tr>
<td>PD1</td>
<td>115</td>
<td>115</td>
</tr>
<tr>
<td>average of 6 ICPs</td>
<td>115</td>
<td>115</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3 ICPRGs</th>
<th>average FPKM in tumor</th>
<th>average FPKM in normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFI30</td>
<td>115</td>
<td>115</td>
</tr>
<tr>
<td>GBP1</td>
<td>115</td>
<td>115</td>
</tr>
<tr>
<td>GBP4</td>
<td>115</td>
<td>115</td>
</tr>
<tr>
<td>average of 3 ICPRGs</td>
<td>115</td>
<td>115</td>
</tr>
</tbody>
</table>

Fig. 1 (abstract P571). ICP coexpression network

Fig. 2 (abstract P571). ICPRG coexpression network

P572
IFNγ-induced nitric oxide cell death is inhibited by L-arginine depletion in renal cell carcinoma
Arnold Zea, PhD1, Charity Silvester 1, Paula Datri, BS2
1Louisiana State University HSC, New Orleans, LA, United States; 2Louisiana Cancer Research Center, New Orleans, LA, United States
Correspondence: Arnold Zea (zea@lsuhsc.edu)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1)P572

Background
In mammals, NO is generated by nitric oxide synthases (NOS 1, 2, 3). All type of NOS catalyzes L-arginine (L-Arg) to produce L-citrulline and nitric oxide (NO) the later known to have anti-tumor activity. L-Arg metabolizes arginase (ARG2) to synthesize polyamines necessary for tumor growth. NOS2 is commonly up-regulated by inflammatory mediators, and it produces NO as long as the molecule is intact and its substrate L-Arg is available. Because ARG2 and NOS2 compete for L-Arg, the metabolism of this amino acid will become a crucial component in modulating cell growth, cell death and resistance in renal cell carcinoma. We hypothesize that L-Arg availability in renal carcinoma cells expressing ARG2 regulates the activity and expression of NOS2 protein as a mechanism that induces resistance against IFNγ-induced tumor activity.

Methods
300,000 Renca cells per well were plated in 6 well plates in RPMI media containing 1,000; 2,000; 4,000 and 6,000 micro-molar of L-Arg and culture for 48h. Then, the cells were stimulated with100U/ml of IFNγamma and cultured for an additional 24 h. At this time, supernatants and cells were harvested and tested for NOS2 protein by immunoblot and NOS2 activity by Greiss Assay (nitrite formation). Supernatants were collected every day during the length of the experiments, to determine L-Arg levels by High-Performance Liquid Chromatography (HPLC). As a control for the experiments, we used CL-19 renal carcinoma cells responsive IFNγ induced-stimuli.

Results
Here, we report that decreased availability of L-Arg in Renca cells blocked the expression of NOS2 protein and NO-induction after IFNγamma stimulation with IFNγamma. Furthermore, the addition of L-Arg to the cell cultures reverted the process. IFNγamma receptor, NOS2 gene expression, ARG2 protein expression did not change under the different experimental conditions.

Conclusions
The lack of IFNγamma-induced responses could likely be due to the tumor’s ability to develop strategies of tumor escape and define a distinct mechanism by which L-Arg can regulate the activity of its associated NOS2 enzyme. Our plan, include testing if, in this phenomena, the inhibition of NOS2 expression and activity by L-Arg depletion occurs via inhibition of translation of NOS2 mRNA.

Discussion
The biological connectivity of 6 known ICPs with IFNγ and its downstream genes was examined by NGS in 79 stringently procured and processed CRC and their normal, patient matched intestinal epithelium pairs. Identification of novel IFNγ-induced molecules with potential ICPRG activity was sought.

Results
In our study, the 6 “classical” ICPs were statistically upregulated and correlated with IFNγ and 183 additional immune related genes in IFNγ positive (FPKM>1) tumors (Figure 1). By ICP coexpression analysis, we identified 3 IFNγ-induced genes (IFI30, GBP1 and GBP4) as potential novel ICPRGs. These 3 genes were statistically upregulated compared to normal tissue, expressed at relatively high abundance (average FPKM = 115) across 79 CRC pairs compared to the abundance of the 6 ICPs (average FPK = 12; Table 1) and correlated with expression of IFNγ and 172 immune-related genes in IFNγ positive tumors (Figure 2). Further evaluation of the TCGA database revealed commonality of IFNγ dependent expression of 6 ICPs and the 3 potential ICPRGs in 638 CRCs, 103 skin cutaneous melanomas (SKCMs), 1105 breast cancers (BCs), 184 esophageal cancers (ESCs), 416 stomach cancers (STCs) and 501 lung squamous carcinomas (LUSC).

Conclusions
The expression of higher abundance and novel ICPRG genes, including IFI30, GBP1 and GBP4 requires further evaluation of protein expression levels in tumors because these genes have the potential to be druggable targets for immunotherapy of CRC as well as other tumors.
Acknowledgements This work is supported by the Stanley S. Scott Cancer Center Funds, and NIH-R25GM121189, NCI-1P20CA209200-01AI grants.

P574
Remodeling translation primes CD8+ T cell anti-tumor immunity
Jessica Thaxton, PhD, McCR, Kiley Lawrence, Katie Hurst, Lauren Ball, PhD, Lee Leddy, MD, McCR, Dongjun Chung, PhD
Medical University of South Carolina, Charleston, SC, United States
Correspondence: Jessica Thaxton (thaxton@musc.edu)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P574

Background
The requisites for translation in T cells are poorly understood and how translation shapes the anti-tumor efficacy of T cells is unknown.

Methods
We used multiple innovative tools to dissect how translation shapes T cell lineages and impacts tumor growth. LC-MS/MS proteomics, cytokine conditioning, immunoblotting, and a novel FACS-based assay of mRNA translation were employed to elucidate the molecular components that control translation in T cells. A novel in vitro tumor microenvironment assay was developed to measure the impact of the microenvironment on T cell translation. Adoptive transfer of T cells to tumor-bearing mice was employed to elucidate how translation is impacted in T cells in tumors, and fresh tumor infiltrating lymphocytes (TILs) from cancer patients were assessed to measure translation in human TILs. Pharmacological modulation of translation was used to test that remodeling protein synthesis is a new strategy to augment T cell-mediated tumor control.

Results
Here we demonstrate that memory T cells are primed by metabolic energy sensor AMP-activated protein kinase (AMPK) to undergo diminished translation relative to effector T cells. However, we show that memory T cells exhibit a remarkable capacity to enhance translation in tumors that effector T cells are unable to duplicate. Study of modulation of translation for applications in cancer immunotherapy revealed that translation is suppressed in CD8 TILs in multiple human tumor types, and that direct ex vivo pharmacological inhibition of the translation elongation step primes powerful T cell anti-tumor immunity by remodeling metabolic properties of T cells.

Conclusions
Our work elucidates the new finding that paths to translation shape CD8 T cell anti-tumor capability. We show that metabolic energy sensors shape protein synthesis in T cells and control anti-tumor immunity, and we demonstrate that direct modulation of translation is a powerful and unique strategy to shape the efficacy of T cells to combat tumor growth.

P575
Targeting the stress response Kinase GCN2 to restore immunity in the tumor microenvironment
Lisa Marshall, MS, Buvana Ravashankar , Lavanya Adysumilli, Deepika Kaveri, Deepa Pookot, Thant Zaw, Raashi Sreenivasan, Mikhail Zibinski, Jeffrey Jackson, Grant Shibuya, Paul Legr, Anqi Ma, Anton Shakhmin, Andrew Ng, Omar Robles, Oezcan Talay, Delia Bradford, Christophe Colas, Scott Jacobson, Jerick Sanchez, Justy Guagua, Steve Wong, Martin Brovaneey, Angela Wadsworth, Goerge Katibah, Gene Cutler, David Wustrow, Paul Kassner, Dirk Brockstedt, Lisa Marshall, MS
RAPT Therapeutics, South San Francisco, CA, United States
Correspondence: Buvana Ravashankar (bravashankar@rappt.com)

Background
The tumor microenvironment (TME) is characterized by deficiencies in oxygen and key nutrients, such as glucose and amino acids, resulting in an overall immune suppressive environment. Stromal cells and myeloid-derived suppressor cells (MDSC) within the tumor create a nutrient-poor environment that inhibits immune function and supports tumor growth. GCN2 (general control nonrepressible 2), a stress response kinase, plays a key role in sensing and modulating the response to amino acid deprivation. GCN2 activation in T cells leads to an induction of the integrated stress response pathway and subsequently to T cell anergy and apoptosis.

Methods
Culturing primary mouse or human immune cells under low nutrient conditions activates the GCN2 pathway limiting T cell proliferation and function. Treatment of these nutrient-deprived T cells with GCN2i resulted in rescue of CD8+ T cell proliferation and effector functions as measured by flow cytometry. In addition, GCN2 inhibition in MDSC alone fully reversed CD33+MDSC-induced T cell suppression and effector functions. Using murine syngeneic tumor models, we demonstrate that the pharmacologic inhibition of GCN2 in-vivo leads to an observed anti-tumor effect.

Results
Furthermore, GCN2 inhibition induced tumor specific immunity by increased antigen-specific T cell frequency and increased cytokine production. Our GCN2i is currently being evaluated to further elucidate the immune contribution in the tumor microenvironment.

Conclusions
The GCN2/eIF2α pathway is activated in immune cells during amino acid deprivation, and this induces a functional suppression of the immune response. Our results demonstrate that inhibition of GCN2 is an attractive approach for relieving T cell suppression and promoting effective anti-tumor activity, demonstrating GCN2 as a promising therapeutic target for the treatment of cancer.

Ethics Approval
The study was approved by RAPT Therapeutics Ethics Board, approval number FL0002.

P576
Tumor-infiltrating regulatory T cell function is metabolically supported through lactate-mediated symbiosis with the tumor microenvironment
McLane Watson, BS1, Paolo Vignali, BA1, Steven Mullet1, Natalie Rittenhouse1, Ashley Menk, MS1, Ryan Whetstone, MS, PhD1, Brett Morrison2, Jeffrey Rothstein2, Amanda Poholek1, Stacy Wendell, PhD1, Greg Delgoffe, PhD1
1University Of Pittsburgh, Pittsburgh, PA, United States; 2Johns Hopkins, Baltimore, MD, United States
Correspondence: Paolo Vignali (pdv7@pitt.edu), Greg Delgoffe (gdelgoffe@pitt.edu)

Background
Regulatory T (Treg) cells are vital for maintaining immune homeostasis and preventing autoimmunity but represent a major barrier to robust cancer immunity as the tumor microenvironment (TME) actively recruits, activates, and promotes their differentiation. Tumor cells have deregulated cellular metabolism leading to a metabolite-depleted, hypoxic, and acidic TME. Highly glycolytic tumor infiltrating CD8 T cells are in direct competition with the tumor for glucose and oxygen which impair their effector function. In contrast, Treg cells maintain their high suppressive function within the TME. Further, studies of in vitro induced and directly ex vivo Treg cells reveal a distinct metabolic profile compared to effector T cells. Thus, it may be that the altered metabolic landscape of the TME and the increased activity of intratumoral Treg cells are linked.

Methods
Fluorescent glucose tracers, extracellular flux analysis, isotopic flux analysis, and RNA sequencing were used to determine the metabolic profile of murine lymph node and B16 tumor resident Treg cells. Mice harboring a Treg specific deletion of the lactate transporter Slc16a1 (MCT1) were used to determine the in vivo significance of Treg cell lactate uptake.

Results
Here we show that Treg cells, especially tumor derived, do not robustly engage in glycolysis or consume glucose. Transcriptomic and functional analysis of glucose consuming Treg cells revealed a diminished Treg cell signature and reduced suppressive capacity. While
both glucose low and high consuming Treg cells expressed glycolysis pathway genes, low glucose consuming Treg cells had enriched expression of the lactate transporter SlC16a1 (MCT1) and lactate hydorgenase (LdhA). Isotopic flux analysis revealed Treg cells take up lactate to generate TCA cycle intermediates and phosphoenolpyruvate (PEP) which we show is critical for intratumoral Treg cell proliferation. Using B16 melanoma bearing mice harboring a Treg specific deletion of lactate transporter MCT1, we demonstrate MCT1 is dispensable for peripheral Treg cell function but required intratumorally resulting in slowed tumor growth and prolonged survival. Analysis of tumor infiltrate demonstrated increased proliferation and cytokine production by intratumoral effector T cells and decreased suppressive capacity of MCT1-deficient intratumoral Treg cells.

Conclusions
Taken together these data support a model in which Treg cells are metabolically flexible to utilize ‘alternative’ metabolites to support their function in nutrient poor environments like that of the tumor. Targeting lactate metabolism via MCT1 directed antibodies or inhibitors for lowering tumor lactate levels provides a promising therapeutic strategy to impair intratumoral Treg suppressive capacity and enhance anti-tumor immunity.

Ethics Approval
Animal work was done in accordance with the Institutional Animal Care and Use Committee of the University of Pittsburgh (protocol #17071235).

Methods
Normal PBMCs isolated from healthy individuals were subjected to HDAC inhibitors with varying specificities: Panobinostat, Entinostat, Vorinostat and OKT-005 and stimulated with PMA/ionomycin and protein export was blocked with BFA. Cells were fixed and permeabilized after 18 hours and stained with markers: CD4, CD8, CD95, CD31, and CCR7 to delineate naive and memory subtypes.

Results
To determine HDACi effects on T-cells, I evaluated cytokine production on bulk CD4 and CD8 T-cells, and observed a decrease in IL-2, consistent with previous literature that HDACi is negatively impacting T-cells overall. However, TNFα also significantly increased, showing HDACi effects are not only due to cytotoxicity, but cytokines are being differentially affected. Interestingly, the cytokine change effect was across both CD4 and CD8 T-cells and when delineated into naive versus memory subsets, the naive T-cells were much more impacted than memory cells, exhibiting more drastic decreases of IL-2 and increases in TNFα. Naive T-cells also exhibited higher acetylation levels of total acetylated lysine and di-acetyl H3 than memory cells 24 hours after drug treatment.

Conclusions
Naive T-cells comprise a large portion of T-cells from PBMCs, which may explain why previous studies with HDACi show immunosuppressive effects. However, anti-tumor immunity largely relies on tumor infiltrating lymphocytes, which consist of memory T-cells. Thus, memory T-cells’ reduced susceptibility to HDACi could explain enhanced anti-tumor immune responses seen previously. Further investigation into the effect of HDACi on distinct T-cell subsets could aid in rationally designing future immunotherapy strategies in cancer.

Acknowledgements
This work was funded by the CPRIT SCHOLAR IN CANCER RESEARCH Grant #RR160093 awarded to Dr. S. Gail Eckhardt. Special thanks to Anna Capasso, Todd Tripplett, Carla Van Den Berg, the personnel of the Developmental Therapeutics Lab for their guidance and support and OnkURE Therapeutics.

P578
In vitro assessment of the impact of chemotherapy agents on immune cell function
Dana Banas, Dawn Streeko, Mye Jacobs, Sium Habte, Matthew Loya, Xiaodong Wang, Krishna Vasudevan, DVM, PhD, Laurence Menard, PhD, Julie Carman, PhD
Bristol-Myers Squibb, Princeton, NJ, United States
Correspondence: Julie Carman (julie.carman@bms.com)

Background
Immunotherapy has transformed cancer treatment, providing durable responses for a subset of patients. Improved responses were recently observed for combinations of checkpoint inhibitors with chemotherapy regimens as compared to either therapy alone [1]. Chemotherapeutics are thought to enhance anti-tumor responses by increasing tumor antigens via immunogenic cell death and by modulating the tumor microenvironment. In addition to killing tumor cells, these agents may also directly impact immune cell function. In order to understand the impact of different classes of chemotherapeutic agents on immune cell function, a panel of compounds was profiled using several in vitro functional assays of human cells.

Methods
T cells and monocytes were isolated from the whole blood of 6-8 healthy donors. Monocytes were differentiatied in vitro to immature dendritic cells by culture with GM-CSF and IL-4 for 7 days. T-cell proliferation was assessed by stimulating isolated T cells with antibodies to CD3 and CD28 for 3 days. Proliferation was measured by uptake of 3H-thymidine. T-cell cytokine production was assessed in an allogeneic mixed lymphocyte culture. Immature dendritic cells were cultured with T cells from HLA-mismatched donors for 5 days. IFNγ in the supernatant was assessed using ELISA. Dendritic-cell maturation was assessed by culturing immature dendritic cells with CD40L overnight. Surface markers (CD80, CD86, CD83, CD32, CD40, HLA-DR, PD-L1) were assessed using flow cytometry.

Results
Consistent with their anti-proliferative activity, several classes of chemotherapy agents potently inhibited anti-CD3 plus anti-CD28-driven T-cell proliferation. These included microtubule targeting agents (paclitaxel, docetaxel, eribulin), gemcitabine, and doxorubicin. Alkylating agents (cisplatin, carboplatin, oxaliplatin) and CDK4/6 inhibitors (abemaciclib, palbociclib) had moderate anti-proliferative activity. PARP inhibitors (rucaparib, olaparib), pemetrexed, and fluorouracil each had weak activity. Although pemetrexed and fluorouracil had weak activity, they did inhibit IFNγ production in the allogeneic mixed lymphocyte culture. Gemcitabine, doxorubicin, CDK4/6 inhibitors, and some of the microtubule targeting agents (paclitaxel, docetaxel) also had strong activity in this assay. Alkylating agents weakly inhibited IFNγ production. In the dendritic-cell maturation assay, eribulin and doxorubicin were the
only compounds among those tested that impacted expression of maturation and activation markers.

Conclusions
Many chemotherapeutic agents inhibit T-cell proliferation and IFNγ production, with IC50 values in the range of concentrations achieved at therapeutic exposures. These data suggest that several of these agents could also negatively impact T-cell–driven anti-tumor responses. This understanding may help guide treatment selection and scheduling of optimal combination therapeutics with checkpoint inhibitors to broaden anti-tumor responses.

Acknowledgements
Bristol-Myers Squibb.

References

Ethics Approval
The protocol was approved by site institutional review boards or independent ethics committees and conducted according to Good Clinical Practice guidelines, per the International Conference on Harmonisation. Volunteers provided written informed consent based on Declaration of Helsinki principles.

P579
Predictive and prognostic relevance of CD8+ tumor-infiltrating lymphocyte density combined with PD-L1 expression in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy
Changhoon Song, MD1, Yoonjin Kwak2, Hye Seung Lee3, Sung-Bum Kang4, Jae-Sung Kim5

1Seoul National University Bundang Hospital, Seongnam, Korea, Republic of; 2Seoul National University Hospital, Seoul, Korea, Republic of; 3Seoul National University Hospital, Seoul, Korea, Republic of

Correspondence: Hye Seung Lee (mw9195@snubh.org), Jae-Sung Kim (jskim@snubh.org)

Background
The classification of tumor microenvironments based on the presence of tumor infiltrating lymphocytes (TILs) and programmed cell death ligand-1 (PD-L1) expression has been used to predict the efficacy of immune checkpoint blockade in several cancer types. Few studies have evaluated the predictive and prognostic role of CD8 and PD-L1 coexpression in locally advanced rectal cancer.

Methods
CD8+ TIL density and tumor PD-L1 expression were assessed by immunohistochemistry using pretreatment biopsies from one-hundred cancer patients. CRT was determined based on Dworak tumor regression grade (TRG); node-positive patients, high CD8 TILs compared to low were significant.

Results
High CD8 TILs showed borderline significant association with better disease-free survival (DFS). Although PD-L1 expression alone was not correlated with DFS, the combination of PD-L1-positive and CD8 low group identified a subtype with poorer DFS. In multivariate analysis, this classification based on combination of CD8 and PD-L1 was independent prognostic factors even when considering the clinical parameters (p = 0.007). Among pathologic node-positive patients, high CD8 TILs compared to low were significantly associated with higher rate of good responders (29.2% vs 5.6%, p = 0.023).

Conclusions
A combination of tumor PD-L1 expression and low CD8+ TIL density was significantly associated with unfavorable survival in locally advanced rectal cancer patients who underwent preoperative CRT. It is proposed that PD-L1 expression in combination with CD8+ TIL density could be a useful predictive and prognostic biomarker in these patients.

Ethics Approval
The study was approved by Seoul National University Bundang Hospital’s Ethics Board, approval number B-1707-406-306.

P580
Immunogenomic landscape of neuroendocrine prostate cancer
Bhavneet Bhinder, MS1, Olivier Elemento, PhD1, Himisha Beltran, MD2, Alison Ferguson3

1Weill Cornell Medicine, New York, NY, United States; 2Dana Farber Cancer Institute, New York, NY, United States

Correspondence: Olivier Elemento (ole2001@med.cornell.edu), Himisha Beltran (hip9004@med.cornell.edu)

Background
Prostate cancer (PCa) shows a modest clinical benefit from immunotherapy. Neuroendocrine prostate adenocarcinoma (NEPC) is a histological subtype of advanced PCa that arises clonally from castrate resistant prostate adenocarcinoma (CRPC) as a mechanism of resistance, but shares pathological, clinical, and molecular features with small cell lung carcinoma (SCLC). We studied the immunogenomics landscape of NEPC compared to other prostate malignancies and SCLC to identify mechanisms of immune evasion and potential immunological targets in NEPC.

Methods
We evaluated RNA-seq data from a 190 patient cohort comprised of benign prostate (n=29), localized prostate adenocarcinoma (PCA; n=68), hormone-naïve metastatic prostate adenocarcinoma (mPCA; n=111), CRPC (n=54), NEPC (n=25) with follow-up data, and SCLC (n=28) [1]. Whole exome sequencing available for 234 cases was used to quantify the mutations and copy number load in the cohort. Unsupervised hierarchical clustering followed by a consensus clustering approach was applied to the expression profiles to determine T-cell immune status for each sample i.e., inflamed or depleted.

Results
Immune cluster analysis revealed a predominantly T-cell depleted immune status across prostate subtypes, where in all de novo NEPC cases belonged exclusively to the immune depleted cluster. Poor overall survival (OS) was associated with the inflamed compared to the depleted immune cluster (HR=2.62; p= 0.002; adjusted for subtype). Significantly higher genomic copy number gains were found in T-cell depleted compared to inflamed cases (p= 0.001); however, no difference in total mutation load was seen. Further analysis of NEPC showed a relatively lower expression of cytokines, cytolytic activity, checkpoint, antigen processing machinery, and HLA presentation genes in NEPC (p<0.001).

Conclusions
NEPC is characterized by a T-cell depleted tumor microenvironment similar to other metastatic prostate cancer subtypes but with higher PD-L1 expression, which is comparable to SCLC. The inverse correlation between OS and infiltration, as well as the novel expression changes in cytokines and checkpoint markers support further investigation into the potential immunological targets for NEPC.

References
Identification of prime master regulators for immunologic constant of rejection at pan-cancer scale using network analysis

Raghvendra Mall, PhD1, Mohamad Saad, PhD2, Jessica Roelands, Master2, Wouter Hendrickx, PhD2, Michele Ceccarelli1, Davide Bedognetti, MD, PhD2
1Harnad Bin Khalifa University, Doha, Qatar; 2Sidra Medicine, Doha, Qatar

Correspondence: Davide Bedognetti (dbedognetti@sidra.org)


Background

Network analysis in biology has led to the discovery of molecular and genetic interactions, biomarkers of disease, and therapeutic targets. Large-scale biomedical data availability offers a unique opportunity to assess the effect and impact of key cellular determinants for an observed phenotype. In this work, we consider the phenotype associated with the expression of the immunologic constant of rejection (ICR) gene set. This gene set consists of 4 major pathways observed in immune rejection of cancerous tissue, Th1 signaling, chemokine production, effector function and immune regulation. Higher expression of these genes is associated with tumor infiltrating lymphocytes and an active immune engagement, often correlated with prolonged survival. [1–6]

Methods

Consensus clustering of tumor samples based on ICR gene expression divides them into three classes, ICR high, medium and low. The ICR high phenotype is associated with better survival in a subset of cancer types which we refer to as ICR enabled (N=8). In other cancer types we observe the opposite. (ICR Disabled, N=4) [7]

Reverse engineering the gene regulatory networks (TF-target) for each cancer subtype from transcriptional profiles (RNA sequences) of tumors obtained via the cancer genome atlas (TCGA) was performed using a machine learning technique called RGBM. We then perform functional gene set enrichment analysis to discover differential active master regulators.

Results

Our aim is to identify key transcription factors (TF) that play fundamental roles in attacking cancer cells, still remain unclear. In this study, we collected tumor tissues and blood samples from 22 kidney cancer patients, before cryoablation and at 3 months after cryoablation. We applied a next generation sequencing approach to characterize T cell receptor beta (TCRB) repertoires using RNA isoforms. We applied a next generation sequencing approach to characterize T cell receptor beta (TCRB) repertoires using RNA isoforms. We then perform functional gene set enrichment analysis to discover differential active master regulators.

Conclusions

Downstream analysis of the master regulators specific to the ICR Low phenotype resulted in identification of the NOTCH signaling pathway, transcriptional regulation of oncogene TP53 and several other cancer related signaling pathways that need to be investigated further to understand mechanisms of poor immune response (ICR Low).

References


Characterization of abscopal effect in cryoablation-treated kidney cancer patients

Taigo Kato, MD, PhD1, Motochide Uemura1, Kazuma Kioytani2, Norio Nonomura1
1Osaka University, Osaka, Japan; 2Japanese Foundation for Cancer Research, Tokyo, Japan

Correspondence: Taigo Kato (kato@uro.med.osaka-u.ac.jp)

Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P582

Background

Cryoablation is one of treatment modalities for kidney cancer and is expected to induce strong local and systemic T cell-mediated immune reactions. So far, in some cases, these immune reactions cause the elimination of distant tumor (abscopal effect). However, the molecular mechanisms of the immune response, particularly for T cells that play fundamental roles in attacking cancer cells, still remain unclear.

Methods

In this study, we collected tumor tissues and blood samples from 22 kidney cancer patients, before cryoablation and at 3 months after cryoablation. We applied a next generation sequencing approach to characterize T cell receptor beta (TCRB) repertoires using RNAs isolated from samples.

Results

TCRB repertoire analysis revealed expansion of certain T cell clones in tumor tissues by cryoablation. We also found that proportions of abundant TCRB clonotypes (frequency of ≥1%) were significantly increased in the post-cryoablation tissues than those of pre-cryoablation tumors. Interestingly, some of these TCRB clonotypes were increased in peripheral blood. Expression analysis of immune-related genes in the tissues of pre- and post-cryoablation showed significantly elevated transcriptional levels of CD8, CD4, GZMA, and CD11c with higher CD8/FOXP3 ratio in the post-cryoablation tissues.

Conclusions

Our findings revealed that cryoablation could induce strong immune reactions in tumors with oligoclonal expansion of anti-tumor T cells, which circulate systemically and induce abscopal effect in distant tumor.

Building a translational pathway using pharmacodynamic and syngeneic tumour models in conjunction with gene expression to enable the development of cancer immune therapies

Louise Brackenbury, PhD1, Tommaso Linnari2, Robert Nunan3, Louise Harvey, BSc2, Clio Andreea, PhD, Bsc (Hons)2, Louise Brackenbury2, S. Rhiannon Jenkinson, PhD2
1Charles River Portishead, Bristol, United Kingdom; 2CRL Portishead, Bristol, United Kingdom

Correspondence: S. Rhiannon Jenkinson (rhiannonjenkinson@cri.com)

Background
In order to develop therapeutics which drive the immune system to target tumour cells and eliminate tumour growth, sophisticated in vitro and in vivo models are required. We have developed models which enable us to combine data from human immune cell in vitro assays and murine pharmacodynamic (PD) and syngeneic tumour models to evaluate which pathways a therapeutic is hitting and whether it is effective at inhibiting tumour growth in vivo. We show here the powerful combination of using TCR transgenic T cell adoptive transfer and syngeneic tumour models with flow cytometry and Nanostring profiling of gene expression within the tumour microenvironment (TME) to determine the effect of therapeutic intervention.

Methods
To determine the effect of checkpoint inhibitors, mice bearing a defined population of ovalbumin (OVA)-specific T cells were challenged either with antigen (PD model), or an OVA expressing tumour (EG7 or MC38). In the PD model, activation, proliferation and differentiation of the immune cells into CTL were assessed. Using the OVA-expressing tumour models, comprehensive TIL analysis was carried out to determine how changes to T cell activation impacted on the wider TME and whether a model tumour vaccine could improve T cell responses. Nanostring analysis of gene expression using the murine immune-oncology 360 panel enabled a deeper analysis of the TME and acted as a powerful tool for the identification of potential PD biomarkers. Tumour killing assays were also performed with human cell lines and PBMC using clinical antibodies targeting the same pathways.

Results
In the PD model, anti-PD-L1 caused robust upregulation of CD25, IFN-γ and granzyme B by antigen-specific CD8+ T cells. Anti-CTLA-4 exerted a similar but less potent effect. Immunisation with peptide increased T cell infiltration in the syngeneic model and this correlated with enhanced T cell functional capacity. Nanostring analysis of tumours saw raised CTL, NK cell and neutrophil gene expression within tumours from peptide immunised mice. Clinical therapeutics targeting PD1 or CTLA-4 drove enhanced tumour killing using human cell-based assays.

Conclusions
These models allow testing of novel therapeutics alongside benchmark reagents. The PD model provides a screening platform to assess enhancement of T cell function before moving into syngeneic models. Nanostring gene expression profiling may direct which in vitro assays should be used to map the immunological mechanisms underlying immune modulation. The use of in vitro and in vivo PD/efficacy models better enable assessment of novel cancer immune therapeutics and allow early identification of potential biomarkers.

Ethics Approval
The study was approved by HRA NRES South West, Bristol (UK), approval number 15/SW/0029.

PS84
Functional cytometric targeting of PD-L1 at the surface of living cells to investigate resistance to immunotherapy in multiple myeloma
Jolene Bradford, MLS, SCYM(ASCP)1, Laura Rico2, Jordi Juncà2, Jorge Bardina3, Angel Bistué-Rovira3, Michael Ward1, Jordi Petriz2
1Thermo Fisher Scientific, Eugene, OR, United States; 2Josep Carreras Leukaemia Research, Badalona (Barcelona), Spain
Correspondence: Jordi Petriz (jpetriz@carrerasresearch.org) Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):PS84

Background
Multiple myeloma (MM) is characterized by accumulation of malignant plasma cells in the bone marrow (BM) with an associated immunosuppressive BM microenvironment. Programmed Death-Ligand 1 (PD-L1) has been shown to suppress immune responses through the interaction with Programmed Death-1 (PD-1). In MM, PD-L1 is overexpressed in MM plasma cells and in Myeloid Derived Suppressor Cells (MDSCs). PD-1 is expressed in T-cells. The interaction between PD-L1 and PD-1 decreases TCR-mediated proliferation and cytokine production. PD-L1 plays an important role in tumor immune evasion and drug resistance, and is considered a therapeutic target. However, some MM individuals do not respond to treatments with PD-L1 or PD-1 inhibitors. The aim of this study was to design and evaluate a direct functional screening assay to identify MM MDSCs PD-L1+ using flow cytometry, and its potential use in MM management.

Methods
Samples were labeled with PE-PD-L1, APC-CD11b, PE-Cy7-CD33, and FITC-HLA-DR (Invitrogen™ eBioscience) to detect MDSCs using no-lyse no-wash methods. Vybrant™ DyeCycle™ Violet Stain (Thermo Fisher) was used to discriminate nucleated cells from erythrocytes and debris. Samples were analyzed using Attune™ NxT Flow Cytometer (Thermo Fisher). PD-L1 expression was studied in n=35 MM subjects, with and without bone marrow stimulation with PMA (Merck), for 10 minutes at 37°C. PD-L1 cell surface expression was compared with cytoplasmic expression (n=11 subjects). Kinetics of PD-L1 expression were also studied over time. Competitive experiments in the presence of Durvalumab (0 ng/µl to 250 ng/µl) were used to study its interaction with PD-L1.

Results
PD-L1 expression was found dramatically increased after stimulation (n=33 subjects, 94.3%) ranging from 2 to 650 times. PD-L1 cytoplasmic levels were found to be undetectable. PD-L1 expression was found to be higher after 1 to 5 minute stimulation, with a progressive decrease up to 1 hour. Co-incubation with Durvalumab resulted in different inhibitory PD-L1 immunofluorescent profiles.

Conclusions
PD-L1 reactivity appears to result from complex interactions that can only be detected with minimal sample perturbation. Since PD-L1 is not found at the cytoplasmic level, PD-L1 may reveal steric changes in response to stimulation, even for a short period of time. These changes may be associated with a PD-L1 immunoregulatory mechanism that may affect therapies targeting the PD-1/PD-L1 checkpoint. Assessment of PD-L1 folding may help to develop better treatment strategies or to predict therapy resistance. No-lyse no-wash methodology in combination with functional assays show promise as an emerging strategy to model conformational changes in the target site.

Ethics Approval
All procedures were performed in accordance with the internal protocols of the laboratory, which were authorized by the HGTiP’s Ethical Committee, in accordance with current Spanish legislation, by the Departament de Medi Ambient i Habitatge (file #1899) of the Autonomous Government of Catalonia (Generalitat de Catalunya).

PS85
Extracellular matrix gene expression and cytotoxic T lymphocyte infiltration in the tumor microenvironment in non-small cell lung cancer
Na Li, PhD, Hongze Sun, Xin Wang, Ying Zhou, Zhifu Zhang, Anushka Dikshit, PhD, Courtney Anderson, PhD, Xiao-Jun Ma
Advanced Cell Diagnostics, Shanghai, China
Correspondence: Xiao-Jun Ma (xijia@bio-techne.com) Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):PS85

Background
Immunotherapy has proven to be a powerful anti-tumor therapy by harnessing the body’s own immune system to target and kill tumor cells. However, immunotherapy is not successful in all cancer patients due to both intrinsic non-responsiveness and adaptive resistance. Developing predictive biomarkers and understanding mechanisms of resistance are major goals of the immuno-oncology community. The extracellular matrix (ECM), an important factor for promoting tumor growth and metastasis, may also act as a physical barrier to prevent immune cell infiltration and promote tumor immune escape. Components of the ECM such as COL11A1, COL4A1, and LOXL2 have been shown to be associated with cancer progression. Furthermore, new data suggests that TGFβ activation leads to up-regulation of ECM proteins and extracellular matrix proteins at the tumor site.
genes in cancer-associated fibroblasts and immune suppression. However, it remains poorly understood which cells in the tumor microenvironment (TME) are the sources of ECM gene expression and how they are related to tumor infiltrating cytotoxic T lymphocytes (CTLs).

**Methods**

In this study, we employed a highly sensitive and specific RNAscope in situ hybridization (ISH) duplex assay to directly visualize the tissue distribution of cells expressing COL4A1, COL11A1, LOXL2, and TGFβ1 in relation to tumor infiltrating CTLs in non-small-cell lung carcinoma (NSCLC), NSCLC tissue microarrays (TMAs) consisting of 63 independent patient FFPE tumor samples were analyzed using this ISH assay with the following probe combinations: Hs-CD8/Hs-IFNG, Hs-CD4/Hs-FOXp3, Hs-LOXL2/Hs-COL4A1, and Hs-TGFβ1/Hs-COL11A1.

**Results**

We observed COL4A1 expression in both tumor and tumor-associated stromal cells in different samples. In contrast, COL11A1 was only expressed in tumor-associated stromal cells. Interestingly, high COL4A1 expression was associated with high CD8+ T cell infiltration, whereas high COL11A1 expression was associated with poor CD8+ T cell infiltration. In addition, tumor expression of TGFβ1 was positively correlated with COL11A1 expression. These data depict a complex landscape of ECM gene expression and their relationship to T cell infiltration in the tumor and TME.

**Conclusions**

Taken together, these results demonstrate that the RNAscope assay provides a powerful approach to directly examine the interactions between tumor, ECM, and T cell immune infiltration and offers advantages over immunohistochemistry (IHC) for identifying the cellular sources of secreted proteins such as ECM components in the TME.

**Conclusions**

DPX-Survivac combination therapy induces robust and sustained survivin-specific responses and promotes T cell infiltration of tumors, without a loss in functionality. The infiltration immune cells beyond T cells has been demonstrated in tumor tissue yet was not consistently detected in PBMCs; a finding that emphasizes the need for a full understanding of the mechanism of action of novel immunotherapies and combinations.

**Ethics Approval**

The study was approved by Dalhousie University's ethics board, approval number 2018-4659.
breast cancer. Additionally, whole-transcriptome analysis of 3D-cultured T cells revealed distinct transcriptional profiles depending on the surrounding collagen-density. Specifically, a high-density matrix induced downregulation of cytotoxic activity markers and up-regulation of regulatory T cell markers. Importantly, these transcriptional changes were accompanied by an impaired ability of tumor-infiltrating T cells cultured in a high-density matrix to kill autologous melanoma cells.

Conclusions
Our study identifies a new immune modulatory mechanism, which could be essential for suppression of T cell activity in the tumor microenvironment.

P588
Development of in vitro immune effector function assays to better approximate the in vivo behavior of biotherapeutics and cell therapies
Chris Langsdorf, BS
Thermo Fisher Scientific, Eugene, OR, United States
Correspondence: Chris Langsdorf (chris.langsdorf@thermofisher.com)

Background
With continued growth in development and approval of biologic drugs and cell therapies, comes a need for more robust and reliable cell-based assays and analysis systems. Here we describe new methods to assess the specific killing of target cells by antibody-mediated complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) by natural killer cells, T cell killing, and antibody-dependent cellular phagocytosis (ADCP).

Methods
These methods are demonstrated with single-cell analysis models compatible with flow cytometry and image-based analysis. Additionally, we have transitioned these assays into more biologically-relevant models such as tumor spheroids and whole blood. T and NK cell penetration and killing of breast and lung cancer spheroids was evaluated using quantitative confocal microscopy. Ramos Burkitt’s lymphoma cells were opsonized with Rituximab, spiked into human whole blood, and complement- and NK-dependent killing evaluated using flow cytometry. Ramos cells opsonized with Binatumomab were spiked into human whole blood and bispecific-dependent T cell killing evaluated with flow cytometry.

Results
T and NK cells were imaged at single-cell resolution as they penetrated and killed tumor spheroids in an antibody-dependent manner. Whole blood analysis with flow cytometry was able to clearly distinguish target cells from white blood cells, and clearly indicated the percent of target cells killed in an antibody-dependent fashion.

Penetration and potency of immune effector cells can be evaluated using whole-spheroid imaging. Flow cytometry provides a robust method to directly measure T, NK, and complement-dependent killing of cancer cells in human whole blood.

P589
IL-15 deficient colon carcinomas have decreased cytolytic lymphocytes and skewed myeloid cell populations
Kimberly Schluns, PhD1, Chih-Chien Chou, PhD1, Rosa Santana-Carrero2, R. Eric Davis, PhD1
1University of Texas MD Anderson Cancer Center, Houston, TX, United States; 2UT MD Anderson Cancer Center/UT Health Graduate School of Biomedical Sciences, Houston, TX, United States
Correspondence: Kimberly Schluns (kischluns@mdanderson.org)

Background
Loss of Interleukin (IL)–15 expression by colon tumors strongly correlates with classification as microsatellite stable, decreased tumor infiltrating T cells, increased metastasis, and poor responses to immunotherapy. To better understand how IL-15 expression regulates tumor-associated immune cells and demonstrate the importance of IL-15 expressed by tumor cells, we developed a mouse model system to examine this by generating MC-38 tumor cells deficient in IL-15 using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system. The MC-38 cells are ideal for this as the tumor cells are the dominant source of sIL-15 complexes in the tumor microenvironment (TME) [1].

Methods
After one round of CRISPR/Cas9 deletion of IL-15, we have generated MC-38 cells that lack one IL-15 allele (i.e. IL-15−/− MC-38 cells) and express decreased levels of soluble IL-15 complexes. A second round of deletion has led to complete deletion of IL-15 in MC-38 cells (i.e. IL-15−/− MC-38). IL-15−/− and IL-15−/− MC-38 cells and wildtype (Wt) MC-38 cells were implanted subcutaneously into Wt mice and tumor growth measure overtime. Additionally, immune cells in tumors were analyzed at earlier time points. RNAseq of tumor-associated myeloid cells was conducted in Wt MC-38 tumors treated with neutralizing IL-15 antibody.

Results
Surprisingly, deletion of one IL-15 allele was sufficient to affect tumor growth as IL-15−/− MC-38 tumors grew faster than Wt MC-38 tumors but had similar growth kinetics in vitro. IL-15−/− MC-38 tumors harbored less CD8 T cells and NK cells than Wt tumors whereas numbers of CD4 T cells were similar. Interestingly, these tumors also had increased CD11b+Ly6G+ and CD11b+Ly6ChiLy6G− myeloid cells (putative MDSCs). Implanted IL-15−/− MC-38 cells also progressed faster than Wt MC-38 cells. Gene expression analysis of myeloid cells showed that blocking IL-15 in tumors increased expression of CXCL4, CD206, Arginase 1, and tryptophan 2,3-dioxynegene and decreased IL-12p40 and IL-6.

Conclusions
These results demonstrate that even partially decreasing the levels of IL-15 in the TME negatively impacts the numbers of CD8 T cells and NK cells and promotes differentiation of putative MDSCs. These results suggest that IL-15 expressed by the tumor cells is a key attribute creating a microenvironment that supports cytolytic lymphocytes by not only acting directly on lymphocytes but also indirectly by skewing the myeloid cells towards pro-inflammatory activities. Overall, the IL-15−/− MC-38 cells is a model that can be used to identify the mechanisms contributing to the poor therapeutic responses observed in human colon carcinomas.

References

Ethics Approval
All animal procedures were conducted in accordance with the animal care and use protocols (00000851-RN02) approved by the IACUC at the UT MD Anderson Cancer Center.

P590
The use of in vitro T cell assays to accelerate cancer development of immunotherapy and immune checkpoint inhibitors
Amin Osmani1, Thibault Jonckheere2, Sofie Pattijn2, Mayuko Oh2, Thibaut Janss1
1ImmunXperts, Gosselies, Belgium; 2ImmunXperts Sa, Gosselies, Belgium
Correspondence: Amin Osmani (amin.osmani@immunxperts.com)

Background
During the last years, significant advancement has been made in the clinical application of cancer immunotherapies. Molecules directed against immune checkpoints and other agonists show great promise for treatment of a variety of malignancies. Next to CTLA-4 and PD-1 blockade, a wide range of therapies with the potential to reverse the tumor-induced suppression are under development.


Methods
Mixed lymphocyte reaction assays using both innate cells and lymphoid cells mimic a real physiological T cell response and are widely used for the potency screening of candidate therapeutics. The use of different allogeneic donor combinations can provide additional information on the profile of the responding population. Other T cell assays such as antigen-specific CMV recall activation assays or SEB activation assays can be used to evaluate the ability of test molecules to promote T cell responses.

Next to these activation assays, the antigen-specificity within a naïve or pre-exposed T cell population can be evaluated by using T cell enrichment assays, which can be set up using different formats depending on the origin of test molecules. Additionally, it might also be beneficial to generate peptide-specific T cell pools or clones to be used for functional testing e.g. in the context of tumor-associated antigens (TAA).

Results
All these in vitro T cell assays are optimized and fine-tuned for the screening of certain types of molecules. An important factor for sensitive and reproducible assays and consistent results is the quality of the primary immune cells. Therefore, all PBMC donor preparations are quality controlled and HLA-typed, and optimized procedures are used to generate functional subpopulations such as dendritic cells and T cell subpopulations.

Conclusions
Early evaluation of the effectiveness of candidate therapeutics and combination therapies can be assessed using mouse models and in vitro bioassays with mouse or human immune cells.

References
Amin Osmani 1, Thibaut Janss 2, Juliette Larry 1, Thibault Jonckheere 2, Severine Guiltaire 1, Sofie Pattijn 2

---

**PS91**

**In vitro functional suppressive bioassays for evaluating candidate therapeutic effectiveness in immuno-oncology**

Amin Osmani 1, Thibaut Janss 2, Juliette Larry 1, Thibault Jonckheere 2, Severine Guiltaire 1, Sofie Pattijn 2

1 ImmunXperts, Gosselies, Belgium; 2 ImmunXperts SA, Gosselies, Belgium

Correspondence: Amin Osmani (amin.osmani@immunxperts.com)

Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):PS91

**Background**
The increasing interest in the tumour microenvironment leads to focus on new bioassays to represent all the players of the cancer immune response. Some of these players like Tumour Associated Macrophages (TAM), Myeloid Derived Suppressor Cells (MDSC) regulatory T cells (Treg) play an important role by downregulating the anti-tumour response. Their regulation mechanisms constitute an important target for new therapeutics. In order to study these mechanisms in a human model, suppressive bioassays, mimicking the suppressive action of these cells on T cells activations, were developed.

**Methods**
Macrophages possess important active and regulatory functions in both innate and adaptive immune responses. Classical activated macrophages, also classified as M1-like macrophages, comprise immune effector cells with an acute inflammatory phenotype while the alternatively activated M2-like macrophages have suppressive and healing capacities. Tumor associated macrophages (TAMs) are present at high densities in solid tumors and share many characteristics with so-called M2 macrophages.

**Results**
Although distinguished classification and in vitro generation and polarization of M1- and M2-like macrophages is challenging, in vitro assays can be a first step to screen the effect of the test molecules on the phenotype and function of the macrophages. For example, macrophage precursors display extraordinary plasticity in response to exogenous and endogenous stimuli which can lead them to M2-polarized macrophages or towards the M1-activated state. Using in vitro polarization and functional macrophage assays, one can screen molecules with the potential to influence M1 and M2 like macrophage generation and polarization. Next to that, the effect of the test molecules on the function of the macrophages can be evaluated using a macrophage suppressive assay. Here the ability of the molecules to reverse the stimulating effect of the M1-macrophages or suppressive effect of the M2-macrophages can be determined. Myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg) can also be found in the tumour microenvironment and present a highly suppressive phenotype. Their role in relation to cancer development and progression has shown to be of great importance. Therefore, the ability of molecules to reverse the suppressive function of the MDSC or Treg on immune effector cells can be evaluated in vitro using these cell-type specific suppressive bioassays.

**Conclusions**
The use of the bioassays contributes to a better understanding of the tumour microenvironment and the steps needed to generate an anti-tumour response by the immune system will help to assess the functional potential of new drugs, design clinical trials and ultimately discover relevant biomarkers.
Conclusions
These results indicate that TGFβ signaling represses CXCR3-dependent trafficking of CD8+ T cells into tumors and can be reversed to improve tumor immunity alone and in combination with radiation therapy.

Trial Registration
NCT02688712

Ethics Approval
This clinical study was approved by Providence Health & Services IRB, approval number 15-050. The animal modeling was performed under the approval of our institution’s IACUC Protocol #37, in our OLAW certified animal facility (Assurance #D16-00526).

P593
Rituximab treatment induces long lasting potentiation of degranulation responses by NK cells in non-Hodgkin lymphoma patients
Dmitry Zhigarev, MS1, Alexander Macfarlane1, Mowafaq Jilali1, R. Katherine Alspaugh, PhD1, Adam Cohen, MD1, Kerry Campbell1
Fox Chase Cancer Center, Philadelphia, PA, United States; 2Pirogov National Research Medical Univ., Philadelphia, PA, United States
Correspondence: Kerry Campbell (kerry.campbell@fccc.edu)

Background
Rituximab is widely used to treat B-cell non-Hodgkin lymphomas (NHL). The antibody depletes B cells in patients by several mechanisms, including antibody-dependent cellular cytotoxicity (ADCC) by NK cells and monocytes, complement-mediated cell death, and signaling apoptosis. We tested degranulation responses by NK cells in peripheral blood from B-cell NHL patients before, during and after rituximab treatment.

Methods
Seventy-five patients with B-cell NHL (follicular lymphoma or marginal zone lymphoma) were monitored for immune phenotype and NK cell function in peripheral blood, as well as 54 healthy volunteers. All blood donors provided informed consent in accordance with our Institutional Review Board. Thirteen NHL patients were treated with rituximab and provided blood samples immediately before the first treatment, during the treatment period and three months after treatment. Peripheral blood mononuclear cells (PBMC) were isolated on Ficoll. Degranulation assays were performed by exposing PBMC to 721.221 EBV-transformed B cell line (natural cytotoxicity) for two hours and staining for LAMP-1 (CD107a). Degranulation was quantified by flow cytometry as percentage of LAMP-1+ CD56dim (mature, cytolytic) NK cells.

Results
NK cell degranulation responses were not significantly different between healthy donors or pretreatment samples from NHL patients. Within the patients treated with rituximab, a significant increase in the degranulation response of CD56dim NK cells was observed between the pretreatment and during treatment samples when assayed under natural cytotoxicity conditions (p < 0.05).

Conclusions
Our results provide evidence that a treatment course of rituximab can potentiate degranulation activity of peripheral blood NK cells under natural cytotoxicity conditions for at least 3 months after the end of therapy. At the same time NK cells become more resistant to activation-induced death during these natural cytotoxicity responses, which may contribute to the improved functional response.

Acknowledgements
We thank the FCCC Biosample Repository for coordinating patient consenting and sample acquisition and support from the FCCC Keystone Program, FCCC Boards of Associates, and NIH grants CA083859 (KSC) and CA09627 (FCCC).

P594
Targeting immune-suppressive myeloid cell pathways for the treatment of cancer
Jesus Banuelos, Susan Lee, PhD, Tim Park, Nell Narasappa, MSc, Dana Piovesan, MSc, Yu Chen, Jenna Jeffrey, PhD, Jarek Kalisiak, Kimberline Gerrick, Hema Singh, Annette Becker, PhD, Jie Chen, Sean Cho, PhD, Bryan Handlos, Akshata Udyavar, PhD, Steve Young, PhD, Jay Powers, PhD, Matthew Walters, PhD, Jo Tan
Arcus Biosciences
Correspondence: Jesus Banuelos (jbaneluels@arcusbio.com)

Background
Elevated levels of myeloid-derived suppressor cells (MDSCs) have been associated with a blunted response to PD-L1 inhibitors in vivo and suppressive myeloid cells have been shown to inhibit T cell responses in vitro. Suppressive myeloid cells mediate their immunosuppressive effects via multiple mechanisms, including expression of immune checkpoint protein ligands, activation of the PI3Kγ pathway, and release of arginase-1 (ARG1), an arginine-depleting enzyme. The significant role of myeloid cells in dampening anti-tumor immunity makes them an attractive target for immunotherapy. To that end, we have developed potent and selective inhibitors against PI3Kγ and ARG1.

Methods
Recombinant and endogenous ARG1 from human granulocytic lysates were used to determine AB474 potency. The ability of AB474 (ARG1 inhibitor), to rescue recombinant ARG1-mediated inhibition of T cell activation was assessed in human T cells isolated from healthy donors. The ability of PI3Kγ inhibition to stimulate immune cells was assessed in CD14+ monocytes or monocyte-derived M1 polarized macrophages and confirmed using mixed lymphocyte reactions. Anti-tumor activity was determined using syngeneic tumor models.

Results
Using sorted immune cells from healthy donor PBMC, we determined that PI3Kγ expression is highest in monocytes, whereas PI3Kδ expression is higher in lymphocytes. Inhibition of PI3Kγ significantly (p < 0.05) elevated levels of ARG1 were observed in cancer patients compared to healthy donors. In particular, ARG1 was highly expressed in polymorphonuclear-MDSCs while lower levels were seen in monocytic-MDSCs. AB474 inhibited the activity of both recombinant and endogenous ARG1 with an IC50 of 15 nM and 20 nM, respectively. Consistent with this observation, AB474 reversed ARG1-mediated suppression of human CD8+ T cell activation. Additionally, single agent AB474 significantly (p < 0.05) enhanced anti-tumor responses and act in concert with immune checkpoint blockade and other immunotherapies.

P595
Gene editing and protein expression in innate immunity cells by electroporation
Jian Chen, PhD, George Sun
Celetrix LLC, Manassas, VA, United States
Correspondence: Jian Chen (jchen@celetrix.com)

Background
The interest in the therapeutic potentials of the innate immune system is growing as we gained more knowledge of role of the innate immune system in fighting cancer. Natural killer (NK) cells and macrophages are capable of attacking tumor cells directly and dendritic cells are important for antigen presentation. Macrophages are also important for modulation of tumor microenvironment that presents both obstacles and opportunities to fighting tumor cells. Gene expression or gene editing in the innate immune cells are not only
important for studying gene functions in these cells, but also important for potential clinical applications.

**Methods**
Using our novel electroporation technology, we have found that the innate immunity cells can all be modified by protein expression plasmid vectors or CRISPR-Cas9 mediated gene editing.

**Results**
Primary NK cells, primary bone marrow monocytes and peripheral blood monocytes need relatively high voltage for electroporation. Primary mouse peritoneal macrophage needs lower voltage and expanded NK cells as well as mature dendritic cells need lowest voltage. Using the same electroporation buffer, we were able to successfully electroporate these different cells using different voltages. The transfection efficiency for plasmids can reach 80% and Cas9 ribonucleoprotein (RNP) with gRNA can also be electroporated successfully.

**Conclusions**
Our capability to modify all of the major types of the innate immunity cells (MDSCs), by electroporation is a significant step that could contribute to harnessing the power of the innate immunity system for immunotherapy of cancer.

---

**P596**  
**Targeted IRAK-M degradation as a novel approach in cancer immunotherapy overcoming innate-driven immunosuppression**  
Kanae Gamo, MS, Naomi Kitamoto, Tomoaki Hayashi, Yoshitake Tomita, Yusuke Tominari  
FIMECS, Inc., Fujisawa, Japan

**Correspondence:** Kanae Gamo (kanae.gamo@fimecs.com)  
*Journal for ImmunoTherapy of Cancer* 2019, 7(Suppl 1):P596

**Background**
IRAK-M has an important role in tightly controlling innate immune responsiveness to preserve immune homeostasis by acting as a negative feedback regulator of TLR/IL-1R signaling pathway. Targeting IRAK-M, which expression is restricted to myeloid cells, would be potentially limiting adverse events against non-target tissues. From supporting evidence for the role of IRAK-M in innate immunosuppressive capacity of myeloid cells in tumor microenvironment, we have generated compounds targeting IRAK-M as an effective cancer-immunotherapy strategy by converting tumors to more inflamed state. Since IRAK-M is a pseudokinase which lacks kinase activity, it is considered 'undruggable' that could not be targeted pharmacologically by the conventional small molecule. Therefore, we have developed heterobifunctional degrader molecules comprising IRAK-M-binding moiety linked to proprietary E3 binders to eliminate IRAK-M protein.

**Methods**
Optimization of IRAK-M degraders have been conducted by applying RatPIDS(TM) which is a proprietary divergent degrader synthetic platform and identified multiple preclinical candidates within a year. We measured the activity of degradation mechanisms in vitro by analyzing degradation rates, protein turnover and proteasome dependence. To assess the effect of IRAK-M degrader on myeloid-derived suppressor cells (MDSCs), we performed MDSC suppression assays in a culture model with CD8+ T cells. One of the drug candidates was profiled extensively in different syngeneic models. Subsets of tumors and spleen from treated mice were analyzed ten days following dosing initiation for myeloid cell populations and phenotype.

**Results**
We demonstrated a dose- and time-dependent degradation of IRAK-M protein in THP1 human monocytic leukemia cells with degrader treatment in a proteasome-dependent manner. MDSC suppression assays revealed that IRAK-M degrader could release the suppressive function of MDSC on both IFNγ production by CD8+ T cells as well as T cell proliferation. When examined in mouse models, IRAK-M degrader showed significant anti-tumor activity in several syngeneic models at tolerated doses and schedules. In the 4T1-HA model, we found increase of LPS-induced TNFα production in white blood cells from compound injected mice associated with degradation of IRAK-M protein as pharmacodynamic effect. FACS analysis showed that IRAK-M degradation translated into increased infiltration of M1-like activated macrophage into tumors and spleen. Advanced profiling of the drug candidate is ongoing in IND-enabling studies.

**Conclusions**
In summary, we demonstrated IRAK-M degrader as a novel and promising immuno-modulatory therapeutic modality and the great potential of shifting the balance between tolerance and immunity by releasing immunosuppressive network activity, leading to a more favorable tumor microenvironment to enhance host immunity.

---

**P597**  
**Myeloid-specific inflammasome signaling promotes tumor growth**  
Cara Lang1, Young Kim, MD2  
1Vanderbilt University, Nashville, TN, United States; 2Vanderbilt University Medical Center, Nashville, United States

**Correspondence:** Young Kim (yk2.kim@vumc.org)  
*Journal for ImmunoTherapy of Cancer* 2019, 7(Suppl 1):P597

**Background**
Tumor infiltrating myeloid cells, such as Myeloid Derived Suppressor Cells (MDSCs) and Tumor Associated Macrophages (TAMs), are important mediators of immune evasion in cancer, and are associated with worse overall survival and progression free survival in various types of solid tumors. However their pro-carcinogenic functions in the tumor microenvironment are unclear. Here, we propose that the inflammasome signaling pathway is a key T cell independent mechanism of myeloid-mediated tumor growth.

**Methods**
In this work, we use various adoptive transfer models to generate bone marrow specific inflammasome knockout mice and utilized a B16 melanoma model to assess changes in tumor growth.

**Results**
We first performed single cell sequencing of Head and Neck Squamous Cell Carcinoma (HNSCC) tumors, and found IL-1β expression is restricted to the tumor infiltrating myeloid cell populations. From our working hypothesis that myeloid inflammasome signaling can promote T-cell independent tumor growth, we initially showed that caspase 1 is important for promoting tumor growth in a myeloid specific manner. However, the mechanisms by which myeloid-intrinsic inflammasome activation promotes T-cell independent tumor growth are not well understood. Here we utilize a B16 melanoma tumor growth model to show that NLRRP3 dependent caspase 1 activation is driving tumor growth in vivo, while AIM2 has no effect on tumor growth. In addition, we have found that circulating T cells in tumor bearing inflammasome knockout mice have higher expression levels of the checkpoint molecule PD-1. We utilized a C57Bl/6 mouse model of B16 melanoma to demonstrate that combination of inflammasome blockade and checkpoint blockade further reduces tumor burden in vivo.

**Conclusions**
This work will have broad implications across all solid tumor types and will allow for the understanding of how myeloid-specific production of IL-1β promotes tumor growth. In addition, the proposed work will contribute to our basic knowledge of inflammasome activation within the tumor microenvironment.

---

**P598**  
**Glioblastoma-associated myeloid cells promote regulatory T and B-cell function via transfer of microvesicle**  
Catalina Lee-Chang, PhH1, Aida Rashidi1, Jason Miska2, Peng Zhang3, Katarzyna Pituch1, David Hou1, Irina Balyasnikova, PhD1, Maciej Lesniak, MD1  
1Northwestern University, Chicago, IL, United States; 2Northwestern University, Chicago, IL, United States

**Correspondence:** Catalina Lee-Chang (catalina.leechang@northwestern.edu)  
*Journal for ImmunoTherapy of Cancer* 2019, 7(Suppl 1):P598

**Background**
Glioblastoma-associated myeloid cells promote T and B-cell function via transfer of microvesicle.
Background
Recent clinical trials in brain tumor immunotherapy have gathered tremendous attention while at the same time establishing a favourable safety profile and preliminary efficacy. Immunotherapy is a promising approach in other malignancies but needs to be tailored specifically to glioblastoma (GBM) given the highly immunosuppressive tumor microenvironment [1, 2]. A hallmark of GBM microenvironment is the massive infiltration of bone marrow-derived tumor-associated myeloid cells (TAMCs) and regulatory T-cells (Tregs) [3-7]. We recently identified the existence of perivascular regulatory B-cells (Bregs) that blocked the activation of cytotoxic CD8+ T-cells in a subset of GBM patients. Even though tremendous progress has been made to understand GBM-mediated immunosuppression [8-10], there is still limited knowledge regarding the mechanisms by which the tumor selects, maintains and promotes immunosuppressive cells in detriment of anti-tumor immunity. A deeper comprehension of these processes will propel the rational design of successful immunotherapies for GBM. Recent studies in our laboratory where tumor-infiltrating myeloid cells were specifically depleted using antibody-targeting drug delivery via nanoparticles in preclinical settings, pointed out to the almost total dependency of Tregs and Bregs on TAMCs to maintain their cellular abundance and immunosuppressive functions. The data presented here highlight the biological relevance of TAMC-derived microvesicle in controlling remotely regulatory lymphocytes.

Methods
Microvesicles were isolated by ultracentrifugation. Microvesicle uptake by lymphocytes was assessed by flow cytometry using fluorescent lipophilic dye.

Results
TAMC can control both Tregs and Bregs via microvesicle production. Microvesicle uptake by Tregs and Bregs was assessed using CD163+ TAMCs from GBM tumors. Proteomics and immunophenotypic analysis of TAMC-derived microvesicles revealed that inactive TGFβ and PD-L1 are transported as cargos. Our data showed that microvesicle-TGFβ controls Tregs and Bregs cellular abundance. On the other hand, microvesicle-PDL1 are transfer and recycled via endocytosis by target cells, conferring them with immunosuppressive properties.

Conclusions
Glioma TAMCs utilize microvesicles to remotely promote Tregs and Bregs survival and immunosuppressive functions. This data suggest TAMC-mediated immunosuppression extends beyond the tumor vicinity limits.

References

Ethics Approval
IRB N° STU00202003, AICUC protocol N° IS00002459

P599
Unveiling tumor-associated macrophages (TAMs) heterogeneity and plasticity by a fully automated sequential chromogenic multiplex assay
Anna Martirosyan, Dr, Jacques Fieschi, PhD
HalioDx, Marseille, France
Correspondence: Jacques Fieschi (jacques.fieschi@haliodx.com)

Background
Among the various immune cells recruited to the tumor microenvironment (TME), tumor-associated macrophages (TAMs) are particularly abundant and play a central role at all stages of cancer progression. TAMs represent a heterogeneous population in terms of cell morphology, functions, and tissue localization. Activated M1 macrophages express pro-inflammatory cytokines and drive potent antitumoral Th1 responses. Alternatively, activated M2 macrophages induce Th2 cells and enhance cancer progression and metastasis. The specific polarization of TAM may therefore skew the TME toward tumor rejection (M1) or favor immune suppression (M2). An additional level of complexity is conferred by their ability to shift between M1 and M2 subtypes (plasticity), depending on microenvironmental stimuli. Although the extensive literature on TAMs protumoral function and poor prognosis, some studies have shown that these cells possess an antitumour activity and their increase correlates with patient’s survival. Noteworthy, emerging studies suggest that TAMs are important in tumor metastases formation by regulating epithelial mesenchymal transition of colorectal cancer (CRC) cells. Until now, the most commonly used marker to identify human macrophages was the pan-macrophage marker CD68. The latter overlooks the prognostic potential of macrophage subsets with different functions in the TME. Therefore, there is a strong and urgent need to dissect TAMs heterogeneity in tumors using more refined approaches such as multiplex technology.

Methods
Here we assessed the presence, abundance and localization of TAMs subsets within the CRC microenvironment by using the Brightplex® solution, an automated sequential chromogenic multiplex assay. A unique combination of biomarkers (CD11b, CD68, CD86, CD163, CD204, CD206, and CD64) was developed to assess M1 and M2 TAMs heterogeneity and plasticity on a single FFPE tumor tissue section by preserving tissue’s spatial contexture.

Results
Briefly, a tissue section was sequentially stained, digitized, unstained and re-stained with antibodies targeting the seven markers. Images of the whole slide were then analyzed by digital pathology and the detection of positive cells was performed for each marker independently. In addition, tissue segmentation tools were used to assess TAMs densities in parenchyma, tumor stroma and invasive margin regions. This new panel of the Immuno-score® Suppressor Cells family enhances the ability to unravel the tumor microenvironment.

Conclusions
Deciphering the heterogeneity and plasticity of TAMs populations in CRC could help to identify new reliable prognostic markers to improve patient’s stratification and design more individualized therapeutic approaches.
AL008 enhances myeloid anti-tumor function by coupling SIRPα antagonism with Fc receptor-mediated activation

Andrew Pincetic, PhD, Jerry Yang, Isaiah Deresa, We-Hsien Ho, Hua Long, Daniel Maslyar, Spencer Liang, Arnon Rosenthal
Alector, South San Francisco, CA, United States

Correspondence: Arnon Rosenthal (ar@alector.com)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P600

Background
The SIRPα-CD47 axis represents a myeloid checkpoint in cancer. Recent clinical data with CD47-targeted therapies that competitively block the interaction with SIRPα show clinical responses in some patients with hematologic and solid cancers when combined with anti-tumor antibody treatments. However, known limitations associated with targeting CD47, such as clearance of red blood cells (RBCs) and disruption of the SIRPα CD47 interaction important for T cell activation, likely hinder the anti-tumor immune response necessary for robust clinical benefit. A therapeutic advantage may be realized by targeting SIRPα and promoting immunostimulatory pathways that drive anti-tumor immunity. Here, we describe the discovery and characterization of a SIRPα-specific antibody, AL008, a first-in-class inhibitor of SIRPα that simultaneously antagonizes SIRPα signaling and stimulates Fcy receptor (FcγR) activation.

Methods
Multiple functional assays were performed to ascertain the mechanism of action of AL008 and to benchmark activity against anti-CD47/anti-SIRPα antibodies in the clinic. For example, in vitro phagocytosis assays determined whether AL008 promoted engulfment of various tumor cell lines by human macrophages. Mixed leukocyte reactions (MLR) assessed the effect of AL008 on human dendritic cell-mediated T cell function. Furthermore, AL008 was administered to non-human primates to obtain pharmacokinetic and immunotoxicology profiles. Anti-tumor activity and pharmacodynamic effects of AL008 were examined in tumor-bearing mouse models expressing human SIRPα and human CD47.

Results
AL008 is a non-competitive inhibitor of SIRPα that triggers SIRPα internalization and degradation from the cell surface and simultaneously activates FcγR. Unlike other competitive antagonist antibodies to SIRPα, which require competition with opsonizing antibodies to promote tumor cell phagocytosis, AL008 stimulates tumor cell engulfment by macrophages in the absence of opsonizing antibody due to intrinsic FcγR activation. Because of its restricted binding specificity towards SIRPα, AL008 promotes dendritic cell-mediated stimulation of T cell proliferation, which contrasts with anti-CD47 antibodies and other anti-SIRPα/γ cross-reactive antibodies. Despite FcγR engagement by AL008, in vitro ADCC assays and in vivo studies in non-human primates verify that AL008 does not deplete myeloid cells or RBCs, which anticipates a significantly improved safety profile in patients. Lastly, inhibition of tumor growth by AL008 in mouse models coincides with downregulation of SIRPα and induction of activation markers on tumor-associated macrophages.

Conclusions
AL008 potentiates the anti-tumor effector functions of macrophages and dendritic cells in vitro, as well as in vivo models. This dual mechanism of AL008, which couples the reversal of inhibitory signal with immunostimulation, provides a novel therapeutic strategy for targeting myeloid cells for immune activation.

Ethics Approval
All in vivo studies were reviewed and approved by Alector Institutional Animal Care and Use Committee (IACUC).

P601
Expression of an immune checkpoint receptor VSIG4 defines new subsets of mouse peritoneal macrophages

Kanaoko Lewis, PhD, Chau Nguyen, Robert Navert, Ryan Gerhart, Sonja Zahnner, Castle Funatake, Homero Sepulveda, Dariusz Stepniak
Thermo Fisher Scientific, Waltham, MA, United States

Correspondence: Dariusz Stepniak (dariusz.stepniak@thermofisher.com)

Background
V-set and Immunoglobulin Domain Containing 4 (VSIG4), also known as Complement Receptor of the Immunoglobulin superfamily (CRg), is a cell surface receptor structurally related to the B7 family of immune regulatory proteins. Expression of VSIG4 on macrophages renders them less responsive to LPS. In addition, VSIG4 promotes immune tolerance by attenuating early T cell activation and supporting the induction and maintenance of Foxp3 in T cells. Expression of VSIG4 on tumor-infiltrating macrophages suggests that it may be implicated in immune evasion.

Methods
Using our new VSIG4 (CRg) antibody (clone NLA14), we demonstrate that Large Peritoneal Macrophages (LPM) in mouse consist of two distinct subsets, the VSIG4+ LPM and VSIG4- LPM.

Results
VSIG4+ LPM co-express Arginase 1 more frequently than the VSIG4- LPM, particularly in C57BL/6 mice. Further comparative analysis of the two LPM populations using a panel of macrophage specific antibodies revealed that VSIG4+ and VSIG4- LPM show a similar pattern of expression that is distinct from Small Peritoneal Macrophages (SPM). This phenotypic diversity within the LPM most likely reflects differences in function and activation status. In vitro cultured macrophages show a spontaneous decrease in the expression of VSIG4, and addition of proinflammatory factors, including IFN-γ and LPS, further reduces VSIG4 expression.

Conclusions
Characterization of VSIG4+ LPM might provide an opportunity to better understand the immunoregulatory role of VSIG4 in tumor infiltrating macrophages.
Recent reports suggest that tissue resident memory cells (TRM) may play an important role in anti-tumor immunity. Specifically, the accumulation of CD103+ tumor infiltrating lymphocytes (TILRM) is associated with favorable prognosis [1,2]. However, relatively little is known regarding T RM differentiation and endogenous T RM are difficult to isolate, impeding their basic study and translational application. Thus a means to generate T RM in vitro would be desirable. TGF-β is known to be critical in establishing T RM populations and attempts to identify other factors have focused on cytokines [3,4]. Oxygen tension is another factor that distinguishes the circulation from peripheral tissues; thus we hypothesized that hypoxia may contribute to a TGF-β1-induced T RM phenotype in human CDB8+ T-cells.

Methods
Naive CDB8+ T-cells from human peripheral blood were activated in normal cell culture conditions (20% O2) or hypoxia (2% O2) and then cultured in the presence of rhTGF-β1. Cells were then analyzed for expression of T RM-associated genes via quantitative real-time PCR (qPCR) and T RM-associated surface markers via flow cytometry. The individual contributions of hypoxia and TGF-β1 to induction of T RM phenotype were assessed by performing in vitro differentiation experiments as described above with or without the addition of rhTGF-β1. CD69-CD103- cells generated in 20% O2, CD69+CD103- cells generated in 2% O2, and CD69+CD103+ cells generated in 2% O2 + TGF-β1 were sorted before RNA-sequencing (n=3).

Results
We demonstrate that differentiation of human CD8+ T-cells in hypoxia and TGF-β1 in vitro led to the development of a T RM phenotype, characterized by an increase in CD69+CD103+ cells expressing CD49a, CD101, and PD-1 – hallmarks of human T RM (n=7, pRM phenotype cells than the additive effects of either condition alone (n=4, pRM and TILRM gene signatures in CD69+CD103+ cells generated in hypoxia and TGF-β1 (Figure 1).

Conclusions
Our findings identify a previously unreported cue for T RM differentiation and enable a facile means of generating human T RM phenotype cells in vitro with the potential for application to multiple existing Adoptive Cell Therapy (ACT) modalities. As hypoxia and TGF-β are common features of the tumor microenvironment our results indicate that these conditions may contribute to generation of CD103+ TIL in vivo.

Acknowledgements
This work was supported by the Parker Institute for Cancer Immunotherapy (PICI); C.Y. is a member of PICI.

References
Severity of cytokine release syndrome as a predictor of infections after T-cell replete haploidentical hematopoietic cell transplantation (haploHCT)

Muhammad Bilal Abid, MD, MRCP (UK), Parameswaran Hari, MBBS, MD, MRCP, Aniko Szabo, Mehdi Hamadani, Mary Beth Graham, Saurabh Chhabra
Medical College of Wisconsin, Milwaukee, WI, United States

Correspondence: Saurabh Chhabra (schaabra@mcw.edu)


Background
Severe cytokine release syndrome (CRS) results in an increased incidence of infections after T-cell engaging therapies. Several retrospective, single-center studies have shown infectious complications with haploidentical hematopoietic cell transplantation (haploHCT) but no data correlating infections with CRS that develops after haploHCT is available. [1-10]

Methods
We evaluated 78 consecutive adult haploHCT recipients at our center for the development of CRS, graded by Lee et al. criteria, and examined the incidence of infectious complications in correlation with CRS severity. All patients received haploHCT for hematologic malignancies between April 2012 and April 2018, using post-transplant cyclophosphamide (PTCy) and tacrolimus/MMF for GVHD prophylaxis. The incidence of infections was examined in two separate time periods in relation to the day of stem cell infusion (day 0): day 0-100 and day 101-180. The study cohort was further stratified by CRS grades into 2 groups: 53% of patients in cohort A, CRS grade 0-1 (n=41) and 47% in cohort B, CRS grade ≥2 (n=37).

Results
Overall, 81% patients developed infections (63/78) within 180 days. Fewer patients in cohort A developed an infection (71% vs. 92%; P=.018). 58% of these infections were of viral origin (104 episodes) and nearly half of those were CMV reactivations (46%). 38% infections were of bacterial origin (70 episodes) and 9% fungal. On multivariate analysis, higher-grade CRS (CRS grade ≥2) was independently associated with an increased frequency of bacterial infections (RR 2.25; 95% CI, 1.12 to 4.53; P=.023) and there was also evidence of higher overall infections (RR 1.6; 95% CI, 0.98 to 2.63; P=.057). Increasing frequency of overall and bacterial infections, including BSI and CLABSI, was observed as CRS became more severe (higher in grade 3 vs grade 2). CMV recipient positivity was independently associated with an increased frequency of overall infections (RR 1.98; 95% CI, 1.23 to 3.18; P=.0048) as well as an expectedly greater viral infections (RR 2.77; 95% CI, 1.60 to 4.78; P=.0003). 10 patients died of infection/sepsis-related causes and the cumulative incidence of infection-related mortality was higher in cohort B (Figures 1-3).

Conclusions
These findings suggest that the severity of CRS developing after haploHCT using PTCy-platform is associated with an increased frequency of bacterial infections, including BSI and CLABSI, and may lead to increased mortality. Pathogenesis of CRS after haploHCT remain an unmet need and potential mechanisms that may confer an increased frequency of infections are also discussed.

References
Background
Metastatic melanoma patients successfully treated with combination immunotherapy using checkpoint blockade often display pre-existing antitumor immunity at time of initial treatment. Cancer vaccination can be used to promote anti-tumor T cell responses in patients lacking such immunity.

Methods
To generate optimal anti-tumor immune responses in melanoma patients, we previously developed a dendritic cell (DC)-based adenovirus-engineered vaccine encoding three common melanoma-associated antigens: Tyrosinase, MART-1, and MAGE-A6. This vaccine was used to treat 35 patients in a Phase 1 clinical trial. Immature DCs were matured using IFNα+LPS, and then transduced with the recombinant adenovirus yielding the vaccine. Patients received three intradermal injections of vaccine over one month. In addition to standard phenotyping and cytokine testing, a human genome RNA microarray was used to transcriptionally profile the DC vaccines produced for each patient. Cryopreserved patient and healthy donor monocytes were also examined in functional assays.

Results
Patient (matured and adenovirally-transduced) monocyte-derived DCs expressed reduced levels of cell surface ICOSL (a costimulatory molecule) vs. DCs generated from healthy donors (HD). Microarray analysis of patient cells revealed that ICOSLG mRNA gene expression was increased post-maturation and viral transduction, and differently expressed between HD and patient cells.

ICOSL surface protein showed a positive trend with the ability of adenovirally-transduced DCs to elicit specific CD8+ T cell responses in vitro to Tyrosinase and MART-1. Using a CMV p65 antigen-based model, we observed reduced activation of naive, CMV-specific CD8+ and CD4+ T cells in seronegative donors when primed using antigen-loaded autologous DCs treated with anti-ICOSL antibody vs. an IgG control. Microarray analysis further suggested that (matured and adenovirally-transduced) patient DCs exhibit dysregulated NFκB signaling vs. DCs isolated from HD, and non-canonical NFκB signaling known to trans-activate ICOSL. Pharmacologic inhibition of NFκB signaling in DCs from HD also resulted in decreased expression of surface ICOSL. We also observed that patient vaccine DC expression of NLRP2 (a natural NFκB inhibitor), negatively correlated with clinical outcome.

Conclusions
Reduced levels of ICOSL on patient vaccine DCs may limit their ability to prime anti-tumor immune responses in vitro (and in vivo). DC-expressed ICOSL appears important for specific T cell priming and is at least partially regulated by intrinsic canonical NFκB signaling pathway. These data identify critical DC stimulatory pathways and inform the next generation DC-based vaccines capable of promoting superior anti-tumor benefits in advanced-stage melanoma patients.

Acknowledgements
This study utilized the UPMC Hillman Cancer Center’s Immunologic Monitoring and Cellular Products Laboratory shared facility, supported in part by award P30 CA047904. This work is funded by the NIH SPORE IN SKIN CANCER Grant 4P50CA121973-09, the Melanoma Skin Cancer T32 Award 129297 (08/1/2017 – 07/31/2017), and the CTSI TL1 Pre-doctoral Scholar Fellowship, TL1 TR001858 (10/01/2018 – 09/30/2019).

Trial Registration
NCT01622933

Ethics Approval
The study was approved by the University of Pittsburgh’s Ethics Board, approval number IRB12010416.

P607
Tumor derived IL-6 promotes early-stage myeloid derived suppressor cells (eMDSCs) via SOCS3 deficiency-related differentiation arrest in breast cancer
Wenwen Zhang, Jinpu Yu
Tianjin Tumor Hospital, Tianjin, China

Correspondence: Jinpu Yu (jinpu_yu@hotmail.com)
Background

Early stage myeloid-derived suppressor cells (eMDSCs) are a newly identified immunosuppressive cell subtype, but less is known about the generation of eMDSCs yet. In this study we elucidated that tumor-derived IL-6 manipulated the development and function of eMDSCs in vitro and vivo.

Methods

We constructed IL-6 knockdown 4T1 mammary tumor-bearing BALB/C models and myeloid lineage specific SOCS3 knockout C57BL/6 model. The system of eMDSCs induction was established, in which bone marrow cells were cocultured with 4T1 cells to induce eMDSCs in vitro.

Results

We identified a subpopulation of CD11b+Gr-1-F4/80-MHCII+eMDSCs in situ in IL-6 knockdown 4T1 mammary tumor-bearing mice models, which displayed more potent suppression on T cell immunity than conventional CD11b+Gr-1+ eMDSCs. The proportion of eMDSCs in tumor tissues was highly correlated with the tumor size and the numbers of lung metastatic nodules. Bone marrow cells were co-cultured with 4T1 cells to induce eMDSCs in vitro, but IL-6R Ab treatment significantly decreased the proportion of eMDSCs. Tumor-derived IL-6 inhibited the expression of SOCS3 and persistently activated the JAK/STAT3 signaling pathways, which further caused the differentiation arrest of myeloid lineage and comparable immunosuppressive capacity of eMDSCs. The conditional myeloid SOCS3 knockout C57BL/6 (SOCS3mKO)mice was constructed to study SOCS3-related amplification of eMDSCs. The eMDSCs increased significantly in SOCS3mKO mice compared to SOCS3fl/fl mice, in which myeloid differentiation arrest was observed. The miRNA array screening indicated mir155-5p was the predominant regulator of SOCS3-related differentiation arrest in eMDSCs. We demonstrated that mir155-5p suppressed transcription factors C/EBPβ and PU.1, and thus promoted the development of eMDSCs. Transfecting mir155-5p inhibitor in myeloid precursors could efficiently reduce the number of eMDSCs and recover myeloid differentiation in vitro.

Conclusions

Tumor derived IL-6 activated the JAK/STAT3/miR155-5p pathway in myeloid precursors by inducing SOCS3 deficiency, which consequently downregulated C/EBPβ and PU.1, induced myeloid differentiation arrest, and promoted the development of eMDSCs.

Acknowledgements

This work was supported by National Natural Science Foundation of China (grant numbers: 81872143, 81702280, 81472473, 81272360) and Key Project of Tianjin Health and Family Planning Commission (16KG126).

Immun-Stimulants and Immune Modulators

P608

ATOR-1017, a 4-1BB antibody developed for tumor-directed immunotherapy of cancer

Doreen Werchau, BS1, Anna Rosen, MSc2, Mia Eriksson, PhD1, Christina Furebring, PhD1, Karin Enell Smith, PhD1, Karin Enell Smith, PhD3

1Alligator Bioscience AB, Lund, Sweden; 2Alligator Bioscience, Lund, Sweden

Correspondence: Karin Enell Smith (kae@alligatorbioscience.com) Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P608

Background

ATOR-1017 is a Fc receptor (FcγR) crosslinking dependent agonistic IgG4 antibody targeting the costimulatory receptor 4-1BB. 4-1BB is highly expressed on tumor infiltrating CD8+ T effector cells (T effs) in several cancer indications. By binding to 4-1BB, ATOR-1017 can enhance the activity of tumor reactive T effs and NK cells within the tumor and induce a potent anti-tumor attack. 4-1BB is an attractive target for immunotherapy, even though 4-1BB targeting antibodies in clinical development so far have been suffering from toxicity or poor efficacy. Therefore, ATOR-1017 was designed to improve tolerability and to enhance efficacy.

Methods

Human 4-1BB knock-in transgenic mice with established murine colon carcinoma MC38 tumors were used to demonstrate anti-tumor efficacy and immune cell infiltration with FACS after systemic treatment with ATOR-1017. In vivo, immune activation (IFN-γ production) of purified human immune cells from healthy donors with ATOR-1017 was analyzed using FcγR expressing cells for crosslinking in the presence of human IgG.

Results

ATOR-1017 reduced tumor growth and improved survival dose dependently in human 4-1BB knock-in transgenic mice with established tumors. No tumor growth was detected after tumor re-challenge in the complete responders previously treated with ATOR-1017, but in the naive untreated control group only. These results demonstrated that ATOR-1017 induced a long-lasting immunological memory. The immunological response induced by ATOR-1017, leading to an efficient tumor eradication, consisted of a significant immune cell infiltration and a high T eff to T regulatory cell ratio within the tumor specifically but not in the spleens. In vitro it was demonstrated that immune activation with ATOR-1017 was blocked dose dependently in the presence of human IgG, due to saturation of the FcγRs which blocked crosslinking of ATOR-1017.

Conclusions

ATOR-1017 induced a potent tumor-directed immune response, leading to an efficient tumor eradication and survival and development of a long-lasting immunological memory. ATOR-1017 is FcγR crosslinking dependent with an activation profile that is expected to minimize the risk for inducing systemic immune activation and toxicity, by directing the immune response to the tumor tissue and tumor draining lymph nodes where 4-1BB as well as certain FcγRs are highly expressed. The FcγR crosslinking-dependency will also reduce the risk for immune activation in the circulation, due to the high concentration of endogenous circulating IgG which will compete with ATOR-1017 for binding to the FcγRs [1,2]. A first-in-human phase I study of intravenously administered ATOR-1017 is planned for 2019.

References


Ethics Approval

The study was approved by Institutional Animal Care and Use Committee (IACUC) of China, approval number 10278L001.

P609

Fc-silenced bispecific antibodies targeting PD-L1 and 4-1BB combine checkpoint blockade and T-cell co-stimulation to promote anti-tumor activity

Alexander Munk, PhD1, Isil Atzantas, PhD2, Friederike Gieseker1, Theodore Salcedo1, Saskia Burn1, Mustafa Diken1, Christian Grunwitz1, Danita Schuurhuis2, Sebastian Kreiter1, David Satijn2, Ozdem Tureci3, Esther Breij, PhD1, Ugur Sahin4,5, Maria Jure-Kunkel2

1BioNTech SE, Mainz, Germany; 2Gennab, Utrecht, Netherlands

Correspondence: Ugur Sahin (ugur.sahin@biontech.de), Maria Jure-Kunkel (mjk@genmab.com)


Background

PD-1/PD-L1-targeting monoclonal antibodies (mAbs) have shown impressive responses in a wide range of tumors, although only in a
subset of patients, leaving room for improvement. 4-1BB agonistic mAbs are potent T-cell co-stimulators and showed promising results in pre-clinical cancer models. However, no 4-1BB agonist has advanced beyond early phase II studies, due to dose-limiting hepatitis or lack of monotherapy efficacy. Fc-silenced bispecific antibodies (bsAbs) targeting PD-L1 and 4-1BB may overcome these limitations by combining immune checkpoint inhibition with conditional agonistic activity.

**Methods**

Fc-silenced PD-L1x4-1BB bsAbs (anti-mouse surrogate: mAbsAb-PD-L1x4-1BB; anti-human: DuoBody®-PD-L1x4-1BB [GEN1046]) were obtained by controlled Fab-arm exchange of PD-L1 and 4-1BB mAbs. Activity of the mouse-specific mAbsAb-PD-L1x4-1BB was tested in vivo in an ovalbumin-specific OT-1 T-cell adoptive transfer and vaccination model in C57BL/6 mice, and in efficacy studies in CT26 and MC38 tumor-bearing BALB/c and C57BL/6 mice, respectively. Tolerability was assessed in C57BL/6 mice and compared to treatment with a 4-1BB agonistic mAb. Induction of T-cell proliferation and cytokine production by DuoBody-PD-L1x4-1BB was analyzed in primary human T-cell assays in vitro and using patient-derived tumor-infiltrating lymphocytes (TILs) ex vivo. The non-clinical safety profile of DuoBody-PD-L1x4-1BB was assessed in cynomolgus monkeys.

**Results**

Surrogate mAbsAb-PD-L1x4-1BB induced significant expansion of adoptively transferred OT-1 T-cells upon ovalbumin vaccination in proof-of-concept studies in vitro. In a therapeutic setting, mAbsAb-PD-L1x4-1BB induced long-term tumor remission in up to 90% of CT26 and MC38 tumor-bearing mice, associated with expansion of tumor-specific CDB+ T-cells. mAbsAb-PD-L1x4-1BB was well tolerated, while an Fc-active mouse 4-1BB agonistic mAb, alone or with a PD-L1-specific mAb, induced a significant increase in serum transaminase levels and liver immune infiltrates.

DuoBody-PD-L1x4-1BB enhanced T-cell proliferation and pro-inflammatory cytokine production in vitro, and was more potent than checkpoint blockade alone or the combination of Fc-silenced PD-L1- and 4-1BB-specific mAbs. 4-1BB agonist activity of DuoBody-PD-L1x4-1BB was strictly conditional and dependent on simultaneous binding of both targets. DuoBody-PD-L1x4-1BB increased TIL expansion ex vivo. DuoBody-PD-L1x4-1BB showed a favorable safety profile in cynomolgus monkeys at doses up to 30 mg/kg (1q3xx2).

**Conclusions**

Dual targeting of PD-L1 and 4-1BB with an Fc-silenced bsAb combines immune checkpoint blockade and conditional T-cell costimulation in one molecule. This distinctive mechanism of action results in potent anti-tumor activity without inducing hepatotoxicity in mice and enhances proliferation of human primary T-cells and TILs in vitro and ex vivo. The clinical safety of DuoBody-PD-L1x4-1BB is currently being assessed in patients with solid cancers in a first-in-human trial (NCT03917381).

**Ethics Approval**

Cynomolgus monkey studies were performed at Charles River Laboratories, Tranent, UK, in accordance with the EU legislations described in Directive 2010/63/EU. This study was licensed by UK Home Office under the Animals (Scientific Procedures) Act 1986 (approval number PBAD559F8, Toxicology of Pharmaceuticals, Protocol 15) and overseen by Gennab B.V.

All mice studies were performed by BioNTech SE at its research facilities in Germany, and the mice were housed in accordance with German federal and state policies on animal research. All experiments were approved by the regulatory authorities for animal welfare in Germany.

The use of tumor tissue resections was approved by BioNTech SE’s Ethics Board, approval number 837.309.12 (8410-F).

---

**P610**

**Caudin18.2 bispecific T-cell engager for gastric cancer immunotherapy**

Swarna Pandian, PhD1, Zusheng Li1, Eugene Chan, MD1, Robert Markelewicz, MD1, Timothy Wyant, PhD2, Sribalaji Lakshmikanthan, PhD2

1Abpro Corporation, Woburn, MA, United States; 2AbproCorporation, Lexington, MA, United States

**Correspondence:** sribalaji.lakshmikanthan@gmail.com

**Journal for ImmunoTherapy of Cancer** 2019, 7(Suppl 1):P610

**Background**

Caudin18.2 (CLDN18.2), a gastric epithelial junction protein, has been discovered as a potential therapeutic target for stomach cancers. The aim of our study was to elucidate mechanism of action for ABP150, a CLDN18.2 specific CD3 engager. Specifically, we assessed the ability of ABP150 to be redirected to CLDN18.2 tumors following T-cell dependent killing.

**Methods**

CLDN18.2 specific clones were obtained by Abpro’s proprietary platform [1]. The clone selection criteria involved Caudin18.2-isofom specific binding and off-target screening; HTS-flow cytometry based cross-reactive studies using ≥5000 other proteins expressed on HER293T specific cell system. The bispecific T-cell engager for ABP150 antibody was engineered as described [1]. The built constructs were transiently transfected into HEK-293S cells grown in FreeStyle 293 Expression Medium followed by purification using Protein A IgG Purification Kit. Purified ABP150 was subjected to Size Exclusion Chromatography (SEC-HPLC) to assess its monomeric state. Relative binding of ABP150 to CLDN18.2 positive tumors and CD3 expressing Jurkat-T cell line was performed using flow cytometry. Following manufacturer’s protocol, T-cell activation and T-cell Dependent Cytotoxicity (TDCC) were examined by T Cell Activation Bioassay (NFAT) and CellTiter-Glo luminescent cell viability assay kits respectively.

**Results**

Out of 7 hybridomas, 2 clones, ABP150-1 and ABP150-2 were finalized based on relative binding affinity and specificity to CLDN18.2. Flow cytometric experiments demonstrated dose-dependent binding to CLDN18.2 positive cells exclusively. No binding to CLDN18.1 isoform was observed. Their ability to bind to T-cells were comparable to ABP100 [2, 3] suggesting functional monovalent binding to CD3. In the off-target screening experiments, both clones showed no cross-reactivity to extracellular membrane proteins. SEC-HPLC analysis displayed ≥95% of monomeric protein with no aggregations. In T-cell activation bioassay, both ABP150 clones presented a dose dependent T cell activation. Further, TDCC experiments resulted in dose dependent tumor killing only in the presence of CLDN18.2 expressing tumors. In absence of CLDN18.2 tumors, no toxicity was observed.

**Conclusions**

Lead CLDN18.2 clones, ABP150-1 and ABP150-2 as T-cell engagers showed CLDN18.2 specific binding and functionally weak CD3 binding (in the absence of target) resulting in strong TDCC response only in the presence of CLDN18.2 tumors. Taken together, we conclude that these two clones are expected to efficiently clear CLDN18.2 tumors without cytokine release syndrome.

**References**

Layer-by-layer nanoparticles for interleukin-12 delivery

Antonio Barberio, BSE, Sean Smith, Santiago Correa, Cathy Nguyen, Paula Hammond, Darrell Irvine, PhD, Mariane Melo, Talar Tokatlian
MIT, Cambridge, MA, United States

Correspondence: Paula Hammond (hammond@mit.edu)


Background

Interleukin-12 (IL-12) is a particularly compelling target for cytokine therapy, as it showed promise in preclinical tests. However, it failed in the clinic to high schedule dependent toxicities, including two patient deaths. An alternative approach is to deliver IL-12 in a nanoparticle (NP) delivery vehicle. Yet, cytokines pose a difficult challenge for NP delivery, as they require efficiently loading labile proteins, maintaining activity on cytokine membrane receptors from a NP that is often internalized, and achieving high association with tumors to prevent systemic leakage. Layer-by-layer (LbL) is a simple electrostatic method of layering polymers onto materials to alter the properties of the carrier. Through incorporation of different polymers, LbL offers the opportunity to address the challenges of cytokine NP delivery.

Methods

A single chain variant of IL-12 was loaded onto liposomal nanoparticles via Ni:His interactions and layered via the LbL process (Figure 1A). Particles were assessed for material properties in vitro including biological activity via their ability to stimulate an interferon-y response. Particles were further tested in vivo for their toxicity and efficacy in multiple tumor models.

Results

LbL IL-12 NPs with poly-L-arginine and poly-L-glutamic acid layers (PLE-IL-12-NPs) were able to efficiently load and deliver active cytokine. PLE-IL-12-NPs showed drastically reduced toxicity compared to carrier-free IL-12. Healthy mice treated with PLE-IL-12-NPs showed no differences in weight to PBS and unloaded NPs, while carrier-free IL-12 treated mice lost 10% of their body weight by the fifth dose when treated daily. Furthermore, PLE-IL-12-NP treated mice showed significantly less systemic cytokine response when compared to carrier-free IL-12. Importantly, PLE-IL-12-NPs also showed no loss in anti-tumor activity at these same doses when delivered against both subcutaneous MC38 and the more difficult to treat HM-1 ovarian cancer cell line. Finally, at significantly higher doses, carrier-free IL-12 again showed significant toxicity while the PLE-IL-12-NPs showed no differences to the controls and lead to pronounced antitumor efficacy in the MC38 model (Figure 1B,C).

Conclusions

PLE-IL-12-NPs show promise as an IL-12 therapy. Most importantly, PLE-IL-12-NPs were able to significantly reduce the toxicity of IL-12 therapy while maintaining its efficacy. Of noted importance, PLE-IL-12-NPs were also able to show efficacy in ovarian cancer, which has been refractory to many immunotherapies in the past. Finally, although the above results demonstrate activity with IL-12, the described particle uses no IL-12 specific methods and can likely be applied across many other cytokines or combinations.

Ethics Approval

These experiments were approved by the Massachusetts Institute of Technology Committee on Animal Care (CAC).
as an immuno-oncology therapeutic, the generation of IL-10 variants with extended half-life is desired.

Methods
The Synthorx synthetic biology platform expands the genetic alphabet (EGA) by one base pair that generates new codons for site-specific incorporation of novel amino acids at any position within the polypeptide, which enables the design of biotherapeutics with improved drug properties. We have applied this platform to rapidly screen and identify residues within the IL-10 amino acid sequence for optimized PEG bioconjugation distal from the IL-10R binding sites, producing a series of single IL-10 variants that were then pegylated. Biochemical characterization of those pegylated variants by SPR and SEC-MALS together with in vitro and ex vivo potency profiling led to the identification of homogeneous Synthorin IL-10 dimers with extended in vivo half-life and minimal interference with IL-10 receptor engagement and activation.

Results
Analytical characterization of purified IL-10 Synthorins showed that they are homogeneous, and dimeric pegylated variants. Among them, THOR-1003 and THOR-1009 showed comparable in vitro potency to native IL-10 for proliferation of the human MC/9 cell line, and in a human recombinant cell assay directly measuring receptor activation, underscoring the importance of choosing the right site for pegylation on the agonist activity of IL-10. Other sites tested resulted in compounds exhibiting up to 1,000-fold decrease in potency in cell-based assays. THOR-1003 and THOR-1009 have been selected for further testing, focusing on the release of IFN and cytolytic enzymes from primary human CD8+ T cells, following stimulation with antigen-presenting cells displaying a CMV peptide epitope. Pharmacokinetics and pharmacodynamics profiling of these molecules in vivo is ongoing.

Conclusions
We have demonstrated that our synthetic biology platform can generate functional, pegylated Synthorin IL-10 variants that retain the folding and structural stability of native IL-10. Two of those Synthorins, THOR-1003 and THOR-1009, exhibit physicochemical properties similar to native IL-10, and functional properties consistent with a fully active agonist that can be dosed in vivo for durable pharmacodynamic effects.

P613 Discovery of pharmacologically differentiated interleukin 15 (IL-15) agonists employing a synthetic biology platform
Carolina Caffaro, PhD, Jerod Psatcin, PhD, Robert Herman, Lina Ma, PhD, David Chen, Ingrid Joseph, PhD, Marcos Millia, PhD
Synthorx, Inc, La Jolla, CA, United States
Correspondence: Marcos Millia (mmillia@synthorx.com)

Background
IL-15, distinctly from IL-2, induces proliferation and survival of CD8+ T memory (Tmem) cells, activates natural killer (NK) cells, and enhances antibody-driven cellular toxicity without the expansion of immunosuppressive regulatory CD4+ T cells (Treg). However, its high potency and resulting toxicity, combined with its short half-life, has limited its potential as an immunotherapeutic agent. We hypothesize that extension of the half-life of IL-15 could provide persistence of signaling for CD8+ Tmem expansion, while reducing potential Cmax-associated toxicities. Further modulation of the interaction with specific receptor chains (the private IL-15Ra and/or IL-2/15Rb) by pegylation might enable tuning of drug exposure (AUC) for preferential stimulation of different cell subsets and therapeutic effects.

Methods
We applied the Synthorx Expanded Genetic Alphabet platform to the rational design of pegylated IL-15 compounds with extended half-life and differential interaction with the IL-15Ra and IL-2/15Rb. In vitro biochemistry and cell bioassays and ex vivo profiling in mouse and human immune cells were used to select initial IL-15 Synthorin candidates for in vivo PK/PD studies.

Results
THOR-924 is a pegylated IL-15 Synthorin with similar binding affinity to IL-15Ra and IL-2/15Rb, and comparable signaling potency, relative to native IL-15. PK/PD responses in mice, demonstrated an extended half-life with sustained induction of pSTAT5 and Ki67 resulting in strong proliferation of peripheral CD8+ Tmem and NK cells, without proliferation of Treg cells. 90-100% of peripheral CD8+ T cells were positive for both pSTAT5 and Ki67 after a single IV dose of 0.3 mg/kg. Additional IL-15 Synthorins, THOR-918 and THOR-908, showed overall reduced potency or specific blockade of IL-15 interaction with IL-15Rs, respectively, by SPR. This selective interaction accounts for the differential in vivo and ex vivo potency of these compounds compared to native IL-15 and THOR-924. Ongoing in vivo studies will shed light on the potential pharmacologic advantages of such activity-modulated IL-15 Synthorins.

Conclusions
IL-15 Synthorins are biochemically differentiated forms of IL-15 with extended half-life and optimized pharmacologic parameters for balancing receptor engagement and activity. The Synthorx platform allows rapid derivation of IL-15 variants with extended half-life and optimized pharmacologic parameters, with promise to advance the immuno-oncology field.

P614 Development of a cancer gene therapy approach based on encoding a single chain IL-12 transgene in an oncolytic T-SIGN virus vector
Sam Illingworth1, Manuela Zonca 1, Ana Silva 1, Alicia Belmonte 1, Nalini Marino1, Carla Cerqueira 1, Lorna Slater 1, Katy West 1, Sara Siebel 1, Samantha Bucktrout 1, Fred Ramsdell, PhD 2, Paul Cockle 1, Brian Champion, PhD 1
1PsiOxus Therapeutics Ltd, Abingdon, United Kingdom; 2Parker Institute for Cancer Immunotherapy, San Francisco, CA, United States
Correspondence: Brian Champion (brian.champion@psioxus.us.com)

Background
T-SIGN virus vectors for cancer gene therapy are transgene-modified variants of enadenotucirev (EnAd), an Ad11p/Ad3 chimeric group B adenovirus, which retain all the functional and epithelial tumor-selectivity properties of EnAd while also mediating the selective expression of transgenes by infected tumor cells. We have created T-SIGN viruses expressing a single chain variant of human IL-12 as the primary transgene modality; production of IL-12 by virus-infected tumor cells could be an effective way of driving T-cell and NK cell activity within the tumor microenvironment to promote effective anti-tumor immunity.

Methods
T-SIGN virus constructs were generated to express either the p35 and p40 chains of human IL-12 separately or as a linked single chain molecule using a short linker sequence. To enable tumor-selective expression of IL-12, transgenes were placed under the control of the virus major late promoter (MLP) which is activated following initiation of genome replication in permissive cells. Tumor cell lines and primary cells derived by gentle disaggregation of surgically excised tumor samples from carcinoma patients were used to evaluate the production and activities of the different IL-12 viruses.

Results
ELISA assays measuring levels of the full IL-12 p70 molecule or the specific p40 chain in infected tumor cell supernatants showed that the virus encoding separate IL-12 chains produced p40 very effectively but very little p70 was detected. By contrast the virus encoding the single chain variant effectively produced p70 at levels >100ng/ml. Using a HEK-Blue IL-12 signalling reporter assay, this p70 protein was shown to be functionally active and thus folded correctly. Primary cells derived from excised patient tumor samples were also evaluated and shown to produce IL-12 when treated with the single chain IL-12 encoding virus. The functional activity of virus encoded
IL-12 was then further demonstrated by its ability to enhance the production of IFNγ by T-cells and NK cells using PBMCs and PBMC-derived T-cell cultures as well as cultures of primary tumor cells.

**Conclusions**

In this study, we have shown that a functionally active single chain variant of human IL-12 can be effectively produced by tumor cells infected with a T-SiGn virus encoding this transgene payload. Ongoing studies are evaluating several different cytokines and chemokines encoded together with the single chain IL-12 transgene for their ability to enhance the activities of IL-12, either directly or indirectly via their ability to recruit IL-12 responsive immune cells in order to optimize the potential for clinical activity.

---

**P615**

Novel immune-cell targeted IL2v to deliver IL-2R signaling to tumor reactive T cells via PD-1 while blocking the PD-1 pathway

Laura Codann Deak 1, Valeria Nicolini 1, Laura Lauener, Mrs 1, Stefan Seebier, Dr2, Marine Richard 1, Esther Bommer1, Maria Karagiann1, Mes1, Johannes Sam, Dr1, Ramona Schlenker, Dr2, Marisa Mariani, Dr1, Petra Schwalie, Dr6, Sylvia Herter, PhD1, Marina Bacac, Dr1, Inja Waldhauer, Dr1, Anne Freimoser-Grundhoeber, Dr1, Volker Teichgraber, Dr1, Christian Klein, Dr rer nat 1, Pablo Umana, PhD1

1Roche Innovation Center Zurich, Zurich, Switzerland; 2Roche Innovation Center Munich, Munich, Germany; 3Roche Innovation Center Basel, Basel, Switzerland

**Correspondence:** Christian Klein (christian.kleinck1@roche.com)

*Journal for ImmunoTherapy of Cancer* 2019, 7(Suppl 1):P615

**Background**

Interleukin-2 (IL-2) has been the first effective cancer immunotherapy to treat metastatic melanoma and renal cell carcinoma for more than three decades. Although only a small fraction of patients benefits from such a treatment, the anti-tumor responses to IL-2 therapy tend to be complete, durable and the responding patients seem to be cured. Unfortunately, the applicability of IL-2 in the clinic is limited by its toxicity (i.e. capillary leak syndrome), unfavourable pharmacokinetic and bio-distribution in the lymphatic system rather than in the tumour, and the detrimental activation/expansion of regulatory T cells (Tregs) through IL2Ra (CD25) binding.

**Methods**

To overcome these limitations, we developed a novel immunocytokine that is constituted of a high affinity bivalent blocking anti-PD-1 antibody and a heterodimeric silent Fc-part fused to a monomeric IL-2 variant (IL2v).

**Results**

IL2v binding to CD25 is abolished, and therefore the binding to Tregs and endothelial cells is reduced. The anti-PD-1 antibody, having roughly 50-fold higher affinity than IL-2v, dictates the preferential cis-delivery of IL-2v to PD-1 positive T cells, such as antigen-experienced tumour-reactive T cells. In addition, the blocking of the PD-1 inhibitory pathway synergizes with the IL-2 signalling cascade translating into more potent T cell activation and effector functions than untargeted IL-2v. Due to reduced expression levels of PD-1 on Tregs compared to tumour-reactive T cells, PD1-IL2v binds preferentially to the latter rescuing them from Treg-mediated suppression. All these properties enabled PD1-IL2v to eradicate aggressive tumours and provide a significant survival benefit over combination of the parental molecules in the tested mouse models.

**Conclusions**

PD1-IL2v is a differentiated immune cell-targeted IL-2v which promotes an effective and long-term anti-tumor immune-response by delivering IL-2v to PD-1+ tumor-specific T cells.

---

**P616**

A novel anti-tumor anti-PDL1-IL7 immunocytokine targeting lymphocytes

Feifei Cui, PhD, Lei Fang, Haijuan Gu, Yuanjuan Yang, Zhengyi Wang, Bingshi Guo

1Mab Biopharma, Shanghai, China

**Correspondence:** Lei Fang (lei.fang@mabiopharma.com)

*Journal for ImmunoTherapy of Cancer* 2019, 7(Suppl 1):P616

**Background**

Lymphocyte counts in the peripheral immune system and tumor are correlated with positive clinical outcomes in PD-(L)1 immunotherapy. Interleukin 7 (IL7) is an immune homeostasis cytokine for T cells. Treatment with recombinant human IL7 preferentially expands recent thymic emigrants, naive and central memory T cells, but spares regulatory T cells. Here we constructed a series of immunocytokine L1I7 comprised of a PDL1 blocking mAb fused with an IL7 molecule with varying degree of attenuated potency. The aim of the study was to identify the right molecule that achieves enhanced biodistribution at the tumor site and an optimal balance between synergistic anti-tumor activity and an acceptable safety profile.

**Methods**

PDL1 binding affinity and antagonist function of L1I7 were evaluated by BiACore and PD1/PDL1 cell-based functional assay, respectively. IL7 receptor (IL7R) binding and internalization were evaluated in human primary CD4+ T cells by flow cytometry (FACS). IL7 potency was evaluated by p-STAT5 signaling assay and human CD4+ T cell proliferation assay. The in vitro synergistic effect of L1I7 was evaluated in the human mixed lymphocyte reaction (MLR) assay. The in vivo tracking assay was conducted by injecting fluorescence-labeled L1I7 into HCC827-transplanted CD34+ hematopoietic stem cells humanized mice. The in vivo efficacy of L1I7 was investigated in B16F10 melanoma syngeneic mouse model with surrogate L1I7. Absolute numbers of tumor-infiltrating CD4+ T and CD8+ T cells were analyzed by FACS.

**Results**

L1I7 series of immunocytokine maintained PDL1 binding and antagonist function when compared with PDL1 mAb. As compared with wildtype L1I7, L1I7 variants showed attenuated IL7 activity as evidenced by reduced IL7R binding/internalization, p-STAT5 activation and CD4+ T cell proliferation. Both wildtype and the attenuated variants were more effective in promoting CD4 T cell activation than anti-PDL1 or IL7 monotreatment in MLR. Similar with PDL1 mAb, L1I7 was enriched in the tumor site whereas IL7 was widely distributed in in vivo tracking experiment. In an anti-PDL1-resistant B16F10 tumor model, L1I7 showed superior efficacy as compared with either anti-PDL1, IL7 alone or in combination, which was correlated with an increased number of tumor-infiltrating CD4+ T and CD8+ T cells.

**Conclusions**

The novel immunocytokine L1I7 is designed to target poor and non-responders to PD-L1 treatment and even PD-L1 treatment relapsed patients. L1I7 represents potentially a best-in-class molecule with enhanced local immunostimulation achieved by concurrent PD-L1 blockade and IL7 stimulation. L1I7 is undergoing preclinical development with an aim to enter clinical studies in 2021.

---

**P617**

Deliver of interleukin-2 to the acidic tumor microenvironment by ultra-pH sensitive nanoparticles for immunotherapy

Xinliang Ding, PhD, Jason Miller, PhD, Ashley Campbell, Jonathan Almazan, Tian Zhao

OncoNano Medicine Inc., Dallas, TX, United States

**Correspondence:** Tian Zhao (tzhao@onconanomed.com)

*Journal for ImmunoTherapy of Cancer* 2019, 7(Suppl 1):P617

**Background**

Immunotherapy has become a powerful strategy for cancer treatment. Immunomodulators such as interleukin-2 (IL-2) can induce anti-tumor immune responses, but their clinical applications are limited by unfavorable pharmacokinetic properties that can elicit serious dose-limiting toxicities (e.g. vascular leak syndrome). [1] We have developed an ultra-pH sensitive nanoparticle platform that targets the acidic tumor microenvironment (TME) with high specificity. At normal pH conditions, the acidic TME is widely distributed in in vivo tracking experiment. In an anti-PDL1-resistant B16F10 tumor model, L1I7 showed superior efficacy as compared with either anti-PDL1, IL7 alone or in combination, which was correlated with an increased number of tumor-infiltrating CD4+ T and CD8+ T cells.

**Conclusion**

The novel immunocytokine L1I7 is designed to target poor and non-responders to PD-L1 treatment and even PD-L1 treatment relapsed patients. L1I7 represents potentially a best-in-class molecule with enhanced local immunostimulation achieved by concurrent PD-L1 blockade and IL7 stimulation. L1I7 is undergoing preclinical development with an aim to enter clinical studies in 2021.
we have encapsulated and delivered IL-2 to the TME to improve its pharmacokinetic properties.

Methods
We have developed an ultra-pH sensitive nanoparticle (ONM-400) with similar pH sensitivity to ONM-100, which is being tested in a Phase 2 clinical trial for intraoperative imaging of tumors. Multiple strategies have been exploited to encapsulate IL-2 including mixing, single emulsion, acid/base titration, double emulsion/solvent evaporation, and covalent conjugation. The ONM-400IL-2 complexes were purified by ultracentrifugation and characterized by dynamic light scattering and transmission electron microscopy. Encapsulation efficiency (EE) and drug loading (DL) were measured for each formulation using ELISA or gel electrophoresis. In addition, IL-2 was labeled with a near-infrared dye (IRDye® 800CW) to study the in vivo tumor accumulation and biodistribution after intravenous injection in mice bearing head and neck tumors using a Li-COR Pearl® camera.

Results
ONM-400 nanoparticles were able to encapsulate IL-2 with high loading. The EE and DL ranged from 81.8% to 35.7% and 8.2% to 3.5%, respectively. In vivo imaging of ONM-400IL-2 showed significantly higher tumor accumulation and less bladder signal compared to free IL-2 at the same dose after IV injection (Fig. 1A). ONM-400IL-2 provided longer and increased IL-2 exposure in tumor than free IL-2 which decreases overtime. Quantitative analysis of the tumor signal at different time points indicated an alteration of pharmacokinetics for IL-2 after encapsulation by the ONM-400 nanoparticle (Fig. 1B). Biodistribution at 24h further revealed a lower accumulation in kidney but higher accumulation in tumor for ONM-400IL-2 versus free IL-2.

Conclusions
The ONM-400 nanoparticles can efficiently encapsulate IL-2 and alter its pharmacokinetics in vivo. These results suggest a great potential for using the ultra-pH sensitive nanoparticle technology to deliver immunomodulators to improve their efficacy and safety profile.

References
1. Riley R, June C, Langer R, Mitchell M. Delivery technologies for cancer vaccination, and covalent conjugation. The ONM-400 strategies have been exploited to encapsulate IL-2 including mixing, single emulsion, acid/base titration, double emulsion/solvent evaporation, and covalent conjugation. The ONM-400IL-2 complexes were purified by ultracentrifugation and characterized by dynamic light scattering and transmission electron microscopy. Encapsulation efficiency (EE) and drug loading (DL) were measured for each formulation using ELISA or gel electrophoresis. In addition, IL-2 was labeled with a near-infrared dye (IRDye® 800CW) to study the in vivo tumor accumulation and biodistribution after intravenous injection in mice bearing head and neck tumors using a Li-COR Pearl® camera.

Fig. 1 (abstract P617). See text for description
Background
NKTR-255 is a polymer-conjugated IL-15 pathway agonist that retains binding affinity to the alpha subunit of the IL-15 receptor and exhibits reduced clearance. Sustained IL-15 pathway activation leads to expansion and activation of NK cells potentially enabling combinatorial immunotherapies including tumor targeting antibodies that mediate tumor killing by antibody dependent cellular cytotoxicity (ADCC). Here we investigate NKTR-255 induced enhancement of NK cell ADCC dependent tumor cell killing in vitro and in vivo in the tumor environment when combined with tumor-targeting monoclonal antibodies in solid tumors.

Methods
NKTR-255 dose dependent enhancement of NK cell cytotoxicity as a single agent or in combination with cetuximab was evaluated in vitro in co-cultures of purified human NK cells with HCT-116 or FaDu tumor cells. Target cell killing was evaluated by flow cytometry based viability scoring. In vivo tumor growth inhibition was measured in xenograft models with diverse histologies including colorectal (Colo25, HT29, HCT-116), lung (H1975S), epidermal (A431), ovarian (SKOV3) and gastric (NCI-N87), Nude or SCID mice in Balb/c background were subcutaneously inoculated on the flank with tumor cells. NKTR-255 was administered intravenously weekly at 0.3mg/kg. Cetuximab or trastuzumab were administered at dose levels and schedules optimized for each tumor type with a once or twice a week schedule. Treatment was initiated at established ~100-150mm3 tumor volumes. Tumor growth inhibition was assessed by tumor size caliper measurements.

Results
NKTR-255 pre-treatment of NK cells led to enhanced cytotoxic activity against HCT-116 and FaDu cells in vitro. Additional enhancement of NK cell dependent killing of tumor cells was observed in the presence of cetuximab antibody in the co-culture assay demonstrating NKTR-255 dependent enhancement of NK cell ADCC. In agreement with in vitro activity, NKTR-255 combination treatment with cetuximab or trastuzumab showed significant tumor growth inhibition in multiple models. Notably tumor models resistant to cetuximab single agent treatment (HT-29 and HCT-116) showed significant growth inhibition in combination treatment with NKTR-255. Trastuzumab targeted tumors showed significant enhancement of antibody mediated tumor growth inhibition in combination with NKTR-255 including 100% complete responses in the SKOV3 model.

Conclusions
NKTR-255 treatment of NK cells enhanced ADCC activity against tumor cells in vitro and in vivo efficacy of ADCC inducing antibodies in human solid tumor xenograft models. Furthermore, antibody single agent treatment resistant tumor models showed tumor growth inhibition in combination treatment with NKTR-255 suggesting potential for increasing response rates of therapeutic antibodies with ADCC mechanism of action.

Ethics Approval
All procedures in this study were reviewed and approved by Nektar Therapeutics Institutional Animal Care and Use Committee.

P620
Complementary effects of RNA encoded, extended half-life IL2 and IL7 synergize in modulating T cell responses and antitumoral efficacy
Lena Kranz 2, Mathias Vormehr, PhD 3, Jan Dieckmann, PhD 2, Claudia Lindemann 2, David Eisel 1, Alexander Muik, PhD 2, Sina Fellermeier-Kopf 3, Friederike Gieseke 2, Bodo Tillmann 1, Sonja Wittzel 5, Marlen Lepper 3, Mustafa Diken 2, Sebastian Kreiter, MD 1, Veronika Jahndel 5, Özlem Türeci 3, Ugur Sahin 1, 2
1Biontech SE, Mainz, Germany; 2Biontech Pharmaceuticals, Mainz, Germany; 3TRON-Translational Oncology gGmbH, Mainz, Germany
Correspondence: Ugur Sahin (ugur.sahin@biontech.de)

Background
Interleukin-2 (IL2) is known to support effector T cell differentiation, proliferation and survival. A particular challenge of IL2 for cancer treatment is the preferential stimulation of regulatory T cells (Tregs) constitutively expressing the high-affinity IL2 receptor alpha chain (CD25). Tregs can undermine the antitumoral activity of tumor-specific effector T cells only transiently expressing CD25. Interleukin-7 (IL7) is a homeostatic cytokine that plays an important role in lymphopoiesis, survival and memory formation, and can increase the expression of CD25 on antigen-specific T cells. Prompted by their complementary effects, we investigated the potential synergy between these two cytokines on the T cell level and on antitumoral activity.

Methods
We designed nucleoside-modified, RNA encoded, extended half-life IL2 and IL7, formulated as nanoparticles for intravenous delivery. The potency of IL2 and IL7 to enhance antitumoral activity of a liposome-formulated RNA vaccine [1] was determined for both cytokines separately and in combination. Therapeutic success and changes in blood T cell subset composition were determined in subcutaneous, syngeneic tumor-bearing mice.

Results
Using nanoparticle formulated, nucleoside-modified RNA coding for extended half-life IL2 and IL7, we demonstrated that IL2 and IL7 each increases the number and frequency of antigen-specific CD8+ T cells in combination with an antigen-specific RNA vaccine compared to the vaccine alone. While the effect on expansion of antigen-specific T cells of IL2 is strong and immediate, IL7 requires repetitive cycles to generate its maximal effect. In addition, IL7 turned out to expand CD8+ T cells with specificities for targets other than the vaccine-encoded antigen better than IL2. As expected, IL2 strongly expanded the number and frequency of Tregs. In contrast, IL7 reduced the fraction of Tregs among CD4+ T cells. The combination of IL2 with IL7 proved to be powerful in overcoming their individual shortcomings: The combination boosted the number of antigen-specific CD8+ T cells beyond the levels of IL2 alone, supported the expansion of CD8+ T cells not specific for the vaccine-encoded target, and further improved the ratio of antigen-specific CD8+ T cells over Tregs. These findings translated into superior antitumoral activity of the combination in subcutaneous mouse tumor models.

Conclusions
Based on the complementary mode of action and the promising preclinical data, clinical evaluation will be pursued.

References

Ethics Approval
Experimental group sizes were approved by the regulatory authorities for animal welfare after being defined to balance statistical power, feasibility and ethical aspects. All mice were kept in accordance with federal and state policies on animal research at BioNTech SE.

P621
Nano-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers
Hye-Hyun Ahn, PhD 1, Christine Carrington 2, Heng-wen Liu 3, Yizong Hu 3, Christy Ng 1, Hwanhee Nam 1, Andrew Park 1, Catherine Stace 1, Will West, PhD 1, Hai-Quan Mao, PhD 3, Martin Pomper, MD, PhD 1, Chris Ullman, PhD 1, IL Minn, PhD 1
1Johns Hopkins University, Baltimore, MD, United States; 2Cancer Targeting Systems, Newton Centre, MA, United States; 3Cancer Targeting Systems, Newton Centre, MA, United States
Correspondence: Chris Ullman (chris.ullman@cts-bioscience.com), IL Minn (ilminn1@jhmi.edu)

Background
Therapies through systemic injection of recombinant immunomodulatory cytokines have not been successful due to low therapeutic index. Here we describe the use of a polycation-encapsulated DNA
plasmid to locally deliver therapeutic cytokine genes under the control of the cancer-selective rat progression elevated gene 3 (PEG-3) promoter1,2 to tumors in the lungs of diseased mice. [1-3]

Methods
A cGMP grade polycationic carrier, in vivo-jetPEI® was chosen to formulate the plasmid DNA construct to aid rapid transition to clinical studies. Clinically compatible vectors were created that featured a CpG-free backbone containing a kanamycin resistant gene, scaffold/matrix attachment regions and CpG-free payload genes. Plasmids were then packaged into size-controlled nanoparticles with in vivo-jetPEI® using a scalable flash nanocomplexation (FNC) manufacturing method3 for production of lyophilized, shelf-stable nanoparticles with an excellent reproducibility under quality assurance and quality control standards.

Results
These well-defined pDNA/IPEI nanoparticles, delivered systemically, were well-tolerated in mice and accomplished significant reduction in levels of acute inflammatory cytokines compared to an equivalent CpG-containing plasmid. In vivo transfection of metastatic lesions in the lung by nanoparticles expressing firefly luciferase from the PEG-3 promoter could be detected by bioluminescent imaging. Furthermore, intravenous delivery of nanoparticles expressing murine single-chain interleukin-12, under the control of PEG-3 promoter, significantly improved the survival of mice in two different models of lung cancer with no marked symptoms of systemic toxicity (Figure 1).

Conclusions
Increased survival in both an orthotopic and a metastatic model of lung cancer using clinically relevant nanoparticles raises the possibility of translation to human therapy.

Acknowledgements
This study is partially supported by a research contract from Cancer Targeting Systems, Inc. (CTS) and an NIH grant R01EB018358.

References

Ethics Approval
All experiments were performed in accordance with protocols approved by Animal Care and Use Committees of the Johns Hopkins University and of the Pennsylvania State University.

Fig. 1 (abstract P621). Expression of mIL-12 provides survival benefits

Background
IL-15 is a cytokine that activates and provides survival benefit to T and NK cells and has great potential for the treatment of cancer. Exploiting the therapeutic value of native IL-15 has been challenging due to its unfavorable pharmacokinetic properties and poor tolerability. Several IL-15-based proteins aimed to overcome these problems are currently in development. NKTR-255 is a polymer-conjugated native IL-15 that is designed to retain a binding affinity to IL-15 receptor alpha (IL-15Ralpha), while the most clinically advanced IL-15-based protein is an IL-15 superagonist (IL-15 mutein/IL-15Ralpha-Fc complex). We investigate the pharmacological properties of NKTR-255 and the IL-15 superagonist to explore differentiation between the IL-15Ralpha dependent and independent cytokines.

Methods
For cellular receptor binding, IL-15Ralpha-overexpressing HEK-293 cells were incubated with rhIL-15, NKTR-255 or IL-15 superagonist to measure surface binding of the cytokines by flow cytometry. The biological activity of cell surface bound cytokines was measured by pSTAT5 induction following co-culture with human PBMCs. Surface expression of IL-15Ralpha was measured by flow cytometry at 20 min or 2 hr following incubation with each of the cytokines. In functional assays, human PBMCs were incubated with each of the cytokines for 1, 2 or 5 days for surface marker characterization, cytokine production or proliferation assay, respectively.

Results
NKTR-255 binds to surface IL-15Ralpha on the receptor-overexpressing HEK-293 cells. Maximal binding was similar to that of rhIL-15, while IL-15 superagonist showed negligible binding. In concordance, the HEK-293 cells incubated with NKTR-255 induced pSTAT5 on human PBMCs, while the HEK-293 cells incubated with IL-15 superagonist failed to induce pSTAT5. Similarly to rhIL-15, incubation of NKTR-255 with human whole blood reduced surface staining of IL-15Ralpha on T and NK cells; in contrast IL-15 superagonist reduced IL-2Rbeta staining. Each of the cytokines dose-dependently induced proliferation of both NK cells and T cells; the EC50 value of NKTR-255 was approximately 20-fold higher than the EC50 values of both rhIL-15 and IL-15 superagonist. Interestingly, NKTR-255-treated NK cells showed more rounds of division than IL-15 superagonist-treated NK cells at the highest concentration. The maximal responses of NKTR-255 for induction of surface CD107a expression in NK cells and IFN-gamma production were also higher than those of IL-15 superagonist.

Conclusions
NKTR-255 is a novel IL-15Ralpha dependent molecule that provides enhanced PK and PD properties relative to the native IL-15 cytokine while IL-15 superagonist is a direct engager to IL-2Rbeta complex. These results indicate the potential of NKTR-255 pharmacology to capture the full spectrum of native IL-15 biology.

P622
Characterization and comparison of NKTR-255, a polymer-conjugated IL-15 versus IL-15 superagonist
Takahiro Miyazaki, MS1, Mekhala Maiti, PhD2, Sara Sheibani, Joanna Wilczek, Olga Zemska, Peiwen Kuo, PhD3, Saul Kivimaëe, Marlene Hennessey, BS, Phi Quach, BS PhD, Ping Zhang, MS PhD, Thomas Chang, PhD, Louis Madakamutil, Jonathan Zalesky, PhD1
Nektar Therapeutics, San Francisco, CA, United States

Correspondence: Takahiro Miyazaki (tmiyazaki@nektar.com)


P623
Bempegaldesleukin in combination with local radiation and systemic checkpoint blockade induces a robust systemic anti-tumor immunity
Alexander Pieper, BS1, Alexander Rakhmilevich, MD, PhD1, Dan Spiegelman1, Ravi Patel, MD, PhD2, Claire Baniel1, Amy Erbe, PhD3, Jacquelyn Hank, PhD3, Deborah Charych, PhD3, Willeim Overwijk, PhD3, Zachary Morris, MD, PhD3, Paul Sondel, MD, PhD3
1University of Wisconsin-Madison, Madison, WI, United States; 2Third Rock Ventures, San Francisco, CA, United States; 3Nektar Therapeutics, San Francisco, CA, United States

Correspondence: Alexander Rakhmilevich (rakhmi@humonc.wisc.edu), Dan Spiegelman (dspiegelman2@wisc.edu), Ravi Patel (rpatel55@wisc.edu), Claire Baniel (cbaniel@gmail.com), Amy Erbe (aerbe@wisc.edu), Jacquelyn Hank (hank@humonc.wisc.edu), Deborah Charych (dcharych@nektar.com), Willeim Overwijk (wooverwijk@gmail.com), Zachary Morris (zmorris@humonc.wisc.edu), Paul Sondel (pmondsel@humonc.wisc.edu)

Background
Bempedalensleukin (NKTR-214) is a first-in-class, CD122-preferential interleukin-2 (IL2) pathway agonist being investigated for its potential ability to leverage the clinically validated IL2 pathway and selectively stimulate an immune response, without overactivating the immune system. We have previously shown a synergistic interaction between local low dose radiation therapy (RT) and NKTR-214 in mice bearing moderate sized melanoma tumors. This combination is less effective, however, in the presence of larger tumors and/or systemic disease. Checkpoint blockade effectively disables immune inhibitory functions, thereby enabling a stronger anti-tumor immune response. We hypothesized the addition of checkpoint blockade to (RT)+[NKTR-214] would help overcome the immune suppression in difficult models, allowing for a stronger anti-tumor effect.

Methods
To generate a model of bulky unresectable disease, C57BL/6 mice were inoculated with B78 melanoma cells on the right flank and tumors were allowed to grow for ~7 weeks (average tumor size ~800mm³). Mice were randomized and treated with 12 Gy external beam RT to the flank tumor and intravenous (IV) NKTR-214 or [RT]+[NKTR-214]+[α-CTLA-4]. To create a model of heterogeneous and disseminated metastatic disease, C57BL/6 mice were inoculated with B78 cells on the right flank and tumors were allowed to grow for ~4 weeks (average tumor size ~185mm³). On the day the treatments began, mice were injected intraperitoneally with B16 Luciferase+ melanoma cells. B16 is parental to B78 melanoma, sharing some common antigens. Mice were treated with: 1) PBS, 2) [NKTR-214]+[α-CTLA-4], 3) [RT]+[α-CTLA-4], 4) [RT]+[NKTR-214]+[α-CTLA-4], or 5) [RT]+[NKTR-214]+[α-CTLA-4]+[T-cell depleting antibodies (α-CD4+α-CD8+)]. Tumor growth and survival were monitored. Metastatic disease burden was evaluated by luciferase imaging.

Results
In very large B78 tumors (~800mm³), [RT]+[NKTR-214]+[α-CTLA-4] caused greater tumor regression than [RT] +[NKTR-214]. In a model of disseminated metastatic disease, [RT]+[α-CTLA-4] slowed primary tumor progression but had little effect on metastatic disease, demonstrated by the group’s similar survival kinetics to the PBS control. Adding [NKTR-214] to [RT]+[α-CTLA-4] not only caused primary tumor regression but also resulted in greater overall survival than all other groups in the B78 primary/B16 metastasis study. Control of the lung metastasis by [RT]+[NKTR-214]+[α-CTLA-4] was T-cell mediated. Though [NKTR-214]+[α-CTLA-4] demonstrated relatively weak control of the primary tumor, this combination slowed metastatic tumor burden displaying a prolongation of survival compared to vehicle and [RT]+[α-CTLA-4] only.

Conclusions
Our preliminary results suggest that [RT]+[NKTR-214]+[α-CTLA-4] has the ability to mount a T-cell dependent anti-tumor response capable of regressing large unresectable tumors and disseminated, heterogeneous metastatic disease in murine melanoma models.

P624
Layer-by-layer nanoparticles for the non-toxic delivery of interleukin-12 to orthotopic ovarian cancer
Sean Smith1, Antonio Robberecht, BSE2, Danielle Raininge, PhD3, Santiago Correa3, Cathy Nguyen2, Mariane Melo, Talar Tokatlian, PhD4, Paula Hammond2
1Massachusetts Institute of Technology, Cambridge, MA, United States; 2MIT, CAMBRIDGE, MA, United States; 3Stanford University, Cambridge, MA, United States

Correspondence: Paula Hammond (hammond@mit.edu)

Background
Ovarian cancer represents an area of great unmet clinical need, with the 5-year survival rate for high grade ovarian cancer at just 25% for those with advanced disease and with only ~10% of patients responding to checkpoint inhibition or other immune therapeutics [1]. Thus, there remains a pressing need to explore alternative strategies to potentiate immunotherapies in ovarian cancer. One attractive class of therapeutics that could play such a role are proinflammatory cytokines. However, many proinflammatory cytokines have been under-utilized in ovarian cancer and other solid tumors, largely due to toxicity concerns. In this study we develop a nanoparticle to deliver interleukin-12 (IL-12), one of the most potent and toxic cytokines, to an orthotopic model of murine ovarian cancer. The layer-by-layer (LbL) method was used to modify liposomes bearing IL-12 with a polymeric surface chemistry that covers the cytokine to limit its accessibility outside of the tumor environment, enhances ovarian cancer targeting, and prevents nanoparticle internalization.

Methods
IL-12 nanoparticles were constructed as shown in Figure 1A. Briefly, His-tagged, single-chain IL-12 was loaded onto the surface of liposomes bearing Ni headgroups. The liposomes were then layered with positively charged poly-L-arginine followed by poly-L-glutamine (PLE). These constructs (PLE-IL12-NP) were fully characterized and tested in vitro. For in vivo testing, female B6C3F1 mice were implanted intraperitoneally with 1MM HM-1 ovarian cancer cells. Beginning 7 days after implantation, mice were treated intraperitoneally 1x/day for five days with PLE-IL12-NP (5 μg). Mice were tracked for tumor burden via luciferase expression, survival, and signs of toxicity.

Results
Incubation with splenocytes confirmed that PLE-IL12-NPs retained the activity of IL-12. Toxicity studies in mice showed that at 5 μg the PLE-IL12-NPs reduced toxicity in terms of weight loss (Figure 2B) and systemic cytokine production (data not shown). Indeed, the weight of mice treated PLE-IL12-NPs was indistinguishable from vehicle treated mice. Antitumor studies against established metastatic ovarian tumors showed that PLE-IL12-NPs were just as efficacious as soluble IL-12 (Figure 2C) extending survival over both vehicle and unlabeled cytokine-bearing liposomes.

Conclusions
PLE-IL12-NPs offer a simple approach to ameliorate the toxicity of IL-12. Indeed, this approach offers promise for the systemic delivery of potent cytokines to hard-to-treat tumors such as ovarian cancer. Ongoing studies are exploring the biodistribution following additional routes of administration, the immunological mechanisms of these responses, and the combination of this approach with checkpoint inhibition.

References

Fig. 1 (abstract P624). Layer-by-layer nanoparticles for IL-12 delivery
This project was reviewed and approved by the Greater Manchester West
Acknowledgements

S3

KY1043, a novel PD-L1 IL-2 immunocytokine directed towards

Background

IL-2 therapy has been approved for the use in certain cancers since

Methods

Results

Conclusions

Acknowledgements

Ethics Approval

This project was reviewed and approved by the Greater Manchester West

References


Ethics Approval
Experimental group sizes were approved by the regulatory authorities for animal welfare after being defined to balance statistical power, feasibility and ethical aspects. All mice were kept in accordance with federal and state policies on animal research at BioNTech SE.

P627
Comparing the functionality of Proleukin® and Akron Interleukin-2 through an analysis of key T cell subsets
Claudia Zylberberg, PhD1, Claudia Zylberberg, PhD2, John Koreth, MBBS, DPhil3, Jerome Ritz, MD 3
1 Akron Biotechnology, Boca Raton, FL, United States; 2 Akron Biotech, Boca Raton, FL, United States; 3 Dana Farber Cancer Institute, Cambridge, MA, United States
Correspondence: Claudia Zylberberg (czyberberg@akronbiotech.com)

Background
Recombinant human interleukin-2 (IL-2) promotes the proliferation of activated T cells and has long been used in vivo to stimulate and maintain the growth of effector T cells and increasingly, to expand T cells in vitro (including genetically engineered CAR-T cells) for adoptive cell therapy in patients with cancer. IL-2 was approved by the FDA for treatment of metastatic renal cancer in 1992 and for treatment of metastatic melanoma in 1998. However, its administration in the approved dose has been associated with serious side effects, including vascular toxicity. There have recently been efforts to address these issues through modifications to the molecule, through the development of fusion proteins, and through the development of low-dose formulations. Akron Biotechnology manufactures IL-2 for use in vitro use. The product is embedded in the manufacturing process for several CAR T therapies. There are opportunities to leverage this IL-2 to treat patients suffering from acute and chronic graft versus host disease (GVHD) following allogeneic hematopoietic stem cell transplantation, as well as a range of other autoimmune diseases.

Methods
CyTOF (cytometry by time-of-flight mass spectrometry): antibody panel designed by Dana Farber Cancer Institute. There are three categories of target proteins: surface proteins, intracellular markers and signaling molecules. Different markers were checked after stimulation with Akron IL-2 or Proleukin® (15 minutes) and verified with lymphocyte subset and intrinsic signaling cascade.

Results
The research focused on three major T cell subset populations (Treg, Tcon and CD8 T cells). Upon stimulation with Akron IL-2 and Proluekin®, CD25, CD122, CD132, CTLA-4, PD-1, PD-L1 markers were checked for individual T cell subsets, observed via t-SNE plot. The data indicated that the antibody panel setting was accurate and reliable; each marker was expressed in the expected T cell subset. For example: CD25 was expressed exclusively in Tregs. The expression of pSTAT5, pSTAT3, and pSTAT1 was identical in Akron IL-2 and Proleukin®, controlling for exposure and dosage (Figure 1 includes summary of pSTATS results). These results confirm that Akron IL-2 and Proleukin® are identical in their ability to boost adaptive immune response.

Conclusions
The toxicity associated with high dose IL-2 has led many to seek alternatives that can achieve positive therapeutic outcomes while minimizing negative side effects. This study demonstrates that Akron’s IL-2 is functionally similar to Proleukin®, validating its utility for the production of adoptive immunotherapies, and potentially for treatment of patients suffering from autoimmune diseases.

P628
Inhibition of histone deacetylase enhances CD8 T-cell functionality and metabolic fitness resulting in strong anti-tumor response.
Pankaj Gaur, PhD1, Vivek Verma, PhD1, Rahul Nnadre1, Fatmahn Alolaqi1, Peter Ordentlich, PhD2, Lei Wang, PhD2, Seema Gupta, PhD3, Samir Khleif, MD1
1 Georgetown University School of Medicine, Washington, DC, United States; 2 Syndax Pharmaceuticals, Waltham, MA, United States
Correspondence: Samir Khleif (skhleif@georgetown.edu)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P628

Background
Tumor microenvironment (TME) often harbors epigenetic alterations mediated by histone acetyltransferases (HATs) and histone deacetylases (HDACs)[1, 2]. The epigenetic dysregulation of T-cells and enhanced numbers of immunosuppressive cells in the TME are associated with decreased anti-tumor effects. Hence, targeting the epigenetic modifications using modulators such as HDAC inhibitors (HDACi) provides the basis for a potential role for these agents in cancer immunotherapy. Earlier, we found that HDACi, entinostat reprograms the TME by increasing the number of central memory T-cells and enhancing the functionality of effector cells, resulting in enhanced anti-tumor responses. However, the mechanisms by which HDACi enhances the effector functions of CD8 cells are not well understood.
Methods
In the TC-1 mouse tumor model, entinostat (3mg/kg) was administered with a tumor-specific vaccine (E7-peptide; 3 doses one-week apart). Tumor growth and mice survival were recorded. Three-days after the second immunization, immune-responses were determined in the tumors. Mitochondrial mass of CD8 cells was estimated by incorporation of Mitotracker dye, while glucose uptake rates were determined by 2-NBDG incorporation.

Results
We found that entinostat, in presence of optimal CD8 cell priming using tumor specific E7-peptide vaccine, significantly delayed the tumor growth and prolonged the mice survival. Immunologically, entinostat significantly enhanced the numbers of total and antigen-specific CD8+ T cells in the TME. Importantly, we observed a significant increase in the numbers of activated to total and antigen-specific granzyme B+ CD8+ T-cells in the TME when combined with the vaccine. The HDAC inhibition also augmented IFN-gamma production in CD8+ T cells. It is now widely appreciated that T-cell differentiation and effector functions are coupled to metabolic reprogramming. Therefore, using in-vitro assay systems, we checked the status of CD8+ T cells treated with the HDAC inhibitor. We found that HDAC inhibition in CD8 cells during antigen-specific activation resulted in significantly increased mitochondrial mass. Activated CD8+ T effector cells are known to rely on glucose metabolism for their energy requirements. Interestingly, the glucose uptake rates of entinostat treated CD8 cells were not different than the non-treated cells indicating that glucose was not utilized differentially in entinostat treated cells. We are further in process of delineating the mechanisms of entinostat mediated enhancement of CD8 cells metabolism.

Conclusions
Overall, our study strongly supports the key role of epigenetic factors in regulating CD8+ T-cell effector and/or memory generation, and metabolic fitness. However, the epigenetic changes that accompany these functional T-cell stages in relation to metabolism remain to be understood.

References
derived peptides, suggesting that the antitumor activity of the molecule was immune mediated. Indeed, ITF3756 was completely ineffective in SCID/beige mice bearing CT26 tumor. Selective in vivo depletion of CD4 and CD8 T cells indicated that the activity of ITF3756 strictly depends on both T cell subsets with a greater contribution of CD8 T cells.

In a model of in vitro human T cell exhaustion, ITF3756 countered the exhaustion process as evidenced by the reduced expression of PD-1 and Lag3. Furthermore, ITF3756 increased the CD8 T central memory and reduced the effector memory subsets.

Conclusions
This study shows in vivo and in vitro mechanisms whereby ITF3756 increases the immune response and constitutes a robust basis for the rational use of selective HDAC6 inhibitors either alone or in combination for the effective induction of antitumor immune response.

Ethics Approval
All the animal procedures (including housing, health monitoring, restraint, dosing, etc) and ethical revision were performed according to the current Italian legislation (Legislative Decree March 4th, 2014 n. 26) enforcing the 2010/63/UE Directive on the protection of animals used for biomedical research.

P631 Immunotherapy plus gene therapy: a novel nanomedicine carrying the RB94 gene that suppresses tumor growth in non-small-cell lung cancer by inducing immunogenic cell death & modulating host immunity
Joe Harford, PhD1, Caroline Doherty1, Manish Moghe2, Antonina Rait, PhD2, Steven Metello, PhD2, Kathleen Pirolo, PhD2, Esther Chang, PhD2, Sang-Soo Kim, PhD1,3
1SynerGene Therapeutics, Inc, Potomac, MD, United States; 2Georgetown Univ Med Ctr, Washington, DC, United States; 3Georgetown University, Washington, DC, United States
Correspondence: Sang-Soo Kim (sangsoo.kim@georgetown.edu)

Background
Lung cancer is the world's most common malignancy (>2 million new cases & >1.7 million deaths annually) [1]. Current lung cancer treatments are woefully inadequate, and immunotherapy has had limited success with but 10-20% of patients with advanced non-small-cell lung cancer (NSCLC) showing durable responses [2]. This has led to a focus on combining immunotherapy with other treatment modalities, and we are exploring combining gene therapy and immunotherapy. scL-RB94, is a cationic liposome encapsulating the RB94 gene that suppresses tumor growth in non-small-cell lung cancer (NSCLC) xenografts (Figure 2) by inducing immunogenic cell death (ICD) and enhancing innate immunity via pleiotropic effects on multiple immune-relevant genes (Figure 8, Box A & B). We are currently exploring the effects of scL-RB94 on adaptive immune responses and in relieving tumor immunosuppression (Figure 8, Box C & D). We hypothesize that combining scL-RB94 with a checkpoint inhibitor will improve response rates compared to immunotherapy alone. With scL-RB94, it may also be possible to reduce the dose of the checkpoint inhibitor to mitigate toxicity. Our longer-term goal is to improve outcomes for NSCLC patients through more effective treatment that combines gene therapy and immunotherapy.

Conclusions
scL-RB94 renders NSCLC tumors more immunologically “hot” by triggering ICD and enhancing innate immunity via pleiotropic effects on multiple immune-relevant genes (Figure 8, Box A & B). We are currently exploring the effects of scL-RB94 on adaptive immune responses and in relieving tumor immunosuppression (Figure 8, Box C & D). We hypothesize that combining scL-RB94 with a checkpoint inhibitor will improve response rates compared to immunotherapy alone. With scL-RB94, it may also be possible to reduce the dose of the checkpoint inhibitor to mitigate toxicity. Our longer-term goal is to improve outcomes for NSCLC patients through more effective treatment that combines gene therapy and immunotherapy.

References
1. IARC Global Cancer Observatory website (http://gco.iarc.fr/).

Ethics Approval
All animal studies was performed under an IACUC-approved protocol in compliance with the Animal Welfare Act, PHS Policy, and other Federal statutes and regulations relating to animals in the AAALAC-accredited animal facility at Georgetown University, which adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council.

Fig. 1 (abstract P631). See text for description

Fig. 2 (abstract P631). See text for description

Inhibition of Growth of Human NSCLC Tumors (H292) in Athymic Mice by scL-RB94
Acute myeloid leukemia induced T cell suppression can be reversed by inhibition of the MAPK pathway

Kaycee Moshofsky, BS, MCR, Kyle Romine, BS, Yoko Kosaka, PhD, Guanming Wu, Shannon McWeeney, PhD, Evan Lind, PhD
Oregon Health & Science University, Portland, OR, United States

Correspondence: Evan Lind (linde@ohsu.edu)

Background
Acute myeloid leukemia (AML) remains difficult to treat due to mutational heterogeneity and the development of resistance to treatment. Targeted agents, such as MEK inhibitors, may be incorporated into treatment, however, the impact of MEK inhibitors on the immune microenvironment in AML is not well understood. A greater understanding of the implications of MEK inhibition on immune responses may lead to greater understanding of immune evasion and more rational combinations with immunotherapies.

Methods
AML murine model
Mice expressing FLT3-ITD under the endogenous FLT3 promotor were crossed to mice with the Tet2 gene flanked by LoxP sites and CRE recombinase under control of the LysM promotor. All mouse experiments were performed in accordance with IACUC protocol #IP00000907.

Primary patient samples
Peripheral blood and bone marrow samples were collected from patients with AML. Peripheral blood was collected from healthy donors. All participants gave informed consent to participate (OHSU eIRB #4422).

Murine proliferation assays
Mononuclear cells were stained with CellTrace CFSE and plated with plate-bound anti-CD3. The mononuclear cells were treated with anti-PD1 and/or trametinib.

Primary patient sample proliferation assays
Mononuclear cells were labeled with CellTrace Violet. Cells were plated with anti-CD3. Cells were treated with combination of anti-PD1 and/or trametinib for 5 days.

Results
In the mouse model, trametinib increases T cell viability and restores T cell proliferation. Importantly, we report greater proliferation in the

Fig. 3 (abstract P631). See text for description

Fig. 4 (abstract P631). See text for description

Fig. 5 (abstract P631). See text for description

Fig. 6 (abstract P631). See text for description
CD8+CD44+ effector subpopulation and impaired activation of CD8+CD62L+ naïve cells. Transcriptome analysis revealed trametinib sensitive samples have an inflammatory gene expression profile, and we also observe increased PD-L1 expression on trametinib sensitive samples. Finally, we demonstrate trametinib consistently reduces PD-L1 and PD-L2 expression in a dose-dependent manner on the myeloid population.

Conclusions
There are many clinical trials studying immunotherapies in AML. However, immunotherapies may fail as monotherapies in clinical trials if there is strong persisting immunosuppression in the tumor microenvironment or due to a lower mutational burden. Previous work in other cancers have demonstrated benefits of using MEK inhibition in combination with immunotherapies, including checkpoint inhibitors, adoptive T cell therapy, and viral therapy. Subpopulations of AML patients may have improved response to immunotherapies when used in combination with targeted agents. For this reason, we believe our data is useful in beginning to determine immune evasion pathways, such as MEK signaling, in AML in order to target these pathways with the combination of targeted inhibitors and immune based therapies, such as checkpoint inhibitors, bi-specifics, vaccines, or CAR T cell therapies.

Acknowledgements
This work was supported by grant US4CA224019 (E.F.L., S.K.M.) from the National Cancer Institute, grant U41HG003751 (G.W.) from the National Human Genome Research Institute, and by the Oregon Clinical and Translational Research Institute (OCTRI) grant T1TR002371 (K.B.M.) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Ethics Approval
All mouse experiments were performed in accordance with IACUC protocol #P00000099. All participants gave informed consent to participate in the study, which is approved by the Institutional Review Board at OHSU (eIRB# 4422).

P633
BPM3150, a metabolic modulating anti-cancer agent, demonstrates immunopotentiating properties by promoting cytotoxic T cells and reversing indices of exhaustion and immunosuppression
Maria-Dorothea Nastke, PhD, Shiva Kazeroonian, PhD, Anne Diets, PhD, Stephane Gesta, PhD, Vivek Vishnudas, PhD, Niven Narain, PhD, Rangaprasad Sarangarajan, PhD
Berg LLC, Framingham, MA, United States
Correspondence: Rangaprasad Sarangarajan (rangaprasad.sarangarajan@berghealth.com)

Background
Regulation of mitochondrial metabolism is crucial for immune cell differentiation and function. Therapeutic agents influencing mitochondrial metabolism can potentially impact immune-mediated tumor elimination to affect efficacy outcomes. BPM3150 is a Coenzyme Q10-containing lipid nanodispersion in clinical development for treatment of solid tumors. In a preclinical model, BPM3150 increased cytotoxic T cell frequency and cytotoxic T cell/ regulatory T cell ratio in tumors. Ex vivo, treatment of PBMCs with BPM3150 lead to an increased frequency of viable CD3+ cells. Proliferation measurements by EdU-incorporation indicated enhanced cytotoxic T cell proliferation, and likewise, BPM3150 increased cytolytic potential of activated cytotoxic T cells, as indicated by measurement of plasma membrane-exposed lysosomal-associated membrane protein 1 (CD107a). Treatment of healthy donor PBMCs with BPM3150 decreased cell surface expression of inhibitory receptors PD-1 and CTLA-4 in cytotoxic and helper T cells. To investigate if BPM3150 regulates the cytokine milieu, cytokine secretion profiles of activated PBMCs treated with BPM3150 were established. Analysis of supernatants by multi-analyte ELISA platform revealed effector cytokines IL-2 and IFN-γ to be dose-dependently increased while IL-10, a key immune-regulatory cytokine, was decreased. Analysis of monocyte depleted PBMCs compared to monocytes alone demonstrated that the observed changes in IL-2 and IFN-γ secretion occur only when both lymphocytes and monocytes are present; however, monocytes alone were identified as the significant source for IL-2.

Conclusions
Collectively, the results identify and characterize immune-modulatory activity of BPM3150, particularly in the T cell compartment, specifically on the regulation of T cell exhaustion and immunosuppression in supporting an anti-cancer effect. The data support the utility of BPM3150 in ‘immunologically cold’ tumor types or in combination with immune checkpoint blockade strategies.

P634
Predicting radiation-induced immune trafficking and activation in localized prostate cancer
Simon Keam, Heloise Halse, Thu Ngoc Nguyen, Catherine Mitchell, Franco Carania, David Byrne, Sue Haupt, Georgina Byland, Phillip Darcy, Shahnne Sandhu, MBBS FRACP, Piers Blombery, Ygal Haupt, Scott Williams, Paul Neeson, PhD
Peter MacCallum Cancer Center, Melbourne, Australia
Correspondence: Scott Williams (scott.williams@petermac.org)

Background
Localized prostate cancer (PCa) treated with high dose rate brachytherapy (HDRBT) has an excellent cure rate in low, but not in high grade group tumours. Localized PCa immune response to radiation damage is unknown. This study explored this question in order to build a rationale for combining HDRBT with immune checkpoint blockade to treat patients with localized higher grade score PCa and improve patient outcomes.

Methods
In this study we used ultrasound guided core biopsies collected from 24 men prior to, and 14 days post-HDRBT (10Gy). Serial FFPE sections were stained by H&E or OPAL, using two 7-plex panels to describe the density and tissue location of T cells (CD8+, CD4+ and CD4+ FoxP3+), B cells, macrophages, dendritic cells, CDL1+ and HMWCK+ cells. The H&E sections were examined by a uro-pathologist. RNA was extracted for RNAseq (3’ Lexogen) and Nanosting gene expression profiling (GEP) using the pan cancer immune gene set.

HDRBT altered the immune context of PCa. We observed a significant increase post-HDRBT in CD4+FoxP3+ T cells and PD1+ macrophages in both the tumor and tumor stroma (Figure 1). All other immune subsets remained unchanged. All patient samples were grouped into one of three tumor inflammation signature (TIS) (1) clusters (1) high, (2) intermediate and (3) low TIS, Fig 2. Clusters one and two had increased expression of 14/16 and 8/16 TIS genes respectively; cluster three had low expression of all TIS genes. A pre-existing TIS signature was present in 8/24 patients; of the remaining patients 13/16 were
converted from a low TIS to intermediate-high TIS gene signature by HDRBT. However, 3/24 PCa tumors did not develop a TIS gene signature post-HDRBT, these tumors had a significantly decreased levels of baseline type I and II IFN response genes, and decreased TNFalpha signalling compared to the 13/16 TIS HDRBT ‘responders’. Finally, we showed that patients with Gleason grade group score (GGG) 4-5 had a pre-existing TIS gene signature level which was not altered by HDRBT (Figure 2); they also exhibited elevated TGFbeta levels pre-HDRBT, that were increased further post-HDRBT.

Conclusions
Our study showed PCa has a heterogeneous immune context including a pre-existing TIS, which is further increased by HDRBT. GGG 4-5 patients expressed high TIS levels post-HDRBT, indicating that anti-PD-1/PDL1 antibodies may be effective in these patients; however TGFbeta remains an additional hurdle for radio-immunotherapy efficacy in these patients.

References

Ethics Approval
This study was approved by the Peter MacCallum Cancer Centre Human Research Ethics Committee, approval number 14/182

Fig. 1 (abstract P634). Radiotherapy induced immune changes in prostate cancer

A

B

C

Fig. 2 (abstract P634). Radiotherapy induced PCa immune gene expression changes

P635
The impact of beta blockers on survival outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Michael Oh, MD, Michael Oh, MD, Alex Guzner, Derek Wainwright, PhD, Nisha Mohindra, MD, Young Kwang Chae, MD, Amir Behdad, Victoria Villaflor, MD
Northwestern University Feinberg School of Medicine, Chicago, United States
Correspondence: Victoria Villaflor (victoria.villaflor@nm.org)

Background
Beta-blockers have been associated with anti-tumorigenic effects, potentially by reducing adrenergic-mediated stress responses. Preclinical studies have additionally shown that beta-blockade may enhance the efficacy of cancer immunotherapy. We investigated lung cancer patients who concomitantly used beta-blockers and immune checkpoint inhibitors, with the hypothesis that beta-blockade would positively impact clinical outcomes.

Methods
We retrospectively reviewed the health records of 104 patients who were treated at Northwestern University between January 2014 through August 2018 with immune checkpoint inhibitors for non-small cell lung cancer (NSCLC). Comparisons of overall survival (OS) and progression-free survival (PFS) were performed using Kaplan-Meier analysis with log-rank test, and a multivariate analysis was performed with a Cox regression model.

Results
Among 104 patients treated with immune checkpoint inhibitors for NSCLC, 27 of them were concomitantly prescribed beta-blockers. Use of beta-blockers was associated with increased PFS, with hazard ratio (HR) of 0.57 and 95% confidence interval (CI) of 0.35-0.93. There was not a significant increase in overall survival (OS) among patients who took beta-blockers (HR 0.63, 95% CI 0.35-1.12). In a regression model, beta blockers were identified as predictive of PFS, as were non-squamous histology, tumor PD-L1 positivity, and lower line of treatment. A subgroup analysis of patients with brain metastases (n=37) suggested greater overall survival among patients taking beta blockers (HR 0.17, 95% CI 0.06-0.54).

Conclusions
Beta-blocker use of at least 1 year was associated with improved PFS among patients treated with immune checkpoint inhibitors for NSCLC in our cohort of patients. This was a small study and these findings should be further validated in prospective clinical studies.
P636
Inhibitors of Ataxia-Telangiectasia Related (ATR) Protein lead to innate immune pathway activation and enhanced response to immune therapy in prostate cancer
Patrick Pille, MD, Zhe Tang, Sanghee Park, Cheng Wu, Zhenyang Dong, Timothy Yap, MD, PhD, Paul Com, Timothy Thompson
University of Texas MD Anderson Cancer C, Houston, TX, United States
Correspondence: Timothy Thompson (timthomp@mdanderson.org)

Background
In prostate cancer (PCa), androgen receptor (AR) signaling regulates the cell cycle and mitigates replication stress via upregulation of CDC6 and the TopB1-ATR-Chk1 pathway, the key axis in replication stress response (RSR) [1]. Preclinical studies and early phase clinical trials of DDR inhibitors, including PARP inhibitors, have shown synergy with immune checkpoint therapy, whereby DDR inhibitors lead to S-phase specific damage, accumulation of cytotoxic DNA and activation of innate immune pathways [2]. DDR inhibitors have rapidly expanded, now including inhibitors of ATR [2]. However, the impact of these novel, potent, highly-specific inhibitors of ATR on immunocompetent PCa preclinical models has not been fully investigated. Furthermore, dynamic changes in DDR and innate immune gene expression profiles that result from various targeted therapies have not been reported. In this study we use preclinical, immunocompetent models of advanced PCa to investigate the efficacy, transcriptional targets, induction of immunostimulatory cytotoxic DNA, and synergy with anti-PD-L1 therapy associated with ATR inhibition.

Methods
We used PCa cell lines derived from ras+myc-induced mouse PCa tumors (RM-1, RM-9 and RM-1-BM) to analyze ATRI (BAY1895344 or VX-970) effects on ATR-driven survival/proliferation, DNA damage, cGAS-STING signaling, and chemokine expression in comparison to olaparib. RM-1-BM xenograft model was used to assess the efficacy and safety of single agent ATR inhibitor, single-agent anti-PD-L1, and the combination in vivo.

Results
Treatment of the PCa cell lines with ATRIs (BAY1895344 or VX-970) or a PARP inhibitor (olaparib) demonstrated dose-dependent (0.125-8 μM) growth suppression and cytotoxic DNA accumulation, while ATRIs showed greater growth suppression than olaparib. ATRi and olaparib treatment generated similar levels of DNA damage (γH2AX); however, ATRi treatments resulted in significantly increased CCL5 and CXCL10 levels compared to olaparib (2-10 fold; P< 0.05), with BAY1895344 demonstrating superior induction of chemokine expression (P< 0.05). cGAS, STING, TBK1 or IRF3 siRNA knockdown significantly suppressed all of these responses (P< 0.05). The combination of BAY1895344 with anti-PD-L1 was safe and resulted in significantly greater tumor response than either single agent in RM-1-BM xenograft models.

Conclusions
ATRI inhibition induces S-phase specific DNA damage, accumulation of cytotoxic DNA, activation of downstream cGAS-STING signaling, and suppression of cancer growth in immunocompetent PCa models. ATRi had greater impact on innate immune pathway activation than olaparib, and the combination of ATRi with anti-PD-L1 was safe and resulted in significant efficacy in our model system. These results will directly inform biomarker-directed clinical trials of ATR inhibitors in combination with immune checkpoint blockade for patients with advanced solid cancers.

Acknowledgements
We would like to acknowledge members of the Bayer-MD Anderson Cancer Center Alliance, including but not limited to Dr. Antje Wengener, Dr. Dominik Mumberg.

References

P637
Immunomodulation of solid tumors by carbon-ion therapy versus conventional photon therapy
Catherine Spina, MD, PhD1, Chizuru Tsuruoka2, Wendy Mao3, Masaaki Sunakos2, Mathew Chaimowitz2, Yi Shang2, Shizuko Kakinuma4, Charles Drake, MD, PhD3, Catherine Spina, MD, PhD3
1Columbia University Irving Medical Center, New York, NY, United States; 2NIRS-HIMAC, Chiba, Japan; 3Columbia University Irving Med Ctr, New York, NY, United States
Correspondence: Charles Drake (cgr@cumc.columbia.edu)

Background
Radiation-induced immunostimulation is of great interest as a strategy to reinvigorate or augment an immunotherapy-induced tumor-specific response. Evidence supports photon therapy (PhRT) as a tumor immunomodulator, pre-clinical data suggest that carbon-ion therapy (CiRT) may be more potent. Here we evaluate the immunomodulatory effects of CiRT, compared to biologically equivalent doses (BEDs) of PhRT in an orthotopic breast cancer mouse model.

Methods
Using the orthotopic 4T1 breast cancer mouse model, we evaluated the immunomodulatory effects of very low (0.4 Gy), low (1 Gy) and high (4 Gy) doses of CiRT (290 MeV/u, SOBP) delivered to mammary tumors at the Heavy Ion Medical Accelerator in Chiba (HIMAC), Japan compared to BEDs (RBE 2) of PhRT (SARRP, Xstrahl 220 kV). Primary tumors were treated 7 days post implantation and harvested 72 hours later for flow cytometric characterization and protein cytokine analysis.

Results
At low doses, CiRT was lymphocyte sparing effect compared to PhRT. Only low and high-dose CiRT resulted in a significant (p<0.05) increase in tumor response.

Conclusions
We demonstrate that at low doses, lymphocytes differ in their sensitivity to CiRT compared to PhRT – CiRT being more lymphocyte-sparing. Very high-dose CiRT induced a more potent and mechanistically diverse pro-inflammatory cytokine response, compared to PhRT. Combining less lymphototoxic at low dose with more potent pro-inflammatory effects at high doses, CiRT may be a more optimal synergistic tool to augment an immunotherapy-induced, tumor-specific response.

P638
Integrim-mediated augmentation of antigenic immunity
Upen德拉 Marathi, PhD1, Yared Hailemichael, PhD2, Nandadeva Lokugamage1, Michael Schotsaert3, Angela Cho1, Imran Chwdhury1, Nisha Garg1, Adolfo Garcia-Sastre4, Lionel Lewis, Siddhartha De1, Peter Vanderslice, PhD1, Jeffrey Actor5, Darren Woodside, PhD5
1M.D. Anderson Cancer Center, Houston, TX, United States; 2M.D. Anderson Cancer Center, Houston, TX, United States; 3The University of Texas Medical Branch, Galveston, TX, United States; 4Ichan School of Medicine at Mount Sinai, New York, NY, United States; 5Texas Heart Institute, Houston, TX, United States
Correspondence: Darren Woodside (dwoodside@texasheart.org)

Background
The use of immune stimulatory agents as systemic drugs to augment adjuvantation can be problematic due to elevated risks of toxicity and non-specific immune responses. Integrins αLβ2/ICAM-1 and αVβ1/VCAM-1 are essential for antigen-specific immune responses. [1,2] In particular, these integrins stabilize receptor-mediated cell adhesion between Antigen Presenting Cells and naive CD4+ T cells, providing a co-stimulatory signal required for effective antigen presentation.[3] THP349 is a first-in-concept, orally bioavailable, positive allosteric activator of these integrins.

References
1. NISHS-HIMAC, Chiba, Japan; 2NIRS-HIMAC, Chiba, Japan; 3Columbia University Irving Med Ctr, New York, NY, United States
Methods
To determine if systemic administration of 7HP349 in combination with known vaccines would increase adjuvantage, 7HP349 was co-administered with T. cruzi TcG2 and TcG4 vaccines against Chagas disease, inactivated vaccine against influenza, and BCG vaccines against M. tuberculosis (MtB) in mice. Moreover, 7HP349 as monotherapy in an immunogenic murine CT26 carcinoma model, and in combination with aCTLA-4/GVAX in a non-immunogenic murine B16 melanoma model. Results
In the CT26 model, 7HP349 monotherapy significantly delayed tumor growth (Table 1). In the B16 tumor model, 7HP349 in combination with GVAX/aCTLA4 significantly increased long-term (>120 day) survival by 2.7-fold over GVAX/aCTLA4. In combination with T. cruzi TcG2/TcG4 vaccines, 7HP349 significantly decreased parasite burden in myocardial (~9.5-fold) and skeletal muscle (~5.3-fold) in challenged mice and increased splenic frequency of polyfunctional CD4+ and CD8+ T cells expressing IFN-gamma, perforin or granzyme B. In addition, in vitro stimulation with Tc antigens of splenocytes from vaccinated animals resulted in maximal release of TNFa, INF-y, IL-10, and IL-6 cytokines when 7HP349 was co-administered with vaccine. 7HP349 increased influenza H1N1 seroconversion and hemagglutinin inhibition titers by ~30 fold when co-administered with inactivated influenza vaccine. 7HP349 addition to a prime-boost immunization regimen with BCG reduced pulmonary mycobacterial burden and inflammation after Mtb challenge compared to vaccine alone. At the 0.5 and 1 mg/kg doses, the therapeutic plasma 7HP349 concentration range of AUC of 50-100 ng.h/mL, appears to be sufficient to engage αL/β2/ICAM-1 and α4β1/VCAM-1 and increase tumor immunity, checkpoint blockade, and T, BCG and H1N1 vaccination. 7HP349 exposures of >1,500 ng.h/mL for 28 days in rats and dogs in cGLP toxicology studies showed no adverse findings. Conclusions
7HP349 as systemic drug may facilitate immune priming against a variety of antigens by stabilizing αL/β2/ICAM-1 and α4β1/VCAM-1 interactions, with a high safety margin. 7HP349 oral drug product is IND ready. Phase I appears to be sufficient to engage αL/β2/ICAM-1 and α4β1/VCAM-1.
Intratumoral application of the RNA-based TLR-7/-8 and RIG-I agonist CV8102 promotes a pro-inflammatory tumor microenvironment and causes a durable anti-tumor response

Michael Meister, PhD, Mohamed Habbeddine, PhD, Katja Fiedler, Johannes Lutz, Malika Ramakrishnan, Regina Heidenreich
CureVac AG, Tübingen, Germany
Correspondence: Regina Heidenreich (regina.heidenreich@curevac.com)

Background
Intratumoral activation of innate immune signaling pathways is a promising approach to overcome the immunosuppressive tumor microenvironment and induce or restore anti-tumor immunity. CV8102, a non-coding RNA complexed with a cationic peptide that signals via TLR-7/-8 and RIG-I [1], has already been shown to exhibit immunomodulatory properties after intradermal injection [2]. Here, we investigated whether intratumoral injection of CV8102 alone or in combination with systemic anti-PD-1 treatment can further enhance the tumor microenvironment and anti-tumor responses.

Methods
Mice were injected subcutaneously with the syngeneic colon carcinoma cell line CT26 or the B cell lymphoma cell line A20 and established tumors were treated intratumorally with CV8102 alone or in combination with systemic anti-PD-1 antibodies. Anti-tumoral efficacy was determined in tumor bearing mice, which were treated twice weekly for three weeks. Additionally, cytokine concentrations, immune cell composition or gene expression within the tumor microenvironment, the draining lymph nodes or serum were analyzed at different time points post injection.

Results
Intratumoral administration of CV8102 led to a dose-dependent anti-tumor response in syngeneic mouse models. Combination of local CV8102 delivery with systemic checkpoint inhibitors (CPIs) further improved the anti-tumoral response and enabled checkpoint inhibition efficacy in anti-PD-1 refractory tumor models. Gene expression profiling revealed activation of the innate immune compartment within the tumor microenvironment, reflected by up-regulation of genes involved in Type I interferon and anti-viral responses as well as RIG-I like, NOD-like and TNF signaling pathways. Accordingly, cytokine/chemokine analysis showed increased intratumoral concentrations of IFN-α/β, IL-6, TNF, MCP1, MIP1α/β and RANTES. Such effects were observed upon CV8102 single agent treatment and were more pronounced upon combination with systemic anti-PD-1 treatment. On the cellular level, intratumoral CV8102 monotherapy caused an increase in numbers and activation of innate immune cells like monocytes, neutrophils and NK cells within tumors and draining lymph nodes. Besides further enhancement of innate immunity, combination therapy synergistically enabled activation of the adaptive immune system and led to the infiltration of CD8+ T cells into the tumor microenvironment.

Conclusions
Our results demonstrate that intratumoral CV8102 delivery is a promising approach for local cancer immunotherapy. By modulating the tumor microenvironment CV8102 induces potent anti-tumoral immune responses and improves CPI efficacy in mice. An ongoing phase I trial is investigating intratumoral CV8102 either as a mono-therapy or in combination with systemic anti-PD-1 treatment in various tumor entities (see abstract by Eigentler et al.).

References

Ethics Approval
The study was approved by the Regierungspraesidium Tuebingen, Germany under Cur 07/18.

Potent tumor-directed T cell activation and tumor inhibition induced by ALG.APV-527, a 4-1BB x ST4 ADAPTIR™ bispecific antibody

Michelle H. Nelson, PhD1, 2, Robert Miller2, Robert Bader2, Doreen Werczuch, BS3, Anneli Nilsson3, Lill Ljung3, Adrian Deronic, PhD3, Allison Chunyk2, Lena Schultz2, Catherine McMahan2, David Bienvenue3, Anna Dahlman3, Sara Fritze2, Maria Askmyr2, Gabriela Hernandez-Hoyos2
1Aptevo Therapeutics, Seattle, WA, United States; 2Aptevo Therapeutics Inc., Seattle, WA, United States; 3Alligator Bioscience AB, Lund, Sweden
Correspondence: Michelle H. Nelson (nelsonm@apvo.com)

Background
4-1BB (CD137) is an activation-induced co-stimulatory receptor that regulates immune responses of activated CD8+ T and NK cells, by enhancing proliferation, survival, cytolytic activity and IFN-γ production. Its ability to induce potent anti-tumor CD8 and NK cell activity makes 4-1BB an attractive target for designing novel therapeutics for immunoncology. However, clinical development of a monospecific 4-1BB agonistic antibody was hampered by dose-limiting hepatic toxicities. ALG.APV-527 is a novel 4-1BB x ST4 bispecific antibody developed to minimize systemic immune toxicities and enhance activity at the tumor site by stimulating 4-1BB function only when co-engaged with ST4, a tumor-associated antigen. The combined preclinical dataset presented here provides an overview of the mechanism of action and the efficacy and safety profile of ALG.APV-527, supporting its advancement into the clinic.

Methods
ALG.APV-527 was built using the ADAPTIR™ platform with binding domains to 4-1BB and ST4 generated using the ALLIGATOR-GOLD® human scFv library and subsequently optimized to increase binding affinity, function, stability and manufacturability. To assess function, induction of IFN-γ secretion by ALG.APV-527 was measured in PBMC cultures sub-optimally stimulated with anti-CD3 antibodies in the presence of ST4+ tumor cells. To measure proliferation, PBMC were labelled with Cell TraceTM and T cells were gated using multicolor flow cytometry. For tumor inhibition studies, human 4-1BB knock-in mice were injected subcutaneously with murine bladder carcinoma MB49 cells transplanted with human ST4, and mice were treated therapeutically with ALG.APV-527. Preclinical safety and pharmacokinetics of ALG.APV-527 were evaluated in single and repeated dose toxicity studies in non-human primates (NHP).

Results
In primary PBMC assays, ALG.APV-527 induced a dose-dependent increase of IFN-γ production but only upon ST4-mediated crosslinking. ALG.APV-527 enhanced CD8+ T cell and NK function and proliferation, preferentially over that of CD4+ T cells. Treatment with ALG.APV-527 led to rejection of established human ST4-positive tumors at doses of 20 μg/mouse, in a syngeneic bladder carcinoma model. ALG.APV-527 is fully NHP cross-reactive and displayed antibody-like pharmacokinetic parameters in NHP studies. Furthermore, the drug was well tolerated after repeated administration at doses in excess of the expected human dose.

Conclusions
ALG.APV-527 induces ST4-dependent CD8+ T cell and NK co-stimulation, and has potent anti-tumor activity in a therapeutic model. Based on preclinical data, ALG.APV-527 is a promising anti-cancer therapeutic for the treatment of a variety of ST4-expressing solid tumors.
Background
The discovery that the tumor immune microenvironment can be used as a biomarker of cancer progression and the advent of immunotherapies are revolutionizing cancer treatments. Notwithstanding these successes, there is still an urgent need for new therapeutics able to increase the proportion of clinical responses. Intratumoral delivery of immunotherapeutic agents constitutes a potential strategy to convert poorly immunogenic tumors into immunogenic tumors and to overcome acquired resistance to current immunotherapies.

Methods
Here we investigate a tumor antigen-agnostic intratumoral approach that harnesses preexisting antiviral T cell responses. To implement such approach, Human cytomegalovirus (HCMV) would be an ideal candidate as it is highly prevalent in human populations and induces polyfunctional T-cell responses that expand with age. In our experimental model, mice persistently infected with murine cytomegalovirus (mCMV) were challenged with TC-1 tumor cells expressing human papillomavirus E6 and E7 oncoproteins or MC38 colon adenocarcinoma tumor cells. We investigated the effects of redirecting pre-existing mCMV-specific T cells by repeated intratumoral injection using minimal MHC class I and/or class II restricted mCMV peptide epitopes combined with polyIC, a Toll-like receptor 3 and RIG-I-like receptor agonist.

Results
Intratumoral injection of mCMV MHC-I and MHC-II restricted peptides led to the expansion of CD8 and CD4 mCMV-specific T cells in situ and in blood. Intratumoral injection of mCMV MHC-I restricted peptides provoked arrest of TC-1 and MC38 tumor growth that sometimes resulted in complete tumor rejection. Interestingly, intratumoral injection of mCMV MHC-II restricted peptides with polyIC, without MHC-I peptides, also substantially delayed tumor growth. In addition, injection of mCMV MHC-II restricted peptides alone or in combination with mCMV MHC-I restricted peptides increased epitope spreading to MHC-I restricted tumor-derived epitopes, promoted clearance of established subcutaneous tumors, and conferred long-term protection against tumor re-challenge. Finally, analysis of the tumor microenvironment using whole tumor RNA gene expression profiling, flow cytometry and confocal microscopy revealed that intratumoral injection of mCMV MHC-I or MHC-II restricted epitopes caused local activation of adaptive and innate immune components.

Conclusions
Our results provide a proof-of-concept for a new generation of tumor antigen-agnostic immunotherapies based on pre-existing antiviral T cells that is potentially applicable to multiple tumor types. The approach induced rapid tumor regression, profound changes in the tumor immune microenvironment, epitope spreading, and long-term antitumor immunity. We are now using our model to decipher the contribution of CD4+ T cell to epitope spreading against tumor-derived epitopes and to evaluate this approach in spontaneous tumor models.

References
1. Momin et al., Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Sci Transl Med. 2019; 11; eaaw2614

Background
Harnessing pre-existing anti-viral immunity for tumor therapy
Cuburu Nicolas, PhD1, Lukas Blakowski2, Sergio Pontejo, PhD3, Rina Kim, BS2, Alexander Bell2, Cynthia Thompson2, Douglas Lowy, MD2, John Schiller, PhD2
1National Cancer Institutes, Bethesda, MD, United States; 2National Cancer Institutes, NIH, Bethesda, MD, United States; 3NIAD, NIH, Bethesda, MD
Correspondence: John Schiller (schillerj@mail.nih.gov)

Conclusions
Our results provide a proof-of-concept for a new generation of tumor antigen-agnostic immunotherapies based on pre-existing antiviral T cells that is potentially applicable to multiple tumor types. The approach induced rapid tumor regression, profound changes in the tumor immune microenvironment, epitope spreading, and long-term antitumor immunity. We are now using our model to decipher the contribution of CD4+ T cell to epitope spreading against tumor-derived epitopes and to evaluate this approach in spontaneous tumor models.

References
1. Momin et al., Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Sci Transl Med. 2019; 11; eaaw2614

Background
Harnessing pre-existing anti-viral immunity for tumor therapy
Cuburu Nicolas, PhD1, Lukas Blakowski2, Sergio Pontejo, PhD3, Rina Kim, BS2, Alexander Bell2, Cynthia Thompson2, Douglas Lowy, MD2, John Schiller, PhD2
1National Cancer Institutes, Bethesda, MD, United States; 2National Cancer Institutes, NIH, Bethesda, MD, United States; 3NIAD, NIH, Bethesda, MD
Correspondence: John Schiller (schillerj@mail.nih.gov)

Conclusions
Our results provide a proof-of-concept for a new generation of tumor antigen-agnostic immunotherapies based on pre-existing antiviral T cells that is potentially applicable to multiple tumor types. The approach induced rapid tumor regression, profound changes in the tumor immune microenvironment, epitope spreading, and long-term antitumor immunity. We are now using our model to decipher the contribution of CD4+ T cell to epitope spreading against tumor-derived epitopes and to evaluate this approach in spontaneous tumor models.

References
1. Momin et al., Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Sci Transl Med. 2019; 11; eaaw2614
A tumor necrosis factor alpha mimic as anti-tumor immune adjuvant

Ketki Velankar, MS, Ngoc Pham, BS, Ellen Gavwalt, Wilson Meng, PhD
Duquesne University, Pittsburgh, PA, United States

Correspondence: Wilson Meng (meng@duq.edu)

Background
Intra-tumoral immunotherapy has emerged as an important modality of delivering anti-tumor immunomodulators. Rich in tumor-associated antigens and antigen-presenting cells, the tumor microenvironment is an apt locale for reprogramming the immune responses from a suppressive phenotype to one that is activating insofar anti-tumor cytotoxic T cell responses can be generated locally and systemically. Herein we report a small peptide that can potentially serve as an adjuvant for enhancing antigen presentation in the tumor microenvironment. Our group discovered the peptide YYTQGL, called pTNF, as a ligand of tumor necrosis factor receptor II (TNFRII) by screening phage display libraries on dendritic cells (DCs) [1]. The peptide binds to DCs in a concentration-dependant, TNFalpha-reversible manner, albeit at micromolar binding affinity. Subsequently, other groups have confirmed the DC-targeting property of pTNF[2,3]. In addition, it has been shown that pTNF upregulates costimulatory molecules on DCs [4,5]. This led us to hypothesize that pTNF can be used as an immune adjuvant in the context of cancer immunotherapy. To transform the low affinity ligand pTNF into a high avidity adjuvant, the peptide is appended with [AEAEAKAK]2, a self-assembling peptide (SAP) that drives oligomerization (Fig. 1a).

Methods
To test the capacity of pTNF_EAK in activating antigen presenting cells, BALB/c mice were injected with 100 mcg of the peptide in each footpad. After 48 hours, the draining lymph nodes were collected and analyzed using flow cytometry. The cells obtained from draining lymph nodes were restimulated ex vivo with a mouse renal adenocarcinoma (RENCA) cell line for 48 hours. The cells were analyzed using flow cytometry and ELISA, quantifying interferon-gamma (IFN gamma) production upon in vitro restimulation.

Results
Preliminary results indicated that pTNF_EAK exhibited self-assembling characteristics based on Congo red staining (data not shown). Flow cytometric analyses showed upregulated CD40 on cells in pTNF_EAK treated draining lymph nodes compared to control footpads injected with saline (Fig. 1b). Upon restimulation in vitro with RENCA cells, pTNF_EAK treated lymph node-derived cells produced higher levels of IFN gamma compared to control cells (data not shown).

Conclusions
pTNF_EAK appears to upregulate the functions of antigen-presenting cells in draining lymph nodes in vivo.

References

Ethics Approval
The study was approved by Duquesne University’s IACUC, protocol number: 1806-04

P646
Reprogramming CD8 cells into metabolically fit stem cell memory
with superior therapeutic activity by MEK1/2 manipulation.

Vivek Verma, PhD, Pankaj Gaur, PhD; Jose Lopez, Fatmah Aloqi, Seema Gupta, PhD, Samir Khleif, MD
Georgetown University Medical Center, Washington, DC, United States

Correspondence: Samir Khleif (snk48@georgetown.edu)

Background
Exhaustion and short persistence are factors that limit the efficacy of endogenously generated or adoptively transferred effector T-cells. Metabolism in T-cells has been found to be a significant factor that contributes to their anti-cancer potential. Interestingly, tumor-induced metabolic insufficiency in immune cells renders these cells exhausted and hence ineffective in controlling the tumors. Hence the mechanisms that would prevent the metabolic degradation in immune cells would have strong anti-cancer potential. Renewable stem-cell-memory CD8+ T-cells (Tscm) are metabolically fit cells that persist longer and produce stronger effector functions. Here, we determined the role of MAP kinase pathway in the generation of Tscm CD8 cells and their metabolic status.

Methods
Mice bearing TC-1 tumors (a mouse lung epithelial cell-line expressing human papillomavirus-specific E7-peptide) were treated with MEKi (selumetinib) in conjunction with tumor-specific E7-peptide vaccine, followed by determination of tumor growth rates and mice survival, and estimation of immune responses in the TME. Also, using in-vitro and in-vivo assay systems, we delineated the kinetics of MEKi-mediated Tscm generation and the molecular mechanisms of metabolic enhancement of CD8 cells.

Results
We found that MEKi treatment of tumor-bearing mice in conjunction with tumor-specific E7-vaccine resulted in a significant reduction in tumor growth and enhancement of mice survival. This treatment resulted in a strong increase in the effector functions and prevention of exhaustion in effector cells. We observed a significant increase in the number of Sc1a+CD95+CD62L−CD44−CD8+ T-cells (Tscm cells) in the TME and under in-vitro conditions. Interestingly, we found that MEKi suppressed the cell-cycle progression in antigen-activated CD8 cells that led to increased mitochondrial biogenesis and fatty-acid oxidation (FAO) by modulating ERK1/2/CyclinD1/PGC1a/SIRT3 signal pathway. FAO was crucial for MEKi-mediated induction of Tscm cells as its pharmacological inhibition or SIRT3KO prevented the
and suggests that STING may be a predictive biomarker for T-VEC responses. These data also support a role for T-VEC in restoring host immune responses in STING-deficient melanoma.

Ethics Approval
This study was approved by the Rutgers University IACUC.

P648
Therapeutic efficacy of oncolytic vaccinia virus requires infection and removal of deleterious host immune cells
Kristin DePeauX, BS, Greg Delgoffe, PhD, Saumendra Sarkar, PhD, Steve Thorne, PhD, Paolo Vignali, BA, Dayana Rivadeneira, PhD
University of Pittsburgh, Pittsburgh, PA, United States
Correspondence: Greg Delgoffe (delgoffeg@upmc.edu)

Background
Oncolytic virotherapy is an attractive immunotherapeutic approach as it can induce robust immune infiltration in immunologically cold tumors. While there is one OV approved for use by the FDA and many others in clinical trials, little is understood of their immunologic mechanism of action. The effect of OV treatment on the existing immune infiltrate in the tumor is especially understudied. Seven days after one intratumoral treatment of oncolytic vaccinia virus (vv) in a murine head and neck squamous cell carcinoma model we observed an influx of CD8 T cells into the tumor, including a large population of effector-memory like PD-1+ cells. However, the suppressive PD-1hi Tim-3+ exhausted T cells (Texh) and Foxp3+ regulatory T cells (Treg) were missing. We hypothesized that vvDD may have the capacity to infect these inhibitory populations and lead to their selective depletion.

Methods
Infection and flow cytometric analyses of T cell populations were performed using both in vitro and in vivo modeling systems. An oncolytic Western Reserve strain of vaccinia virus (vv) was used at a multiplicity of infection of 10 for all in vitro experiments and at 2.5E6 PFU per mouse for in vivo experiments. T-reg specific BCL2 overexpressing mice were generated by crossing Rosa26-BCL2-IRES-GFP mice to Foxp3-YFP-cre mice.

Results
Analysis of the immune infiltrate of treated tumor-bearing mice revealed that Texh and Treg in the tumor were actively infected by virus. This may lead directly to the death of these infected T cells. This phenomenon was recapitulated in vitro under nutrient limited conditions. This was further investigated in vivo using a mouse model where the anti-apoptotic protein BCL2 was selectively overexpressed in Tregs. In this model the death of Tregs is prevented in the tumor. These mice were unable to clear tumor after vv treatment while all wild-type animals did.

Conclusions
These data suggest that the mechanism of action of oncolytic vaccinia also includes the direct ability of the virus to infect immune populations in the tumor. Infection of regulatory T cells in the tumor leads to their death. By preventing the death of these cells, treatment efficacy is lost, thus highlighting the importance of this mechanism during oncolytic vaccinia treatment.

P649
Targeting subtypes of circulating myeloid cells during oncolytic vaccinia virus therapy
Bora Lee1, Jen Jiang1, Mong Cho, MD, PhD1, Euna Cho2, Tae-Ho Hwang, PhD, DDS1
1Pusan National University, Pusan, Korea, Republic of; 2Bionoxx Inc, Yangsan, Korea, Republic of
Correspondence: Tae-Ho Hwang (thhwang@pusan.ac.kr)

Background
Oncolytic virus (OV) is an emerging class of cancer treatment which has received increasing attention. The pharmacodynamics (safety and efficacy) of OV shows large inter-individual variability—the
clinical outcomes of OV treatments can range from complete response to possibly treatment-related early death in different patients [1,2]. The innate immune system as well as adaptive immune system play critical roles in governing the OV treatment outcomes. This study aimed to investigate the therapeutic potential for the interaction between circulating myeloid cells, oncolytic vaccinia virus (OVV), and cancer cells; and to optimize the treatment outcomes of OTS-400 (OVV series with modified HSV-tk insertion).

Methods
The functional outcome of interaction between circulating immune cells, OV, and cancer cells was evaluated qualitatively and quantitatively using a trans-well co-culture system and analyzed by fluorescence-activated cell sorting. After identification of subtypes of OV-disfavoring myeloid cells (OV-DMCs), candidate chemicals, including clinically used drugs, were screened to find the best modulators for OV-DMCs affecting clinical outcome of OTS-400 series in >3,000 tumor-bearing animals.

Results
Time to 90% lethality after intranasal administration of Western Reserve (107 pfu) vaccinia virus was significantly prolonged by inhibition of OV-DMCs, 30 days++; by stimulation, 7 days; and by no modulation, 11 days (Log-rank p-value

Conclusions
OV-DMCs play a critical role in the pharmacodynamics of OVV therapy in a variety of preclinical tumor models. Targeting OV-DMCs may significantly improve the treatment outcome for the upcoming clinical trials of the combination therapy of OTS-400 and PD-L1 inhibitor scheduled in early 2020.

Acknowledgements
This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (HA16C0013) and National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (NRF-2015R1A5A2009656).

References

P650
Systemic immunity against disseminated subcutaneous and intracranial melanomas induced by oncolytic adenovirus Delta-24-RGDOX
Hong Jiang, PhD, Dong Ho Shin, Teresa Nguyen, BS, Frederick Lang, MD, Candelaria Gomez-Manzano, MD, Juan Fuego University of Texas MD Anderson Cancer Center, Houston, TX, United States
Correspondence: Juan Fuego (jfuego@mdanderson.org) Journal for ImmunoTherapy of Cancer 2019; 7(Suppl 1):P650

Background
Immune checkpoint blockade has revolutionized cancer therapy; however the therapeutic benefit is limited to only a subset of patients with immunogenic (“hot”) tumors and is compromised by immune-related adverse events. We have reported that intratumoral injection of oncolytic adenovirus Delta-24-RGDOX, an oncolytic adenovirus expressing immune co-stimulator OX40 ligand (OX40L), induces efficacious anti-glioma immunity and immune memory in syngeneic glioma mouse models. We hypothesized that localized treatment with the virus is effective against disseminated melanomas, including intracranial melanomas.

Methods
We tested the therapeutic effect of injecting Delta-24-RGDOX into primary subcutaneous (s.c.) tumors derived from luciferase-expressing B16-Red-FLuc cells in s.c./s.c. and s.c./intracranial (i.c.) melanoma models in C57BL/6 mice. The growth of treated s.c. and untreated disseminated s.c. and i.c. tumors, luciferase-expressing ovalbumin-specific (OT-I-Luc) T cells within the tumor were monitored via bioluminescence imaging. Cells were profiled for surface markers using flow cytometry.

Results
In both s.c./s.c. and s.c./i.c. models, three injections of Delta-24-RGDOX significantly inhibited the growth of both the virus-injected s.c. tumor and untreated distant s.c. or i.c. tumor, thereby prolonging survival. The surviving mice were protected from rechallenging with the same tumor cells. The virus treatment increased the presence of T cells and the frequency of effector T cells in the virus-injected tumor and mediated the same changes in T cells from peripheral blood, tumor-draining lymph nodes (TDLNs), spleens, and brain hemispheres with untreated tumor. Moreover, Delta-24-RGDOX decreased the frequency of exhausted T cells and regulatory T cells in the virus-injected and untreated i.c. tumors. Consequently, the virus promoted the in situ expansion of tumor-specific T cells and their migration to tumors expressing the target antigen.

Conclusions
Intratumoral injection of Delta-24-RGDOX induced an in situ antivaccination of the treated melanoma, resulting in systemic immune activity against the disseminated tumors. This is the first report demonstrating that localized treatment with an oncolytic virus in the subcutaneous tumor is able to reject intracranial tumors, suggesting Delta-24-RGDOX could be applied to patients with brain melanoma metastasis. Furthermore, given the immunogenicity, cancer-selectivity and localized application of the virus, Delta-24-RGDOX is expected to be efficacious in patients with immunosuppressive (“cold”) tumors as well and have an improved safety profile in cancer patients compared to immune checkpoint blockade treatment strategies.

P651
Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune amming
Eric Quemeneur, PharmD, PhD, Eric Quemeneur, PharmD, PhD, Patricia Kleinpeter, MSc, Jean Baptiste Marchand, PhD, Laetitia Fend Transgene S.A., Illkirch-Graffenstaden, France
Correspondence: Eric Quemeneur (quemeneur@transgene.fr) Journal for ImmunoTherapy of Cancer 2019; 7(Suppl 1):P651

Background
Oncolytic virus (VACV) has been intensively used as oncolytic virus for the treatment of various types of cancers over the last years. Targeted gene deletion have enabled the selection of new VACV variants that retain tumor-specific replication, and oncolytic potential, but are safer for the surrounding healthy tissues. Recent examples of such deleted VACVs are TG6002, deltaJ2R(TK-)-deltaJ4L(RR-)-Fcu1 (Foloppe et al. 2019), and DeltaJ2R(TRGDOX)deltaJ4L(Fcu1 (Pelin et al. 2019). It is also well established that VACV secretes various factors interfering with major immune pathways, largely contributing to immune evasion for the virus. However, to our knowledge, none of these factors has already been used in the field of cancer immunotherapy.

Results
We here report the identification of M2L as a strong binder to both CD80, and CD86 co-stimulatory receptors. This binding antagonizes the interaction with their natural ligands CD28, and CTLA-4. M2L can also stabilize the interaction between CD80, and PD-L1 in vitro. We characterized M2L as a secreted homo-oligomeric protein (8 x 35 kDa), and could determine that apparent affinities are in the same range as natural ligands. It proved as active as CTLA-4, as an inhibitor for lymphocyte activation in a MLR assay.
M2L properties thus make it a potential new immuno-suppressive drug. Interestingly, M2L is largely conserved within the poxvirus family, and we could demonstrate that its ortholog from myxomavirus can also interact with CD36.

Expecting to reinforce the immunogenic properties of VACV, we engineered a triple-deleted Vaccinia virus (TD, Delta22R, Delta4L, DeltaM2L). Oncolytic activity was not affected by the deletion of M2L, as assessed both in the regular mouse tumor xenograft models (HCT116), or in the syngeneic models (B16F10). We could demonstrate a worse tolerance for the TD variant in a humanized model, where the CD80/CD86 pathway might be prominent in the neutralizing response.

Conclusions
Finally, the TD oncolytic backbone might be interesting for the development of our invirIO™ platform. Recent results with triple-deleted VACV expressing immune engagers will be presented.

References
1. Kleinpeter et al. By binding CD80 and CD86, the Vaccinia virus M2 protein blocks their interactions with both CD28 and CTLA4 and potentiates CD80 binding to PD-L1. J. Virol. 2019, 93: e00207-19
2. Foloppe et al. The enhanced tumor specificity of TG6002, an armed oncolytic Vaccinia virus deleted in two genes involved in nucleotide metabolism. Mol Ther Oncolytics 2019, 14: 1-14

P652
The fully human antibody SRF617 is a potent enzymatic inhibitor of CD39 with strong immunomodulatory activity
Michael Warren, Sonia Das, Austin Dulak, Taqeer Zaidi, Erik Devereaux, Jamie Strand, Benjamin Lee, MD PhD, Secil Koseoglu, Pamela Holland, PhD, Vito Palombella, PhD, Andrew Lake, PhD
Surface Oncology, Inc, Cambridge, MA, United States

Background
The purine nucleoside adenosine diphosphate (ADP) and ATP, generated as a result of tissue damage or immunogenic cell death, can initiate proinflammatory responses [2]. Extracellular adenosine accumulates in cancerous tissues through the degradation of ATP and constitutes an important mechanism of tumor immune escape, induction of angiogenesis, and metastasis [3]. Reduction of ATP and subsequent increase of extracellular adenosine production in the tumor microenvironment (TME) depend on the concerted enzymatic activity of two ectonucleotidases, CD39 (ENTPD1) and CD73 (NTSE), which convert ATP to adenosine monophosphate (AMP) and AMP to adenosine, respectively. Targeting this enzymatic pathway by inhibition or loss of CD39 has been shown to have antitumor effects in multiple studies [4-7]. The preclinical characterization of SRF617, a fully human CD39 antibody that potently inhibits CD39-mediated conversion of ATP to AMP, is described.

Methods
A series of studies were conducted to examine the CD39 targeting properties of SRF617. Biolayer interferometry (BLI) and flow cytometry. De cellular binding assays were used to examine the affinity of SRF617 to both recombinant and cellular CD39. The malt-achite green phosphate detection assay was used to assess the enzymatic inhibitory properties of SRF617 on recombinant and cellular CD39. In vitro functional assays to observe SRF617 modulation of dendritic cell (DC) maturation and T-cell proliferation were performed. Antitumor activity of SRF617 was assessed in a MOLP-8 xenograft model with multiple pharmacodynamic endpoints including immune cell infiltration, target occupation, and in situ CD39 activity.

Results

Conclusions
These studies demonstrate that SRF617 blocks CD39 enzymatic activity, thereby reversing the anti-inflammatory/immunosuppressive TME caused by reduced extracellular ATP and the generation of adenosine triphosphate. These findings support future clinical studies of SRF617 as an immune-modulating medicine in patients with cancer.

References

Ethics Approval
Mice were used in compliance with protocols approved by the IACUC of Mispro Biotech Services, Cambridge, MA (#2017-03-21SUR-1).

P653
Labeling method for flow cytometric analysis of radioactive tumors following immunotherapy and molecular targeted radionuclide therapy (mTRT): demonstration of augmented immune infiltrate
Peter Carlson, BS, Manasi Mohan, Ravi Patel, MD, PhD, Lauren Nettenstrom, Dagma Sheerar, Kathryn Fox, Mat Rodriguez, Anna Hoefges, MS, Reinier Hernandez, PhD, Chris Zahm, PhD, Douglas McNeel, MD, PhD, Jamey Weichert, PhD, Zachary Morris, MD, PhD, Paul Sondel, MD, PhD
The University of Wisconsin School of Medicine, Madison, WI, United States

Correspondence: Paul Sondel(pmsondel@humonc.wisc.edu)


Background
We are investigating low dose mTRT as an immunomodulator in combination with in situ tumor vaccines (ISV). Most shared resource flow cytometry facilities do not analyze radioactive samples. To study the immunomodulatory effect of mTRT, we evaluated different fixation and cryopreservation protocols allowing radioactive tumor samples to be stained, frozen and safely stored until radioactivity decayed to background, enabling flow analyses. Our aim is to identify a protocol which most accurately reflects the tumor immune microenvironment (TME) of a freshly analyzed sample.

Methods
We generated syngeneic B78 melanoma flank tumors in C57BL/6 mice. Cohorts of mice received: 1) no treatment; 2) our previously reported ISV regimen (12 Gy local external beam radiation and intratumoral injections of hu14.18-IgL2 immunocytokine [1,2]); or 3) a

Results

combination of ISV and 50μCi of 90Y-NM600 mTRT [3]. We then harvested, dissociated and labeled tumor infiltrating immune cells according to one of four protocols: 1) freshly labeled cells; 2) freezing cells before staining; 3) freezing cells just before fixation; or 4) freezing cells after staining and fixation. Cells were labeled with panels specific for adaptive and innate immune cells.

Results
All three staining protocols involving cryopreservation performed similarly to freshly stained cells. Protocols 2 and 3 resulted in increased PD1 expression compared to fresh cells, suggesting cryopreservation and thawing of unfixed cells impacts the detection of the activation state of the lymphocytes. Protocol 4 most closely resembled the labeling of “fresh” cells. In comparing untreated tumors to those treated with ISV, we analyzed half of each sample “fresh” and half using staining protocol #4. We observed the same immune stimulatory effect of in situ vaccination using both protocols, confirming that freezing cells after labeling and fixing can be used to evaluate changes in the TME. Lastly, we used protocol #4 on a time course of weekly harvested tumors following mTRT alone, in situ vaccine alone, or combination mTRT+ISV. We demonstrated greater immune infiltrate and an increased CD8/Treg ratio when combining mTRT with ISV than either alone.

Conclusions
We demonstrate that fixation and cryopreservation after labeling closely reproduces the analyses of freshly dissociated tumors. We confirm this by comparing tumors treated with several immunotherapies using both the traditional and modified protocols. Lastly, we use this protocol with radioactive specimens to demonstrate that low dose mTRT followed by ISV results in greater immune infiltrate and activation with this combination compared to ISV or mTRT alone.

Acknowledgements
Thank you to Areceus Technologies of Madison, WI for their kind gift of the NM600 mTRT agent.

References

P654
CD137 agonists as an adjunct to immune checkpoint inhibitors to overcome resistance in melanoma
Sreedevi Danturti, PhD, Lena Sophie Mayer, MD, Vesselin Tomov
University of Pennsylvania, Fountainville, PA, United States
Correspondence: Vesselin Tomov (vesselin.tomov@uphs.upenn.edu)

Background
Melanoma is currently the fifth most common cancer in men and sixth most common in women with an estimate of 7230 deaths from the disease in 2019 in the United States. Treatment with the immune checkpoint inhibitors anti-CTLA-4 and anti-PD-1 has tremendously improved outcomes for patients with metastatic disease, but although durable response can be observed in over 50% of the patients treated with monotherapy, resistance is still present. Studies suggest that combining therapies (e.g. immune checkpoint inhibitors, radiotherapy, and/or agonistic antibodies) are more effective than monotherapy. 4-1BB (CD137) is expressed on various cell populations including T cells, dendritic cells and macrophages. 4-1BB agonists have been proved to be effective in multiple murine tumor models and have had modest responses in early clinical trials. We hypothesize that 4-1BB agonists augment the anti-PD-1 anti-tumor immune response resulting in improved overall survival and decreased tumor burden in melanoma resistant to pre-treatment with a combinational therapy of anti-CTLA-4 and radiation

Methods
499 melanoma cells, derived from unirradiated B16-F10 tumors resistant to treatment with anti-CTLA-4 and radiation, were implanted on both flanks of C57BL6 mice. Treatment with 4-1BB agonists and/or anti-PD1 was given on day 10, 13 and 16 post-implantation. The anti-tumor response was assessed by both overall survival and tumor burden. Tumors were harvested on day 17-20 for protein, transcriptomic and flow cytometric immune profiling

Results
Dual immunotherapy with 4-1BB agonist and anti-PD-1 significantly improves overall survival, whereas there is no benefit from treatment with either antibody alone. With combinational treatment, complete remission was achieved in 45.8%, however, there is still resistance to immunotherapy with response and nonresponse. Investigating mechanisms of response and non-response to dual immunotherapy with 4-1BB and anti-PD1, we identified cells from the innate and adaptive immune system to play important roles in the anti-tumor response. Our proteome array analysis revealed several proteins of the myeloid and lymphoid compartment to be upregulated in the non-responders. Transcriptomic profiling by Nanostring IO 360 pan cancer panel in the non-responders and responders to immunotherapy corroborated our findings and detected important genes of the myeloid and lymphoid compartment especially macrophages and CD8+T cells respectively.

Conclusions
Overcoming resistance to immunotherapy crucially depends on cells of the innate and adaptive immune system especially the macrophages and CD8+ T cells. Investigation of response mechanisms revealed potential targets that might be effective amplifiers of the anti-tumor response to overcome resistance after immunotherapy.

P655
EOS100850, an A2A receptor antagonist demonstrates efficacy in murine syngeneic tumor models regardless of adenosine concentrations
Romain Pinson, MSc, Anne Catherine Michaux, Diane Jamart, Preillion, MSc, Lucas Chaible, Chiara Martinoli, PhD, Gregory Driessens, PhD, Erica Houthuyts, PhD, Stefano Crosignani, PhD, Reece Marillier, PhD
Cer Innova Therapeutics, Gosselies, Brussels, Belgium
Correspondence: Gregory Driessens (gregory.driessens@cerinnovatherapeutics.com)

Background
Extracellular adenosine, acting predominantly through the A2A receptor (A2AR), mediates immunosuppression which includes suppression of Th1 responses and cell-mediated cytotoxicity as well as increasing the activity of Tregs and MDSC. We have developed EOS100850/1, a novel, non-brain penetrant and highly selective inhibitor of A2AR with sub-nanomolar Ki. In vivo, EOS100850/1 significantly delays tumor growth in different syngeneic models when combined with aCTLA-4 or aPD-L1. In vitro, we have demonstrated that EOS100850/1 maintains its potency in high adenosine environment (>10uM) using human PDX models. However, these PDX were engrafted on to immunodeficient mice and therefore any possible contribution of the immune infiltrating cells for generation of adenosine was not taken into account. Thus, the first aim of this study was to determine the adenosine levels in immunocompetent tumor models. The second aim was to confirm that EOS100850/1 can mediate antitumor efficacy in vivo regardless of the ambient adenosine concentration in the tumor microenvironment (TME).
Methods
MCA205, CT26, A20, and EMT6 tumor cells were subcutaneously implanted into immunocompetent syngeneic mice. When tumors reached 100-200mm3 and again at 600-700mm3 tumor extracellular fluid was collected by microdialysis and the adenosine concentration was measured by LC/MS. In a second study, the antitumor effect of EOS100850/1 administered orally at 0.6mg/kg QD was evaluated in models with different level of adenosine concentration (MCA205 and CT26) in combination with oxaliplatin or doxorubicin dosed at 10 or 5 mg/kg, respectively.

Results
The adenosine concentrations in individual tumors ranged from 2 to 50μM across different models, while adenosine levels in the non-tumor region were always lower than 1μM. For most tumors, size did not affect the concentration of adenosine, except for CT26, where there was a 2 fold increase when tumors grew from 100-200mm3 to 600-700mm3. MCA205 tumors displayed the highest adenosine concentration with an average of 33μM while CT26 was considered intermediate with an average of 16μM. EOS100850/1, in combination with chemotherapy, demonstrated similar tumor growth inhibition in both models, regardless of the concentration of adenosine.

Conclusions
These data demonstrate that the adenosine concentrations vary in the tumor microenvironment of different syngeneic tumor models and that EOS100850/1 is able to inhibit the A2AR induced immunosuppression and therefore tumor growth in combination with chemotherapy regardless of the adenosine concentration in the TME.

Acknowledgements
We would like to thank the CRO Explicyte for performing the microdialysis experiments.

Ethics Approval
The study was approved by La S.A. Biophore ULB Charleroi, approval number BUC 2016-02.

PE656
PEGylated cationic liposomal-oxaliplatin display impressive anti-cancer efficacy by dual-targeting of immunosuppressive populations and cancer-cells
Lars Petersen, PhD1, Lars Ringgaard, PhD1, Fredrik Melander, PhD2, Ragnhild Østrem, PhD1, Kasper Kristensten, PhD1, Jonas Henrikson, PhD1, Dennis Elema, PhD3, Andreas Kjær, MD, PhD2, Thomas Andresen, PhD1
1Technical University of Denmark, Kgs. Lyngby, Denmark; 2Rigshospitalet & University of Copenhagen, Copenhagen, Denmark
Correspondence: Thomas Andresen (tlan@dtu.dk)
Journal for Immunotherapy of Cancer 2019, 7(Suppl 1):PE656

Background
Liposomal drug delivery systems have historically focused on tumor accumulating properties. This is generally achieved by securing a long-circulating half-life of liposomes that then accumulate by the enhanced permeation and retention (EPR) effect. Several important therapeutic targets beyond the cancer cells have been identified in the tumor microenvironment. Pro-tumorigenic myeloid populations in the tumor microenvironment are potent suppressors of anti-cancer cytotoxic T-cells and their depletion improve therapeutic outcome [1,2]. Liposomal drug delivery systems, that not only induce immunogenic cell death of cancer cells but also eliminate potent immunosuppressive populations are therefore highly attractive.

Methods
Weakly cationic PEGylated Oxaliplatin (L-OHP) liposomes (R2) were formulated (POPC/cholesterol/DOTAP/chol-PEG/Chol, (52.5/36/7.5/4)) in combination with chemotherapy. Liposome biodistribution and pharmacokinetics were investigated using rhodamine B labeled stealth and R2 liposomes. L-OHP levels in the tumors were measured using inductively coupled plasma mass spectrometry (ICPMS). Real-time in vivo biodistribution was evaluated by PET/CT using copper-64-radiolabeled stealth and R2 liposomes according to a previously described technology [3].

Results
The in vitro half-maximal inhibitory concentration (IC50) of CT26 cancer cells was comparable between R2 liposomes and free L-OHP (2.2 and 2.0 μM). Due to in vitro stability, IC50 value for stealth L-OHP liposomes could not be achieved even at the highest concentration evaluated. PET/CT scans and ICPMS demonstrated that the R2 liposomes had a shorter circulating half-life and significant lower tumor accumulation compared to stealth liposomes, but higher than free L-OHP. However, the R2 L-OHP liposomes displayed an impressive anti-cancer efficacy with >60% of treated CT26 tumor-bearing mice displaying a complete response (CR), while no CR’s were observed in the L-OHP stealth liposome treated group. Advanced flow cytometric analysis of the tumor microenvironment identified that both R2 and stealth liposomes accumulated in central immunosuppressive myeloid populations but only R2 L-OHP liposomes were able to eliminate these compared to stealth and free L-OHP.

Conclusions
Here we report the potent anti-cancer effect of weakly cationic PEGylated L-OHP liposomes that depletes suppressive populations and eradicates CT26 tumors. The data demonstrate how advanced drug delivery systems may provide important immunomodulating properties in addition to direct cancer-cell cytotoxicity.

References

Ethics Approval
The study has been approved by The Danish Animal Experiments Inspectorate.

PE657
Selective T cell redirection proteins (STR) enhance the anti-tumor activity of checkpoint inhibitors (CPIs) and can lead to long-lasting immunity against the tumor
Meir Azulay, PhD
NeoTx LTD, Rehovot, Israel
Correspondence: Meir Azulay (meir@neotx.com)

Background
Tumor-targeted superantigens (TTS) such as Naptumomab Estafenatox (Nap) are fusion proteins that consist of genetically engineered Superantigens (Sag) linked to Fragment antigen binding (Fab) moieties directed to tumor-associated antigens. Unlike CD3-based T cell redirection approaches (e.g. BiTEs) which bind and activate all T cells, TTS only bind and activate subsets of T cells that contain certain TCR β variable (TRBV) regions, e.g. TRBV 7-9 [1] and are thus defined as STR. We previously reported the synergistic anti-tumor effect of combining CPI with our lead STR compound, Nap (ST4 targeted Sag) or its murine surrogate protein [2]. Here, we present new pre-clinical data showing that STR not only enhances the anti-tumor effect of CPIs, but also stimulates the overall immune response that could lead to long term immunity against the tumor.

Methods
The combination of Nap with PD-L1 inhibitor (durvalumab) was tested in vitro against high (MDA-MB 231) and low (RKO) ST4-expressing cancer cell lines in the presence of human PBMCs. For the
in vivo studies, mice bearing EpCAM transfected MC38 tumors were treated with TTS (consisting of a Fab against EpCAM), an anti-PD-1 antibody, or the combination. Tumor growth and survival were assessed and tumor recurrence following re-challenge was evaluated.

**Results**

Combination of Nap with durvalumab had synergistic anti-tumor effect against both high and low ST4-expressing cancer cell lines. Coincident treatment of MC38-EpCAM tumor bearing mice with TTS and anti-PD-1 achieved complete tumor rejection in 4 of 10 mice and significantly prolonged survival and delayed outgrowth of tumors compared to the monotherapies. All cured mice rejected re-challenge with MC38-EpCAM and parental MC38 tumors, indicating long-term memory responses.

**Conclusions**

Our studies show that combination of CPI with STR overcomes the limited effect of CPI monotherapy regardless of tumor antigen expression level. In addition, our in vivo studies demonstrate that the combination of STR with CPI may lead to long term durable responses not possible in most patients receiving single agent CPI therapy. Moreover, the ability of these “cured mice” to reject tumor rechallenge suggests that STRs cause release of secondary antigens that prime subsequent immune responses. Taken together, our data suggests that combining anti-PD(L1) with STR may be a promising therapeutic strategy for patients with solid tumors. Clinical phase 1/2 trial was recently initiated investigating the combination of Nap with durvalumab in subjects with selected advanced or metastatic solid tumors (NCT03983954).

**Trial Registration**

NCT03983954

**References**


**Fig. 1 (abstract P658). See text for description**

**P659**

**ENPP1 antagonists in combination with radiation or checkpoint inhibitors demonstrate antitumor activity in syngeneic mouse models of pancreatic adenocarcinoma, neuroblastoma, TNBC, and colon cancer**

Lingyin Li, PhD1, Mark Smith, PhD2, Betty Chang, PhD2

1Stanford University, Stanford, CA, United States ;

2Angarus Therapeutics, Cupertino, CA, United States

**Correspondence:** Betty Chang (bchang@angarus.com) Journal for ImmunoTherapy of Cancer 2019; 7(Suppl 1):P659

**Background**

Ectonucleotide pyrophosphatase 1 (ENPP1) was identified as the extracellular hydrolase for cGAMP, the natural ligand for STING [1,2]. Multiple lines of evidence suggest cancer cells produce soluble extracellular cGAMP, resulting in activation of CD14+ PRMCs, and subsequent production of IFNβ in cell culture. Inhibition of ENPP1 and ionizing radiation further increase extracellular cGAMP concentrations and anti-cancer immunity in mice. Genetic knockout of ENPP1, in breast cancer cells or in the host, delayed tumor progression, demonstrating antitumor activity of ENPP1 deficiency. ENPP1 downregulation correlated with survival advantage in breast cancer patients. Here, systemic delivery of extracellular ENPP1 antagonists were
evaluated in syngeneic mouse tumor models alone and in combination with ionizing radiation and/or immune checkpoint inhibitors.

**Methods**

Novel SMi to ENPP1 were synthesized and characterized. ANG-1084 and ANG-1623, were identified as leads, and tested for potency, selectivity, stability, and PK. ANG-1623 was delivered at 50 mg/kg/d systemically for 7-28 days in models of pancreatic adenocarcinoma, neuroblastoma, orthotopic TNBC, and colon carcinoma.

**Results**

ANG-1084 and 1623 have IC50 of <0.5 nM against human ENPP1 with cGAMP as substrate at pH7.6, and are selective against hENPP2/3, PDEs, CERP44 and stable in human and mouse microsomes. ANG-1623 had no hits in a 468-kinase-screen at 1 μM, and its protein binding was 66% and 55% in human and mice, respectively. ANG-1084 and 1623 did not have CYP liability and hERG IC50 was >25 μM. In addition, both were superior in potency, selectivity, and hERG to the published ENPP1 Q5-1. ANG-1623 at 50 mg/kg/day had single agent activity in the Panc02 model, with 63% TGI (p<0.001) and 81% TGI (p=0.001, 5/15 tumor free). ANG-1623 in combination with radiation and/or checkpoint inhibitors had significant anti-tumor effects in Neuro-2a, orthotopic 4T1 or MC38 models.

**Conclusions**

Novel selective and potent small molecule inhibitors were designed to inhibit extracellular ENPP1. Lead molecule ANG-1623 has desirable properties of a drug and was subsequently tested in syngeneic mice tumor models: 4T1, Panc02, Neuro-2a, and MC38, where it was administered subcutaneously for 7 to 28 days. The drug was well tolerated and demonstrated significant anti-tumor activity alone or in combination with radiotherapy and/or anti-PD-L1. Since ENPP1 antagonists aim to preserve extracellular cGAMP produced by tumors either naturally or induced by ionizing radiation, and are delivered systemically, they may be promising alternatives to synthetic CDNs that are restricted to intratumoral injections of surface tumors, and pose challenges in optimal dose determinations.

**References**

2. Carozza, JA et al., 2′,3′cGAMP is an immunotransmitter produced by cancer cells and hydrolyzed by ENPP1. 2019; bioRxiv539312 doi: https://doi.org/10.1101/539312

**P660**

TNFα suppresses the immunogenicity of STING-agonists

Anthony Desbiens, PhD1, Kelsey Svick Gauthier2, Ed Lennmenn3, Weiquin Liu4, Brian Francica5, Gabrielle Reiner6, Steven Bender7, Jeffry McKenna8, DPPh9, Yan Feng5, PhD10, Lianzeng Zheng5, PhD10, Andrea van Elsas1, Sarah McWhirter10, Aduro Biotech, Berkeley CA, United States; 2Arcus Biosciences, Hayward, CA, United States; 3Tempest Therapeutics, San Francisco, CA, United States; 4University of California-Berkeley, Berkeley, CA, United States; 5Genomics Institute Novartis, San Diego, CA, United States; 6Novartis Institutes for BioMedical Res., Cambridge, MA, United States;

Correspondence: Anthony Desbiens (TDESBIEN@ADURO.COM) Journal for ImmunoTherapy of Cancer 2019; 7(Suppl 1);P660

**Background**

The stimulator of interferon genes (STING)-pathway is a critical component of the adaptive immune response against tumors. Aduro Biotech is developing the synthetic cyclic dinucleotide (CDN) STING agonist, ADU-S100 (MIW815), as a cancer treatment.

**Methods**

A dose-response analysis of intratumorally administered STING agonists in syngeneic mouse tumor models was performed to determine immunogenicity and tumor control.

**Results**

Data show that low to mid-range doses caused increased tumor collapse and the activation and expansion of tumor-specific CD8 T cells.

In contrast, overstimulation of the STING pathway with high-doses of ADU-S100 or more potent STING agonists failed to induce tumor-specific CD8 T cells and caused disruption of tumor draining lymph nodes. Blocking tumor necrosis factor-alpha (TNF-alpha) signaling restored induction of tumor-specific CD8 T cells during overstimulation of STING and preserved lymph node integrity.

**Conclusions**

These data demonstrate that the induction of anti-tumor CD8 T cells is inhibited by TNF-alpha during overstimulation of the STING pathway, suggesting that intervention in TNF-alpha signaling may broaden the therapeutic window of STING agonists.

**Ethics Approval**

All animals were used according to protocols approved by Institutional Animal Use Committee of Aduro Biotech.

**P661**

Development and characterization of next generation small molecule STING agonists

Stefan Chmielewski, PhD, Magdalena Zawadzka, Jolanta Mazurek, Karolina Głuza, Katarzyna Wójcik-Jaszczyńska, Maciej Kujawa, Grzegorz Topolnicki, Grzegorz Ciwiernia, Aleksandra Poczaj, Eliza Zimolag, Magdalena Mroczkowska, Agnieszka Gibas, Marcin Lei, Sylwia Sudol, Marek Wronowski, Kinga Michalik, Katarzyna Banaszak, Katarzyna Wilkik, Diego Malusa, Michal Combik, Karolina Wiatrowska, Łukasz Dudek, Jose Alvarez, Anna Rajda, Maciej Rogacki, Faustyna Gajdosz, Aniela Golas, Katarzyna Wnuk-Lipinska, Ewelina Gabor-Worwa, Charles Fabritius, Luigi Stasi, Peter Littlewood, Krzysztof Brzózka, Monika Dobrzańska, Selvita, Krakow, Poland

Correspondence: Monika Dobrzańska (monika.dobrzanska@selvita.com) Journal for ImmunoTherapy of Cancer 2019; 7(Suppl 1);P661

**Background**

Stimulator of Interferon Genes (STING) is a major player in the initiation of robust innate immune activation leading to initiation and enhancement of a tumor-specific adaptive immunity. Several clinical and pre-clinical studies employ modified cyclic dinucleotides, natural STING ligands. Yet, relative instability and chemical nature limit their use as systemic immuno-therapeutics. Herein, we present potent and selective non-nucleotide, non-macrocyclic, small molecule direct STING agonists, structurally unrelated to known chemotypes with potential for systemic administration.

**Methods**

Binding to recombinant STING protein was examined using FTS, MST, FP and crystallography studies. Phenotypic screen was performed in THP-1 Dual reporter cells. Human macrophages (HMDM) and dendritic cells (HDCM) were differentiated from monocytes (obtained from PBMC) in the presence of GM-CSF and GM-CSF/IL-4 for HMDM and HMDC, respectively. Human T cells were isolated from PBMC, activated with plate-bound anti-CD3/anti-CD28 and exposed to compounds followed by viability and proliferation assessment using flow cytometry. Mouse bone marrow-derived dendritic cells (BMDC) were obtained from C57BL/6 or STING Gt mice and differentiated with mIL-4 and mGM-CSF. Cell maturation marker expression and the presence of phosphorylated forms of the STING pathway proteins were assessed by flow cytometry and Western Blotting. BALB/c mice were injected with compounds and the cytokine release was measured in the plasma. Additionally, mice were inoculated with CT26 cells and the compound was administered followed by the regular tumor growth monitoring.

**Results**

Selvita’s agonists bind to all tested recombinant STING proteins: human, mouse, rat and monkey. Selvita’s compounds induce cytokine responses and upregulate DC maturation markers on BMDC in low nM range only in the presence of STING, confirming their high selectivity. They trigger pro-inflammatory cytokine release from human PBMC and HMDM and induce dendritic cell maturation regardless of the STING haplotype. In vitro polarization of immuno-suppressive M2d macrophages into pro-inflammatory M1-like phenotype was demonstrated. The compounds have fine-tunable ADME properties
with particularly good solubility, permeability, human plasma stability and plasma protein binding. Systemic in vivo administration led to robust upregulation of STING-dependent pro-inflammatory cytokines suggesting immune activation which translated into efficacy in vivo in subcutaneous CT26 model.

Conclusions
Selvita’s STING agonists activate STING-dependent signaling in both mouse and human immune cells promoting anti-tumor immunity. Treatment with Selvita’s STING agonists led to tumor growth inhibition by engagement of the immune cells. The compounds show good selectivity and in vitro ADME properties enabling development for systemic administration as a single agent or in combinations with immunotherapies or targeted agents.

P662
Inhibiting DNA methylation can reverse epigenetic silencing of STING in melanoma and enhance antitumor T-cell activity
Rana Falahat, PhD1, James Mulé, PhD1, Anders Berglund, PhD1, Patricio Perez-Villarroel1, Shota Aoyama, MD1, Shari Pilon-Thomas, PhD2, Glen Barber, PhD2
1Moffitt Cancer Center, Tampa, FL, United States; 2University of Miami Miller School of Medicine
Correspondence: James Mulé (james.mule@moffitt.org)

Background
STING pathway is an innate immune sensing mechanism for the detection of immunogenic tumors. We have recently shown that STING signaling is heterogeneously regulated across human melanoma cell lines. While intact activation of STING signaling in a subset of melanoma cell lines enhances their antigenicity, defects in STING pathway limit their sensitivity to lysis by human melanoma tumor infiltrating lymphocytes (TIL) [1]. In addition, we have reported a high incidence of STING gene methylation in a variety of tumors including melanoma [2]. Based on these findings, we hypothesized that reconstitution of STING expression through DNA demethylation would reverse STING signaling in STING-defective melanoma cell lines and could therefore promote antitumor T-cell activity.

Methods
Using methylation microarray analysis, we identified human melanoma cell lines with aberrant STING promoter methylation across a panel of 16 cell lines and subjected them to treatment with the DNA methyltransferase inhibitor 5-aza-2’-deoxycytidine (5AZADC). We next evaluated the induction of STING expression by immunoblot. We assessed phosphorylation of IRF3 and induction of IFN-beta and CXCL10 in 5AZADC-treated melanoma cells following their stimulation with the STING agonist 23’-cGAMP. We also co-cultured 5AZADC-treated melanoma cell lines with their HLA-matched human melanoma TIL in the presence or absence of 23’-cGAMP and assessed TIL production of IFN-y.

Results
We identified 6 STING-negative human melanoma cell lines with high levels of STING promoter methylation. Immunoblot analysis revealed inhibiting DNA methylation by 5AZADC treatment can partially or completely restore STING expression in all 6 cell lines. Stimulation with 23’-cGAMP resulted in phosphorylation of IRF3 and induction of CXCL10 (>1200 pg/ml) in 6 of 6 5AZADC-treated cell lines. In co-culture studies 5AZADC-treated melanoma cells stimulated up to a 4-fold increase in TIL production of IFN-y compared to untreated controls in the presence of 23’-cGAMP (510 to 2100 pg/ml, p < 0.05).

Conclusions
We provide evidence that DNA methylation is a major contributor to the suppression of STING signaling in melanoma. Reconstitution of STING expression through DNA demethylation can restore STING signaling in STING-defective melanoma cell lines and promote antitumor T-cell activity. Collectively, these observations argue that targeting epigenetic loss of STING in melanomas should be considered as a strategy to improve the efficacy of clinical interventions using STING agonists.

Acknowledgements
NCI P50 CA168536; Cindy and Jon Gruden Fund, Chris Sullivan Fund, V Foundation, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.

References

P663
Evaluating loss of cGAS and STING expression using a novel multiplex immunohistochemistry detection approach
Jeanette Rheinhardt1, Adam Markman1, Hideki Goda, PhD,2, Etsuko Futaya1, Masaru Takahashi2, Hiroyuki Yokota1, Kenji Nishikawa2, Hisatake Okada1, Kenneth Bloom1, George Abe1, Joseph Krueger1, Apollina Goel1, PhD1
1Invicro, LLC, Boston, MA, United States; 2Konica Minolta Inc. Bio-Healthcare unit, Tokyo, Japan
Correspondence: Joseph Krueger (jkrueger@invicro.com)

Background
The cGAS-STING (cyclic GMP-AMP synthase-stimulator of interferon genes) pathway is becoming an important point of focus in the expanding landscape of next-generation immunotherapies. STING agonists can induce systemic anti-tumor immunity and thus may be also synergistic with other immunotherapies (i.e. immune checkpoint blockade, cancer vaccines, and CAR-T cell therapy). Importantly, a functional cGAS-STING pathway may be essential for response to oncolytic viral therapy. However, advanced stages of solid cancers (i.e. melanoma and colon adenocarcinoma) frequently show loss of STING or cGAS and would not be expected to respond to STING agonists. Since STING agonists have now entered clinical trials, there is an emerging need for predicting patient response which can accurately classify patients according to STING or cGAS expression. Here, we show application of a novel immunohistochemistry (IHC)-based approach using fluorescent nanoparticles (Quanticeill™) to deliver highly sensitive and quantitative analysis of STING and cGAS within the tumor contexture.

Methods
cGAS and STING expression were simultaneously detected in melanoma tissues using our novel fluorescent nanoparticle IHC approach (Quanticeill™). Serial sections were stained with chromogenic IHC to correlate between the expression of cGAS/STING and the patterns of tumor-infiltrating immune cells.

Results
Our results show that the Quanticeill assay format enables a more objective and quantitative scoring of target proteins compared to standard IHC assay formats. The ability to multiplex cGAS and STING enables simultaneous quantitative analysis of these two critical markers to characterize distinct patient phenotypes with tumors associated with diverse immune contexture.

Conclusions
We show that our technique quantitatively measures cGAS and STING expression in cancer tissue biopsies with high sensitivity. The multiplexed IHC format has immediate value for predictive and prognostic application in STING agonist-based single/checkpoint inhibitor combination therapies.

Acknowledgements
Hemi Dimant, Arvind Gandhi, Stephan Collins, Mark Lawson.
P664

Development of small molecule STING agonists that can evoke host anti-cancer immune defences following local or systemic delivery

Nicole Haynes, PhD1, Theresa Connor1, Ben Morrow, PhD2, Judy Doherty1, Matthew Dennis, PhD1, Jonathan Hubert, PhD2, Sukhdeep Spall1, Anthony Cuzzupe2, Karen White, PhD3, Susan Charmean, PhD, Professor4, Aaron Lock5, Vicky Avery, PhD, Professor5, Stewart Nuttal3, Tom Peat6, PhD1, Olan Dolezal, PhD1, Pat Pilling6, Jezrael Revalde6, Tim Yow2, Greg Amdt1, Hendrik Falk, PhD1, Mark Devlin, PhD, COO7, Ian Street, PhD1, Pohl Khoa, PhD7, Paul Supplee7, Brendon Monahan, PhD, CSO8

1Cancer Therapeutics CRC, Peter MacCallum Cancer Centre, Melbourne, Australia; 2Cancer Therapeutics CRC, Monash University of Pharmaceutical Sciences, Melbourne, Australia; 3Cancer Therapeutics CRC, CSIRO, Melbourne, Australia; 4Cancer Therapeutics CRC, Walter and Eliza Hall Institute, Melbourne, Australia; 5S'Thesis Research, Melbourne, Australia; 6Monash University of Pharmaceutical Sciences, Melbourne, Australia; 7Cancer Therapeutics CRC, Griffith Institute for Drug Discovery, Melbourne, Australia; 8Cancer Therapeutics CRC, Children’s Cancer Institute, Melbourne, Australia

Correspondence: Brendon Monahan (brendon@cancercrc.com)


Background

STING is a ubiquitously expressed innate immune sensor which is essential for the production of host defence-related proteins including type I interferons and proinflammatory cytokines that promote the recruitment and effector activity of innate and adaptive immune cells [1]. Targeted activation of STING and the associated release of type I interferons can enhance the sensitivity of antigen presenting cells to neoantigens and promote their ability to prime T cell-based anti-cancer immune responses [1,2]. This can lead to the establishment of T cell inflamed tumor microenvironments that are more susceptible to the anti-tumor effects of checkpoint blockade therapy [3]. The Cancer Therapeutics CRC (CTx) is developing direct small molecule STING agonists that can be administered systemically as an adjunct to immune checkpoint antibody therapy.

Methods

A phenotypic screen was run using an IFN-β-luciferase reporter cell line looking for activation of Type I Interferon genes when screened against CTx small molecule libraries. Validated hits were deconvoluted by STING SPR to confirm direct STING binding. A mature medicinal chemistry program is underway with an established screening cascade including in vitro target engagement and primary cell functional assays, structural biology, in vivo PK/PD, and efficacy assays to determine mechanism(s) of action and demonstrate therapeutic index.

Results

CTx has developed potent drug-like small molecule STING agonist compounds that show direct STING binding. Cellular activity is dependent upon STING (inactive in STING-/− cells), independent of cGAS (active in cGAS-/− cells), and can be blocked by TBK1 inhibitors. Compounds show activity in primary mouse and human cells across a range of STING variants. Dose-dependent in vivo PD biomarker responses, including increased plasma IFN-β levels, were seen when administered intravenously (IV) or intratumorally (IT). In vivo, single agent efficacy of CTx STING agonists has been tested in multiple syngeneic mouse models of solid cancer. Treatment via IT or LV administration was well tolerated and evoked therapeutically beneficial immune-mediated anti-tumor responses. Successful induction of immunological memory, in response to STING agonist treatment was demonstrated in tumor-rechallenge experiments. In less responsive models, where intermediate efficacy was observed, increased tumor growth control could be achieved by co-treating mice with our STING agonist and anti-PD-1 antibody therapy.

Conclusions

CTx has a mature STING agonist program that has successfully produced direct STING activators that can promote primary DC function and elicit immune-mediated anti-tumor responses in mouse models of solid cancer.

References


P665

Enhancing IFN-β production through synergy between the STING and TLR pathways

Emily Higgs, BA; Thomas Gajewski, MD, PhD

University of Chicago, Chicago, IL, United States

Correspondence: Thomas Gajewski (tgajewski@medicine.bsd.uchicago.edu)


Background

Previous work from our laboratory has shown that tumors activate the STING pathway in antigen-presenting cells. STING signaling leads to IFN-β production which is required for T cell priming through dendritic cells. While the best defined transcription factor for IFN-β gene expression is IRF3, other transcriptional regulators also contribute, including NF-κB. Enhancing STING activation and downstream IFN-β production has therapeutic potential, and STING agonists are currently being evaluated in clinical trials. However, innate immune activation in response to a pathogen rarely occurs by activating only one signaling pathway, and targeting multiple pathways may lead to more robust activation. Activating multiple innate immune pathways similar to a natural infection could improve the therapeutic efficacy of STING agonists.

Methods

In vitro experiments were performed using macrophages and bone marrow-derived dendritic cells stimulated with the STING agonist DMXAA alone or in combination with several TLR agonists. Cells were subjected to several downstream analyses, including qPCR, Western blotting, and immunofluorescent imaging to visualize transcription factor localization.

Results

Each innate immune agonist was titrated to identify the dose inducing maximal IFN-β expression. DMXAA induced greater peak IFN-β expression than any individual TLR agonist. After testing several combinations, we found that LPS + DMXAA induced significantly greater IFN-β transcription than the sum of either agonist alone. To explain this synergy, we assayed each step of STING pathway signaling. Initial activation leads to STING aggregation, and LPS did not increase STING aggregation beyond that induced by DMXAA. Additionally, LPS did not increase IRF3 phosphorylation nor IRF3 nuclear translocation in combination with DMXAA. Rather, LPS increased the phosphorylation and nuclear translocation of the NF-κB subunit p65. These results suggest that the synergy in IFN-β production is achieved through IRF3 activation downstream of STING signaling and NF-κB activation downstream of TLR4 signaling. Additional mechanistic experiments are ongoing.

Conclusions

TLR activation by LPS synergized with STING signaling to augment IFN-β production beyond the level of either agonist alone. Mechanistically, STING pathway activation preferentially signals through IRF3 whereas TLR4 pathway activation preferentially signals through NF-κB.
Selective activation of antigen-presenting cells by exoSTING Enhances tumor antigen-specific immune response

Su Chul Jang, PhD, Kelvin Zhang, Nuruddeen Lewis, PhD, Tong Zi, Joanne Lim, Rane Harrison, Raymond Moniz, Katherine Kimwin, Chang Ling Sia, Christine McCoy, Kevin Dooley, Ke Xu, Jorge Sanchez-Salazar, Raymond Bourdeau, Agata Villiger-Oberbék, William Dahlberg, Shil Patel, Kyriakos Economides, Sriram Sathyaranarayan

Codiak Biosciences, Cambridge, MA, United States

Correspondence: Sriram Sathyaranarayan (siram.sathy@codiakbio.com)


Background

Activation of the STING pathway by direct intra-tumoral administration of synthetic cyclic dinucleotide (CDN) agonists has shown anti-tumor activity in animal models and early stage human clinical trials. At higher doses CDN induces local tissue damage due to non-selective uptake into cells at the injection site, including ablation of immune effector cells (CD8+ T cells and Antigen Presenting Cells [APC]) [1]. CDN administration has been shown to result in a bell-shaped dose response curve, wherein anti-tumor effects are lost at high doses [1]. We have developed a novel engineered exosome therapeutic candidate, exoSTING™, which selectively activates the STING pathway in tumor-resident APCs demonstrating greater potency than free CDN and without immune ablation.

Methods

Exosomes were engineered to overexpress PTGFRN, an exosome surface protein, and loaded ex vivo with a proprietary CDN. In vivo pharmacodynamics (PD) and anti-tumor responses were demonstrated in a B16F10 syngeneic mouse model and ex vivo histoculture of human tumor explants (head and neck squamous cell carcinoma [HNSCC] and non-small cell lung cancer [NSCLC] patients) was utilized to evaluate PD after intra-tumoral administration.

Results

ExoSTING™ was preferentially taken up by differentiated macrophages and dendritic cells. In vivo proliferation studies showed a 100-fold increase in potency of macrophage activation by exoSTING™ treatment compared to free CDN. In contrast, T-cells failed to take up exosomes and were not activated by exoSTING™. We have shown that intra-tumoral administration of exoSTING™ in B16F10 tumors preserves the viability of T-cells and APCs, reduces collateral tissue damage, and eventually recruits more T-cells into tumors, whereas free CDN induces immune cell ablation. NanoString gene expression analysis showed increased immune cells-related gene signatures in tumort cells after dosing with exoSTING™ but not free CDN-exposed tumors. ExoSTING™ produced a systemic tumor-specific T-cell response as demonstrated by growth inhibition of non-injected distal tumors, which was further enhanced by combination with anti-PD-1 checkpoint blockade. Activity of exoSTING™ was also examined in ex vivo human tumor histo-culture. ExoSTING™ induced IFNβ mRNA expression in a dose-dependent manner and induced more IFNβ, CXCL9, CXCL10, and IFNγ mRNA expression than equivalent amounts of free CDN.

Conclusions

ExoSTING™ is an engineered exosome therapeutic candidate that specifically targets the STING pathway in APCs in the tumor microenvironment, resulting in enhanced PD effects, avoidance of T-cell uptake and enhanced anti-tumor immune responses compared to free CDN. Human clinical testing is planned to begin in the first half of 2020.

References

TTI-10001, a novel non-CDN small molecule STING agonist, is well tolerated at doses below the MTD using all three modes of delivery. Conclusions

Mouse tumor model was observed when TTI-10001 was administered with excellent oral bioavailability (85%) and a long tumor retention time (T1/2: ~4-8h) following all three routes of administration. Treatments with TTI-10001 induced dose-dependent expression of pro-inflammatory cytokines in tumors including interferon beta, tumor necrosis factor alpha, and interleukin 6. Significant off-target effects were observed in vitro. TTI-10001 was well tolerated in mice with no weight loss or overt morbidity after repeated systemic dosing. Potential dose-dependent anti-tumor efficacy in the MC38 syngeneic mouse tumor model was observed when TTI-10001 was administered at doses below the MTD using all three modes of delivery.

Methods

TTI-10001 was administered as a single dose (oral, i.v., or i.t.) to MC38 tumor-bearing mice and plasma or tumor samples were collected for pharmacokinetic (PK)/pharmacodynamic (PD) analysis. Repeat administration (oral, i.v., or i.t.) of TTI-10001 was used for maximum tolerated dose (MTD) studies or efficacy studies in single or dual flank MC38 tumor-bearing mice. Off-target effects were assessed using the SafetyScreen4™ panel.

Results

Mice dosed with TTI-10001 demonstrated favorable drug exposure with excellent oral bioavailability (85%) and a long tumor retention time (T1/2: ~4-8h) following all three routes of administration. Treatment with TTI-10001 induced dose-dependent expression of pro-inflammatory cytokines in tumors including interferon beta, tumor necrosis factor alpha, and interleukin 6. Significant off-target effects were observed in vitro. TTI-10001 was well tolerated in mice with no weight loss or overt morbidity after repeated systemic dosing. Potential dose-dependent anti-tumor efficacy in the MC38 syngeneic mouse tumor model was observed when TTI-10001 was administered at doses below the MTD using all three modes of delivery.

Conclusions

TTI-10001, a novel non-CDN small molecule STING agonist, is well tolerated in vivo and displays an excellent PK/PD profile that results in potent anti-tumor activity by i.t., oral, and i.v. routes of administration. These data highlight the potential of TTI-10001 to achieve best-in-class status among next generation STING agonists.
While ICPIs (immune checkpoint inhibitors) have fundamentally changed the practice of cancer therapy for tumors arising from many different tissues, ways to increase both response rate and durability are critically needed. Combining stimulators of innate immunity with activators of adaptive immunity should lead to better treatment outcomes. We have therefore created a series of novel orally administered, systemically acting Toll-like receptor 7 (TLR7) agonists for long-term combination therapy with enhancers of adaptive immunity like ICPIs. Our molecules incorporate a set of atypical properties critical to achieving this product profile [1].

Methods

Key assays in our testing cascade include:
- Cellular reporter assays and human PBMC assays to evaluate selectivity, potency and other characteristic aspects of cellular pharmacology (e.g. targeted cytokine and chemokine profiles)
- Characterization in cynomolgus monkeys
  - Appropriate PK with active TLR7 agonist
  - Efficient oral delivery into systemic circulation with prodrugs of the TLR7 agonist
  - Targeted pharmacodynamic response at relevant oral dose (gating for candidate selection)

Additional descriptive assays include:
- Evaluation of potency and cellular pharmacology in monkey PBMCs
- In vitro predictors of pharmacokinetics and safety
- Pharmacodynamic response in rodents
- Antitumor activity in syngeneic rodent tumor models

Results

While TLR7 agonists having appropriate potency and specificity were discovered early in our program, systemic oral delivery even with an optimized prodrug approach was relatively poor. Modification of the lead TLR7 agonist itself increased efficiency of oral delivery by the prodrug from 14% for Compound A to 99% for Compound C (Figure 1) while also modestly increasing potency in PBMC assays. Surprisingly, Compound C is significantly less potent in monkey plasmacytoid dendritic cells (PDCs) than in human PDCs. Consequently doses of the prodrug of Compound C eliciting our targeted degree of immune induction in cynomolgus monkeys are higher than anticipated. In contrast, Compound B has equivalent potency in human and monkey PBMC assays. While either of these compounds may be suitable for development, we continue to investigate additional compounds that retain the preferred features found in Compounds B and C while having greater potency in cellular assays.

Conclusions

From our original starting point - a relatively weak TLR7 agonist with no oral bioavailability - we have invented a novel series of molecules that are designed to be dosed QOD continuously over a 24-month period to appropriately engage innate immunity at a level that is well-tolerated by the patient while increasing treatment response rate and durability.

References

Deep TLR Primed T cells. Following ACT into immunocompetent syngeneic tumor-bearing animals, the T cell product was evaluated for efficacy and immune cell activation.

Results
ACT with Deep TLR Primed PMEL T cells inhibited tumor growth significantly more than ACT of PMEL T cells alone or combined with systemically delivered TLR agonists. Deep TLR Primed cells displayed higher proliferation but lower PD-1 expression in blood and tumors and caused a trend towards an increase in CD8+ DC, plasmacytoid DC, and MDSC in the TME. Despite their remarkable efficacy, ACT of Deep TLR Primed PMEL T cells caused no treatment-specific weight loss and elicited substantially lower levels of plasma IFNg and IL-12 than systemic TLR7 agonist delivery.

Conclusions
Deep TLR Primed T cells display superior efficacy, PD, and safety compared to T cells alone or co-administered with systemic TLR agonists. Torque’s Deep-Primed™ technology allows the delivery of small molecules to the TME, with controlled doses. Compared to intratumoral delivery, systemically delivered Torque’s Deep-Primed™ tumor antigen-specific autologous T cells can target a wider variety of tumors, including distant metastases. It has the potential to improve agonist PK profile through sustained delivery over time in TME and draining lymph nodes, with limited systemic exposure.
Acknowledgements
This work was financially supported by the Basic Science Research Programs (2018R1D1A1B07047950) of the National Research Foundation (NRF), Republic of Korea.

References

Ethics Approval
The study was approved by Sungkyunkwan University’s Ethics Board, approval number SKIUACUC2019-01-07-1.

P674
In situ vaccination using a tumor-binding polymeric glyco-adjuvant for the induction of anti-tumor immunity
Tiffany Marchell, David Wilson, Aaron Alpar, Jeffrey Hubbell University of Chicago, Chicago, IL, United States
Correspondence: Jeffrey Hubbell (hubbell@uchicago.edu)

Background
Difficulty translating therapeutic vaccination success from murine models to the clinical treatment of cancer has highlighted the need for vaccination strategies that may be more broadly applicable. To address this problem, we developed an in situ vaccination strategy to adjuvant tumor cells directly, utilizing the tumor itself as the antigen source in initiating tumor-reactive cellular responses. Our engineered vaccine is comprised of a novel polymeric TLR7-agonist (pTLR7) [1] chemically linked to tumor-binding antibodies. We hypothesized that following intratumoral administration, our pTLR7-(tumor-binding antibody) conjugates (pTLR7-tAbs) would bind to surface molecules expressed by tumors, thereby increasing persistence of the adjuvant within the tumor. Given the ease of conjugation of pTLR7 to various antibodies, our in situ pTLR7-tAb vaccination platform is tunable in specificity from highly tumor-specific to widely applicable, depending on the choice of antibody used.

For generalizability between tumor models, we selected an anti-CD47 antibody to create anti-CD47-pTLR7 conjugates for testing our vaccination.

Methods
Efficacy studies were conducted in poorly immunogenic orthotopic murine tumor models of EMT6 breast cancer and B16F10 melanoma. Biodistribution and intratumoral retention studies were conducted using an in vivo imaging system (IVIS). Intratumoral T cell and antigen presenting cell numbers, frequencies, and activation phenotype were assessed via flow cytometry.

Results
Tumor retention studies tracking fluorescently labeled pTLR7-tAbs showed pTLR7-tAbs are retained within the tumor microenvironment (TME) 3-fold longer than isotype control antibody-pTLR7 constructs. Interestingly, following vaccination, pTLR7-tAb treated tumors showed increased numbers and activation of intratumoral antigen presenting cells (APCs). Assessment of tumor infiltrating lymphocytes (TIL) showed pTLR7-tAb vaccination stimulated tumor antigen TRP2-specific T cell responses in the B16F10 melanoma model and converted these immunologically ‘cold’ tumors into T cell inflamed tumors, with increased numbers of CD4+ and CD8+ T cells. Strikingly, we observed complete remission (CR) in 50% of ‘cold’ immune-excluded EMT6 breast cancer tumors and delayed tumor progression of B16F10 melanoma after treatment with pTLR7-tAbs (p

Conclusions
Together, these data support the use of our pTLR7-tAb platform for in situ vaccination and as a therapeutic tool for enhancing anticancer immunity.

References

P675
Multimodal intratumoral immunotherapy potentiates complete immunologic tumor elimination of breast cancer origin diffuse liver metastases
Erik Soule 1, Jason Williams, MD 1, Jason Williams, MD 2
1 University of Florida College of Medicine, Gainesville, FL, United States; 2 Williams Cancer Institute, Foley, AL, United States
Correspondence: Jason Williams (dwilliams@cancerimmunoelo.com)

Background
Depending on the origin of the primary lesion, patients with distant metastases of aggressive solid tumors have traditionally been deemed incurable. A complete abscopal effect, or cure, is a rare exception rather than the rule. This is secondary to cancer stem cells providing resilience to treatment and propensity to recur after remission [1]. Harnessing the potential of the immune system to recognize and destroy malignant cells harboring tumor antigens may allow stage 4 cancer to be completely eliminated from the body [2, 3]. This report describes a case of diffuse liver metastases from advanced breast cancer; eliminated immunologically by intratumoral injection of immunostimulatory pharmacotherapy. α-OX40 refers to a stimulatory monoclonal antibody with a dual mechanism of action on T cells designed to potentiating long-term immunity. Activating the OX40 protein triggers a sustained immune response in effector T cells while also potentiating the demise of regulatory T cells. Intratumoral α-OX40 was shown to work synergistically with intratumoral CpG, a toll-like receptor 9 agonist, in a mouse model of breast cancer [4]. To our knowledge, this is the first report of an α-OX40 antibody administered intratumorally, in vivo, in a human patient.

Methods
Two liver metastases were treated with combination immunotherapy suspended in montanide, an oil adjuvant. A combination of α-OX40, CpG, ipilimumab, and ketorolac was injected into two accessible, dominant, hepatic lesions under computed tomography guidance with general anesthesia. A CT scan was performed 6 weeks post-procedure, and a PET/CT was performed 12 weeks post-procedure. Tumor markers CA125, CA27.29, and CA15.3 were monitored weekly for 12 weeks post treatment.

Results
No suspicious uptake was noted anywhere in the body on the 12-week post-procedure PET/CT. Complete abrogation of all diffuse liver metastases was documented at that time. At 12 weeks post treatment tumor markers CA125 decreased by 98% to 35 from a baseline of 1767, CA27.29 decreased 93% to 11.2 from a baseline of 1511, and CA15.3 decreased 93% to 56 from a baseline of 821.

Conclusions
Intratumoral injection allows a much higher proportion of immunotherapy to directly interact with the tumor microenvironment compared to intravenous injection. With intratumoral dosing of multimodal immunotherapy in an order of magnitude less than intravenous dosing, a patient with stage 4 breast cancer was able to achieve complete immunologic tumor elimination at 12 weeks
follow-up. This durable abscopal effect remains complete 20 weeks post-treatment.

References

Consent
Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

P676
Intratumoral delivery of TransCon™ TLR7/8 Agonist provides potent anti-tumor activity as a monotherapy and in combination with IL-2 while minimizing systemic cytokine induction
Luís Zuniga, PhD1, Torben Leßmann2, Lars Holten-Andersen3, Nicola Bisek4, Joachim Zettler5, Sebastian Stark6, Frank Faltinger6, Oliver Kracker7, Samuel Weisbrod7, Robin Müller8, Tobias Voigt9, Kornelia Bigott4, Mohammad Tabrizifard10, Vibeke Breinholt11, Kenneth Sprogøe4, Juha Punnonen1
1Ascendis Pharma, Inc., Palo Alto, CA, United States; 2Ascendis Pharma GmbH, Heidelberg, Germany; 3Ascendis Pharma A/S, Copenhagen, Denmark
Correspondence: Juha Punnonen (jp@ascendispharma.com)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P676

Background
Local delivery of pattern recognition receptor agonists (PRRAs) to the tumor microenvironment (TME) stimulates innate immune sensors such as toll-like receptors (TLR) and can enhance antigen uptake and presentation, induce proinflammatory immune cell recruitment, and reverse tumor-associated immunosuppression (1, 2). Local delivery of PRRAs, such as STING or TLR agonists, has shown encouraging preclinical and clinical anti-tumor benefit (3-5). However, current approaches to deliver PRRAs to the TME suffer from the lack of local retention in the TME and rapid drug clearance, thus limiting anti-tumor benefit, promoting systemic treatment-related adverse events (e.g. cytokine storm), and necessitating frequent and often impractical dosing regimens. Additionally, systemic toxicity associated with current PRRA treatments may limit combination therapies (2, 6).

Methods
Given the need for safe and effective intratumoral therapies, we developed a sustained-release TransCon™ (refers to “transient conjugation”) TLR7/8 Agonist prodrg by conjugating resiquimod to a hydrogel via a TransCon linker to provide consistent intratumoral release of unmodified resiquimod.

Results
In vivo pharmacokinetics in rodents, following local injection of TransCon TLR7/8 Agonist, showed long-term resiquimod release over several weeks with minimal systemic exposure compared to an equivalent dose of unconjugated resiquimod. Intratumoral injection of TransCon TLR7/8 Agonist also demonstrated prolonged release. Furthermore, in a syngeneic tumor model, a single intratumoral injection of TransCon TLR7/8 Agonist mediated significant tumor growth inhibition and was associated with significantly lower systemic pro-inflammatory cytokine induction when compared to an equivalent dose of unconjugated resiquimod. Intratumoral delivery of TransCon TLR7/8 Agonist was well tolerated and mediated tumor growth inhibition in a dose-dependent fashion. Finally, in a bilateral syngeneic tumor model, TransCon™ TLR7/8 Agonist mediated significant tumor growth inhibition in both injected and non-injected tumors as a monotherapy and when combined with systemic IL-2 treatment.

Conclusions
These data provide strong evidence that a single dose of TransCon TLR7/8 Agonist can mediate long term local release of unmodified resiquimod with minimal systemic exposure and systemic pro-inflammatory induction compared to an equivalent dose of unconjugated resiquimod. Moreover, TransConTLR7/8 has potent anti-tumor effects as a monotherapy and in combination with cytokine therapy, suggesting further evaluation as a monotherapeutic and in combination with other immunotherapies is warranted. TransCon TLR7/8 Agonist represents a potentially novel PRRA therapy class that may overcome the shortcomings of existing PRRA treatments by providing a potent anti-tumoral response and reducing adverse events related to systemic drug exposure.

References

P677
Warehouse approach for the development of personalized cancer vaccines by using Personal Antigen Selection Calculator (PASCal) without need for tumor biopsy
Zsolt Csizsovszki, PhD1, Levente Molnár1, Péter Páles1, József Tóth1, Orsolya Lőrincz2, Katalin Pántya2, Eszter Somogyi2, István Miklós2, Wolfgang Schönharting2, Sybille Urban3, Tim Röhnisch4, Mónika Megyesi1, Enikő Tőke1
1Treos Bio Zrt., Budapest, Hungary; 2Treos Bio Zrt. and MTA Rényi Institute, Veszprém, Hungary; 3PMCR GmbH, Karlsruhe, Germany; 4Interdisciplinary Oncology Center, Munich, Germany
Correspondence: Enikő Tőke (eniko.toke@treosbio.com)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P677

Background
Analysis of current data with cancer vaccines suggests that the lack of efficacy is likely due to their two primary design challenges: 1. Vaccines have little chance of destroying heterogeneous tumor cells since they rarely induce polyclonal T-cell responses; 2. Even when polyclonal T-cell responses have been successfully induced, they are often directed against tumors where the target is absent (not expressed). Recent mutated neoantigen-based vaccines (MNeoV) aim to solve this latter issue, however only about 10-20% of selected epitopes proved to induce CD8+ T-cell responses in patients. In addition, development of MNeoV for commercial use is challenging. To overcome these limitations, we developed PASCal for improved selection of peptides (epitopes) that induce T-cell responses targeted against heterogeneous tumor cells.

Methods
PASCal operates by 3 modules: (1) validated epitope database containing 108 true HLA-epitope pairs (2) Expression frequency-based shared tumor antigen database established for 19 indications based on >96,000 tumor biopsies. (3) Validated algorithm for the identification of immunogenic peptides by the selection of personal epitopes (PEPs) binding to multiple autologous HLA alleles.[1,2] Using PASCal, a library of 3,286 immunogenic 20mer peptides derived from 184
antigens associated with 19 cancer indications -based on 16,000 subjects’ HLA genotype (both class I&II alleles) was compiled. Personal vaccines were selected and tested for 3 HLA-genotyped metastatic cancer patients (with ovarian-, breast- and colorectal cancer). Immunogeneity of the vaccines was tested by IFN-γ ELISPOT. Signed informed consent were obtained from each patient, including allowance of publication.

Results

Personal cancer vaccines were selected to fulfill the following criteria: 12 immunogenic peptides derived from 12 different tumor-specific antigens frequently expressed in the patient’s disease type, with the expected number of expressed antigens on the patient’s tumor cells of at least 3 (by statistical estimation). CD8+ T-cell responses were induced by 97%, CD4+ T-cell responses by 85% of peptides, confirming aimed polyclonal T-cell responses. Long-lasting CD8+ T-cell responses were detected ex vivo 4.5 months, in vitro 14 months after last vaccination. Pre-existing T-cell reactivities were detected against at least 25% of vaccine antigens demonstrating their presence in the patient’s immune system. While considered as the optimal strategy for targeting neoantigens is ATLAS screening using autologous cells. These studies demonstrated that ATLAS screening can identify true neoantigens has been elusive due to poor predictive value of in silico selection. ATLAS™ is a T cell response profiling platform that does not use predictive methods, but instead employs high-throughput ex vivo screening of putative neoantigens using autologous antigen presenting cells and T cells. Antigens are characterized as stimulatory or inhibitory by significant up- or downregulation of stimulatory or inhibitory neoantigens, the majority of which were not predicted by peptide binding affinity. Strikingly, when an adjuvanted antigen cocktail containing a top stimulatory neoantigen was therapeutically administered as monotherapy into tumor-bearing mice, tumor outgrowth was either significantly delayed or completely abrogated in all mice (n=12). Conversely, therapeutic immunization with adjuvanted inhibitory neoantigen peptides resulted in no benefit and in some cases led to a significant increase in tumor growth kinetics representative of tumor hyperprogression. Stimulatory antigen vaccination induced significant antigen-specific inflammatory T cell responses, whereas T cell responses to inhibitory antigens were variably reduced by 97%, CD4+ T-cell responses by 85% of peptides, confirming the success of vaccine design strategy aiming to induce polyclonal T-cell responses against at least 3 antigens expressed by the tumor.

Conclusions

PEPs outperform traditional screening by ATLAS, which identifies stimulatory but also inhibitory potential neoantigens. This study suggests that a PEP approach to neoantigen selection can lead to better T cell responses in patients participating in clinical trials. In a recent interim analysis, 91% of vaccine neoantigens selected as stimulatory by ATLAS, elicited T cell responses in patients participating in the GEN-009 Phase 1/2 clinical trial of a personalized cancer vaccine (NCT03633110). Animals were housed within a USDA registered, AAALAC accredited and OLAW assured (#A4591-01) animal facility in accordance with the Institutional Animal Care and Use Committee (IACUC).

References

Ethics Approval
This study was performed in accordance to the Declaration of Helsinki (amendment 37). Signed informed consent were obtained from each patient, including allowance of publication.
Consent
Signed informed consent were obtained from each patient, including allowance of publication.

P678

Vaccine neoantigens empirically identified through the ex vivo ATLAS platform promote potent therapeutic responses to cancer in mice

Victoria Devault, PhD, Hanna Starobinets, PhD, Samnit Adhikari, Brendan Classon, PhD, Jessica Flechtner, PhD, Hubert Lam, PhD
Genocea Biosciences, Cambridge, MA, United States

Correspondence: Jessica Flechtner (jessica.flechtner@genocea.com) Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P678

Background

Neoantigens are mutated tumor antigens that make attractive targets for immunotherapy as they are recognized as foreign by the immune system. While considered as the optimal strategy for targeting immune tumor killing while minimizing risks of autoimmunity, identification of true neoantigens has been elusive due to poor predictive value of in silico selection. ATLAS™ is a T cell response profiling platform that does not use predictive methods, but instead employs high-throughput ex vivo screening of putative neoantigens using autologous antigen presenting cells and T cells. Antigens are characterized as stimulatory or inhibitory by significant up- or downregulation of inflammatory T cell cytokine secretion relative to controls. Neoantigen identification using an autologous cell assay allows differentiation of desired as well as potentially unwanted antigen-specific T cell responses that are biologically-relevant to the patient.

Methods

ATLAS screening of the B16F10 melanoma mutanome was performed, consisting of whole exome sequencing, non-synonymous mutation library construction, and screening of splenic CD8+ T cells from tumor-bearing C57BL/6 mice. Stimulatory or inhibitory neoantigens that modulated secretion of IFNγ and/or TNFα were identified and corresponding synthetic long peptides were evaluated in a therapeutic B16F10 tumor challenge model. Vaccine immune responses were measured by ELISPOT, flow cytometry and immunohistochemistry, and animals were monitored for tumor growth and survival.

Results

ATLAS screening of B16F10 melanoma identified 66 stimulatory and 57 inhibitory neoantigens, the majority of which were not predicted by peptide binding affinity. Strikingly, when an adjuvanted antigen cocktail containing a top stimulatory neoantigen was therapeutically administered as monotherapy into tumor-bearing mice, tumor outgrowth was either significantly delayed or completely abrogated in all mice (n=12). Conversely, therapeutic immunization with adjuvanted inhibitory neoantigen peptides resulted in no benefit and in some cases led to a significant increase in tumor growth kinetics representative of tumor hyperprogression. Stimulatory antigen vaccination induced significant antigen-specific inflammatory T cell responses, whereas T cell responses to inhibitory antigens were variably reduced by 97%, CD4+ T-cell responses by 85% of peptides, confirming the success of vaccine design strategy aiming to induce polyclonal T-cell responses against at least 3 antigens expressed by the tumor.

Conclusions

Currently, the only method to reliably and comprehensively identify neoantigen targets and rationali ommit potentially deleterious antigens is ATLAS screening using autologous cells. These studies demonstrated that ATLAS screening can identify true neoantigens has been elusive due to poor predictive value of in silico selection and establish a model for further mechanistic study. In a recent interim analysis, 91% of vaccine neoantigens selected as stimulatory by ATLAS, elicited T cell responses in patients participating in the GEN-009 Phase 1/2 clinical trial of a personalized cancer vaccine (NCT03633110). Animals were housed within a USDA registered, AAALAC accredited and OLAW assured (#A4591-01) animal facility in accordance with the Institutional Animal Care and Use Committee (IACUC).

P679

Scheduling androgen deprivation with AR-targeted vaccination affects anti-tumor efficacy in prostate cancer

Melissa Garnat-Huber, PhD, Douglas McNeel, MD, PhD
University of Wisconsin Madison, Madison, WI, United States

Correspondence: Douglas McNeel (dm3@medicine.wisc.edu) Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P679

Background

Androgen deprivation therapy is the primary treatment for recurrent and metastatic prostate cancer. Androgen deprivation can also modulate the immune system and cause effects such as T cell infiltration into the prostate, affect antigen processing and/or presentation and possibly affect T cell homeostasis. In previous studies, we have shown that immunizing tumor-bearing mice using a DNA vaccine against the androgen receptor significantly slowed down tumor growth compared to control. Furthermore, combining androgen deprivation with vaccination against the AR further augments the anti-tumor response compared to the AR vaccination alone. In this study, we hypothesized that the timing of DNA vaccination with respect to androgen deprivation treatment, may impact the efficacy of the anti-tumor effect.

Methods

We implanted the androgen-responsive mouse prostate tumor line MycCaP into 6 week old male FVB mice. The tumors were allowed to grow for up to 32 days, then mice were treated with androgen deprivation therapy (degarelix). Vaccines consisted of either the AR ligand binding domain within the pTVG4 backbone (pTVG-AR), or the pTVG4 backbone alone (control). Immunizations were either started one week after tumor implantation (Vx→ADT), or one day following androgen deprivation (ADT→Vx). Mice treated with AR vaccine before androgen deprivation (AR→ADT) had slower tumor growth compared to the control plasmid (pTVG4 →ADT) but not when vaccinated after ADT (ADT→Vx).

References
1. Classon, PhD, Jessica Flechtner, PhD, Hubert Lam, PhD
Genocea Biosciences, Cambridge, MA, United States

Correspondence: Jessica Flechtner (jessica.flechtner@genocea.com) Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P678

Background

Neoantigens are mutated tumor antigens that make attractive targets for immunotherapy as they are recognized as foreign by the immune system. While considered as the optimal strategy for targeting immune tumor killing while minimizing risks of autoimmunity, identification of true neoantigens has been elusive due to poor predictive value of in silico selection. ATLAS™ is a T cell response profiling platform that does not use predictive methods, but instead employs high-throughput ex vivo screening of putative neoantigens using autologous antigen presenting cells and T cells. Antigens are characterized as stimulatory or inhibitory by significant up- or downregulation of inflammatory T cell cytokine secretion relative to controls. Neoantigen identification using an autologous cell assay allows differentiation of desired as well as potentially unwanted antigen-specific T cell responses that are biologically-relevant to the patient.

Methods

ATLAS screening of the B16F10 melanoma mutanome was performed, consisting of whole exome sequencing, non-synonymous mutation library construction, and screening of splenic CD8+ T cells from tumor-bearing C57BL/6 mice. Stimulatory or inhibitory neoantigens that modulated secretion of IFNγ and/or TNFα were identified and corresponding synthetic long peptides were evaluated in a therapeutic B16F10 tumor challenge model. Vaccine immune responses were measured by ELISPOT, flow cytometry and immunohistochemistry, and animals were monitored for tumor growth and survival.

Results

ATLAS screening of B16F10 melanoma identified 66 stimulatory and 57 inhibitory neoantigens, the majority of which were not predicted by peptide binding affinity. Strikingly, when an adjuvanted antigen cocktail containing a top stimulatory neoantigen was therapeutically administered as monotherapy into tumor-bearing mice, tumor outgrowth was either significantly delayed or completely abrogated in all mice (n=12). Conversely, therapeutic immunization with adjuvanted inhibitory neoantigen peptides resulted in no benefit and in some cases led to a significant increase in tumor growth kinetics representative of tumor hyperprogression. Stimulatory antigen vaccination induced significant antigen-specific inflammatory T cell responses, whereas T cell responses to inhibitory antigens were variably reduced by 97%, CD4+ T-cell responses by 85% of peptides, confirming the success of vaccine design strategy aiming to induce polyclonal T-cell responses against at least 3 antigens expressed by the tumor.

Conclusions

Currently, the only method to reliably and comprehensively identify neoantigen targets and rationally omit potentially deleterious antigens is ATLAS screening using autologous cells. These studies demonstrated that ATLAS screening can identify true neoantigens has been elusive due to poor predictive value of in silico selection and establish a model for further mechanistic study. In a recent interim analysis, 91% of vaccine neoantigens selected as stimulatory by ATLAS, elicited T cell responses in patients participating in the GEN-009 Phase 1/2 clinical trial of a personalized cancer vaccine (NCT03633110). Animals were housed within a USDA registered, AAALAC accredited and OLAW assured (#A4591-01) animal facility in accordance with the Institutional Animal Care and Use Committee (IACUC).
Furthermore, when immunizations were given before androgen deprivation and continued after androgen deprivation, the emergence of castration resistance was further delayed.

Conclusions
These results have implications on the scheduling of androgen deprivation with immunotherapy for the treatment of prostate cancer, and correspond to similar results observed in human clinical trials with anti-tumor vaccines.

P680
Discovery of immunogenic ERV-derived antigens as targets for melanoma immunotherapy
Ray Jupp, PhD1, George Kassiotis2, Nicola Ternette3, George Young1, Duncan Howie1, Fabio Marino1, Matthew Davies1, Hayden Selvadurai1, Alvaro Sanchez1, Jonathan Dodd1, Laura Lozza1, Elizabeth Soilleux3, Peter Mason1, Kevin Pojasek1
1Evaax Ltd, Oxford, United Kingdom; 2The Francis Crick Institute, London, United Kingdom; 3University of Oxford, Oxford, United Kingdom; 4University of Cambridge, Cambridge, United Kingdom; 5Evaax, Inc, Somerville, MA, United States
Correspondence: Kevin Pojasek (kpojasek@svhealthinvestors.com)

Background
Recent advances in immunotherapy have confirmed that adaptive immune responses can recognize and eliminate cancer cells. Past approaches using tumor-associated antigens have elicited poor immune responses and the cancer vaccine field has shifted to single nucleotide variant-derived neoantigens to avoid T-cell depletion by central tolerance. These highly personalized vaccines are beginning to show promise. We hypothesized that highly immunogenic target antigens exist within the cancer genome and become aberrantly expressed due to the epigenetic changes that accompany neoplasia. We utilized markers of endogenous retroviruses (ERVs), which are particularly abundant in repressed regions of DNA, to search for novel, high-value melanoma antigens, to circumvent the need for personalization.

Methods
We created a de novo pan-cancer transcriptome assembly with RNA-seq reads from 31 cancer types obtained from TCGA. Transcript sequences were subsequently filtered to identify those containing ERV elements. Next, they were subject to differential expression analysis selecting those expressed in the melanoma patients compared to normal tissues (utilizing GTEx data). To discover bona fide antigens encoded by our melanoma-specific transcripts, we interrogated the ORFs from these transcripts using public and independently-generated mass spectrometry-based immunopeptidomics data from melanoma samples. HLA-bound peptides from these analyses matching the known proteome were removed, and those peptides solely mapping to our predicted ORF sequences were used to identify novel transcript-derived antigens specifically expressed and presented in primary melanoma tissue. Confirmation of tumor cell-specific expression of antigen-encoding transcripts was carried out using RNASeqAtlas. The ability of detected epitopes from our discovered antigens to elicit an adaptive immune response was assessed by characterization of antigen-specific T-cell responses from naive donors.

Results
Our de novo assembly revealed the presence of approximately 100 melanoma-specific transcripts encoding over 2,000 potential antigens (ORFs). Interrogation of these ORFs against M5 immunopeptidomic datasets mapped HLA-bound peptides to dozens of ORFs, demonstrating identification of our novel antigens in multiple melanoma patient tissues. RNASeqAtlas revealed melanoma-specificity at the transcript level, with little to no transcript expression identified across normal tissues. Assessment of immunogenicity in naive subject T cells revealed strongly reactive T cells that were able to kill peptide-pulsed APCs, indicating a lack of central-tolerance deletion of T cells specific for these ERV-derived peptides.

Conclusions
We have identified a number of novel melanoma-specific antigens that are shared among patients. T cells reactive for these antigens can be detected in naive subjects, and thus these antigens show promise as candidates for development of off-the-shelf cancer vaccine-based immunotherapies.

Acknowledgements
The results presented here are based in part upon data generated by The Cancer Genome Atlas (TCGA) Research Network (http://cancergenome.nih.gov/), and the Genotype-Tissue Expression (GTEx) Project (supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NC, NHGRI, NHLBI, NID, NIMH, and NINDS). Primary patient material utilized in this study was provided by the Cambridge University Hospitals NHS Trust Human Research Tissue Bank.

Ethics Approval
All work involving the use of human tissue was approved by the NHS Health Research Authority South Central - Oxford A Research Ethics Committee (reference number 04/Q1604/21), and North West - Haydock Research Ethics Committee (reference number 19/NW/0216).

P681
DNA methyltransferase inhibition immunosensitizes diffuse intrinsic pontine gliomas to peptide vaccine through augmentation of EphA2 and MHC I expression
Rajeev Kumar1, Lauren McCarl1, Alexandra Foster1, Shubhanchi Nigam1, Xinjuan Ma1, Marissa Campagna1, Alberto Bronciser1, Katherine Warren1, Ian Pollack1, Gary Kohanbash1
1University of Pittsburgh, Pittsburgh, PA, United States; 2National Cancer Institute, Bethesda, MD, United States
Correspondence: Gary Kohanbash (gary.kohanbash2@chp.edu)

Background
Diffuse intrinsic pontine glioma (DIPG) is one of the most lethal pediatric brain tumors. DIPG is insensitive to chemotherapy and surgically inaccessible, creating an urgent need for novel therapeutic approaches. We have been evaluating peptide vaccine immunotherapies that target glioma-associated antigens (GAAs). Enhancing the expression of these immunogenic GAAs and MHC I on tumor cells may promote immune-mediated tumor recognition and killing following peptide vaccine immunotherapy. DNA methyltransferase (DNMT) inhibitors have been shown to augment the expression of MHC, tumor antigens, and other immunosensitizing molecules. Guadecitabine (SGI-110), a next-generation DNMT inhibitor, has been developed to prolong tumor cell exposure to its active metabolite, decitabine. In this study, we investigated whether SGI-110 can immunosensitize glioma cells to peptide vaccine immunotherapy by enhancing their surface expression of MHC I and a GAA, EphA2. [1-5]

Methods
We developed a novel C57BL/6-syngeneic DIPG model by culturing cells from a Sleeping Beauty de novo DIPG induced in a neonatal mouse using a K27M-mutated histone 3.3 plasmid and other onco-genic plasmids. Murine SB-DIPG-11 and human DIPG cell lines were treated with SGI-110 for 5 days. For vaccination, mice were intradermally injected with 100μg each of HBV core128-140 (MHC-II, lab restricted) and the GAA peptides hgp10025-33, mEphA2671-679, and mEphA2682-689, emulsified in 40μg of poly(I:C) and IFA. Control mice received HBV core128-140, also emulsified in poly(I:C) and IFA. Five days after tumor injection, mice received 2.0 mg/kg/day of SGI-110 for 6 days.
Results
Flow cytometry analysis showed that SB-DIPG-11 cells express both MHC I (H-2Kb/H-2Db) and EphA2 on their surface. In vitro, treatment of SB-DIPG-11 or C57BL/6-syngeneic GL261 cells with SGI-110 resulted in a dose-dependent increase of MHC I and EphA2 surface expression. In vivo, subcutaneous administration of SGI-110 in combination with an EphA2-targeted peptide vaccine significantly prolonged the survival of mice bearing orthotopic DIPG-like tumors compared with the control treatment. Stable EphA2 knockdown reverted the survival benefit of SGI-110 in combination with peptide vaccine. Analysis of dissociated tumor tissue by flow cytometry showed elevated levels of MHC I and EphA2 in mice receiving SGI-110 or SGI-110 and peptide vaccine.

Conclusions
Compared to control, combination therapy proved the most effective, significantly prolonging the survival of tumor-bearing mice. Based on these data, we have begun evaluating whether subcutaneous or intracerebroventricular administration of the SGI-110 is more effective in combination with peptide vaccine. Overall, SGI-110 may sensitize children with DIPG to peptide vaccine immunotherapy.

Acknowledgements
his research was supported by funding from the Pediatric Brain Tumor Foundation’s Project ‘All In’ for DIPG, St. Baldrick’s Foundation, the National Cancer Institute, the National Institute for Biomedical Imaging and Bioengineering, the Pittsburgh Foundation’s Copeland Fund, and UPMC Children’s Hospital of Pittsburgh’s Scientific Program.

References

P682
AI-augmented design of effective therapeutic cancer vaccines and adoptive cell therapies
Piotr Stepniak , Giovanni Mazzocco, MSc, Alexander Myronov, MSc, Iga Niemiec, MSc, Katarzyna Gruba, MSc, Piotr Skoczylas, MSc, Anna Saneczko-Duin, PhD, Michal Drwal, MSc, Jan Kaczmarczyk, PhD, Ardigen S.A., Krakow, Poland

Correspondence: Piotr Stepniak (piotr.stepniak@ardigen.com)
Journal for ImmunoTherapy of Cancer 2019; 7(Suppl 1):P682

Background
The strong involvement of neoantigens-driven CD8+ T-cells is considered a substantial element of immune-mediated tumor rejection. Neoantigens are, in fact, not subject to central immune tolerance and may constitute ideal agents for eliciting tumor-specific immune responses. For these reasons, neoantigens are rapidly gaining interest [1] as central components of personalized cancer vaccines (PCVs), as shown by the number of PCV clinical trials. One of the challenges in the design of PCVs is that only a small fraction of potential neoantigens arising from somatic mutations are immunogenic [2]. Several aspects including highly individual antigenic landscape, restricted number of targetable neoantigens per tumor, complex tumor subclonal structure, private neoantigen-specific T-cell repertoire, presence of inhibitory neoantigens, immune-escape mechanisms, etc. make the prediction of effective neoantigens a particularly challenging task.

Methods
For each of the vaccine design tools, we assess the enrichment of immunogenic neoepitopes within the suggested vaccine compositions (e.g., top 20 peptides) using early-enrichment metrics [4]. We analyze the results in an indication-specific fashion in order to assess whether there are significant differences among cancer types. Finally, for each vaccine design method, we assess additional important properties of the resulting target neoepitopes, such as toxicity, tolerance, and peptides’ manufacturability.

Acknowledgements
This research was supported by funding from the Pediatric Brain Tumor Foundation’s Project ‘All In’ for DIPG, St. Baldrick’s Foundation, the National Cancer Institute, the National Institute for Biomedical Imaging and Bioengineering, the Pittsburgh Foundation’s Copeland Fund, and UPMC Children’s Hospital of Pittsburgh’s Scientific Program.

References

P683
Incomplete Freund’s adjuvant reduces arginase, enhances a Th1 dominant cytokine environment, and supports CD40 L expression
Karyn Pollack, MD, Max Meneveau, MD, Alexander Koeppel, Samuel Young, Stephen Turner, Katia Sol-Church, MD, Ileana Mauldin, PhD, Craig Slingluff, MD
University of Virginia, Charlottesville, VA, United States

Correspondence: Craig Slingluff (C.Slingluff@hscmail.mcc.virginia.edu)

Background
Immunogenicity of cancer vaccines is impacted by adjuvants and schedule, but systematic assessments of their effects have not been
performed. Montanide ISA-51, an incomplete Freund's adjuvant (IFA), is used in many vaccine trials, but concerns have been raised about negative effects in murine studies [1, 2]. However, we found in humans that IFA enhances systemic immune responses over a toll-like receptor (TLR) agonist alone [3] and that repeat vaccination at one site (same site vaccination, SSV) creates tertiary lymphoid structures (TLS) in the vaccine site microenvironment (VSME) [4]. We hypothesized that one vaccine with peptides +IFA +pICLC or SSV x 3 with peptides in IFA will create an immunogenic milieu locally at the VSME, with activated and mature dendritic cells (DC), TLS-associated chemokines, and a Th1-dominant VSME.

Methods
Biopsies of the VSME were obtained from participants on two clinical trials (MEL48, NCT00705640; MELS8, NCT01585350) who were immunized with multiple melanoma peptides (MELITAC 12.1) in adjuvants comprised of IFA and/or the toll-like receptor (TLR)3-agonist pICLC. Biopsies were obtained either a week after one vaccine or a week after SSV x 3. Controls included normal skin and skin injected with IFA without peptides. Gene expression analysis was performed by RNAseq. Multiparameter immunofluorescence histology (mIF) was performed for selected markers.

Results
VSME samples were evaluated from 27 patients. One vaccine with peptides in pICLC + IFA enhanced expression of CD80, CD83, CD86 (p<0.01), CD40 and CD40L (p<0.0001) over normal skin; these effects were significantly enhanced for SSV with peptides + IFA (Figure 1). CD40L protein expression by CD4 T cells was confirmed by mIF (Figure 2). Vaccines containing pICLC increased expression of TBX21 (T-bet) but did not decrease GATA3 over normal skin, whereas SSV with peptides in IFA dramatically enhanced TBX21 and decreased GATA3, with high expression of IFNγ and STAT1 (Figure 3). SSV with peptides in IFA also dramatically enhanced expression of TLR adapter molecules TICAM-1 (TRIF) and MYD88 (Figure 4). Furthermore, SSV with IFA and peptides also enhanced expression of chemokines associated with TLS formation (not shown).

Conclusions
These findings suggest that SSV with peptides in IFA enhances CD40L expression by CD4 T cells, supports a Th1 microenvironment, with accumulation of activated and mature DC. Increased expression of TLR adapter proteins after SSV with peptides in IFA might implicate effects of the skin microbiome. Reduced ARG1 may reflect diminished suppressive myeloid activity in the VSME.

Trial Registration
Samples from two clinical trials were used, including MEL48, NCT00705640; MELS8, NCT01585350.

References

Ethics Approval
Patients were studied following informed consent, and with Institutional Board Review (IRB) (HSR-RB 13498 and 15781, respectively) and FDA approval.

Consent
Written informed consent was obtained from patients for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Highly efficient selection of tumor neoantigens improves therapeutic cancer vaccine efficacy
Guilhem Richard, PhD1, Gad Berdugo, MSc, MBA1, Michael Princiotta, MS, PhD1, Leonard Moise, PhD2, Matthew Ardito, BA2, Christine Boyle2, Dominique Bridon1, William Martin, BA MD2, Anne de Groot, MD2
1EpiVax Oncology, Providence, RI, United States; 2EpiVax, Inc., Providence, RI
Correspondence: Gad Berdugo (gberdugo@epivaxonco.com)

Background
Recent advances in whole exome sequencing have produced a renewed interest in therapeutic cancer vaccines targeting tumor-specific neoantigens. A central challenge to the development of successful therapeutic cancer vaccines is the identification of neoantigen sequences that elicit effector T cell responses able to control tumor growth while avoiding the induction of inhibitory immune pathways. In the study reported here, we present data highlighting the efficiency of neoantigen selection using the innovative Ancer™ screening platform and demonstrate antigen-specific responses and tumor control in a mouse tumor model.

Methods
The CT26 mutanome was evaluated with Ancer™, an innovative and automated neoantigen prediction platform that combines proprietary machine learning-based MHC class I and MHC class II neo-epitope identification tools with removal of inhibitory regulatory T cell (Treg) epitopes for optimal personalized cancer vaccine design. MHC class I- and MHC class II-restricted CT26 neoantigens, devoid of putative Treg epitopes, were ranked according to their immunogenic potential and tumor expression level. The immunogenicity and efficacy of the 20 highest Ancer-ranked neoantigens, delivered subcutaneously as a peptide pool with poly-ICLC (Oncovir) as adjuvant was evaluated in naïve and CT26 tumor-bearing BALB/c mice.

Results
T cell responses to individual peptide neoantigens were determined using ELISpot assay for IFNγ production. While around 20% of neoantigen sequences identified in studies using commonly available predictive algorithms are immunogenic, we found that up to 65% (13 out of 20) of the computationally predicted peptide sequences included in the CT26-Ancer™ vaccine were immunogenic (Figure 1). Responding T cells were both CD8+ and CD4+ and were shown to be multi-functional by flow cytometric analysis for IFNγ, TNFα and IL-2 production.

Tumor control was demonstrated by immunizing BALB/c mice implanted with syngeneic CT26 tumor cells with the CT26-Ancer™ vaccine. Average tumor volumes in CT26-Ancer™ immunized mice were significantly reduced by 45% (unpaired t test, p = 0.0156) and 38% (unpaired t test, p = 0.0291) at days 21 and 25 post implantation, respectively, compared to vehicle (poly-ICLC) immunized tumor-bearing animals (Figure 2).

Conclusions
The results presented here highlight the efficiency of the Ancer™ platform in selecting highly immunogenic neoantigen targets and that these responses are able to control tumor growth in a peptide formulation. Using advanced in silico methods to select antigenic targets for use in therapeutic cancer vaccines promises to improve the efficacy of tumor immunotherapy. While confined to mice, these studies further validate our personalized cancer vaccine process for future human clinical studies.

Fig. 1 (abstract P684). See text for description

Fig. 4 (abstract P684). See text for description
somatic mutations that are transcriptionally re-activated by EZH2, we observed a cluster of genes with transactivator CIITA and MHC class II genes. Moreover, by employing computational prediction tools, we selected genes harboring mutations with potential to serve as neoantigens.

In this study, we have identified a common mechanism of EZH2-mediated epigenetic suppression of genes involved in tumor immune pathways. Emerging studies have provided evidence for an additional role of EZH2 dysregulation in the landscape associated with the silencing of gene transcription. In cancer, dysregulation of EZH2 results in the redistribution of H3K27me3 to inactive regions of the genome.

Conclusion
Our data illustrate the potential for targeting EZH2 to increase the immunogenicity of tumors through relieving epigenetic suppression of tumor antigen presentation machinery and silenced neoantigens. As EZH2 inhibitors are currently under clinical investigation, targeting EZH2 represents a promising combination approach with checkpoint inhibitors to elicit responses in poorly immunogenic tumors.

References

P685
Inhibition of EZH2 enhances tumor immunogenicity through diversification of tumor antigen presentation
Jing Qiu, PhD, , Thomas Paul Pfizer, San Diego, CA, United States
Correspondence: Thomas Paul (Thomas.A.Paul@pfizer.com) Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P685

Background
A central challenge to elicit effective anti-tumor T cell responses remains limited expression of productive tumor antigens or antigen presentation machinery. During immune editing, cancers utilize epigenetic silencing of cancer neo-antigens as well as components of the antigen presentation machinery to escape immunosurveillance[1]. As a result, therapeutic approaches that have the potential to reactivate epigenetically silenced genes that enhance tumor immunogenicity are attractive drug combinations with checkpoint blockade[2].

EZH2 is an epigenetic modifier responsible for H3K27 histone methylation associated with the silencing of gene transcription. In cancer, dysregulation of EZH2 results in the redistribution of H3K27me3 to the promoters of genes involved in the regulation of cell cycle, cell survival, and cellular differentiation. Emerging studies have provided evidence for an additional role of EZH2 dysregulation in the transcriptional repression of genes involved in tumor immune pathways.

Methods
ChIP-seq, RNA-seq, and exome-seq was conducted on murine tumor cell lines treated with the EZH2 inhibitor PF-06821497. Peptides with mutations that are upregulated by EZH2 inhibitor treatment were computationally selected based on their predicted binding affinity to the corresponding MHC class I and class II expressed in each cell line. Presentation of peptide candidates were further validated by immunopeptidomics. Predicted peptides were synthesized and tested in pools for their ability to elicit antigen-specific T cell responses.

Results
In this study, we have identified a common mechanism of EZH2-mediated epigenetic suppression of genes involved in tumor immune recognition. Using epigenomic profiling, we demonstrate the involvement of EZH2 in the repression of genes involved in tumor antigen presentation including MHC class I and class II and numerous genes harboring mutations with potential to serve as neoantigens. Inhibition of EZH2 combined with IFN stimulation results in reduced H3K27me3 and transcriptional up-regulation of the MHC class I and transactivator-CIITA and MHC class II genes. Moreover, by employing computational prediction tools, we observed a cluster of genes with somatic mutations that are transcriptionally re-activated by EZH2 inhibition. The re-expression of these genes is predicted to represent over 100 potential neoantigens with high binding affinity to MHC class I and class II molecules.

Conclusions
Our data illustrate the potential for targeting EZH2 to increase the immunogenicity of tumors through relieving epigenetic suppression of tumor antigen presentation machinery and silenced neoantigens. As EZH2 inhibitors are currently under clinical investigation, targeting EZH2 represents a promising combination approach with checkpoint inhibitors to elicit responses in poorly immunogenic tumors.

References

P686
The NCI PREVENT Program portfolio for precision cancer immunoprevention
Shizuko Sei, MD1, Shizuko Sei, MD2, Shizuko Sei, MD2, Altaf Mohammer, PhD2, Jennifer Fox, PhD2, Romaine Fernandez, PhD2, Daniel Boring, RPh, PhD2, Mark Miller, PhD2, Robert Shoemaker, PhD2
1National Cancer Institute (NCI), Bethesda, MD, United States; 2NCI, Bethesda, MD, United States
Correspondence: Shizuko Sei (seis@mail.nih.gov)

Background
The NCI PREVENT Program portfolio is a peer-reviewed program that supports the preclinical development of innovative cancer preventive interventions towards clinical applications (https://prevention.cancer.gov/major-programs/prevent-cancer-preclinical/). One of the Program’s current focus areas is cancer immunoprevention. Recent advances in cancer immunotherapies have clearly demonstrated that the immune system can mount effective antitumor immune responses, if tumor-associated immunosuppression is overcome, for example, by immune checkpoint blockade. It is conceivable that cancer vaccines can arm the host with antitumor immunity that intercepts, arrests, and/or reverses tumorigenesis if delivered before or early in the tumorigenic process. PREVENT seeks to develop effective vaccines for precision cancer immunoprevention in high-risk groups in partnership with principal investigators (PIs) with innovative ideas.

Methods
PREVENT utilizes NCI contract resources to operate its agent development pipeline, which consists of three key stages: early proof of concept phase, secondary testing phase, and advanced preclinical development phase. Competitively selected contractor pools with necessary technical expertise are in place to implement approved projects under NCI oversight. Data and materials generated through PREVENT are returned to the applicant PIs for further agent development. A wide array of organ-specific preclinical cancer models is available to assess agent efficacy and toxicity.

Results
Since the Program’s inception, a total of 21 cancer preventive vaccine projects have been selected for support. Of those, two have progressed to the clinical trial stage with two additional projects in the advanced development phase. The PREVENT immunoprevention portfolio consists of a variety of vaccination approaches that target oncogenic drivers, early tumor associated antigens, and infectious agents known to induce cancers. These vaccines are developed for clinically identifiable high-risk cohorts, such as genetically predisposed populations (individuals with Lynch syndrome, BRCA1/2 mutations, and familial adenomatous polyposis, etc.) and those diagnosed with pre-cancerous lesions.
These findings support the new concept that tumour independent antigens can be used to develop vaccines against solid tumours. Importantly, DCOne™ cells can be used as a carrier for intratumoural delivery of foreign proteins.

P687

Novel vaccination strategies using tumour-independent antigens to induce anti-tumour immunity in solid tumours

Vinod Sommandas, Satwinder Singh, Erik Manting, Satwinder K. Singh

DCPrime b.v., Leiden, Netherlands

Correspondence: Satwinder K. Singh (s.singh@dcprime.com)


Background

Induction of optimal anti-tumour immune response is challenging as tumour antigens are self-antigens and antigen-specific receptors against self-antigens are negatively selected in the body. Therefore, anti-tumour immune responses that are present in the body harbour low affinity antigen-specific receptors that will not optimally eradicate tumours. The new insights on tumour-specific antigens (TSA) has led to personalised vaccines. However, not every tumour type has high mutation burden resulting in TSA and thus these tumour types cannot rely on these strategies. Also TSA are patient-specific and the broad application in cancer patients is limited. In this study we present a novel vaccination strategy which uses foreign (non-self) antigens to mount robust immune responses enabling solid tumour eradication. This strategy is based on two key elements: to induce immunity against a foreign antigen, and to mark the tumour as a target for the induced immune response with the same foreign antigen. To proof the concept, we selected keyhole limpet hemocyanin (KLH) as a foreign immunogenic neo-antigen which will serve both as a vaccine composition and tumour marker to elicit effective anti-tumour immune response.

Methods

As solid tumour models, A375 melanoma or U87-MG glioblastoma cells were subcutaneously engrafted into CD34 humanised NCG. Mice received intraperitoneal (i.p.) vaccination with KLH. The tumour marking was done intratumourally (i.t.) by using DCONe™ mDC loaded with KLH protein. Tumour reduction and immune responses induced against KLH were evaluated.

Results

We observed reduced tumour growth in both A375 and U87-MG tumour models in KLH vaccinated mice where KLH served as vaccine and i.t. injection of DCONe™ mDC loaded with KLH protein for tumour marking compared to the mice injected with PBS. We observed that both in U87-MG and A375 mice, there was no significant difference regarding anti-KLH IgM concentration between treated groups and the PBS control group over time. Noteworthy, the mice from the KLH/KLH loaded DCONe™ treated group produced significantly more anti-KLH IgG than the PBS control group at sacrifice.

Conclusions

These findins support the new concept that tumour independent antigens can be used to develop vaccines against solid tumours.
P689
Amphiphile-modifications target mKRAS-antigen and adjuvant to lymph nodes and enable polyfunctional mKRAS-specific immune responses with potent cytolytic activity
Martin Steinbuck, Peter DelMuth, PhD; Lochana Seenappa, MS
Elicio Therapeutics, Cambridge, MA, United States
Correspondence: Peter DelMuth (pete.delmuth@elicio.com)
Background
Subunit vaccines targeting tumor antigens have shown limited capacity for expanding cytotoxic T-cells against tumors in the clinic. Especially in the case of KRAS-driven tumors, responses elicited by conventional vaccines have been exceedingly weak. For molecular immunogens including peptides and oligonucleotides, inefficient delivery to immune cells residing in the lymphatics is a significant challenge limiting their ability to induce cancer-directed immune responses of sufficient strength and functionality to impact tumors. Improving the targeting of immunogens to lymph nodes (LN), where resident immune cells potently orchestrate immunity, can substantially amplify their ability to induce effective tumor-directed immunity. Here, we demonstrate such an approach for significantly enhancing mKRAS-directed T-cell responses by precisely targeting antigens and adjuvants directly to the draining LN through a simple one-step conjugation to albumin-binding lipids. These amphiphilic conjugates (‘Amphiphiles’) then ‘hitch-hike’ on albumin into the LNs where they elicit strong immune responses. LN accumulation of structurally optimized amphiphiles in mice is greatly improved over soluble equivalents.
Methods
C57BL/6J mice received two or more doses of benchmark or amphiphile-modified vaccines, comprised of mKRAS peptide and CpG adjuvant, subcutaneously injected into the tail base in two-week intervals. Immunological readouts were performed 7 days post dosing. For ELISpot analysis of IFNγ and Granzyme B production and flowcytometric analysis of Th1/2 cytokines, splenocytes were harvested and re-stimulated with antigen overnight. In vivo, cytolytic capabilities of antigen-specific T-cells were evaluated by pulsing CFSE-stained splenocytes from naïve mice with mKRAS antigen and injecting these cells intravenously into immunized mice. Recovery of CFSE-labeled target cells from immunized mice was performed 24 hours later and analyzed flowcytometrically.
Results
We show robust immune responses that yield strong activation against all common mutations in the mKRAS protein compared to low or undetectable responses generated by soluble or benchmark treatments. Further, this response is composed of CD4+ as well as CD8+ T-cells resulting in the production of high levels of TH1-associated cytokines upon re-stimulation with mKRAS-specific peptides in vitro. In vivo, robust cytolytic function towards mKRAS-presenting targets can be measured in T-cells.
Conclusions
By targeting immunogens directly and precisely to the LNs, the Amphiphile platform can significantly amplify the potency of subunit vaccines. In the case of mKRAS, substantially improved cytolytic immune responses represent a promising therapeutic strategy for targeting mKRAS-driven tumor growth and survival in a large fraction of human tumors. Furthermore, this platform technology is simple, rapid and scalable for broad clinical application.

P690
Improving the immunogenicity of modified vaccinia virus Ankara (MVA) vaccine vector by deletion of the vaccinia ESR gene encoding a dominant cGAS inhibitor
Liang Deng, PhD, MD, Ning Yang, Yi Wang, MS, Peihong Dai, Stuart Shuman, MD
Memorial Sloan Kettering Cancer Center, New York, NY, United States
Correspondence: Liang Deng (dengl@mskcc.org)
Background
Modified vaccinia virus Ankara (MVA) is a highly attenuated vaccinia strain that belongs to the poxvirus family. MVA is a promising vaccine vector for infectious diseases and cancers due to its immunogenicity, safety, and a large capacity to accommodate insertions of transgenes. However, MVA has certain disadvantages that need to be overcome to improve its immunogenicity and vaccine efficacy. Those include suboptimal induction of type I IFN in dendritic cell (DC) subsets, presumably due to the expression of a viral inhibitory protein(s) for the cGAS/STING-mediated cytosolic DNA-sensing pathway, as well as the induction of cell death in infected DCs [1,2].
Methods
To identify vaccinia viral inhibitors of the cGAS/STING pathway, we performed an unbiased screen of 70 vaccinia viral early genes in HEK293 T cells using a dual-luciferase system. We discovered that the vaccinia ESR gene encodes a dominant inhibitor of cGAS.
Results
Whereas MVA infection of bone marrow-derived DCs (BMDCs) induces cGAS degradation in a proteasome-dependent manner, recombinant MVA with deletion of the ESR gene (MVAΔESR) infection fails to do so. MVAΔESR infection of BMDCs induces much higher levels of cyclic GMP-AMP (cGAMP) production, IFNB gene expression, and IFN-beta protein secretion compared with live MVA or Heat-inactivated MVA. In addition to BMDCs, MVAΔESR infection of plasmacytoid DCs (pDCs) and CD103+ DCs also activates the cGAS/STING/IFNβ pathway very efficiently. Furthermore, MVAΔESR infection of DCs triggers DC maturation and induces antigen cross-presentation by DCs in a cGAS-dependent manner. MVAΔESR-infected DCs are much less prone to cell death compared with MVA-infected DCs, and they appear activated and healthy for more than five days in vitro cell culture. Using MVAΔESR virus expressing mcherry under vaccinia synthetic early-late promoter, infected DCs appear to have robust transgene (mcherry) expression. We engineered a recombinant MVAΔESR expressing chicken ovalbumin (OVA) as a model antigen. Vaccination with MVAΔESR-OVA either through skin scarification or via intradermal injection generates stronger OVA-specific CD8+ T cell responses compared with MVA-OVA.
Conclusions
In this study, we discovered that the vaccinia ESR gene encodes a dominant cGAS inhibitor. Expression of ES5 protein by MVA leads to proteasome-dependent degradation of cGAS. Deletion of the ESR gene from the MVA genome dramatically improves the immunogenicity of MVA, likely through stronger type I IFN induction, more robust DC maturation, and marked reduction of cell death compared with the parental virus.

References

Ethics Approval
The study was approved by the Committee on the Ethics of Animal Experiments of Sloan Kettering Cancer Institute, approval number 19-01-002.

P691
Monodonal microbial EDP1503 induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity
Humphrey Gardner, MD, Shubhra Kashyap, MS, Peter Sandy, PhD, Holly Ponichtera, PhD, Shannon Argueta, PhD, Chris Davitt, PhD, Michael Goldberg, PhD, Mark Carlson, MS, Maria Sizova, PhD, Valeria Kravitz, MS, Erin Troy, PhD, Sam Andrews, MS, Mark Bodmer, PhD, Lois Francisco-Anderson, PhD
Evelo Biosciences, Cambridge, MA, United States
Correspondence: Lois Francisco-Anderson (loise@evelobio.com)
Background
Monodonal microbial EDP1503 induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity

Ethics Approval
The study was approved by the Committee on the Ethics of Animal Experiments of Sloan Kettering Cancer Institute, approval number 19-01-002.
Background
Systemic immunity is regulated by interactions of commensal bacteria with immune cells in the gut. Enrichment of specific intestinal microbes has been shown to enhance the anti-tumor response to PD-1 blockade in both murine models and cancer patients. Here we report that oral administration of a monoclonal microbial, EDP1503, induces systemic anti-tumor immunity via the direct activation of antigen presenting cells (APCs) and natural killer (NK) cells with subsequent induction of T cell immunity.

Methods
The clinical efficacy of EDP1503 was investigated in subcutaneously implanted isograft tumor models as well as an intravenous lung metastasis model. Mechanism of action was dissected by ex vivo analysis of the tumor microenvironment (TME) and gut-draining lymph nodes, and further interrogated by in vitro functional studies with murine and human cells.

Results
EDP1503 increases expression of costimulatory molecules on CD11c+ dendritic cells (DCs) within the mesenteric LNs with an accompanying increase in proinflammatory CD103+ DCs within tumor draining lymph nodes. Direct stimulation of DCs with EDP1503 results in the upregulation of the proinflammatory cytokines TNFα, IL-1B and IL-12. In addition, EDP1503 amplifies both myeloid and lymphocyte responses via production of DC-derived growth factors, M1 polarization of macrophages, and production of the lymphocyte-recruiting chemokines, CXCL9 and CXCL10. Mechanistically, EDP1503 triggers specific pattern recognition receptors, resulting in a proinflammatory signature from APCs and enhanced cytolytic activity by NK cells. Dissection of the tumor microenvironment reveals increased activated Ki67+ NK cells and CD8+ T cells producing IFNγ. Moreover, in vivo, treatment of mice with EDP1503 results in decreased tumor volume, delayed tumor growth and reduction in the number of metastatic foci in a CD8+ T and NK dependent manner. The prominent anti-tumor effects of EDP1503 are further augmented by combination with anti-PD-1 neutralizing Abs.

Conclusions
Together, these data clearly demonstrate the ability of an orally delivered non-colonizing monomeric microbe to enhance innate and adaptive anti-tumor immunity and substantiates the rationale for ongoing clinical trials. EDP1503 is currently in Phase 1b/2 studies (NCT03775850; NCT03595683) with enrollment open at multiple sites.

P962
Blockade of PGE2 production and signaling enhances the magnitude and selectivity of BCG-promoted immune responses in the human bladder cancer microenvironment
Omar Ibrahim, BPharm, Melissa Grimm, PhD, Weijian Jiang, Khurshid Guru, Gurkamal Chatta, MD, Pawel Kalinski, MD, PhD
Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Correspondence: Pawel Kalinski (pawelkalinski@roswellpark.org)

Background
Bacillus Calmette–Guérin (BCG) is commonly used in the treatment of non-muscle invasive urothelial cancer (bladder cancer; BCa), but its benefit is typically transient and limited to a fraction of patients. We observed that the impact of BCG on human BCa tissue involves undesirable induction of immunosuppressive factors and regulatory Treg cell- and myeloid- derived suppressor cell (MDSC)- attracting chemokines. Prompted by these observations, we evaluated the molecular pathways regulating the patterns of BCG-induced inflammation in BCa tumor microenvironments (TME), and the feasibility of their modulation to selectively enhance local attraction and function of the desirable cytotoxic CD8+ T cells (CTLs) and counteract local MDSCs and Treg accumulation.

Methods
Human monocyte-derived macrophages and freshly resected human bladder cancer specimens were cultured ex vivo in the absence or presence of BCG, indomethacin (COX-1/2 blocker), celecoxib (selective COX-2 blocker) or selective EP4 blocker (ARY-007). The expression of inflammatory mediators and chemokine genes, secretion of chemokines and their cellular sources were analyzed by quantitative PCR, ELISAs and immunofluorescence microscopy. Migration of CTLs was evaluated ex vivo, using 24-transwell plates. Data were analyzed by Student’s t-test or Wilcoxon test. Spearman’s correlation is used for correlativity analysis by using z-score downloaded from cBioportal.

Results
We observed that the BCG-driven induction of MDSC- and Treg-attracting chemokines in human macrophages and whole BCa explants was correlated with its induction of COX-2, the key enzyme controlling the PGE2 biosynthesis. Blockade of COX-2 activity using selective or non-selective COX-2 inhibitors (celecoxib, indomethacin) or interference with EP4-driven PGE2 signaling (using selective EP4 blocker, ARY-007) strongly elevated the production of CTL attractants (CXCL9, CXCL10 and CCL5), but suppressed the induction of MDSC/Treg attractants (CCL22, CXCL8, CXCL12), and several immunosuppressive mediators including COX-2, IL-10, NOS2 and IDO. Our functional studies demonstrated that the combination of BCG with PGE2 antagonism selectively enhances CTL attraction.

Conclusions
We observed that PGE2 represents a nodal point controlling the balance between desirable/immunostimulatory and undesirable/immunosuppressive components of BCG activity and that interference with PGE2 synthesis or its signaling improves the magnitude and characteristic of the BCG orchestrated immune response in BCa TME. Our data suggest that PGE2 antagonism may be used to enhance the therapeutic effects of BCG treatment.
EnaV and tumor-specific T cells. EnaV had a profound effect on tumor models that were refractory to either tumor-specific T cells and/or ICAB. Mechanistically, RNA and proteomic profiling revealed that EnaV treatment induced an inflammatory response in tumors, including markers of immunogenic cell death. Combining EnaV with tumor-specific T cells and anti-PD1 proved superior to either treatment alone in melanoma and lung cancer models. This effect was also seen in a model which showed no response to anti-PD1 treatment alone, suggesting that EnaV can create a de novo sensitization to anti-PD1.

Conclusions
Our findings demonstrate that EnaV and immunotherapy cooperatively exert a strong anti-tumor response in therapy-refractory melanoma and lung cancer models. Importantly, even in models fully refractory to either T cells and/or anti-PD1, EnaV treatment restores sensitivity to promote tumor elimination. Together, these results indicate that targeting AXL-positive, immunotherapy-resistant tumor fractions with EnaV enhances ICAB sensitivity, thus warranting further investigations into this combination in a clinical setting.

References

Ethics Approval
The collection and use of human tissue was approved by the Medical Ethical Review Board of the Antoni van Leeuwenhoek. Animal experiments were approved by the animal experimental committee of the institute and performed according to Dutch law.

P694
Engineering extracellular matrix-binding checkpoint inhibitor antibodies to achieve localized cancer therapy
Jun Ishihara, PhD, Ako Ishihara, John Michael Williford, Jeffrey Hubbell
University of Chicago, Chicago, IL, United States
Correspondence: Jeffrey Hubbell (jhubbell@uchicago.edu)

Background
Cancer immunotherapies using checkpoint inhibitor antibodies (CPI) show considerable antitumor response in the clinic. However, a substantial number of patients suffered from treatment-related adverse events. A number of patients receiving combination CPI therapy could not continue with the therapy due to adverse events. Immunotherapies serve to activate immune responses, and as such, side-effects include the symptoms of systemic lymphocyte activation and auto-immune disease induction, which typically results from drug action in healthy organs. One strategy to address this problem is through localized drug delivery systems, thereby restricting their actions to the disease site. Here, we report two technologies of tumor localized CPI antibodies via conjugation to an extracellular matrix promiscuous binding peptide derived from placenta growth factor-2 (PIGF-2123-144) or a collagen-binding domain (CBD) derived from the blood protein von Willebrand factor (VWF) A3 domain. PIGF-2123-144 conjugated CPI retains at the injection site long-term; thus PIGF-2123-144-CPI is effective when injected peri-tumor. CBD-CPI harnesses the specific exposure of tumor stroma collagen to blood stream due to the abnormal leakiness of the tumor vasculature; thus CBD-CPI is effective when it is injected intravenously.

Methods
PIGF-2123-144 peptide was synthesized chemically. CBD recombinant proteins were produced in HEK-293F cells and purified by AKTA system. We have used a chemical cross linker to conjugate PIGF-2123-144 and CBD to CPI antibody. B16F10 and BafPten melanoma, MMTV-PyMT breast cancer, CT26 models were used. 100μg each of CBD-anti-CTLA4+anti-PD-L1 was administered.

Results
We show that PIGF-2123-144-conjugated CPI localized to the injection site for long time, and limiting the CPI exposure to the body and toxicity including diabetes induction risk (AB). Also, PIGF-2123-144-CPI was more efficacious than unmodified CPI, injected at same dose and same way, when injected near tumor (C). PIGF-2123-144-CPI increased intratumoral effector CD8+ T cell number compared to CPI. Next we have tested CBD conjugated CPI, injected intravenously. Intravenously administered CBD protein accumulated mainly in tumors in an orthotopic MMTV-PyMT breast tumor model (D). CBD-conjugation to CPI decreased systemic toxicity, such as T cell infiltration into the liver (E). CBD-CPI significantly suppressed tumor growth compared to their unmodified forms in B16F10 melanoma, CT26 colon carcinoma and MMTV-PyMT breast cancer models (F). CBD-CPI increased tumor-infiltrating CD8+ T cells; increases in the ratio of effector CD8+ T cells to T regulatory cells were observed.

Conclusions
Our data suggest that the tumor-matrix binding localized CPI technology can improve both safety and efficacy of CPI therapy, with high translational promise.

References
Tumor targeting of a STING agonist with an antibody-drug conjugate elicits potent anti-tumor immune responses

Naniye Malli Cetinbas, PhD, Kalli Catcott, PhD, Kenneth Avocetien, Keith Bentley, PhD, Tyler Carter, PhD, Chen-Ni Chin, PhD, Susan Clardy, PhD, Timothy Etias, PhD, Brian Jones, PhD, Eoin Kelleher, Rebecca Mosher, MD, Mark Nazzaro, Barrett Nehilia, PhD, Marina Protopopova, PhD, Pamela Shaw, Kelly Sluncm, Liuliang Qin, Josh Thomas, PhD, Liping Yang, Dorin Toader, PhD, Marc Damelin, PhD, Jeremy Duvall, PhD, Raghida Bukhald, PhD, Timothy Lowinger, PhD
Mersana Therapeutics, Cambridge, MA, United States
Correspondence: Raghida Bukhald (rbukhald@mersana.com), Timothy Lowinger (lowinger@mersana.com)

Efficacy studies of a novel multi-targeted systemic therapy (aPD-L1/ODN1826) and deep-immune profiling of metastatic murine mammary adenocarcinoma in syngeneic immunocompetent models

Alan Epstein, MD, PhD1, Alison Smith, MD, PhD candidate2
1University of Southern California Keck S, Los Angeles, CA, United States; 2University of Southern California, Los Angeles, CA, United States
Correspondence: Alan Epstein (aepstein@usc.edu)

Background
While checkpoint inhibitors have found stunning success as single agent therapies, their clinical efficacy only extends to a subset of patients across multiple cancers. Even among likely responder preclinical models, response rates are often triggered by an early, unknown stochastic event. Ultimately, we do not know why some tumors respond and some do not. Previous work from our laboratory devised a strategy for dramatically improving systemic administration of an immune agonist of Toll-like receptor 9 (TLR9) known as CpG Oligodeoxynucleotide (ODN) whose anti-tumor efficacy has been traditionally limited to intra- and peri-tumoral injections.[1,2] Through antibody-guided delivery of conjugated CpG ODN to the tumor microenvironment (TME), TLR9 activation promotes dendritic cell maturation thus upregulating cross-presentation of TME antigens.

Methods
Here we describe our latest multi-targeted approach which tackles immune suppression by overcoming mechanisms of acquired resistance to immunotherapy and synergizing therapeutic responses. This novel antibody immunoconjugate (AIC) targets murine TLR9 by tethering ODN1826 to a checkpoint inhibitor antibody against programmed death ligand 1 (aPD-L1) thereby stimulating and disinhibiting the immune system. Our studies of aPD-L1/ODN1826 showed superior in vivo efficacy over their free agent counterparts when delivered by intraperitoneal injection to D2F2 tumor-bearing BALB/c1 mice. All animals were treated humanely and in accordance with the guidelines of the USC’s Institutional Animal Care and Use Committee.

Results
Tumor growth inhibition was calculated by using the geometric mean of relative tumor volumes. The AIC demonstrated a statistically significant delay in tumor growth compared to single agents ODN1826 (~71.6%, p≤0.001) and aPD-L1 (~51.8%, p≤0.01).

Conclusions
By transitioning to bioluminescence imaging techniques of tumor cells, we overcome the limitations of traditional tumor volume measurement by caliper and capture a fuller picture of both early therapeutic response events and metastatic disease. Additionally, subsequent deep immunophenotyping by Mass CyTOF combined with recent advancements in Digital Spatial Profiling, we can establish a more comprehensive method of tumor immune profiling. Elucidating the immune status of murine tumor models is a critical factor for predicting therapeutic response and understanding the mechanisms underlying immune suppression and activation.

Acknowledgements
This work was supported by Cancer Therapeutics, Inc., Los Angeles, CA.

References

Ethics Approval

All animals were treated humanely and in accordance with the guidelines of the USC’s Institutional Animal Care and Use Committee under protocol 20265.

P697
Pre-clinical characterization of the mechanism of action of a CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting regulatory T cells in solid cancers
Francesca Zammarchi, PhD1, Simon Chivers2, Patrick van Berkel, PhD3, Francesca Zammarchi, PhD3
1ADC Therapeutics, London, United Kingdom; 2ADC Therapeutics Ltd. UK, London, United Kingdom

Background
Regulatory T cells (Tregs) play an important role in the establishment and progression of tumors and are considered a major obstacle to tumor rejection by immunotherapies [1]. Moreover, the intratumoral balance between Tregs and effector T cells (Teffs) appears to influence the outcome of immunotherapies [2], and poor prognosis in solid tumors is often associated with high tumor infiltration by Tregs and a low ratio of Teffs/Tregs [3].

Methods
Sur301 is an antibody-drug conjugate (ADC) composed of PC61, a rat monoclonal antibody directed against mouse CD25, conjugated to a pyrrolobenzodiazepine (PBD) dimer via a protease-cleavable linker, with a drug-to-antibody ratio of 2 [4]. We have previously shown that sur301 has potent and durable anti-tumor activity in vivo against CD25-negative immunogenic solid tumors with infiltrating CD25-positive Tregs and, when used at a sub-optimal dose, its activity is further enhanced in combination with PD-1 blockade [4]. Sur301 anti-tumor activity, either alone or combined with an anti-PD-1 antibody, was significantly reduced in the absence of CD8+ T cells, and when tumor-free survivors were re-challenged, they did not develop new tumors indicating that sur301 was able to induce tumorspecific—protective immunity [4].

Results
In order to characterize the mode of action of sur301, we analysed the immunophenotype of Tregs and Teffs isolated from tumors, blood and spleens of mice bearing established MC38 tumors following a single dose of sur301 either alone or in combination with an anti-PD-1 antibody. Additionally, we performed a T cells dynamic study in non-tumor bearing immunocompetent mice over a period of 21 days. Spleen, lymph node, thymus and blood were analysed of sur301 either alone or in combination with an anti-PD-1 antibody. Moreover, the clinical models of solid tumors either alone

P698
Chimeric protein MICA-G129R Bridges Breast Cancer Cells and Natural Killer Cells
Hui Ding, PhD candidate, Yanzhang Wei
Clemson University, Clemson, SC, United States

Correspondence: Yanzhang Wei (ywei@clemson.edu)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1)P698

Background
Major histocompatibility complex class I chain-related protein A (MICA) is a stress-induced ligand for the activating receptor NKGD2 on natural killer (NK) cells. It is expressed on the cell surface of most cancer types at the early stages, but usually down-regulated or shed in advanced cancers leading to immune evasion [1,2]. Prolactin is an essential protein hormone for normal reproduction and maintenance of pregnancy, and contributes to pathogenesis of gynecologic malignancies [3]. The prolactin receptor (PRLR) was found over-expressed in many cancers, especially breast cancer [4]. G129R is a mutant of human prolactin with a single amino acid substitution. It still binds to PRLR but inhibits the growth of breast cancer cells [5]. We aim to create a chimeric protein with MICA and G129R, and use it to bridge breast cancer cells and NK cells. The MICA portion in the chimeric protein binds to the NKGD2 receptor and activate NK cells, and the G129R portion targets to the PRLR on the breast cancer cells and leads NK cells to them.

Methods
A chimeric gene was created by cloning and fusing the cDNA of the extracellular domain of MICA and the cDNA of G129R into a plasmid, and then transfected into HEK293 cells to produce MICA-G129R protein. The MICA-extracellular domain only protein and the G129R only protein were also generated as controls. When the proteins were added into the co-culture of NK cells (NK-92 cell line) and breast cancer cells (T47D cell line), the cytotoxicity was measured using a lactate dehydrogenase (LDH)-based assay, the granzyme B released by NK-92 cells was detected using ELISA, and the apoptosis of the T47D cells was examined using a caspase 3/7 luminescence assay.

Results
We successfully generated HEK293 stable clones to produce MICA-G129R, MICA and G129R proteins. The proteins were all confirmed using Western blot. The chimeric protein MICA-G129R was proved to be able to bind to NK-92 cells and T47D cells using immunofluorescent staining. The chimeric protein MICA-G129R significantly increased the cytotoxicity of the NK-92 cells to T47D cells in their co-culture. The granzyme B secretion of NK-92 cells was induced, and the caspase3/7 in the T47D cells were elevated in the co-culture of NK-92 and T47D with the presence of MICA-G129R.

Conclusions
The chimeric protein MIG-G129R can bridge NK cells and breast cancer cells, and induce the cytotoxicity of NK cells to kill the breast cancer cells.

References

P699

DSP107—A first in class, bifunctional fusion protein targeting both innate and adaptive immunity

Adam Foley-Comer, MD1; Shirley Greenwald1; Ewa Cendrowsicz2; Rinat Tabakman3; Shira Amiili; Alexandra Aronin1; Liat Ben-Gigi-Tamir1; Elina Zorede-Khvallevsky4; Yosi Golan5; Michal Dranitzki-Elhalel5; Ayelet Chajut1; Amnon Peled, PhD2; Edwin Bremer6

1Kahr Medical, Raanana, Israel; 2University Medical Center, Groningen, Netherlands; 3Hadassah Hebrew University Medical Center, Groningen, Netherlands

Correspondence: Ayelet Chajut (ayelet@kahr-medical.com)


Background
Checkpoint inhibitors have transformed cancer treatment in certain patient subgroups. To improve response rates, considerable effort is now being invested developing novel immune-oncology (IO) drugs and exploring IO target combinations.

DSP107 is a bit-functional, trimeric protein consisting of the fused extracellular domains of human SIRPα and 4-1BBL that uniquely combines activation of both innate and adaptive immunity in a single product. Interaction of CD47, frequently overexpressed on cancer cells, with SIRPα on phagocytes transmits a “don’t eat me” signal. Binding of DSP107 to CD47 on tumor cells blocks the inhibitory signal delivered to phagocytes and cross-presents trimerized 4-1BBL to activated tumor antigen-specific T-cells that express the 4-1BB costimulatory receptor. Cross-presentation and trimerization of the 4-1BBL are required for optimal 4-1BB activation.

Methods

DSP107 was manufactured in CHO-S cells. Binding and affinity to CD47 and 4-1BB were evaluated by Biacore, FACS and ELISA. T-cell activation, proliferation, IFN-γ secretion, cytotoxicity and phagocytosis were confirmed in vitro using lymphoma, leukemia and carcinoma cell lines. In-vivo efficacy was tested against hCD47-MC38 tumors in h41BB-KI-C57BL/6 mice and against SUDHL4 (lymphoma) in humanized NSG mice. Safety was evaluated in a non-GLP, repeat-dose study in cynomolgus monkeys.

Results

DSP107 binds to CD47 and 4-1BB with high affinity (1.2 nM and 0.7 nM, respectively). Cell based reporter assays showed CD47 binding dependency for signaling through 4-1BB. Using in vitro assays, DSP107 amplified T-cell activation and proliferation, and augmented T-cell mediated elimination of cancer cells (0.5-5 nM). DSP107 also augmented macrophage-mediated phagocytosis of tumor cells as monotherapy and in combination with targeted monoclonal antibodies (6-12 nM). DSP107 led to statistically significant tumor growth inhibition (TGI) as monotherapy (lymphoma model; p

Conclusions
DSP107 is a bifunctional, fusion protein with a unique mechanism of action. In vivo, DSP107 was efficacious as monotherapy and in combination with anti-PD-L1. Doses ≤ 50 mg/kg were safe and well tolerated in monkeys. IND-enabling studies are ongoing and clinical studies will commence in Q2/2020.

Ethics Approval
With reference to the study in h41BB-KI-C57BL/6 mice, the protocol for the cynomolgus monkey study (Covance Study 8402826) was reviewed and approved by the Establishment Animal Welfare and Ethical Review Body. This study also complies with the permissions and conditions contained within Project Licence P98E2EBFD "Safety Testing of Medicinal Products Using Non-Human Primates" as authorised by the UK Home Office.

The protocol for the cynomolgus monkey study (Covance Study 8402826) was reviewed and approved by the Establishment Animal Welfare and Ethical Review Body. This study also complies with the permissions and conditions contained within Project Licence P98E2EBFD "Safety Testing of Medicinal Products Using Non-Human Primates" as authorised by the UK Home Office.
reactive PD-L1 antibody, avelumab, was generated for testing in human CD27 transgenic mice. A pilot study of CDX-527 was performed in cynomolgus macaques.

**Results**

CDX-527 was found to be a potent PD-1 inhibitor and a stronger CD27 agonist than anti-CD27 monoclonal antibodies. CDX-527 can interact simultaneously with CD27, PD-L1 and Fc receptors and has greater activity in mixed-lymphocyte reactions compared to the combination of the parental antibodies, indicating that cross-linking by both Fc receptors and PD-L1 leads to enhanced activity. This enhanced T cell activation requires concurrent T cell receptor activation. In huCD27 transgenic mice, the surrogate PD-L1×CD27 bispecific demonstrates more potent induction of antigen-specific T cell responses and antitumor activity than the combination of the parental antibodies. A pilot study of CDX-527 in cynomolgus macaques confirmed a good PK profile with a half-life of 5.3 days, increase in serum chemokines, with no adverse effects of treatment noted in clinical observations or clinical chemistry.

Conclusions

CDX-527 effectively combines PD-1 blockade and CD27 costimulation into one molecule that is more potent than combination of the parental antibodies. CDX-527 IND-enabling studies are ongoing with the IND submission planned for early next year.

**References**


**Ethics Approval**

Animals were sourced from IACUC-approved commercial sources. Murine studies were approved by the Celldex IACUC of Hampton, NJ or the Celldex IACUC of Needham, MA. The pilot primate study was approved by the Citox Lab USA IACUC of Stilwell, KS.

---

**P701**

A next generation bispecific antibody platform for effective tumor cell killing with minimal cytokine release

Udaya Rangaswamy, PhD, Harbani K Malik-Chaudhry, PhD, Brian Avanzino, PhD, Aarti Balasubramani, Andrew Boudreau, BA, Benjamin Buelow, Kevin Dang, BA, Laura Davison, PhD, Kathrine Harris, Sharon Hartstein, Brett Jorgensen, BA, Hannes Kehm, Yuping Li, Kyle Lorentsen, PhD, Harish Medlari, Duy Pham, BA, Kirthana Prabhakar, Ute Schellenberger, PhD, Harshad Ugamraj, BA, Nathan Trinklein, PhD, Roland Buelow, PhD, Suhasini Iyer, PhD

Teneobio, Menlo Park, CA, United States

**Correspondence:** Suhasini Iyer (sijyer@teneobio.com)


**Background**

Bispecific T cell redirecting antibodies (T-BsAbs) targeting tumor cells and T cells are an increasingly popular form of cancer immunotherapy. The dual targeting redirects T cells to specifically cause cytotoxicity of tumor cells upon formation of an immunological synapse between the T cells and tumor cells, making this specificity an advantage over conventional monoclonal antibody therapy. Evidence from clinical data of Blinatumomab, the only FDA approved bispecific antibody, suggests that T-BsAbs are associated with cytokine release syndrome (CRS), similar to other T cell targeting therapies such as Muromonab or CAR-T, thus warranting a newer generation of bispecific antibodies which can limit CRS.

**Methods**

Antibodies against CD3 were developed by immunization of OmniFab® animals. Anti-TAA (tumor associated antigen) antibodies (UniAbsTM) for various solid and liquid tumor antigens were developed by immunizations of transgenic humanized rats (UniRatsTM). Antibody discovery entailed antibody repertoire deep sequencing, high throughput gene assembly, cloning and screening. This strategy resulted in a novel class of anti-CD3 antibodies with varying affinities and different target epitopes. Bispecific antibodies were generated by knob in hole technology utilizing one such anti-CD3 domain, termed anti-CD3_F2B in combination with different anti-TAA arms. Specific anti-tumor activity of the T-BsAbs were evaluated by measuring cytotoxicity of tumor cells in the presence of T cells. Supernatants from these co-cultures were used to measure cytokines, namely IL-2 and IFNγ. In vivo studies were performed in a mouse xenograft model by injecting drug into NOG mice engrafted with human tumor cells and adoptively transferred human PBMCs (peripheral blood mononuclear cells).

**Results**

Our novel T-BsAbs targeting various solid and liquid tumor indications cause efficient tumor cell lysis, but with minimal cytokine release in respective in vitro tumor cell and T cell co-culture models. Additionally, one such molecule, anti-CD19×CD3 T-BsAb effectively cleared CD19+ tumor cells in NOG mice in the presence of adoptively transferred human PBMCs.

**Conclusions**

This next generation of T-BsAbs thus shows promise as an effective therapy against multiple cancer indications.

**Ethics Approval**

Animal studies were done in accordance with IACUC protocol # AUP-17-0331-M-2

**P702**

Informing rational immunotherapy combinations for enhancing therapeutic activity of Bi-Specific T cell Engager (BiTE®) antibody constructs in solid tumors

DEEPALI SAWANT, PhD, Brian Belmontes, Famke Aeffner, Olivier Noland-Stevaux, Jackson Egen, Jason DeVoss, PhD

Amgen, South San Francisco, CA, United States

**Correspondence:** Jason DeVoss (jdevoss@amgen.com)


**Background**

Bi-specific T cell Engager (BiTE®) antibody constructs are synthetic cancer immunotherapies aimed at inducing polyclonal anti-tumor T cell responses by re-directing T cells to specific surface antigens expressed on tumors. BiTE® molecules are bispecific proteins with 2 linked scFvs; one targeting the CD3 surface receptor on T cells and the other targeting an antigen expressed on cancer cells. This class of immunotherapies is currently showing promising results in hematological malignancies, with Blinicyt® (Blinatumomab) leading to complete remissions in 69% of patients with CD19+ B-ALL. While BiTE® antibody constructs are currently undergoing testing in solid tumors, only limited clinical data are available. However, multiple features of solid tumors, such as restricted T cell recruitment, limited BiTE® biodistribution, and an immunosuppressive microenvironment could potentially negatively influence BiTE® activity.

**Methods**

We have engineered a knock-in mouse expressing a chimeric mouse/human CD3ε receptor recognized by BiTE® antibody constructs from the endogenous mouse CD3ε genomic locus to elucidate the pharmacokinetic, pharmacodynamic and efficacy parameters governing BiTE® activity in preclinical models.

**Results**

We have evaluated tumor types with varying baseline T cell densities to understand the relationship between T cell density and BiTE® activity in a tumor. In addition, we have assessed the reliance of BiTE® activity on cytotoxic function of pre-existing tumor-resident T cells, recruitment of new T cells from the periphery, and local T cell proliferation across tumor models. These datasets are being employed to interrogate the immune determinants of efficacy that drive BiTE® activity.

**Conclusions**

These studies will allow defining key mechanisms that may limit BiTE® efficacy in solid tumors and informing optimal therapeutic
combination strategies capable of maximizing the potential of BiTE® therapy in solid tumors.

Ethics Approval
All in vivo work was conducted under an IACUC approved protocol and in an AAALAC accredited facility.

P703
Co-stimulation of OX40 or LTβR reprograms exhausted lymphocytes to acquire an effector phenotype in the setting of combined TIGIT and checkpoint blockade

George Fromm, PhD 1, Suresh De Silva, PhD 2, Arpita Patel, BA 2, Kyung Jin Yoo 2, Kelsey Johannes, BS 2, Kaiven Huang 2, Taylor Schreiber, MD, PhD 2
1Shattuck Labs, Inc, Apex, NC, United States; 2Shattuck Labs, Durham, NC, United States
Correspondence: George Fromm (gfromm@shattucklabs.com)

Background
Recently, the role of TOX as a key transcription factor guiding T cells towards exhaustion have shed light on strategies to reprogram tumor infiltrating lymphocytes. While inhibition of TOX prevented acquisition of an exhausted phenotype, it did not result in acquisition of effector properties. This may explain why additional inhibition of TIGIT/LAG3/TIM3 in the setting of PD-1 blockade has not yielded marked clinical improvement. Instead, these results hint that while checkpoint blockade may be required to destabilize an exhausted phenotype, pushing exhausted lymphocytes toward an effector phenotype may require co-stimulatory signaling. To explore this, we developed two Agonist Redirected Checkpoint (ARC) constructs which combine TIGIT/PVR inhibition with either OX40L or LIGHT mediated co-stimulation, and compared the activity of these compounds to TIGIT/OX40/LTβR antibodies alone or with PD-1 or CTLA-4 checkpoint blocking antibodies.

Methods
Human TIGIT-Fc-OX40L and TIGIT-Fc-LIGHT (and the murine surrogates) were purified, and target binding assessed by ELISA, Octet, and cell-surface binding assays. Functional activity was confirmed using NFKb/NIK signaling, cytokine/chemokine stimulating, and immune cell activating assays. Anti-tumor efficacy of mouse TIGIT-Fc-OX40L and TIGIT-Fc-LIGHT was assessed alone and in combination with anti-PD1 and anti-CTLA4 in murine CT26 and B16.F10 tumors.

Results
Each respective domain of TIGIT-Fc-OX40L and TIGIT-Fc-LIGHT bound human and cyno PVR, OX40, LTβR, and HVEM with low nanomolar affinity. Due to the hexameric structure, the OX40L domain clustered OX40 receptors on the cell surface and stimulated NFKB signaling in a single-cell system lacking effector Fc receptors, and stimulated IL-2, TNFa, and IFNg secretion from human PBMCs in the presence of SEB. TIGIT-Fc-LIGHT uniquely induced non-canonical NFKB/NIK signaling, stimulated CCL2/CXCL8 expression and IL-8 secretion, and induced antigen-independent proliferation and differentiation of CD8-depleted human PBMCs. Both murine TIGIT-Fc-OX40L and TIGIT-Fc-LIGHT were effective at controlling CT26 and B16.F10 growth, and programmed a memory response that mediated the rejection of secondary tumor re-challenge. Anti-tumor efficacy of both ARCs was enhanced when combined with checkpoint blockade of PD-1 or CTLA-4; resulting in complete tumor rejection. Lastly, both ARCs have concluded non-human primate dose-range finding studies and have demonstrated distinct target activity.

Conclusions
The addition of OX40L or LIGHT as co-stimulatory molecules dramatically improved the efficacy of checkpoint blockade to TIGIT both alone and in combination with PD-1 or CTLA-4 blockade. Pharmacodynamic evidence from NHP suggests that hexamerized OX40L and LIGHT activate OX40 and LTβR effectively, compared to existing data from agonist monoclonal antibodies to the same targets, and may uniquely reverse immune exhaustion.

P704
An Fc effector enhanced EGFR/cMet bispecific antibody (JNJ-61186372), mediates EGFR/cMet downmodulation and therapeutic efficacy through monocyte and macrophage tropocytosis

Snumrithi Vijayaraghavan, PhD, Snumrithi Vijayaraghavan, PhD, Lorniane Lipert, Kristen Chevalier, Barbara Bushey, BS, Benjamin Henley, Ryan Lenhart, Jocelyn Sendecki, MS, Marilisa Beqiti, Hillary Millar, MS, Kathryn Packman, PhD, Matthew Lorenzi, PhD, Sylvie Laquerre, Sheri Moores, PhD
Janssen R&D, Spring House, PA, United States
Correspondence: Snumrithi Vijayaraghavan (svijayar@its.jnj.com)

Background
Agents targeting mutant EGFR in NSCLC have become standard of care but acquired resistance invariably develops due to new mutations in EGFR and activation of compensatory pathways such as cMET. JNJ-61186372 (JNJ-372) is an anti-EGFR and cMet bispecific low-fucose antibody (hulgG1) with enhanced Fc function designed to target tumors with activated EGFR and cMET signaling through a novel mechanism of action. An ongoing first-in-human study to assess the safety and efficacy of JNJ-372 in patients with advanced, treatment refractory NSCLC revealed JNJ-372 to have clinical activity in patients with diverse EGFR-mutated NSCLC, including Exon 20 mutations TKI resistance mutations (T790M, C797S) and resistance due to MET amplification. Our previous studies demonstrated that the Fc inactive version (IgGs2igma) of the EGFR/cMet antibody was significantly impaired in its ability to inhibit tumor growth compared to the Fc enhanced JNJ-372. The IgGs2igma variant also reduced the ability of the bispecific antibody to mediate downregulation of EGFR and cMet signaling. These observations suggested that the interaction of the Fc domain of the antibody with the Fc gamma receptors on innate immune cells may play a crucial role in the mechanism of action of JNJ-372.

Methods
To examine this hypothesis, we performed a comprehensive assessment of the Fc effector functions of JNJ-372, including effects on EGFR and cMet levels, downstream signal transduction, and role in mediating anti-tumor activity.

Results
Despite observing potent anti-tumor activity of JNJ-372 in EGFR mutant xenograft models, only modest anti-proliferative effects were observed in NSCLC cell lines in vitro. Interestingly, the in vitro addition of isolated human immune cells (PBMCs) notably enhanced JNJ-372-mediated EGFR and cMet downregulation, and dose-dependent tumor cell killing. Through depletion or enrichment of specific cell types, we demonstrated that monocytes and/or macrophages are necessary and sufficient for JNJ-372 Fc interaction-mediated EGFR/cMet downmodulation and that macrophages are required for in vivo efficacy. Finally, we show that the monocyte/macrophage-mediated down-modulation of EGFR/cMet signaling occurs through tropocytosis.

Conclusions
Collectively, these observations represent a novel Fc-dependent mechanism of action of JNJ-372 and support the continued clinical development in patients with aberrant EGFR and cMET signaling.
**Background**

Previous studies examining vaccination against guanylyl cyclase C (GUCY2C) in colon cancer patients revealed pre-existing immunity to the adenovirus serotype 5 (Ad5) vaccine vector as a barrier to effective vaccination in patients, which was confirmed in animal models [1]. To overcome this challenge, we have generated an alternative vaccination approach using a chimeric viral vector composed of Ad5 in which the fiber molecule has been replaced with that from Ad35. The fiber is the major target for Ad5- and Ad35-specific neutralizing antibodies in human populations is very low. Therefore, we hypothesized that this chimeric vector (Ad5:F35) will be insensitive to Ad5-specific immunity, overcoming pre-existing immunity in patients.

**Methods**

The immunogenicity and antitumor efficacy, safety, and biodistribution of the Ad5:F35 vaccine (Ad5:F35-GUCY2C-S1) was evaluated in mouse models of metastatic colorectal cancer. Moreover, the sensitivity of Ad5 and Ad5:F35 vaccines to pre-existing Ad5 immunity was compared in animal models. Finally, the ability of patient sera to neutralize Ad5 and Ad5:F35 vector was compared.

**Results**

Like the previous Ad5 vaccination, and Ad5:F35 induced CD8+ T cell responses in adenovirus-naïve BALB/c mice. IFNγ ELISPOT data showed that Ad5 and Ad5:F35 vaccination produced similar CD8+ T cell response and there was no significant difference in survival rates of Ad5- and Ad5:F35-vaccinated mice with metastatic colorectal cancer. Repeated administrations of Ad5:F35 resulted in no toxicity and little vector persistence in any examined tissues, demonstrating the safety of this approach. In unvaccinated patients, Ad5-specific neutralizing antibody titers were present in 50% (5/10) of patients, while those neutralizing Ad5:F35 were present in only 1/10 patients.

**Conclusions**

These studies demonstrate that a chimeric adenoviral vector composed of Ad5 with the Ad35 fiber is an advantageous alternative to Ad5 alone for vaccinating human populations. While Ad5 and Ad5:F35 vaccines produce comparable GUCY2C-specific immunity, antitumor efficacy, and safety profiles in adenovirus-naïve mice, Ad5:F35 is less sensitive to pre-existing Ad5-specific immunity. Planned clinical studies will examine the safety and efficacy of Ad5:F35-based vaccines in colon cancer patients.

**Acknowledgements**

The authors thank the Center for Cell and Gene Therapy, Baylor College of Medicine for assistance in Ad5:F35 vaccine manufacturing.

**References**


**Ethics Approval**

This study was approved by the Thomas Jefferson University IRB (#13S.462) and IACUC (Protocol #02092).

**Consent**

No sensitive or identifiable patient data is included in this abstract.

---

**P706**

A TCR-CD3 bispecific fusion protein mediates increased presentation of peptide-HLA which associates with improved T cell activation and tumour cell killing

Duncan Gacsyone, PhD, Duncan Gacsyone, PhD, David Depoil, PhD, Karolina Rygiel, Nathaniel Davies, PhD, Cheryl McAlpine, MSN, Rupert Kenefeck

Immunocore, Abingdon, United Kingdom

**Correspondence:** Rupert Kenefeck (rupert.kenefeck@immunocore.com) *Journal for ImmunoTherapy of Cancer* 2019, 7(Suppl 1):P706

**Background**

Immune mobilising TCRs against cancer (ImmTAC) molecules are soluble bispecific fusion proteins comprised of affinity-enhanced TCR and anti-CD3. ImmTAC molecules redirect T cells to kill tumour by binding to specific peptide HLA (pHLA) complexes on cell surface via the TCR moiety and recruiting T cells via anti-CD3. Tebentafusp, an ImmTAC recognising gp100-derived pHLA, has monotherapy activity in advanced melanoma (NCT01211262) and pivotal studies are ongoing. Here, using novel TCR-based labelling of individual surface pHLA molecules, we examine the effect of ImmTAC on peptide presentation and T cell response in vitro and explore tumour gene expression in tebentafusp treated patients.

**Methods**

pHLA epitope numbers were quantitated using a novel semi-automated single molecule pHLA counting technique (derived from [1]) and HLA levels determined by flow cytometry. PBMC response was measured by IFNγ ELISPOT and tumour killing (Incucyte, xCELLigence or Phenix). To assess changes in tumour, paired baseline and on-treatment biopsies from tebentafusp-treated patients (n=9) (NCT01211262) were analysed for gene expression (NanoString).

**Results**

Activation of T cells, induced by ImmTAC co-incubated with 70 different tumour cell lines, correlated tightly with pHLA presentation as predicted by gene expression (n=70, R2=0.74) and with single molecule surface pHLA numbers based on TCR labelling (n=19, R2=0.86). Baseline pHLA numbers ranged from undetectable to ~500 per cell, with as few as 10-15 pHLAs per cell sufficient to drive T cell mediated killing.

The number of pHLA per tumour cell could be increased by incubation with T cells and ImmTAC, presumably due to release of T cell derived inflammatory cytokines [2], or by incubation alone with IFNγ (~3-fold, p).

In patients treated with tebentafusp, comparison of on-treatment changes in tumour biopsies from partial response vs progressive disease patients, found HLA-associated antigen processing gene expression to be significantly enriched (p=0.006).

**Conclusions**

Using a state-of-the-art single molecule surface pHLA detection technology, T cell activation by ImmTAC is highly sensitive and correlates with pHLA number. T cell activation by ImmTAC further augments HLA expression and pHLA presentation indicating a feed-forward loop. Evidence of this is suggested by enrichment of HLA-associated antigen processing genes in tumour biopsies from patients responding to tebentafusp. By this mechanism, ImmTAC may promote overall tumour immunogenicity and epitope spreading, thus amplifying native T cell responses.

**Trial Registration**

Trial Registration Reference NCT01211262

**References**


P707

Matrix-binding IL-12 enhances tumor inflammation and drives complete remission in established cold murine tumors
Aslan Mansurov, BChen, Jeffrey Hubbell, Jun Ishihara, PhD
University of Chicago, Chicago, IL, United States
Correspondence: Jeffrey Hubbell (jhubbell@uchicago.edu)

Background
Checkpoint inhibitor (CPI) immunotherapy has achieved remarkable success in the clinic, yet its efficacy in poorly immunogenic, immune-excluded tumors has been modest. Interleukin (IL)-12 is an attractive cytokine capable of activating the innate and adaptive arms of immunity, yet immune-related adverse events have been a major barrier in its translation as an anticancer cytokine. To overcome this, we engineered collagen-binding IL-12 (CBD-IL-12), which, after intravenous administration, accumulates in the tumor stroma due to exposed collagen associated with disordered tumor vasculature.

Methods
N/A

Results
B16F10 melanoma is a poorly immunogenic and checkpoint-unresponsive tumor model. Single i.v. administration of CBD-IL-12 to mice bearing moderately-sized B16F10 tumors (~60 mm3 at the start of therapy) resulted in complete remission (CR) in 10 out of 17 mice, whereas none were cured by equimolar IL-12. EMT6 breast cancer is an immune-excluded, “cold” tumor model and is minimally responsive CPI therapy. In this model, single i.v. treatment with CBD-IL-12 achieved CR in 13 out of 15 treated mice, whereas equimolar i.v. IL-12 treatment achieved CR in 6 out of 15 mice. To investigate the pharmacodynamic mechanisms of enhancement of antitumor efficacy of CBD-IL-12, we sought to measure intratumoral (i.t.) IFNg kinetics in B16F10 melanoma. Single treatment with CBD-IL-12 resulted in sustained levels of i.t. IFNg for at least 4 days post-therapy, whereas i.t. levels of IFNg rapidly declined after treatment with unmodified IL-12, showing the effect of CBD-IL-12 retention within tumor matrix. Systemic administration of CBD-IL-12 to B16F10 tumor-bearing mice significantly decreased systemic toxicities, such as serum IFNg, ALT, and pancreatic damage (i.e., lipase, amylase) compared to equimolar IL-12. Ability to administer CBD-IL-12 systemically enables treatment of both primary and metastatic tumors. In the pulmonary metastatic model of B16F10, CBD-IL-12 decreased the tumor burden two-fold compared to equimolar unmodified IL-12. Treatment with CBD-IL-12 induced dramatic differences in both the innate and the adaptive immune compartments in the lungs of treated mice as assessed by flow cytometry. Additionally, we investigated whether CBD-IL-12 can synergize with CPI therapy in the CPI-unresponsive B16F10 melanoma model. Treatment of mice bearing large, established B16F10 tumors (~120 mm3) with only two cycles CBD-IL-12 + CPI cured 7 out of 12 mice, whereas no CR was observed in either monotherapy group, confirming the synergistic antitumor effects of CBD-IL-12 and CPI.

Conclusions
Collectively, our data show that CBD-IL-12 can safely cure large, established tumors without antigen-specific approach, greatly increasing the therapeutic index of IL-12.

Ethics Approval
All animal experiments performed in this work were approved by the Institutional Animal Care and Use Committee of the University of Chicago.

Immunotherapy Toxicities

P708

Real world evidence of patient clinical profiles with advanced solid tumor malignancies receiving immune checkpoint inhibitors to investigate potential predictors for immune-related adverse events
Stephanie Berg, DO1, Joseph Clark, MD3, Jose Guevara2, Elizabeth Elliott, DO1, Stephanie Berg, DO1, Michael Wesolowski2, Blaine Knox, MD1, Daniel Linden, DO1, Courtney Wagner, MD1
1Loyola University Medical Center, Maywood, IL, United States; 2Loyola University Chicago, Chicago, IL, United States
Correspondence: Stephanie Berg (sberg2@luc.edu)

Background
Immune-related adverse events (irAEs) related to immune checkpoint inhibitors (ICIs) may target any organ and originate from autoreactive T cells injuring host tissues. There is a need to uncover potential predictors for irAE development in patients (pts) receiving ICIs. Real-world evidence has been utilized previously to inform therapeutic development, outcomes research, and quality improvement [1]. Our study uses real world evidence in a prospective fashion to investigate potential characteristics which exist in pts that could predict irAEs occurrence. We predict that there may be specific clinical variables present before ICI administration that result in increased susceptibility to irAEs.

Methods
We designed a prospective study at Loyola University Medical Center to document clinical profiles of pts diagnosed locally advanced or metastatic solid tumors. Selected tumor types included: malignant melanoma (MM), renal cell carcinoma (RCC), small cell and non-small cell lung cancer, urothehal carcinoma, head and neck carcinoma, and melan cell carcinoma. Only irAE events graded above 2 were verified according to CTCAE V5.0 criteria.

Statistical analysis used involved univariable cox proportional hazards model and Type III Wald Chi square criterion. Overall survival was calculated using Kaplan Meier estimates and univariate Cox proportional hazards regression models. P-values are reported for overall variable significance.

Results
Pt enrollment and data collection began in March 2017 and ended May 2019. We have enrolled 124 patients on our study; at the time of analysis 98 patients had at least 6 months of follow up. The most commonly reported irAEs were: thyroid dysfunction (23%), hepatitis (14%), rash (11%), and colitis (7%). In our population the majority of these patients were men (69.4%), identified as white and non-Hispanic (82.5%), and most had MM (40%). Numerous clinical variables were utilized in univariable binary logistic regression models to try to predict irAE development (Table 1). Tobacco use (p = 0.06) was the only variable that had a trend towards statistical significance in unadjusted analyses (Table 2).

Conclusions
Our results do show a similar incidence of irAEs in our population (42.4%) as compared to other studies [2,3]. Previous data in NSCLC demonstrated that tobacco smokers commonly have higher PD-L1 tumor proportion scores and can have a higher response rate to ICIs than never smokers, but the authors did not remark on irAE occurrence [4]. In our study, we did see a trend regarding pts who are current or recent tobacco users tend to develop less irAEs than never smokers. This finding will need to be explored on further analyses studying irAEs.

References
Background

Immunem checkpoint inhibitors have been approved in over 10 different types of malignancies. Immunotherapy blocks immunoinhibitory pathways, and allows for reversal of immunosuppression caused by malignant tumors [1]. Immunotherapy can cause immune-related adverse events (IrAE) including rash, pneumonitis, colitis, endocrinopathy, nephritis, adrenal insufficiency, hepatitis, and uveitis [2]. Limited data exists to predict which patients will have the greatest response to therapy. Additionally, the correlation between IrAE and immunotherapy effectiveness has not been well investigated. The aim of the current study is to determine the relationship between IrAE and immunotherapy efficacy.

Methods

Data was obtained using a retrospective chart review of Oschner patients with metastatic cancer who received at least one cycle of immunotherapy (Nivolumab, Pembrolizumab, Atezolizumab, or Durvumab) with no other drug combination between October 1st, 2014 and February 1st, 2019. Data collection included demographics, ECOG Performance Status recorded at the initiation of treatment, imaging results, time on treatment, best response to treatment, date of progression of disease, and presence or absence of IrAE while on treatment. Treatment response was analyzed using RECIST 1.1. Overall survival (OS) was calculated by the Kaplan-Meier survival method.

Results

A total of 456 patients were included for analysis. The median age was 67.6. The median time on immunotherapy for all patients was 112 months. Of the 456 patients, 175 (38.3%) had an IrAE while on immunotherapy. Hypothyroidism was the most prevalent adverse event (13.8%) followed by rash (10.5%). Out of 16 patients on Durvulamab, 12 had an IrAE (75%) (Table 1). The overall response rate (ORR) was 23.7% in the total population (Table 2). The development of IrAE correlate with OS and response rate. Of the patients with a reported IrAE, 58.3% had an overall response (OR), compared to 41.7% of those without IrAE (Table 2, Figure 1). Complete response (CR) occurred in 38 patients (8.3%), 21 (55.3%) of those with an IrAE, as compared to 17 (44.7%) of those without an IrAE. Partial Response occurred in 70 patients (15.4%), 42 (60.0%) of those with an IrAE as compared to 28 (40.0%) of those without an IrAE (Table 2, Figure 2). There is a significant increase in OS. At 24 months, 35 of 175 patients with IrAE were still on treatment compared to 26 out of 281 patients with no IrAE, p

Conclusions

Our results suggest that the presence of IrAE may represent a potential predictive indicator for treatment response to immune checkpoint inhibitors.

References

1. van den Bulk J, Verdegaal EME, de Miranda NFCC. Cancer immunotherapy: broadening the scope of targetable tumours. Open Biol. 2018;8(6).


Table 1 (abstract P708).

<table>
<thead>
<tr>
<th>Table 1 (abstract P708). See text for description</th>
</tr>
</thead>
</table>

Table 2 (abstract P708).

| Table 2 (abstract P708). See text for description |

P709

Immunotherapy adverse events predict treatment response

Diana Maslov, MD, MS; Diana Maslov, Katherine Thomas, MD, MS2; Victoria Simenson, MD1; Caitlin Sullivan, MD2; Alaa Msharved, MPH1; Jessica Boyce3; Jonathan Lu, MD2; John Kucharczyk, MD4; Marc Matrana5

1Ochsner Medical Center, Jefferson, LA, United States; 2Louisiana State University, New Orleans, LA, United States; 3Ochsner Clinical School, New Orleans, LA, United States; 4New York University Winthrop Hospital, New York, NY, United States

Correspondence: Diana Maslov (diana.maslov@ochsner.org) Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P709
Immune checkpoint inhibitors increase the risk of hypothyroidism in patients with primary head and neck cancer compared to other cancers

Omar Alaber, MD, Apoorva Chandar, Prateek Mendiratta, MD, Monaliben Patel, MD, Chris Hoimes, MD, Pierre Lavertu, MD, Ankit Mangla, MD, Ankit Mangla, MD

Case Western Reserve University, Cleveland, OH, United States

Correspondence: Ankit Mangla (Ankit.Mangla@UHhospitals.org)

Background
Radiotherapy (RT) in patients with primary head and neck cancer (HNC) and those receiving immune checkpoint inhibitors (ICI) for any cancer, are independent risk factors for developing hypothyroidism. In this study, we sought to determine if the risk of hypothyroidism in patients with HNC who received RT, is increased by ICI compared to other primary malignancies (lung, gastrointestinal, skin, melanoma or urinary).

Methods
Data were obtained from a commercial de-identified database (Experian, IBM, Inc.) that integrates electronic health records from 26 major integrated U.S. healthcare systems from 1999 to July 2019. Cases were defined as patients with a Systematized Nomenclature of Medicine Clinical Terms (SNOMED) diagnosis of primary HNC who received RT anytime between 1 and 90 days following their diagnosis and then received ICI (Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab and/or Ipilimumab) 60 days after RT. Incidence of hypothyroidism was defined as anyone who had a new diagnosis of hypothyroidism at least 1 day following initiation of ICI. The comparison group comprised of patients with SNOMED diagnosis of primary lung, gastrointestinal, skin, melanoma or urinary cancer, who had received RT followed by ICI similar to cases and had a new diagnosis of hypothyroidism at least 1 day following initiation of ICI. The comparison group comprised of patients with SNOMED diagnosis of primary lung, gastrointestinal, skin, melanoma or urinary cancer, who had received RT followed by ICI similar to cases and had a new diagnosis of hypothyroidism at least 1 day following initiation of ICI. The comparison group comprised of patients with SNOMED diagnosis of primary lung, gastrointestinal, skin, melanoma or urinary cancer, who had received RT followed by ICI similar to cases and had a new diagnosis of hypothyroidism at least 1 day following initiation of ICI. All patients with previous/concurrent history of thyroid cancer, malignant lymphomas and hypothyroidism were excluded. Odds ratios (OR) and confidence intervals (CI) for the OR were calculated.

Results
We recorded 221,760 patients with an active diagnosis (within the last 5 years) of primary HNC, and 547,570 patients with an active diagnosis of a primary lung, gastrointestinal, skin, melanoma or urinary cancer in the database. Out of 260 HNC patients, 60 patients (23%) had a new diagnosis of hypothyroidism. Out of 1890 patients with other primary cancers, 290 (15%) had a new diagnosis of hypothyroidism. When compared to controls, cases had a 1.65 (CI = 1.2 – 2.3) times higher odds of developing hypothyroidism. Male cases and adults >65 years were significantly more likely to develop hypothyroidism.

Conclusions
The risk of developing hypothyroidism after ICI is higher in patients with HNC compared to other primary cancers. Men and older adults were more likely to become hypothyroid, but fewer numbers limit
generalizability of our subgroup analyses. Other limitations included reliance on diagnosis coding, the retrospective nature of the study and lack of histological validation of SNOMED codes. Strengths include a strict definition of cases and controls and the inclusion of only incident hypothyroid patients.

Table 1: Association of Immunotherapy with Hypothyroidism

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Number of hypothyroid cases (cases)</th>
<th>Number of hypothyroid patients (comparison)</th>
<th>OR</th>
<th>CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>60</td>
<td>290</td>
<td>1.05</td>
<td>1.2–2.3</td>
</tr>
<tr>
<td>Incidence of hypothyroidism (within the first 60 days)</td>
<td>40</td>
<td>220</td>
<td>1.45</td>
<td>1.0–1.9</td>
</tr>
<tr>
<td>Incidence of hypothyroidism (Beyond 60 days)</td>
<td>20</td>
<td>70</td>
<td>2.3</td>
<td>1.3–3.8</td>
</tr>
<tr>
<td>Cause of death</td>
<td>50</td>
<td>260</td>
<td>1.6</td>
<td>1.1–2.2</td>
</tr>
<tr>
<td>Male</td>
<td>40</td>
<td>160</td>
<td>1.82</td>
<td>1.2–2.7</td>
</tr>
<tr>
<td>Female</td>
<td>20</td>
<td>130</td>
<td>1.5</td>
<td>0.8–2.5</td>
</tr>
<tr>
<td>Adults (18–65 years)</td>
<td>50</td>
<td>150</td>
<td>1.55</td>
<td>0.96–2.4</td>
</tr>
<tr>
<td>Adults (age &gt; 65 years)</td>
<td>30</td>
<td>160</td>
<td>1.83</td>
<td>1.15–2.8</td>
</tr>
</tbody>
</table>

Fig. 1 (abstract P710). Association of Immunotherapy with Hypothyroidism

P711
Single-center analysis of safety and efficacy of immune checkpoint inhibitors (ICI) in non-hematologic malignancies: Effects of age and eosinophilia
Justin Moyers, MD1, Justin Moyers, MD2, Dhanu Desai3, Jasmine Mitchell4, Jeffrey Ahn5, Steven Hardin6, Mie Mie Thinn7
1Loma Linda University HealthCare, Loma Linda, CA, United States; 2Loma Linda University Medical Center, Loma Linda, CA, United States; 3Veteran Affairs Loma Linda, Loma Linda, CA, United States
Correspondence: Justin Moyers (jtmoyers@llu.edu)

Background
Trials conducted for ICI efficacy have largely included the young and healthy, while elderly patients have been excluded or under-represented.[1] In our clinic’s real-world population of predominantly elderly men, we aimed to compare the rate of clinically significant side effects and hospitalizations. There are no serologic markers for predicting response to ICI, but small series have suggested eosinophilia predicts improved survival.[2]

Methods
This is a retrospective observational study approved by the local IRB including all patients (n=147) who received ICI for non-hematologic malignancies from 2013-2019 at VA Loma Linda Healthcare System. Data were collected by chart review. Fisher’s exact test was performed on primary objectives of rate of hospitalization and grade 3-5 toxicities as graded by CTCAE between cohorts. The elderly cohort was defined as 70 years or greater, while younger cohort was defined as less than 70 years. Eosinophilia was defined as absolute count >5 x108/L on at least 2 occasions. Kaplan-Meier survival estimates were used to calculate secondary outcome of overall survival.

Results
There were 73 patients in elderly cohort and 74 in younger cohort. 28% of the older while 26% of the younger cohort (p=0.75) experienced immune-mediated grade 3-5 adverse events (AEs). During course of treatment, Elderly were hospitalized 50% vs 58% (p=0.36; HR=1.35) in younger population. AEs lead to a significantly increased rate of ICI discontinuation in 24% of the older population while only 10% in the younger cohort (p=0.02; HR=0.33). In metastatic melanoma (n=36) survival between the younger (n=21) and elderly (n=15) cohorts were similar with median OS of 24.9 and 27.8 months (p=0.77), respectively. Similarly, survival in those with NSCLC (n=51) survival were 16.3 and 16.9 months (p=0.86), respectively for younger (n=21) and elderly (n=30) cohorts. Results are summarized in Table 1. An exploratory analysis examined presence of eosinophilia and survival amongst all ages. In metastatic melanoma (n=36), those with eosinophilia (n=12) had a median overall survival of 42.0 vs 8.2 months (p=0.03) (Figure 2). In metastatic non-small cell lung cancer (n=51) those with eosinophilia (n=11) had a trend towards improved survival 20.8 vs 9.8 months (p=0.08).

Conclusions
Elderly patients in our cohort did not experience more frequent grade 3-5 AEs or hospitalization, but more elderly patients discontinued treatment due to AEs. Intriguingly, a significant increase in overall survival was seen in those with eosinophilia during ICI therapy in metastatic melanoma.

References

Ethics Approval
The study was approved by VA Loma Linda Healthcare System Institutional Review Board, protocol #1290.

Table 1 (abstract P711). See text for description
Conditional immune toxicity rate with immune checkpoint inhibitors

Pier Vitale Nuzzo, MD, PhD1, Gregory Russell Pond, MSc, PhD2, Amin Nassar, MD2, Sarah Abou Alawi, MD2, Ronan Flippot, MD2, Catherine Curran2, Kenny Kilbridge, MD2, Xiao Wei, MD2, Bradley Mcgregor, MD2, Lauren Harshman, MD2, Toni Choueiri2, Guru Sonpavde, MD2
1Dana-Farber Cancer Institute, Boston, MA, United States 2McMaster University, Hamilton, Canada

Correspondence: Guru Sonpavde
(Gurup_Sonpavde@DFCI.HARVARD.EDU)

Background

Treatment with immune checkpoint inhibitors (ICIs) can result in immune-related adverse events (irAEs). IrAE cumulative incidence (CI) rate is a measure that accounts for elapsed time since treatment initiation and estimates the risk of irAE development conditioned on time elapsed without experiencing an irAE. We sought to evaluate the CI of irAEs in metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma (mRCC) patients treated with ICI.

Methods

We identified a cohort of mUC and mRCC patients who received ICI at Dana-Farber Cancer Institute (DFCI). The severity of irAEs was graded using CTCAE v.5.0. The CI of irAE was calculated accounting for the competing risk of death. Monthly landmark intervals were determined, and the monthly incidence and CI of irAEs at each landmark time was calculated based on the ratio of patients with irAE after the landmark time if alive with no prior irAEs at landmark time.

Results

A total of 470 patients were treated between July 2013 and October 2018 (199 mUC (42.3%); 271 mRCC (57.7%); median age, 65 (22-91) years; 342 men (72.8%)). Overall 341 (72.6%) received ICI monotherapy, 86 (18.3%) ICI+ other class of agents, and 43 (9.2%) combination therapy. The 2 AML patients had near undetectable levels. At onset of hypothyroidism, 3/8 hypothyroidism patients had either elevated anti-thyroid peroxidase and/or anti-thyroglobulin autoantibodies. The 2 AML patients had near undetectable levels.

Table 1 (abstract P712). See text for description

<table>
<thead>
<tr>
<th>Time (days)</th>
<th>irAEs (No.)</th>
<th>Patients Alive On Start Day of Time Period (No.)</th>
<th>Incidence of irAEs (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-30</td>
<td>47</td>
<td>470</td>
<td>10.0</td>
</tr>
<tr>
<td>31-60</td>
<td>28</td>
<td>415</td>
<td>6.8</td>
</tr>
<tr>
<td>61-90</td>
<td>24</td>
<td>358</td>
<td>6.7</td>
</tr>
<tr>
<td>91-120</td>
<td>13</td>
<td>313</td>
<td>4.2</td>
</tr>
<tr>
<td>121-150</td>
<td>19</td>
<td>271</td>
<td>7.0</td>
</tr>
<tr>
<td>151-180</td>
<td>11</td>
<td>223</td>
<td>4.9</td>
</tr>
<tr>
<td>181-210</td>
<td>11</td>
<td>194</td>
<td>5.7</td>
</tr>
<tr>
<td>211-240</td>
<td>5</td>
<td>177</td>
<td>2.8</td>
</tr>
<tr>
<td>241-270</td>
<td>6</td>
<td>164</td>
<td>3.7</td>
</tr>
<tr>
<td>271-300</td>
<td>2</td>
<td>147</td>
<td>1.4</td>
</tr>
<tr>
<td>301-330</td>
<td>2</td>
<td>133</td>
<td>1.5</td>
</tr>
<tr>
<td>331-360</td>
<td>0</td>
<td>119</td>
<td>0.0</td>
</tr>
<tr>
<td>≥361</td>
<td>18</td>
<td>110</td>
<td>16.4</td>
</tr>
</tbody>
</table>

Conclusions

This is the first study to our knowledge that quantitates the incidence of developing irAEs with ICI conditioned on time elapsed without development. Although the incidence of irAEs decreased over time on therapy, irAEs require continuous vigilant monitoring because of the long tail in its incidence. Further evaluation of the conditional irAE rate is warranted in prospective studies in conjunction with evaluation of predictors of early and late irAEs.

Ethics Approval

The study was approved by Dana Faber Cancer Institution's Ethics Board, approval number 02-021 /17-000.

Immunological features of immune-related adverse events during anti-PD-1/PD-L1 immune checkpoint inhibition

Meghali Goswami, MPhil, Gege Gui, Katherine Lindblad, Jaydria Del Rivero, MD, Jennifer Marte, BS MD, Pradeep Dagar, PhD, Christin Destefano, MD, Julie Thompson, RN, Bogdan Popsescu, MD, Laura Dillon, PhD, Cheryl Johnson, Steven Soldin, PhD, Catherine Lai, MD, MPH, James Guiley, MD, PhD, FACP, Christopher Hourigan, MD, PhD
National Cancer Institutes, Bethesda, MD, United States

Correspondence: Christopher Hourigan (hourigan@nih.gov)


Background

Immune checkpoint inhibition (ICI) against PD-1/PD-L1 has shown remarkable efficacy in many solid tumors. However, the PD-1 checkpoint is critical for peripheral tolerance, and endocrine toxicities are common immune-related adverse events (irAEs) of PD-1/PD-L1 inhibitors.

Methods

We characterized immune features in relapsed/refractory acute myeloid leukemia (AML) patients who developed irAEs during treatment with pembrolizumab and decitabine (PD-AML, NCT02996474). Two of 10 patients developed hypothyroidism, a known irAE. A third developed central diabetes insipidus, thought possibly related to pembrolizumab. TCRβ sequencing was performed using the ImmunoSEQ platform (Adaptive Biotechnologies) on gDNA from longitudinal blood and bone marrow samples of AML patients. We performed 10x Genomics 5’ single-cell RNA / VDJ sequencing (scRNAseq) and cell surface protein profiling with oligo-conjugated antibodies (Biolegend) on FACSPurified CD3+ T cells from mononuclear cells of an AML patient at hypothyroidism diagnosis. In a cohort of 8 patients who developed hypothyroidism during anti-PD-1/PD-L1 treatment, including the 2 AML patients and 6 patients with solid tumors receiving avelumab on NCT01772004, we tested for anti-thyroid autoantibodies and performed HLA sequencing.

Results

We first queried for the presence of circulating anti-thyroid autoantibodies. At onset of hypothyroidism, 3/8 hypothyroidism patients had either elevated anti-thyroid peroxidase and/or anti-thyroglobulin autoantibodies. The 2 AML patients had near undetectable levels.
Sequencing of HLA loci did not reveal any consistent overlap. We next examined TCR repertoire dynamics in AML patients during treatment. Through TCRb sequencing, we identified several expanded T cell clonotypes whose expansion coincided with irAE onset in all 3 AML irAE (Figure 1). To further explore genetic and proteomic signatures of these expanded clones in a representative AML hypothyroidism patient, 8578 T cells were sequenced with scRNAseq. All expanded TCRb clonotypes of interest were captured and paired TCRa chains identified. Most clones were CDB+ and expressed high levels of cell surface PD-1, TIM-3, HLA-DR, and CD27, with no CCR7 and moderate CD45RO, indicating an activated effector memory phenotype (Figure 2). These clonotypes had high PDCD1 and CD27 transcripts as well and an expression profile suggestive of activation, proliferation, and degranulation.

Conclusions
We performed a detailed characterization of immunological and molecular features accompanying the development of irAEs during anti-PD-1 ICI and identified specific T cell clonotypes that may have contributed to anti-PD1-induced irAEs in relapsed/refractory AML patients. Our data suggest that several immunological mechanisms may mediate irAEs. We believe irAEs offer a model system for discerning mechanisms of action of PD-1/PD-L1 inhibitors on T cells.

Acknowledgements
This research is supported in part by the Intramural Research Program of the NHLBI, NIH and the Center for Human Immunology, NIH.

Methods
We recently described a model whereby transient depletion of T regulatory cells (Tregs) using the FoxP3-GFP-DTR mice, prior to treatment with immune modulating antibodies, increased physical and biochemical immune related adverse events (irAEs) similar to what is observed in humans.

Results
In this study, we demonstrated how Treg depletion can model clinical irAEs and investigate methods to alleviate the toxicity induced by agonistic anti-CD40 and anti-CD137. First we demonstrated that biochemical irAEs such as increased inflammatory cytokines and liver toxicities were observed after transient Treg depletion and anti-CD40 and its severity varied depending on the mouse strain. We further demonstrated that treatment of these mice with anti-TNF reduced irAEs severity such as liver toxicity. Next, we demonstrated that Treg depletion specifically in the tumor in combination with systemic anti-CD137 suppressed tumour growth without inducing severe irAEs contrary to peripheral Treg depletion and anti-CD137 treatment where all mice died due to severe irAEs.

Conclusions
This study further highlights how Treg depletion can be used to rapidly model clinically observed irAEs and investigate methods to alleviate the toxicity of potent immunotherapies.

P715
Strategies to mitigate immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer
Célia Jacobberger-Foissac, PhD, Stephen Blake, Jing Liu, Stacey Allen, Juming Yan, Heidi Harjunpaa, Mark Smyth, Michele Teng, PhD, Michele Teng, PhD
QIMR Berghofer Medical Research Institute, Brisbane, Australia

Correspondence: Michele Teng (micheleteng@qimrberghofer.edu.au)

Background
The clinical success of checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 alone or in combination has paved the way for the development of new immunotherapy options and combination therapies. In addition to checkpoint inhibitors, agonistic antibodies against co-stimulatory receptors, such as CD40 or CD137, are currently being evaluated clinically. In preclinical studies, different agonistic antibodies have shown promise. However, mouse models failed to predict the severe toxicities induced by anti-CD137 during early clinical trials, which can limit their clinical utility in combination therapies.

Methods
We described a model whereby transient depletion of T regulatory cells (Tregs) using the FoxP3-GFP-DTR mice, prior to treatment with immune modulating antibodies, increased physical and biochemical immune related adverse events (irAEs) similar to what is observed in humans.

Results
In this study, we demonstrated how Treg depletion can model clinical irAEs and investigate methods to alleviate the toxicity induced by agonistic anti-CD40 and anti-CD137. First we demonstrated that biochemical irAEs such as increased inflammatory cytokines and liver toxicities were observed after transient Treg depletion and anti-CD40 and its severity varied depending on the mouse strain. We further demonstrated that treatment of these mice with anti-TNF reduced irAEs severity such as liver toxicity. Next, we demonstrated that Treg depletion specifically in the tumor in combination with systemic anti-CD137 suppressed tumour growth without inducing severe irAEs contrary to peripheral Treg depletion and anti-CD137 treatment where all mice died due to severe irAEs.

Conclusions
This study further highlights how Treg depletion can be used to rapidly model clinically observed irAEs and investigate methods to alleviate the toxicity of potent immunotherapies.

P716
An in vivo PBMC humanized mouse model for determining checkpoint and bispecific antibody treatment related cytokine release syndrome
Chunting Ye1, Mingshan Cheng1, Michael Brehm2, Dale Greiner2, Leonard Shultz1, James Keck, PhD1, James Keck, PhD1
1The Jackson Laboratory, Sacramento, CA, United States; 2University of Massachusetts Medical School, Worcester, MA, United States

Correspondence: James Keck (james.keck@jax.org)

Background
Although antibodies and CAR-T cell therapies have been successfully used for cancer treatment, they can have significant adverse effects such as cytokine release syndrome (CRS). The animal models and in vitro human PBMC assays presently in use unfortunately do not reliably predict the occurrence of CRS in patients. This significant gap between pre-clinical testing of novel therapies and clinical trials demonstrates a critical need for translational protocols that more accurately predict immune toxicity.

Methods
We have developed a rapid, sensitive and reproducible in vivo humanized mouse model for quantitating CRS. NSG mice and derivative
strains are engrafted with human PBMCs for 6 days then treated with various therapeutics such as bispecifics, pembrolizumab, avelumab, atezolizumab, ipilimumab, and anti-CD28 or OKT3 antibodies to determine their cytokine release levels in the mouse 6 hours later. In addition to single agent therapies, drug combinations with pembrolizumab, lenalidomide, ATG and anti-CD28 were also performed.

**Results**

At day 5 of PBMC engraftment, levels of human CD45+ cells ranged between 10 to 15% CD45+ human cells in peripheral blood consisting of approximately 70% CD3 T cells and 25% CD56 NK cells. All FACS tested cytokines, human IFN-γ, IL-2, IL-4, IL-6, IL-10 and TNF were upregulated 6 hours after injection with OKT3, ATG, anti-CD28, various checkpoint inhibitor and bispecific antibody drug treatments. Rectal temperatures of treated mice dropped from 37 to 38°C to about 36 °C at 6 post treatment. Clinical observations of mice showed health related issues with OKT3 and bispecific antibody treatment. Using multiple PBMC donors, variable cytokines release levels were evident with anti-CD28 treatment while most donors showed a high response to OKT3. The cytokine release levels were also determined to be consistent with a dose response or variable PBMC engraftment. The cytokine levels were also higher in some PBMC donors with drug combination studies such as pembrolizumab combined with lenalidomide or ATG; anti-CD28 combined with ATG. Direct comparison of the newly developed vivo model with a standard in vitro CRS assay demonstrated an increased sensitivity and accuracy in predicting CRS.

**Conclusions**

We have developed a rapid, sensitive and reproducible novel in vivo PBMC humanized mouse model that is able to differentiate human PBMC donors based on individual safety response to single agent and combination therapeutics of immune checkpoint inhibitors and possibly bispecific antibody and CAR-T therapy. Together these data indicate that our newly developed in vivo CRS assay has clinical relevance for future drug development.

**Ethics Approval**

The study#16000 was approved by The Jackson Laboratory IACUC committee on 3/12/19 and expires 3/12/22.

---

**P717**

**Involvement of IL17 in a case of fatal neuroendocrine toxicity associated with dual immune checkpoint blockade**

Luca Mazzarella, MD PhD1, Silvia Giugliano2, Paolo D’Amico1, Carmen Belli1, Bruno Duso1, Giuseppe Curigliano, MD, PhD1, Maria Rescigno, MD, PhD2

1IEO Istituto Europeo di Oncologia IRCCS, Milan, Italy; 2Istituto Humanitas, Rozzano (MI), Italy

**Correspondence:** Giuseppe Curigliano (giuseppe.curigliano@ieo.it)

**Background**

Severe neurological and endocrine toxicities are well recognized adverse events of immune checkpoint inhibitors (ICI). However, the underlying pathophysiology is poorly understood and classical circulating markers are often non-informative, making it difficult to obtain a precise diagnosis and to initiate timely and effective treatment.

**Methods**

We studied the case of a patient who developed fatal combined neurological and endocrine toxicity while on treatment with dual immune checkpoint blockade for his metastatic sarcomatoid mesothelioma. The syndrome was characterized by insulin-dependent diabetes, hypophysitis (see figure 1) with impairment of multiple endocrine axes and a myasthenia-like syndrome with predominant involvement of cranial districts. We tested in vitro dendritic cell (DC) activation upon incubation with patient’s plasma. By cytokine bead array (CBA), we compared patients’ levels of circulating cytokines (IFNg, IL4, IL5, IL6, IL13, IL17A and TGFb) with those in healthy subjects and cancer cases with comparable treatment history but no toxicity.

**Results**

Incubation with patient’s plasma resulted in upregulation of multiple DC activation markers, most prominently CD25 and CD11b. Levels of IL17A in patients’ plasma (18.3 ± 5.6 pg/ml) were significantly higher than in healthy controls (1.9 ± 1.9 pg/ml) or cancer cases with no toxicity (1.3 ± 1.8 pg/ml) (p=0.04 by one-way ANOVA, figure 2).

**Conclusions**

This is the first clinical report of an association between ICI-related neuroendocrine toxicity and elevation of IL17A, a Th17-produced cytokine involved in numerous autoimmune disorders of the central nervous system. If confirmed in larger series, this findings may point to a role for IL17A as a diagnostic and therapeutic target in the management of severe neuroendocrine toxicities.

**Ethics Approval**

The study was approved by the IEO Institution’s Ethics Board through its procedure for observational studies, approval number 2062.
P718
A case of dual-mechanism hematologic immune-related adverse event in a patient with metastatic melanoma treated with combined nivolumab and ipilimumab

Daniel Olson, MD1, Daniel Olson, MD1, Melissa Tjota, MD, PhD1, Padma Rajagopal, MD1, Girish Venkitaraman, MD, MD2, Jason Luke, MD, FACCP1, Thomas Gajewski, MD, PhD1
1The University of Chicago, Chicago, IL, United States; 2The University of Pittsburgh, Pittsburgh, PA, United States

Correspondence: Daniel Olson (dolson2@medicine.bsd.uchicago.edu)

Background
The combination of the immune checkpoint inhibitors (ICI) anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab) has become a mainstay of treatment for select patients with metastatic melanoma. The use of combination ICIs, while demonstrating higher grades of anti-tumor activity over either ICI alone, also results in more frequent immune-related adverse events (irAEs) [1]. While the CTLA-4 and PD-1 pathways regulate autoimmunity at different stages of an immune response, the exact mechanisms by which ICIs generate specific irAEs is not yet well-understood.

Methods
Here we report a case of simultaneous T cell-mediated red cell aplasia and antibody-mediated auto-immune hemolytic anemia (AIHA) in a patient receiving combined ICI therapy for metastatic melanoma.

Results
A 29-year-old woman with melanoma metastatic to the small bowel presented with worsening fatigue after completing four cycles of combination nivolumab and ipilimumab. Laboratory results were strongly suggestive of AIHA, including: a hemoglobin of 6.1g/dL, undetectable haptoglobin, elevated lactate dehydrogenase, and a positive Coombs test. However, the reticulocyte count was abnormally low for the degree of anemia (reticulocyte production index 0.0). She was given transfusion support and started on high-dose intravenous, then oral steroids. By the following visit, the hemoglobin fell to 5.5g/dL with ongoing reticulocytopenia. Intravenous steroids were again initiated and a bone marrow biopsy was performed; this demonstrated a substantial T cell infiltrate. The marrow core biopsy sections were hypercellular with an atypical lymphoid infiltrate. 25% of all cells stained as CD8+, and the CD4:CD8 ratio was abnormally shifted to 1:3, showing predominance of CD8+ T cells. Perforin was also increased suggesting a cytotoxic T cell phenotype. These observations were consistent with T cell-mediated destruction of the absent red cell precursors. Given lack of reticulocyte response to corticosteroids, T cell-directed immunosuppression was initiated with cyclosporine A along with continued steroid administration for AIHA. The reticulocyte count increased over the next week; within one month the hemoglobin level had normalized. A steroid taper was completed, and all immunosuppression was ceased within three months. Upon repeat imaging, the patient experienced a complete response to ICI therapy and remains in observation alone.

Conclusions
This report describes a rare case of two concurrent hematologic irAEs in a patient treated with combined ICI therapy: 1) autoantibody mediated AIHA and 2) CD8+ T cell-mediated red cell aplasia. Successful treatment resulted only after the second underlying mechanism of toxicity was uncovered. Prompt recognition of these unusual presentations of irAEs are now is now key to effective irAE management.

References

P719
CD8+ T cell integrin 4β7 expression: a potential predictor of severity and steroid sensitivity in checkpoint inhibitor induced colitis

Anna Olsson-Brown, MBChB (Hons), BSc (Hons)1, Joseph Sacco, MSc2, MBChB, MRCP, Ph1, Anna Olsson-Brown, MBChB (Hons), BSc (Hons)2
1University of Liverpool, Clatterbridge Cancer Centre, Liverpool, United Kingdom; 2University of Liverpool, Liverpool, United Kingdom; 3University of Oxford, Oxford, United Kingdom

Correspondence: Anna Olsson-Brown (acob@liv.ac.uk)

Background
Colitis a common immune related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy with severe toxicity occurring in up to 25% of patients receiving therapy[1]. It is one of the most complex irAEs to treat often requiring inpatient management and the use of additional immunosuppression beyond corticosteroids. The use of infliximab is widely accepted but use of gut specific agents such as the anti-integrin therapy vedolizumab is increasing. The rationale is that as a high gut targeted therapy it presents the potential for therapeutic benefit without risking impact on oncological efficacy. However the evidence for this remains limited and patient selection unclear.

Methods
As part of an established observational study peripheral PBMCs were isolated from patients presenting with colitis secondary to ICI therapy for malignant melanoma. Samples were taken at the onset of colitis at the time of endoscopical investigation. Control patients had received at least 4 months of ICI therapy without any irAEs. Those with colitis were assessed for severity via endoscopic/ histological assessment and followed up to determine the duration of corticosteroids required. Mass Cytometry utilizing a Fluidigm Helios (CyTOF3) platform was undertaken with a 16 marker panel including 12 cellular markers and 4 gut homing markers (Table 1). Cytometry analysis was undertaken using Cytobank software. Data was analysed using ANOVA in GraphPad Prism v8.2.0.

Results
A total of 18 patient samples were analysed (12 colitis patients and 6 controls). Colitis patients were stratified by endoscopichistological severity and duration of steroid therapy (80 days). The populations of CD8, CD4 and Treg populations were not found to be significantly different between affected patients and tolerant controls. With regards to the gut homing markers the expression of the 4β7 integrin heterodimer was found to be differentially expressed on peripheral CD45+CD3+CD8+ cells. There was a significant difference in expression in those found to have mild and severe colitis on investigation with those having severe endoscopy findings having an elevated 4β7 expression (p=0.0315). Additionally there was an increased expression of 4β7 in patients who required long-term steroid-related to those requiring short term steroids (p=0.0105).

Conclusions
This is preliminary data however the differential expression of CD45+CD3+CD8+ 4β7 at the initiation of toxicity highlights its potential to predict steroid sensitivity. Given the increased expression of 4β7 in patients with severe investigative findings could endorse the use of anti-integrin directed therapy in patients with investigation-diagnosed severe ICI-induced colitis.

Acknowledgements
Dr Anna Olsson-Brown is a MRC Clinical Research Fellow based at the University of Liverpool and is supported by the North West England Medical Research Counical Fellowship Scheme in Clinical Pharmacology and Therapeutics which is funded by the medical research council (Award Ref MR/N025989/1) Roche Pharma, Eli Lily and company limited, UCB Pharma, Novartis, the University of Liverpool and the University of Manchester. The authors would also like to acknowledge the support of the cell sorting and isolation facility, Technology Directorate, University of Liverpool.
The use of in vitro assays to reduce the risk of unwanted immunogenicity

Amin Osman3, Thibault Jonckheere3, Sofie Pattijn3, Mayuko Oh3, Jana Schockaert, MS3

The ImmunXpert S.A., Belgium

Correspondence: Amin Osman (osman@immunxpert.com)


The use of in vitro assays to reduce the risk of unwanted immunogenicity

Amin Osman3, Thibault Jonckheere3, Sofie Pattijn3, Mayuko Oh3, Jana Schockaert, MS3

The ImmunXpert S.A., Belgium

Correspondence: Amin Osman (osman@immunxpert.com)


The use of in vitro assays to reduce the risk of unwanted immunogenicity

Amin Osman3, Thibault Jonckheere3, Sofie Pattijn3, Mayuko Oh3, Jana Schockaert, MS3

The ImmunXpert S.A., Belgium

Correspondence: Amin Osman (osman@immunxpert.com)


The use of in vitro assays to reduce the risk of unwanted immunogenicity

Amin Osman3, Thibault Jonckheere3, Sofie Pattijn3, Mayuko Oh3, Jana Schockaert, MS3

The ImmunXpert S.A., Belgium

Correspondence: Amin Osman (osman@immunxpert.com)


The use of in vitro assays to reduce the risk of unwanted immunogenicity

Amin Osman3, Thibault Jonckheere3, Sofie Pattijn3, Mayuko Oh3, Jana Schockaert, MS3

The ImmunXpert S.A., Belgium

Correspondence: Amin Osman (osman@immunxpert.com)


The use of in vitro assays to reduce the risk of unwanted immunogenicity

Amin Osman3, Thibault Jonckheere3, Sofie Pattijn3, Mayuko Oh3, Jana Schockaert, MS3

The ImmunXpert S.A., Belgium

Correspondence: Amin Osman (osman@immunxpert.com)


The use of in vitro assays to reduce the risk of unwanted immunogenicity

Amin Osman3, Thibault Jonckheere3, Sofie Pattijn3, Mayuko Oh3, Jana Schockaert, MS3

The ImmunXpert S.A., Belgium

Correspondence: Amin Osman (osman@immunxpert.com)


The use of in vitro assays to reduce the risk of unwanted immunogenicity

Amin Osman3, Thibault Jonckheere3, Sofie Pattijn3, Mayuko Oh3, Jana Schockaert, MS3

The ImmunXpert S.A., Belgium

Correspondence: Amin Osman (osman@immunxpert.com)


The use of in vitro assays to reduce the risk of unwanted immunogenicity

Amin Osman3, Thibault Jonckheere3, Sofie Pattijn3, Mayuko Oh3, Jana Schockaert, MS3

The ImmunXpert S.A., Belgium

Correspondence: Amin Osman (osman@immunxpert.com)


The use of in vitro assays to reduce the risk of unwanted immunogenicity

Amin Osman3, Thibault Jonckheere3, Sofie Pattijn3, Mayuko Oh3, Jana Schockaert, MS3

The ImmunXpert S.A., Belgium

Correspondence: Amin Osman (osman@immunxpert.com)


The use of in vitro assays to reduce the risk of unwanted immunogenicity

Amin Osman3, Thibault Jonckheere3, Sofie Pattijn3, Mayuko Oh3, Jana Schockaert, MS3

The ImmunXpert S.A., Belgium

Correspondence: Amin Osman (osman@immunxpert.com)


The use of in vitro assays to reduce the risk of unwanted immunogenicity

Amin Osman3, Thibault Jonckheere3, Sofie Pattijn3, Mayuko Oh3, Jana Schockaert, MS3

The ImmunXpert S.A., Belgium

Correspondence: Amin Osman (osman@immunxpert.com)


The use of in vitro assays to reduce the risk of unwanted immunogenicity

Amin Osman3, Thibault Jonckheere3, Sofie Pattijn3, Mayuko Oh3, Jana Schockaert, MS3

The ImmunXpert S.A., Belgium

Correspondence: Amin Osman (osman@immunxpert.com)

Opportunistic infection outcomes in patients receiving corticosteroids for immune checkpoint inhibitor toxicity

Michael Cook, MD, Michael Cook, MD, Michael Atkins, MD
MedStar Georgetown University Hospital, Washington, DC, United States

Correspondence: Michael Cook (mrc5282@gmail.com, mba41@georgetown.edu)


Background
Immune checkpoint inhibitor (ICI) therapy is commonly used in the treatment of advanced malignancy. Immune-related adverse events (irAEs) are a common side effect from therapy, requiring high dose corticosteroids to limit morbidity[1,2]. Currently the NCCN recommends Pneumocystis jiroveci pneumonia (PJP) prophylaxis in patients treated with 20mg of prednisone equivalent for at least four weeks, but little is known about the incidence of PJP, opportunistic infections (OI), or non-opportunistic infections in this patient population.

Methods
We performed a retrospective analysis of patients treated with ICI therapy at five MedStar Health hospitals from January 2011 to April 2016. We identified 758 patients treated with ICIs; 113 were prescribed a minimum of 20mg of prednisone equivalent for more than four weeks for immune related adverse events. The incidence of use of non-corticosteroid immunosuppressive medication, prophylactic antibiotic usage, OI, non-OI infection, and infection outcome was analyzed.

Results
Of the 113 patients the most common cancers were melanoma (69) and non-small cell lung cancer (21). The most common ICI therapies implicated were nivolumab plus ipilimumab (35), nivolumab (28), ipilimumab (25), and pembrolizumab (20). The median starting steroid dose was 100mg of prednisone, and 25% of patients (n=28) were taking additional immunosuppressive medications (infliximab, n=15; mycophenolate mofetil, n=8; vedolizumab, n=2; tocilizumab, methotrexate, anti-thymoglobulin, 1 each). PJP prophylaxis with sulfamethoxazole/trimethoprim was given to 12% of patients (n=14). The incidence of patients with any documented infections, which required antimicrobial therapy during ICI treatment, was 19% (n=22). These infections included 4 patients (3%) with opportunistic infections (Table 1; 2 reactivations of non-disseminated varicella zoster infection (VZV), PJP, and Listeria monocytogenes endophthalmitis, 1 each). Additional non-OI included Clostridium difficile (n=5), oral candidiasis (n=4), hospital acquired/ventilator associated pneumonia (n=3), urinary tract infection (n=3) cellulitis (n=2), community acquired pneumonia, osteomyelitis/bacteremia, and sinusitis, 1 each.

Conclusions
Our findings suggests that the incidence of OI is low (< 3%) in patients treated with prolonged corticosteroid therapy alone for irAEs due to ICIs and raise questions about the value of prophylactic antibiotics in this population. Further, given the distribution of OI in this analysis, sulfamethoxazole/trimethoprim as the lone choice of prophylactic antimicrobial coverage could also be questioned. Further analyses are needed to validate above findings.

References

Ethics Approval
The study was approved by MedStar Georgetown University Hospital Ethics Board, approval number 2017-0559.
Background
Understanding of the immunobiology of checkpoint inhibitors (CPI) induced immune related toxicities, as well as immune related colitis, and how these compare to the immune signatures in tumors could lead to the development of strategies that de-couple autoimmunity from anti-tumor immunity. Interleukin 6 (IL-6), a pleiotropic cytokine promoting tumor progression and essential for Th17 lineage commitment of naive CD4+ T-cells has been implicated in the development of autoimmune diseases. Here, we are presenting clinical and preclinical data on the impact of IL-6 blockade to de-couple autoimmunity and tumor immunity.

Methods
Total RNA from patient-matched colitis and normal colon FFPE tissue from patients (n=23) receiving CPI were profiled with the 770 gene NanoString nCounter PanCancer Immune Profiling Panel (NanoPCIP). The gene expression fold increase normal vs. iREC normal colonic tissue and baseline vs. on-treatment tumor samples from patients responding or non-responding per RECIST v1.1 to ipilimumab-based therapy were analyzed. To evaluate the effect of IL-6 blockade on anti-tumor activity, mice with B16.BL6 or CT-26 tumor received systemic anti-CTLA-4, anti-PD-1 or anti-CTLA-4 and anti-PD-1 with or without anti-IL-6 (mAb114) blockade and tumor sizes were measured and immune cell profiles were analyzed using cyttof and flow cytometry and chemokine and cytokine levels were quantitated by Luminex.

Results
In patients with colitis, the highest significantly upregulated differentially expressed gene (DEG) in inflamed colon tissue encoded for IL-6 (+24.1) followed by genes for neutrophil and monocyte chemotactic molecules. Interestingly, IL-6 was also the highest upregulated DEG in non-responding tumors numerically. There was no overlap between DEGs upregulated in colitis and responding-tumors. Gene sets expression analysis indicated significantly higher Th17 than Th1 upregulation in colitis compared to normal colonic. Further imaging cytof and flow cytometry and chemokine and cytokine levels were quantitated by Luminex.

Conclusions
Our human-tissue data demonstrates that IL-6-mediated-inflammation may be more prevalent in colitis than in responding-tumors, and in mice blocking IL-6 enhances CPI anti-tumor response. Targeting IL-6 may ameliorate colitis without hindering anti-tumor immunity. A clinical trial evaluating concomitant IL-6 blockade with ipilimumab and nivolumab is being initiated.

References

Correspondence: Adi Diab (Adi@mdanderson.org)

Interleukin-6 blockade to de-couple CTLA-4 blockade colitis from anti-tumor efficacy
Yared Hailemichael, PhD, Daniel Johnson, MD, Wai Foo, Kenneth Hess, BS, MS, PhD, Cara Haymaker, PhD, Chantal Saberian, MD, Salah Bentebibel, Elizabeth Burton, Yinghong Wang, MD, PhD, Scott Woodman, Patrick Hwu, MD, Adi Diab, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Analysis of healthcare provider management of immune-related adverse events and concordance with NCCN Guidelines
Megan Cartwright, PhD1, Megan Cartwright, PhD1, Krista Marcello, BA1, Jillian Scavone, PhD2, Kevin Obholz, PhD2, Timothy Quill, PhD2, John Thompson3
1Clinical Care Options, LLC, Reston, VA, United States; 2National Comprehensive Cancer Network®, University of Washington, Seattle, WA, United States

Background
Immune checkpoint inhibitors (ICIs) have dramatically altered the therapeutic landscape across oncology. However, ICIs are associated with a unique safety profile involving immune-related adverse events (irAEs) that require prompt recognition and management to ensure optimal patient safety. In 2017, we developed an online interactive decision support tool at www.clinicaloptions.com/immuneAETool to provide healthcare providers (HCPs) case specific, evidence-based guidance on management of irAEs and reported substantial variances in practice compared with expert recommendations [1]. The National Comprehensive Cancer Network® (NCCN) publishes guidelines for managing irAEs in patients treated with ICIs across all organ systems [2]. In 2019, our interactive tool was updated to incorporate case-specific irAE management recommendations from the new NCCN Guidelines [3]. Here, we report a comparison of HCP-reported planned irAE management strategies vs the corresponding NCCN recommendations provided via the 2019 irAE tool.

Methods
To use the online tool, HCPs enter the organ system affected and the grade or severity of the symptom along with their planned management strategy. The HCPs were then shown the NCCN management recommendation for that specific irAE scenario. After viewing the NCCN management recommendation, HCPs were asked if it affected their intended management approach.

Results
Between February and June 2019, 737 HCPs entered 972 unique case scenarios into the tool. 58% of cases were entered by clinicians who treat ≤20 patients/year with ICIs. The most frequently entered irAEs involved the gastrointestinal, dermatologic, and pulmonary systems (28%, 24%, and 19% of cases), similar to our previous practice analysis [1]. Overall, the planned irAE management strategy of HCPs matched the NCCN recommendations in 39% of cases, with the greatest divergence in cardiovascular and dermatologic irAE management (Figure 1). The proportion of cases in which the planned management strategies of HCPs matched the NCCN recommendations also varied by symptom grade/severity, with lower concordance (31%) observed for the management of grade 3/4 events compared with grade 1/2 events (43%). 48% of HCPs indicated that the NCCN recommendations provided by the tool changed their management plan.

Conclusions
These data suggest that many HCPs are challenged to optimally manage irAEs associated with ICI and are not managing their patients in concordance with the NCCN guidelines. Use of an online tool providing easy access to NCCN Guidelines recommendations improves patient care and safety. A detailed analysis of the tool.

Table 1 (abstract P722). See text for description

<table>
<thead>
<tr>
<th>DEG</th>
<th>IC</th>
<th>irAE</th>
<th>Staining duration (days)</th>
<th>Additional Immunosuppressive medication</th>
<th>Prophylactic Antibiotics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Listeria Monocytogenes</td>
<td>Niv/Ip</td>
<td>Colitis</td>
<td>27</td>
<td>Infliximab</td>
<td>N/A</td>
</tr>
<tr>
<td>PIP</td>
<td>Niv/Ip</td>
<td>Colitis, Rash</td>
<td>89</td>
<td>Infliximab</td>
<td>N/A</td>
</tr>
<tr>
<td>VZV</td>
<td>Niv/Ip</td>
<td>Pneumonia</td>
<td>101</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>VZV</td>
<td>Niv/Ip</td>
<td>Pneumonia</td>
<td>113</td>
<td>Sulfamethoxazole/ Trimethoprim</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Adrenal insufficiency, 6% had subsequent workup with ACTH, 11% of the undiagnosed patients, 5% had biochemical and clinical findings suggestive of adrenal insufficiency, including fatigue, nausea, hypotension, and hyperkalemia, that was not further worked up in the setting of pembrolizumab and 10% in the setting of nivolumab. No anti-21 hydroxylase antibodies were drawn.

Conclusions
As ICIs are being used with increasing frequency, it is crucial for health care providers to recognize the characteristics of immune-mediated adrenal insufficiency and initiate the appropriate workup, treatment, and referrals. Based on our preliminary findings, we have found that a majority of cortisol levels are ordered as part of routine screening of ICI infusion but without proper work-up or follow up when levels meet criteria for AI. Few patients receive ACTH or antibody testing and are initiated on adrenal replacement or referred to endocrinology. Thus, we recommend a greater awareness and more systematic approach to diagnosing and managing AI in patients on ICIs.

References

Machine Learning, Artificial Intelligence, and Computational Modeling

P726
Applying deep learning classification for tumor identification across immunohistochemical markers on serial sections to eliminate the need for image co-registration

Mark Anderson, BSc, Mark Anderson, BSc, Karen McClymont, Lorcan Sherry, PhD, Alison Bigley, CSci, FBMS
OracleBio, North Lanarkshire, United Kingdom

Correspondence: Mark Anderson (mark.anderson@oraclebio.com)

Background
Artificial intelligence deep learning networks are being increasingly applied to resolve complex pattern recognition challenges in quantitative digital pathology. Khorasani [1], utilized deep learning to discriminate and classify tumors and associated subtypes using a range of immunohistochemically (IHC) labelled tumor sections, even where tumors were significantly heterogeneous.

Image co-registration is commonly employed in brightfield quantitative workflows where serial sections have been IHC labelled with different markers, one of which is a tumor marker such as pan-Cytokeratin, which is used to guide the tumor locations in the corresponding serial section. Frequently, alignment errors occur in particular at the periphery of tumor foci, where either tumor cells are missed or adjacent stroma is incorrectly classified as tumor.

Deep learning classifiers can be trained across a range of sections and markers to define tumor regions of interest (ROI), utilizing a range of features from each stained sample to generate a classifier, capable of identifying tumor ROI independent of the tissue, stain or marker.

Here we use serial tissue microarray (TMA) sections of gastric adenocarcinoma, labelled with pan-Cytokeratin and CD3, to exemplify the use of a deep learning approach to distinguish tumor foci without requiring serial section image co-registration.

Methods
Exemplar TMA serial sections of gastric adenocarcinomas were IHC labelled for pan-Cytokeratin and CD3, using DAB chromogen and were treated with hydrocortisone, 2% were referred to endocrine. Of the undiagnosed patients, 5% had biochemical and clinical findings suggestive of adrenal insufficiency, including fatigue, nausea, hypotension, and hyperkalemia, that was not further worked up in the setting of pembrolizumab and 10% in the setting of nivolumab. No anti-21 hydroxylase antibodies were drawn.

Conclusions
As ICIs are being used with increasing frequency, it is crucial for health care providers to recognize the characteristics of immune-mediated adrenal insufficiency and initiate the appropriate workup, treatment, and referrals. Based on our preliminary findings, we have found that a majority of cortisol levels are ordered as part of routine screening of ICI infusion but without proper work-up or follow up when levels meet criteria for AI. Few patients receive ACTH or antibody testing and are initiated on adrenal replacement or referred to endocrinology. Thus, we recommend a greater awareness and more systematic approach to diagnosing and managing AI in patients on ICIs.

References

Machine Learning, Artificial Intelligence, and Computational Modeling

P726
Applying deep learning classification for tumor identification across immunohistochemical markers on serial sections to eliminate the need for image co-registration

Mark Anderson, BSc, Mark Anderson, BSc, Karen McClymont, Lorcan Sherry, PhD, Alison Bigley, CSci, FBMS
OracleBio, North Lanarkshire, United Kingdom

Correspondence: Mark Anderson (mark.anderson@oraclebio.com)

Background
Artificial intelligence deep learning networks are being increasingly applied to resolve complex pattern recognition challenges in quantitative digital pathology. Khorasani [1], utilized deep learning to discriminate and classify tumors and associated subtypes using a range of immunohistochemically (IHC) labelled tumor sections, even where tumors were significantly heterogeneous.

Image co-registration is commonly employed in brightfield quantitative workflows where serial sections have been IHC labelled with different markers, one of which is a tumor marker such as pan-Cytokeratin, which is used to guide the tumor locations in the corresponding serial section. Frequently, alignment errors occur in particular at the periphery of tumor foci, where either tumor cells are missed or adjacent stroma is incorrectly classified as tumor.

Deep learning classifiers can be trained across a range of sections and markers to define tumor regions of interest (ROI), utilizing a range of features from each stained sample to generate a classifier, capable of identifying tumor ROI independent of the tissue, stain or marker.

Here we use serial tissue microarray (TMA) sections of gastric adenocarcinoma, labelled with pan-Cytokeratin and CD3, to exemplify the use of a deep learning approach to distinguish tumor foci without requiring serial section image co-registration.

Methods
Exemplar TMA serial sections of gastric adenocarcinomas were IHC labelled for pan-Cytokeratin and CD3, using DAB chromogen and were treated with hydrocortisone, 2% were referred to endocrine. Of the undiagnosed patients, 5% had biochemical and clinical findings suggestive of adrenal insufficiency, including fatigue, nausea, hypotension, and hyperkalemia, that was not further worked up in the setting of pembrolizumab and 10% in the setting of nivolumab. No anti-21 hydroxylase antibodies were drawn.

Conclusions
As ICIs are being used with increasing frequency, it is crucial for health care providers to recognize the characteristics of immune-mediated adrenal insufficiency and initiate the appropriate workup, treatment, and referrals. Based on our preliminary findings, we have found that a majority of cortisol levels are ordered as part of routine screening of ICI infusion but without proper work-up or follow up when levels meet criteria for AI. Few patients receive ACTH or antibody testing and are initiated on adrenal replacement or referred to endocrinology. Thus, we recommend a greater awareness and more systematic approach to diagnosing and managing AI in patients on ICIs.

References

Machine Learning, Artificial Intelligence, and Computational Modeling

P726
Applying deep learning classification for tumor identification across immunohistochemical markers on serial sections to eliminate the need for image co-registration

Mark Anderson, BSc, Mark Anderson, BSc, Karen McClymont, Lorcan Sherry, PhD, Alison Bigley, CSci, FBMS
OracleBio, North Lanarkshire, United Kingdom

Correspondence: Mark Anderson (mark.anderson@oraclebio.com)

Background
Artificial intelligence deep learning networks are being increasingly applied to resolve complex pattern recognition challenges in quantitative digital pathology. Khorasani [1], utilized deep learning to discriminate and classify tumors and associated subtypes using a range of immunohistochemically (IHC) labelled tumor sections, even where tumors were significantly heterogeneous.

Image co-registration is commonly employed in brightfield quantitative workflows where serial sections have been IHC labelled with different markers, one of which is a tumor marker such as pan-Cytokeratin, which is used to guide the tumor locations in the corresponding serial section. Frequently, alignment errors occur in particular at the periphery of tumor foci, where either tumor cells are missed or adjacent stroma is incorrectly classified as tumor.

Deep learning classifiers can be trained across a range of sections and markers to define tumor regions of interest (ROI), utilizing a range of features from each stained sample to generate a classifier, capable of identifying tumor ROI independent of the tissue, stain or marker.

Here we use serial tissue microarray (TMA) sections of gastric adenocarcinoma, labelled with pan-Cytokeratin and CD3, to exemplify the use of a deep learning approach to distinguish tumor foci without requiring serial section image co-registration.

Methods
Exemplar TMA serial sections of gastric adenocarcinomas were IHC labelled for pan-Cytokeratin and CD3, using DAB chromogen and were treated with hydrocortisone, 2% were referred to endocrine. Of the undiagnosed patients, 5% had biochemical and clinical findings suggestive of adrenal insufficiency, including fatigue, nausea, hypotension, and hyperkalemia, that was not further worked up in the setting of pembrolizumab and 10% in the setting of nivolumab. No anti-21 hydroxylase antibodies were drawn.

Conclusions
As ICIs are being used with increasing frequency, it is crucial for health care providers to recognize the characteristics of immune-mediated adrenal insufficiency and initiate the appropriate workup, treatment, and referrals. Based on our preliminary findings, we have found that a majority of cortisol levels are ordered as part of routine screening of ICI infusion but without proper work-up or follow up when levels meet criteria for AI. Few patients receive ACTH or antibody testing and are initiated on adrenal replacement or referred to endocrinology. Thus, we recommend a greater awareness and more systematic approach to diagnosing and managing AI in patients on ICIs.

References
counterstained with hematoxylin. The stained slides were digitized using a Zeiss scanner. The sections were analyzed using DeepLabV3 network in Visiopharm Oncotopix Software. Classes were established for tumor, stroma and background, at x10 input magnification, using identical example training labels across the IHC images.

**Results**

Tumor and stroma were accurately identified across the serial sections using a single deep learning algorithm. Applying a Dice similarity coefficient confirmed a high-level correlation between manual ROI and deep learning classifications for the 2 markers.

**Conclusions**

The exemplar data demonstrated the application of a single classifier, across IHC images, enabling the identification of tumor and stroma, irrespective of marker. This approach has demonstrated that it is possible to accurately utilize multifaceted features, from different IHC markers on TMA tissue sections, for the accurate classification of tumor and stroma ROI. This approach provides an alternative method to co-registration of images for tumor assignment across serial sections.

### References


**P727**

Single-cell systems neuroimmunology reveals immunosuppressive checkpoint blockade receptor expression correlates with ventricular stem cell niche contact in human glioblastoma

Todd Bartkowiak, PhD1, Sierra Barone, BS2, Allison Greenplate, PhD1, Justine Sinnaeve, BS1, Nalin Leelatan, Akshikumar Mistry, MD2, Caroline Roe, BS1, Bret Mobley, MD1, Lola Chambless, MD2, Reid Thompson, MD2, Kyle Weaver, MD1, Rebecca Ihrie, PhD2, Jonathan Irish, PhD2

1Vanderbilt University, Nashville, TN, United States; 2Vanderbilt University Medical Center, Nashville, TX, United States

**Correspondence:** Rebecca Ihrie (rebecca.ihrie@vanderbilt.edu), Jonathan Irish (jonathan.irish@vanderbilt.edu)

**Journal for ImmunoTherapy of Cancer** 2019, 7(Suppl 1):P727

### Background

Glioblastomas make up more than 60% of adult primary brain tumors and carry a median survival of less than 15 months despite aggressive standard therapy. Immunotherapy, now standard of care for many solid tumors, offers an appealing alternative platform that may improve survival outcomes for patients with glioblastoma; however, predictive features that could inform responsiveness to different immunotherapeutic modalities remains to be elucidated. Recent studies have demonstrated that patients whose tumors show radiographic contact with the ventricular-subventricular zone (V-SVZ) have diminished survival outcomes compared to V-SVZ contacting and non-contacting glioblastomas. These results provide key insights into the immune microenvironment of glioblastoma, identifying the potential for clinically actionable immunotherapeutic targets that may be optimized to treat glioblastomas based on V-SVZ contact status.

### Methods

Whole slide (40x-magnified) H&E images of lung adenocarcinoma from TCGA were used to train a computational model to infer TMB and PD-L1 status. Modeling occurred in two layers: first, a two-layer model achieved an accuracy of 81% in predicting both TMB (AUC = 0.81) and PD-L1 status (AUC = 0.86) in the testing dataset.

### Results

On the basis of tumor contact with the V-SVZ, the Citrus and FlowSOM clustering algorithms computationally identified consequential distinctions in the abundance of five T cell, macrophage, and microglia subsets among glioblastomas. In addition, differential expression of five functional immune markers (three activating receptors and two inhibitory receptors) was observed in seven distinct immune cell subsets infiltrating tumors. Critically, the abundance of identified immune subsets and relative immune receptor expression levels correlated significantly with tumor contact status and patient outcomes. Biaxial gating analysis and parallel computational pipelines confirmed that comparable cell subsets could be identified with traditional approaches and unsupervised algorithmic analysis.

### Conclusions

Single-cell mass cytometry in conjunction with the Citrus and FlowSOM clustering tools identified key differences in immune cell abundance between V-SVZ contacting and non-contacting glioblastomas. These results provide key insights into the immune microenvironment of glioblastoma, identifying the potential for clinically actionable immunotherapeutic targets that may be optimized to treat glioblastomas based on V-SVZ contact status.

### Ethics Approval

This study was approved by the Institutional Review Board at Vanderbilt University, approval #131870, #030372, and #181970.
Conclusions
Biomarker inference from digital H&E images has the potential to be highly accurate and to supplement or replace certain tissue-based tests. Use of known biological features makes the model interpretable and verifiable by pathologists. This method may enable testing in patients whose tumor tissue has been exhausted or who cannot undergo re-biopsy to enable biomarker testing. This technology can return test results within hours instead of days or weeks, enabling rapid treatment decision-making and start. Ongoing work to improve accuracy of the model, assess model correlation to PD-L1 by IHC and gene panel-derived TMB, and to evaluate the model’s correlation to clinical outcomes is in progress.

P730
An empirical framework for validating artificial intelligence-derived PD-L1 positivity predictions using samples from patients with urothelial carcinoma
Andrew Beck, MD, PhD1, Benjamin Glass 1, Hunter Elliott 1, Jennifer Kerner 1, Aditya Khosla 1, Abhik Lahiri 1, Harsha Pokkalla 1, Dayong Wang 1, Ilan Wapinski 1, George Lee, PhD, PhD1, Vipul Baxi, MS, Cysr Hedvat, MD, PhD, Dimple Pandya 2, Michael Montalto 2
1PathAI, Inc. Boston, MA, United States; 2Bristol-Myers Squibb, Princeton, NJ, United States
Correspondence: Ilan Wapinski (ilan.wapinski@pathai.com)

Background
Assessing PD-L1 immunohistochemistry (IHC) expression may play a role in identifying patients likely to benefit from anti-PD-1/PD-L1 therapies in some advanced cancers, including urothelial carcinoma (UC). Studies have shown variable inter-observer agreement for pathologist assessment of PD-L1 expression, with generally higher levels of concordance for tumor cell scoring compared with immune cell scoring [1,2]. Thus, immune cell PD-L1 scoring may be more challenging to implement than scoring on tumor cells. We evaluated the performance of an artificial intelligence (AI)-based predictor of PD-L1 expression on tumor and/or immune cells in the tumor microenvironment and compared this with manual evaluations by a network of pathologists to identify whether the AI platform performed more consistently.

Methods
PD-L1 was assessed using the PD-L1 IHC 28-8 pharmDx assay (Dako, Agilent Technologies Co). The training set for this exploratory analysis consisted of 293 pretreatment samples from patients with advanced UC, commercially procured or from clinical trials of nivolumab [3,4]. From these, we obtained 105,514 annotations of tumor and immune cells from 43 pathologists. To establish a reference dataset for manual vs digital concordance using the platform (PathAI, not intended for diagnostic use), we generated 80150x150-ence dataset for manual vs digital concordance using the platform tumor and immune cells from 43 pathologists. To establish a reference UC, commercially procured or from clinical trials of Agilent Technologies Co). The training set for this exploratory analysis consisted of 293 pretreatment samples from patients with advanced UC, commercially procured or from clinical trials of nivolumab [3,4].

References

Ethics Approval
The protocol was approved by site institutional review boards or independent ethics committees and conducted according to Good Clinical Practice guidelines, per the International Conference on Harmonisation. Patients provided written informed consent based on Declaration of Helsinki principles.

P731
Identification and validation of shared neoantigens for cancer immunotherapy
Jennifer Busby, PhD, Melissa Rotunno, Tyler Murphy, William Brinton, Michael Zhong, Lina Kim, Abu Jalloh, Amanda Costa, Michael Fray, Aaron Yang, Meghan Hart, Matthew Davis, Rita Zhou, Elizabeth Maloney, Alexis Mantila, Karin Jooss, PhD, Aleksandra Nowicka, Christine Palmer, PhD, James Sun, Roman Yelensky, PhD, Jennifer Busby, PhD
Gritstone Oncology, Inc, Cambridge, MA, United States
Correspondence: Roman Yelensky (yelensky@gritstone.com)

Background
Neoantigens can be targeted with cancer immunotherapies, including cell therapy and immunization, but most neoantigens are private to each patient, necessitating fully personalized treatments. Identification of solid tumor-presented neoantigens that may be shared across patients holds great value for the generation of off-the-shelf therapies.

Methods
We pursued an immunopeptidomics strategy to identify which recurrent mutations in cancer lead to neoantigenic peptides presented on the surface of tumor cells. 498 frozen resected tumor samples and 6 cell lines across 14 tumor types (including 139 NSCLC and 139 CRC) were subjected to transcriptome RNASeq. Transcriptomes were analyzed to identify recurrent driver mutations and used to predict HLA peptide epitopes with our deep learning model EDGE [1]. Additionally, single HLA class I allele expressing K562 cells were transduced with vectors expressing shared mutations of interest. Predicted peptides were assayed in the tumors and cell lines by Class I HLA immunoprecipitation and targeted mass spec. For a subset of peptides, we evaluated if CD8 T-cell precursors are found in the naive repertoire of HLA-matched donors.

Results
16 neoantigens (distinct HLA/mutation pairs) derived from 10 driver mutations were detected by M5 in 27 tumors and 3 single allele cell lines. Only 1 of these neoantigens (KRAS G12V/HLA-A*11:01) was pathologist-based scoring in all cell types tested, and especially for immune cells where manual correlation is low. These results suggest that AI-powered assessment represents a reproducible and potentially generalizable approach to interpretation of IHC assays.
previously reported in patients. The driver mutation with most neoantigens was KRAS G12V, with peptides detected on 4 HLA alleles, accounting for ~40% of patients with the mutation. Importantly, HLA-A*0201 was not found to present KRAS G12V. Other neoantigen peptides were detected in genes including KRAS, CTNNB1 and TP53. When combined with the few published neoantigens, the set was estimated to cover 9% of NSCLC, 11% of MSS-CRC, and 19% of pancreatic cancer patients, accounting for HLA restriction. Precursor CD8 T cells were detected for 6 out of 7 tested HLA/peptide pairs arising from mutations in KRAS and CTNNB1, recognized by a median of 46 TCR clonotypes, highlighting their immunogenic potential.

Conclusions
We analyzed immunopeptidomes of human tumors and cell lines and validated 15 novel shared neoantigens, the largest set to date. The study enables off-the-shelf immunotherapies for significant fractions of patients and highlights the value of HLA screening, as mutations are presented by specific HLA alleles. Shared neoantigen targets identified in this study, among others, are currently being tested in patients in the SLATE clinical immunotherapy program. Patient coverage will likely extend as additional classes of neoantigens are identified and added to off-the-shelf immunotherapy products.

References

P732
Reverse causal inferencing on lung adenocarcinoma patients reveals a stem cell-like molecular subtype associated with pack year history
Renee Deehan, Sergey Korkhov, Alexis Forozan, Scott Marshall, PhD, Renee Deehan, Nimisha Schneider QuartzBio, a Precision for Medicine company, Plan-les-Ouates, Switzerland

Correspondence: Renee Deehan (reneed.ee@precisionformedicine.com)

Background
Advances in high throughput measurement technologies (-omics data) have made it possible, and increasingly affordable, to generate high complexity, high volume data for oncology research. Coordinate efforts in computational modeling and machine learning applications to biological data have yielded increasingly sophisticated methods to deeply characterize the mechanisms of disease pathogenesis and heterogeneity among patients; which are predicates to the rapid development and timely and safe administration of efficacious treatments. Open source repositories that catalog, harmonize and host -omics data collected from clinical or preclinical studies, generously donated by patients and researchers, provide revolutionary access to otherwise siloed data. The combination of these advances enabled us to characterize the molecular phenotypic heterogeneity that exists within lung adenocarcinoma cohort from The Cancer Genome Atlas [1].

Methods
We applied a reverse inferencing approach that systematically interrogates RNAseq measurements from tumor and control biopsies against our library of cause and effect gene networks curated from published experiments. If patterns observed in the data are significantly similar to those in a network, an inference about the directional activity of that network can be made. Our library was nucleated through an open sourced knowledge graph [2] and enhanced with updated and relevant knowledge using the Biological Expression Language framework [3].

Results
In LUAD tumor cells, we detected a pattern of gene signatures which indicated a tumor stem cell-like phenotype characterized by predicted decreases in the activity of pro-differentiation factors FOXP2 and PHOX2B and an increased response to hypoxia. Analysis of patients with heavy (>40) versus light (<10) pack-year burden suggested an augmented dedifferentiation profile in heavy smokers, including decreased SOX6, HNF1A and increased FAT1 signaling, which has also been recently implicated in resistance to immune checkpoint inhibitors in NSCLC patients [4]. Expression of PD-L1 has been associated with cumulative inhaled smoke exposure in lung cancer patients, and with mechanisms inferred from our analysis (e.g., increased MIR140 signaling) [5,6].

Conclusions
Our in silico analysis of lung cancer patient biopsies generated hypotheses implicating stem cell signaling in tumors, and a further stratification of this signal based on patient pack year burden. Given the implication of tumor stem cells in resistance to drug treatments in cancers, there is increased focus on immunotherapies as a mechanism to circumvent this resistance, and the role of PD-L1 in this milieu requires further examination. Understanding the molecular makeup of these subtypes is critical when considering clinical research treatment strategies in immuno-oncology.

References
3. Open BEL. https://openbel.org

P733
Quantitative systems pharmacology modeling of B-cell acute lymphoblastic leukemia treatment with bispecific T-cell engaging antibodies for investigation of bell-shaped dose response
Oleg Demin Jr, MSc; Oleg Demin Jr; MSc, InSysBio, Moscow, Russian Federation
Correspondence: Oleg Demin Jr (demin_jr@insysbio.com)

Background
Kinetics of bispecific therapeutic antibody bound with its targets (trimer complex) is more complex than simple monospecific antibody bound with one target. Theoretically, the dependence of concentration of trimer complex on dose is bell-shaped. The aim of this work is to investigate dose response behavior of bispecific T-cell engaging antibodies under physiological conditions on the basis of quantitative systems pharmacology (QSP) model of B-cell acute lymphoblastic leukemia (B-ALL) treatment with blinatumomab, CD19/CD3 bispecific T-cell engager.

Methods
Developed mathematical model consist of: (1) physiologically-based pharmacokinetic (PBPK) model of blinatumomab including binding to target receptors – CD3 on T cells and CD19 on leukemic cells; (2) adult B-ALL progression model including dynamics of normal cells (B cells and its precursors, neutrophils, platelets); (3) specific lysis of CD19+ cells (both normal and leukemic cells) by CD3+ T cells in presence of blinatumomab. Model describes immunological synapse between CD3+ T cells and CD19+ cells, and formation of trimer complex of blinatumomab with CD3 and CD19. Parameters of the model were identified on the basis of published in vitro and in vivo data on healthy subjects and adult relapse/refractory B-ALL patients, but not clinical data. Blinatumomab clinical data on pharmacokinetics (PK) and pharmacodynamics (PD) were used to validate the model.

Results
Model was able to reproduce clinical PK data on blinatumomab without fitting. PD of blinatumomab was validated against data on

Page 121 of 237
dynamics of CD19+ cells in blood of B-ALL patients. Model shows that there is no response at very low doses (up to 8 ug/m2/day) which correspond to clinical data where there is no response at doses up to 5 ug/m2/day [1]. The threshold numbers of trimer complexes in synapse for activation of specific lysis in presence of blinatumomab were 38 for CD4 T cells and 16 for CD8 T cells. The decrease in concentration of trimer complex (bell-shaped behavior) can be observed in the model only at doses above 10^6 ug/m2/day, whereas approved dose of blinatumomab is 15 ug/m2/day or 28 ug/day. Model analysis showed that under physiological conditions bell-shaped dose response can be observed only when density of target receptors is very low in comparison with amount of bispecific antibodies.

Conclusions
Developed model demonstrates capability of QSP modeling to reproduce treatment efficacy clinical data on the basis of in vitro data. Dose response behavior depends on properties of bispecific T-cell engaging antibody as well as target expression.

References
Background
Multiplexed imaging is a rapidly growing field that promises to substantially increase the number of proteins that can be imaged simultaneously. We have developed Multiplexed Ion Beam Imaging by Time of Flight (MIBI-TOF), which uses elemental reporters conjugated to primary antibodies that are then quantified using a time of flight mass-spectrometer. This technique allows for more than 40 distinct proteins to be visualized at once in the same clinical samples. This has already yielded significant insights into the interactions and relationships between the many different immune cell populations present in the tumor microenvironment. However, one of the remaining challenges in analyzing such data is accurately determining target protein expression values for each cell in the image. This requires the precise delineation of boundaries between cells that are often tightly packed next to one another. Current methods to address this challenge largely rely on DNA intensity to make these splits, and are thus mostly limited to nuclear segmentation.

Methods
We have developed a novel convolutional neural network to perform whole-cell segmentation from multiplexed imaging data. Rather than relying only on DNA signal, we use a panel of morphological markers. Our method integrates the information from these distinct proteins, allowing it to segment large cancer cells, small lymphocytes, and normal epithelium at the same time without requiring fine-tuning or manual adjustment.

Results
By combining our novel imaging platform with new computational tools, we are able to achieve extremely accurate segmentation of whole cells in tissue. Our approach compares favorably with many of the currently used tools for segmentation. We show that our improvements in accuracy come both from our novel imaging approach as well as algorithmic advances. We perform significantly better than traditional machine learning algorithms trained on the same dataset. Additionally, we show that our algorithm can be trained to identify cells across a range of cancer histologies and disease grades.

Conclusions
We have developed a robust and accurate approach to whole-cell segmentation in human tissues. We show the superiority over this method over current state of the art algorithms. The accurate segmentation generated by our approach will enable the analysis of complex tissue architectures with highly overlapping cell types, and will help to advance our understanding of the interactions between cell types in the diseased state.

P736
Combining Multiplexed Ion Beam Imaging (MIBI) with Convolutional Neural Networks to accurately segment cells in human tissue
Noah Greenwald, BA1, Leeat Keren1, Shirley Greenbaum1, Mara Fong1, Gautam Chaudhry1, Zion Abraham1, Jackson Mosesley1, David Van Valen1, Michael Angelo, MD, PhD1
1Stanford University, Palo Alto, CA, United States; 2Cal Tech, Pasadena, CA, United States
Correspondence: Michael Angelo (mangelo@stanford.edu)

P737
Model-based meta-analysis of the exposure-response and clinical efficacy across approved anti-PD(L)1 agents
Apurvasena Parikh, PhD1, Apurvasena Parikh, PhD1, Srieneeranj Kasiachyanula, PhD1, Rajeev Menon2, Megan Gibbs3, Sven Mensing4, Benjamin Engelhardt2
1AbbVie Inc., Redwood City, CA, United States; 2AbbVie Inc., North Chicago, IL, United States; 3AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany
Correspondence: Apurvasena Parikh (apurvasena.parikh@abbvie.com)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P737

Background
The objective of this model-based meta-analysis is to characterize the exposure-response (overall response rate [ORR]) across approved anti-PD(L)1 agents (nivolumab, pembrolizumab, atezolizumab, avelumab and durvalumab) to quantify the effect of drug, patient and trial characteristics on ORR, and assess the relationship between ORR and efficacy outcomes such as 6-month progression-free survival (PFS) and 12-month overall survival (OS).

Methods
A clinical outcomes database was generated using published data for anti-PD(L)1 agents through March 2018. Reported exposures following Cycle 1 were normalized by the potency of the anti-PD(L)1 agents using respective IC50 values. Exposure-response (ORR) analysis was conducted using bayesian mixed effects modeling (R software), and included weighting by the number of subjects in each trial arm. Tumor type, number of prior therapies, ECOG performance, line of treatment, region, age, and gender were evaluated as model covariates. Impact of PD-L1 expression cut-off values was assessed to estimate the effect of PD-L1 expression on ORR. Correlation analyses were conducted between ORR, 6-month PFS and 12-month OS.

Results
Clinical data from 56 trials in approximately 11,000 subjects, and approximately 45 trials in 9,000 subjects across approved anti-PD(L)1s was included for the exposure-response and correlation analyses, respectively. A log-transformed linear model best described the flat exposure-response relationship, with tumor type as the most significant covariate (p < 0.001); the predicted ORR across the agents at approved dose ranges was 22% (95% CI: 16 – 30%) in non-small cell lung cancer. ORR appeared to increase by approximately 8 - 12% with greater PD-L1 expression (≥5% and ≥10% cut-offs respectively). ORR was correlated with 6-month PFS and 12-month OS (correlation coefficient, r = 0.6-0.7), and indicated a significant effect of tumor type on the correlation.

Conclusions
The model-based meta-analysis of exposure-response shows similar ORR depending on tumor type, across anti-PD(L)1 at the approved clinical doses. Improved efficacy was predicted with greater (i.e. ≥ 5%) PD-L1 expression.

P738
Artificial intelligence-based tumor purity assessment of digitized histology samples in multiple tumor types from clinical trials of nivolumab
George Lee, PhD, George Lee, PhD, Sujaya Sinivasan, Natallia Kalinava, Ariella Sasson, Vipul Baxi, MS
Bristol-Myers Squibb, Princeton, NJ, United States
Correspondence: George Lee (george.lee@bms.com)

Background
Tumor purity (TP) estimation is routinely performed for whole exome sequencing (WES) analysis to ensure signal is derived from cancer cells and not from other cells in the tumor microenvironment. Low TP has been shown to impact assessment of immunotherapy-related biomarkers including tumor mutational burden (TMB) [1]. While several methodologies exist to estimate TP by WES, a majority of studies do not compare against pathologist estimation, the gold standard. In this study, we utilize artificial intelligence (AI)-based image analysis to estimate TP, and further benchmark two methodologies of TP estimation on WES against pathologist and AI estimates across 1509 pretreatment samples from patients with melanoma, non-small cell lung cancer, small cell lung cancer, or urothelial carcinoma enrolled in clinical trials of nivolumab.

Methods
To assess TP by WES, paired tumor-normal samples were processed by Sentience [2] or Streika [3] somatic variant callers with subsequent ScicClone [4] tumor heterogeneity analysis. For comparison, we evaluated corresponding serial tumor sections of hematoxylin and eosin (H&E) and immunohistochemistry (IHC) digitized images for TP. A subset of H&E slides were read by pathologists, while scanned IHC images were read by deep-learning algorithms on the PathAI platform (Bristol, MA) for each tumor type, to distinguish cancer cells from immune and other non-cancerous cell types based on morphology.
Results

For 280 samples whereby pathologist TP estimates were available, we found Pearson correlations of \( r = 0.32 \) and \( r = 0.276 \) for Sentieon and Strelka, respectively. Correlations improved with AI-based TP estimation, to \( r = 0.439 \) (Sentieon) and \( r = 0.321 \) (Strelka). Additionally, we analyzed the ability of WES-derived TP estimates to predict whether a sample had ≥60% TP as measured by pathologist or AL, according to TCGA sample acceptance guidelines [5]. Using pathologist-based TP, AUCs of 0.643 (Sentieon) and 0.625 (Strelka) were achieved. Using AI-based TP, AUCs improved to 0.753 and 0.714, respectively. Similar trends for Sentieon and Strelka were found when AI-based TP assessment was used to benchmark the larger dataset (n=1509), showing \( r = 0.565 \) and 0.547, and AUCs of 0.784 and 0.777.

Conclusions

We demonstrated that AI-based image analysis can provide a more accurate assessment of TP compared with visual assessment by pathologist for all tumor types tested. Additionally, comparison with AI-based image analysis and pathologist estimates suggest that Sentieon TP estimates from WES data correlate better with AI-based TP estimates by AI or AI-benchmarked WES may allow us to better identify patients suitable for immunotherapy via TMB and other biomarkers.

Acknowledgements

Bristol-Myers Squibb.

Trial Registration

NCT01928394, NCT02387996, NCT01673867, NCT02041533, NCT01844505

References


Ethics Approval

The trial protocols were approved by site institutional review boards or independent ethics committees and conducted according to Good Clinical Practice guidelines, per the International Conference on Harmonisation. Patients provided written informed consent based on Declaration of Helsinki principles.

P739

Analysis of H&E images using deep learning for the prediction of distant metastatic recurrence in early stage melanoma

Michael Moore, BA 1, Eric Robinson, BA 1, Prathamesh Kulkarni, PhD 2, Robyn Gattrell, MD 1, Jaya Pradhan, DMD, MPH 1, Emanuelle Rick, BA 1, Chiu Wang, MD 1, Parul Balasubramanian, PhD 3, Robert Phelps, MD 1, Tammin Ferringer, MD 1, Andrew Chen, BS 3, Raul Rabadán, PhD 1, Bethany Rohr, MD 1, Basil Horst, MD 1, David Rimm, MD, PhD 1, Jing Wang, MD 1, Yvonne Saenger, MD 1

1. Columbia University Irving Medical Center, New York, NY, United States; 2. NYU Medical Center, New York, NY, United States; 3. Columbia University/New York Presbyterian, New York, NY, United States; 4. Jiaotong University School of Medicine, Shanghai, China; 5. Karolinska Institute, Stockholm, Sweden; 6. Icahn School of Medicine at Mount Sinai, New York, NY, United States; 7. Geisinger Medical Center, Danville, PA, United States; 8. Columbia University, New York, NY, United States; 9. University of British Columbia, Vancouver, Canada; 10. Yale University Medical Center, New Haven, CT, United States

Correspondence: Jing Wang (jing.wang2@nyumc.org), Yvonne Saenger (yms4@cumc.columbia.edu)


Background

Patients with primary melanoma are at a high risk for recurrence, creating a need for biomarkers. Tumor infiltrating lymphocytes (TILs) have been previously shown to generally correlate with clinical outcome. Using qmIF, we previously found that spatial relationships of immune cells within the tumor impact prognosis [1]. Herein we show that clustering of tumor and immune cells correlates with clinical outcome and find that nuclear size increases with tumor stage. Further, we applied a deep neural network (DNN) in H&E images that includes pre-defined features as well as raw image analysis to predict distant metastatic recurrence (DMR).

Methods

H&Es and qmIF were evaluated on patients with stage I-III melanoma. QmIF data was analyzed using pair correlation function (PCF) to evaluate spatial relationships between cells. H&E images were processed using Qupath for nuclear segmentation and cell classification as well as the generation of data related to cell location, density, and clustering features to identify relevant tissue areas for training of network parameters. DNN architecture was composed of both convolutional neural network (CNN) and recurrent neural network (RNN) layers (Figure 1). The DNN model was trained on 108 patients from four independent institutions (Columbia, Mount Sinai, NYU and Geisinger) and validated on 115 patients from Yale and Geisinger. The DNN model analyzes image and feature information locally within an H&E image generated a prediction vote per region within the H&E image, and votes were averaged across all regions to produce an overall recurrence prediction score.

Results

PCF analysis of qmIF images finds that non-recurrent patients have higher degrees of clustering between tumor cells and CD8+ T cells as well as tumor cells and HLA-DR+ macrophages (p=0.004). Prediction scores from the DNN correlated with DMR in both validation cohorts (Figure 2, AUC = 0.94 and 0.77 for Yale and Geisinger, respectively). A multivariable Cox proportional hazards model indicated that the recurrence prediction score was an independent prognostic factor for both Yale (HR = 2.54, 95% CI: 1.54-4.19, p<0.001**) and Geisinger (HR = 8.43, 95% CI: 2.58-27.51, p=0.001**).

Conclusions

Our DNN model incorporating features as well as raw image analysis produces an accurate prediction of DMR in H&E images of early stage melanoma, a readily available clinical pathology resource. Though larger studies are needed to further validate the DNN model, it may serve as a useful digital pathology tool to provide critical prognostic information and potentially aid in the selection of melanoma patients for adjuvant therapy.

Acknowledgements

This publication was supported by the National Institutes of Health through Grant Numbers R01FD006108 (Y.M. Saenger), R01NS100065 (J. Wang), and KL2TR001874 (R.D. Gartrell-Corrado). X.C is funded by the Medical Scientist Training Program (T32GM007367). R. Rabadán was supported by the NCI Center for Topology of Cancer Evolution and Heterogeneity (U54CA193313). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This project also received funding from the Melanoma Research Alliance (Y.M. Saenger), Columbia University’s Irving Institute for Clinical and Translational Research (Y.M. Saenger), and Swim Across America (R.D. Gartrell-Corrado). D.L. Rimm was supported by funds from Navigate BioPharma (Novartis subsidiary), Yale SPORE in Lung Cancer (PO1CA196530) and Yale Cancer Center (P30CA016359). The funding sources had no role in study design; collection, analysis, and interpretation of data; preparation of the manuscript; or the decision to submit for publication.

References

Methods
For the 3D-EX platform, tumor organoids were processed from fresh tumor tissue from NSCLC cancer patients obtained with IRB consent. Tumor organoids were then treated with pembrolizumab ex-vivo and treatment-mediated changes in tumor immune microenvironment were analyzed using multicolor flow cytometric analysis, multiplex cytokine assay as well as gene expression profiling by NanoString’s 770 gene Immune Panel. For the integrated multi-omics analyses, machine learning techniques included—but were not limited to—Wilcoxon Rank-Sum Test, clustering, and principal component analysis.

Results
Here we present the results from the integrative analyses of multi-omics data generated from the ex vivo treatment of 11 fresh tumor samples in the ex vivo assays. We probed multiple biological layers in parallel, ranging from genome, epigenome, transcriptome, and proteome to phenotype profiling. Our data revealed that integrative analyses using information across these data modalities deliver more comprehensive insights into the pembrolizumab mode of action and identified compensatory mechanisms likely contributing to resistance to the drug treatment. Furthermore, we identified potential molecular signatures of response to treatment.

Conclusions
Our results demonstrated that multiple types of omics data obtained from Nilogen’s comprehensive 3D ex vivo drug testing platforms can reveal cellular mechanisms that are active in individual tumors and may classify them into subtypes for response to drug treatment. As such, implementation of the functional 3D ex vivo assay combined with integrative multi-omics data in clinical studies may enable us to ascertain which components of the tumor immune microenvironment to target within a patient.

P741
Prediction of biomarkers and combinational therapies for anti-PD1 therapy using a computational network approach
Chia Chin Wu, PhD, Andrew Futreal, Jianhua Zhang, Chia-Chin Wu
MD Anderson Cancer Center, Houston, TX, United States
Correspondence: Chia-Chin Wu (jzhang22@mdanderson.org)

Background
Despite the remarkable success, only a subset of patients can benefit from the anti-PD1 therapy. Therefore, there is a growing need to understand the resistance mechanisms for identifying predictive biomarkers and therapeutic targets for improving the therapy efficacy.

Methods
We hypothesized that aberrations of any gene close to MHC class I genes in a gene network are likely to deregulate MHC I pathway and affect tumor response to anti-PD1. First, the network guilt-by-association method [1] was used to calculate association scores of genes with the MHC I genes in the network. Second, pathways that enrich genes with high scores would be associated with the anti-PD1 response. Third, TCGA data was integrated with the top predicted genes to build up a signature-based response predictor of anti-PD1 for a specific cancer type. Forth, the drug target data [2] and immune infiltrate correlation data was mapped to the top predicted genes, to identify compounds that could enhance response to anti-PD1 for a cancer type.

Results
Our approach successfully identified genes (e.g. MYC) (Table 1) and pathways (e.g. WNT) (Fig. 1A) known to be associated with anti-PD1 response. Our prediction was further comprehensively validated by four lists of genes identified by the CRISPR screening (Fig. 1B). The integration analysis of TCGA data and our prediction reveals that our top 10% prediction significantly enrich genes whose expression are significantly correlated with the immune infiltrate score in most of cancer types (Figure 1C).

P740
Leveraging artificial intelligence to advance immuno-oncology drug development using functional ex-vivo 3D-tumor organoid platforms of fresh patient tissue samples
Jenny Kreahling, PhD, Daniel Santago, PhD, Vijayendra Agrawal, PhD, Mibel Pabon, PhD, Soner Altiok, MD, PhD., Melba Page, PhD
Nilogen Oncosystems, Tampa, FL, United States
Correspondence: Soner Altiok (soner@nilogen.com)

Background
Traditionally, omics data analysis of biologic samples has been conducted in a single-level manner. However, integrative analysis offers an effective way to harness strength across multi-level omics data and can be more powerful than single-level analysis. In recent years we have developed complementary 3D ex vivo platforms utilizing unpropagated fresh patient tumor organoids with intact microenvironment to interrogate the efficacy of immuno-oncology drug and drug combinations. Here we aimed to develop a multiomic data integration and informatics platform to better understand the cellular and molecular mechanisms of pembrolizumab and its mode of action.
with anti-PD1 response would be tissue or lineage dependent (Figure 1D). The signature-based predictor built based on TCGA skin cutaneous melanoma (SKCM) data achieves an accuracy of AUC = 0.72 for 243 melanoma samples from 5 cohorts (Fig. 2A), which is slightly worse than IMPRES [3] (Fig. 2B) considering immune aspects different from ours. Integration of the predictions of ours and IMPRES improves the performance (Fig. 2C). In addition, most of targets of compounds that have been used or in clinical trial for combination treatment with anti-PD1 are in the top list of our prediction (AUC=0.83). By integrating drug target data, we further identified compounds, recently shown to be able to enhance tumor response to anti-PD1, such as inhibitors of GSK3B, CDK, and PTK2 (Table 1).

**Conclusions**

These results suggest that our approach is an effective method to identify genes/pathways associated with anti-PD1 and can be employed to screen potential drugs for combination regimens with anti-PD1.

**References**


**Table 1 (abstract P741).** Some selected genes in the SKCM prediction

<table>
<thead>
<tr>
<th>Compounds</th>
<th>Gene</th>
<th># of samples with alterations</th>
<th>Predicted percentile rank</th>
<th>Immune correlation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denileukin diftitox</td>
<td>EE2</td>
<td>Mut: 3</td>
<td>94.2</td>
<td>-0.568</td>
</tr>
<tr>
<td>Belinostat</td>
<td>HDAC4</td>
<td>Mut: 11</td>
<td>94.29</td>
<td>-0.346</td>
</tr>
<tr>
<td>Enzastaurin</td>
<td>PRKCE</td>
<td>Mut: 7</td>
<td>94.71</td>
<td>-0.335</td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>PRMT5</td>
<td>Mut: 7</td>
<td>90.86</td>
<td>-0.316</td>
</tr>
<tr>
<td>Defectinib</td>
<td>PTK2</td>
<td>Amp: 191</td>
<td>90.42</td>
<td>-0.309</td>
</tr>
<tr>
<td>-</td>
<td>MYC</td>
<td>Amp: 191; Mut: 5</td>
<td>99.89</td>
<td>-0.307</td>
</tr>
<tr>
<td>Aminocycline</td>
<td>CDK4</td>
<td>Amp: 58; Mut: 8</td>
<td>94.96</td>
<td>-0.259</td>
</tr>
<tr>
<td>Tidagrasib</td>
<td>GSK3B</td>
<td>Mut: 3</td>
<td>96.1</td>
<td>-0.258</td>
</tr>
<tr>
<td>Niraparib</td>
<td>PARP2</td>
<td>Mut: 6</td>
<td>95.65</td>
<td>-0.222</td>
</tr>
<tr>
<td>Pseudophedrine</td>
<td>PRMT1</td>
<td>-</td>
<td>98.36</td>
<td>-0.211</td>
</tr>
<tr>
<td>-</td>
<td>B2M</td>
<td>Del: 90; Mut: 5</td>
<td>99.9</td>
<td>0.65</td>
</tr>
<tr>
<td>IFNGR1</td>
<td>Del: 220; Mut: 3</td>
<td></td>
<td>91.66</td>
<td>0.396</td>
</tr>
</tbody>
</table>

**Note:** 1. Copy number amplification is denoted “Amp.”
2. Copy number deletion is denoted “Del.”
3. Mutation is denoted “Mut.”

**P742**

**Computational analysis of feedback regulations of TIM-3**

JIAN ZHU, PhD, JIAN ZHU, PhD, Rebecca Zhu,*

*OmicsHealth LLC, Bethesda, MD, United States; **OmicsHealth LLC, Bethesda, MD, United States; †Winston Churchill High School, Potomac, MD, United States.

**Correspondence:** JIAN ZHU (jian.zhu@omicshealth.com)


**Background**

TIM-3 is an inhibitory immune checkpoint protein currently under clinical investigation. As many oncology targets, TIM3 is potentially regulated by feedback loops (FBL). Positive (+)FBLs sustain while negative (-)FBLs restrict TIM-3’s expression and activity upon its induction. In the case of TIM-3 inhibition, (-)FBLs are capable of rescuing TIM-3’s activity and confer therapeutic resistance. However, feedback regulations of TIM-3 have not been systematically investigated. In this study, a computational approach was developed based
Background
Concurrent inhibition of IDO1 and PD-1 may have enhanced antitumor effects. However, inhibition of IDO1 failed to enhance efficacy of anti-PD-1 in late phase clinical trials. In this study, computational models were established to identify factors involved in interactions between these two types of agents.

Methods
Abstracts published on IDO1, PD-1, PD-L1, anti-PD1/PD-L1 were downloaded from PubMed, and analyzed by text mining. The information on interactions among gene, compound/therapy, cell/animal model, pathway/disease, and clinical study was extracted. Networks were constructed to simulate effects of IDO1 inhibition on anti-PD-1.

Results
The IDO1/anti-PD-1 network consists of 79 nodes, 227 interactions with 1277 possible regulatory paths from IDO1 to anti-PD-1. 675 paths are associated with agonism and 602 with antagonism between IDO1 inhibition and anti-PD-1. Up-regulation of TNF-alpha, IFN-gamma, type I immunity & CD8+ T cells, and down-regulation of Tregs, MDSC, JAK/STAT pathway, IL-6 and PD-L1 are associated with enhancement of anti-PD-1 by IDO1 inhibition. Besides, treatments with PARP inhibitor, EGFR inhibitor or radiation may enhance the combination efficacy of IDO1 and PD-1 inhibitors. Up-regulation of TIM-3 and NK cells are associated with reduced activities of anti-PD-1 upon IDO1 inhibition. PD-L1 is a predictive biomarker for anti-PD-1 response and its expression can be regulated by IDO1. The IDO1/PD-L1 network consists of 83 nodes, 204 interactions and 318 paths. Up-regulation of IL-6, Ahr, MDSC, JAK/STAT, HIF1A, IL10, NF-kappaB & MYC was associated with induction of PD-L1 by IDO1.

Conclusions
As the network analyses revealed, inhibition of IDO1 could either up- or down-regulate PD-L1, and enhance or reduce efficacy of anti-PD-1. Multiple factors, other than PD-L1, play roles in determining the efficacy of combining IDO1 and PD-1 inhibitors.

Fig. 1 (abstract P743). IDO1 - anti-PD-1 network

Microbiome and Other Environmental Factors

P744
Physical fitness influences the composition of human T cell populations
Michael Gustafson, PhD1, Michael Gustafson, PhD1, Courtney Wheatley-Guy, PhD1, Svetlana Bornschlegl2, Allian Dietz, PhD2, Dennis Gastineau, MD1, Emmanuel Katsanis, MD3, Richard Simpson, PhD3, Bruce Johnson, MD1
1Mayo Clinic Arizona, Phoenix, AZ, United States; 2Mayo Clinic, Rochester, MN, United States; 3University of Arizona, Tucson, AZ, United States
Correspondence: Michael Gustafson (gustafson.michael@mayo.edu)

Background
Despite the remarkable success of cancer immunotherapies, a significant proportion of patients fail to respond. In order to overcome this, a number of ongoing approaches are being tested to address this need including combinatorial treatment strategies, biomarker identification, target optimal responses, and neoantigen discovery. One
potential avenue that is emerging is the application of exercise to promote overall health. While the mechanisms of exercise-mediated improvements in health are certainly multi-factorial, a substantial amount of data suggests that physical activity can improve outcomes in cancer patients, in part by, improving immunological function. As such, we propose that physical activity may enhance the efficacy of immunotherapy by restoring the quantity and function of leukocyte subsets in cancer patients.

Methods

T cells and other immune cell populations were analyzed by flow cytometry from two different cohorts of healthy men[1, 2]. Physical fitness parameters including maximum rate of oxygen consumption (VO2max), physical activity, lean body mass, and BMI were assessed or measured and tested for correlations with T cell populations.

Results

Here, we provide evidence demonstrating that the compositions of human T cells circulating in peripheral blood are altered by physical fitness. In one cohort, late differentiated KLRG1+/CD57+/CD28- T cells were inversely associated with a cardiorespiratory fitness parameter, VO2max. In another we show several T cell populations that are associated with distinct fitness parameters. For example, in baseline peripheral blood samples, PD-1+ T cells were increased in sedentary subjects compared to active ones, numbers of CD8+ T cells and memory CD4+ T cells correlated with lean body mass, and a population containing stem cell memory CD8+ T cells were correlated with VO2max.

Conclusions

These results suggest that distinct T cell populations may be uniquely sensitive to both negative (age, obesity, and lack of physical activity) and positive (exercise) physiological inputs. These findings provide hypothesis-generating insights into how exercise might be utilized to overcome the immunosuppressive environment in cancer patients potentially improving their responses to immunotherapies.

References


Ethics Approval

These studies were approved by the Institutional Review Board by their respective institutions, Mayo Clinic and University of Houston.

Consent

Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

P745

Tumor cell metabolism as a barrier to immunotherapy in melanoma

Ashley Menk, MS1, Greg Delgoffe, PhD1, Yana Najjar, MD2, Ashley Menk, MS3, John Kirkwood, MD4

1University of Pittsburgh, Pittsburgh, PA, United States; 2UPMC Hillman Cancer Center, Pittsburgh, PA, United States

Correspondence: Greg Delgoffe (delgoffeg@upmc.edu)

Background

Immunotherapy has been paradigm-shifting for melanoma, but durable responses only occur in a subset of patients. While we have previously shown that tumor-infiltrating T cells have repressed metabolic machinery, the environment itself is nutrient poor due to the deregulated metabolism of tumor cells. Recent studies have suggested that T cells compete with tumor cells for glucose and oxygen which may be limiting anti-tumor immunity. We hypothesize resistance to immunotherapy may be due to deficiencies in the metabolic makeup of the tumor microenvironment, and that we can infer that environment’s metabolism in patients by metabolically profiling tumor cells.

Methods

Melanoma patient samples were profiled by Seahorse analysis in parallel to flow cytometric analysis of tumor infiltrating lymphocytes (TIL). Murine melanoma cells were generated including RNAi constructs to specific metabolic pathways. Responses to PD-1 blockade and adoptive T cell immunotherapy were monitored and lymph node or TIL T cells were tested for effector function, metabolism, and localization by flow cytometry and immunofluorescence.

Results

Analysis of melanoma patient biopsies showed striking heterogeneity in the metabolism of tumor cells. Patients with more metabolically active tumors have more dysfunctional TIL, while tumors that were metabolically quiescent contained T cells with superior effector function. Profiling of patient tumor cells prior to PD-1 blockade therapy revealed that patients with metabolically oxidative tumors had poorer responses while patients with quiescent tumors experienced longer-term response. To confirm the role of oxidative metabolism and further investigate the role of tumor cell metabolism, we generated murine melanoma lines in which glucose or oxidative metabolism was inhibited. Tumor cells in which oxidative metabolism showed an increased response to PD-1 blockade immunotherapy while tumor cells with inhibited glycolytic metabolism responded better to adoptive T cell therapy.

Conclusions

Our data suggest that the metabolic makeup of the tumor microenvironment, driven through deregulated oxidative or glycolytic metabolic behavior of the tumor cell, determines whether T cells have a permissive microenvironment for effective immunotherapy, and that inhibiting tumor cell metabolism may be an attractive strategy to improve the efficacy of immunotherapy.

P746

Global metabolomics of advanced gastric cancer patients identifies signatures associated with response and clinical benefit from nivolumab

Carrie Brachmann, PhD1, Carrie Brachmann, PhD1, Daniel Cooper2, Kari Wong2, Ethan Grant1, Daniel Catenacci, MD3, David Cunningham4, Jean-Philippe Metges5, Eric Van Cutsem, MD, PhD6, Zev Wainberg, MD3, Dung Thai7, Pankaj Bhargava8, Emron Elbudware9, Ondrej Podlaha10, Wadud Khan11, Jennifer Wargo, MD, MMSc12, Manish Shah, MD7

1Gilead Sciences, Foster City, CA, United States; 2Metabolon, Inc, Morrisville, NC, United States; 3University of Chicago Medical Center, Chicago, IL, United States; 4Sloan-Kettering Cancer Center, Houston, TX, United States; 5Brest University Hospital; 6University Hospitals Leuven & KU Leuven, Leuven, Belgium; 7UCI School of Medicine, Santa Monica, CA; 8UT MD Anderson Cancer Center, Houston, TX, United States; 9Weill Cornell Medicine, NY Pres Hosp, New York, NY

Correspondence: Carrie Brachmann (carrie.brachmann@gilead.com)

Background

The gut microbiome has been reported to impact the immune response to checkpoint blockade [1]. Circulating metabolites relate to both host and microbiome biology and were explored in an advanced gastric cancer population treated with nivolumab.

Methods

Plasma samples (pre-treatment, week 2, week 8 and end of study) from patients enrolled in a randomized phase 2 study in >2nd line advanced gastric or gastroesophageal junction patients [2] were extracted for analysis on the LC/MS/MS and Polar LC platforms. 141 patients were treated and all received nivolumab. This analysis evaluates all patients as a single population, since andecaliximab failed to provide additional benefit [2-4]. ANCOVA analyses were performed for samples stratified by responder/non-responder status or patients that received clinical benefit versus those that did not receive clinical benefit and were adjusted for age and sex. Clinical benefit was defined as patients living >1 year post treatment or had a tumor response. Results with nominal p
Results
Metabolic profiling of human plasma detected 1364 metabolites. The majority of metabolic changes that occurred while the patients were on treatment were detected at end of study (151 and 35 significantly altered metabolites in non-responders and responders, respectively) when compared to the pre-treatment time point. Clinical benefit from checkpoint blockade was associated with higher levels of bacterial-derived indoles, host-derived tryptophan catabolites, lower primary and secondary bile acids, lower levels of lactate, and altered glutamine catabolism. Similar differences were observed when responders and non-responders were compared.

Conclusions
The association of microbial indoles and host-derived tryptophan catabolites with benefit suggests the activation of immunosuppressive mechanisms in non-responders and those who did not experience clinical benefit. Combined with the differences in secondary bile acids, these data suggest a role for the microbiome. Indeed, tryptophan catabolites can be produced by Clostridiales and enrichment of these bacteria are linked to improved response to anti-PD1 therapy [5]. In addition, differences in circulating lactate, glutamine, and glutamate between responders and non-responders suggested differences in tumor metabolic preferences, flexibility, or overall activity.

Acknowledgements
The authors gratefully acknowledge the patients and their families who participated in this study.

Trial Registration
Clinicaltrials.gov NCT02862535

References

Ethics Approval
This study was approved by the institutional review board or independent ethics committee appropriate for each site.

P747
Leveraging the Second Genome platform to develop microbiome-based cancer immunotherapies
Dhwani Haria, Jayamary Ravichandar, Lynn Yamamoto, Cheryl-Emiliane Chow, Bernat Raja, Joana Dreux, Kareem Graham, Kathryn Iverson, Shoko Iwai, Sunit Jain, Yuliya Katlinskaya, Sabina Lau, Jina Lee, Michelle Lin, Paul Loriaux, Nicole Narayan, Erica Rutherford, Connor Skennerton, Thomas Weimmaier, Michi Wilcoxon, Yonggan Wu, Todd DeSantis, Yoshikazu Takeuchi, Karim Dabbagh, Helena Kiefel, PhD, Helena Kiefel, PhD
Second Genome, South San Francisco, CA, United States
Correspondence: Helena Kiefel (helena@secondgenome.com)

Background
The gut microbiota has emerged as an important player in cancer pathology and increased evidence supports its influence on clinical response to immune checkpoint inhibitor (ICI) therapy. However, the specific gut bacteria-derived molecules responsible for the improved response to ICI therapy remain unknown. Second Genome has developed a unique discovery platform to identify, screen, and validate microbiome-derived peptides that promote response to cancer-immunotherapy.

Methods
Using our multi-technology meta-analysis of published datasets characterizing the baseline microbiome from melanoma patients treated with anti-PD-1, we have identified gut microbiota strains differentially abundant in responders versus non-responders that are concordant across multiple cohorts. Next, peptides from the strains associated with responder signatures were predicted from their genome sequences. In addition, we identified and selected predicted bacterially-derived peptides associated with responder signatures from assembled metagenomes. All predicted peptides were screened using phage display technology to select binders to immune cells known to play a role in the tumor microenvironment (TME).

Results
Selected microbiome-derived peptide binders were evaluated for activity in cell-based assays using isolated human primary T cells, dendritic cells, and macrophages. We show that several selected peptide binders induce secretion of proinflammatory cytokines and chemokines (e.g., IP-10, TNF) from human primary monocyte-derived dendritic cells, as well as effector cytokine secretion (e.g., IFNγ, IL-2) from human primary T lymphocytes. Additionally, we have identified microbiome-derived peptide binders with capacity to inhibit an M2-like phenotype in macrophages (decreased LPS-induced IL-10 secretion).

Conclusions
Collectively, our results demonstrate the potential of Second Genome’s discovery platform to identify and characterize novel immunomodulatory factors produced by the gut microbiota. Second Genome’s discovery platform offers a unique approach to identify novel agents with potential for use as therapies in cancer immunotherapy.

P748
A rationally-designed consortium of human gut commensals induces IFNg+ CD8+ T cells and enhances tumor immunity
Amanda Prince, PhD1, Johnny Lightcap2, Amit Reddy2, Sachin Deshmukh2, Steve McClellan2, Bruce Roberts, PhD1, Rose Szabady1, Arthur Frankel2
1Vedanta Biosciences, Inc., Cambridge, MA, United States; 2University of South Alabama, Mobile, AL, United States
Correspondence: Bruce Roberts (broberts@vedantabio.com), Arthur Frankel (afrankel@health.southalabama.edu)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P748

Background
Efficacy of immune checkpoint inhibitor (ICI) therapy is associated with the composition of the gut microbiome, but the mechanism remains to be elucidated. Recent data from Tanoue et al. [1] demonstrated a consortium of 11 bacteria (VE800) induced IFNg production in intestinal CD8+ T cells and enhanced anti-PD-1 cancer activity in tumor models. Vedanta has developed VE800 as a microbiome therapeutics to enhance the efficacy of ICI therapy. Here, we aimed to further understand the requirements for VE800 efficacy in pre-clinical models and to understand how immune modulation by VE800 affects tumor immunity.

Methods
VE800 IFNg production in colonic T cells as a readout for VE800 anti-cancer efficacy. Mice were pre-treated with different antibiotics to establish a permissive niche for colonization and given VE800. To determine which bacteria were critical contributors to VE800 function, we created various combinations of individual VE800 bacterial strains and measured induction of IFNg+ CD8+ T cells in the intestines of germ-free mice. Consortia unable to induce IFNg+ CD8+ T cells were tested for their anti-tumor efficacy. Additionally, we have identified microbiome-derived peptide binders with capacity to inhibit an M2-like phenotype in macrophages (decreased LPS-induced IL-10 secretion).
treated with ICI on days 4, 8, and 12. VE800 was administered three times a week for three weeks prior to sacrifice to assess levels of tumor infiltrating cells.

**Results**

Our data suggest that bacterial density drives VE800 efficacy for induction of IFNγ+ CD8+ T cells. We further established that the complete VE800 consortium provides maximal IFNγ induction, and that removal of specific strains impairs IFNγ induction. Utilizing the B16 tumor model, colonization of VE800 strains was observed in tumor-bearing mice receiving the complete consortia. Additionally, the complete VE800 consortium restored ICI efficacy in antibiotic-treated tumor-bearing mice (Figure 1). However, bacterial consortia incapable of inducing IFNγ+ CD8+ T cells do not promote anti-tumor immunity. Pre-treatment with antibiotics abolished the therapeutic effect of ICI, which was accompanied by a reduced level of tumor infiltrating immune cells indicating the important, supportive role played by gut microbiota.

**Conclusions**

Our data suggests VE800 induces IFNγ+ CD8+ T cell induction and provides the necessary microbial component to promote anti-tumor immunity in combination with dual checkpoint inhibitor therapy in the multiple tumor models.

**References**

A targeted next generation sequencing assay to analyze and characterize the gut microbiome for health research

Anna McGeachy, PhD, Shruti Sarda, David Merrill, Birgit Drews, Wing Lee, Heesun Shin, Janice Au-Young, Rajesh Gottimukkala, MS, Aren Ewing, Fiona Hyland
Thermo Fisher Scientific, South San Francisco, CA, United States
Correspondence: Fiona Hyland (fiona.hyland@thermofisher.com) Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P751

Background
The gut microbiota has emerged as a promising biomarker to assess the efficacy of immune-modulatory drugs in the CTLA-4 or PD-1 pathways. Targeted Next Generation Sequencing may provide a lower cost approach for characterizing the Gut Microbiome. Sequencing of 16S rRNA is one approach to characterize microbial diversity. However, 16S sequencing alone is often insufficient to gain species level information. Here we describe a Targeted Sequencing panel comprising both 16S and species-specific primers using Ion AmpliSeq™ technology. This assay can be used to understand the composition and diversity of the human gut microbiome at the species level.

Methods
Our improved assay includes customized primers to multiple hyper-variable regions of the 16S region. However, 16S alone can still be insufficient in distinguishing highly homologous organisms such as Bacteroides and Lactobacillus. We have designed species-specific primers that provide high strain coverage and high specificity performance. We have tested primers for 75 species associated with human health and disease, from genera such as Bifidobacterium, Clostridium, Ruminococcus and Bacteroides. With this approach, we can analyze reads generated from sequencing to report taxonomic classifications and relative abundance for organisms in the sample with high specificity and sensitivity.

Results
We designed a multiplexed Ion AmpliSeq™ assay including 16S targets and species-specific markers targeting important microbial species. Using the Ion Genestudio S5™ system, we sequenced two mock community controls comprising of 20 and 12 bacterial strains. With our more comprehensive 16S design, we positively identified all the organisms at Genus level with 100% sensitivity. With the data generated from the species-specific primers, we identified all the targeted species in the ATCC samples at the Species level. We also created mixed population pools using DNA from clonal isolates of 40 different bacterial strains. We identified all 40 microbes at Genus level with 100% sensitivity using 16S alone. We improved the detection limit from 10^2 to 10^1 bacterial cells.

Conclusions
Presented work advocates for the importance of function-oriented microbiome research in ICT. Furthermore, BiomeScout enables detection of a cross-cohort signal which is currently in testing phase.

References

P752
Antitumor activity of neoantigen cancer vaccine delivered by DNA electroporation is driven by the microbiota
Lucia Lionè1, Erika Salvatori1, Antonella Conforti2, Gennaro Giliberto3, Luigi Aurisicchio4, Fabio Palombo, PhD1, Fabio Palombo, PhD4
1Takis, Rome, Italy; 2Evvivax, Rome, Italy
Correspondence: Fabio Palombo (palombo@akisbiotech.it) Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P752

Background
The microbiota has an impact on different aspects of cancer immunology. We reasoned that it might also influence cancer vaccine delivered by DNA-EP.

Methods
Mice were treated with antibiotics (ABX) for two weeks and vaccinated with a plasmid DNA encoding MC38 neoantigens delivered by electroporation (EP) [1]. Analysis of T cell immune responses was carried out with flow cytometry either in the peripheral blood or in the spleen. One week after last vaccination mice were challenged with MC38 cells. The microbiota was monitored in the feces by bacterial cultures and NGS analysis of 16S.

Results
Unexpectedly, ABX treatment allowed a statistically significant reduction of tumor growth in mice vaccinated with DNA-EP. In these experimental conditions, the DNA vaccine is not effective in controlling tumor growth in ABX treated mice. ABX treatment allowed a statistically significant reduction in tumor growth in mice vaccinated with DNA-EP. In these experimental conditions, the DNA vaccine is not effective in controlling tumor growth in ABX-treated mice. However, ABX treatment allowed a statistically significant reduction in tumor growth in mice vaccinated with DNA-EP. In these experimental conditions, the DNA vaccine is not effective in controlling tumor growth in ABX-treated mice.

Conclusions
Clostridiaceae have been associated with the production of specific short-chain fatty acids (SCFA) mainly butyrate and with the induction of T-reg. Very recently the metabolites produced by the intestinal microbiota have been also associated with memory potential of activated CD8+ T cells [2]. The observation that anti-tumor properties of DNA-EP depends on the lack of normal mouse microbiota suggests new possibilities for improving this potent vaccine method.

References
P753

Trial in progress: A phase I study of live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours

John Weinberg, MD1, John Weinberg, MD2, Jonathan Krell, PhD, MRCP, MBChB, BSc3, 4D pharma plc, Leeds, United Kingdom; 3Imperial College, London, London, United Kingdom

Correspondence: John Weinberg (john.weinberg@4dpharmaplc.com)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P753

Background

The gut microbiome has emerged as a therapeutic approach to immune-stimulation treatment of solid tumours[1,2,3]. MRx0518 is a gut microbiome-derived, oral live biotherapeutic, identified as inducing an immunostimulatory response, particularly in stimulating immune cell populations and signalling pathways relevant for anti-cancer therapy. For example, the bacterial flagellin moiety leads to an NFκB-related cytokine responses[4]. Preclinical studies have demonstrated that MRx0518 reduced tumour growth in syngeneic models of kidney, lung and breast cancer. MRx0518 increased CD8 T cell infiltration into the tumour and decreased Tregs along with up-regulation of tumour TLR5.

This study, one of the first oncology trials conducted with live biotherapeutics, is a single-centre, double blind, neoadjuvant window study in patients with resectable solid tumours to evaluate the safety, tolerability and preliminary efficacy of MRx0518.

Methods

The trial consists of 2 parts. In Part A, 20 patients receive 1 capsule (bid) of MRx0518 for 2–4 weeks prior to tumour resection. In Part B, 80 patients receive 1 capsule (bid) of MRx0518 and 20 patients receive 1 capsule (bid) of placebo for 2–4 weeks prior to resection. The primary end points are safety and tolerability of MRx0518 (Parts A and B). Secondary end point includes response in respect of intra-tumoral markers compared to placebo, and clinical outcomes including overall survival. Exploratory end points include surrogate biomarkers of treatment effect, the effect on microbiota and impact on tumour and circulating T-cell populations. Recruitment is ongoing.

Clinical trial information: NCT03934827

Eligibility is limited to treatment-naive patients with confirmed solid tumours amenable to primary surgery resection with a comparison of the diagnostic biopsy and surgical excision specimen to assess the biomarker response.

Trial Registration
www.clinicaltrials.gov
NCT03934827

References


Ethics Approval

The study was approved by the East of England – Cambridge East Research Ethics Committee, reference 18/EE/0091.

P754

Using advanced imaging techniques to study the interactions among malignant cells, immune system, and microbiota in lung adenocarcinoma

Chen Zhao, MD1, Weihe Li1, Chengchong Jin, PhD2, Tyler Jacks2, Ronald Germain, MD, PhD3
1National Institutes of Health (NIH), North Bethesda, MD, United States; 2Massachusetts Institute of Technology (MIT), Cambridge, MA, United States; 3National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, United States

Correspondence: Ronald Germain (rgermain@nih.gov)

Background

Lung cancer is the leading cause of cancer-related mortality worldwide. Although immune checkpoint inhibitors have shown encouraging results in the treatment of lung adenocarcinoma, the response rate and overall survival are still low, especially in patients with low PD-L1 expression in the tumor site. Existing evidence suggests that interactions involving lung cancer cells, microbes, and immune cells in the tumor microenvironment affect tumor progression and patients’ responses to treatments.

Methods

Here we used advanced imaging techniques, such as histo-cytometry [1], Clearing-enhanced 3D (Ce3D) microscopy [2] and multiplex FISH, together with single-cell RNA sequencing and high-dimensional unsupervised spatial-temporal analysis, to study the tumor-immune microenvironment in an autochthonous genetically engineered mouse model of lung adenocarcinoma, which is driven by an activating mutation of Kras and a loss of function mutation of p53.

Results

These studies have revealed a role for local dysbiosis in tumor progression, a connection to interleukin-17 secreting gamma-delta T cells in the immune response to the tumor, and the presence in the tumor micro-environment of an unexpectedly heterogeneous population of neutrophils, a cell type known to have adverse effects in lung adenocarcinoma.

Conclusions

Together, these findings are beginning to produce a more complete picture of the three-way interaction among malignant cells, the immune system, and the microbiota in driving tumor progression, with implications for possible interventions to decrease tumor support and facilitate useful anti-tumor immunity.

Acknowledgements

This research was supported by the Intramural Research Programs of NIAID and NHLBI, NIH.

References


P755

Microbiome spatial patterns as markers of cancer immune therapy response

Bokai Zhu, BS, Yunhao Bai, BS, Suzin Jiang, PhD1, Xavier Rovira-Clave1, Justin Sonnenburg, Garry Nolan2

1Massachusetts Institute of Technology (MIT), Cambridge, MA, United States; 2Stanford University, Stanford, CA, United States

Correspondence: Suzin Jiang (sizunj@stanford.edu), Xavier Rovira-Clave (xrovira@stanford.edu), Garry Nolan (gnolan@drowlab.com)

Background

In the past decade, numerous studies of microbiota have shown the tremendous impact of this symbiont community on human health.

Ethics Approval

The study was approved by the East of England – Cambridge East Research Ethics Committee, reference 18/EE/0091.
With the advancement of high-throughput sequencing technologies, the composition of microbiota communities, which used to be elusive, can now be quantified and categorized, even towards the resolution of single bacterial strains. More importantly, numerous therapeutic implications associated with the microbiome have been discovered and are under active exploration. Accumulating evidence support that microbiota can specifically influence the efficacy of certain cancer immunotherapies: 1. Species of Bifidobacterium are positively correlated with anti-PD-1 therapy in mice; 2. Species of Bacteroidales can trigger Th1 response and promote DC maturation during anti-CTLA-4 therapy; 3. Antibiotic treatment remarkably decreases the effect of anti-CTLA-4 therapy. These discoveries have motivated various research projects, aiming to identify novel microbial-based intervention to enhance the efficacy of cancer immunotherapy in patients. One of the major confounding factors impeding a more detailed understanding of these microbial-host interactions is the lack of appropriate methodology to explore the microbial-tumor interactions and microbial anti-tumor activation of the immune system.

Methods
Mice harboring a humanized gut microbiome were sacrificed, and colon tissue collected. We then performed Multiplexed Ion Beam Imaging of these samples to understand the spatial structure of the microbiome and corresponding host responses by a combination of ISH and antibody staining. To establish a highly specific bacteria phylum specific ISH library, oligo probes were designed to detect specific bacteria groups and antibody targeting cell types markers or host response presented in the same location.

Results
We have optimized and validated a panel of ~20 antibodies either targeting cell type markers presented in the small intestine and colon, including immune cell (CD3, CD4 etc.), intestinal epithelial cell (DCLK-1etc.), or targeting host functional marker including histone modification (H3K27me3, H3K27ac), inflammatory response (MPO, pSTAT3 etc) or mucus secretion (UEA-1). We have also built an oligo design pipeline to establish a highly specific oligo probe panel targeting the major Bacteria phylum in the human gut microbiome.

Conclusions
We introduce microMIBI, a multiplexed imaging technique that combines bacteria-specific ISH with host specific protein detection, with potentially >40 parameters (Figure 1). We can achieve co-detection of the spatial structure of bacteria and host protein expression. This allows us to understand the functions of specific bacteria neighborhoods and their interactions with the host tumor and immune system. We hope that these interactions will elucidate novel microbial markers to infer anti-cancer immunogenic outcomes.

Acknowledgements
We thank Matt Newgren for tireless technical support on the MIBI instrument, Rachel Finck, Xiao-Jun Ma and Bingjing Zhang for helpful discussions. B.Z. is supported by the Stanford Graduate Student fellowship and the Leukemia & Lymphoma Society Career Development Program. X.R.-C. was supported by grants from the NIHR-Parkes Institute for Cancer Immunotherapy, the Bill and Melinda Gates Foundation, as well as the Rachford and Carlota A. Harris Endowment Professorship to G.P.N.

Consent
Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Novel Single-Agent Immunotherapies

P756
HER2-targeting TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR- dependent manner
Joseph Gonzalez1, Cecelia Pearson1, Shelley Ackerman, PhD1, Justin Kenkel1, Po Ho1, Angela Luo1, Murray Nguyen1, Jason Paik, MD PhD2, Arthur Lee3, Richard Lauria1, Hai Li1, Cindy Kreder1, Karla Henning1, Steve Chapin1, Bruce Devens1, Brian Safina1, David Jackson1, Edgar Engleman2, David Dornan, PhD1, Michael Alonso1
1Bolt Biotherapeutics, Redwood City, CA, United States; 2Stanford University, Palo Alto, CA, United States
Correspondence: Michael Alonso (malonso@boltbio.com)

Background
Antigen presenting cells (APCs) process tumor antigens and facilitate recruitment of tumor-specific T cells to generate a robust anti-tumor immune response. APCs are present in almost all tumor types, including those that are refractory to checkpoint inhibitors; however, the highly immunosuppressive tumor microenvironment (TME) often renders APCs unable to effectively process and present tumor antigens. To overcome this immunosuppressive TME and rescue the function of tumor-infiltrating APCs, we developed an immune-stimulating antibody conjugate (ISAC) through covalent attachment of a TLR7/8 agonist to a HER2-targeting monoclonal antibody.

Methods
For human in vitro assessment of ISACs, primary PBMCs or myeloid APCs were isolated from human healthy donor blood and activation was measured by flow cytometry, cytokine-bead array, and ELISA-based methods. Various ISACs were assessed in vivo using human HER2 expressing tumor xenograft models (HCC1954, JIMT1, and COLO205) as well as rHER2-expressing syngeneic tumor models (MMC and CT26-rHER2).

Results
In vitro co-cultures with human primary leukocytes and HER2-positive cancer cell lines revealed that the anti-HER2 ISAC potently activates APCs, leading to increased co-stimulatory molecule expression and secretion of pro-inflammatory cytokines. In myeloid-focused in vivo models utilizing HER2-positive human tumor cell line xenografts, which are resistant to trastuzumab, anti-HER2 ISAC treatment led to tumor regression and clearance. Importantly, antigen density and receptor occupancy were key factors dictating response to ISAC treatment. Further mechanistic studies revealed that anti-HER2 ISAC
efficacy was TLR- and FcR-dependent. Cell-specific depletion studies also demonstrated a dependence on phagocytic cells for tumor regression and clearance. In syngeneic tumor models in which anti-HER2 ISAC treatment led to tumor clearance, animals rechallenged with the parental tumor cell line lacking HER2 antigen expression were protected from tumor growth. In addition, depletion of CD4 and CD8 T cells prior to rechallenge led to loss of immunological memory.

Conclusions
These data provide a strong rationale for pursuing an anti-HER2 TLR7/8 ISAC into the clinic for the potential treatment of HER2-positive cancers.

P757
Novel SIRP antibodies with differentiated characteristics for targeting innate immunity in cancer
Gabriela Andrejeva, PhD, Benjamin Capoccia, PhD, Michael Donio, MS, Ronald Hiebsch, BS, Robyn Puro, PhD, Myriam Bouchlaka, PhD, Daniel Pereira, PhD
Arch Oncology, St. Louis, MO, United States
Correspondence: Daniel Pereira (dperreira@archoncology.com)

Background
Unleashing the adaptive immune response from checkpoint blockade has shown therapeutic efficacy in oncology, although in a subset of patients. The ability of innate immune cells to acquire tumor-associated antigen and effectively present it to T cells is fundamental to a successful immune attack on cancer. Macrophage-mediated tumor cell phagocytosis can enact significant tumor clearance. In addition, macrophages represent the most abundant immune cell type in many solid tumors and are often linked to poor prognosis due to the ability of cancer cells to block phagocytosis and manipulate macrophages into facilitating malignant progression. The interaction of tumor CD47 with SIRPα on macrophages, dendritic cells and neutrophils presents such an immune blockade. We have previously presented data on AO-176, a clinical stage humanized anti-CD47 antibody that is highly differentiated among agents in this class of checkpoint inhibitors. Here we also evaluate a portfolio of novel anti-SIRP antibodies with differentiated properties as another approach to targeting the CD47/SIRPα axis.

Methods
We used solid-phase ELISA and cell binding assays to characterize target binding and blocking by our antibodies. Immunomodulatory effects were tested using in vitro phagocytosis, T cell stimulation by allogeneic dendritic cells and antigen-specific T cell assays.

Results
Here we present novel discovery-stage antibodies that either bind human SIRPα variant 1 or both variant 1 and variant 2, the two most common variants in the human population. Interestingly, our antibodies may or may not block the SIRPα-CD47 interaction, however, they are unique and differentiated among reported anti-SIRP antibodies in that they induce phagocytosis of several solid and hematologic tumor cell lines as single agents. They also exhibit enhanced phagocytosis when combined with tumor-opsonizing antibodies, including our highly differentiated anti-CD47 antibody, AO-176. Finally, while our antibodies also bind to SIRPγ, but differ in ability to block the interaction to CD47 in solid phase assays, they do not block SIRPγ in cell-based assays involving T cells. Consequently, they show no adverse effects on T cell proliferation or activation in allogeneic co-cultures of T cells with dendritic cells, and in a CMV antigen recall response assay.

Conclusions
Our novel anti-SIRP antibodies induce promising and differentiated in vitro single agent and combination phagocytosis and show no adverse effects on T cell functionality. These data support their future development, both as single agent antibodies and in combination with other anti-cancer drugs.

Ethics Approval
All human material was purchased from Astarte Biologics, INC., 2212 – 20th Ave SE, H-150, Bothell, WA 98021.

P758
COBRA: A novel conditionally active bispecific antibody that regresses established solid tumors in mice
Anand Panchal, Andishesh Bagheir, MS, Maia Vinogradova, Tim Chen, Russell Wall, Stéphanie Levon, Pui Seto, Jessica Krakow, Brian Hillier, Ying Zhu, Danielle Dettinger, Jeremiah Degenhart, Aakash Datt, Eileen Kwok, Lucy Quach, Patricia Culp, Chad May, Bob DubRidge
Maverick Therapeutics, Brisbane, CA, United States
Correspondence: Bob DubRidge (bdubridge@mavericktx.com)

Background
Despite clinical success with bispecific antibodies (bsAbs) targeting hematological malignancies (e.g., blinatumomab, a CD19xCD3 bsAb), efficacy in solid tumor indications remains a significant challenge. Because T-cell redirecting bsAbs are so potent, even low levels of cell surface target antigen expression on normal tissues may quickly become a safety liability and severely restrict the dose levels that can be achieved in patients. Additionally, identifying “clean” targets that are uniquely expressed on the tumor and not on normal tissues is very difficult at best, further narrowing the therapeutic landscape for T-cell redirected bsAbs.

To overcome these challenges, we have developed a novel recombinant bsAb platform called COBRA (Conditional Bispecific Redirected Activation). COBRAs are engineered to enable targeting of more widely expressed and validated tumor cell surface antigens by focusing T-cell engagement within the tumor microenvironment.

Methods
COBRA molecules are designed to bind to target antigen, which may be expressed on both tumor and normal cells, yet not engage T-cells unless exposed to a proteolytic microenvironment, which is common in tumors but not in normal healthy tissues. Once bound to the tumor target antigen, protease-dependent linker cleavage allows COBRAs to convert an inactive anti-CD3 scFv to an active anti-CD3 scFv binding domain. Upon conversion, COBRAs are then able to simultaneously co-engage T-cells and target antigen, resulting in a potent cytolytic T-cell response against the tumor cells. In addition, COBRAs are designed with a half-life extension moiety that is removed from the active molecule upon proteolytic cleavage. This allows for a sustained presence in the circulation of the inactive COBRA prior to tumor target binding, and more rapid clearance of unbound active COBRA molecules, thereby decreasing the potential for cytotoxic activity in normal tissues (Figure 1).

Results
Here we report the novel design of the COBRA molecule MVC-101 and demonstrate its ability to engage CD3 and Epidermal Growth Factor Receptor (EGFR) to elicit potent cytotoxic activity in vitro and in vivo (Figure 2, 3).

Conclusions
In T-cell dependent cellular cytotoxicity (TDCC) assays, we demonstrate that protease dependent activation increases the potency of MVC-101, yielding a therapeutic with sub-picomolar potency. We further demonstrate that administration of MVC-101 in mice with established xenografts results in protease cleavage dependent, T-cell mediated tumor regressions in multiple tumor models (Figure 4). Finally, MVC-101 has an extended half-life in vivo upon administration, and rapid clearance post proteolytic activation, resulting in an improved safety profile over conventional T-cell redirected bsAbs.
DZD2269, a novel A2AR antagonist capable of overcoming high adenosine induced immunosuppression

Yu Bai, MSc , Xin Zhang, Jie Zheng, Yingchun Wang, Lingli Zhang, Zhenfan Yang

Dizal Pharmaceutical Co., Ltd, Shanghai, China

Correspondence: Yu Bai (Yu.Bai@dizalpharma.com), Zhenfan Yang (Pamela.Yang@dizalpharma.com)


Background

Extracellular adenosine is a potent immunosuppressive metabolite. While its level is normally low in circulating blood, it could reach over 1,000-fold higher in tumor microenvironment, at 50 to 100 μM [1-3]. Adenosine exerts its biological effect through adenosine receptors. Available evidence suggests that A2aR is the key mediator for its immune suppressive effect [4,5]. Several A2aR antagonists are in early clinical development. While potent at low adenosine level, they loss their activity totally when measured at the adenosine level found in tumor microenvironment. DZD2269 was designed to fully block A2aR in a wide range of adenosine concentrations. It has the right DMPK properties consistent with once daily oral dosing. Results from GLP toxicity studies support its clinical evaluation in healthy volunteers and cancer patients.

Methods

The binding assay was measured by testing the ability of DZD2269 to replace radio-labelled ligand for each adenosine receptors. The potency of A2aR antagonists and selectivity towards related receptors was determined by measuring cAMP levels or calcium influx change in adenosine receptor overexpressed CHO cells, following NECA or ADO stimulation. Reversed adenosine induced Immune suppression assay were quantified following compound treatment in the presence and absence of NECA in CD3/CD28 stimulated PBMC. NECA-stimulated mouse whole blood was utilized for measuring the p-CREB level. In addition, in vivo anti-tumor activity of DZD2269 alone or in combination with anti-CTLA4, radiotherapy and chemotherapy was evaluated in several syngeneic model.

Results

DZD2269 binds to human A2aR with a Ki of 5.4nM. Adenosine or its stable analogue NECA potently inhibited TNF-α, IFN-γ and IL-2 secretion from human T cells in a dose-dependent manner. DZD2269 effectively overcame 10μM NECA (equal to 100μM adenosine) induced immunosuppression and restored TNF-α, IFN-γ and IL-2 secretion. Adenosine inhibited CD8+ cell proliferation which could be reversed by DZD2269. The antitumor activities of DZD2269 was evaluated in several syngeneic mouse tumor models. DZD2269 monotherapy reduced tumor growth in these models. The most profound anti-tumor growth effects were found when DZD2269 was administered in combination with anti-CTLA4 Ab, radiotherapy and chemotherapy. Our results showed that p-CREB level could be a useful pharmacodynamic biomarker. It negatively correlated with DZD2269 exposure in
animal models. Inhibition of p-CREB to basal level was required for achieving maximum efficacy.

Conclusions
DZD2269 is a potent, selective A2aR antagonist, which effectively reverses high adenosine induced immunosuppression. Its safety profile supports its clinical evaluation in healthy volunteers and cancer patients.

References

Ethics Approval
All in vivo studies were approved by Institutional Animal Care and Use Committee of Dizal.

P760
Local modulation of T cell PD-1 using self-delivering RNAi as a potential immunotherapeutic
John Barrett, PhD , James Cardia, Melissa Maxwell, Mani Kadiyala, MS, Dingyue Yan, PhD, Winnie Tam, Simon Fricker, PhD, Gerrit Dispersyn, PhD
Phio Pharmaceuticals, Malborough, MA, United States
Correspondence: John Barrett (jbarrett@phiopharma.com)

Background
The ability of tumor cells to evade the immune system (immune escape) as well as their acquired resistance to anti-cancer drugs constitute important barriers to the successful management of cancer. Interaction between the Programmed Death Ligand 1 (PD-L1) on the surface of tumor cells with the Programmed Death-1 (PD-1) receptor on cytotoxic T lymphocytes leads to inactivation of these immune effectors and, consequently, immune escape. Restoration of anti-tumor immunity by blocking PD-1 signaling using antibodies has proven to be beneficial in cancer therapy. However, systemic anti-PD-1 therapy has been shown to induce Grade 3-4 colitis, pneumonitis and in-creased LFTs. The ability to elicit local inhibition of PD-1 should circumvent the systemic toxicity of current anti-PD-1 therapy.

Ph-762 is a chemically modified self-delivering RNA inhibitor containing an asymmetric duplex structure (≤ 15 base pair duplex) and a single-strand phosphorothioate tail specifically targeting PD-1 mRNA expression. Ph-762 is efficiently delivered to the immune cells without the need for specialized formulations or mechanical transfection as is observed with current RNAi’s.

Methods
PD-1 mRNA knockdown was assessed by qRT-PCR on total cellular RNA using Taqman probe sets. T cell phenotyping was performed using flow cytometry. T cell IFN-y release was assessed via ELISA.

Results
Ph-762 rapidly and efficiently transected T cells. Ph-762 elicited a concentration dependent silencing of primary human PD-1 mRNA levels, IC50 of ~ 0.4 μM, with silencing persisting for up to 7 days posttreatment while media alone and nontargeting control (NTC) did not affect PD-1 mRNA levels. This in turn resulted in a concentration dependent reduction in PD-1 surface protein expression (IC50 of ~ 0.4 μM). Ph-762 transfection did not alter T cell viability when compared to media control. Ph-762 CD3+CD8+ T cells were able to recognize allogenic tumors as demonstrated by increased IFN-γ production when co-cultured with melanoma cells. The increased CD3+CD8+ functionality resulted in enhanced tumor cell kill when compared to media alone or NTC. Similar effects were observed with mPh-762 (murine surrogate) in mouse T cells.

Conclusions
These findings support the hypothesis that local PD-1 mRNA silencing by Ph-762 is a viable approach for overcoming tumor-induced immunosuppression resulting in enhanced T cell functionality and tumor cell kill which warrants further investigation in patients.

P761
Tumor-targeted bacterial nanocells carrying a super-cytotoxic drug elicit an anti-tumor immune response, long-term survival, prolonged tumor remission, and resistance to tumor re-challenge
Himanshu Brahmbhatt, PhD
EnGeneIC Pty Ltd, Lane Cove West, Australia
Correspondence: Himanshu Brahmbhatt (hbrahmbhatt@engeneic.com)

Background
Despite efficacy of current immunotherapy in specific cancers, most tumors still develop resistance by exploiting different immune evasion pathways. Bacterial nanocells (designated as EDVs; EnGeneIC Dream Vector) can be loaded with a variety of chemotherapeutic drugs and targeted with antibodies directed to the cancer cell surface, to release a toxic payload intracellularly [1,2]. Here we present evidence that targeted EDVs packaged with the highly toxic drug PNU159682 (D682), resulted in an anti-tumor immune response and resistance to tumor re-challenge.

Methods
Syngeneic mouse tumor models, CT26Ep12.1 (colon) and 4T1 (breast) expressing EpCAM receptor were intravenously treated with saline, 1x10^9 EpCAM targeted EDVs (Ep-EDV), or 1x10^9 EpCAM targeted nanocells loaded with PNU-159682 (Ep-EDV-D682). Tumors were measured three times per week and tumors and spleen were isolated for immune cell analysis by flow cytometry. Separately, mice received 4 doses of saline, 2x10^9 Ep-EDV, or 2x10^9 Ep-EDV-D682 and tumor growth was monitored until tumors reached 1000 mm3 (endpoint). Mice were re-challenged on day 15 with a tumor inoculation on the other flank as was a Naïve cohort. Spleens were collected from control mice upon sacrifice and from surviving Ep-EDV-D682 treated mice 50 days post initial tumor inoculation for flow cytometric analysis of memory T-cell populations.

Results
Immune cells isolated from CT26Ep12.1 and 4T1 mice treated with Ep-EDV-D682 showed a significant increase in M1/M2 macrophages, activation of NK cells concurrently with a predominantly Th1 cytokine response. Dendritic cell maturation followed, generating anti-tumor CD8+ T-cells. Mice exhibited a significant increase in long term survival, with 40% CT26Ep12.1 and 35% 4T1 showing complete regression and no relapse respectively. On rechallenge with tumor cells, 0% of CT26Ep12.1 and 25% 4T1 mice formed tumors compared to 100% of saline controls and a naïve cohort. T-cell populations in the spleens of surviving Ep-EDV-D682 treated CT26Ep12.1 mice exhibited significant increases in total T-cell numbers (CD3+) including both CD4+ and CD8+ and both tumor models showed an increase in memory T-cell populations.

Conclusions
Targeted nanocells carrying a super-cytotoxic payload are capable of a dual attack on the tumor in syngeneic mouse models of colon and breast cancer. Firstly, tumor cell killing occurs via a very effective drug, followed by development of an anti-tumor immune response, resulting in long-term survival and resistance to re-challenge. The current study highlights the potential of targeted nanocells as a novel and versatile cancer cyto-immuno-therapeutic.

Acknowledgements
J. MacDiarmid and H. Brahmbhatt contributed equally to these studies
References


Ethics Approval

Mouse experiments were approved by the EnGeneIC Animal Ethics committee, under the following approval numbers, AEC 1/2016, AEC 14/2016, AEC 15/2016, AEC 11/2017, and AEC 05/2019.

P762

Antibodies to ILT3 (LILRB4) abrogate myeloid immunosuppression and combine with PD1 blockade to enable T cell activation and function

Philip Brandish, PhD, Jeanne Baker, Alan Byford, Michael Caniga, Craig Chappell, Holly Cherwinski, Daniel Cua, Laurence Fayadat-dillman, Brian Hall, Barbara Joyce-Shahk, BS, Veronica Juan, Carl Miezckowski, Anthony Palmieri, Yujie Qu, MD, Latika Singh, Peter Stivers, Jie Zhang-Hoover Merck, Boston, MA, United States

Correspondence: Philip Brandish (philip.brandish@merck.com)

Background

Accumulating clinical data suggest that infiltration of solid tumors with immunosuppressive myeloid cells is associated with a lower likelihood of response to T cell checkpoint immunotherapy. As such, modulation of the activation state and function of the myeloid compartment is a critical next frontier in cancer therapy. Immunoglobulin-like transcript 3 (ILT3, also known as LILRB4) expressed on dendritic cells (DCs) has been previously implicated in the promotion of antigen-specific tolerance, and we have found increased expression of ILT3 on mononcytic myeloid-derived suppressor cells (MDSCs) that are effectors of antigen-independent immune suppression.

Methods

To study the role of ILT3 in these aspects of immunity, we created antibodies that are highly potent and selective for ILT3 over other ILT family members.

Results

These antibodies effectively antagonized polarization by IL-10 to enhance dendritic cell activation state and enable T cell priming. Furthermore, in a mixed lymphocyte reaction using IL-10 polarized DCs and allogenic CD8+ T cells, anti-ILT3 combined with pembrolizumab afforded greater CD8+ T cell activation compared to either agent alone. Turning to MDSCs, we found that anti-ILT3 antibodies impaired the acquisition of a suppressive phenotype by monocytes co-cultured with cancer cells, resulting in diminished suppression of autologous CD8+ T cell activation. Finally, anti-ILT3 antibodies inhibited tumor growth and stimulated an increase in markers of immune activation in a humanized mouse model of cancer, the subject of a companion poster.

Conclusions

These data support the testing of anti-ILT3 antibodies in humans for the treatment of cancer.

Ethics Approval

All mice were maintained under specific pathogen-free conditions in accordance with Merck Research Laboratories (MRL) Institutional Animal Care and Use Committee (IACUC) regulations and were performed in accordance with guidelines in approved protocols.

P763

Target Engagement and PK/PD quantification in humanized tumor model for anti-ILT3 mAb discovery

Alan Byford, MSc, Yujie Qu, MD, Xiaoyan Du, Daping Zhang, Yvonne Yannoni, Laurence Fayadat-dillman, Brian Hall, Jeanne Baker, Michael Meahl, Scott Pruitt, MD, PhD, Lily Moy, Philip Brandish, Jie Zhang-Hoover Merck, Boston, MA, United States

Correspondence: Jie Zhang-Hoover (jie.zhang-hoover@merck.com)


Background

Target engagement (TE) and translational pharmacodynamics (PD) biomarkers are critical in drug discovery and development. We explored and compared multiple TE & PD readouts after anti-ILT3 mAb treatment in a humanized murine SK-MEL-5 tumor model: 1) ILT3 receptor occupancy on mononcytic myeloid cells in the tumor and blood vs. total blood soluble ILT3 (sILT3) levels; 2) levels of activation markers HLA-DR and LOX-1 on mononcytic myeloid cells that are associated with antigen presentation and activation of T cells.

Methods

Hu-NSG mice with subcutaneous SK-MEL-5 or Panc 08.13 tumors were treated with an anti-human ILT3 mAb. Cell surface ILT3 receptor occupancy and activation markers were quantitated by FACS analysis. Plasma anti-ILT3 mAb and total soluble ILT3 (sILT3) concentrations were measured using electrochemiluminescence immunoassay.

Results

TE assessed by ILT3 occupancy on the surface of CD14+ myeloid cells and by plasma total sILT3 levels was detected after single dose administration of the anti-ILT3 mAb ranging from 0.003 to 20 mg/kg. Levels of ILT3 receptor occupancy on CD14+ myeloid cells correlated with the dose administered and exposure levels of anti-ILT3 mAb in the plasma in both tumor models. ILT3 receptor occupancy in the tumor and total sILT3 in the blood were saturated in the mice treated with 10 mg/kg of anti-IL-3 mAb, while saturation of ILT3 receptor occupancy in the blood was reached at a lower dose (1 mg/kg). The percentage of tumor myeloid cell ILT3 receptor occupied correlated with total plasma sILT3 levels after mAb treatment. Expression of immune activation related markers LOX-1 and HLA-DR on CD14+ myeloid cells were upregulated in a time and exposure dependent manner in the SK-MEL-5 hu-NSG model that expresses high levels of ILT-3, but not in Panc 08.13 with low ILT3 expression.

Conclusions

High levels of ILT3 receptor occupancy in the tumor were required for the upregulation of immune activation markers in the humanized tumor model. HLA-DR could be used as an immune response PD biomarker for assessing anti-ILT3 mAb activity in vivo. A proof-of-concept was established for using total sILT3 in the blood as a surrogate for tumor TE after anti-ILT3 mAb treatment that could be used for human dose projection.

Activity of the anti-ILT3 mAb in vitro and tumor efficacy in vivo is described in a companion poster.

Ethics Approval

The study was approved by Merck Institutional Animal Care and Use Committee, approval number 2022-200518-FEB.

P764

Directly targeting FOXP3 with AZD8701, a first-in-class high affinity antisense oligonucleotide to relieve immunosuppression in cancer

Charles Sinclair1, Alexey Revenko2, Alison Peter1, Molly Taylor1, Anisha Solanki, PhD1, Melissa Chapman1, James Yates1, Helen Angell, BSc PhD2, Frederick Goldberg1, Robert MacLeod2, Larissa Carnevalli, PhD1

1AstraZeneca, Cambridge, United Kingdom; 2Ionis Pharmaceuticals, Carlsbad, CA, United States

Correspondence: Larissa Carnevalli (larissa.carnevalli@astraZeneca.com)

Background
Regulatory T cells (Treg) critically maintain immuno-suppression in the tumor microenvironment, representing an attractive immuno-oncology target. The Treg lineage is defined by expression of the FOXP3 transcription factor, which controls immune-suppressive functions.

Methods
We have discovered a clinical candidate AZD8701, a next-generation antisense oligonucleotide inhibitor of FOXP3 (utilizing the Ionis Gen 2.5 cEt-modified ASO platform).

Results
AZD8701 treatment knocked down FOXP3 in primary human Tregs via free uptake (IC50 65nM), which was also associated with modulation of known FOXP3 target genes including 25-50% reduction in CTLA4, ICOS, CCR8 and GITR. Tregs treated with AZD8701 further exhibited reduced suppressive functions in in vitro suppression assays, which confirmed the functional effects of FOXP3 modulation. Finally, AZD8701 promoted dose-dependent knockdown of FOXP3 in human tumors, including >50% decrease in FOXP3 expression in many cases predicted to correspond to clinically achievable doses. To support the importance of FOXP3 in immuno-oncological settings, we characterized murine surrogate FOXP3 ASOs in the context of synergistic tumour bearing mice. Murine FOXP3 ASOs similarly promoted >50% FOXP3 knockdown in mice and were well tolerated with no overt toxicological findings at high doses, over a maximum of 12 weeks of treatment. Murine FOXP3 ASOs significantly attenuated tumour growth in A20 and ID8-VEGF syngeneic models, which was associated with some complete tumour regressions. Moreover, we found that mouse surrogate FOXP3 ASOs promoted additive/enhanced therapeutic effects when combined with immune checkpoint blockade. Additionally, an increase in tumour infiltrated CD8+ T cells and activation markers (e.g. Granzyme B) correlated with increased anti-tumour response in A20 tumour model.

Conclusions
In summary, AZD8701 represents a first-in-class clinical candidate to target Tregs in cancer in a highly selective manner, and may provide therapeutic benefit to patients either as a monotherapy or in combination with immune checkpoint blockade.

P765
First in class antibody targeting Galectin-9 promotes anti-tumor response against pancreatic and other solid cancers
Lineao Chen, PhD1, Wei Wang, MD1, Akiko Koide, PhD1, Adrian Seifert, MD2, Lena Seifert3, Aleksandra Filipovic, MD, PhD4, George Miller1, Shohei Koide1, PhD1
1NYU Langone, New York, NY, United States; 2University Hospital Carl Gustav Carus, Dresden, Germany; 3German Cancer Research Center, Heidelberg, Germany; 4PureTech Health, London, United Kingdom
Correspondence: Shohei Koide (Shohei.Koide@nyumc.org)

Background
Regulatory T cells (Treg) critically maintain immuno-suppression in the tumor microenvironment, representing an attractive immuno-oncology target. The Treg lineage is defined by expression of the FOXP3 transcription factor, which controls immune-suppressive functions.

Methods
We have discovered a clinical candidate AZD8701, a next-generation antisense oligonucleotide inhibitor of FOXP3 (utilizing the Ionis Gen 2.5 cEt-modified ASO platform).

Results
AZD8701 treatment knocked down FOXP3 in primary human Tregs via free uptake (IC50 65nM), which was also associated with modulation of known FOXP3 target genes including 25-50% reduction in CTLA4, ICOS, CCR8 and GITR. Tregs treated with AZD8701 further exhibited reduced suppressive functions in in vitro suppression assays, which confirmed the functional effects of FOXP3 modulation. Finally, AZD8701 promoted dose-dependent knockdown of FOXP3 in human tumors, including >50% decrease in FOXP3 expression in many cases predicted to correspond to clinically achievable doses. To support the importance of FOXP3 in immuno-oncological settings, we characterized murine surrogate FOXP3 ASOs in the context of synergistic tumour bearing mice. Murine FOXP3 ASOs similarly promoted >50% FOXP3 knockdown in mice and were well tolerated with no overt toxicological findings at high doses, over a maximum of 12 weeks of treatment. Murine FOXP3 ASOs significantly attenuated tumour growth in A20 and ID8-VEGF syngeneic models, which was associated with some complete tumour regressions. Moreover, we found that mouse surrogate FOXP3 ASOs promoted additive/enhanced therapeutic effects when combined with immune checkpoint blockade. Additionally, an increase in tumour infiltrated CD8+ T cells and activation markers (e.g. Granzyme B) correlated with increased anti-tumour response in A20 tumour model.

Conclusions
In summary, AZD8701 represents a first-in-class clinical candidate to target Tregs in cancer in a highly selective manner, and may provide therapeutic benefit to patients either as a monotherapy or in combination with immune checkpoint blockade.
on their recognition of identical, or closely related, pHLA determinants of the NY-ESO-1157-165 cancer testis antigen-derived peptide, SLLMWITQC, presented by HLA-A*02:01 (A2-SLL), the MAGE-A1161-169/MAGE3-A3168-176 melanoma-associated antigen-derived peptides, EADPTGHSY (A1-EAD) and EVDPIGHLY (A1-EVD), presented by HLA-A*01:01, and the WT126-134 Wilms tumour antigen derived peptide, RMFPNAPYL, presented by HLA-A*02:01 (A2-RMF).

Results
We demonstrate that affinity-enhanced TCRs engage pHLA using a comparatively broad and balanced energetic footprint, with interactions distributed over several HLA and peptide side-chains. As ImmTAC molecules, these TCRs also retained pHLA-selectivity, with potent killing of antigen-positive cell lines and minimal off-target activity in cellular assays. Conversely, TCR-mimic antibodies tended to exhibit binding modes focussed more towards hotspots on the HLA surface and tolerate amino acid degeneracy. In cellular assays, the antibody-based bispecifics exhibited greater cross-reactivity to antigen-negative cell lines and as such, a reduced specificity window.

Conclusions
These findings extend our understanding of the basic principles that underpin pHLA-selectivity and exemplify a number of molecular approaches that can be used to probe the specificity of pHLA-targeting molecules, aiding the development of future reagents.

P767
Single-cell cytometry with the genesis system - A scalable solution for high-parameter epitope detection
Jon Bell, BS, MS1, Yad Deol, PhD, MS1, Shaun Connor, BS, MBA1, Tyler Burns, PhD2
1Celsee, Inc., Hudson, OH, United States; 2Celsee, Berlin, Germany
Correspondence: Jon Bell (jon.bell@celsee.com)

Background
This poster illustrates an exciting new way to characterize cell populations far beyond traditional methods. Using Single-Cell Cytometry removes common detection limitations of both flow and mass cytometry. Here we describe Celsee’s ability to detect 60 different antibodies in a single run.

Methods
25,000 cells were isolated using Celsingle 250K Slide on the Genesis System and sample preparation protocol was performed. PBMCs were stained with 60 oligo-labeled antibodies (BioLegend, CA, USA) and sequencing was performed on the MiSeq (Illumina, CA, USA). Analysis method via Seurat (Satija Lab).

Results
We observed signal from all 60 antibodies across the population of thousands of cells analyzed. Plotting all cells together via dimensional reduction provides a global view of similar and different sub-populations present in our PBMC sample (Figure 1). Importantly, separation of populations such as T, B, and NK cells (Figure 2) were observed. The T cell populations showed both CD8 and CD4 are mutually exclusive as well as CD45RO and CD45RA (Figure 3). For the B cell population, we observed signal across multiple CD markers as expected (e.g. CD 19). As for NK Cells, expression of CD16, CD45RA, and CD8 are in concordance with our observations. Aggregating data across major cell types shows expression across all 60 antibodies tested (Figure 4).

Conclusions
These data highlight the simplicity and feasibility of multiplexing 60 antibodies in a single run with the Genesis System. Whether one wishes to analyze 10 markers or over 100, this application is highly scalable both in cell number and number of markers analyzed. Given the obvious difficulties in legacy flow cytometry and mass cytometry instruments, Single-Cell Cytometry is poised to deliver limitless protein detection with Celsingle technology making the Genesis System a practical and economical solution for cytometry related experimentation.

Consent
Yad Deol, Shaun Connor, Jonathan Bell, Tyler Burns
Antagonism of signaling through the vasoactive intestinal peptide receptor as a novel immunotherapy in preclinical models of melanoma

Sruthi Ravindranathan, PhD 1, Shuhua Wang, MD 1, Rebecca Pankove, MS 1, David Francis 2, Susan Thomas, PhD, BS 2, Rohan Dhamsania, BS 1, Brian Pollack1, Edmund Waller, MD, PhD, FACP 1

1Emory University, Atlanta, GA, United States; 2Georgia Institute of Technology, Atlanta, GA, United States

Correspondence: Rohan Dhamsania (rohan.dhamsania@emory.edu)

Background

Only 40% of the patients with metastatic melanoma respond to FDA-approved immune-checkpoint blockade therapies. 25%-40% of these patients relapse within 3 years of treatment [1]. Thus, it is imperative to explore more rigorous cancer immunotherapies.

Vasoactive Intestinal Peptide (VIP) is a 28-aminoacid immunosuppressive neuropeptide. Its potent immunosuppressive effects are shown in mouse models of leukemia and lymphoma, with downregulation of PD-1 and PD-L1 expression in activated T cells and dendritic cells respectively, following treatment with peptide antagonist of VIP (ANT-00) that competitively blocks binding of native VIP to VIP receptors [2]. ANT-00 treatment also significantly enhanced proliferation of splenic T cells in-vitro [2]. Interestingly, according to the cancer genome atlas (TCGA), metastatic melanoma patients with low VIP mRNA have better survival than patients with high VIP mRNA expression in tumor (Figure 1A). Thus, we hypothesize that pharmacological inhibition of VIP-signaling pathway would be efficacious in melanoma immunotherapy.

Methods

Murine melanoma cell lines: B16F10, B16F1, SM1 and D4M were cultured in DMEM-based media for 24 hours and cell-free supernatant was quantified for VIP concentration via VIP-specific Enzyme Immunoassay (EIA). Presence of VIP receptors on B16F10 cells was confirmed using western blot. Cytotoxic effect of ANT-00 on B16F10 cells was analyzed using MTT assay. C57BL/6 mice inoculated with B16F10 cells were treated with ANT-00 before/after tumors were palpable. Treatment regimen involved daily subcutaneous administration of 0.1-10ug of ANT-00 or ANT-08 (a more potent VIP antagonist) throughout the duration of treatment. Phenotypic differences in immune infiltrates were analyzed via flow cytometry.

Results

All melanoma cell lines secrete low levels of VIP (Figure 1B). Although B16F10 cells express similar VIP receptors levels (Figure 2A), ANT-00 didn’t have direct cytotoxic effect on B16F10 cells (Figure 2B, 2C). ANT-08 dosed at 1-10ug/mouse/day-controlled tumor growth for up to 10 days of treatment, with the anti-tumor effect diminishing with subsequent treatment beyond 10 days (Figure 3E-G). Moreover, when B16F10 bearing mice were treated daily with 1.0ug of ANT-08 for 10 days after tumors were palpable, a significant improvement in survival was observed compared to PBS-treated control animals (p<0.01, Figure 4). Immunophenotyping of infiltrating lymphocytes in excised tumors revealed that ANT-08-treated group had significantly higher levels on proliferating CD4+ T cells (p=0.04) (Figure 4), supporting a role of VIP antagonism in activating anti-cancer immunity.

Conclusions

In preclinical melanoma models, pharmacological antagonism of VIP-signaling significantly increased survival rates (Figure 4) by activating adaptive T cell immunity. Thus, inhibiting VIP-signaling is a novel potential immunotherapy for melanoma.

Acknowledgements

I would like to thank Dr. Edmund Waller, Dr. Sruthi Ravindranathan and entire Waller for their constant support. I would like to acknowledge Laney Graduate School and Winship Cancer Institute of Emory University for providing me the platform to pursue cancer immunotherapy research.

References

Inhibition of arginase in combination with anti-PDL1 leads to increased infiltration and activation of CD8+ T cells, NK cells, and CD103+ dendritic cells in the mouse syngeneic MC38-OVA tumor model

Aatman Doshi, MS, Susan Cantin, Michael Secinaro, Yanjun Wang, Laura Prickett, Sharon Tentarelli, Scott Mlynarski, Eric Gangl, M. Raymond Finlay, Wenlin Shao, PhD, Alwin Schuller
Astrazeneca, Waltham, MA, United States

Background
The tumor microenvironment (TME) has multiple mechanisms of immunosuppression, one being recruitment of arginase (ARG)-expressing myeloid cells. ARG is an enzyme that catalyzes hydrolysis of L-arginine into urea and L-ornithine. L-arginine is a semi-essential amino acid required for optimal function of T cells and natural killer (NK) cells. Arginine depletion in the TME inhibits T cell and NK cell function resulting in immunosuppression [1]. Therefore, inhibition of ARG can reverse immunosuppression and optimize anti-tumor immunity.

Methods
Human CD8+ T cell and NK cell proliferation was evaluated in various concentrations of L-arginine by measuring CellTrace Violet (CTV) dilution in response to stimulation (anti-CD3/anti-CD28 stimulation for CD8’s; IL2/IL15 for NK’s). Syngeneic mouse tumor models (MC38-OVA, LLC) were assessed for anti-tumor activity and immune system activation with an ARG inhibitor as a monotherapy and in combination with an anti-PDL1 checkpoint inhibitor. The ARG inhibitor was administered orally BID at 30 mg/kg, and anti-PDL1 was dosed with intraperitoneal injections 2QWx2 at 10 mg/kg. Four, ten and fourteen days post-treatment, phenotype and activation status of T cell, NK cell and CD103+ dendritic cell (DC) populations within tumor and lymph nodes (LN’s) were evaluated using multi-color flow cytometry. Furthermore, the functional response of CD8+ cytotoxic T cells was evaluated by ex vivo restimulation with phorbol 12-myristate-13-acetate (PMA) and ionomycin prior to analysis.

Results
Human CD8+ T cells and NK cells showed decreased proliferation with decreased L-arginine concentration. L-arginine threshold for optimal proliferation was determined to be ~30 uM for CD8+ T cell and ~9 uM for NK cells. Furthermore, CD8+ T cells showed dose-dependent decreases in cytotoxic molecules (e.g., granzyme A, granzyme B, perforin) with decreased L-arginine. While ARG inhibitor monotherapy showed 30% tumor growth inhibition (TGI) in the MC38-OVA tumor model in vivo, combining with anti-PDL1 significantly improved efficacy (87% TGI), with 7/10 tumors regressing. An in vivo PD combination study of ARG inhibitor with anti-PDL1 showed increases in multiple tumor immune cell populations (~4-fold CD8+ T cells, 2-fold NK cells, 2-fold CD103+ DCs) and increased CD8 T cell activation. Moreover, ARG inhibitor resulted in an increase of IFNg and TNFa producing CD8+ T cells in the periphery (draining LN).

Conclusions
Our pre-clinical data demonstrates that an ARG inhibitor in combination with a checkpoint inhibitor can reverse tumor immunosuppression leading to strong immune activation and anti-tumor responses, suggesting arginase inhibitors could provide an opportunity to increase activity of checkpoint inhibitors clinically.

References

Ethics Approval
The study was approved by AstraZeneca’s Institutional Animal Care and Use Committee (IACUC).
**P770**

A novel class of multi-specific antibodies targeting NKp30 on innate immune cells

Moinia Draghi, PhD1, Allison Nelson1, Amanda Oliphant1, Alan Leung1, Jay Vekeria1, Zach Frye1, Claire Chottin1, Sara Haserlat1, Rachel Rennard1, Caitlin Gougher1, Rachel McCrory1, Lucy Liu1, Kenneth Rogers2, François Villinger3, Piotr Bobrowicz4, Michael Schmidt5, Jennifer Watkins-Yoon6

1Compass Therapeutics, Cambridge, MA, United States; 2New Iberia Research Center, New Iberia, LA, United States

**Correspondence:** Moinia Draghi (monia.draghi@compasstherapeutics.com)


**Background**

Cancer immunotherapies have demonstrated remarkable clinical benefits and durable responses even for late-stage cancers. Most of the attempts of current therapies in development are focused on harnessing the adaptive immune system by unleashing antitumor T cell responses. However, there is emerging evidence that cancers develop multiple strategies to escape T cell recognition, hence approaches that do not require T cell recognition should be explored. Tumors can be effectively eradicated by natural killer (NK) cells and other innate-like lymphocytes such as gamma delta T cells that can elicit potent antitumor response in both mouse cancer models and patients. Therefore exploiting therapeutics that enhance NK and gamma delta T cell responses for the treatment of cancer represents a promising and complementary approach to current existing immunotherapies.

**Methods**

Using our common light chain discovery platform we have developed a novel class of multi-specific antibodies that bind to one or two antigens at the surface of tumor cells and engage both CD16 and NKp30 activating receptors on NK and gamma delta T cells.

**Results**

Unlike conventional monoclonal antibodies that require high levels of target antigen for efficacy, our TAAxNKp30 engagers can potently activate NK and gamma delta T cells to kill tumor cells that express high, medium and low levels of tumor antigen. Furthermore, our NKp30 engagers can activate NK cell subsets with low or null expression of CD16A without inducing off-target effect and NK-versus-NK toxicity. Compass NKp30xBCMA engagers show efficacy in vivo and when tested in cynomolgus monkeys, displays pharmacokinetics similar to monoclonal antibodies and a favorable toxicity profile as compared to BCMAxCD3 bispecific T cell engagers currently tested in clinical settings. Furthermore, transcriptomic profiling of NK cells co-cultured with BCMA positive tumor cells in the presence of NKp30xBCMA reveals a differentiated immune signature as compared to a BCMA-IgG1 monoclonal antibody.

**Conclusions**

Compass NKp30 engagers are highly differentiated from monoclonal antibodies for their capability to activate different subsets of NK and gamma delta T cells and induce killing of tumor cells expressing low levels of tumor associated antigen. Our multi-specific antibodies show in vivo efficacy while maintaining a favorable toxicity profile as compared to T cell engagers. They are highly manufacturable, with expression, purity, stability and pharmacokinetics identical to monoclonal antibodies. Taken together, our results provide the rationale for developing multifunctional NKp30 engagers for the treatment of hematological and solid tumors.

**P771**

An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T cells (Tregs)

Kwong Tsang, PhD1, Massimo Fantini, PhD2, Justin David2, M Maria Morelli3, MD3, Christina Annunzata3, MD3, Philip Arlen4, MD4

1Precision Biologics/NHI, Bethesda, MD, United States; 2Precision Biologics, Inc, Bethesda, MD, United States; 3National Cancer Institute, Bethesda, MD, United States

**Correspondence:** Kwong Tsang (ktsang13@gmail.com)


**Background**

NEO-201 is an IgG1 mAb reactive against many different carcinomas, but not reactive against most normal tissues. Functional analysis revealed that NEO-201 is capable of engaging innate immune effector mechanism (ADCC, CDC and enhancing NK activity) to kill tumor cells. Previous studies showed that NEO-201 attenuates growth of human tumor xenografts in mice, and demonstrates safety/tolerability in non-human primates with a transient decrease in neutrophils being the only adverse effect observed. A clinical trial evaluating NEO-201 in adults with chemo–resistant solid tumors is ongoing at the NIH Clinical Center. Preclinical evaluation showed that NEO-201 reacts against human regulatory T cells (Tregs) and here we further investigated the phenotypic and functional effects of NEO-201 on human Tregs in vitro.

**Methods**

PBMCs were collected from 5 normal donors and used for phenotypic and functional analysis. EasySep StemCell Treg isolation kits anti-biotin kits (biotin-labeled NEO-201 mAb) were used to isolate PBMCs enriched for Tregs. Phenotypic and functional analyses were performed using flow cytometry for markers: CD4, CD25, CD127, FoxP3, CD15s, CD45RA,CCR4, NEO-201 antigen, CEACAMS and CEACAM6. The ability of NEO-201-isolated Tregs to suppress autologous CD4+ T responder cell proliferation was assessed using an co-culture suppression assay and the ability of NEO-201 to mediate killing ofersonized Tregs was evaluated using a CDC assay.

**Results**

The % of NEO-201+ cells in the population of CD4+CD25highCD127−negFoxP3+CD15s+CCR4+Tregs ranged from 60%-80%. NEO-201+Tregs were CD45RA negative. Isolated CD4+NEO-201+ Tregs were capable of suppressing CD4+ T responder cell proliferation, and NEO-201 mAb mediated CDC activity against Tregs.

**Conclusions**

NEO-201 reacts against human Tregs and can be used as a novel marker to identify and to purify Tregs. Tregs isolated using NEO-201 mAb were functionally suppressive and could be eliminated by CDC. This study demonstrates for the first time that this tumor-targeting mAb may also mediate through a novel mechanism down regulating Treg-mediated immunosuppression of antitumor immunity.

**P772**

Antagonism of TNFR2: Focus on novel antibodies with preference for tumor microenvironment Tregs and onco genes expressed on the tumor

Michael Khodadoust, MD PhD1, Youn Kim, MD1, Michael Yang3, Heather Torrey, PhD2, Lisa Tran2, Denise Faustman, MD, PhD2

1Stanford University School of Medicine, Palo Alto, CA, United States; 2Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, United States

**Correspondence:** Denise Faustman (faustman@helix.mgh.harvard.edu)


**Background**

In diverse human and murine cancers, tumor necrosis factor receptor 2 (TNFR2) is heavily expressed in the tumor microenvironment on regulatory T cells (Tregs) and myeloid-derived suppressor cells. Clinical data consistently show TNFR2 overexpression in the tumor microenvironment on Tregs after checkpoint failures. TNFR2 also serves as an onco gene for direct tumor expansion. One major challenge to creating antagonistic antibodies to the TNF superfamily receptors has been that natural ligands such as TNF have a very high affinity and strongly promote agonism. Using sequential receptor peptide fragment mapping, we have made TNFR2 antagonistic antibodies in which a select region of this receptor creates antagonism resistant to TNF. Here we share new data on cell-specific and disparate TNFR2 expression in the tumor microenvironment and show that these novel antibodies preferentially target the tumor microenvironment, not peripheral Tregs.

**Methods**

We analyzed TNFR2 expression in humans using mean fluorescent intensity (MFI) of TNFR2 on Tregs, T effector (Teff) cells and primary
tumor cells from subjects with lymphoma vs controls and analyzed over 1000 human cell lines from different primary tumor sites. We studied the effect of dominant TNFR2 antagonists on secreted soluble TNFR2 (sTNFR2), a marker of extreme agonism, by culturing human T cells with TNFR2 antagonistic antibodies. We also screened dominant TNFR2 antagonists for their ability to kill cancer cells, kill tumor cell lines, eliminate tumor-associated Tregs and induce T effector proliferation in subjects with advanced Stage IV cutaneous T cell lymphoma (CTCL, or Sézary syndrome) and cell lines of diverse tumor origins.

Results
The TNFR2 antagonists killed tumor-residing Tregs and cancer cells expressing the oncogene in vitro. This new antagonist class does not require antibody-dependent cellular cytotoxicity (ADCC). Framework class switching experiments show no need for Fc region function, and the construction of Fab2 fragments also shows efficacy. Dominant TNFR2 antagonists rapidly stopped sTNFR2 secretion, a known serum biomarker of poor cancer prognosis.

Conclusions
Dominant TNFR2 antagonists kill both tumor-residing Tregs and cancer cells expressing the oncogene in human specimens but not normal circulating cells. TNFR2 antagonistic antibodies may represent a new cancer treatment approach.

Ethics Approval
A human studies protocol was approved by the Massachusetts General Hospital (MGH) Human Studies Committee (MGH-2001P001379) and Stanford University Human Studies Committee (IRB 5538 and IRB 13844).

P773
ONCR-177, an oncolytic HSV designed to safely and potently activate systemic anti-tumor immunity
Sonia Feau, Melissa Hayes, Brian Haines, Agnieszka Denslow, Jacqueline Gunsha, Daniel Warnba, Shreya Khatalwad, Lingxin Kong, Jacob Spinale, Prajna Behera, Peter Grzesik, Jennifer Lee, Terry Farkaly, Edward Kennedy, Lorena Lerner, Christophe Queva
Oncorus, Cambridge, MA, United States
Correspondence: Christophe Queva (christophe.queva@oncorus.com)

Background
Oncolytic viruses (OVs) represent a new class of therapeutic agents for the treatment of cancers that poorly respond to immune checkpoint inhibitors. OVs promote anti-tumor responses by a dual mechanism of action: the selective oncolysis of tumor cells, followed by the development of systemic anti-tumor immune responses [1].

Methods
ONCR-177 is a highly engineered recombinant oncolytic Herpes Simplex Virus (oHSV) designed to be a safe and efficacious therapy for the treatment of solid tumor indications. ONCR-177 expresses five tumor Ag targets, PD-1 and CTLA-4, to counter T cell exhaustion. ONCR-177, or FLT3LG for expansion and recruitment of classical dendritic cells (cDC), and antagonists to two clinically validated immune checkpoint targets, PD-1 and CTLA-4, to counter T cell exhaustion. ONCR-177, or its mouse surrogate virus mONCR-171, was tested in a series of experiments designed to demonstrate local and systemic anti-tumor activity, and mechanisms of action.

Results
In vitro co-culture studies, DCs loaded with ONCR-177 oncolysates were superior in stimulating MART1+ tumor antigen-specific T cells compared to lysates from the unarmed vector. Intra-tumoral administration of mONCR-171 resulted in durable local and distant complete tumor regressions and survival benefit across several syngeneic bilateral tumor models representing various degrees of HSV permissivity.

P774
Intratumoral depletion of regulatory T cells using CD25 targeted photoinmunotherapy elicits anti-cancer immune activity and synergizes with PD1 checkpoint blockade in immunocompetent mouse models
Michelle Hsu, Stephanie Okamura, Daniele Bergeron, Estela Solis, Dany Citrnick, Roger Heim, Jerry Fong, PhD, Miguel Garcia-Guzman Rakuten Medical, San Diego, CA, United States
Correspondence: Jerry Fong (jerry.fong@rakuten-med.com)

Background
Photoimmunotherapy (PIT) is an investigational cancer treatment platform that utilizes an antibody-dye (IRDye® 700DX, IR700) conjugate and illumination with a non-thermal, red-light laser for selective cell killing. These preclinical studies describe the intratumoral depletion of regulatory T cells (Tregs), a significant source of immune suppression, with an anti-CD25-IR700 conjugate using photoimmunotherapy (CD25 PIT). Anti-cancer activity and subsequent immune responses following CD25 PIT administered alone or in combination with anti-PD1 treatment were evaluated in immunocompetent mouse models.

Methods
Immunocompetent mice inoculated with CT26 tumors were treated with CD25 PIT alone or in combination with anti-PD1 treatment. Tumor volume was determined by caliper measurements in target (illuminated) and distal (non-illuminated) tumors. Target tumors were harvested and intratumoral immune responses were characterized by flow cytometry. To evaluate the activation of systemic immune responses, cytotoxic T lymphocyte assays were conducted with splenocytes derived from mice treated with CD25 PIT alone or in combination with anti-PD1. Tumor re-challenge studies were conducted to assess for a tumor-specific immune memory response. Anti-cancer responses to CD25 PIT combined with anti-PD1 treatment were also evaluated in CD8+ T cell-depleted mice.

Results
Single tumor bearing mice treated with saline, anti-PD1 antibodies, CD25 conjugate without PIT, CD25 PIT alone, or in combination with anti-PD1...
antibodies, resulted in complete response (CR) rates of 0% (0/15), 8.3% (1/12), 0% (0/15), 50.0% (5/10), and 73.9% (17/23), respectively. CD25 PIT combined with anti-PD1 led to synergistic anti-cancer activity in target and distal tumors. All CR mice prevented formation of new tumors when inoculated with the same tumor type, but tumor growth occurred when inoculated with a different tumor type, suggesting a tumor specific immune memory response. Flow cytometry analysis of intratumoral immune responses revealed an increase of CD8+ T cells in the targeted tumor one week after PIT treatment, with a majority of CD8+ T cells lacking exhaustion markers (PD1-CTLA4-). CD25 PIT treatment also led to an increase of tumor antigen specific cytotoxic lymphocytes in the spleen. CD8+ T cell depletion abrogated the anti-cancer responses induced by CD25 PIT combined with anti-PD1 treatment.

Conclusions
Depletion of intratumoral Tregs by CD25 PIT resulted in the local activation of CD8+ T-cell mediated anti-cancer activity, and a systemic tumor specific immune memory response. CD25 PIT treatment combined with anti-PD1 therapy led to synergistic anti-cancer activity in target and distal tumors. These results support the exploration of CD25 PIT in patients for the treatment of cancers that present with Treg immunosuppression.

Ethics Approval
All animal studies conducted followed the guidelines put out by the “Guide to the Care and Use of Laboratory Animals” by the National Research Council.

P775 Crosslink-independent CD137 agonism is associated with liver inflammation
Miguel Gaspar, PhD, John Pravin, Leonor Rodrigues, MSC, Alexander Koers, PhD, Mihriban Tuna, PhD, Neil Brewis, PhD
F-star Biotechnology Ltd, Cambridge, United Kingdom

Correspondence: Miguel Gaspar (miguel.gaspar@f-star.com)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P775

Background
Stimulating existing anti-cancer immune responses by activating T cell costimulatory receptors of the Tumor Necrosis Factor Receptor Superfamily (TNFRSF) is potentially the next significant stage of cancer immunotherapy. Clustering of TNFRSF members is required to initiate signal transduction and crosslinking of TNFRSF-specific antibodies via Fcγ receptor (FcγR) interaction is typically required to mimic this effect. However, TNFRSF antibodies have been described which can initiate crosslink-independent agonism and signal transduction by simply binding to their receptor. CD137 is a costimulatory TNFRSF member expressed on activated T cells and interaction with CD137L results in increased T cell proliferation, survival and cytotoxic activity. Some agonist antibodies targeting CD137 have been shown to induce liver inflammation both in the clinic or in preclinical models, with the latter being associated with increased liver T cell infiltration.

Methods
To understand factors contributing to toxicity, different CD137 agonist antibodies were compared for their ability to activate T cells in the presence or absence of secondary crosslinking antibodies, used to mimic the effect of FcγR-mediated crosslinking. A bispecific antibody targeting OX40 and CD137 (FS120), with activity independent of FcγR-mediated crosslinking, was also used to test the ability of using binding to co-expressed receptors as an alternative mechanism of crosslinking. The anti-mouse CD137 agonist antibodies as well as an anti-mouse OX40/CD137 bispecific (FS120 surrogate) were also tested in vivo for their ability to induce liver T cell infiltration, activation and proliferation.

Results
The CD137 antibodies tested showed varying levels of in vitro potency in stimulating T cells and certain antibodies were able to induce crosslink-independent activation. The CD137 antibody clone present in urelulumab, which induced hepatotoxicity in the clinic, showed crosslink-independent activity and was more potent as compared to the clone present in utomilumab, which was well tolerated in the clinic. An anti-mouse CD137 antibody (clone 3H3) also showed crosslink-independent activity and increased sustained liver T cell infiltration, activation and proliferation as compared to a crosslink-dependent clone (Lob123). FS120 surrogate showed activity in vitro which was not associated with increased liver T cell infiltration in vivo.

Conclusions
CD137 agonist antibodies associated with increased liver inflammation were found to be crosslink-independent, suggesting this factor may contribute to their hepatotoxicity risk. FS120 surrogate did not show increased liver T cell infiltration suggesting this has the potential to be a well-tolerated and effective mechanism of crosslinking and agonising CD137, as well as OX40, and is independent of FcγR-mediated crosslinking.

P776 Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity
Laurent Gauthier, PhD1, Ariane Morel, PhD1, Nadia Ancerz1, Benjamin Rossi1, Audrey Blanchard-Alvarez1, Gwendoline Grondin1, Sylvia Trichard1, Cédric Cesari, Melody Sapet1, Frédéric Bosco1, Hélène Rispaud-Blanc1, Franceline Guillot1, Stéphanie Comen1, Alain Roussel1, Béatrice Amigues2, Guillaume Habib1, Flavien Caraguel1, Sandrine Arrufat1, Romain Ropark1, PhD1, François Rogemar1, Yannis Morel, PhD1, Eric Vivier3,4
1Immune Pharma, Marseille, France; 2AFMB, Marseille, France; 3MImAbs, Marseille, France

Correspondence: Laurent Gauthier (laurent.gauthier@immune-pharma.fr)

Background
Over the last decade, various new therapies have been developed to promote anti-tumor immunity. Despite interesting clinical results in hematological malignancies, the development of bispecific killer cell engager antibody formats directed against tumor cells and stimulating anti-tumor T-cell immunity has proved challenging, mostly due to toxicity problems.

Interest has recently focused on the use of NK cells for therapeutic interventions, as these cells have anti-tumor properties. NK cells express several activating receptors that can be targeted to induce NK cell-mediated anti-tumor immunity, such as CD16, NKG2D, and the natural cytotoxicity receptors NKp30, NKp44 and NKp46. The full activation of NK cells has been shown to require the co-engagement of different cell surface receptors.

Methods
We report here the design, production and characterization of a new generation of trifunctional NK cell engagers (NKCEs) consisting of mAb fragments targeting the activating NK cell receptor NKp46 together with a Tumor Antigen (TA) and an Fc fragment, to promote antibody-dependent cell-mediated cytotoxicity (ADCC) via the activating receptor CD16 expressed on NK cells. The approach used was based on innovative IgG-Fc multispecific antibody formats and first-in-class agonist anti-NKp46 mAbs activating NK cells only when cross-linked by tumor cells, with no off-target effects.

Results
Trifunctional NKCEs were more potent in vitro than clinical therapeutic antibodies targeting the same tumor antigen. They had similar in vivo pharmacokinetics to full IgG antibodies, no off-target effects and efficiently controlled tumor growth in mouse models of solid and invasive tumors.

Conclusions
Trifunctional NKCEs targeting CD19, CD20 or EGFR as tumor antigens triggered tumor killing by human primary NK cells in vitro. In vivo, they induced NK cell accumulation in tumors and promoted tumor clearance in preclinical mouse models of solid and invasive cancers. Our multispecific technology provides a versatile platform with many different format options and the potential to co-engine up to three activating receptors on NK cells and two different tumor antigens on cancer cells. The trifunctional NKCEs reported here should favor NK cell targeting to the tumor microenvironment, in which NKp46 expression levels remain high in many tumor conditions, by contrast to CD16, NKG2D, NKp30 and NKp44. The co-targeting of NKp46 and CD16 led to...
full NK cell activation. Together with the stronger anti-tumor activity of these molecules in preclinical models than of gold standard mAbs, such rituximab, obinutuzumab and cetuximab, these results support the clinical development of NKCEs for cancer immunotherapy, as a complement to existing immuno-oncology approaches.

References
Engineered monomeric JAG1 and multimeric DLL1 Notch ligand constructs enhance antitumor immunity by reducing exhaustion of T-effector memory cells

Uttam Laksmi Mounika Goruganthu, M Tech1, Anil Shanker, PhD2, David Carbone, MD, PhD3, Elena Tchekneva, MD1, Anneliese Antonucci1, Michael Koenig1, Longzhu Piao1, Anwari Akhter, PhD1, Parvathi Ranganathan1, Nicholas Long1, Thomas Magliery1, Jason Evans1, Rajeswara Arasada1, Pierre Massion, MD2, Mikhail Dikov, PhD1, Roman Uzhchenko, PhD MD3, Portia Thomas1, Asel Biktasova, MD, PhD2, Duafalia Dudimah2, Maria Teresa De Aquino, PhD2

1The Ohio State University, Columbus, OH, United States; 2Meharry Medical College and Vanderbilt University, Nashville, TN, United States

Correspondence: Anil Shanker (ashanker@mmc.edu), David Carbone (david.carbone@osumc.edu), Mikhail Dikov (mikhail.dikov@osumc.edu)


Background
Notch receptor-ligand interactions are an important regulation governing T-cell-mediated immune responses and are highly contextual. Dendritic cells (DC) expressing JAG1 on their cell surface can drive naïve T-cells to a regulatory phenotype (Treg), which are immunosuppressive and dampen antitumor immune responses, whereas DC-expressed DLL1/4 can support Th1 or cytotoxic T-cell responses, facilitating tumor regression. Activation of Notch receptors on T-cells requires polyvalent interactions with ligand-bearing DC, whereas soluble monovalent ligands act as competitive inhibitors and suppress Notch signaling. We exploited this mechanistic detail of Notch receptor-ligand interaction to design novel ligand-based reagents comprised of receptor binding domains that significantly improved antitumor immune responses.

Methods
We engineered monomeric soluble JAG1 (N-EGF3, sJAG1) and multimeric DLL1 constructs and evaluated their immunological effects in lung and pancreatic cancer murine models. FACS was used for immunophenotyping. ELISpot was used to evaluate cytokine production. In vitro experiments were performed using T: DC (3:1 ratio) co-culture with allogeneic BMDC and CD3+CD28-labeled beads. Mice with CD11c (DC)-specific Dll1−/− and Jag2−/− were used to assess ligand-specific T-cell responses. Correlative studies were performed in tumor-infiltrating immune cells from primary human lung biopsies.

Results
Treating tumor-bearing mice with monovalent sJAG1 and multivalent DLL1 elicit antigen-specific T-cells, significantly reduce Treg frequency in spleen and lymph nodes, improve anti-tumor immunity, attenuate tumor growth, and increase IFN-γ production by splenocytes and improve mice survival compared to untreated mice. The frequency of effector CD8+T-cells increased upon addition of ligand-based constructs to T+DC co-culture in vitro. Remarkably, PD-1 expression by CD8+ T-effector memory (TEM) cells was reduced 3-fold with sJAG1 treatment indicating their reduced exhaustion and improved effector activity by selective ligand-mediated interventions. These observations were validated in tumor-bearing mice with DC-specific Dll1−/− and Jag2−/−. While DLL1 expression in mice was important for cytotoxic antitumor immune responses, JAG2 expression sustained a Th2 response. A highly significant correlation was observed between the proportion of JAG1 or JAG2-expressing tissue-resident DCs and the numbers of PD-1-expressing TEM cells in cells-infiltrating human lung tumors. Our study substantiates a pre-clinical rationale for incorporating selectively engineered Notch ligands to modulate antitumor T-cell immunity.

Conclusions
Data demonstrate efficacy of functional Notch ligand-based constructs in reducing exhaustion and improving anti-tumor T-cell responses. The findings provide a strong rationale for the clinical application of a new approach of Notch ligand-based therapeutics as single agents or in combination to enhance efficacy of current immunotherapies in improving outcomes of solid tumors refractory to checkpoint therapy.
**P778**

**ATRC-101: A first-in-class engineered fully human monoclonal antibody that targets a tumor-restricted ribonucleoprotein complex**

Jeffrey DeFalco, PhD1, Daniel Emerling, PhD1, Amy Manning-Bog, PhD1, Gilson Baia, PhD1, Shaun Lippow, PhD1, Alexander Scholz, PhD1, Yanhong Zhu, MD1, Guy Cavet, PhD1, Wayne Volkmuth, PhD1, Ish Dhawan, PhD1, Jonathan Benjamin, MD, PhD1, William Robinson, MD PhD1, Tito Serafini, PhD1, Norman Greenberg, PhD1

1Atreca, Redwood City, CA, United States; 2Stanford University, Palo Alto, CA, United States

**Correspondence:** Norman Greenberg (n.greenberg@atreca.com)

*Journal for Immunotherapy of Cancer* 2019; 7(Suppl 1):P778

**Background**

The checkpoint inhibitor (CPI) class of immunotherapeutic drugs demonstrates a key role for active T cells in anti-tumor immune responses and positive clinical outcomes in cancer treatment. However, the role of B cells and their antibodies in anti-tumor immune responses is less clear. We propose that B cells might aid in tumor control by producing antibodies that target tumor antigens and thereby induce tumor cell lysis or prime anti-tumor T cell responses. To this end we built a proprietary technology called Immune Repertoire Capture™ (IRC™) to characterize the active B cell response in patients whose immune systems are responding to disease [1]. We are now using IRC™ to discover antibodies that can identify novel targets and have established a screening and validation platform to identify those antibodies with the potential to become next generation therapeutics.

**Methods**

Our IRC™ technology was used to generate unbiased and virtually error-free, natively paired heavy and light chain sequences of antibodies expressed by individual B cells isolated from patient samples. We expressed plasmablast-sourced antibodies that, in part, had evidence of progressive affinity maturation and class switching and then performed in vitro and in vivo studies to further characterize each antibody for their (i) target identity, (ii) activity profile in vitro (iii) ability to cause tumor growth inhibition, regression and immunologic memory in vivo in a panel of model systems and (iv) safety profile in non-human primates.

**Results**

Using our methodology we now report on ATRC-101, a fully human IgG1/kappa engineered version of an antibody and identified by IRC™ from a plasmablast B cell isolated from a patient with NSCLC adenocarcinoma who had been treated, in part, with checkpoint inhibitor therapy. ATRC-101 binds to a novel target comprised of both a polyadenylate-binding protein (poly(A)-binding protein) and polyadenylated ribonucleic acid (poly(A) RNA). Despite the wide patterns of distribution and gene expression reported for poly(A) RNA-binding family members, thorough analyses of tissue sections via immunohistochemistry (IHC) and immunofluorescence (IF) demonstrate that target expression is remarkably tumor-associated in both human and mouse. In immunologically "cold" syngeneic mouse models such as EMT6, ATRC-101 demonstrates robust and persistent antitumor activity as monotherapy. No safety signals are observed in non-human primates at dose levels up to and including 100 mg/kg in repeat dose studies.

**Conclusions**

Based on robust in vitro and in vivo data ATRC 101 is now being advanced to the clinic for evaluation in solid tissue malignancies.

**Acknowledgements**

We acknowledge the significant effort and contributions of our colleagues from the histology, in vivo pharmacology, in vitro pharmacology and target identification groups as well as our consultants. This include Iraz Aydin, Adam Abtaie, Jerald Aurellano, Felix Chu, Cathrin Czupalla, Gregg Espiritu Santo, Sheila Fernandez, Nicole Haaser, Benjamin Haugen, Donghyooin Kim, Yvonne Leung, Alan Liu, Fengliu Liu, Earth Light Lowe, Sumi May, Harbell Mike, Beatriz Millare, Xiao Peng, Judevin Sapugay, Yann Chong Tan, Steve Tobi, Nikhil Vad, Mauricio Velasco-Delgado, Jenny Wu, Danhui Zhang, Patricia Zuno, Douglas Miller, John Hill and Kevin Baker.

**References**


**Ethics Approval**

The study was approved by WRB (Western Institutional Review Board) on Jun11, 2013. The WRB study number is 20130121.

---

**P779**

**HER2/PD-L1/CD3/HSA tetra-specific antibody mediates cytolytic synapse-restricted PD-L1 blockade and potent depletion of HER2+ tumors**

Tea Gunde, PhD1, Alexandre Simonin1, David Urech1, Stefan Warth1, Christian Hess1, Matthias Brock1, Eva Oswald1, Julia Zeberer1, Dania Diem1, Dana Mahler1, Diego Morenzoni1, Simone Muntwiler1, Benjamin Kütter1, Robin Heiz1, Naomi Flückiger1, Sebastian Meyer1, Timothy Egan1

1Numab Therapeutics, Wädenswil, Switzerland; 2Charles River Discovery Service Germany, Freiburg, Germany; 3Numab US LLC, Northborough, MA, United States

**Correspondence:** David Urech (d.urech@numab.com)

*Journal for Immunotherapy of Cancer* 2019; 7(Suppl 1):P779

**Background**

TAA/CD3 bispecific antibodies are highly effective at depleting cancer cells and have achieved encouraging results in the clinical setting. However, two prominent issues occasionally attenuate their efficacy in patients: 1) pre-existing or treatment-emergent expression of PD-L1 on tumor cells and 2) drug-induced cytokine bursts leading to cytokine release syndrome (CRS). Addressing these two issues in the context of a single, conveniently dosed, next-generation molecule could improve rates, and durations, of patient responses while rendering CD3-mediated T cell-stimulation more tolerable. In service of this goal, we constructed a HER2/PD-L1/CD3/HSA tetra-specific MATCH4 molecule (ND022), whose aPD-L1 domain is affinity-tuned to necessitate HER2-blocking by the molecule in order to block PD-1 signaling and whose eHSA domain not only extends serum half-life, but also potentially reduces cyto-kine release without surrendering antitumoral efficacy.

**Methods**

We produced a novel HER2/PD-L1/HSA tri-specific scMATCH3 (ND030) and ND022 to evaluate the con-tribution of the aPD-L1 domain to tumor cell-depletion and to confirm that PD-L1-blockade is restrict-ed to the cytolytic synapse. In a series of in vitro experiments, we applied these molecules to co-cultures of reporter T cells or human peripheral blood mononuclear cells (hPBMCs) and either HCC1954 (PD-L1+HER2+) or HCC827 (PD-L1+HER2−) cancer cell-lines. We then applied both molecules, in a controlled experiment, to humanized NOG mice xenografted with HCC1954 breast cancer cells to evaluate antitumoral efficacy in vivo.

**Results**

Both ND030 and ND022 strictly inhibit PD-1-signaling on T cells when such cells are co-cultured with a PD-L1+HER2+ cancer cell-line, but not on HER2− cells, confirming cytolytic synapse-restricted PD-L1-binding. Compared to a HER2/CD3 bispecific single-chain diabody, ND022 depletes HER2+ cells with equal potency. When anchored to HER2+ cells, ND030 less potently inhibits PD-1-signaling than nivolumab in vitro, but its tumor-directed PD-L1-blockade results in
superior antitumoral efficacy in vivo. ND022 outperforms trastuzumab + nivolumab combination therapy in vivo, eliciting a complete response in 8/8 mice.

**Conclusions**

ND022 is a next-generation tetra-specific molecule with exquisite antitumoral efficacy in HER2+ cancer models. The molecule’s prophylactic qPD-L1 domain is inert in the absence of PD-L1/HER2 co-expression but potently blocks PD-L1 on PD-L1+HER2+ tumor cells, enabling safe administration to patients with both PD-L1+ and PD-L1– tumors.

---

**P780**

**Selection and in vitro characterization of ABBV-368, a novel anti-OX40 agonist antibody**

Fiona Harding, PhD2, Marcia Stickler1, Margo Werner1, Jennifer Tran1, Nicole Belmar, BS1, Archana Thakur1, Enrico DiGiammarino32, David Powers32

1AbbVie Biotherapeutics Inc., Redwood City, CA, United States; 2AbbVie, North Chicago, IL, United States

**Correspondence:** Fiona Harding (fiona.harding@abbvie.com)

**Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P780**

**Background**

OX40 (CD134, TNFRSF4) is a type I transmembrane cell surface protein member of the TNF receptor superfamily transiently expressed on recently activated T cells, present at a low level on memory CD4 T cells, and is expressed on activated and intratumoral T regulatory cells. OX40 can also be expressed on B cells, CD8 T cells, neutrophils and NK and NKT cells following activation. OX40 ligand binding to OX40 results in signaling via TRAF family proteins and upregulation of pro-survival molecules such as Bcl-2, Bcl-XL and survivin. In addition, OX40 signaling in the absence of CD3 signaling may contribute to homeostasis of OX40 expressing memory cells. Targeting OX40 expressed by T regulatory cells has been shown to impact suppressive capacity and to lead to the active depletion of OX40 positive T regulatory cells from the tumor microenvironment. Finally, conversion of naïve CD4+ T cells into T regulatory cells is inhibited by OX40-mediated signals. We sought to create an anti-OX40 agonist antibody with both T cell stimulatory activities and demonstrated ability to inhibit T regulatory activity.

**Methods**

A set of anti-human hybridoma clones was created and screened based on binding by ELISA and NKf8 bioactivity in a reporter cell-based assay. Four potential leads were humanized and tested for binding affinity by Biacore analysis, cross-reactivity to cynomolgus monkey OX40, reporter cell activity, IFN-γ secretion in human cell based MLR assays, inhibition of Tregulatory cell conversion in vitro, and activity in human CD4 T cell activation assays.

**Results**

ABBV-368 was selected based on the best bioactivity in these assays. Interestingly, the lead candidate was found to have a modest affinity of 42 nM. ABBV-368 binds to the CRD II/III region and inhibits OX40L binding. In an ADCC reporter cell assay, ABBV-368 showed ADCC activity when target cells expressed high levels of OX40. ABBV-368 uniquely demonstrates an ability to signal NFkB in reporter cell lines in the absence of crosslinking. ABBV-368 was tested for bioactivity in human cell engrafted mouse models. ABBV-368 treatment resulted in excellent anti-tumor activity in a humanized mouse tumor model, enhanced GVHD in a human PBMC induced model and showed anti-tumor activity in a human OX40 transgenic mouse.

**Conclusions**

ABBV-368 is an anti-OX40 agonist antibody with unique signaling activity that is efficacious in human cell in vitro and in vivo models and represents a promising clinical candidate currently being evaluated in several ongoing Phase I clinical trials (NCT03071757; NCT03893955; NCT03818542).

**Acknowledgements**

All authors are employees of AbbVie. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.

---

**P781**

**A new approach used to characterise off target peptide repertoires for T cell receptors that target the cancer tests antigen NY-ESO-1-HLA-A*02:01**

Stephen Harper1, Charlotte Coles, PhD1, Rachel Mulvaney1, Sunir Malla, PhD1, Andrew Walker, PhD1, Katherine Smith1, Angharad Lloyd1, Jane Harper1, Zoe Donnels1, Andrew Knox1, Andrea Stacey1, Joseph Duks1, Emma Baston1, Suzanne Griffin1

1Immunocore Ltd, Milton, Abingdon, United Kingdom; 2GlaxoSmithKline, Stevenage, United Kingdom

**Correspondence:** Stephen Harper (stephen.harper@immunocore.com), Sunir Malla (Sunir.Malla@immunocore.com)


**Background**

T cell receptor (TCR) cross-reactivity or poly-specificity is thought to be essential for adequate recognition of the potential pathogenic repertoire. Furthermore, understanding a TCRs potential off-target repertoire forms an important part of an immunotherapeutic TCR safety profile. Understanding the extent to which TCRs targeting the same antigen overlap in their off-target repertoire will further elucidate the molecular rules governing TCR cross-reactivity.

**Methods**

We characterised three newly isolated TCRs specific for the cancer tests antigen NY-ESO-1 a.a 157-165 presented on HLA-A*02:01. We describe TCR-pHLA crystal structures and use a novel single chain HLA phage display approach to determine peptide variant specificity profiles.

**Results**

We show that all three TCRs have different peptide specificity profiles, enabling recognition of distinct off-target peptides. Two of the TCRs have overlapping specificity profiles and engage the same central peptide feature, whereas a third TCR has a non-overlapping specificity profile. Although this third TCR engages NY-ESO-1-HLA-A*02:01, the interaction involves an alternate NY-ESO-1 peptide conformation, recognising an antigenic feature which would typically be buried and resulting in off-target peptides sharing little similarity with the cognate peptide.

**Conclusions**

We demonstrate that TCRs targeting the same antigen can achieve the necessary specificity to achieve self-tolerance despite recognising distinct peptide repertoires. This reconciles how an individual’s limited TCR repertoire, following negative selection in the thymus, is able to recognise a vastly larger antigenic pool. These findings significantly advance our understanding of TCR-antigen specificity and we anticipate that approaches such as these will play a crucial role in increasing the safety of TCR-based immunotherapeutic molecules in the clinic.

---

**P782**

**A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism**

Kristen Hurov, PhD, Punit Upadhyaya, Marriana Kleyman, Jessica Kublin, Tom Stephen, Jun Ma, Liz Repash, Julia Kristenson, Sophie Watcham, Lihuong Chen, Sailaja Battula, PhD, Johanna Ladhennanta, Kevin McDonnell, PhD, Nicholas Keen

1Immunocore Ltd, Milton, Abingdon, United Kingdom; 2GlaxoSmithKline, Stevenage, United Kingdom

**Correspondence:** Kristen Hurov (kristen.hurov@bicycletx.com)

**Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):P782**

**Background**

4-1BB (CD137/TNFRSF9) is an inducible costimulatory receptor belonging to the TNF receptor superfamily. Despite compelling preclinical data, 4-1BB agonistic antibodies have been hampered by failure to delineate hepatotoxicity from efficacy in the clinic [1]. Next generation strategies are focused on bispecific approaches aimed at...
promoting target-mediated clustering of 4-1BB to limit systemic and liver toxicities [2,3]. Bicycles® represent a new class of drugs - fully synthetic, constrained bicyclic peptides that have antibody-like affinity and selectivity to their targets. Unlike traditional biologic approaches, the small size (~2 kDa) and tunable pharmacokinetic (PK) parameters of Bicycles enable superior tumor penetration and allow exploration into the relationship between pulsatile dosing and 4-1BB activation while de-risking hepatotoxicity concerns due to a differentiated renal clearance mechanism combined with tumor-localized activation.

Methods

We envisioned clustering and activation of 4-1BB could be achieved by conjugating a 4-1BB binding Bicycle to a tumor antigen targeting Bicycle. The synthetic simplicity and highly modular nature of the Bicycle® platform enabled us to rapidly explore this hypothesis. The functional activity of the molecules was analyzed using a suite of relevant in vitro assays and animal models.

Results

Nectin-4/PVR/LA is highly expressed in numerous tumors, including bladder, pancreatic, and lung. Synthetic “bisspecific” Nectin-4/4-1BB Bicycles exhibit extremely potent (EC50~100 pM) and Nectin-4-dependent 4-1BB agonism in an engineered 4-1BB reporter system and induce robust production of pro-inflammatory cytokines when human peripheral blood mononuclear cells (PBMCs) are co-cultured with Nectin-4-expressing tumor cells. Importantly, 4-1BB agonism is also achieved in ex-vivo experiments utilizing patient-derived lung tumor samples with an intact immune microenvironment. We observed profound changes in immune markers, including IL-2, and increased CD8+ T cell proliferation only in lung tumors expressing Nectin-4. Excitingly, we have demonstrated in vivo anti-tumor activity in a Nectin-4 overexpressing syngeneic tumor model. Daily dosing at 1mg/kg led to tumor growth inhibition in 4 out of 5 animals including 2 complete responses despite the PK parameters predicting only transient target coverage.

Conclusions

These data indicate that the biological effect of the bispecific Bicycle agonist persists beyond the detection of the molecule in systemic circulation and suggests that continuous coverage of the target may not be necessary when activating 4-1BB with low molecular weight and highly tumor penetrant Bicycles. We have extended the Bicycle dual targeted approach to other tumor and immune cell targets and have found this concept to be extremely generalizable, paving the way for future novel non-biologic immune cell engaging immunotherapies.

References


Cryopreserved human dissociate tumor cells (DTCs) and PBMCs were purchased from approved vendors that follow stringent Institutional Review Board (IRB) and Ethics Committee compliance. The care and use of animals were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of WuXi AppTec (Approval #ON1-003-2017V1) and conducted in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
Efficacy and pharmacodynamic activity of the SBT6050 surrogate was evaluated in combination with anti-PD1. This combination enabled upregulation of PD-L1 and MHCI in the TME. Similarly, in vitro, SBT6050 activation and reprogramming of myeloid cells was evaluated using primary human myeloid cell:HER2-expressing tumor cell co-culture assays with flow cytometry and MSD-based ELISA read-outs. Efficacy and pharmacodynamic activity of the SBT6050 surrogate alone or in combination with anti-PD1 was examined in vivo in HER2-expressing EMT6 and CT26 tumor models. SBT6050 potent effect on innate and adaptive immune responses was demonstrated in mouse tumor models. Systemic immunity was observed as evidenced by dose-dependent increases in tumor antigen-specific CD8+ T cells in the spleen using p15E tetramers. Re-challenge studies of CR mice showed no tumor regrowth, suggesting immune-mediated rejection and memory T cell activity. In the B16F10 model, exoLL-12 achieved a 75% reduction in tumor growth and significantly reduced the number of lung nodules in mice intravenously challenged with B16F10 in addition to the effect on the primary tumor in the flank. Using a specific immunoassay for IL-12p70, RIL-12 was found to have a short tumor retention time of 3 h, whereas exoLL-12 was still detectable 48 h post-injection. This resulted in exoLL-12 having prolonged IFN-γ release as demonstrated by IFN-γ release assays using primary human or mouse target cells as appropriate. SBT6050 is a HER2-targeted TLR8 agonist antibody conjugate, designed to overcome primary resistance to and synergize with checkpoint inhibition in HER2-expressing tumors. Given these findings, the SBT6050 surrogate was evaluated in combination with anti-PD1. This combination enhanced the single agent efficacy observed with the SBT6050 surrogate. Intratumoral pharmacodynamic activity associated with combination therapy will also be presented.

References
**P786**

**Network meta-analysis (NMA) and matching-adjusted indirect comparison (MAIC) of pembrolizumab versus atezolizumab for second-line (2L) locally advanced/metastatic urothelial carcinoma (mUC)**

Dave Gelb, Yichen Zhong, PhD, Rodolfo Fleury Perini, James Luke Godwin, Yizhen Lai, Stella Arndorfer², Maria Lorenzi, MSc², Haojie Li Merck & Co, Inc., Kenilworth, IL, United States; ²Precision Xtract, Oakland, CA, United States

**Correspondence:** Haojie Li (haojie.li@merck.com)  

**Background**

KEYNOTE-045 (ClinicalTrials.gov identifier: NCT02256436) demonstrated statistically and clinically meaningful improvements in overall survival (OS) in 2L mUC subjects treated with pembrolizumab versus investigator’s choice of vinflunine, docetaxel, or paclitaxel (median survival, 10.1 versus 7.3 months; P < 0.001). IMvigor 211 (ClinicalTrials.gov Identifier: NCT02302507) showed no significant improvement in the primary endpoint of OS (median survival, 11.1 versus 10.6 months; P = 0.41) in 2L mUC subjects treated with atezolizumab versus investigator’s choice of chemotherapy. No head-to-head trial has compared the efficacy of pembrolizumab versus atezolizumab for 2L mUC patients.

**Methods**

To synthesize RCT evidence and indirectly compare the relative treatment effects of pembrolizumab versus atezolizumab, fixed-effect Bayesian network meta-analysis (NMA) was conducted to determine the relative efficacy of both treatments. Hazard ratios (HRs) for OS were estimated with 95% credible intervals (CrIs). Furthermore, an anchored matching-adjusted indirect comparison (MAIC) was conducted using individual patient-level data (IPD) from KEYNOTE-045 and published data from IMvigor 211. In the MAIC, to adjust for differences in baseline potential effect modifiers between these trials, data for subjects from KEYNOTE-045 were re-weighted to match the baseline characteristics reported in IMvigor 211.

**Results**

Pembrolizumab consistently showed favorable OS benefit over atezolizumab in both analytical approaches (NMA method: HR [95% CrI] = 0.83 [0.63-1.07]; MAIC method: HR [95% confidence interval] = 0.72 [0.53-0.97]).

**Conclusions**

These results suggest that pembrolizumab offers a better probability of prolonging OS compared to atezolizumab as 2L therapy for mUC patients. In the absence of direct comparison and sufficiently powered studies, these analyses provide valuable insight on the relative efficacy of pembrolizumab versus atezolizumab for patients, physicians and payers, using the best available methods and evidence.

**P787**

**Novel humanized CD3ε mouse model for evaluation of bi-specific T-cell engager antibodies**

Xiaofei Zhou, Quinn Li, Dru Li, Rui Huang, Yuelei Shen  
Biocytogen, Boston, MA, United States

**Correspondence:** Xiaofei Zhou (info@biocytogen.com)  

**Background**

CD3ε is one of the key signaling subunits of the CD3 co-receptor of the T cell receptor (TCR) complex. This TCR complex plays critical role in mediating T cell activation and cellular immune response. In recent years, bispecific antibodies that target human CD3ε and redirect T cell cytotoxicity toward tumor cells has been extensively investigated and some have shown clinical success and promise. However, due to the relatively low homology between the extracellular domain of human CD3 and mouse CD3, mouse antibodies that recognize human CD3 do not cross-react with mouse CD3. Hence, a murine model suitable for directly evaluating CD3-specific therapy is needed.
currently being evaluated in the phase 1 first in human study in patients with advance/metastatic cancers in US.

Methods
It is not a clinical trial abstract.

P789
Vaccination of high-risk neuroblastoma patients with anti-id antibody ganglidiomab to maintain protective immunity after passive immunotherapy with anti-GD2 antibody ch14.18/CHO

Hans Lailoner, PhD1, Holger Lode, MD, PhD2, Nikolai Siebert, PhD3, Sascha Troschke-Meurer, BS4, Oliver Mutschlechner1
1HL Bioscience Research GmbH, Vienna, Austria; 2University Clinic Greifswald, Greifswald, Germany

Correspondence: Holger Lode (lode@uni-greifswald.de)

Background
Disialoganglioside GD2 is abundantly expressed on neuroblastoma (NB) with little expression on normal cells, thus is a suitable target for immunotherapy. Chimeric anti-GD2 antibodies ch14.18 (dinutuximab) and ch14.18/CHO (dinutuximab beta) were developed and are now marketed in US and Europe resp. for passive immunotherapy of high-risk NB. Active immunization based on GD2 following antibody therapy may induce a long-lasting protective immunity to further extend thetherapeutic benefit of NB immunotherapy. Anti-idiotypic antibody ganglidiomab to ch14.18 was raised and shown to carry an internal image of GD2 in vitro and in murine models [1]. Here we describe results of a compassionate need program in NB patients vaccinated with alum adsorbed ganglidiomab, following ch14.18/CHO immunotherapy.

Methods
Between 2012 and 2014, six high-risk NB patients (2-8 y); 4 in CR, 2 with disease) following multimodal therapies including stem cell transplant and ch14.18/CHO immunotherapy were repeatedly treated under compassionate need with 0.5mg alum adsorbed ganglidiomab by subcutaneous vaccination (5-10 vaccinations every 2 weeks). Blood for serum antibody response to ganglidiomab and GD2 by ELISA as well as complement lysis to a NB cell line was investigated. Last patient follow-up was in 2019.

Results
Vaccinations were well tolerated with mild transient local reactions only. In immune sera of all patients a marked induction of antibodies to ganglidiomab and to its variable regions was detected. In 3 of 6 patients also an induction of antibodies to GD2 was found. Induction of cytolytic activity via complement of GD2+ LAN1 NB cells was seen in 2 patients. All six patients were alive without evidence of disease at their last follow up in 2019, i.e. 5 years after start of vaccinations.

Conclusions
Repeated s.c. injections of alum adsorbed ganglidiomab may evolve as additional well tolerated immunotherapy modality after ch14.18 antibody treatment to maintain a long-lasting immunity for prevention of progression or re-occurrence of disease. A clinical trial program is warranted to explore this hypothesis.

References

Ethics Approval
Compassionate need treatment

P790
The anti-tumor activity of an anti-CD39 antibody (ES002) in a multiple myeloma model is dependent on NK cells

Yangsheng Qiu, Qinglin Du, PhD, Meiling Sun, Rui Gao, PhD, Huimin Kong, Roumei Xing, Yufei Shi, Mengying Xu, Zhihao Wu, PhD, Hongtao Lu, PhD
Elipsence Biopharma, Shanghai, China

Correspondence: Hongtao Lu (hongtaolu@elipsence.com)

Background
CD39-CD73-adenosine pathway plays an important immuno-suppressive role within the tumor microenvironment (TME) as adenosine receptor signaling suppresses effector T cells and enhances immune inhibitory effects of Tregs and MDSCs. To overcome the immunosuppression by adenosine in TME, we choose to target CD39 for two main reasons: 1). CD39 plays a pivotal role in converting extracellular ATP into adenosine. Blocking CD39 enzymatic activity will not only lead to the inhibition of adenosine generation, but also maintain extracellular ATP which enhances T cell priming by dendritic cells (DCs). 2). CD39 is expressed highly in Tregs and exhausted T cells, inhibition of CD39 activity will likely suppress Treg inhibition and reinvigorate exhausted T cells.

Methods
We have generated a CD39 antibody, ES002, by traditional hybridoma technology using human CD39 overexpressing HEK293 cells as immunogen, and the antibody was subsequently humanized through complementarily determining region grafting. ES002 binding to CD39 and inhibition of ATPase activity were evaluated through protein-based and cell-based assays. The immunological function of ES002 was studied in an in vitro Elipsence proprietary Immunoassay platform (ImmuShine). The in vivo efficacy of ES002 was investigated in a multiple myeloma CDX cancer model. The effector immune cells were each depleted to analyze their respective roles in tumor growth inhibition.

Results
ES002, a humanized anti-hCD39 antibody, binds to human and cynomolgus CD39 with sub-nanomolar binding affinity and effectively blocks CD39 ATPase activity. We found that CD39 was highly upregulated in Tregs within tumor microenvironment in several cancer types including NSCLC, HCC and CRC. ES002 reversed Treg inhibition of IFN-gamma production by effector T cells. ES002 enhanced the expression of costimulatory molecules on monocytes and dendritic cells activated by ATP. ES002-pretreated DCs can functionally enhance T cell proliferation and IFN-gamma production in an MLR assay. ES002 significantly suppressed tumor growth in a multiple myeloma CDX tumor model and depleting antigen presenting cells (APC) or NK cells in these animals completely abolished the anti-tumor activity of the antibody.

Conclusions
We have successfully developed a potentially best-in-class anti-CD39 therapeutic antibody with strong efficacy in tumor growth inhibition. The antibody appears to have dual functions. It suppresses Treg inhibition on effector T cells. It engages APC and NK cells for its antitumor efficacy in vivo.

P791
Anti-tumor activity of a small molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1)

Andy MacKinnon, PhD, Deepthi Bhupathi, MS, Jason Chen2, Rosalyn Dang, Tony Huang, Weiqun Li, PhD, Yong Ma, Natalia Sotirovskas, MS, Sandra Spurlock, Susanne Steggerda, PhD, Winter Zhang, Francesco Parlati, PhD
Calithera Biosciences, Inc., South San Francisco, CA, United States

Correspondence: Andy MacKinnon (amackinnon@calithera.com)

Background
Altered metabolism is an important mechanism by which tumors evade detection and destruction by the immune system. Metabolic control of immune responses can occur through depletion of essential nutrients or accumulation of toxic metabolic products in the tumor microenvironment that impair immune cell function and promote tumor growth. The secreted enzyme interleukin 4 (IL-4)-induced gene 1 (IL4I1) is an L-phenylalanine oxidase that catabolizes phenylalanine and produces phenylpyruvate and H2O2, an inhibitor of T cell proliferation. IL4I1 may promote cancer progression by suppressing the cytotoxic activity of T cells.

References
Methods
IL4I1 enzymatic activity was measured using an HRP-coupled enzyme assay. RNA in-situ hybridization was carried out on the RNAscope platform. Syngeneic mouse tumor models were used to evaluate the anti-tumor activity of small molecule IL4I1 inhibitor 220307. The level of phenyl-pyruvate in tumor homogenates was measured by LC/MS.

Results
Interrogation of The Cancer Genome Atlas (TCGA) revealed high expression of IL4I1 in multiple solid tumor types and correlated with reduced overall patient survival (HR = 1.5, p = 4.4 x 10-15). Expression of IL4I1 was further validated using RNA in-situ hybridization in human tumor microarrays. IL4I1 was found to be highly expressed in a subset of cells in several solid tumor types, with notably high expression in ovarian tumors and B cell lymphomas.

We identified 220307, a potent, orally-bioavailable small-molecule inhibitor of IL4I1 (IC50 = 274 nM). Twice-daily oral administration of 220307 resulted in single-agent tumor growth inhibition in several syngeneic mouse tumor models (e.g. B16-F10 and LLC) and when combined with checkpoint blockade agents, that significantly reduced tumor growth. Oral dosing of tumor-bearing mice with 220307 reduced the levels of phenyl-pyruvate in the tumor, consistent with inhibition of IL4I1 enzymatic activity. The anti-tumor activity of 220307 was immune cell-mediated, since anti-tumor efficacy was abrogated in CD8-depleted mice or in SCID mice, and 220307 had no direct anti-proliferative activity on tumor cells grown in vitro (IC50 > 50 µM). These data support an immune-mediated anti-tumor effect of IL4I1 inhibition by 220307.

Conclusions
These results indicate that small-molecule inhibition of IL4I1 may represent a novel strategy for cancer immuno-therapy.

References

Ethics Approval
All procedures performed on animals were in accordance with regulations and established guidelines and were reviewed and approved by an Institutional Animal Care and Use Committee or through an ethical review process.

P793
ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, utilizes multiple mechanisms to elicit potent anti-tumor immunity superior to checkpoint blockade alone
Mark Maurer, BS; Chelsea Gudgeon, BS; Katherine Lewis, PhD, Sherri Mudri, BS; Stacey Dillon, PhD, Martin Wolfson, BS, Steven Levin, PhD, Kristine Swiderek, PhD, Stanford Peng, MD, PhD
Alpine Immune Sciences, Seattle, WA, United States
Correspondence: Mark Maurer (mark.maurer@alpineimmunesciences.com)

Background
Although immune checkpoint inhibitors (CPI) targeting the CTLA-4 and PD-1/PD-L1 pathways have demonstrated significant clinical activity in many cancers, many patients fail to respond, or they develop acquired resistance due at least in part to insufficient anti-tumor T cell activation and/or exhaustion. Based on this C-D28 hypothesis, CPIs have been combined with T cell costimulation and shown to enhance and sustain anti-tumor responses preclinically. ALPN-202 is a variant CD80 vlg™-Fc fusion protein that mediates PD-L1-dependent CD28 costimulation and inhibits the PD-L1 and CTLA-4 checkpoints (Figure 1). Studies were conducted to characterize the unique mechanism of action of this molecule and further elucidate CD80/PD-L1 biology.

Methods
X-ray crystallography and cell-based reporter assays were used to demonstrate the simultaneous binding of PD-L1 and CD28 to the single CD80 vlg domain of ALPN-202. PD-L1-dependent CD28 costimulation was evaluated using primary human T cells stimulated by antigen presenting cells (APC) with or without surface PD-L1. ALPN-202 antitumor activity was mechanistically evaluated in vivo using a human PD-L1-transduced MC38 tumor model, by combining ALPN-202 treatment with anti-PD-L1, anti-CTLA-4, or anti-CD28 blocking 

Results
GUCY2C-CD3 bispecific showed preferential biodistribution to GUCY2C expressing xenograft tumors compared to normal tissue. The drug demonstrated potent dose-dependent efficacy in several CRC models with no signs of toxicity. Bispecific treated tumors not only showed recruitment of activated T cells to the tumor site, but also upregulated checkpoint mechanisms, such as PD-L1 on tumors and exhaustion markers on TILs. Consequently, Anti-PD-1/PD-L1 checkpoint blocking antibodies provided enhanced efficacy when combined with GUCY2C-CD3. Additionally, significant combination benefit was observed when GUCY2C-CD3 was combined with an Anti-VEGF-A blocking antibody.

Conclusions
Our preclinical data demonstrate that a GUCY2C-CD3 bispecific can selectively target colorectal tumors, including those with KRAS or BRAF mutations, which are difficult to treat with currently approved therapies. This bispecific shows combination benefits with T cell checkpoint blockade agents, as well as anti-angiogenesis agents, in further enhanced with mechanisms that address immune evasion.

Acknowledgements
We would like to thank Dr. John Hill, Ph.D. for his insightful discussions.

References
antibodies. Anti-tumor activity was evaluated by serial tumor volume measurements, and intratumoral immune responses were assessed by flow cytometry and/or RNA-Seq analyses.

**Results**

The CD80 vIgD:PD-L1 crystal structure was elucidated at a resolution of 3.15 Å, revealing a non-overlapping binding interface distinct from the previously published CD28:CD80 interaction (Figure 2). Using cell-based reporter and cytokine release assays, monomeric and dimeric CD80 vIgD domains elicited conditional CD28 costimulation which was blocked when combined with anti-PD-L1 or anti-CD28 antibodies. In vivo, ALPN-202 demonstrated activity superior to PD-L1 blockade alone, while coadministration with either anti-CD28 or anti-PD-L1 prevented ALPN-202-mediated conditional CD28 costimulation resulting in reduced anti-tumor activity and RNA signatures consistent with lower T cell infiltration and activation (Figures 3 and 4).

**Conclusions**

The CD80 IgV domain utilizes separate, non-competing epitopes to bind CD28 and PD-L1. Exploitation of this attribute via directed evolution-based discovery has yielded ALPN-202, a variant CD80 vIgD-Fc fusion protein capable of simultaneously engaging PD-L1 on tumor cells and CD28 or CTLA-4 on T cells, conferring the unique abilities to block both the PD-L1 and CTLA-4 checkpoints as well as eliciting conditional CD28 costimulation only in the presence of PD-L1. The significantly superior activity of ALPN-202 over CPI-only therapies in vitro and in vivo suggests that conditional CD28 costimulation, together with checkpoint inhibition, may result in meaningfully improved clinical anti-tumor responses.

**Ethics Approval**

Animal experiments and euthanasia protocols performed in this study were approved by the Alpine Immune Sciences Institutional Animal Care and Use Committee (IACUC protocol IR 17-01).

---

**P794**

A novel fully synthetic dual targeted EphA2/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism

Sailaja Battula, PhD, Punit Upadhyaya, Marianna Kleyman, Jessica Kublin, Eric Haines, PhD, Jun Ma, Liz Repash, Tom Stephen, Julia Kristensson, Lihong Chen, Kristen Hurvo, Johanna lahdensanta, Kevin McDonnell, PhD, Nicholas Keen

Bicycle, Lexington, MA, United States

**Correspondence:** Sailaja Battula (sailaja.battula@bicycletx.com)


**Background**

4-1BB (CD137) is a member of TNF superfamily involved in the activation of several immune cells including T cells and NK cells. Agonism of this receptor is a promising immunotherapeutic approach as there is ample evidence suggesting that the systemic administration of agonistic anti-4-1BB antibodies is effective pre-clinically [1] however it’s success in clinical trials is limited due to hepatotoxicity and Fcγ receptor-mediated hyperclustering. Bicycles® represent a new therapeutic modality - fully synthetic, constrained bicyclic peptides. We hypothesized that Bicycle 4-1BB agonists with rapid clearance, minimal liver exposure, and no Fc receptor interaction may induce 4-1BB mediated anti-tumor activity while avoiding liver toxicity. Furthermore, with an optimized 4-1BB-binding Bicycle in-hand, we are now developing a new set of tumor-specific immune cell agonist therapies to obtain potent activation of immune cells exclusively at the tumor site. The modular nature of Bicycle® platform allowed us to rapidly generate fully synthetic dual targeting Bicycles linking immune-agonising molecules to a tumor target such as Erythropoietin-producing hepatocellular A2 receptor (EphA2). EphA2 overexpression is observed in human cancers and correlates with tumor progression. Here, we present substantial preclinical data demonstrating the potent immunomodulatory activity of EphA2/4-1BB targeting Bicycles.
Methods
Tumor targeting EphA2/4-1BB Bicycles are chemically synthesized using our proprietary Bicycle platform and the molecules are tested for activity in various in vitro assays and relevant animal models.

Results
EphA2/4-1BB Bicycles engage EphA2 and 4-1BB simultaneously with nanomolar potency. EphA2/4-1BB Bicycles showed enhanced 4-1BB reporter signaling in co-culture assays consisting of cancer cell lines endogenously expressing EphA2 and 4-1BB Jurkat NF-kB/luc reporter cells. Moreover, these dual targeting Bicycles also potentiate cytokine secretion by human primary immune cells when co-cultured with EphA2-expressing cells. In addition, EphA2/4-1BB molecules demonstrate increased immune cell mediated cancer cell killing in T cell mediated cell killing assays. The agonistic activity of these molecules is fully dependent on tumor target expression, as such activity is absent in co-culture with target-null cell lines. In vivo testing of EphA2/4-1BB Bicycles in PBMC-humanized mice bearing HT29 xenografts showed an increased proportion of CD8+ T cells in tumor tissue but not the circulating immune cells, suggesting a local tumor target specific activation of T cells without systemic 4-1BB agonism.

Conclusions
The unique ability of EphA2/4-1BB dual targeting Bicycles to precisely and potently activate immune cells in tumors without systemic immune activation is very promising and provides us a rationale for developing first-in-class Bicycles to target EphA2+ cancers.

References
2. Ethics Approval
In vivo study work was approved by Jackson Laboratories’ IACUC; Approval number Ps69-4-A19-R1

P795
Anti-MUC1 monoclonal antibodies derived from the first non-viral prophylactic cancer vaccine clinical trial can target cancer cells and facilitate their immune-mediated elimination
Michelle McKeague, PhD, Jason Lohmueller, PhD, Eric Ricci, William Lu, Olivera Finn, PhD
University of Pittsburgh, Pittsburgh, PA, United States
Correspondence: Olivera Finn (ojfinn@pitt.edu)

Background
Monoclonal antibody therapies have transformed cancer treatment. These antibodies can be broadly characterized into two categories, immune modulating and direct targeting antibodies. Immune modulating antibodies modify immune cell function regardless of tumor antigen expression while direct targeting antibodies bind directly to antigens on tumor cells and mediate their anti-tumor functions through inhibiting signaling, targeting toxins or by additionally interacting with the immune cells or complement through their Fc domains.

A promising candidate for direct targeting antibodies for cancer therapy is Mucin-1 or MUC1, a protein over-expressed and hypoglycosylated on many epithelial tumors compared to normal cells. Hypoglycosylated MUC1 peptide was used in the first non-viral prophylactic cancer vaccine trial in healthy individuals at risk for colon cancer. A dozen antibodies were cloned from one individual who had a strong IgG response to the vaccine [1]. Importantly, in all patients who made antibodies to the vaccine, there have not been adverse events in >8 years, increasing the likelihood that these agents could be safely used as passive antibody therapies in patients that have cancer.

Methods
Each antibody was tested for its ability to bind to multiple different MUC1+ cancer cells and to interact in co-cultures with NK cells, macrophages, and complement to mediate antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and/or complement-dependent cytotoxicity (CDC). Because MUC1 contains a variable number of tandem repeat (VNTR) domain containing 20-120 repeats, multiple antibodies can bind to a single MUC1 molecule. Different MUC1 constructs were tested of varying repeat lengths. Additionally, some constructs kept the extracellular domain tethered to the membrane, unable to be shed from the cell surface, as is the case for several endogenous mucins.

Results
Several of the antibodies could mediate ADCC and ADCP, although none of the antibodies mediated an appreciable amount of CDC. In contrast to published studies of anti-CD20 (rituximab) and anti-CD52 (alemtuzumab) the amount of antibody binding did not always correlate with increased antibody effector function.

Conclusions
Fully human MUC1 IgG1 antibodies generated in healthy individuals at risk for cancer were capable of mediating immune effector functions such as ADCC and ADCP and are candidates for further testing as human therapeutics. Because the amount of antibody binding did not always correlate with increased functionality, these results suggest properties other than antigen density control efficiency of direct targeting antibody tumor cell elimination and are currently under investigation.

Acknowledgements
Supported by grants from the NIH (T32 CA20284, F32 CA236457, R35 CA210039) and the American Cancer Society (PF LIB 152429)

References
Results
By head-to-head comparison of inhouse developed dual A2A/A2B antagonists to compounds currently pursued in clinical development we have demonstrated the best-in-class characteristics of our molecules. Our compounds maintain sub- or low nanomolar antagonistic potency in a high adenosine conditions on both A2A and A2B receptor. Multilevel pharmacological characterization spans whole range from receptor binding and CAMP accumulation assay in cell lines overexpressing target receptors to functional assays in primary human immune cells demonstrating the reversal of immune suppression induced by adenosine. Our compounds showed superior activity in antagonizing adenosine-mediated immunosuppression in T-cells (cytokines IL2 and TNFa in CD4+ and CD8+), NK cells (cytotoxicity against target cancer cells), moDCs (cytokines IL12 and TNFα, effect driven specifically by A2B receptors) and macrophages (suppression of adenosine induced VEGF release by M2). High activity of our compounds in human whole blood assays demonstrate that low nanomolar concentration is sufficient to fully antagonize adenosine. This activity in combination with checkpoint inhibitors has been confirmed in syngeneic in vivo mouse models.

Conclusions
New class of dual A2A/A2B adenosine receptor antagonists combines two crucial activities which addresses distinct, cell type mediated mode of action of adenosine related immunosupression. The dual A2A/A2B antagonism profile as well as the ability to antagonize both receptors at very high adenosine conditions are key features differentiating current series from other adenosine receptor antagonist in clinical development.

Acknowledgements
Project supported by the European Regional Development Funds under the Measure 1.1.1. Operational Program - Smart Growth (POIR.01.01.01-00-0987/16-00).

P798
Think globally act locally: Biodistribution of BETA-PRIME, a replication-competent type 5 adenovirus enhanced with a trap for the immunosuppressive cytokine, TGF-Beta
Christopher Larson, MD PhD, Bryan Oronsky, MD PhD, Tony Reid, MD PhD
EpicentRx Inc., La Jolla, CA, United States

Background
Transgene-enhanced oncolytic adenoviruses (OVs) represent a promising novel therapeutic option for the treatment of cancer especially for patients with chemotherapy- and immunotherapy-resistant, advanced, aggressive, and systemic disease. The precise mechanisms by which intratumorally injected OVs trigger an immune response and induce an abscopal effect on distant lesions remain undefined. BETA-PRIME, a type 5 adenovirus, which carries a TGF-beta trap transgene that binds to and neutralizes the immunosuppressive cytokine, TGF-beta, has been shown in an immunocompetent mouse model to eradicate both locally injected and non-injected tumors. Single dose biodistribution of the TGF-beta trap transgene was evaluated in tumor bearing mice, providing a possible explanation for its systemic activity.

Methods
In 129S1 immunocompetent mice bearing ADS-12 tumors (mouse lung carcinoma), BETA-PRIME was injected intratumorally and intravenously at the following dose levels in groups of 25 mice each (Table 1).

<table>
<thead>
<tr>
<th>Group</th>
<th>Article Route</th>
<th>Dose (per animal)</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>None</td>
<td>None</td>
<td>Untreated</td>
</tr>
<tr>
<td>Group 2</td>
<td>Vehicle IV</td>
<td>0.1 mL</td>
<td>IV Vehicle</td>
</tr>
<tr>
<td>Group 3</td>
<td>Vehicle IV</td>
<td>0.2 mL</td>
<td>IV Vehicle (high volume)</td>
</tr>
<tr>
<td>Group 4</td>
<td>BETA-PRIME IV</td>
<td>0.2 mL</td>
<td>IV Low Dose</td>
</tr>
<tr>
<td>Group 5</td>
<td>BETA-PRIME IV</td>
<td>5E9 VP/0.1 mL</td>
<td>IV Low Dose</td>
</tr>
<tr>
<td>Group 6</td>
<td>BETA-PRIME IV</td>
<td>5E10 VP/0.1 mL</td>
<td>IV High Dose</td>
</tr>
</tbody>
</table>

Results
A single viral injection resulted in long-term TGF-beta trap expression of over a week in the serum from all doses of intravenous and intratumoral groups while in vehicle treated mice TGF-beta trap was not detected. In the high dose IV group the TGF-beta trap was detected at concentrations of 210-585 ng/ml while in high-dose intratumoral mice circulating TGFβ was detected at concentrations of 4-13 ng/ml.

Conclusions
Despite local injection of BETA PRIME, systemic levels of the TGF-beta trap transgene were observed, which demonstrates that the virus follows the “think globally act locally” dictum and may in part account for evidence of regression of non-injected, distant tumor lesions.

Table 1 (abstract P798). See text for description

P799
Innate leukocyte chemoattractant chemerin is an intrinsic tumor suppressor in prostate cancer
Zhongping Xu, PhD, Woo Jae Shin, BA, Kevin Kim, Brian Zabel, PhD
Russell Pachynski, MD

Background
Chemerin (RARRES2) is an innate leukocyte chemoattractant known to recruit cells that express its chemotactic receptor (CMKLR1) along its concentration gradient. Chemerin downregulation has been shown in several tumor types, but not specifically investigated in prostate cancer. Our previous work has shown that augmented chemerin in the tumor microenvironment can suppress tumor growth by recruitment of immune effector cells. Here, we show in preclinical models of immune competent prostate cancer that chemerin can act as a potent tumor suppressor, and may play a role in immunosurveillance during tumorigenesis.

Methods
Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) C1 and C2 cells were lentivirally transduced with murine RARRES2. Monodispersed cell populations were obtained by limiting dilution. Constitutive chemerin secretion was evaluated by ELISA, and functional chemoattractant assays used to confirm the ability of secreted chemerin to recruit CMKLR1+ immune cells. In vitro cell proliferation and surface expression of markers (e.g MHC, PD1L) were examined on control and chemerin-expressing tumor lines. Control and chemerin-expressing TRAMP lines were inoculated subcutaneously into male C57BL/6 mice. Tumor growth was serially assessed. To study the effect of chemerin/CMKLR1 on immunosurveillance of spontaneous
tumorogenesis, B6 TRAMP WT mice were crossed with CMKL1R knock-out (KO) or RARRES2 KO mice.

**Results**

No significant difference in vitro cell proliferation, nor differences in expression of CMKL1R, MHC class I, CD1d, CD44, or PD-L1 levels was found between control or chemerin-expressing lines. Tumors were palpable (~50 mm3) in TRAMP C1 control after 4 weeks after inoculation, and tumors reached ~1000 mm3 at 8 weeks. Tumor growth was significant delayed in the chemerin-expressing TRAMP C1 cohort (< 0.04).

**Conclusions**

Here we show for the first time that modulation of chemerin, an innate leukocyte chemoattractant, can result in significant prostate tumor suppression using an immune competent preclinical model. Deficiency of chemerin/CMKL1R in TRAMP transgenic mice leads to significant increase in prostate tumor growth, suggesting a role for immune surveillance. Profiling of tumor infiltrating leukocytes, immune subset depletion studies, and gene expression profiling is ongoing.

**Ethics Approval**

The study was approved by Washington University’s IACUC institutional review board, approval number 20170174.

---

**P800**

Development of PY314, a monoclonal antibody that selectively depletes tumor-associated macrophages, for the treatment of solid tumors

Venkataramna Siram, PhD, Mikhail Binnewies, Joshua Pollack, Erick Lu, Nadine Jahchan, Xiaoyan Du, Anitra Pal, Evan Greger, Kevin Baker, Michel Streuli, PhD, Len Reyno
Pionyr Immunotherapeutics, South San Francisco, CA, United States

**Correspondence:** Michel Streuli (michel.streuli@pionyrtx.com) Journal for ImmunoTherapy of Cancer 2019; 7(Suppl 1):P800

**Background**

The proportion of patients who benefit from checkpoint inhibitor (CPI) therapy is modest, and additional immune pathways need to be targeted to improve overall patient outcomes. The abundance of immune-suppressive, tumor-associated macrophages (TAMs) is thought to be a key CPI resistance mechanism. To target TAMs, we developed monoclonal antibodies (mAbs) that specifically bind the cell surface protein Triggering Receptor Expressed on Myeloid Cells 2 (TREM2).

**Methods**

We developed a lead anti-TREM2 mAb, termed PY314, that was designed to deplete TREM2-positive TAMs. PY314 binding to TREM2 was evaluated using surface plasmon resonance and cell binding assays. In vivo efficacy and pharmacodynamic studies were conducted in a variety of syngeneic mouse tumor models. Cellular and molecular characterization of post-treatment tumor immune infiltrates was performed using flow cytometry and RNA sequencing.

**Results**

The PY314 mAb binds with high affinity to human, cynomolgus and mouse TREM2. Administration of PY314m, a murinized version of PY314, to tumor-bearing mice resulted in the reduction of TAMs in a variety of mouse syngeneic tumor models, including the CT26 and EMT6 models. More specifically, PY314m depleted MHC class II-low, M2-like TAMs, which are pro-tumorigenic. In EMT6 tumors, PY314m single agent treatment significantly shifted the TAMs within the TME from a M2-like phenotype to an inflammatory M1-like phenotype, and treatment resulted in a 40% cure rate. PY314m treatment in combination with an anti-PD-1 mAb in mice harboring CT26 tumors, that are otherwise resistant to anti-PD-1 treatment, resulted in a ~40% cure rate. Analysis of intratumor immune cell infiltrates suggested that TAM modulation resulted in enhanced functional activity of T cells within the TME. These results demonstrate that PY314 in combination with anti-PD-1 can convert CPI-resistant tumors into treatment responsive tumors. Furthermore, tumor rechallenge studies using animals cured of their tumors demonstrated that the PY314m/anti-PD-1 mAb combination treatment resulted in secondary tumor rejection, suggesting the development of long-term immunological memory. In pilot, four-week, multi-dose mouse and non-human primate toxicokinetic studies, PY314 was generally well tolerated at all tested doses.

**Conclusions**

Collectively, the available preclinical and nonclinical data support PY314 immunotherapy, alone or in combination with a CPI, in cancer patients who are resistant or refractory to CPI therapies, to improve both the overall response rates as well as the durability of responses. First in human clinical testing will start in 2020.

---

**P801**

Development of the first in class immunotherapy targeting immuno-suppressive 61 containing y6 T cells for the treatment of pancreatic ductal adenocarcinoma and other solid tumors

Tanya Panchenko, PhD, Wei Wang, Eric Denbaum, Takamitsu Hattori, Akiko Koide, PhD, Aleksandra Filipovic, MD, PhD, George Miller, Shohei Koide
1 NYU Langone, New York, NY, United States; 2 PureTech Health, London, United Kingdom

**Correspondence:** Shohei Koide (shohei.koide@nyulangone.org) Journal for ImmunoTherapy of Cancer 2019; 7(Suppl 1):P801

**Background**

Targeting and engineering y6 T cells has recently emerged as an orthogonal therapeutic approach in oncology with capacity to modulate both innate and adaptive immune properties. In solid tumors such as pancreatic ductal adenocarcinoma (PDAC), melanoma, glio-blastoma, ovarian, and breast cancer, y6 T cells express immunosuppression-related molecules and possess a pro-tumorigenic capacity. We have shown that intra-tumoral y6 T cells from PDA, colorectal cancer (CRC) and hepatocellular carcinoma (HCC) potently suppress patients’ y6 T cells. To harness the therapeutic potential of y6 T cell blockade, we developed highly specific, fully human antibodies against 61-subset of y6 T cell receptor (y6-1 TCR).

**Methods**

We determined the amino acid sequences of tumor specific 61-TCR chains from primary PDA, CRC and gastric cancer samples. Multiple y6-TCR proteins were produced and used to screen a proprietary synthetic, human antibody library using phage display. Surface plasmon resonance and bead-based assays were used to measure binding affinity and specificity. Affinity maturation was performed to improve cross-reactivity to monkey y6-1 TCR. Cell based assays were used to evaluate antibody-dependent cell cytotoxicity and phagocytosis (ADCC and ADCP). The levels of y6-1 T cell infiltration was measured in patient tumors. Efficacy in reversing immunosuppression was assayed using patient-derived organotypic tumor spheroids (PDOTS, n = 32), which recapitulate complex tumor architecture.

**Results**

Because the tumor-derived 61 chains showed diverse CDR3 sequences, we developed antibodies that bind diverse 61 TCRs. Our first-in-class anti-61 antibodies had low nanomolar affinity to 61 TCRs and showed no binding to 62 TCRs. Our lead clinical candidate showed no preference for the y chains of the TCR, which enables it to target diverse set of y6-1 TCRs. It had equivalent affinity for the human and cynomolgus monkey y6-1 TCRs and was potent in mediating cell based ADCC and ADCP. We showed that patient tumors can have a high 61 T cell infiltration (up to 40% of the total T cell infiltrate). Our lead candidate achieved reproducible and robust efficacy in the up-regulation of pro-inflammatory T cell activation markers in PDOTS from a diverse set of gastrointestinal tumors. Furthermore, y6 knockout mice had an improved response to checkpoint inhibitors, anti-PD1 and anti-CTLA4, in melanoma and lung cancer models.

**Conclusions**

We have defined a novel therapeutic immuno-oncology strategy and translated it to develop a lead clinical candidate anti-61 monoclonal antibody. Our efficacious, novel immunotherapy has the potential to be transformative for the treatment of cancers where y6-1 T cells drive a pro-tumorigenic, immunosuppressive environment.
Background

Around 40% of newly diagnosed lung cancer patients have tumors that have metastasized and non-small cell lung cancer (NSCLC) has a poor prognosis. Advances in treatment, such as targeted therapy and immunotherapy have significantly improved NSCLC patient outcome. In a collaborative study, between Celsee, IncellDx, Cytek Biosciences, and Qognit, single-cell immune and cancer marker profiling of primary tumor cells was employed to investigate possible signatures that might predict the presence or absence of circulating tumor cells (CTCs). This low-cost screening tool could be used to select patients for ongoing CTC monitoring for disease progression and response to therapy. A comprehensive study on 10 NSCLC was performed on patient tissue samples with paired blood samples.

Methods

Solid tissue biopsy samples were dissociated into single cells and stained with a total 26 immune, and cancer markers (aneuploidy) that were then analyzed with high-parameter flow cytometry. A total of 72 pairwise comparisons were assessed as biomarkers for their correlation with CTC number. Strong correlations were observed between CTC number and the frequency of PD-1 expressing lymphocytes. This was evident with the CD103+CD4+ T lymphocytes which are indicative of T-regulatory cells that are proximal to the tumor. (The PD-1/PD-L1 pathway is a target for NSCLC immunotherapy.) As part of the study, the lower limits of the reproducible detection (LOD) of the Genesis System was evaluated. 5 PD-L1+ CTCs were reproducibly detected in 4 mL of whole blood. This represents a capture rate as low as 1 in a 1,000,000 cells, which is much higher than the 50-60% capture rate observed with legacy systems.

Results

Correlations in CTC number and the frequency of immune PD-1+ lymphocytes with the PD-1+CD103+CD4+ T lymphocytes which are a biomarker for T-regulation cells, are proximal to the tumor. CTC number is correlated with the frequency of CD44+E-cadherin- cancer cells. Unsupervised clustering analysis based on the biomarker analysis separated the CTC negative patients from the CTC positive patients.

Conclusions

Profiling multiple immune and cancer markers on cancer samples with multi-parametric flow cytometry yielded protein expression information at the single cell level. Clustering analysis of the proteomic data revealed a signature driven by PD-1 expression on CD103+CD4+ T cells that was predictive of the presence of CTCs. High efficacy of cell capture and accuracy of the Genesis System make it ideal for CTC enumeration and monitoring (Figures 1-6).

Acknowledgements

Xiaoyang Wang1, Pin-I Chen1, Maria Jaime2, Huimim Gu3, Keith Shults1, Santosh Putta3, Fariba Fazeli1, Janine Fernandez1, Vishal Sharma4, Will Chow4, Priya Gogoi4, Kalyan Handique and Bruce K Patterson1. 1IncellDx Inc, San Carlos, CA 2 Cytek Biosciences Inc, Fremont, CA. 3 Qognit Inc, San Carlos, CA 4 Celsee Inc, Ann Arbor MI

References

Xiaoyang Wang1, Pin-I Chen1, Maria Jaime2, Huimim Gu3, Keith Shults1, Santosh Putta3, Fariba Fazeli1, Janine Fernandez1, Vishal Sharma4, Will Chow4, Priya Gogoi4, Kalyan Handique and Bruce K Patterson1. 1IncellDx Inc, San Carlos, CA 2 Cytek Biosciences Inc, Fremont, CA. 3 Qognit Inc, San Carlos, CA 4 Celsee Inc, Ann Arbor MI

Table-Statistical Significance.

Fig. 1 (abstract P802), Single-Cell Immune and Cancer Marker Profiling.

Fig. 2 (abstract P802), Single-Cell Immune and Cancer Marker Profiling.

Fig. 3 (abstract P802), Single-Cell Immune and Cancer Marker Profiling.
CUE-101, a novel HPV16 E7:pMHC:IL-2:Fc fusion protein, enhances tumor antigen specific T cell activation for the treatment of HPV16-driven malignancies

Steven Quayle, PhD1, Natasha Girgis, PhD1, Dharma Raj Thapa1, Zohra Merazga, MS1, Miguel Moreta1, Sandrine Hulot, PhD1, Alyssa Nelson, BS1, Lauren Kraemer, BS1, Dominic Beal, PhD1, Mark Haydock, BS1, Luke Witt, BS1, Jessica Ryabin, BS1, Jonathan Soriano, MSc1, Emily Spaulding, PhD1, John Ross, PhD1, Rodolfo Chaparro, PhD1, Ronald Seidel, PhD1, Anish Suri, PhD1, Saso Cemerski1, Kenneth Pienta, MD2, Mary Simcox, PhD1

1Cue Biopharma, Inc, Cambridge, MA, United States; 2Johns Hopkins School of Medicine, Baltimore, MD, United States

Correspondence: Steven Quayle (squayle@cuebio.com)


Background
Human papilloma virus (HPV)-driven cancers cause significant morbidity and mortality worldwide. CUE-101 is a novel therapeutic fusion protein designed to selectively activate tumor antigen-specific (AgS) T cells to treat HPV16-driven cancers. CUE-101 is comprised of two human leukocyte antigen (HLA) molecules presenting an HPV16 E7 peptide, four affinity-attenuated human interleukin-2 (IL-2) molecules, and an effector attenuated human immunoglobulin G (IgG1) Fc domain.

Methods
Human E7-specific T cells (Astarte Biologics, Bothell, WA) and human PBMCs were tested to demonstrate cellular activity and specificity of CUE-101, while in vivo activity of CUE-101 was assessed in HLA-A2 transgenic mice. Anti-tumor efficacy with a murine surrogate (mCUE-101) was tested in the TC-1 syngeneic tumor model. Tetramer staining and flow cytometry identified cell populations and activation markers.

Results
The mutated IL-2 domains of CUE-101 exhibit reduced functional activity relative to wildtype IL-2. In AgS T cells, CUE-101 selectively binds and induces receptor signaling and concentration-dependent IFNγ secretion. From E7(11-20)-responsive PBMCs, CUE-101 selectively expands AgS CD8+ T cells in a concentration-dependent manner with minimal expansion of regulatory T cells. The AgS T cells expanded by CUE-101 treatment are polyfunctional cytotoxic T lymphocytes as shown by production of IFNγ, TNF-alpha, and cytotoxic granules in response to native peptide-loaded presenting cells. Furthermore, CUE-101 induces expansion of an oligoclonal T cell repertoire comparable to that expanded with peptide/IL-2. In vivo studies in HLA-A2 mice confirm that intravenous administration of CUE-101 elicits polyfunctional AgS cells from naive and peptide-immunized mice without significantly altering the frequencies of other immune lineages. A CUE-101 surrogate demonstrates anti-tumor activity both alone and in combination with an anti-PD-1 antibody in the TC-1 model. Efficacy in this model was associated with expansion of E7 peptide-reactive T cells and establishment of immunologic memory as shown by tumor rejection upon rechallenge with TC-1 cells in the absence of additional dosing.

Conclusions
Consistent with its design, CUE-101 demonstrates selective expansion of an HPV16 E7(11-20)-specific population of cytotoxic CD8+ T cells in vitro and in vivo. These results support its potential for clinical efficacy in an ongoing Phase 1 trial (NCT03978689).

Ethics Approval
All animal studies were approved under SmartLabs Institutional Animal Care and Use Committee protocol MIL-100 and were performed in compliance with federal guidelines.

In vivo efficacy of a PD-L1 targeted Engineered Toxin Body (ETB) comprised of direct cytotoxicity and T-cell mediated tumor targeting

Brigitte Brieschke, BS, Sara LeMar, Joseph Dekker, PhD, Garrett Cornelison, Asis Sarkar, Garrett Robinson, Jay Zhao, PhD, Aimee Iberg, PhD, Jack Higgins, PhD, Hilario Ramos, PhD, Erin Willert, PhD

Molecular Templates, Austin, TX, United States

Correspondence: Erin Willert (erinwillert@mtem.com)


P804

In vivo efficacy of a PD-L1 targeted Engineered Toxin Body (ETB) comprised of direct cytotoxicity and T-cell mediated tumor targeting

Brigitte Brieschke, BS, Sara LeMar, Joseph Dekker, PhD, Garrett Cornelison, Asis Sarkar, Garrett Robinson, Jay Zhao, PhD, Aimee Iberg, PhD, Jack Higgins, PhD, Hilario Ramos, PhD, Erin Willert, PhD

Molecular Templates, Austin, TX, United States

Correspondence: Erin Willert (erinwillert@mtem.com)

Background

Engineered Toxin Bodies (ETBs) are comprised of a deimmunized Shiga-like toxin-A subunit (DI-SLTA) genetically fused to an antibody-based targeting domain. Multiple ETBs are now in clinical development. Our next evolution of the platform, antigen seeding technology (AST), retains the primary characteristics of these ETBs - self-internatization, routing to the cytosol, and enzymatic and irreversible inactivation of ribosomes by DI-SLTA - but in addition, can also deliver a viral antigen for presentation in complex with MHC-I to resident viral-specific cytotoxic T lymphocytes (CTLs). The fusion protein provides a powerful, dual mechanism of action to specifically target and destroy PD-L1 positive tumor and inhibitory immune cells.

Methods

In vitro activity of ETBs was measured by cell viability and kinetic imaging of labeled target cells in an effector T-cell co-culture assay. Repeat dosing studies in non-human primates (NHPs) and murine models harboring human PD-L1 positive patient derived tumors were used to evaluate tolerability and efficacy.

Results

ETBs targeting PD-L1 showed potent and specific activity across human tumor cell lines at picomolar concentrations in vitro. PD-L1 positive monocytes, but not PD-L1 negative lymphocytes, from human peripheral blood are targets of these ETBs. In co-culture assays, AST capable ETBs had a deeper response when target cells express both PD-L1 and the appropriate MHC-I allele in the presence than in the absence of antigen specific CTLs. In vivo, PD-L1 targeted ETBs induced tumor growth delay and regression and provided a survival benefit in multiple NSCLC PDX models with variable PD-L1 staining, as compared to controls. These ETBs were also tolerated in repeat dosing NHP studies.

Conclusions

The potent and direct activity of ETB mediated tumor cell destruction is demonstrated across tumor cell lines from multiple indications, on PD-L1 positive immune cells ex-vivo, and by tumor growth and survival benefits in PDX models. Potency differences observed in vitro across ETBs correlate with efficacy on low PD-L1 models. Additional in vivo models to further elucidate the potential of the exemplary AST capable ETBs are ongoing, and clinical trials are expected to initiate next year. The AST capable, PD-L1 targeted ETBs provide dual novel mechanisms to deplete PD-L1 positive cells and control malignancies. Both the DI-SLTA mediating direct cell kill and activation of viral-specific CTLs circumvents a need for high mutational burden or reliance on IL-27-mediated immune escape.

Ethics Approval

In vivo animal studies were approved by Champions Oncology's Institutional Animal Care and Use Committee (2017-TOS-001).

P805

SRF388, a first-in-class, fully human monoclonal antibody targeting IL 27, blocks the immunoregulatory effects of IL-27 in immune cells and demonstrates preclinical in vivo antitumor activity

Matthew Rausch, PhD, Jing Hua, Devapregasan Moodley, Kerry White, Katherine Walsh, Christine Miller, Jamie Strand, Pamela Holland, PhD, Vito Palombella, PhD, Jonathan Hill, PhD
Surface Oncology, Inc., Cambridge, MA, United States

Correspondence: Matthew Rausch (mrausch@surfaceoncology.com)

Background

IL-27 is a heterodimeric member of the IL-12/IL-23 cytokine family, consists of two subunits, IL-27p28 and Epstein-Barr virus-induced gene 3 (EBI3). IL-27 signals through a heterodimeric receptor composed of glycoprotein (gp130) and IL-27 receptor subunit alpha (IL 27RA). Binding of IL-27 to its receptor induces signaling through the JAK-STAT pathway to alter immunoregulatory receptor and prot-flammatory cytokine expression in immune cells, limiting the intensity and duration of T-cell responses during infection and cancer. Given the immunoregulatory function of IL-27, it was hypothesized that blockade of IL-27 signaling may represent a novel and promising strategy to treat cancer.

Methods

To explore the therapeutic potential of IL-27 blockade, SRF388, a first-in-class, fully human anti-IL-27 monoclonal antibody that binds to the p28 subunit of IL-27 with high affinity, was developed. The ability of SRF388 to inhibit IL-27-induced phenotypic changes in human peripheral blood mononuclear cells (PBMCs) was assessed in vitro. To explore the ability of SRF388 to inhibit IL-27 signaling in vivo, mice overexpressing recombinant human IL-27 (hIL 27) were treated with SRF388, and T cells were analyzed by flow cytometry. Finally, the antitumor activity of IL-27 blockade with SRF388 was assessed in mice.

Results

SRF388 prevented IL-27 from binding to IL-27RA, inhibited IL-27-induced STAT1 phosphorylation in human cell lines and primary T cells, and blocked IL-27-responsive immunoregulatory receptor expression in human PBMCs. Expression of IL-27 in mice promoted the expression of PD-L1, Tim-3, Tigit, and Lag-3 on murine T cells, a response that was fully inhibited by the administration of SRF388. Treatment of human PBMCs with rhl-27 altered the expression of many of the same markers. Moreover, IL-27 counteracted the activity of PD-1 blockade in upregulating cytokine production by activated human PBMCs. Notably, SRF388 blocked all of these IL-27-mediated responses. Lastly, blockade of IL-27 signaling with SRF388 demonstrated antitumor activity in mice.

Conclusions

Collectively, these data demonstrate that IL-27 exerts multiple immunosuppressive effects and that SRF388, a first-in-class antibody targeting IL-27, can potentiate antitumor responses in cancers that rely on IL-27-mediated immune escape.

Ethics Approval

Mice were used in compliance with protocols approved by the IACUC of Mispro Biotech Services, Cambridge, MA (#2017-03-21SUR-1), Charles River Accelerator and Development Lab, Cambridge, MA (KCR-008), or Charles River Laboratories, Worcester, MA (#I023).
**Results**

We described the first crystal structure of the human GITR/GITR-L complex at a resolution of 2.85 Å which revealed an unusual receptor-mediated non-covalent dimer of two GITR-GITR-L trimeric assemblies forming a hexagonal network. Trimeric GITR interacts with its trimetric GITR-L in the canonical cysteine-rich domain-dependent modality. Peptide mapping revealed an o-glycosylation site in the CRD1 subdomain of GITR which induced partial heterogeneity. Structure-based alignment of GITR demonstrated good superposition with 4-1BB and OX40. The CRD3-mediated GITR homodimer interface contains a network of hydrophobic interactions at the c-terminus, which suggest a propensity for native oligomerization. Since free GITR-L or bivalent antibodies cannot create the optimized clustering demonstrated by the crystal structure, we sought to achieve enhanced bioactivity by engineering novel GITR-L constructs which achieve various levels of GITR clustering. T cell co-stimulation was shown to increase with higher GITR-L oligomeric organization. Superior in vitro bioactivity was observed with a hexameric GITR-L complex construct.

Our data suggests that GITR-L or bivalent antibody-mediated GITR agonism on T cells is critically dependent on the receptor’s structural conformational geometry. Guided by the crystal structure of the GITR/GITR-L, we found that optimized receptor organization induces enhanced bioactivity of human T cells in vitro. These novel engineered GITR-L moieties may represent a new strategy to design effective co-stimulatory biotherapeutics.

**Conclusions**

Neoadjuvant VSV treatment is well-tolerated, and shows preliminary evidence of biological activity and clinical efficacy. Updated results describing anti-tumor immunity that is attributable to oncolytic VSV and its effects on patient outcomes will be presented. These data will indicate if intravenous neoadjuvant VSV-IFNβ-NIS therapy improves clinical outcomes in canine osteosarcoma and inform clinical studies to evaluate this therapeutic approach as an addition to current neoadjuvant osteosarcoma therapies. This approach may shed light on the relative roles of viral oncolysis and immune responses in mediating tumor killing and indicate biomarkers that are indicative or predictive of clinical efficacy in heterogeneous cancer.

---

**P807**

Characterization of anti-tumor immune responses and effects on survival of neoadjuvant oncolytic vireotherapy in spontaneous osteosarcoma

Kelly Makielski, DVM, MS, DACVIM, Aishwarya Sathyanarayan, PhD

Shruthi Naik, PhD, Jaime Modiano, VMD, PhD, Stephen Russell, MD, PhD, Michael Henson, DVM, PhD, Kathleen Stuebner, Flavio Alexandru Tabarani, Gerard O’D, Andrea Eckert, Donna Groschen, Lauren Mills, PhD, Milica Scott, BS, Aaron Sarver, PhD, Michael Farrar, Ingrid Cornax, PhD

*Mayo Clinic, Rochester, MN, United States; University of Minnesota, Minneapolis, MN, United States*

**Correspondence:** Shruthi Naik (naik.shruthi@mayo.edu), Jaime Modiano (modiano@umn.edu), Stephen Russell (sij@mayo.edu)

**Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):807**

**Background**

There is a critical, unmet clinical need for effective therapies for osteosarcoma, a rare bone cancer that primarily affects adolescents and young adults. The rarity and heterogeneity of these cancers have hindered research in this field. Comparative oncology studies in naturally occurring osteosarcoma in companion dogs provide opportunities to advance development in a clinically realistic setting where the tumors resemble their human counterparts but where the barriers of rarity and cost are lower. Vascular stomatitis virus (VSV) is a rapidly replicating, robustly immunogenic oncolytic virus platform with demonstrated cytotoxicity in canine osteosarcoma cell lines. The aim of this study is to evaluate neoadjuvant VSV-IFNβ-NIS therapy for osteosarcoma using a comparative oncology approach, and characterize anti-tumor immune responses in spontaneous canine osteosarcoma.

**Methods**

Dogs with spontaneous osteosarcoma were enrolled in a veterinary clinical trial. Dogs were randomized to receive neoadjuvant oncolytic VSV-IFNβ-NIS (109 TCID50/kg) or placebo followed by standard of care (SOC) amputation and carboplatin chemotherapy. Tumor tissues and peripheral blood mononuclear cells were collected pre-and post-VSV therapy to characterize local and systemic antitumor immune responses.

**Results**

28 dogs were enrolled and treated on the study. Intravenous VSV-IFNβ-NIS was well-tolerated and post infusion symptoms included mild, transient fever and evidence of acute cytokine responses. Preliminary efficacy analyses show survival outcomes exceed that of historic control populations treated with standard of care. Tumor pathology indicated the presence of tumor necrosis and inflammation in VSV treated dogs. Patient specific osteosarcoma cell lines were isolated following surgical tumor resection and tested in vitro to characterize susceptibility to VSV infection and oncolysis. Experiments are underway to characterize T-cell responses against virus and tumor associated antigens. We will evaluate correlation of tumor pathology, in vitro tumor cell line susceptibility, and antiviral and antitumor immune responses to survival outcomes.

**Conclusions**

Neoadjuvant VSV treatment is well-tolerated, and shows preliminary evidence of biological activity and clinical efficacy. Updated results describing anti-tumor immunity that is attributable to oncolytic VSV and its effects on patient outcomes will be presented. These data will indicate if intravenous neoadjuvant VSV-IFNβ-NIS therapy improves clinical outcomes in canine osteosarcoma and inform clinical studies to evaluate this therapeutic approach as an addition to current neoadjuvant osteosarcoma therapies. This approach may shed light on the relative roles of viral oncolysis and immune responses in mediating tumor killing and indicate biomarkers that are indicative or predictive of clinical efficacy in heterogeneous cancer.
using increasing dose levels of AT1412. Although a transient drop in circulating platelet counts was observed upon antibody injection, AT1412 was well tolerated up to 10 mg/kg antibody (highest dose tested) and did not lead to other adverse events nor were any co-agulation factors affected.

Conclusions

Taken together, applying AIMM’s proprietary B-cell immortalization technology [2] we isolated a tumor-selective anti-CD9 antibody (AT1412). AT1412 was shown to induce tumor rejection as a single agent and enhances the activity of anti-CD1 antibodies. Preliminary data from single-dose administration in monkeys suggested that AT1412 can be safely administered. Preclinical development of AT1412 is currently ongoing.

Acknowledgements

Funding: Dutch Cancer Society, grant UVA 2010-4822

References


Ethics Approval

The protocol for the melanoma clinical study was approved by the Medical Ethics Committee of the Leiden University Medical Center and conducted in accordance with the Declaration of Helsinki. The patient gave written informed consent. Blood from healthy individuals was obtained in accordance with national guidelines and oral informed consent. Animal experiments were approved by the local ethical committee (AMEC: A11412).

P809

Preclinical development of a novel, allogeneic, OX40L-secreting, therapeutic cancer vaccine for use in combination with a gp96-secreting vaccine for solid tumors

Matthew Seavey, PhD, Jason Rose, MS, Patrick Dilllon, PhD, Jayalakshmi Mistrya, MS, Vikas Tahiliani, PhD, Jeff Hutchins, PhD

Heat Biologics, Inc., Durham, NC, United States

Correspondence: Matthew Seavey (mseavey@heatbio.com)


Background

Heat Biologics is focused on developing and optimizing a next generation cellular vaccine platform that incorporates a tumor antigen chaperone (gp96-lg) with costimulation into a single tumor cell line overexpressing a host of cancer associated neoantigens. Viagnenpumatucel-L (HS-110), a human lung adenocarcinoma cell line, stably transfected to express gp96-lg, is being tested in a phase 1/2 clinical trial (NCT#02439450) for NSCLC. A similar line was generated that complements HS-110, providing costimulation in the form of secrerted OX40-lg (HS-130).

Methods

As a model, mouse surrogates of each human product (HS-110 and mHS-130) were generated to activate and expand adoptively transferred OVA-specific T cells (OT-1) responding to tumor challenge with B16F10 cell line over expressing OVA. To identify the best ratio of mHS-110 to mHS-130, multiple dose ratio and dose escalation studies were performed to measure T cell expansion (peripheral and intratumoral) in the context of tumor challenge.

Results

Combining mHS-110/gp96-lg with mHS-130/OX40L-lg at a ratio of 1 to 1, i.e, 339 ng/10^6 cells/24 hrs of gp96-lg to 441 ng/10^6 cells/24 hrs of OX40L-lg provided the optimal dose combination for long-term survival and expansion of tumor specific CD8+ T-cells, tumor infiltrating lymphocytes (TILs) and greatest tumor growth inhibition (TGI). The no observed effect level (NOEL) was determined to be 38 ng of gp96-lg to 50 ng of OX40L-lg with the minimum active biological effect level (MABEL) being 113 ng gp96-lg to 147 ng OX40L-lg. Dosing mice with mHS-130, HS-130 and an OX40 agonist as a positive control, the no observed adverse event level (NOAEL) was determined to be 20 mg/kg for the OX40 agonist antibody, 219.5 ng/animal or 0.01097 mg/kg of human OX40L-lg/24 hrs for HS-130, and 387.2 ng/animal or 0.01936 mg/kg of mouse OX40L-lg/24 hrs. The serum cytokines detected in response to cellular injection were those frequently associated with acute innate immune responses (CXCL10, MCP-3, CCL4, TNFalpha, CXCL1).

Conclusions

Best dose group combination mHS-110/gp96-lg to mHS-130/OX40L-lg was at a ratio of 1 to 1.3, at a dose rate of 339 ng/10^6 cells/24 hrs of gp96-lg to 441 ng/10^6 cells/24 hrs of OX40L-lg, with a NOEL of 38 ng gp96-lg to 50 ng OX40L, a MABEL of 113 ng gp96-lg to 147 ng OX40L-lg. These results support the clinical translation of this approach of combining a T cell activation platform with costimulation.

References


P810

An engineered bi-function fusion protein (CD86-Fc-NKGA2a) to reverse NK cell tolerance of malignant cells

Casey Shuptrine, PhD, Taylor Schreiber, MD, PhD

Shattuck Labs Inc, Durham, NC, United States

Correspondence: Taylor Schreiber (tschreiber@shattucklabs.com)


Background

As clinical outcomes improve for immunotherapeutic regimens based on PD-1/L1 blockade, the proportion of cancer patients who develop resistance to PD-1/L1 blockade will increase. Some resistance mechanisms, including MHC-I and β2M downregulation, reflect the nature of PD-1/L1 as a T-cell centric checkpoint. Recent clinical success by groups targeting non-T cell immune cells has highlighted the potential of enhancing macrophage or NK cell targeted immunotherapies for the treatment of a wide variety of cancers. Future combinatorial approaches will likely utilize agents targeting multiple different immune cells to effectively arm both the adaptive and the innate immune systems. As a prime example of this, the anti-NKG2a monoclonal antibody Monalizumab, has shown promising preclinical and clinical anti-cancer effects, especially when combined with an ADCD competent antibody [1]. Therefore, targeting non-classical innate immune checkpoint has the potential to synergize with currently approved cancer therapies. Here we report the generation of a two-sided fusion protein, CD86-Fc-NKGA2a, which was designed to provide competitive inhibition of the NK-centric HLA-E checkpoint, which providing co-stimulation to T cells via CD28.

Methods

Human and mouse variants of CD86-Fc-NKGA2a were produced and characterized using a variety of biochemical assays to determine the correct molecular weight, subunit composition and binding affinity; molecular assays to characterize in vitro cell binding, in vitro functional activity, in vitro lysis capabilities; and anti-tumor efficacy in multiple syngeneic model systems.
Results
The NKG2a domain recombinant and cell-expressed HLA-E with high affinity. The CD86 domain recombinant CD28 and CTLA-4, with a higher affinity for CTLA-4. CD86-Fc-NKG2a also stimulated NF-κB signaling in CHO/CD82/NFκB-luciferase cells. When tested head-to-head in a therapeutic CT26 murine tumor model, mCD86-Fc-NKG2a demonstrated stronger anti-cancer activity compared to anti-NKG2a antibody controls. The combination of the CD86-Fc-NKG2a with anti-PD1 and anti-CTLA-4 antibodies was effective in controlling tumor growth in immune competent mice. In vitro cell lysis assays, with PBMCs and isolated NK cells, have further elucidated the effect of CD86-Fc-NKG2a on NK cell mediated tumor cell death.

Conclusions
The presented data demonstrates the feasibility and function of a dual fusion protein, designed to competitively inhibit the NKG2a/HLA-E NK checkpoint pathway, while providing costimulation via CD86. CD86-Fc-NKG2a provided superior tumor control in comparison to antibodies blocking the ideal platform for such TME repotting of CTLA-4 or PD-1 blockade. Combined inhibition of NK and T cell checkpoint pathways may reduce the probability of PD-1 resistant disease due to downregulation of MHC-I or other antigen presentation mechanisms.

References

P811
Utilizing novel oncolytic vaccinia virus for selective expression of immunotherapeutic payloads in metastatic tumors
Adrian Pelin1, Mike Huh, PhD1, Matthew Tang, PhD1, Fabrice Le Boeuf, PhD1, Brian Keller, Jessica Duong1, Katherine Clark-Knowles, PhD1, Victoria Jennings, PhD1, Julia Petryk1, Alan Melcher2, Mathieu Crupi, PhD1, Raghurath Sinagavelu, PhD1, Larissa Pikor, PhD1, Caroline Breitbach, PhD1, Steven Bernstein, MD2, Michael Burgess, MD, PhD3, John Bell, PhD1
1Ottawa Hospital Research Institute, Ottawa, Canada; 2Leeds University, Leeds, United Kingdom; 3Tatumstone Biologics, San Francisco, CA, United States
Correspondence: John Bell (jbell@ohri.ca)

Background
Despite the profound clinical impact that immune checkpoint inhibitors (ICIs) have had, they benefit only a fraction of cancer patients due in part to the multitude of immunosuppressive networks within the tumor microenvironment (TME). Therefore, strategies to selectively re-program the TME from that of immunosuppression to immune stimulation are anticipated not only to improve the clinical efficacy of ICI, but also that of other immunotherapeutic approaches. Oncolytic viruses (OVs) encoded with the NKG2A blocking antibodies, and was engineered virus, TBio-6517. The data presented here demonstrates the feasibility and function of a dual fusion protein, designed to competitively inhibit the NKG2a/HLA-E NK checkpoint pathway, while providing costimulation via CD86. CD86-Fc-NKG2a provided superior tumor control in comparison to antibodies blocking the ideal platform for such TME repotting of CTLA-4 or PD-1 blockade. Combined inhibition of NK and T cell checkpoint pathways may reduce the probability of PD-1 resistant disease due to downregulation of MHC-I or other antigen presentation mechanisms.

Methods
Using a combination of functional genomics and bio-selection strategies, we generated a novel Vaccinia Virus (VACV) backbone, denoted as SKV, having augmented oncolytic activity, improved tumor selectivity and less immunosuppression compared to wild-type VACV. We next engineered SKV to encode three potent immune modulators: anti-CTLA4 antibody, membrane tethered IL12p35 and FLT3L. Various immunocompetent syngeneic mouse tumor models and human xenograft tumor models were used to characterize this engineered virus, TBio-6517.

Results
SKV generates more potent anti-tumor effects and shows enhanced synergy with ICIs compared to that of other clinical VACV candidates. SKV increases tumor T-cell infiltration while decreasing the number of Treg cell and g-MDSC levels. Tumor-selective transgene expression has been demonstrated in murine tumor models in which therapeutic payload concentrations were achieved within the tumor (e.g. >7.5 ng/ml FLT3L) without any detectable transgene product detected in the systemic circulation. Expression of the therapeutic payload in TBio-6517 increased survival and tumor control compared to the SKV backbone control in syngeneic mouse tumor models, including humanized CTLA-4 immune checkpoint knock-in mice.

Conclusions
Our new best-in-class recombinant VACV robustly stimulates systemic anti-tumor immunity and has a substantially improved pre-clinical safety profile compared to other VACV clinical candidates. Additional ongoing toxicity and efficacy studies are being conducted prior to clinical evaluation of the novel virus construct.

Ethics Approval
This study was approved by the University of Ottawa’s ACVS Animal Care Committee.

P812
Development of PY159, a monoclonal antibody that repolarizes tumor-associated inhibitory myeloid cells, for the treatment of solid tumors
Linda Liang, Michel Streuli, PhD, Chris Chan, Antra Pal, PhD, Erick Lu, Joshua Pollack, Mikhail Binnewies, Xiaoyan Du, Antra Pal, Vladi Juric, Evan Greger, Kevin Baker, Len Reyno
Pionyr Immunotherapeutics, South San Francisco, CA, United States
Correspondence: Michel Streuli (michel.streuli@pionyr.com)

Background
To improve the proportion of patients who benefit from checkpoint inhibitor (CPI) therapy additional immune pathways likely need to be targeted. Tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and tumor-associated neutrophils (TANs) exhibit a spectrum of functional phenotypes ranging from immunosuppressive M2-like macrophages or N2-like neutrophils that promote tumor growth to pro-inflammatory M1-like macrophages and N1-like neutrophils that promote anti-tumor immunity. Therapies that shift the balance of inhibitory myeloid cells towards a more pro-inflammatory phenotype are expected to positively impact anti-tumor immune responses and convert CPI-resistant tumors into CPI-sensitive tumors.

Methods
Human whole blood, peripheral blood mononuclear cells, isolated myeloid cells, or dissociated tumor cells were treated with monoclonal antibodies (mAbs) and analyzed by flow cytometry and Meso Scale Discovery. In vivo efficacy and pharmacodynamic studies were conducted in MC38, CT26, and EMt6 tumor models. Cellular and molecular characterization of tumors was performed using flow cytometry and RNA sequencing.

Results
We identified Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) as a target on TAMs, TANs, and MDSCs, and developed anti-human and anti-mouse TREM1 mAbs, termed PY159 and PY159m, respectively. These mAbs activated downstream signaling pathways, induced secretion of a highly selective subset of pro-inflammatory factors, and increased the expression of HLA-DR and CD40, which play critical roles in antigen presentation and T cell activation. Molecular profiling of PY159m-treated syngeneic tumors demonstrated activation of innate and adaptive immune pathways, suggesting that PY159 therapy repolarizes TREM1-positive myeloid cell into pro-inflammatory cells. In vivo, PY159m had anti-tumor activity in a number of syngeneic tumor models. PY159m in combination with anti-PD-1 converted anti-PD-1 resistant tumors into treatment-sensitive
tumors. Furthermore, mice cured of their tumors by PY159m combination therapy were resistant to tumor re-challenge suggesting that targeting myeloid cells promotes long-term immunological memory. A survey of the immune infiltrates by both flow cytometry and RNA expression from a variety of indications showed that TREM1-positive myeloid cells were present at a high frequency in all tested tumors. In a pilot, single-dose non-human primate tolerability/pharmacokinetic (PK) study PY159 was generally well tolerated at all tested doses.

Conclusions
The available preclinical and nonclinical data support PY159 immunotherapy, alone or in combination with a CPI, in cancer patients who are resistant or refractory to CPI therapies, to improve both the overall response rates as well as the durability of responses. First in human clinical testing will commence in 2020.

P813
TAS0313, a novel cocktail vaccine of multivalent HLA-A2-, A24- and A3 superfamily-restricted epitopes, demonstrates a synergistic antitumor effect with anti-PD-1 antibody
Yuki Tanaka, MS, Hiroshi Wada, MS, Risa Goto, Toshihiro Osada, Keisuke Yamamura, Satoshi Fukaya, Kazuhisa Minamiguchi, Koichi Ikizawa, Teruhiro Utsugi
Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan
Correspondence: Yuki Tanaka (yuuki-tanaka@taiho.co.jp)

Background
Many peptide vaccines have failed in clinical trials due to insufficient efficacy. Therefore, improving the efficacy of peptide vaccines is essential for cancer vaccine development. Long peptide vaccines are expected to have a better antitumor effect than short epitope vaccines. We thus developed three novel long peptide vaccines, TAS0314, TAS0315 and TAS0316, composed of 12 HLA-A2-, A24- or A3 superfamily-restricted cytotoxic T lymphocyte (CTL) epitopes with arginine linkers. The purpose of this preclinical study was to evaluate the immunological characteristics of TAS0313, a cocktail vaccine of TAS0314, TAS0315 and TAS0316, using HLA knock-in (KI) mice.

Methods
We immunized HLA-A2-, A24- and -A31 KI mice with TAS0313, and evaluated the epitope-specific CTL induction in lymph nodes using an interferon-γ ELISPOT assay. The antitumor effect against B16F10 tumor cells expressing HLA-A2 and TAS0314 epitope was evaluated using HLA-A2 KI mice treated with either TAS0313 monotherapy or TAS0313 in combination with anti-PD-L1 monoclonal antibody (mAb). Epitope-specific CTLs in tumors were measured by epitope-specific HLA tetramer staining.

Results
TAS0313 induced all of the detectable epitope-specific CTLs in the HLA KI mice. Prophylactic immunization with TAS0314 significantly inhibited subcutaneous tumor growth on day 14 after tumor inoculation (Vehicle: 359.59 mm3; TAS0314: 127.07 mm3). Combination treatment with TAS0314 and anti-PD-1 mAb significantly prolonged the survival of mice when compared to TAS0314 or anti-PD-1 mAb monotherapy. The tumor-free rate was 53.33% in the combination TAS0314 and anti-PD-1 mAb group, 13.33% in the TAS0314 monotherapy group, and 6.6% in the anti-PD-1 mAb monotherapy group.

Immunization with TAS0314 induced epitope-specific CTL infiltration into tumors (5.06% of the CD8 T cells). Furthermore, combination treatment with TAS0314 and anti-PD-1 mAb remarkably increased the CTL infiltration (16.6% of the CD8 T cells).

Conclusions
We demonstrated that TAS0313 can enhance CTL induction and anti-tumor effects in vivo. In addition, the combination therapy of TAS0313 and anti-PD-1 mAb resulted in a synergistic antitumor effect by increasing the infiltration of epitope-specific CTLs into tumors. Based on these results, Phase I/II studies evaluating the efficacy of combination therapy with pembrolizumab in urothelial carcinoma patients and monotherapy in glioblastoma patients are currently underway.

Ethics Approval
All animal studies were approved by the Taiho Institutional Animal Care and Use Committee.

P814
Antibody-interferon-gamma fusion protein for the treatment of B-cell lymphomas
Alex Vasuthasawat, Reiko Yamada King, Kham Trinh, Neiki Rokni, Sherie Morrison, PhD, John Timmerman, MD, UCLA, Los Angeles, CA, United States
Correspondence: John Timmerman (timmerman@mednet.ucla.edu)

Background
The interferons, including IFNα/IFNβ (type I) and IFNγ (type II) are essential mediators of anti-cancer immunity. To achieve efficient targeting of IFNs to tumor sites, we have developed antibody (Ab)-IFN fusion protein technology [1]. A fusion protein targeting human CD20 (anti-huCD20-huIFNγ) exhibited stronger direct anti-proliferative effects, complement-dependent cytotoxicity (CDC), Ab-dependent cell-mediated cytotoxicity (ADCC), and in vivo potency against B-cell lymphoma xenograft models compared to the parent Ab rituximab. Based on these results, a phase I, first-in-human, dose-escalation trial of anti-huCD20-huIFNγ for B-cell non-Hodgkin lymphoma is now underway (NCT02519270). We now report on the construction and characterization of anti-CD20 fusions containing IFNγ, the IFN species secreted by effector CD8+ T cells, NK cells, and NKT cells.

Methods
The VH and VL regions from antibody 2B8 recognizing human CD20 were engineered in recombinant form with human IgG1 constant regions, and fused at the C-terminus with mIFNgamma. Tumor cell proliferation in vitro was measured by [3H]-thymidine incorporation, ADCC by LDM release using mouse splenocyte effectors, CDC by PI exclusion, and in vivo tumor growth using the huCD20-expressing syngeneic mouse B cell lymphoma 38C13-huCD20. Tumor-infiltrating lymphocytes were measured by flow cytometry.

Results
Anti-hCD20-mIFNγ suppressed the in vitro proliferation of 38C13-huCD20 lymphoma cells by up to 70% (at 1 nM). Anti-hCD20-mIFNg also showed enhanced ADCC against lymphoma cells compared with unfused, parent antibody (16-20% at E:T ratio of 20:1, versus 9-12%, respectively) (Figure 1), while CDC was identical to unfused antibody. In vivo efficacy with 70-80% cures was demonstrated in mice bearing established subcutaneous 38C13-huCD20 tumors, with systemic (i.v.) injection of 100 mcg anti-hCD20-huIFNγ fusion protein on days 5, 6, 7, and 9 after tumor inoculation, in repeated experiments. Mechanistic studies showed that depletion of natural killer (NK) cells (using anti-asialo-GM1) significantly abrogated tumor clearance (p=0.01), while depletion of macrophages (caldronate liposomes) had lesser, borderline effects (p= 0.05) (Figure 2), and depletion of complement (cobra venom factor) or T cells (CD4+ or CD8+) had no significant effects on tumor eradication. Subcutaneous mouse B cell lymphomas treated with intratumoral injections of anti-hCD20-mIFNγ displayed increased tumor-infiltrating CD8+ T cells (mean 20.6% versus 5% in PBS-treated controls, p=0.008), and CD4+ T cells (mean 15.3% versus 6.6%).

Conclusions
Anti-hCD20-mIFNγ fusion protein has in vitro and in vivo efficacy in a syngeneic, immunocompetent model of B cell lymphoma, with NK cells and possibly macrophages implicated in the mechanism(s) of tumor eradication.

References
Targeting multiple immune checkpoint proteins with novel small molecule inhibitors of Sec61-dependent cotranslational translocation

Jennifer Whang, PhD1, Janet Anderl1, Andrea Fan1, Christopher Kirk1, Eric Lowe1, Dustin McMinn1, Beatriz Millare1, Meera Rao1, Jack Taunton, PhD2

1Kezar Life Sciences, South San Francisco, CA, United States; 2University of California, San Francisco, CA, United States

Correspondence: Dustin McMinn (dmcminn@kezarbio.com).

Background
Antibody-based immunotherapies have demonstrated improved anti-tumor responses and success in the clinic. Nevertheless, a majority of patients either do not respond or develop resistance to single agent checkpoint inhibitors, thus driving exploration into the rational design of combination therapies. Expression of secreted and transmembrane proteins, including checkpoint molecules, involves cotranslational translocation, which is facilitated by the ribosome-signal recognition particle-Sec61 complex [1]. Amino-terminal signal sequences unique to each protein direct nascent polypeptides through the Sec61 channel into the endoplasmic reticulum for expression and function. While many Sec61-targeting compounds have demonstrated anti-tumor effects by broadly inhibiting protein translocation, some compounds have been identified to exert signal sequence-specific blockade [2]. Here we present small molecule inhibitors of Sec61 capable of selectively targeting multiple co-inhibitory immune checkpoint proteins.

Methods
Target protein inhibition was assayed using HEK293 cells overexpressing wild-type or R66I-mutant Sec61, which was previously shown to confer resistance to published Sec61 inhibitors [3]. Tumor cells or T cells were incubated with compound in vitro, and surface expression of immune checkpoint proteins was examined by flow cytometry. T cell functions were examined in vitro following anti-CD3/anti-CD28 stimulation or in T cell co-culture systems. Cytokine production was measured by electrochemiluminescence-based assay. CD73 enzymatic activity was measured in cell-based assays using the AMP-Glo™ assay.

Results
We identified a series of compounds that selectively block Sec61-dependent cotranslational translocation of select immune checkpoint proteins. In particular, the compounds more readily inhibited PD-1, B7H3, CD47, CD73, and CD96 compared to other co-inhibitory molecules, such as TIM3, TIM3 and CTLA-4. Following in vitro compound treatment, decreased PD-1 and CD96 surface expression was observed on activated T cells. Furthermore, the compounds enhanced T cell production of interleukin-2 and interferon gamma in mixed lymphocyte reactions. Select inhibitors also down-regulated surface expression of CD73 on SKOV3 tumor cells. Consistent with this result, compound treatment of SKOV3 cells reduced CD73 hydrolysis of AMP, suggesting these inhibitors may rescue CD73-mediated suppression of T cell functions.

Conclusions
Small molecules targeting Sec61-dependent cotranslational translocation provide a new approach for blocking multiple immune checkpoint proteins with a single agent. We have identified novel Sec61 inhibitors that have the capacity to regulate T cell functions and/or the tumor microenvironment. Based on these data, in vivo studies will further elucidate the efficacy of Sec61 inhibitors as immunotherapeutics.

References

DRP-104 induces durable responses in vivo by inhibiting tumor glutamine addiction, remodeling the tumor microenvironment and stimulating both the innate & adaptive immune systems

Yumi Yokoyama, PhD, Michael Nedlykovych, PhD, Robert Wild, PhD
Dracen Pharmaceutical, New York, NY, United States

Correspondence: Robert Wild (rwild@dracenpharma.com).

Background
Glutamine is an essential amino acid for rapidly proliferating cancer cells, thus depriving the same fuel from immune cells and contributing to tumor immune evasion. DRP-104 was designed as a novel prodrug of the broad acting glutamine antagonist 6-Diazo-5-oxo-L-norleucine (DON). DRP-104 is inert in its prodrug form, affords high levels of plasma and gastro-intestinal (GI) tissue stability; has high tumor cell permeability and preferential tumor versus plasma/GI tissue distribution for DON. Here we sought to (1) characterize in vitro biochemical and biological activities, (2) identify the immune-modulatory mechanism of action, and (3) evaluate in vivo anti-tumor efficacy of DRP-104 as a single agent.

Methods
Anti-tumor and immunomodulatory effects of DRP-104 were evaluated in vitro using biochemical, cellular and functional assays. Tumor distribution was assessed by LC-MS/MS. Metabolomic analysis was performed by Metabolon. Immuno-phenotyping was performed in tumor and blood samples by flow cytometry, Nanostring, and Luminex. Tumor growth inhibition and survival analysis was performed in syngeneic tumor models.
Results
DRP-104 and its active moiety DON showed glutamine dependent inhibition of cancer cell growth in vitro, correlating with broad glutamine pathway inhibition. In vivo, DRP-104 is preferentially converted to DON in tumors and has minimal plasma/GI tissue distribution. Metabolomic profiling in tumor samples showed widespread changes indicative of disruption of tumor anabolism and canonical cancer metabolism pathways. In addition, glutamine and various other amino acids were significantly increased while several immune-suppressive metabolites were decreased. DRP-104 treatment resulted in substantial and broad changes in various immune cell infiltrates, such as increased TIL, T, Tm, NK and NKT cells. T cells were more proliferative and less exhausted, NK cells showed increased activation markers and TAMs were polarized to M1 phenotype. DRP-104 treatment resulted in significant reduction in PD-L1 expression on tumors, macrophages and dendritic cells. Pro-tumorigenic proteins, such as VEGF and IL-8, were decreased. Finally, DRP-104 showed significant tumor growth inhibition including curative effects as a single agent in mouse syngeneic tumor models.

Conclusions
DRP-104 is a novel, broad acting glutamine antagonist with potent single agent anti-tumor activity. DRP-104 treatment causes not only wide-spread shutdown of glutamine pathways resulting in dramatic metabolic remodeling of the TME but also results in enhanced infiltration and function of immune cells involving both innate and adaptive immunity. This unique mechanism of action suggests DRP-104 may function as a novel metabolic checkpoint inhibitor and supports clinical development of DRP-104 to potentially treat a wide variety of cancers.

References

P818
EGFR Exon-20 insertion-based neoantigen stimulated effective T-cell immunity against non-small cell lung cancer
Jinpu Yu, Dandan Liu
Tianjin Tumor Hospital, Tianjin Shi, China
Correspondence: Jinpu Yu (jinpu_yu@hotmail.com)

Background
Certain Epidermal growth factor receptor (EGFR) mutations are targets of tyrosine kinase inhibitors (TKIs) and predictive biomarkers of clinical response to TKI therapy. However, NSCLC patients with EGFR exon-20 insertions respond poorly to TKI therapy. Considering higher sequence divergence correlated with more immunogenic of neoantigen, we investigated whether EGFR exon-20 insertion-based neoantigen peptide could stimulate effective T-cell immunity against NSCLC.

Methods
The immunogenic T cell epitopes of EGFR exon-20 insertions coding peptide were predicted using multiple public bioinformatic
results off their expression level and major histocompatibility complex (MHC) class I-binding capacity. The most immunogenic EGFR exon-20 insertion-based neoantigen peptides were synthesized to validate its efficacy to induce specific anti-tumor T-cell immunity in vitro.

Results

Ninety-one types of insertions in EGFR exon-20 were identified, among which two types occurred with considerable high mutation frequencies: V769_D770insASV (19.02%) and D770_N771insSVD (19.2%). Both EGFR exon-20 insertions coding peptide displayed higher MHC class I binding score than other insertions, which implied more immunogenicity to induce effective T-cell immunity. Therefore, PBMCs of a NSCLC patient with V769_D770insASV insertion in EGFR was collected and primed with V769_D770insASV coding long peptide (E-ASV) in vitro for 14d, and specific anti-tumor CD8+ T cells were induced and amplified which produced significantly high level of interferon-γ (IFN-γ) upon E-ASV re-stimulation.

Conclusions

E-ASV could induce cytotoxic T lymphocyte (CTL) responses in vitro, and EGFR exon-20 insertion-based neoantigen peptide might become an alternative immunotherapeutic approach for NSCLC.

Acknowledgements

This work was supported by National Natural Science Foundation of China (grant numbers: 81872143, 81702280, 81472473, 81272360) and Key Project of Tianjin Health and Family Planning Commission (16KG126).

P819

Regulation of isatuximab-mediated antibody-dependent cellular cytotoxicity of multiple myeloma cells: Rationale for combining isatuximab with anti-PD-1/anti-TGFβ to enhance anti-myeloma activity

Anlai Wang1, Zhili Song1, Guang Yang1, Rita Greco1, Joachim Theilhaber1, Elvis Shehu1, Beatriz Ospina1, Fangxian Sun1, Yu-Tzu Tai1, Kenneth Anderson, MD2, Chen Zhu2, Marielle Chiron, PhD1, Francisco Adrián3

1Sanofi Oncology Research, Boston, MA, United States; 2Dana-Farber Cancer Institute, Boston, MA, United States; 3Dana-Farber Cancer Institute, Boston, MA, United States

Correspondence: Anlai Wang (anlai.wang@sanofi.com)


Background

CD38 is a transmembrane protein with relatively low expression levels on immune cells and some non-hematological tissues. Under disease conditions, CD38 is expressed in a number of hematological malignancies. In particular, high levels of CD38 expression are found in malignant cells from patients with multiple myeloma (MM) and germinal center B-cell diffuse large B-cell lymphoma (DLBCL) [1,2]. Therefore, eliminating these tumor cells by targeting CD38 is an attractive therapeutic option. Isatuximab is an investigational anti-CD38 monoclonal antibody with promising clinical activity in patients with relapsed/refractory multiple myeloma (RRMM) [3,4]. Antibody-dependent cellular cytotoxicity, mediated by natural killer (NK) cells, is regarded as a key mechanism of isatuximab anti-myeloma activity [5-7]. MM cells are known to suppress NK cells through the production of immunosuppressive cytokines and the induction of checkpoint inhibitor PD-1/PD-L1 expression [8,9].

Methods

To determine potential mechanisms that may affect the efficacy of isatuximab, we conducted in vitro studies using a panel of CD38 expressing MM and DLBCL cell lines, as well as primary MM cells from patients. MM cells were exposed to isatuximab and peripheral blood mononuclear cells (PBMCs) that had been cultured in the presence or absence of the MM cells. The expression of the checkpoint inhibitor PD-1 and PD-L1 was measured at regular intervals in NK cells co-cultured with MM cells. To investigate whether cytokines present in the MM tumor environment could induce PD-L1 expression on MM cells or affect isatuximab antitumor activity we treated MM cell lines with combinations of IL-6, TGFβ1, and IFNα.

Results

PD-1 expression on PBMCs was induced shortly after co-culture with MM cells. The activity of isatuximab-mediated ADCC was decreased in MM cell exposed PBMCs, suggesting that PD-1 expression on NK cells plays a critical role in restricting the functionality of NK cells and isatuximab-mediated ADCC. We also observed decreased cytolytic activity and isatuximab-mediated ADCC against MM cells following NK cell exposure to TGFβ1. PD-1 expression was unaltered by TGFβ1 exposure.

Conclusions

Our observations demonstrate that ADCC is a key mechanism for the antitumor activity of isatuximab and provides a rationale supporting the testing of isatuximab in combination with anti-TGFβ or anti-PD1 antibodies to determine whether isatuximab-mediated killing of CD38-expressing tumor cells is improved.

Acknowledgements

Study funded by Sanofi. Medical writing support provided by Aspire Scientific (Bollington, UK), funded by Sanofi.

References


Other

P820

Analysis of synergy between early-incorporation immunotherapy and extracranial radiotherapy in stage IV non-small cell lung cancer

Corbin Jacobs, MD, Parth Chodavadia, BS, Frances Wang, MS, Joseph Salama, MD, Christopher Kelsey, MD, Jeffrey Clarke, MD, Neal Ready, MD, PhD, Jordan Torok, MD

Duke University, Durham, NC, United States

Correspondence: Jordan Torok (jordan.torok@duke.edu)


Background

Emerging evidence suggests that combining radiotherapy (RT) and immunotherapy (IT) may enhance outcomes for metastatic non-small cell lung cancer (NSCLC) patients. However, there remains limited data on the immunomodulatory effects of extracranial RT. This study examined real-world practice patterns, predictors of survival, and
Comparative effectiveness of extracranial radioimmunotherapy (RT+IT) versus early-incorporation IT alone (defined as receiving IT within 120 days of diagnosis) based on sequencing, irradiated site, and dose-fractionation in patients with metastatic NSCLC.

Methods
Patients diagnosed with stage IV NSCLC between 2004-2016 treated with IT alone or RT+IT were identified in the National Cancer Database. The Cochrane-Armstrong trend test assessed for significant trends in practice patterns over time. OS was analyzed using Cox proportional hazards models and the Kaplan-Meier method. Propensity score matching with respect to diagnosis year, age, race, sex, comorbidity index, insurance status, facility type, histology, organs with metastasis, and chemotherapy receipt was performed to account for baseline imbalances. Biologically effective doses (BED) were stratified based on the median (30 Gy/10 fractions = 39 Gy10), and SBRT was defined as above median BED in ≤5 fractions.

Results
Early-incorporation IT utilization increased from 0.3% in 2010 to 13.2% in 2016 among patients with stage IV NSCLC (p<0.0001). Rates of RT+IT also increased from 38.8% in 2010 to 49.1% in 2016 among those who received IT (p<0.0001). On unadjusted analysis, patients who received RT+IT demonstrated worse OS compared to patients who received IT alone (HR 0.89, p=0.0001). On adjusted analysis, patients who received RT+IT was associated with improved OS (HR 0.86, p=0.0058), treatment at academic facilities (HR 0.83, p=0.0001), and SBRT (HR 0.60, p=0.0009); after propensity-score matched multivariate analysis, patients who received above median BED (excluding SBRT) also showed improved OS (HR 0.85, p=0.0485).

Conclusions
Utilization of RT+IT in metastatic NSCLC is increasing. SBRT+IT was associated with improved OS on multivariate analysis, and RT+IT in propensity-score matched patients receiving ≥39 Gy10 was associated with improved OS on multivariate analysis. There were no significant differences in OS based on RT+IT sequencing or site irradiated. Whether these observations reflect patient selection or possible immunomodulatory benefits of RT is unclear and warrants further study.

Ethics Approval
The Institutional Review Board deemed this study exempt from review given the de-identified nature of the data.

P821
Induction of anti-tumor immune responses in ovarian cancer with c-MET inhibitor Capmatinib
Maureen Drakes, PhD1 Swati Mehrotra, MD1, Ronald Potkul, MD1, MS, Sharon Stack, PhD2, Patrick Siff, MD3
1Loyola University Chicago, Maywood, IL, United States; 2University of Notre Dame, South Bend, IN, United States
Correspondence: Maureen Drakes (mdrakes@luc.edu)

Background
Ovarian cancer is generally asymptomatic until the advanced stages. The majority of patients will eventually die of their disease [1]. Our goal is to investigate novel therapies which can improve this outcome. c-mesenchymal-epithelial transition receptor (c-MET) is a receptor tyrosine kinase which is upregulated in ovarian cancer. The disease promoting properties of c-MET in tumors is primarily due to the overexpression of the wild type gene, and binding to its ligand hepatocyte growth factor (HGF) [2,3]. In our laboratory, we found c-MET expression in 52/54 (96%) ovarian cancer patient sections (28/54; 52% with high expression). c-MET signaling controls tumor growth, invasion, resistance to therapy, the maintenance of cancer stem cells, and immune suppressive pathways, which may all contribute to worsening of ovarian cancer [4,5,6].

Methods
The c-MET/ HGF pathway is often studied in the context of its tumorigenic properties, but the focus of this research was to study its potential to regulate T cell immune responses in ovarian cancer, with the future goal of using this molecule in combination therapy design. We hypothesize that attenuation of the c-MET/ HGF pathway may induce anti-tumor effector T cell immune responses, thereby overcoming underlying immune suppression in ovarian cancer. Ovarian cancer was induced in C57/B16 (H-2Kb) mice by intraperitoneal injection of syngeneic ID8-RFP ovarian tumor cells. We studied the efficacy of a c-MET inhibitor Capmatinib (INCB28060) monotherapy on disease outcome by measuring immune responses in spleen cells.

Results
c-MET Inhibitor Capmatinib treatment of mice resulted in an average ascites volume of 4.34 ml (Figure 1), and vehicle treatment 9.2 ml (>2 fold decrease, n=5/group). The average weight increase was 6.5 mg with Capmatinib treatment, versus 9.8 mg vehicle mice (n=5, p=0.06, borderline significant by t-test). We measured the anti-tumor potential of spleen cells stimulated with anti-CD3 antibody. A higher percent of CD8+ T cells secreted anti-tumor cytotoxic molecule granzyme B from Capmatinib treated mice (62.8%), in comparison with (49.6) vehicle (Table 1). Additionally, in cells of Capmatinib treated mice, 3 of 5 (60%) released greater than 5000 pg/ml granzyme B (Figure 2), compared with only 1 of 5 (20%) from vehicle treated mice.

Conclusions
With these anti-tumor responses, the performance of Capmatinib for ovarian cancer treatment is promising. Pre-clinical studies are ongoing with this inhibitor alone and in combination with anti-programmed death-1(PD-1) antibody for better outcome, and studies are planned to use this treatment with conventional therapy.

References

Ethics Approval
Studies were conducted with the approval of our IACUC board (protocol LU 205167).
Evidence that a germline genetic variant impairs a robust anti-tumor immune response in a substrain of C57BL/6 mice
Jessica Fessler, BS, Vyara Matson, PhD, Thomas Gajewski, MD, PhD
University of Chicago, Chicago, IL, United States
Correspondence:
Thomas Gajewski (tgajewsk@medicine.bsd.uchicago.edu)

Methods
Mice obtained from Envigo, Taconic, and Jackson labs were injected subcutaneously with various C57BL/6-derived cell lines including the melanoma line B16.F10.SIY (B16.SIY) expressing a model antigen to quantify tumor-specific immune response [5]. Tumor growth was measured over time, and T cell responses and phenotyping measured in the spleen and tumor. Fecal 16S rRNA gene amplicon sequencing was performed. Whole-genome sequencing was performed from DNA isolated from bulk mouse splenocytes and aligned to the C57BL/6J genome.

Results
Tumors grew significantly faster in mice purchased from the vendor Envigo compared to mice acquired from either Jackson or Taconic, and showed a significantly impaired antitumor CD8+ T cell response. Manipulation of Envigo microbiota through co-housing with either Taconic or Jackson mice, or oral gavage of fecal material did not influence tumor control suggesting little to no contribution of the microbiota. To determine whether a genetic abnormality unique to Envigo mice may account for their weak anti-tumor immune response, we bred Envigo mice to either Jackson or Taconic mice and studied tumor control in the F1 and F2 generation. We found that both the Envigo-Jackson F1 and Envigo-Taconic F1 uniformly resemble the slower growing Jackson and Taconic tumors. The Envigo-Jackson or the Envigo-Taconic F2 generation, however, showed variable control, following Mendelian inheritance with 25% of the F2 exhibiting Envigo-level fast tumor growth. Using bone marrow chimeras, we found that the inferior Envigo tumor control tracked with the hematopoietic compartment rather than with the host. Whole-genome sequencing revealed Envigo-specific polymorphisms and genetic variants distinct from both Jackson and Taconic mice. Detailed genetic analysis is on-going.

Conclusions
Our results indicate that mice from Envigo likely harbor a germline variant that impairs their anti-tumor immune response. Current work is focused on identifying the variant mediating inferior anti-tumor immunity.

References

The Cancer Moonshot Immuno-Oncology Translational Network
Alan Hutson, PhD , Song Liu, Martin Morgan, Kunle Odunsi, MD, PhD
Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Correspondence: Alan Hutson (alan.hutson@roswellpark.org)

Background
Among the factors that influence response to immunotherapy, germline genetics has been linked to outcome [1,2]. Identifying genetic variants in murine models that influence antitumor immunity may prove important to understanding how germline differences impact immunotherapy efficacy more generally, and could identify novel therapeutic targets.

C57BL/6 mice represent an important model system for in vivo experimentation, but strain-level discrepancies have prompted recent scrutiny. Mice housed under different conditions or from different vendors can harbor distinct commensal communities, resulting in profound phenotypic differences [3,4]. Additionally, genetic drift over decades of breeding at different facilities has led to the designation of “substrains” within the C57BL/6 classification with some genetic differences already defined.

Methods
Mice obtained from Envigo, Taconic, and Jackson labs were injected subcutaneously with various C57BL/6-derived cell lines including the melanoma line B16.F10.SIY (B16.SIY) expressing a model antigen to quantify tumor-specific immune response [5]. Tumor growth was measured over time, and T cell responses and phenotyping measured in the spleen and tumor. Fecal 16S rRNA gene amplicon sequencing was performed. Whole-genome sequencing was performed from DNA isolated from bulk mouse splenocytes and aligned to the C57BL/6J genome.

Results
Tumors grew significantly faster in mice purchased from the vendor Envigo compared to mice acquired from either Jackson or Taconic, and showed a significantly impaired antitumor CD8+ T cell response. Manipulation of Envigo microbiota through co-housing with either Taconic or Jackson mice, or oral gavage of fecal material did not influence tumor control suggesting little to no contribution of the microbiota. To determine whether a genetic abnormality unique to Envigo mice may account for their weak anti-tumor immune response, we bred Envigo mice to either Jackson or Taconic mice and studied tumor control in the F1 and F2 generation. We found that both the Envigo-Jackson F1 and Envigo-Taconic F1 uniformly resemble the slower growing Jackson and Taconic tumors. The Envigo-Jackson or the Envigo-Taconic F2 generation, however, showed variable control, following Mendelian inheritance with 25% of the F2 exhibiting Envigo-level fast tumor growth. Using bone marrow chimeras, we found that the inferior Envigo tumor control tracked with the hematopoietic compartment rather than with the host. Whole-genome sequencing revealed Envigo-specific polymorphisms and genetic variants distinct from both Jackson and Taconic mice. Detailed genetic analysis is on-going.

Conclusions
Our results indicate that mice from Envigo likely harbor a germline variant that impairs their anti-tumor immune response. Current work is focused on identifying the variant mediating inferior anti-tumor immunity.
Background
Immunological destruction of tumors is a multistep, coordinated process that can be targeted at several critical points along the cancer immunity cycle to elicit tumor rejection, and to prevent emergence of cancer. Despite regulatory approval of many immune-based interventions in the past decade, a number of barriers remain to be addressed in order to fully harness the therapeutic potential of the immune system and improve outcomes for cancer patients. In 2016, the Cancer Moonshot Blue Ribbon Panel convened by the NIH recommended to “create a translational science network devoted to immunotherapy” [1].

Methods
The Immuno-Oncology Translational Network (IOTN) was created in 2018 to improve the efficacy, durability, and safety of immunotherapy across the spectrum of human cancers, and develop immunoprevention approaches that will prevent cancers before they occur [2]. The consortium structure of the IOTN will enable rapid translation of basic discoveries to translation and clinical application by fostering highly collaborative team science. The NIH program stewardship of the IOTN is led by a trans-NIH adult immunotherapy implementation team, which provides scientific and programmatic oversight to ensure the IOTN meets the goals defined by the Cancer Moonshot Blue Ribbon Panel.

Results
The IOTN currently consists of 12 research groups spanning immunoprevention, novel therapeutic targets, cell-based therapies, neoantigen and TCR approaches, multimodal therapies, immuno-suppression and immuno-responsiveness. These studies are conducted in diverse tumor types, including brain, breast, colon, liver, lung, oral, ovarian, prostate and skin cancers. These efforts include a Cellular Immunotherapy Data Resource (CIDR) program and a Data Management and Resource-Sharing Center (DMRC). CIDR provides a data registry for collecting outcomes of patients receiving cellular immunotherapies. DMRC provides overall administrative, software development, data analytical and data coordinating support to facilitate research integration across the IOTN, as well as outreach to other Cancer Moonshot initiatives and the larger scientific community. To synergistically tackle scientific gaps that cannot be addressed by individual research projects, the IOTN has formed six working groups: 1) Bioinformatics and Computational Biology, 2) Cancer Antigens, 3) Immune Mechanisms, 4) Immuno-radiotherapy, 5) Immuno-prevention, and 6) Translational and Cellular Therapy. The IOTN will expand in 2019 to include additional immunoprevention and immunotherapy research projects, as well as new initiatives including immunology centers and immune-related adverse events research projects.

Conclusions
The major anticipated deliverable of the IOTN collaborative consortium is the acceleration of clinical translation of basic discoveries to overcome barriers that limit the efficacy of immunotherapy across the spectrum of human cancers.

Acknowledgements
This work is supported by an IOTN Moonshot grant U24CA232979-01.

References
cohort (Figure 2C). Furthermore, increased tumor core CD8+ and CD4+FOXP3+ T cells (CD8highCD4FOXP3high) was an independent predictor for prolonged GC patient survival, regardless of established clinical variables (Figure 2D-E). Gene ontology analysis revealed CD8highCD4FOXP3high GC was strongly associated with an interferon-gamma (INF-γ) gene signature (Figure 3A-B), this INF-γ gene signature was also predictive of better survival in a combined analysis of publicly available GC datasets (Fig 3C), increased GC tumor PDL1 expression (Figure 3D) and has also been predictive of response to anti-PD-1 therapy [2]. Finally, systemic immune system changes were observed in CD8highCD4FOXP3high GC patient tumors, including significantly increased effector and central memory CD4+ T cells, and decreased PDL1+ dendritic cells (Figure 4A-C). Finally, a model depicts primary GC immune context features associated with good vs poor clinical outcome (Figure 4D).

Conclusions
Our study showed a new biomarker (CD8highCD4FOXP3high) in primary GC patients for good clinical outcome, this biomarker was prognostic across all GC molecular sub-groups. Importantly, the biomarker associated gene signature indicates there is potential for immunotherapy strategies in the adjuvant setting to improve GC patient outcomes.

References

Ethics Approval
This study was approved by the Peter MacCallum Cancer Center Human Research Ethics committee, approval number 12/25.

Fig. 2 (abstract P825). CD8+FoxP3CD4 biomarker defines good outcome patients

Fig. 3 (abstract P825). CD8+FoxP3CD4 tumours have a T cell inflamed gene signature
Background
A standard treatment for refractory advanced SCAC has not yet been established; however, preliminary Phase 1b/2 results with PD-1 inhibitors showed promising activity [1, 2]. INCMGA00012 is a humanized IgG4 monoclonal antibody that recognizes human PD-1 and has demonstrated acceptable tolerability with evidence of clinical activity in a Phase 1 study of solid tumors (NCT03059823) [3, 4, 5, 6]. This trial is evaluating the safety and efficacy of INCMGA00012 in patients with locally advanced or metastatic SCAC, including those with well-controlled HIV infection.

Methods
This is a single-arm Phase 2 trial in patients ≥18 years old with disease progression during or following 1 or 2 prior systemic treatments for metastatic SCAC, which must have included a platinum-based treatment. Patients with well-controlled HIV disease are eligible. All patients have measurable disease per RECIST v1.1. Approximately 81 patients will be enrolled. INCMGA00012 is administered as a flat dose at the recommended phase 2 dose (RP2D) of 500 mg Q4W for up to 2 years. The primary endpoint of the study is overall response rate (ORR) according to RECIST v1.1. HIV control will be assessed as an exploratory endpoint.

Results
Results: As of July 22 2019, 32 patients have received at least one dose of INCMGA00012. Median (range) age was 64 (39-81) years. The majority of patients were female (68.8%), white (90.9%), and had ECOG performance status of 0 (28.1%), 1 (68.8%), or 2 (3.1%). Three patients were known to be HIV-positive. Median time on treatment was 2 months (0.14, 10.25). Updated safety and efficacy data will be reported at the meeting.

Conclusions
Conclusions: Immunotherapy holds promise as a treatment for platinum-refractory SCAC. INCMGA00012 is an investigational PD-1 inhibitor with favorable pharmacology that is being developed for SCAC and a wide range of solid tumors. Preliminary results from this large Phase 2 trial will be presented. This trial will provide important clinical data for a rare tumor type with limited treatment options.

Acknowledgements
Clinical trial management was provided by Tristan Richard (Incyte Corporation, Wilmington, DE). Trial Registration
NCT03597295

References

Ethics Approval
The study was approved by institutional review boards or independent ethics committees of participating institutions.

P827
Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers
Rachel Sanborn, MD1, Nashat Carliall, MD2, Mark O’Hara, MD3, Nina Bhawardaj, MD, PhD4, Michael Gordon, MD5, Ralph Hauke, MD6, Rodolfo Bordoni, MD7, Danny Khallil, MD PhD8, Tracey Rawls9, Laura Vitale, BS10, Richard Gedrich11, Thomas Hawthorne12, Tibor Keler, PhD13, Eirc Forsberg, BS14, Lawrence Thomas, PhD15, Michael Yellin, MD16

1 Providence Cancer Institute, Portland, OR, United States; 2 Gabrall Cancer Center, Canton, OH, United States; 3 Hospital of the University of PA, Philadelphia, PA, United States; 4 Icahn School of Medicine at Mount Sinai, New York, NY, United States; 5 HonorHealth Research Institute, Scottsdale, AZ, United States; 6 Nebraska Cancer Specialists, Omaha, NE,
Background

CD40 plays multiple roles in anti-tumor immune responses, including within the tumor microenvironment (TME). Agonist anti-CD40 mAbs have demonstrated anti-tumor activity in pre-clinical and clinical studies. CDX-1140 is a human IgG2 anti-CD40 mAb with unique characteristics selected to achieve optimal agonist activity at doses associated with TME penetration. CDX-1140 may synergize with CDX-301, a dendritic cell growth factor known to increase CD141+ DCs critical for tumor antigen cross-presentation.

Methods

A Phase 1 dose-escalation (DE)/expansion study evaluating safety, PK, PD, and clinical activity of CDX-1140 monotherapy (advanced solid tumors/NHL) and in combination with CDX-301 (advanced solid tumors) (NCT03329950). DE evaluates CDX-1140 0.01-3.0 mg/kg (monotherapy) and 0.09-3.0 mg/kg (combination) Q4W. In combination DE, CDX-301 75 mcg/kg sc daily x 5 is given prior to the first two CDX-1140 infusions. Biomarker assessments include characterizing effects on peripheral blood immune cells and cytokines and on the TME in paired tumor biopsies. Backfill and/or expansion cohorts will further explore the activity of monotherapy and combination.

Results

CDX-1140 monotherapy DE through 3.0 mg/kg across 10 tumor types (n=32; 30 solid tumor/2 NHL) is complete without reaching a MTD. Treatment related AEs (>20%) were arthralgia, nausea and fatigue. Transient and mostly low-grade increases in liver transaminases were seen in some patients. Treatment-related SAEs in ≥ 1 monotherapy patient included: fatigue (n=2; both grade 3), cytokine release syndrome (n=2; grade 2 and 3), pneumonitis (n=2; both grade 3), nausea (n=1; grade 3) and pyrexia (n=1; grade 1). CDX-1140 exposure increased with dose (T1/2 ranged from 0.4-3.0 days). Serum cytokine increases and changes in peripheral immune cells demonstrated immune activation consistent with CD40 agonism. Of the clinically evaluable monotherapy patients (n=24), four had SD lasting up to 5.4 months.

In combination, 14 patients have been dosed through 0.72 mg/kg of CDX-1140 and DE is ongoing. Treatment related AEs (>20%) have been myalgia and fatigue; with no treatment related SAEs. Enhancement of some serum cytokine levels, e.g., IL-12p40, compared to CDX-1140 monotherapy, was observed. A patient with gastrointestinal cancer treated in combination (CDX-1140 0.36 mg/kg) has an unconfirmed PR, with 41% reduction in target lesions (liver and lymph node).

Conclusions

To date, CDX-1140 has shown the expected PK, PD, and safety profile up to 3 mg/kg. Combination with CDX-301 has been well tolerated, with evidence of enhanced biological and clinical activity. Analyses are planned to explore the treatment effects on the TME. Additional combinations, including with checkpoint blockade, are planned.

Trial Registration

NCT03329950

Ethics Approval

The study was approved by the following IRBs: Providence Health and Services (Oregon) (#2017000532), WIRB for Gabrail Cancer Center Research (#1188814), University of Pennsylvania (# 828733), Mount Sinai School of Medicine (#18-00206), WIRB for Honor Health (#1180854), WIRB for Nebraska Cancer Specialist (#1189918), WIRB for North Side Hospital (#1249506), Memorial Sloan Kettering Cancer Center (#18-225A2)[1].
Results

We found that TLS localized within the tumor area (TLS-AT) are predictive of a longer disease free survival in N0 NSCLC patients, whereas the presence of peritumoral TLS (TLS-PT) does not associate with the patient survival, but with higher tumor grade. TLS-AT presence is significantly correlated with hMENA11a expression in tumor cells, whereas the presence of TLS-PT correlates with the absence of hMENA11a. We evidenced that a low level of stromal FN along with the expression of hMENA11a, associated with TLS-AT. Searching for the mechanisms involved, we found that the hMENA11a knock out in NSCLC cells modulates the expression of several genes: down-regulates the TLS regulator LTβR and up-regulates FN1. Finally, we found that the depletion hMENA11a in the H1650 NSCLC cells reduces the formation of the chemokine CXC-chemokine ligand 13 (CXL13) a critical cytokine induced after LTβR-LTβR signalling [5] [6].

Conclusions

Our findings indicate that the alternative splicing of hMENA is crucial in the reciprocal signaling between tumor cells and their immune microenvironment, by participating in tertiary lymphoid structure neo-genesis and spatial distribution.

Acknowledgements

This work is supported by AIRC.

References


Ethics Approval

This study was approved by the ‘Comitato Etico Centrale IRCCS Lazio’; approval number: ifo_058.IFO_ADO.REGISTRO UFFICIALE.U.0012817 20-11-2017

P829

The pattern of expression of hMENA isoforms impacts tumor immune microenvironment of early node-negative non-small cell lung cancer

Sheila Spada, PhD, Francesca Di Modugno, PhD, Anna Di Carlo, Isabella Spreduti, Enzo Gallo, Mariangela Panetta, Belinda Palermo, Francesca De Nicola, Lorenzo D’Ambrosio, Barbara Antoniani, Paola Trono, Francesco Facciolo, Paola Visca, Paola Nisticò*, MD
Regina Elena National Cancer Institute, Rome, Italy
Correspondence: Paola Nisticò* (paola.nistico@ifo.gov.it)

Background

Actin cytoskeleton dynamics act as platforms for gene regulation and key signaling transduction pathways involved in the cross-talk among tumor cells and cellular and non-cellular components of the tumor microenvironment (TME). The actin regulatory protein hMENA undergoes tissue specific splicing, generating two alternatively expressed isoforms hMENA11a and hMENA11a/s that respectively inhibit or increase cell invasiveness [1]. TGFβ [2] and β1 integrin signalling and the secretion of several key extracellular matrix (ECM) proteins [3] and is crucial in TGFβ mediated-EMT [2]. Early node-negative NSCLC patients show a prolonged disease-free survival when expressing high tumor hMENA11a/low stromal FN1[3]. Recently, tertiary Lymphoid Structures (TLS), sites of transient lymphoid neo-genesis and determinants of antitumor immunity, have been associated with a favorable clinical outcome in NSCLC patients [4].

Methods

The pattern of hMENA isoform expression, TLS presence and localization and stromal fibroblastin were evaluated in 94 primary tumors of node negative NSCLC patients by immunohistochemistry. We evaluated the role of hMENA isoform expression on lymphotxin beta receptor (LTBR), by gain and loss of function, RNA-SEQ and QRT-PCR.

Conclusions

We confirmed the low incidence of severe CRS reported by investigators and regrouped cytokine-mediated AEs under the umbrella of CRS. Without mandatory corticosteroid pre-treatment, CRS was generally low grade, reversible with standard management including IVF and short course corticosteroids, decreased in frequency and severity after initial doses and infrequently led to discontinuation. Patients with higher grade CRS tended to have greater increases in serum cytokines.

Trial Registration

NCT01211262

References


Ethics Approval

This study was approved by following institutions’ Ethics Boards: Oxfordshire Research Ethics Committee; 10/WMEAD/237, Approved on October 24, 2012.


P830

Optimization of RG1-VLP vaccine performance in mice with novelTLR4 agonist-based adjuvants

Jason Marshall, PhD , Athina Zacharia, PhD
Leidos, Inc., Frederick, MD, United States
Correspondence: Jason Marshall (jason.marshall2@nih.gov)

Background

We are testing in vitro 2 candidate vaccine adjuvants (lipid A structures) that are generated by using bacterial enzymatic combinatorial chemistry (BECCH). We have selected two BECC compounds (438 and 470) designed by Dr. Bob Ernst at the University of Maryland, Baltimore to be used as adjuvants to the RG1-VLP vaccine for the
prevention of human papillomavirus (HPV) infection and associated cancers. Advancement of the RG1-VLP vaccine formulated with aluminum hydroxide and the BECC compounds could result in a more effective HPV vaccine that induces more robust and longer-lasting protection, increases HPV strain-specific coverage, allows fewer injections and decreases manufacturing costs.

Methods
Mice were vaccinated 3X IM with 2 ug RG1-VLP + 25 ug of BECC438 or BECC470 formulated +/- Alhydrogel (alum) and compared to alum alone or PHD, a commercial TL4RAL HPVI6 L1 subunit and RG1 L2 epitope-specific Ab titters were measured in the sera by ELISA. Neutralizing Ab titters were measured using a cell-based assay in which antisera from vaccinated mice were used to inhibit in vitro infection of LoVo-T cells with HPV pseudovirions expressing alkaline phosphatase.

In study 2, blood was collected at earlier time points to determine if the addition of BECC compounds induced significant humoral immunity at earlier time points. After 3X IM vaccinations with RG1-VLPs + alum or alum/BECC, spleens were harvested and HPVI6 L1 VLP-specific IFN-g ELISPOT was performed on splenocytes.

Results
BECC compounds improve HPV16-L2-specific Ab production in mice
BECC compounds improve neutralizing Ab production to several HPV strains
BECC compounds accelerate anti-HPV humoral responses
BECC compounds accelerate appearance of HPV-neutralizing Abs
Induction of T cell responses by BECC

Conclusions
Combining the adjuvants Alhydrogel and BECC compounds increases the magnitudes of antibodies specific to HPVI6 L1 and the RG1-specific L2 epitope as well as of neutralizing titters to HPVI6/18/39/6. BECC470 outperforms BECC438 as well as standard TL4R4 agonists PHAD and 3D-PHAD to augment anti-HPV humoral responses in several key assays.

BECC470 accelerates the appearance of L1 and L2 antibody levels after 2 vaccinations to equal or exceed levels achieved by Alhydrogel alone after 3 vaccinations.

The presence of BECC470 also induces a substantial T cell response specific to HPVI6 L1 VLPs that is absent with Alhydrogel alone.

Adjuvant optimization of the RG1-VLP vaccine with TL4R4 agonist BECC compounds may lead to VLP dose sparing and an accelerated schedule, resulting in enhanced protective immunity while saving time and cost of goods.

Regulatory, Financial, and Access Considerations

P831
Inclusion of people living with HIV in anti-PD(L)1 clinical trials: Results of an NCI-driven initiative to broaden eligibility in clinical trial development
Joshua Reus, MD, Diana Stern, MD, Ramya Ramaswamy, KP, Kathyn Luain, MD, Helen Chen, MD, Howard Streicher, MD, Raviem Kem, RPh, Pharm D, MPH, Richard Little, MD, Elad Sharon, MD, MPH, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Creating New Haven Health System, Bridgeport, CT, United States; 1NIH/NCI, Bethesda, MD, United States

Correspondence: Elad Sharon (sharone@mail.nih.gov)

Background
Certain cancers occur at higher rates in people living with HIV (PLWH) as compared with the general population and are a leading cause of mortality among PLWH in developed countries [1]. Anti-programmed death (ligand) 1 (PD-(L)1) therapies are approved to treat cancers that affect PLWH, however HIV is a common exclusion criterion in clinical trials. Collaborative efforts by multiple professional groups have led to recently published guidelines on modernizing clinical trial eligibility to include PLWH [2,3]. In 2007 the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) began efforts to include PLWH in clinical trials culminating with changes to its formal protocol templates in early 2018. We reviewed CTEP approved final protocols for anti-PD(L)1 agents and compared HIV-specific eligibility criteria in the initial letter of intent (LOI) with the final protocol to evaluate the effectiveness of CTEP policy to include PLWH in immunotherapy clinical trials.

Methods
LOIs including anti-PD(L)1 agents (nivolumab, pembrolizumab, atezolizumab, durvalumab) submitted to CTEP with study approval between January 2014 and May 2018 were included in this analysis. Only LOIs approved for protocol development that proceeded to final activated clinical trials were included. Studies designed specifically for PLWH were excluded. We compared the frequency of PLWH inclusion at initial LOI submission and final approved protocol.

Results
Eighty-seven studies were included in this analysis; 39 included nivolumab, 23 pembrolizumab, 19 atezolizumab, and 6 durvalumab. Sixty-eight trials were pilot, phase I, phase II/III, or phase II. Nineteen studies were phase II/III or III. At the LOI-stage, 14 of 87 proposals (16%) included PLWH. Eleven of 68 pilot/II/III LOIs (16%) and 3 of 19 phase II/III or III LOIs (16%) included PLWH. After CTEP policy intervention, 61 of 87 final approved protocols (70%) included PLWH. Forty-seven of 68 pilot/II/III protocols (69%) and 14 of 19 phase II/III or III protocols (74%) included PLWH. Also, of 36 LOIs that initially excluded PLWH, 24 (67%) included PLWH in their final approved protocols.

Conclusions
CTEP advocacy had a meaningful impact on inclusion of PLWH in anti-PD(L)1 clinical trials independent of study phase. These data demonstrate that collaborative efforts lead to inclusion of underrepresented populations in clinical trials and suggest interventions for other underrepresented populations including patients with other chronic viral infections, brain metastases, and end-organ dysfunction can be effective. These data also demonstrate that efforts to include PLWH have not yet reached parity with other comorbid conditions, such as diabetes or heart disease.

References

P832
Systematic literature review (SLR) of intravenously (IV) administered oncology therapies for which a subcutaneous (SC) formulation has also been developed
Brad Schenkel, MSC, Elize Wu, Ali McBride, Marilia Hernani, Robin Wyn, Klaudia Komatska, Bristol Myers-Squibb, Lawrence Township, NJ, United States; 2The University of Arizona Cancer Center, Tucson, AZ, United States; 3Adelphi Values PROVE, Bollington, United Kingdom
Correspondence: Brad Schenkel (Brad.Schenkel@bms.com)

Background
SC administration of immuno-oncology (I-O) therapies is being explored as a less-invasive and more-convenient alternative to IV administration. However, further research is needed to fully understand the additional benefits that the SC route can offer. This review aimed to evaluate comparative data on the efficacy, safety, and
pharmacokinetics/pharmacodynamics (PK/PD) of these two administration methods in oncology, along with differences in time requirements, costs, and patient reported outcomes.

**Methods**

Literature published from 2009–2019 was identified through OVID-indexed databases and supplemented with conference proceedings, recursive searching, and additional clinicaltrials.gov searches. Studies of any design that provided comparative data between IV and SC formulations on the following outcomes were included: efficacy, safety, PK/PD, HRQoL, time savings, adherence, persistence, preference, satisfaction, and cost. This SLR focused on the following anti-cancer therapies, for which both IV and SC formulations are either being developed in phase 3 clinical trials or are approved by either the FDA or EMA: alectuzumab, atezolizumab, blinatumomab, bortezomib, daratumumab, pem-brolizumab, pertuzumab, rituximab, and trastuzumab.

**Results**

A total of 100 publications met the inclusion criteria. Most publications reported on trastuzumab (38), rituximub (26), or bortezomib (25); fewer publications reported on alectuzumab (3), daratumumab (3), rituximab/trastuzumab (4), and alectuzumub/rituximab/trastuzumab (1). In 48 publications, SC had non-inferior efficacy relative to IV formulations; statistically significant differences were reported in only 3 publications. The relative tolerability of SC and IV formulations was also similar across 68 publications. However, in 9 publications, SC trastuzumab and rituximab appeared to be associated with higher incidence of (mostly low-grade) injection-site reactions compared to IV infusion. When pharmacokinetic outcomes were reported, overall systemic exposure to therapy was similar between formulations. SC administration was also associated with time savings, based on 39 publications, with reduced health-care professional (HCP) time and patient chair time being major factors. In combination with other factors, such as reduced drug wastage, this led to overall cost savings with SC administration. In 33 publications that considered preference, SC formulations were associated with higher treatment satisfaction and were preferred by patients and HCPs. Data on HRQoL, however, were rarely reported.

**Conclusions**

Our SLR suggests that SC and IV formulations had generally similar efficacy and tolerability profiles, while SC administration led to substantial cost and time savings and was usually preferred by patients and HCPs. Therefore, SC I-O therapy presents several advantages over IV, and switching from IV to SC administration could be beneficial from multiple stakeholder perspectives.

### Timing of ImmunoTherapy Administration

**P833**

Timing of IL-2 treatment delivery after transplantation of B16 melanoma in a murine model differentially influences tumour growth

Suzanne Edwards, BSc, Brendon Coventry, MD PhD

University of Adelaide, Adelaide, SA, Australia

**Correspondence:** Brendon Coventry (brendon.coventry@adelaide.edu.au)

*Journal for ImmunoTherapy of Cancer* 2019, 7(Suppl 1):P833

**Background**

The immune system is a dynamic homeostatic entity which fluctuates in response to antigenic stimulation but provides overall stability, with the capacity to generate an active immune response when required. The nature of this fluctuation is currently poorly understood, but there is significant ramifications for when antigen is delivered for vaccination, or when other immunomodulatory agents are administered to influence immune system function. Immune reactivity usually commences at first exposure to antigen, including first exposure to tumour antigens. We aimed to investigate whether there was any difference on tumour growth compared with controls according to when Interleukin-2 (IL-2) was administered after tumour transplantation (Day 0).

**Methods**

B16 F0 melanoma was transplanted into C57BL/6 mice and a peritumoural dose of 20,000 IU of IL-2 (or PBS vehicle control) was given on different days after transplantation to observe for any effect on tumour growth determined by the timing of the day of dose delivery. IL-2 or PBS control treatments were administered to comparator groups on days 4, 5, 6, 7, 8, 9 and 10, and again on day 14 after the day of transplantation (Day 0). A linear mixed-effects model compared ‘tumour size’ (logarithmic transformation) versus interaction of Day (categorical version) and control/treatment group, controlling for repeated measurements over time.

**Results**

IL-2 exerted a repeatable effect observed only on Day-7 after transplantation causing statistically significant reduced tumour growth over comparable control (PBS) treated animals. Control untreated tumours were over double the size of tumours treated with IL-2 administered at Day-7. The extent of this effect was not obtainable for IL-2 injection administered under identical conditions but on other days either before or after Day-7 after transplantation, indicating that a potential ‘window of sensitivity’ to immunotherapy treatment might exist.

**Conclusions**

There appears to be a differential in-vivo effect on control of tumour growth depending on the day of delivery of IL-2 after transplantation and first antigen exposure. This unusual timing effect requires further study and might have important implications for the timing of therapy delivery and could explain some of the differential variable effects observed with human immunotherapies.

### Tumor and Stromal Cell Biology

**P834**

The actin regulatory protein hMENA is a key player in the paracrine TGF-β-mediated crosstalk between tumor cells and cancer associated fibroblasts

Roberta Melchioni1, Paola Trono1, Francesca Di Modugno, PhD1, Anna Di Carlo1, Sheila Spada, PhD1, Giuliana Falacca1, Isabella Spereduto1, Barbara Antoniani1, Daniel D’Andrea1, Paolo Visca1, Gian Luca Grazi1, Francesco Facciolo1, Aldo Scarpa2, Paola Nistico’, MD1

1Regina Elena National Cancer Institute, Rome, Italy; 2Imperial College London, London, United Kingdom; 3ARC-NET University of Verona, Verona, Italy

**Correspondence:** Paola Nistic’ (paola.nistico@ifo.gov.it)

*Journal for ImmunoTherapy of Cancer* 2019, 7(Suppl 1):P834

**Background**

The bi-directional communication mediated by paracrine loop between cancer cells and cancer associate fibroblasts (CAFs) critically affects tumor growth and aggressiveness. TGF-β is a key regulator of epithelial mesenchymal transition (EMT), an inducer of CAF activation and extracellular matrix (ECM) production, suggesting its mechanistic role in cancer cell-CAF crosstalk. Recently, stromal-TGFβ signaling has been associated with T cell exclusion and poor response to immune checkpoint PD-1/PD-L1 blockade, suggesting the relevance of identifying stromal-derived TGF-β mediated pathways [1,2].

The actin regulatory protein hMENA has been implicated in the metastatic progression of several human cancers. Our group identified two tissue specific splicing-derived isoforms, the epithelial hMENAα1α1 and mesenchymal hMENAα2Δv6 [3]. The expression of hMENAΔv6, along with the lack of hMENAα1α1, is crucial for TGFβ-mediated EMT [4], and the pattern of hMENA isoform expression represents a prognostic factors in PDAC and early stage NSCLC patients [4,5,6].

We have recently identified a role for hMENA/hMENAα2Δv6 in CAF activation and function and herein, we aimed at identifying their role in the TGFβ-mediated crosstalk between cancer cells and CAFs in NSCLC and PDAC.

**Methods**

The role of hMENA isoforms in TGF-β-CAF activation was analyzed by loss and gain of function experiments. To analyze hMENA-driven
regulation of TGF-β ligands (TGF-β1, TGF-β2, and TGF-β3) we employed the Bio-Plex Pro™.

To study the role of hMENA expression in CAFs on cancer cell signaling pathway activation, we cultured cell lines with shhMENA-CAF-conditioned media and analyzed their effect on the phosphorylation of AKT, ERK, STAT1/3 by immunoblotting.

Results
We found that hMENA/hMENAΔv6 overexpression identify a subset of CAFs with pro-tumoral functions in NSCLC and PDAC. hMENA/hMENAΔv6 silencing in CAFs downregulated the expression of TGF-β1 and 2, inhibited the TGF-β signaling activation, in turn impairing the autocrine TGF-β-mediated CAF activation and functions.

Moreover, hMENA silencing in NSCLC cells specifically regulates the expression and secretion of TGF-β in turn impairing the autocrine TGF-β-mediated signaling pathways also in view of the new advance of CAF-TGF-β signaling mediated by tumor cell secretoma.

Conclusions
In conclusion these novel findings provide the evidence for a crucial role of hMENA and its tissue specific splicing program as regulator of TGF-β-mediated cross-talk between tumor cells and CAFs. We highlight the importance of inhibiting hMENA-mediated signaling pathways also in view of the new advance of combined immunotherapy and TGF-β inhibitors in the clinical practice.

Acknowledgements
This supported by AIRC (IG 19822) and AIRC 5x1000 (P609).

References
2. Di Modugno F, Iapicca P, Boudreau A, Mottolese M, Terrenato I, Perracchio L, Carstens RP. hMENA Δv6 silencing in CAFs downregulated the expression and secretion of TGF-β and impaired the activation of CAF-TGF-β signaling mediated by tumor cell secretoma.

Conclusions
In conclusion these novel findings provide the evidence for a crucial role of hMENA and its tissue specific splicing program as regulator of TGF-β-mediated cross-talk between tumor cells and CAFs. We highlight the importance of inhibiting hMENA-mediated signaling pathways also in view of the new advance of combined immunotherapy and TGF-β inhibitors in the clinical practice.

Acknowledgements
This supported by AIRC (IG 19822) and AIRC 5x1000 (P609).

References
2. Di Modugno F, Iapicca P, Boudreau A, Mottolese M, Terrenato I, Perracchio L, Carstens RP. hMENA Δv6 silencing in CAFs downregulated the expression and secretion of TGF-β and impaired the activation of CAF-TGF-β signaling mediated by tumor cell secretoma.

Conclusions
In conclusion these novel findings provide the evidence for a crucial role of hMENA and its tissue specific splicing program as regulator of TGF-β-mediated cross-talk between tumor cells and CAFs. We highlight the importance of inhibiting hMENA-mediated signaling pathways also in view of the new advance of combined immunotherapy and TGF-β inhibitors in the clinical practice.

Acknowledgements
This supported by AIRC (IG 19822) and AIRC 5x1000 (P609).

References
2. Di Modugno F, Iapicca P, Boudreau A, Mottolese M, Terrenato I, Perracchio L, Carstens RP. hMENA Δv6 silencing in CAFs downregulated the expression and secretion of TGF-β and impaired the activation of CAF-TGF-β signaling mediated by tumor cell secretoma.

Conclusions
In conclusion these novel findings provide the evidence for a crucial role of hMENA and its tissue specific splicing program as regulator of TGF-β-mediated cross-talk between tumor cells and CAFs. We highlight the importance of inhibiting hMENA-mediated signaling pathways also in view of the new advance of combined immunotherapy and TGF-β inhibitors in the clinical practice.

Acknowledgements
This supported by AIRC (IG 19822) and AIRC 5x1000 (P609).

References
2. Di Modugno F, Iapicca P, Boudreau A, Mottolese M, Terrenato I, Perracchio L, Carstens RP. hMENA Δv6 silencing in CAFs downregulated the expression and secretion of TGF-β and impaired the activation of CAF-TGF-β signaling mediated by tumor cell secretoma.

Conclusions
In conclusion these novel findings provide the evidence for a crucial role of hMENA and its tissue specific splicing program as regulator of TGF-β-mediated cross-talk between tumor cells and CAFs. We highlight the importance of inhibiting hMENA-mediated signaling pathways also in view of the new advance of combined immunotherapy and TGF-β inhibitors in the clinical practice.

Acknowledgements
This supported by AIRC (IG 19822) and AIRC 5x1000 (P609).

References
The study was approved by Animal Care research Ethics Committee, NUI. 

**References**


**Ethics Approval**

The study was approved by Animal Care research Ethics Committee, NUI Galway.

---

**P836**

Immunopathological properties of the fibroblastic niche for cancer stem cells and the niche-targeted immunotherapy

Toshihiko Torigoe, MD, PhD, Yoshihiko Hirohashi, MD, PhD
Sapporo Medical University, Sapporo, Japan

**Correspondence:** Toshihiko Torigoe (torigoe@sappmed.ac.jp)

**Journal for ImmunoTherapy of Cancer** 2019; 7(Suppl 1):P836

**Background**

Cancer stem-like cells (CSCs) are a small subpopulation of cancer cells that have unique characteristics such as tumor-initiating capacity and cellular stress tolerance. These cells have a huge impact on the field of cancer therapy since they are resistant to standard chemoradiotherapy and responsible for disease recurrence [1, 2].

**Methods**

We have studied the immunopathological properties of CSCs derived from colon, breast, and gynecological cancers to develop CSC-targeted immunotherapy. The following characteristics were revealed in the present study.

**Results**

1. **CSC-specific antigens:** CSCs expressed several germ cell-specific genes, and some of them had crucial roles in the maintenance of tumor initiation capacity. Importantly, they were highly immunogenic since antigen-specific cytotoxic T-cells (CTLs) were efficiently induced from peripheral blood lymphocytes. The CTLs exerted specific cytotoxicity against CSCs. Adoptive transfer of the CTLs efficiently protected tumor growth in mouse models.

2. **Fibroblastic niche for CSCs:** CSCs recruited fibroblasts, which enhanced the tumor initiation capacity and immune resistance of CSCs. Gene expression analysis revealed that fibroblast growth factor 4 (FGF4) and FGF2, a receptor for FGF4 were involved in the fibroblastic niche of CSCs. siRNA-mediated knockdown of FGFR2 abrogated the pro-tumorigenic character of the fibroblasts.

3. **Innate immune resistance of CSCs:** Some CSCs constitutively expressed PD-L1 on the cell surface through the activation of PI3K/AKT signaling.

**Conclusions**

Based on these unique properties of CSCs, we propose a niche-targeted combination immunotherapy for cancer.

**References**


---

**P837**

Roles of nitric oxide synthase and cyclooxygenase inhibition in potentiating immune response in murine models of 4T1 mammary tumor

Veena Somasundaram, PhD, Anne Gilmore, Debashree Basudhar, Erika Palmenteri, David Scheiblin, William Heinz, Robert Cheng, Lisa Ridnour, PhD, Stephen Lockett, Daniel McVicar, PhD, David Wink
National Cancer Institute, NIH, Frederick, MD, United States

**Correspondence:** David Wink (wink@mail.nih.gov)

**Journal for ImmunoTherapy of Cancer** 2019; 7(Suppl 1):P837

**Background**

Anticancer versus protumor behavior of tumor microenvironment (TME) largely depends on tumor cell-macrophage interactions which are regulated by nitric oxide (NO) in mouse models as well as patients. NO induces diverse effects in cancer cells and TME based on its localized flux. High expression of inducible nitric oxide synthase (NOS2) and co-expression with high cyclooxygenase 2 (COX2) is associated with poor prognosis in ER- breast cancer patients and pharmacological inhibition of these two proteins reduces primary tumor growth in nude mouse tumor models [1, 2]. However, the role of the immune system in this effect is largely unknown. As tumors are nutrient deprived, we hypothesized that NO flux dependent metabolic changes in TME could determine the outcome of the tumor-immune system crosstalk.

**Methods**

4T1 mammary tumor model in wild type (wt) and Nos2 knockout (Nos2-/-) BALB/c mice was utilized to study the effects of host Nos2 and Cox2 on tumorigenesis and pulmonary metastasis. Bone marrow derived macrophages (BMDMs) from wt and Nos2-/- mice were stimulated with cytokines to produce low, medium and high NO flux and effects on metabolism were studied using Seahorse bioanalyzer and microscopy. Effects of varying NO flux on local oxygen tension (pO2) was analyzed using a novel, in vitro chamber system that forms cell-generated hypoxic and metabolic gradients by restricting the diffusive exchange of oxygen and metabolites to a monolayer of cells–analogous to diffusion between capillaries and nearby tissue.

**Results**

Absence of Nos2 in the immune system reduces pulmonary metastasis while pharmacological inhibition of Cox2 delays tumor growth preferentially in Nos2-/- mice. High NO flux delayed onset of hypoxia and improved local pO2. Nos2high cells harbored depolarized mitochondria and were Cox2low. Also, Nos2 and Cox2 expression in 4T1 mouse tumors was spatially distinct, and paracrine Nos2/Cox2 regulation by prostaglandin E2 (Cox2 product) and NO, respectively modulated inflammatory status and treatment response.

**Conclusions**

High levels of NO such as those from inflammatory murine macrophages regulate several effects in neighboring cells due to a cumulative effect of the metabolic changes occurring in Nos2high single cells through localized extracellular NO flux. Maintenance of higher levels of NO requires Nos2 and Cox2, which are spatially separated in cultured cells and tumor tissues. Importantly, while Cox inhibition reduces primary tumor volume, Nos2 inhibition reduces lung metastasis suggesting that the spatial localization of Nos2 and Cox2 may provide diagnostic and therapeutic options for targeting these aggressive cell niches.

**Acknowledgements**

This work was supported by the NIH Intramural Research Programs Cancer and Inflammation Program, Optical Microscopy and Image Analysis Laboratory and the NIH Post-Baccalaureate Intramural Research Training Award Program at the National Cancer Institute. This project was funded in whole or in part with Federal funds from the National Cancer Institute, NIH, under Contract HHSN26120080001E.
P838
Disrupting hypoxic tumor niches to sensitize pancreatic cancer to immunotherapy
Arthur Liu, BS, Michael Curran, PhD
The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Correspondence: Michael Curran (MCurran@mdanderson.org)

Background
Despite the clinical success of immune checkpoint blockade therapy in providing durable responses in advanced cancers such as melanoma, its use as a monotherapy in patients with pancreatic cancer has shown little efficacy [1]. We have previously shown that hypoxia in the tumor microenvironment acts as a major barrier to host immunity, and that the hypoxia-activated prodrug TH-302 (Evofosfamide) potentiates CTLA-4/PD-1 blockade therapy [2]. Mechanistically, TH-302 decreased tumor hypoxia and increased accumulation of CD31+ endothelial cells, suggestive of improved oxygen supply and normalization of tumor vasculature. While TH-302 initiates a cellular remodeling process that diminishes tumor hypoxia, it remains unclear to what extent this involves alterations in tumor angiogenesis directly versus indirectly, and thus whether hypoxia reduction could be improved through concurrent anti-angiogenic therapy.

Methods
We utilized TH-302 and a vascular endothelial growth factor receptor-2 (VEGFR-2) blocking antibody (DC101) to assess the relationship between blockade of angiogenesis and the hypoxia reduction activity of TH-302. Using an orthotopic, transplantable model of pancreatic cancer, we investigated the use of DC101 and TH-302 to impact tumor hypoxia, vessel normalization, and infiltration of CD8+ T cells.

Results
We found that orthotopic transplanted pancreatic tumors contain hypoxic tumor niches that lack T cell infiltration. High-dose DC101 (40mg/kg) in combination with TH-302 (50mg/kg) significantly increased the frequency of tumor infiltrating CD8+ T cells relative to mice treated with TH-302 alone. Preliminary data suggests that compared to low-dose DC101 (10mg/kg), the combination of 40mg/kg DC101 and TH-302 increases the percentage of hypoxia-exposed CD8+ T cells and is associated with expansion of intercellular adhesion molecule 1 (ICAM-1)+ expressing CD31+ cells. Additionally, combination DC101 and TH-302 promote major histocompatibility complex (MHC)-II presentation and simultaneously reduces programmed death-ligand 2 (PD-L2) expressing endothelium.

Conclusions
We found that the combination of DC101 and TH-302 promotes infiltration of CD8+ T cells. This is in part associated with re-activation of tumor endothelium to a pro-inflammatory state favoring T cell adhesion and extravasation. These results indicate that combining TH-302 mediated tissue remodeling with VEGFR-2 blockade can enhance both reduction of hypoxia and induction of tumor immunity in a refractory model of pancreatic cancer.

References
Background
The recent success of immunotherapeutic approaches has demonstrated that the immune system plays a critical role in fighting cancer. Syngeneic mouse tumor models retain intact immune systems and therefore are particularly relevant for studying immunologically based targeted therapies, either alone or in combination with other drugs. Although developed decades ago, the immunologic and molecular characteristics of syngeneic mouse tumor models and their microenvironment have been poorly investigated. In this work, we set out to characterize a panel of commonly used murine syngeneic tumor models covering all the major cancers in order to investigate the correlations between different parameters and improve preclinical model selection for target validation and drug development.

Methods
We are currently characterizing 5 syngeneic tumor models in C57BL/6 mice (B16, LL2, PAN02, EO771, MC38) and their microenvironment by flow cytometry and RNA sequencing. For flow cytometry analysis we use antibody panels to identify various myeloid and lymphoid cells and a panel to characterize the composition of other tumor associated cells such as cancer associated fibroblasts (CAFs) and endothelial cells. Furthermore, we monitor tumor sizes and measure the relative physical stiffness of tumor tissues by shear rheology. Lastly, we sort CAFs and perform RNA sequencing.

Results
The flow cytometry analysis revealed striking differences across the different models, especially in relation to the ratio of CD45+ cells within the tumor. Models such as B16F10 and EO771 displayed particularly low immune infiltration levels while, in contrast, we have found that the PAN02 model has a significantly higher level of CD45+ cells compared to all the other models. The MC38 and LL2 models displayed intermediate levels of immune infiltration but are associated with increased levels of myeloid immunosuppressor cells such as mMDSC. Furthermore, we have focused our attention on the extracellular matrix components and found positive correlation between the percentage of CAFs and the relative physical stiffness of tumor tissues for models such as EO771 and PAN02. Ongoing RNA-seq analysis of the tumors and CAFs will hopefully provide significant insights in the biology of these tumors and their microenvironment.

Conclusions
Thus far, we can conclude that the characterization of syngeneic tumor models and their microenvironment reflects the immunologic diversity observed in the clinic and provides a resource to select relevant models to study and test the efficacy of immunotherapies in vivo.

Results
NCG mice remain humanized up to 34 weeks post-engraftment. Over time the mean CD45+ levels in PB can reach 83.67%, whereas on average between 1.85-14.22% of single live cells were residual mCD45+ leukocytes. Circulating human lymphocyte subsets (total T, CD4, CD8, DP, B, NK, (NK/T, CD30) could be quantified in PB at Days 92, 124, 180 and 236 post-engraftment. Study survival rate was 100% up to Day 226 with 63% surviving up to Day 250. Current studies are ongoing to monitor CD34+ donor variability. Of note, at Days 124 and 180 the average proportion of mature B-cells was lower compared to other subsets and time points. Individual mice (n=4) suspected of graft-versus-host disease (GVHD) showed increased CD30 expression on T-cells and higher CD4:CD8 ratios, when compared to non-GVHD mice (n=7), coupled with changes in clinical signs. Bone marrow, PB, spleen, liver and lung tissues were collected at Days 166 (n=3) and 223 (n=3) post-engraftment. Phenotyping by flow cytometry defined human immune cells in each tissue compartment that retained the ability to differentiate into common lymphoid (total and proliferating T, CD4, CD8, Treg) and myeloid populations (CD11b, DC, M1, M2 macrophages). Distribution of both lineages was preserved without subset loss up to 31 weeks post-engraftment. Likewise, splenic T-lymphocytes secreted cytokines (IFN-γ, IL-2, TNF-α) after PMA/ionomycin stimulation.

Conclusions
The last part of the protocol of FESTIN has been developed as a new humanized model with stable graft function. Phenotypic data acquired by flow cytometry demonstrate reconstitution of human immune cells. These repopulate and maintain lymphoid and myeloid differentiation, where T-lymphocytes can also generate polyfunctional responses. Both lineages are detectable in the periphery and infiltrate mouse tissues. This new model needs to be further evaluated for testing human immunotherapies in pilot tumor cell line studies.

P842
The pattern of expression of hMENA isoforms impacts tumor immune microenvironment of early node-negative non-small cell lung cancer
Paola Nisticò’ MD , Francesca Di Modugno, PhD, Sheila Spada, PhD, Anna Di Carlo, Isabella Sperduti, Enzo Gallo, Mariangela Panetta, Belinda Palermo, Francesca De Nicolò, Lorenzo D’Ambrosio, Barbara Antoniani, Paola Trono, Francesco Facciolo, Paolo Visca, Regina Elena National Cancer Institute, Rome, Italy
Correspondence: Paola Nisticò’ (paola.nistico@fio.gov.it)

Background
Actin cytoskeleton dynamics act as platforms for gene regulation and key signaling transduction pathways involved in the cross-talk among tumor cells and cellular and non-cellular components of the tumor microenvironment (TME). The actin regulatory protein hMENA undergoes tissue specific splicing, generating two alternatively expressed isoforms hMENA11a and hMENA6v that respectively inhibit or increase cell invasiveness [1], TGFβ [2] and β1 integrin signaling and the secretion of several key extracellular matrix (ECM) proteins [3] and is crucial in TGFβ-mediated-EMT [2]. Early node-negative NSCLC patients show a prolonged disease-free survival when expressing high tumor hMENA11a/low stromal FN1 [3]. Recently, tertiary Lymphoid Structures (TLS), sites of transient lymphoid neo-genesis and determinants of antitumor immunity, have been associated with a favorable clinical outcome in NSCLC patients [4].

Methods
The pattern of hMENA isoform expression, TLS presence and localisation and stromal fibronectin were evaluated in 94 primary tumors of node negative NSCLC patients by immunohistochemistry. We evaluated the role of hMENA isoform expression on lymphotixin beta receptor (LTBR), by gain and loss of function, RNA-SEQ and QRT-PCR.

Results
We found that TLS localized within the tumor area (TLS-AT) are predictive of a longer disease free survival in N0 NSCLC patients,
whereas the presence of peritumoral TLS (TLS-PT) does not associate with the patient survival, but with higher tumor grade. TLS-AT presence is significantly correlated with hMENA11a expression in tumor cells, whereas the presence of TLS-PT correlates with the absence of hMENA11a. We evidenced that a low level of stromal FN along with the expression of hMENA11a, associated with TLS-AT. Searching for the mechanisms involved, we found that the hMENA11a knock out in NSCLC cells modulates the expression of several genes: down-regulates the TLS regulator LTβR and up-regulates FN1. Finally, we found that the depletion hMENA11a in the H1650 NSCLC cells reduces the induction of the chemokine CXC-chemokine ligand 13 (CXCL13) a critical cytokine induced after LTβR-LTβR signalling [5] [6].

Conclusions
Our findings indicate that the alternative splicing of hMENA is crucial in the reciprocal signaling between tumor cells and their immune microenvironment, by participating in tertiary lymphoid structure neo-genesis and spatial distribution [7, 8].

Acknowledgements
This work is supported by AIRC.

References
7. Ethics Approval

This study was approved by the Comitato Etico Centrale IRCCS Lazzar.

P843
Oral cancers expressing Glycoprotein-A repetitions predominant (GARP) show poor prognosis
Rieneke van de Ven, PhD1, Jan Kloosterman, BSc, Irene Nauta, MSc, Sonja Ganzevles, BSc, Elisabeth Bloemen, Prof Dr C, René Leemans, MD, PhD, Ruud Brakenhoff, MD, PhD
AMsterdam UMC, VU University Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands
Correspondence: Rieneke van de Ven (vandevene@vumc.nl)

Background
While immune checkpoint inhibitors targeting the programmed-death receptor-1 in recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) (all regions) showed an encouraging 11% increase in 2-year overall survival (OS) (from 6-17%) [1], those data at the same time stress the need for the identification of additional, targetable, suppressive pathways in this disease. Glycoprotein-A repetitions predominant (GARP), a docking receptor for the latent transforming growth factor-beta (TGF-β) complex, facilitates TGF-β activation. Since TGF-β is a known immune-suppressive cytokine, we assessed GARP expression on oral squamous cell carcinoma (OSCC) specimen and analyzed whether its expression relates to clinical outcome.

Methods
Formalin-fixed paraffin embedded OSCC surgical resection specimen collected between 2005-2014 at our institute (n=56) were stained with anti-human GARP (clone: Plata-1) or an IgG2b isotype control antibody. DAB was used for visualization. Sections were scanned on a Vectra Polaris scanner, and images were analyzed using Phenochart. For some patient samples (n=38) CD45 immune infiltrate data within the tumor region were available. All patient materials were handled and used following the medical ethical guidelines as described in the Code of Conduct for Proper Secondary Use of Human Tissue of the Dutch Federation of Biomedical Scientific Societies or written informed consent was obtained in accordance with the Declaration of Helsinki. Graphpad Prism 8 software was used for statistical analyses.

Results
GARP expression was detected in 57% of OSCC (32/56). The majority of the GARP+ tumors (n=24) displayed a marginal expression pattern for GARP, with GARP being expressed on tumor cells located at the tumor invasive border. A diffuse expression pattern, with all tumor cells expressing GARP, was observed in 19% (n=6) of GARP-positive tumors. Two tumors had both marginal and diffuse expression. CD45+ immune infiltration within the total tumor area (tumor core plus invasive margin) was similar for GARP-negative and GARP-positive tumors. Survival analysis showed a significantly reduced 5-year OS for GARP-positive versus GARP-negative tumors with a hazard ratio of 2.90 (95% CI: 1.30– 6.46; p<0.02 by Log-rank Mantel-Cox test). Though low in number in the current cohort, patients with tumors with only diffuse expression had an even poorer outcome compared to GARP-negative and marginal-GARP expressing tumors.

Conclusions
We found clear expression of GARP on OSCC tumor cells in over fifty percent of the patient samples. Expression of GARP on OSCC was linked with a poor prognosis. Ongoing research is focused on determining the immune suppressive effects of tumor-derived GARP expression.

References
1. Ferris RL et al., Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oncol. 2018; 81: 45-51.

Ethics Approval
All patient materials were handled and used following the medical ethical guidelines as described in the Code of Conduct for Proper Secondary Use of Human Tissue of the Dutch Federation of Biomedical Scientific Societies or written informed consent was obtained in accordance with the Declaration of Helsinki.

P844
Investigating the immunologic landscape and tumor-specific target identification in human clear cell renal carcinoma
Nivedita Chowdhury, MS1, Aleksandar Obradovic2, David Aggen, MD, PhD1, Michael Johnson1, Charles Drake, MD, PhD2
1Johns Hopkins Medical Institution, New York, NY, United States; 2Columbia University Medical Center, New York, NY, United States
Correspondence: Charles Drake (cqd2139@cumc.columbia.edu)

Background
Evaluation of the mutational landscape of cancers has revealed significant correlation between mutation burden and response to immunotherapy in cancers such as melanoma and non-small cell lung carcinoma[1,2]. Clear cell renal carcinoma (RCC) is considered an exception as it has a low SNV (single nucleotide variant) burden and yet, a similar response rate. Factors within the tumor microenvironment (TME) play a critical role in regulating response to targeted immunotherapy. While it is well-accepted that ccRCC is characterized by T-cell infiltration (TILs), differential activation states and effect of
Targeting of Lactate Dehydrogenase C and its effects on the tumor immune microenvironment: two birds with one stone

Targeting LDHC to mitigate cancer cell growth and survival in renal cancer. A loss-of-function TNBC cell line model was established to study the effect of LDHC targeting on clonogenic ability, genomic stability and cellular senescence. In addition, immune modulation by LDHC was assessed using the ProteomeProfiler cytokine antibody array and through evaluation of PD-L1 tumor cell expression. Intergation of TCGA and METABRIC RNA-seq data revealed that LDHC was markedly upregulated in TNBC compared to non-TNBC (Figure 1A), with a significant poorer overall and disease-specific survival in TNBC patients with higher LDHC expression (Figure 1B). Silencing of LDHC increased polyplody (Figure 2A-B) as a likely result of increased cellular senescence (Figure 2C) and reduced clonogenicity (Figure 2D). Together these findings indicate that targeting LDHC could significantly reduce tumor burden. Furthermore, LDHC silencing induced substantial dysregulation of immunosuppressive cytokines illustrating the potential immunomodulatory effects of LDHC targeting (Figure 3A-B). For instance, LDHC silencing reduced the expression of factors involved in M2-macrophage polarization (CD14, Serpin E1, CHI3L1, IGFBP2, IL-10), inhibition of tumor infiltration of T cells and macrophages (MIF, CH13L1, IL-10) or myeloid-derived suppressor cell infiltration (MIF, CD14). Moreover, LDHC silencing increased the ratio of non-glycosylated/glycosylated PD-L1 with primarily nuclear localization, thus negatively affecting the stability and immunosuppressive function of PD-L1 (Figure 3C-D).

Conclusions

Our findings demonstrate a positive correlation between LDHC expression and worse survival in specifically triple negative breast cancer. We provide in vitro evidence of the therapeutic potential of targeting LDHC to mitigate cancer cell growth and survival in addition to improving immunosurveillance.

Acknowledgements

This work was supported by a grant from the Qatar Biomedical Research Institute (grant number VR94), awarded to Dr Julie Decock.

References


Ethics Approval

This study was approved by the Institutional Review Boards of the Johns Hopkins Medical Institutions (Protocol#RB00033839) and of Columbia University Medical Center (Protocol#AAA05706).

Fig. 1 (abstract P845). LDHC expression and triple negative breast cancer
Background
Standard treatment of oropharyngeal squamous cell carcinoma (OPSCC) is associated with high morbidity, whereas immunotherapeutic approaches using PD-1:PD-L1 checkpoint blockade only show moderate response rates in OPSCC patients. Therefore, the development of a complex therapeutic protocol combining checkpoint inhibition with other targets is needed for optimal responses. The importance of tumor-infiltrating B cells (TIL-Bs) in shaping antitumor immunity has been underestimated.

Methods
In this study, we assessed the density and distribution of TIL-Bs in FFPE samples from 2 independent cohorts of OPSCC patients. Then we assessed the phenotype of TIL-Bs by means of flow cytometry in fresh samples immediately after radical surgery. The acquired data were correlated with the clinical outcome of the patients.

Results
Here, we observed that CD20+ TIL-Bs and CD8+ T cells formed non-organized aggregates with clearly interacting cells and the densities of both intraepithelial CD20+ B cells and B/CD8+ T cell interactions have prognostic significance for the overall survival of OPSCC patients. Furthermore, a high density of TIL-Bs was associated with an activated B cell phenotype and a high density of direct B cell/CD8+ T cell interactions significantly correlated with the abundance of HPV16-specific CD8+ T cells.

Conclusions
Our results indicate that high abundance of TIL-Bs and high density of direct B cell/CD8+ T cell interactions can preselect patients with excellent prognosis who would profit from less invasive treatment. Furthermore, including B cells as an additional target in novel immunotherapeutic protocols may help to establish the desired sustained antitumor T cell responses in OPSCC patients.

Acknowledgements
This study was financially supported by the Grant Agency of Charles University, project number 344216.

Ethics Approval
All patient studies were conducted in accordance with Declaration of Helsinki and approved by an institutional review board, namely the Ethics Committee of the University Hospital Hradec Kralove and the Ethics Committee of the University Hospital Motol.

P847
Macrophages-induced H19 up-regulation activate the miR-193b/MAPK1 axis and promotes cell aggressiveness in hepatocellular carcinoma
Jinpu Yu, Yingnan Ye
Tianjin Tumor Hospital, Tianjin Shi, China

Background
Dysregulation of long noncoding RNA (lncRNA) H19 has been implicated in hepatocellular carcinoma (HCC), but the concrete regulatory mechanism is lack of research. Our study aims to systematically study the role and regulation of H19 in HCC and find prognostic biomarkers and potential targets for HCC.

Methods
We mined gene expression profiles of 457 HCC samples from TCGA and TJMUCH cohorts (GSE116174 and GSE116182) and further validated in 64 FFPE HCC tissues. Genetically modified HCC cell lines HepG2 were applied to investigate the pathological functions of lncRNA H19 and its interaction with corresponding target miRNAs and mRNAs.

Results
LncRNA H19 overexpression in situ was significantly correlated with poor prognosis of HCC patients, which induced EMT, promoted stemness and accelerated invasion of HCC cells in vitro. Co-expression network analysis indicated lncRNA H19 and its interaction with corresponding target miRNAs and mRNAs.

Conclusions
LncRNA H19 overexpression in situ was significantly correlated with poor prognosis of HCC patients, which induced EMT, promoted stemness and accelerated invasion of HCC cells in vitro. Co-expression network analysis indicated lncRNA H19 and its interaction with corresponding target miRNAs and mRNAs.
193b and protect MAPK1 from miR-193b-mediated gene knockdown. Forced overexpression of H19 attenuated miR-193b-mediated inhibition on multiple driver oncogenes (EGFR, KRAS, PTEN and IGF1R) and MAPK1 gene, thus triggered EMT and stem cell transformation in HCC. LncRNA H19 positively correlated with CD68+ TAMs in situ which induced H19 overexpression and activated H19-centered cRNA network to promote HCC aggressiveness in vitro.

**Conclusions**

TAMs-induced lncRNA H19 promotes HCC aggressiveness via triggering and activating the miR-193b/MAPK1 axis, mediates the crosstalk between HCC and immunological microenvironment, and causes poor clinical outcomes. LncRNA H19 is a valuable predictive biomarker and potential therapeutic target in HCC.

**Acknowledgements**

This work was supported by National Natural Science Foundation of China (grant numbers: 81872143, 81702280, 81472473, 81272360) and Key Project of Tianjin Health and Family Planning Commission (16KG126).

**Ethics Approval**

This study was approved by the Ethics Committee of Tianjin Medical University (No. TMUhMEC 2012018). All experiments were performed in accordance with the principles of the Declaration of Helsinki and written consent was obtained from all patients.

**P848**

**MiR-17 Cluster Promoted M2-polarized tumor associated macrophages related cell aggressiveness via inducing the imbalance of TGF-β1/BMP7 pathways in hepatocellular carcinoma**

Yingnan Ye, Junya Ning, Jinpu Yu
Tianjin Tumor Hospital, Tianjin, China

**Correspondence:** Junpu Yu (junpu_yu@hotmail.com)

**Background**

TGF-β1 and BMP7 are important members of TGF-β superfamily, which have similar downstream transduction pathways and interfere mutually. The antagonistic effects between both pathways has been widely studied in kidney disease and bone formation, and less studied in HCC. This study is intended to elucidate the crosstalk between TGF-β1/BMP7 pathways in the progression and invasion of HCC.

**Methods**

The immunohistochemistry staining method was used to exam the expressions of TGFBR2, TGFBR1, BMP7, BMPR2 and ACVR1 proteins in 64 HCC samples. Genetically modified HCC cell lines HepG2 and Hep3B were applied to investigate the related molecule mechanisms of antagonistic effects of TGF-β1 and BMP7 pathway in HCC.

**Results**

In 64 HCC samples, the expression of TGFBR2 was significantly negatively correlated with ACVR1 expression. TGFBR2-ACVR1+ HCC patients showed higher portal vein invasion and shorter survival time than non-TGFBR2-ACVR1+ HCC patients, which implied that down-regulated TGFBR2 and up-regulated ACVR1 dramatically promoted HCC invasion and metastasis in vivo. We separately knocked down TGFBR2 and overexpressed ACVR1 in HCC cell lines HepG2 and Hep3B cells, and found that down-regulated TGFBR2 and up-regulated ACVR1 dramatically promoted HCC invasion and metastasis. In vitro, we separately knocked down TGFBR2 and overexpressed ACVR1 in HCC cell lines HepG2 and Hep3B cells, and found that down-regulated TGFBR2 and up-regulated ACVR1 dramatically promoted HCC invasion and metastasis. In vitro, we separately knocked down TGFBR2 and overexpressed ACVR1 in HCC cell lines HepG2 and Hep3B cells, and found that down-regulated TGFBR2 and up-regulated ACVR1 dramatically promoted HCC invasion and metastasis.

**Conclusions**

In summary, the miR-17 cluster promoted M2-TAMs related cell aggressiveness via inducing the imbalance of TGF-β1/BMP7 pathways in HCC.

**Acknowledgements**

This work was supported by National Natural Science Foundation of China (grant numbers: 81872143, 81702280, 81472473, 81272360) and Key Project of Tianjin Health and Family Planning Commission (16KG126).

**Ethics Approval**

This study was approved by the Ethics Committee of Tianjin Medical University (No. TMUhMEC 2012018). All experiments were performed in accordance with the principles of the Declaration of Helsinki and written consent was obtained from all patients.

**P849**

**Melanoma-associated vitiligo skin maintains resident memory CD8 T cells with specific TCR profiles contributing to long-term tumor protection**

Jichang Han, Aleksey Molodtsov, Yanding Zhao, Keiske Shirai, Mary Jo Turk, Christina V. Angeles
Dartmouth College, Lebanon, NH, United States

**Correspondence:** Christina V. Angeles (christinav.angeles@hitchcock.org)

**Background**

Vitiligo, an immune-related adverse effect (irAE) which targets normal melanocytes in the skin, is associated with significantly improved overall survival in metastatic melanoma patients treated with immunotherapy [1]. The presence of tissue memory T cells (TRM) correlates with better prognosis in multiple cancer types and by our lab previously showed that the generation of potent TRM responses against melanoma cells depends on the induction of autoimmune vitiligo [2,3]. The present studies test the hypothesis that TRM in melanoma patient’s vitiligo skin shares the same TCR clonotypes with tumor infiltrating lymphocytes (TILs) which indicates that TRM provides durable, long-term tumor protection.

**Methods**

Seven melanoma survivors who received immunotherapy with the irAE of vitiligo were recruited to the study. Genomic DNA was extracted from matched skin, tumor and blood specimens and TCR chain deep sequencing was performed by Adaptive Biotechnologies. Fresh matched tumor, skin and blood samples from four patients were collected, and paralleled single cell RNA (scRNA) and single cell TCR (scTCR) sequencing were performed using the 10X platform. Gene expression profiles were analyzed using the Seurat V3.0 package. Matched TCR clonotypes were identified as those TCRβ chain sequences in bulk level TCR sequencing, or paired TCRα, β chain sequences in scTCR sequencing, that are the same between different tissues.

**Results**

TRM-like CD8 T cells were found in all melanoma patients’ vitiligo skins. Instead of a single population, one of the TRM-like CD8 T cell populations had highly upregulated IFN-γ, TNF, CXC3, GZMA, GZMB, NKG7 and PFN1 genes (TRM-IFNG), while the other population expressed high levels of AP-1 transcription factors (TRM-AP1). Matched T-cell clonotypes were found among tumor, skin and blood and phenotypes. These clonotype-matched T cells included both TRM-like and circulating memory T cells. Tumor-skin matched TCR repertoire had significantly higher clonal expansion level than tumor-blood matched TCR repertoire. The TCR repertoire of TRM-like T cells with matched clonotypes were more clonally expanded compared to that of the circulating memory T cells. Focusing on the TRM-like population, TRM-IFNG had a higher enriched level of matched T-cell clonotypes between tumor and skin compared to the TRM-AP1 population. Using TCGA metastatic melanoma patients’ datasets, pa-
tients with TRM-IFNghigh TRM-AP1high gene expression profiles had better prognosis compared to patients with TRM-IFNglow TRM-AP1high gene expression profiles.

Conclusions
These data suggest that TRM-like CD8 T cells with TCR clonotypes matched between tumor and skin maintains a tumor protecting population in long-term melanoma survivors’ vitiligo skin.

References

Ethics Approval
This study was approved by Dartmouth College/Dartmouth Hitchcock Medical Center’s Committee for the Protection of Human Subjects, approval number 29821

P850
Metabolically reprogram MDSCs by targeting Pim kinases to overcome resistance to PD-1 blockade immunotherapy
C Yao Chen¹, Paytsar Topchyan¹, Aimin Jiang, PhD³, Yiliang Chen¹, Roy Silverstein², Weiguo Cui², Gang Xin¹
¹Blood Center of Wisconsin, Milwaukee, WI, United States; ²Medical College of Wisconsin, Milwaukee, WI, United States; ³Roswell Park Cancer Institute, Buffalo, NY, United States
Correspondence: Weiguo Cui (Weiguo.Cui@BCW.edu)

Background
Despite the unprecedented success of immune checkpoint blockade (ICB) therapy, many patients still respond poorly, owing to multiple resistance mechanisms. Among these mechanisms, myeloid cells, constitute the largest populations of immune cells in the tumor microenvironment, and are considered as one of the major barriers for successful therapy and the promoters for immune evasion and metastasis. Despite the frequent clinical observation that patient with high levels of tumor-infiltrating myeloid cells usually fail to respond to ICB therapy and correlate with worse prognosis (ref), little is known about the crucial mechanisms governing these cells. Consequently, limited approaches have been developed to effectively abolish the intratumoral myeloid cells to restore sensitivity to ICB therapy.

Methods
To address these knowledge gaps, we employed single-cell sequencing (scRNA-seq) to assess transcriptional and metabolic changes in myeloid cells that associated with resistance to PD-1 blockade in pre-clinical cancer models.

Results
Our study revealed that the resistant tumor was dominated by immunosuppressive myeloid cells enriched for fatty acid metabolism pathway activity, which in turn substantially abrogated the fatty acid oxidation and immunosuppressive function. More intriguingly, using AZD1208 to pharmacologically inhibit Pim kinase disrupted the myeloid cell-mediated immunosuppressive microenvironment and promoted T cell-mediated tumor regression, working synergistically with anti-PD-L1 therapy in various solid tumor models. Additionally, sensitivity to ICB in non-responders can be restored by selective treatment with AZD1208.

Conclusions
Overall, we have identified Pim1 as a metabolic modulator in MDSCs that may cause ICB resistance and can be therapeutically inhibited to sensitize non-responsive tumors to ICB therapy.

Fig. 1 (abstract P850). A precision medicine approach for overcome resistance to ICB

Oral Presentations
Biomarkers, Immune Monitoring, and Novel Technologies

O1
Flexible Copper-64-nanoparticle-based cell labeling system allows for in vivo tracking of adoptively transferred T-cells by PET/CT
Hólmarfríður Halldórsdóttir, MSc¹, Lars Ringgaard, PhD¹, Martin Bak, PhD¹, Ditte Jæger, MSc², Esben Christensen, MSc¹, Fredrik Melander, PhD¹, Mie Hübbe, MSc¹, Rasmus Eliasen, PhD¹, Frederikke Fliedner, MSc¹, Andreas Kjaer, MD, PhD¹, Anders Hansen, DVM, PhD¹, Jonas Henriksen, PhD¹, Thomas Andresen, PhD¹
¹Technical University of Denmark, Kongens Lyngby, Denmark; ²University of Copenhagen, Copenhagen, Denmark; ³Rigshospitalet & University of Copenhagen, Copenhagen, Denmark
Correspondence: Thomas Andresen (tlan@dtu.dk)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):O1

Background
To fully exploit the potential of adoptive cell transfer (ACT) therapy, an improved understanding of in vivo T-cell trafficking and engraftment following transfer is paramount. In vivo tracking of adoptively transferred cells by PET/CT represents an attractive imaging technology for ACT due to the quantitative capacity with high spatial and temporal resolution [1]. We have developed a flexible copper-64-nanoparticle-based cell labeling system, which allows for prolonged cell tracking.

Methods
The labeling protocol was optimized for T-cell copper-64-micelle labeling in vitro and >90% loading efficiency was achieved with intact cell viability. Stability of the copper-64-micelles labeled T-cells was evaluated by co-incubating the T-cells with celltrace+ splenocytes. In vivo, labeled T cell biodistribution and tumor accumulation in mice were investigated using PET/CT imaging in relation to radiation and various cancer immunotherapies. PET/CT scans were performed at multiple time-points up to 40 hours after ACT.
Results
Whole-body irradiated mice displayed significantly higher copper-64 activity (4.6 +/- 0.1% of injected dose) in the thymus compared to controls (2.1 +/- 0.1% of injected dose). Additionally, there was correspondence between T cell number of the injected clone in selected organs and radioactivity. This demonstrates that the signal is T-cell specific and retained in vivo in T-cells over time. We investigated the activity of labeled T-cells in tumors treated with an intratumoral sustained release depot of a TLR7 agonist (TLR7 Immunoglobulin). The TLR7 Immunoglobulin has been demonstrated to increase tumor protein levels of chemokines: CXCL-10, IFN-gamma, and TNF-alpha, with importance for T-cell accumulation. PET/CT imaging showed that accumulation of ACT labeled T-cells was increased by pre-treating tumors with TLR7 Immunoglobulin.

Conclusions
This flexible radiolabeling technology provides a novel method for tracking T-cells in vivo over several days. The flexibility of the system offers labeling of multiple murine and human cell populations, for high-resolution in vivo cell tracking.

References

Ethics Approval
The study has been approved by The Danish Animal Experiments Inspectorate.

O2
Combining transcriptomic and tissue-based immune biomarkers to improve recurrence prediction in stage II-III melanoma
Robyn Gartrell, MD1, Andrew Chen, BS2, Emanuelle Rizk, BA3, Douglas Marks, MD3, Margaret Bogardus, BA1, Basil Horst, MD2, Rui Chang, MD2, Anthea Monod, PhD2, Raúl Rabadán, PhD2, Yvonne Saenger, MD2
1Columbia University/ New York Presbyterian, Newton, NJ, United States; 2Columbia University Irving Medical Center, New York, NY, United States; 3New York University Langone Health, Mineola, NY, United States; 4University of British Columbia, Vancouver, Canada; 5University of Arizona, Tucson, AZ, United States; 6Tel Aviv University, Tel Aviv, Israel

Correspondence: Yvonne Saenger (yms4@columbia.edu)

Background
Biomarkers that predict clinical response in stage II-III melanoma are critical to helping clinicians weigh benefits of immunotherapy against potential toxicities. Individual biomarkers are often insufficient to clearly stratify patients, thus the combination of transcriptomic and tissue-based immune biomarkers may help identify more precise and predictive biomarkers. We previously found that the ratio of CD8+ cytotoxic T lymphocytes (CTLs) to CD68+ macrophages and melanoma immune profile (MIP), a 53 immune gene signature, both predict recurrence and disease specific survival (DSS) in patients with primary stage II-III melanoma (1,2).

Methods
We performed quantitative multiplexed immunofluorescence (qmIF) and nanoString analysis on a cohort of 78 patients with stage II-III melanoma and known DSS who were diagnosed at Columbia University Irving Medical Center (CUIMC) between 2000 and 2012. MIP was computed based on gene expression using nanoString, and the CTL/macrophage ratio was found using qmIF. We assessed the similarity of each sample’s gene expression profile to the cellular subtype signatures from LM22, the reference standard for CIBERSORT. Differential expression was evaluated using t-test with Benjamini-Hochberg (BH) correction. We used Spearman correlation to evaluate the association of the top immune genes (>1 fold change) with the CTL/macrophage ratio. We combined the CTL/macrophage ratio with MIP using the log-rank (Mantel-Cox) test to compare low- to medium-risk, low- to high-risk, and medium- to high-risk patients.

Results
We found that recurrent patients had decreased M1 and increased M2 macrophage signatures relative to non-recurrent patients (p=0.042 and p=0.048, respectively) using CIBERSORT. The M1 macrophage signature further correlated with density of HLA-DR+ macrophages as assessed by qmIF (p=0.022). Next, we evaluated the differential expression of genes in MIP identifying 9 with >1 log-fold change and significant by BH. We then evaluated the correlation of these 9 genes with stromal density of CD3+, CD68+, and CD68+ as well as the ratio of CTL/macrophage as determined by qmIF. Importantly, the CTL/macrophage ratio had no correlation with these 9 genes, allowing for combination of MIP with the CTL/macrophage ratio. This composite biomarker significantly distinguished low- and medium-risk patients from high-risk patients (Figure 1, p=0.0031 and p=0.0258, respectively).

Conclusions
Combining multiple modalities to stratify patients into risk groups is a critical step to improving the management of melanoma patients. Here, we find that a composite biomarker consisting of the MIP signature and CTL/macrophage ratio successfully stratifies patients into three risk groups predictive of DSS, thus highlighting the potential use of combination biomarkers for adjuvant therapy.

Acknowledgements
The authors of this publication were supported by the National Institutes of Health through Grant Numbers RO1FD006108 (Y.M. Saenger) and K23TR001874 (R.D. Gartrell-Corrado). A.X.C is funded by the Medical Scientist Training Program (T52GM007367). Yvonne Saenger is also supported by funding from the Melanoma Research Alliance and by an Irving Assistant Professorship at Columbia University’s NIH/NCATS CTSA Program hub: UL1TR001873. Robyn Gartrell-Corrado is also supported by Swim Across America. R. Rabadán, A. Monod, and A. Chen have been supported by the NCI Center for Topology of Cancer Evolution and Heterogeneity (U54CA193313). A. Monod wishes to acknowledge the support of the New Frontiers in Research Fund–Fonds Nouvelles Frontières en Recherche (SSHRC-NFRF-FNFR, Government of Canada) NFRE-2018-00431. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funding sources had no role preparation of the manuscript or the decision to submit for publication.

References

Ethics Approval
This study was approved by Columbia University Irving Medical Center’s (CUIMC) Institutional Review Board, Protocol AAAO2758.

Fig. 1 (abstract O2). Combination of MIP and CD8/CD68 ratio predicts DSS.
Immune infiltration correlates with TP53 mutational status in a multi-cohort acute myeloid leukemia study
Sergio Rutella, MD, PhD, FRCPath, Jayakumar Vadakekolathu, PhD, Stephen Reeder, BS, Jenny Ashton-Thompson, Melissa Courtney, Amanda Coults, PhD, Tressa Hood, MS, Sarah Church, PhD, Clare Coveney, PhD, Jan Davidson-Moncada, MD, PhD, Jorn Meinel, MD, Marc Schmitz, MD, Francesco Marincola, MD, Martin Bornhauser, MD
1Nottingham Trent University, Nottingham, Nottingham University Hospitals, Darmstadt, Germany; 2Refuge Biotechnologies, Half Moon Bay, CA, United States
Correspondence: Sergio Rutella (sergio.rutella@ntu.ac.uk)

Background
Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Although immunotherapy may be an attractive modality to exploit in AML, the ability to predict the groups of patients and the types of cancer that will respond to immune targeting remains limited [1-2]. Herein, we aimed to determine whether prognostic molecular lesions, including TP53 mutations, correlate with the AML immune milieu and identify a patient subgroup that may benefit from immunotherapy approaches.

Methods
The Cancer Genome Atlas (TCGA) discovery cohort consisted of RNA-sequencing data from 162 AML patients with complete cytogenetic and clinical annotation. The second public cohort consisted of RNA-sequencing data from 281 AML patients treated on the Beat AML Master Trial. Immune cell type-specific and biological activity scores were computed as previously published [3]. GeoMx(TM) Digital Spatial Profiling (DSP) [4] was used to characterize the expression of 31 immuno-oncology-related proteins in FFPE bone marrow (BM) samples from 10 patients with newly-diagnosed AML (SAL cohort).

Results
Immune gene sets stratified TCGA-AML patients into two distinct clusters expressing genes associated with adaptive immune responses and an interferon (IFN)-gamma-dominant tumor microenvironment (TME) and gene modules capturing BM infiltration with monocytes, macrophages and other myeloid cells. Patients with adverse-risk molecular lesions, including somatic TP53 and RUNX1 mutations, clustered in the immune-infiltrated subgroup (Fig. 1A-B). In contrast, the majority of TCGA-AML cases with favorable/intermediate-risk molecular lesions were classified as immune-depleted. Similarly, 16 out of 17 TP53-mutated Beat AML cases (validation cohort) expressed high levels of CD8 transcripts, markers of cytotoxicity and downstream IFN signaling genes compared to TP53 wild-type (WT) cases. We next analyzed protein profiles in BM specimens from a third independent AML series (SAL cohort) using GeoMix DSP (Fig. 1C). We identified four microenvironmental protein signatures (SIG1-4). Abnormalities in SIG3 genes (i.e., mRNA up-regulation, gene amplification, deep deletion and mis-sense mutations of PD-L1, FoxP3, cytotoxicity molecules, PTEN and BCL2) were predominantly observed in TCGA patients with IFN-gamma-dominant AML and correlated with higher tumor mutational burden, adverse cytogenetic features, TP53 mutational status and worse clinical outcomes (Fig. 1D).

Conclusions
Concurrent with previous reports in breast cancer with genetic instability [5], this study provides evidence for a correlation between IFN-gamma-dominant AML subtypes and TP53 mutations, an established adverse prognosticator, and could support the implementation of immunotherapy clinical trials in this specific patient subgroup.

Acknowledgements
Grant support: Qatar National Research Fund (#NPRP8-2297-3-894), Roger Coulter Foundation (Dorset, UK) and John and Lucille van Geest Foundation to S.R.

References

Ethics Approval
The study was approved by Technical University of Dresden’s Ethics Board.
Results
For the CAR-T target candidates, BCMA and ROR1, RNA ISH revealed that BCMA was only expressed in the xenograft tumor and in no mouse organs, while ROR1 was found to be expressed at low levels in mouse lung and liver, as well as in the xenograft tumor. Duplex RNA ISH assays with probes targeting the CAR 3' UTR and either IFNG or GZMB mRNA allowed for highly sensitive and specific detection of CAR-T cells and their activation state in both tumor and normal tissues from vehicle, anti-BCMA CAR-T cell, or anti-ROR1 CAR-T cell treated mice. Activated anti-BCMA CAR-T cells expressing GZMB and IFNG were found only in the xenograft tumor, where BCMA was expressed. In contrast, activated anti-ROR1 CAR-T cells were found almost exclusively in mouse lung and liver, with very few anti-ROR1 CAR-T cells being found in the xenograft tumor, consistent with the previously observed pulmonary and hepatic toxicity of anti-ROR1 CAR-T cells that was not predicted by IHC analysis of ROR1 protein presumably due to lack of antibody sensitivity. Lastly, a multiplex ISH-IHC approach confirmed the presence of activated BCMA CAR-T cells in the xenograft tumor through simultaneous detection of the BCMA 3' UTR, IFNG, GZMB, and CD3.

Conclusions
These data demonstrate how the RNAseq assay can be utilized for CAR-T cell efficacy and safety/toxicity assessment in preclinical models by detecting very low levels of target antigen expression in off-tumor tissues and monitoring CAR-T cell pharmacodynamics and activation in tumor models and can also be applied for assessing TCR-T cell activity in tumors.

O5 The road-map to tumor-infiltrating lymphocyte (TIL) therapy: Understanding genetic alterations for improved patient treatment
Caitlin Creasy, MS1, Yuzhong Meng, PhD1, Tatiana Karpinets, MS1, Cara Haymaker, PhD1, Marie Andrié Forget, PhD1, Chip Stewart, PhD1, Carlos Antonio Torres Cabala, MD1, Shari Pilon-Thomas, PhD4, Arnold Sarnaik, MD3, Levi Garraway, MD, PhD1, Patrick Hwu, MD1, Rodabe Amaria, MD1, Rameen Beroukhim, MD, PhD2, Chantale Bernatchez1.
1UT MD Anderson Cancer Center, Houston, TX, United States; 2Harvard Medical School, Boston, MA, United States; 3Broad Institute, Cambridge, MA, United States; 4Moffitt Cancer Center, Tampa, FL, United States
Correspondence: Chantale Bernatchez (ChBernatchez@mdanderson.org)

Background
Treatment of metastatic melanoma has vastly improved over the past decade due to the rise of immunotherapy. Adoptive cell therapy (ACT) of tumor-infiltrating lymphocytes (TIL) has yielded a 40-50% response rate in this subset of patients. Although this living therapy yields durable responses, it is unknown why some patients do not respond or are not afforded lasting protection. Previously, we have demonstrated that phenotypic differences of the infused TIL, LDH levels, as well as number and type of prior systemic therapies impact responses. To gain further insight into the role of genetic alterations and response to TIL therapy, we interrogated pre-treatment tumor tissue from TIL treated patients.

Methods
Tumor samples were collected from 74 patients from MD Anderson Cancer Center (MDACC) and 10 patients from Moffitt Cancer Center. A subset of patients from MDACC also had tumor biopsies collected at recurrence (n=6). Whole exome sequencing (WES), and RNA sequencing, were assessed along with response, progression free survival (PFS), and overall survival (OS).

Results
WES on pretreatment tumor tissue first revealed that a high neoantigen burden is predictive of long-term OS, but is not associated with PFS or response to treatment. Interestingly, when compared with mutation rates found in TCGA, we found mutations of the genes KCNQ2 and SFTA3 were enriched in the overall patient cohort from both centers (1.9 vs 13% for KCNQ2 and 0.6 vs 6% for SFTA3). To our knowledge, this observation was never reported prior and could be linked to the difference in stage of the disease between TCGA (mostly stage III) and our cohort (stage IV). When assessing the clonal evolution in the biopsies collected at recurrence vs the matched pre-treatment tumor tissue, no common driver DNA alteration could be identified, however changes in the prevalence of tumor subclones could be observed. RNA sequencing analysis revealed three genes significantly enriched in patients experiencing long-term PFS, long-term OS, and response to therapy (PDE1C, RTKN, and NGFR), while one gene enriched with the inverse outcomes (ELFN1).

Conclusions
Using genetic information, we uncovered potential biomarkers for response to TIL ACT in metastatic melanoma which can be assessed prior to treatment. This analysis also highlights potential routes of immune escape.

Trial Registration
Trial NCT00338377 was conducted at UT MD Anderson Cancer Center and trials NCT01005745, NCT01701674, and NCT01659151 were conducted at Moffitt Cancer Center.

Ethics Approval
This study was approved by UT MD Anderson Cancer Center’s and Moffitt Cancer Center’s Ethics Board.

O6 Enhanced presence of a myeloid-like NK cell subpopulation is associated with MHC class I-deficient tumor escape
Yinin Du, PhD1, Curtis Perry, MD, PhD2, William Damsky, MD, PhD2, Katherine Hastings, PhD2, Patricia Rodriguez-Morales1, Dan Chen, PhD1, Kacie Traina1, Ivy Phung1, Ting Zhou1, Aaron Ring, MD, PhD1, Katherine Politi, PhD2, Susan Kaech, PhD1
1Salk Institute for Biological Studies, La Jolla, CA, United States; 2Yale University, New Haven, CT, United States; 3University of California San Diego, La Jolla, CA, United States
Correspondence: Susan Kaech (skaech@salk.edu)

Background
Recent advances in immunotherapies (e.g. anti-PD-1 or -CTLA-4) aiming to enhance anti-tumor immunity have shown promising results in cancer patients. However, resistance to these therapies is a major challenge we face today [1]. An emerging mechanism of cancer resistance to immune checkpoint inhibitors is impairment of major histocompatibility class I (MHC-I) antigen presentation through disruption of B2M (encoding a critical component of MHC-I) [2]. While it is intuitive that compromised CD8 T-cell responses are directly responsible for defective control of tumors with low or absent MHC-I, it is critical that we better understand why other immune cells, especially natural killer (NK) cells, also fail to suppress the growth of these types of tumors, as they are known for their rapid and effective response targeting infected cells with low or absent MHC-I expression [3].

Methods
Using CRISSPR/Cas9-mediated genetic knockout of B2M in our murine melanoma model, as well as single-cell RNA sequencing (sc-RNAseq) and flow cytometry, we were able to effectively probe the phenotype and function of tumor-infiltrating NK cells.

Results
Our preliminary sc-RNAseq analysis indicated that B2M-/- (B2M-KO) tumor NK cells appear to acquire a “neo-phenotype” accompanied by increased expression of myeloid cell-like genes (Figure 1). We hypothesize these genetic changes underlie the functional impairments in MHC-I-deficient tumor NK cells. Further validation using both standard (Figure 2) and imaging-based flow cytometry indicated that B2M-KO tumor NK cells exhibit enhanced co-expression of CSF1R and CSAR, two molecules that are critical for myeloid survival and differentiation and are known to disrupt effector CD8 T-cell and NK cell functions. Moreover, our analysis revealed impaired effector and...
cytotoxic capacity of CSAR/CSF1R co-expressing NK sub-population. Additionally, treating tumor-bearing B6 mice with a CSF1R inhibitor led to delayed B2M-KO tumor growth that is NK-dependent (Figure 3).

Conclusions
We hereby demonstrate enhanced presence of a myeloid-like NK sub-population in the context of B2M or MHC-I deficiency in our murine melanoma model, for which such phenotype is linked to compromised anti-tumor immunity. Future works will seek to find out if myeloid-like phenotypes are observed in tumoral NK cells in human cancer patients. Our research, therefore, has significant implications in cellular and therapeutic targeting for CD8 T-cell resistant tumors.

References

Ethics Approval
The study was approved by Salk Institute's Institution Review Board (IRB), approval number 10086.

O7
P-BCMA-ALL01 — a nonviral, allogeneic anti-BCMA CAR-T therapy with potent antitumor function for the treatment of multiple myeloma
Maximilian Richter, PhD, Stacey Cranert, PhD, Yening Tan, MS, Min Tong, MS, Christine Domingo, BS, Elvira Argus, PhD, Samad Ibitokou, PhD, Jenessa Smith, PhD, Christopher Martin, PhD, Xinxin Wang, PhD, Burton Barnett, PhD, Eric Ostertag, MD, PhD, Julia Cornella, PhD, Devon Shedlock, PhD
Poseida Therapeutics, San Diego, CA, United States
Correspondence: Devon Shedlock (shedlock@poseida.com)

Background
Chimeric antigen receptor (CAR)-T therapy has shown great promise against relapsed/refractory multiple myeloma (MM) by targeting the B cell maturation antigen (BCMA), an example being Poseida’s P-BCMA-101 product candidate. Nevertheless, the need to manufacture an individualized product from highly variable patient material, lengthy vein-to-vein time and high manufacturing cost remain challenges of autologous CAR-T. Employing the nonviral piggyBac® (PB) DNA Modification System in combination with the high-fidelity Cas-CLOVER™ (CC) Site-Specific Gene Editing System, we have developed P-BCMA-ALL01, an off-the-shelf allogeneic CAR-T cell product candidate aimed at overcoming the limitations of autologous therapy.

Methods
For manufacture of P-BCMA-ALL01 from healthy donor T cells, the PB system is used to stably deliver the transgene, while the CC system is used to knockout expression of T cell receptor (TCR) and MHC, while avoiding unwanted off-target cutting. We also use a proprietary "booster molecule" to increase the yield, enabling the production of hundreds of patient doses from a single manufacturing run. P-BCMA-ALL01 final product is >95% CAR+, >99.5% TCR-KO and is comprised of a high percentage of desirable TSCM cells (CD45RA+, CD62L+), similar to P-BCMA-101, contributing to safety and durability.

Results
Preclinical evaluation of P-BCMA-ALL01 demonstrated potent efficacy in coculture assays against multiple BCMA+ cell lines. In addition, P-BCMA-ALL01 secreted IFNγ and mediated robust (70-90%) killing of cell targets. Moreover, product generated from multiple different donors showed strong potency in an NSG xenograft model implanted with RPMI-226, an aggressive human MM-derived tumor model. Untreated animals showed rapid tumor progression and succumbed to disease within the standard 5-7 weeks. In contrast, mice treated with P-BCMA-ALL01 from any donor showed reduction of tumor burden below the limit of detection by caliper within ~2 weeks and remained tumor-free for the duration of the study. TCR-KO P-BCMA-ALL01 cells were readily detectable in the blood of tumor-bearing animals, demonstrating good durability in mice.

Conclusions
Altogether, P-BCMA-ALL01 exhibited potent effector function in preclinical studies and will be rapidly advanced into the clinic for the treatment of MM.
O8
The Thrombospondin-1/CD47 signaling axis serve as potential markers of immune checkpoint blockade response modulating immune cell bioenergetics in the tumor microenvironment.

Elizabeth Stirling, Adam Wilson, Mitra Kooshki, Lilya Yamaleyeva, Guanxu Jin, Wei Zhang, Lance Miller, MS, PhD, Pierre Triozzi, MD, David Soto-Pantoja, PhD
Wake Forest School of Medicine Comprehensive Cancer Center, Winston Salem, NC, United States
Correspondence: David Soto-Pantoja (dsoptopan@wakehealth.edu)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):OC8

Background
CD47 is a widely expressed receptor that controls innate and adaptive immunosurveillance by engaging its counter receptor SIRPα or by binding to its ligand Thrombospondin-1 (TSP1). TCGA data shows that high expression of TSP1 is associated with low survival probability of melanoma patients and its expression is elevated in metastatic melanoma versus localized lesions.

Methods
TSP1 expression was examined by single cell RNA sequencing in melanoma patient’s peripheral blood mononuclear cells (PBMCs) and was validated by ELISA. Expression of CD47 was examined by Flow cytometry. T cell antigen-specific responses were determined using isolated CD8+ T cells from Pmel-1 transgenic mice in an in vitro cell impedance platform. Cellular bioenergetics was measured using a Seahorse® bioanalyzer. Mechanisms of TSP1/CD47 regulation of the tumor microenvironment were examined in the B16 melanoma model and oxygen tension was measured by photoacoustic imaging.

Results
scRNAseq shows that TSP1 expression localizes to the myeloid population (CD163+, CD11b+) and it is induced in patients after the first cycle of anti-PD1 therapy suggesting that TSP1 could serve as a potential marker of immune checkpoint blockade (ICB) response (N=16, p < 0.05).

Conclusions
Our data indicates TSP1/CD47 expression serves as markers of ICB response and targeting this pathway may impact cell bioenergetics to reduce tumor burden.

Acknowledgements
DSP is supported by The NCI Career Development Award (1K22CA181274) and ERS is supported by a NIGMS T32 (GM127261).

Ethics Approval
Human subject studies were approved by the institutional review board (IRB) and animal studies were approved by the Institutional Animal Care and Use Committee, Wake Forest Health Sciences.

O9
Enhancing affinity of CD22-directed CART T cells increases activation signaling and in vivo response to CD22lo leukemia
Zachary Walsh, BA, Mark Kohler, MD, PhD, Terry Fry, MD Children’s Hospital Colorado, Aurora, CO, United States
Correspondence: Terry Fry (terry.fry@ucdenver.edu)

Background
T cells modified with a chimeric antigen receptor (CAR) targeting CD22 have demonstrated exciting efficacy in clinical trials, inducing remission in 70% of patients with relapsed and refractory B-precursor acute lymphoblastic leukemia (B-ALL) including those resistant to CD19 targeted immunotherapy [1,2]. However, follow-up data from these trials has demonstrated that a considerable percentage of patients will relapse following CD22-directed CART therapy (CD22-CART), commonly with decreased leukemic expression of CD22.

Methods
In this study, we investigated the mechanistic connection of antigen density to CART function measured by the phosphoproteomic signature upon CAR stimulation. To model a spectrum of leukemic CD22 expression, we used previously-generated variants of the NALM6 B-ALL cell line which are modified to stably express varying levels of CD22. We studied CD22-CART signaling in the presence of these cell lines using phospho-flow cytometry. We further evaluated CD22-CART efficacy in vivo using a murine xenograft model of refractory B-ALL.

Results
We found that decreased CD22 antigen density on target leukemia cells is associated with a diminished percentage and intensity of ERK phosphorylation in CD22-CART, an indicator of T cell activation. These findings were corroborated by an observed decrease in the T cell activation markers PD-1 and CD69 as leukemic CD22 expression decreased. In an attempt to improve CD22 CART efficacy in the setting of low antigen density, we explored multiple mechanisms to improve CD22-CART signaling. Using a high affinity variant of the CD22-CAR (CD22-CARTV1), we noted increased in both the p-ERK intensity and percentage of p-ERK-positive CART in response to CD22lo leukemia in vitro, which led to improved in vivo leukemic clearance and CAR persistence. Additionally, using the BRAF inhibitor Vemurafenib, we were able to increase the intensity of p-ERK in CD22-CART. Finally, we noted that PD1hi and CD69hi CD22-CART demonstrated a higher percentage of p-ERK after antigen stimulation, suggesting that expression of these markers may be predictive of CART response.

Conclusions
Together, our results indicate the promise of the high affinity CD22-CARTV1 for the treatment of CD22lo leukemia and suggest that modification to CART design and targeted therapies to enhance signaling are viable, clinically relevant strategies to improve CART efficacy and persistence.

References

Acknowledgements
This study was approved by the University of Colorado’s Institutional Animal Care and Use Committee, approval number 00751.

Ethics Approval
This study was approved by the University of Colorado’s Institutional Animal Care and Use Committee, approval number 00751.

Fig. 1 (abstract 09). See text for description.
Background
Cancer therapy has been revolutionized by immunotherapy in recent research or clinic[1-4]. Two forms of immunotherapy have demonstrated significant clinical activity: antibodies targeting checkpoint proteins[5] and adoptive cellular therapy (ACT). Among ACT, chimeric antigen receptor (CAR) engineered T cell has gained great success targeting hematopoietic malignancy[6-8]. These receptors take advantage of scFv from antibody specific to antigen expressed on tumor surface and activate the T cells targeting tumor cells once interact with tumor cells[9-13].

Despite promising clinic outcome in hematopoietic tumor therapy, CAR-T cell therapeutic performance in solid tumor patients is less satisfactory[14,15]. The potential challenge includes the difficulty of CAR-T to migrate and persist in solid tumor where the immunosuppressive tumor microenvironment (TME) greatly restricts the function of CAR-Ts. One significant obstacle for the study of CAR-T cells for solid tumor treatment is the lack of reliable orthotopic tumor models that can be implanted with tumor cells targeting hemopoietic malignancy regardless of approaches to alter TME[16]. These receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 161, 2791-2797 (1998).

Methods
Here, we took the advantage of orthotopic NT2 mammary tumor in FVB-Neu mice, a model in which T cells develop central tolerance to Neu-expressing tumors, similar to human patients presenting with HER-2+ breast tumors[16]. Neu expressing tumors can be targeted by anti-Neu CAR-Ts we developed from antibody hybridoma, which is similar to the HER-2/neu-specific CAR T cells currently used in clinical trials.

Results
We demonstrated conventional method expanded CAR-T with IL-7 and IL-15 (7/15 CAR-Ts) failed to induce in vivo tumor growth control in established mammary tumors regardless of approaches to alter the TME. However, CAR transduced CD4 and CD8 T cells cultured under Th17 condition (Th/Tc17 CAR-Ts) has better persistence and expansion in vivo compared to 7/15 CAR-Ts. Furthermore, the enhanced cytolysis of Th/Tc17 CAR-Ts was licensed by locally STING agonist treatment, and lead to short term tumor growth control. Finally, the combination of TME modulation by myeloid-derived suppressive cells (MDSCs) depletion led to profound tumor regression in mice receiving Th/Tc17 CAR-Ts with STING administration, and the tumor resolution was accompanied with cytokine release like symptom that caused mortality in animals with the fastest tumor shrinkage.

Conclusions
In conclusion, we found STING agonist administration can enhance the therapeutic effect of Th/Tc17 CAR-T in vivo against breast tumor in immunocompetent host and further combination of MDSC depletion can lead to tumor clearance with CRS like symptom. Our work provides significant new insight into approaches to improve CAR-T efficacy for solid tumor, which can be rapidly translated into clinic.

References


Checkpoint Blockade Therapy

O11 Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade
Shuming Chen, PhD, Alsha Soni, Tracee McMuller, John-William Sidhorn, MSE, Farah Succiaria, MD, Alan Berger, Jody Hooper, Drew Pardoll, MD, PhD, Evan Lipson, Janis Taube, MD, MSC, Suzanne Topalian, MD Johns Hopkins University School of Medicine, Baltimore, MD, United States

Correspondence: Shuming Chen (schen72@jhmi.edu)

Background
Immune checkpoint blockade has become a pillar of oncology for its effectiveness in treating some patients with advanced cancers. However, ≤90% of patients develop minor to severe immune-related adverse events (irAEs), marked by normal tissue inflammation and significantly associated with a higher tumor regression rate [1]. Glucocorticoids often administered to manage irAEs may blunt anti-tumor immunity. This study was undertaken to investigate the functional relationship between anti-tumor and anti-self immunity that could uncover more refined approaches to both irAE management and tumor control.

Methods
Under the Johns Hopkins Legacy Gift Rapid Autopsy Program, multiple biopsy samples were collected over 6 years from diagnosis to death in a melanoma patient experiencing both tumor regression and irAEs after receiving anti-PTD-1 and anti-CTLA-4. Fourteen specimens including tumor, inflamed and non-inflamed normal tissues were collected. Laser-capture microdissected (LCM) anti-tumor and anti-self inflammatory infiltrates from eight FFPE samples were subjected to gene expression profiling (GEP) by multiplex qRT-PCR for 123 immune-related genes; infiltrates from six of these samples underwent TCRVB sequencing and deep learning analysis. Expression of 14 immune cell subset and regulatory molecules was assessed in 12 samples by immunohistochemistry (IHC).

Results
GEP revealed genes abundantly expressed across all samples, including those involved in MHC and antigen presentation (B2M, CD74, HLA-DRA), IFN signaling (STAT1, CXCL9), innate immunity (LYZ, DDX58/RIG-I), and immunosuppression (TGFβ1, TGFIT, LGALS9/galectin-9, HAVCR2/Tim-3). Some genes were poorly expressed across all samples, including those related to lineage differentiation or function of neutrophils (CEACAM8/CD66b, CSF2/GM-CSF), Th2 cells (IL4, IL13), and Th17 cells (IL17, IL22, IL22RA2, IL23A). Inflammatory infiltrates in normal tissues significantly over-expressed genes associated with regulatory T cells (FOXP3, CD4, TGFβ1), immunosuppression (SOCS1, CSF1R, IL27/EBB3, KLRG1), and the COX2 pathway (IL18, PTGER1/EP1, PTGER4/EP4). Focal LCM&GEP was more informative than quantitative whole slide IHC analysis. TCRSeq revealed relatedness among samples from normal tissue inflammation, however dominant clones were not shared with tumor infiltrates.

Conclusions
Rapid autopsy in an individual with melanoma allowed a unique opportunity to study the effects of immune checkpoint blockade on tumor regression and normal tissue inflammation in multiple organs. We found enhanced immunosuppression in inflamed normal tissues, reflecting intrinsic homeostatic mechanisms. TCRSeq indicated that anti-tumor and anti-self immunity may be parallel processes caused by distinct T cell clones. Individual genes upregulated in irAEs, such as IL1B, EP1 and EP4 (prostaglandin receptors), are targetable with existing drugs and may present new opportunities to specifically suppress irAEs while promoting anti-tumor immunity.

Acknowledgements
Supported by the Johns Hopkins Bloomberg–Kimmel Institute for Cancer Immunotherapy, NCI R01CA142779, Melanoma Research Alliance, Bristol-Myers Squibb, Moving for Melanoma of Delaware, LaVerne Hahn Charitable Trust, and the Barney Foundation.

References

Ethics Approval
The study was approved by the Johns Hopkins Institutional Review Board, approval number NA_0036610.

O12 B-cells activated by checkpoint blockade immunotherapy and radiation improve overall survival in squamous cell carcinomas
Yangwoon Kim, BA, Sarek Shin, Sayuri Miyachi, Philip Sanders, Loren Moll, MD, J. Silvio Gutkind, Ezra Cohen, MD, Joseph Califano, Andrew Sharabi, MD, PhD University of California, San Diego, CA, United States

Correspondence: Andrew Sharabi (sharabi@ucsd.edu)

Background
Many studies examining tumor immunology and the effects of radiation therapy (RT) and PD-1 checkpoint blockade immunotherapy (CBI) have focused on T-cells or myeloid cells. However, B-cells are a critical arm of the adaptive immune system and generate antibodies targeting tumors for eradication. Nevertheless, the role of B-cells in response to RT or CBI and resultant patient outcomes remains largely unknown. Here we studied B-cells in HPV-associated squamous cell carcinomas and identified dramatic changes induced by RT and CBI, and novel B-cell markers associated with improved overall survival.

Methods
For human studies we analyzed two independent databases of tumor RNA-seq from over 800 head and neck (HNSCC) and cervical cancer patients, including a prospective validation cohort. We performed proteomics array on samples from patients treated with CBI and RT to analyze antigen specific B-cell responses. For murine studies syngeneic head and neck models were used including MEF and AT-84. C3H and C57B/6 mice with palpable flank tumors were treated with combinations of RT and CBI. B-cell surface markers in the spleen, lymph nodes, and tumor were analyzed by flow cytometry. BCR sequencing was performed and analyzed using ImmunoSeq platform. Single-cell RNA sequencing (scRNA seq) was performed using the 10X Genomics platform and analyzed using Seurat v3.

Results
RT and CBI induced dramatic changes in systemic B-cell activation, T1 and T2- type B-cells, memory cells, plasma cells, and antigen specificity. B-cell depletion significantly increased tumor growth using HNSCC models. BCR sequencing identified that CBI and RT increase the maximum productive frequency and clonality, and modified CDR3 length. scRNA seq of sorted B-cells identified striking increases in B-cell germline center development after CBI and RT. Proteomics analysis revealed remarkable increases in IgG antibody levels in patients with objective responses after CBI and RT. Finally, analysis of tumor RNA sequencing data from two independent databases of over 800 patients identified CD19 and IGJ as novel B-cell specific prognostic biomarkers for 3-year overall survival (OS; 3-year OS hazard ratio = 0.545, P < 0.001).

Conclusions
RT and CBI activate multiple B-cell subpopulations, modulate B-cell germline center formation and maturation, and enhance B-cell mediated antigen-specific immune responses. Furthermore, we discovered CD19 and IGJ as novel B-cell prognostic biomarkers for 3-year overall survival.
survival in patients with HPV-associated squamous cell carcinomas. These findings establish a key role for B-cells in HPV-associated tumor biology and reveal a novel B-cell-mediated immune mechanism by which PD-1 blockade may improve patient outcomes.

**Ethics Approval**

Patients in the JHU cohort were recruited under protocol NA_00-36235, which was approved by the JHU IRB. Patients in the University of California, San Diego (UCSD) cohort were recruited under IRB approved protocol UCSD HRPP 151570 (ClinicalTrials.gov Identifier: NCT02843165).

**O13**

**Overcoming resistance to anti-PD1 therapy by targeting Bone Morphogenetic Proteins**

Maria Cortez, PhD1, Fatemeh Maspourour 1, Cristina Ivan, PhD1, Jie Zhang1, Ahmed Younes1, Yue Lu1, Marcos Estesico1, Hannapour Borsoumian1, Hari Menon1, Mauricio da Silva Caetano1, Pishab Ramapiyani1, Jonathan Schoenhals1, Xiaohong Wang1, Ferdinandos Skoulidis1, George Calin1, Patrick Hwu1, MD1, James Welsh1

1The University of Texas MD Anderson Cancer, Houston, TX, United States; 2UT Southwestern, Dallas, TX, United States

**Correspondence:** Maria Cortez (macortez@mdanderson.org)

*Journal for ImmunoTherapy of Cancer* 2019; 7(Suppl 1):O13

**Background**

Although anti-PD1 antibodies have produced durable control in some patients, most do not respond to this therapy and even those who do often develop resistance. The mechanisms underlying immunosuppression and resistance to PD1 inhibitors in lung cancer are not well understood, raising fundamental questions about the drivers of this resistance and how to enhance antitumor immune function to overcome treatment resistance. Here, we report that overexpression of bone morphogenetic protein (BMP)-7, a member of the TGF-beta superfamily, represents a new mechanism for resistance to anti-PD1 therapy in preclinical models and in patients with disease progression on immunotherapies.

**Methods**

Paraffin-embedded tissues from mouse and patients treated with pembrolizumab or ipilimumab were examined via IHC. BMP7 and cytokines/chemokines serum levels were analyzed by Elisa. Macrophages and CD4+T cells were isolated using magnetic beads and used in co-culture experiments. Anti-PD1-resistant 344SQ murine lung cancer cells (p53R172HΔ−) and parental cells were inoculated into syngeneic 129Sv/Ev mice, which were treated with anti-PD1, follistatin, anti-CTLA-4 or anti-PDL1. Tumor tissues were analyzed as follows: methylation status by reduced representation bisulphate sequencing and pyrosequencing methylation assay; protein levels by reverse-phase protein array. Tumor-infiltrating lymphocytes were isolated for flow cytometry and gene expression analyses using Nanostring. Prism 8.0 software and R were used for statistical analyses.

**Results**

BMP7 was upregulated in mouse and human tumors resistant to immunotherapies, and BMP7 levels were higher not only in blood from mice bearing resistant tumors but also in pretreatment blood from patients with disease progression on anti-PD1. BMP7 specifically regulated p38α expression via SMAD1 activation in mouse and in cancer patients with progression on immunotherapies. BMP7 is secreted by tumor cells and acts on immune cells, promoting downregulation of p38α and p38α-regulated cytokines and chemokines IL-1α, IL-1β, TNF-α, RANTES, IFN-γ, and IL-2. We found increased numbers of CD4+ and CD8+ IFN-γ+ T cells and decreased percentages of M2 macrophages in BMP7-knockdown tumors treated with anti-PD1 compared with control. Knockdown of BMP7 or its neutralization via follistatin in combination with anti-PD1, anti-CTLA4 or anti-PDL1 extended survival and re-sensitizes resistant tumors to immunotherapies.

**Conclusions**

Our studies revealed that BMP7 impinged effector T cell functions while favoring the generation of immunosuppressive cells precluding response to immunotherapy. Knockdown of BMP7 or its neutralization via follistatin in combination with anti-PD1 re-sensitizes resistant tumors to immunotherapies. Collectively, our results support that targeting BMP7 may represent a new approach to overcome resistance to checkpoint blockade in cancer.

**O14**

**Immune selection for IFN-γ signaling mutant cancer cells involves tumor heterogeneity and clonal cooperation**

Thomas Gajewski, MD, PhD1; Shuyin Li, PhD1; Jason Williams1, Emily Higgs1, Alexandra Cabanov1, Xiaozhong Wang2, Haochu Huang2

1University of Chicago, Chicago, IL, United States; 2Northwestern University, Chicago, IL, United States

**Correspondence:** Thomas Gajewski (tgajewski@medicine.bsd.uchicago.edu), Haochu Huang (haochu.huang@gmail.com)

*Journal for ImmunoTherapy of Cancer* 2019; 7(Suppl 1):O14

**Background**

Immune checkpoint blockade therapies have transformed the landscape of cancer care. Durable clinical responses have been observed in a subset of patients with historically difficult-to-treat cancer types. Despite these successes, many patients do not respond, indicating a primary resistance. Additionally, a significant proportion of patients develop progressive/recurrent disease after an initial clinical benefit, known as secondary resistance, a setting in which tumors may arise under a strong immune selection pressure. Further work is needed to elucidate and target secondary mechanisms of resistance, which may in turn improve treatment outcomes for patients.

**Methods**

To identify genes critical to immunotherapy resistance, B16.SIY cells were transduced with a genome-scale gRNA lentivirus to generate loss of function mutants. In vitro-primed CD8+ T cells isolated from C57Bl6 mice and the mice were subsequently treated with anti-PDL1 antibody. The tumor microenvironments were analyzed by flow cytomtery. Results

The genome-wide CRISPR screen identified Ifngr2 and Jak1 mutants resistant to CD8+ T cell killing in vitro. However, when implanted into mice, these mutant tumors paradoxically were better controlled immunologically and the anti-tumor CD8+ T cell response was augmented. This phenotype mapped to defective PD-L1 upregulation on mutant tumor cells which improved the anti-tumor efficacy of CD8+ T cells. To reconcile these observations with clinical reports of anti-PD-1 resistance linked to emergence of IFN-γ signaling mutants, wild-type and mutant tumor cells were mixed prior to implantation and anti-PD-L1 treatment, to recapitulate tumor cell heterogeneity. Under these conditions, IFN-γ signaling mutant tumor cells indeed grew out.

**Conclusions**

Our results illustrate the complexity of functions for IFN-γ in anti-tumor immunity and demonstrate that intra-tumor heterogeneity and clonal cooperation can contribute to patterns of immunotherapy resistance.
O15
Replication stress response defects predict response to immune checkpoint blockade across multiple cancer lineages
Daniel McGrail, PhD, Patrick Pilie, MD, Truong Nguyen Anh Lam, Hui Dai, MD, Eric Jonasch, MD, Shiaw-Yih Lin, PhD
MD Anderson Cancer Center, Houston, TX, United States
Correspondence: Shiaw-Yih Lin (sylin@mdanderson.org)

Background
Immune checkpoint blockade (ICB) has provided robust, durable responses for a subset of patients. Initial studies focused on high-mutation burden, or “mutator,” cancers identified potential protein, mutational, and gene expression biomarkers for patient response. While emerging clinical data indicates ICB may also contribute to treatment of “non-mutator” cancers, such as renal cell carcinoma and glioblastoma, we and others have found established clinical biomarkers exhibit minimal activity at predicting response in non-mutator patient cohorts.

Methods
To analyze predictive biomarkers for ICB response, we gathered 11 non-mutator patient cohorts across 5 different tumor lineages treated with ICB, along with a profiling molecular data including gene expression profiling, PD-L1 immunohistochemistry, tumor mutation burden (TMB), and relevant clinical information. Mechanistic studies using flow cytometry, microscopy, and quantitative cellular fractionation were performed using human and mouse cell lines. Pre-clinical models of ICB treatment were used to validate ICB response mechanisms and analyze immune populations with multispectral imaging.

Results
We demonstrate accurate prediction of ICB response in all 11 non-mutator patient cohorts spanning 5 tumor lineages using a gene expression signature indicative of replication stress response (RSR) defects. Across these cohorts the average area under the receiver-operator characteristic (ROC) curve was 0.82 (range 0.72-1.00). No other evaluated biomarker, including mutation/neoantigen burden, PD-L1 immunostaining, and the T cell inflamed gene expression signature, was able to predict outcomes across these cohorts. Pre-clinical studies show that RSR defect-high tumors cells undergo RPA exhaustion downstream of aberrant origin firing, leading to accumulation of immunostimulatory cytoplasmic DNA. Consistent with this, pharmacological induction of RSR defects induced accumulation of cytoplasmic DNA and sensitivity to ICB, whereas suppression of origin firing reduced cytoplasmic DNA causing ICB resistance. Both multispectral immunostaining of preclinical models and in silico analysis of patient cohorts failed to uncover any conserved relationship between infiltrating immune populations and response to ICB.

Conclusions
The RSR defect gene signature can accurately identify patients who will benefit from ICB across numerous non-mutator tumor lineages, and the benefits of ICB may be further expanded by pharmacological induction of the RSR defect phenotype.

Ethics Approval
All samples used were collected in accordance with their respective institutes’ Ethics Boards. All animal studies were approved by IACUC at The University of Texas MD Anderson Cancer Center.

Clinical Trial Completed
O16
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) – Final Results of the phase II AVETUX trial (AIO-KRK-0216)
Mascha Binder1, Eray Goekkurt2, Sylvie Lorenzen3, Jorge Riera-Knorrenschild4, Reinhard Depenbusch5, Thomas Ettrich6, Steffen Doerfler6, Salah Al-Batran7, Meinolf Karthaus8, Uwe Pelzer9, Donjete Simnica9, Lisa Wabereg9, Axel Hinke10, Carsten Bokemeyer11, Susanna Hegewisch-Becker12, Joseph Tintelnot, MD13
1University Cancer Center Hamburg, Hamburg, Germany; 2University Hospital Halle, Halle, Germany; 3Hematology-Oncology Practice Hamburg (HO), Hamburg, Germany; 4Rechts der Isar Hospital, Technical Univ, Munich, Germany; 5University Clinics Giessen-Marburg, Marburg, Germany; 6Private Practice Onkodoc GmbH Gütersloh, Gütersloh, Germany; 7Center for Internal Medicine I, Universi, Ulm, Germany; 8Private Practice Onkazentrum Dresden, Dresden, Germany; 9Institute of Clinical Cancer Research, K. Frankfurt, Germany; 10Neuperlach Clinic, Neuperlach, Germany; 11Charite, Berlin, Germany; 12CCRC, Duesseldorf, Germany; 13University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Correspondence: Eray Goekkurt (goekkurt@hope-hamburg.de)

Background
Single agent PD-1/L1 inhibition is efficacious in MCRC patients (pts) with high microsatellite instability (MSI-H). For the vast majority of MCRC pts with MSI stable (MSS) phenotype the role of immunotherapy still needs to be determined. Based on the induction of immunogenicity by chemotherapy, particular oxaliplatin and immunogenic cell death by cetuximab in combination with chemotherapy the standard 1st line regimen FOLFOX and cetuximab in combination with avelumab was evaluated.

Methods
The single arm phase II AVETUX trial combined mFOLFOX6 and cetuximab with avelumab (10mg/kg day 1 from cycle 2 onwards) in RAS/BRaf wildtype (local lab) MCRC pts. Primary endpoint was 12 month progression-free survival rate. Secondary endpoints included overall response rate (ORR), tolerability, overall survival and translational research evaluating tissue including PD-L1 expression (tumor/immune cells) and serial ctDNA. Efficacy analyses were done by intention to treat (ITT).

Results
Overall 43 pts were enrolled. Median age was 61 (range 29-82), 14 pts (33%) were female and 39 (91%) left sided. 30 pts (70%) had liver mets and 17 (40%) liver mets only. 2 pts were MSI-H, one MSI-low and 40 MSS. Besides immediate and otherwise unexplained fever in 4 pts treatment was well tolerated and avelumab was not associated with unexpected adverse events to standard FOLFOX/cetuximab. Central tissue review found 4 pts to be ineligible due to low frequent KRAS or BRAF mutation (15-31%). Thus, ITT included 39 pts. The ORR was 79.5%, including 6 complete (CR) and 25 partial responses (PR). Further 5 stable diseases were noted, thus disease control rate was 92.3%: 2 pts had progression and 1 was not evaluable. Early tumor shrinkage (ETS) rate (≥20% after 8 weeks) was 79.5% (1 CR, 27 PR and 3 SD with ≥20% -
A novel enantio-specific cationic lipid R-DOTAP + HPV16 E6 & E7 antigens induces potent antigen-specific CD8+ T cell responses in vivo in subjects with CIN and high-risk human papillomavirus infection

Lauren Wood, MD1, Lance Edwards, MD2, Daron Ferris, MD3, Nicole Nevadunsky, MD3, Sara Isani, MD3, Greg Conn, PhD1, Frank Bedu-Addo, PhD1, Mark Einstein, MD3.

1PS Biotechnology, Berkeley Heights, NJ, United States; 2Suffolk Obstetrics and Gynecology, Port Jefferson, NY, United States; 3Augusta University, Augusta, GA, United States; 4Montefiore Medical Center, Bronx, NY, United States; 5Rutgers-NJMS, Newark, NJ, United States

Correspondence: Lauren Wood (lwood@psbiotech.com)

Background
Persistent human papillomavirus (HPV) 16 DNA infection is associated with up to 60% of cervical cancers as well as the high grade cervical intraepithelial neoplasia (CIN) that precedes them. Current treatment strategies focus on excision of these virally mediated precancerous lesions and cancers, which lead to preterm birth and other issues highlighting an unmet clinical need for medical therapeutics. Therautic vaccines to date have been limited in their ability to generate high levels of HPV16-specific CD8 cytolytic T cells (CTL) in vivo. Here we describe a phase I dose escalation study of PDS0101, a novel multi-functional HPV16-specific immunotherapeutics which acts via anti-virus cross presentation and induction of type I interferons [1] in women with high-risk (hr) HPV infection and CIN. (NCT02065973)

Methods
Twelve females (median age 33 years, range 24-51), with confirmed CIN1 and hrHPV DNA infection received PDS0101 administered subcutaneously at doses of 1.0, 3.0 and 10.0 mg of R-DOTAP with a fixed 2.4 mg dose of HPV16 peptide mix. Vaccines were administered at Days 1, 22, and 43, with immune monitoring pre-treatment, 14 days after each vaccination and at Day 133. HPV16-specific CD8+ T-cell induction was assessed by Granzyme B ELISPOT. All subjects were monitored for safety and tolerability of vaccination.

Results
Four of 12 subjects (33%) had HPV16, with 8 subjects (67%) having two or more HPV genotypes. A total of 15 HPV genotypes were documented (mean 2.5 genotypes/subject). Two subjects had high pre-existing HPV responses. The remaining 10 subjects had low HPV16-specific T-cell responses pre-vaccination: 100% (10/10) developed vaccine-induced HPV16-specific T-cell responses on day 14; 9 of 10 (90%) had IFN-γ responses while 6 of 9 (67%) had granzyme B responses. Comparable CD8 T cell reactivity was observed in the 3.0 and 10.0 mg R-DOTAP cohorts as assessed by mean fold-increase over baseline as shown in Table 1. All doses were well-tolerated with the most common toxicity of self-limiting local injection site reactions that resolved within several days.

Conclusions
PDS0101 is associated with induction of potent HPV16-specific CD8 T cells with a granzyme B cytolytic profile and is safe and well tolerated. The 3.0 mg R-DOTAP dose has been selected for further studies in subjects with high grade CIN2/3 and HPV16DNA infection as well as HPV16-related head and neck cancer.

Trial Registration
NCT02065973

References

Ethics Approval
The investigators from each respective institution obtained approval of the study from a properly constituted institutional review board (IRB) prior to study initiation. These included Schulman IRB (now Advarya IR), BRANY IRB (#IRB00000800), and Georgia Regents University IRB (now Augusta University IRB).

Table 1 (abstract 017). See text for description
taken 3 to 4 months following the initiation of vaccination. Patients with EGFR mutations (n=16) were given the option of continuing EGFR inhibitor (EGFRi) therapy concurrent with NeoAg vaccination, despite previously experiencing disease progression on EGFRi.

Results
Following NeoAg vaccination, 7 RECIST-based objective clinical responses were observed, with all responders being amongst the 16 patients harboring EGFR mutations. Immune monitoring demonstrated robust EGFR NeoAg-specific T cell responses in 5 responding patients, with 3 patients generating dominant CD8+ T-cell responses against a single NeoAg peptide encompassing the widely shared L858R driver mutation. Importantly, patients that continued receiving EGFRi therapy showed significantly extended overall survival compared to patients who stopped EGFRi prior to immunization (13.8 vs. 7.6 months, P=0.038). Molecular and cellular analyses showed that EGFRi impacted multiple immunomodulatory pathways in EGFR-mutated lung tumor cells to favor immune cell infiltration and HLA-mediated antigen presentation, providing a potential mechanism of synergy with NeoAg vaccination.

Conclusions
These findings identify shared EGFR mutations as immunogenic NeoAgs with therapeutic potential, and suggest that EGFRi in combination with NeoAg vaccination may facilitate improved clinical outcomes for patients with NSCLC, even in the setting of prior EGFRi failure.

Trial Registration

References

Ethics Approval
This study has been performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Tianjin Beichen Hospital, Tianjin, China.

O19
Final results from a phase 2 study using off-the-shelf activated natural killer (aNK) cells in combination with N-803, an IL-15 superagonist, in patients with metastatic Merkel cell carcinoma (MCC)
Shailender Bhatia, MD, Candice Church, PhD, Kelly Paulson, MD, PhD, Robert Pierce, MD, Paul Nghiem, MD, PhD, John Lee, MD, Bridget Adcock, BS, Patrick Soon-Shiong, MD, Sunandana Chandra, MD
1University of Washington; Fred Hutchinson Cancer Research Center, Seattle, WA, United States ; 2University of Washington, Seattle, WA, United States ; 3Fred Hutchinson Cancer Research Center, San Diego, CA, United States ; 4ImmunityBio, Inc, Culver City, CA, United States ; 5Northwestern University Feinberg School of Medicine, Chicago, IL, United States
Correspondence: Shailender Bhatia (sbhatia@uw.edu), Sunandana Chandra (sunandana.chandra@northwestern.edu)

Background
Metastatic MCC, a virus-associated cancer, is associated with high objective response rates (ORRs) to PD-1/PD-L1 blockade. Unfortunately, ~50% of patients are refractory due to MHC-I downregulation and other mechanisms of immune evasion. Allogeneic aNK cells are cytotoxic to tumor cells with deficient MHC-I, and N-803 increases the number and cytotoxicity of NK and memory CD8+ T cells. aNK plus N-803 therapy could reverse refractoriness to immune checkpoint inhibitors (ICI) in MCC (and other immunogenic cancers).

Methods
In this phase 2 trial, aNK monotherapy (2×10^9 cells/m^2, expanded on-site) was administered intravenously on days 1 and 2 of each 2-week cycle; a subsequent protocol amendment added subcutaneous N-803 (10 μg/kg) on day 1 prior to aNK infusion. Key eligibility criteria included unresectable stage III or IV MCC, and ≤ 2 prior systemic therapies. Endpoints included ORR by RECIST 1.1, progression-free survival, safety, and immunologic changes in the tumor microenvironment.

Results
Seven subjects were enrolled; 3 received aNK monotherapy, and 4 received aNK plus N-803. Two of 7 subjects had objective responses (ORR=29%; one partial response (PR) and one unconfirmed complete response (CR)) after aNK (with/without N-803) therapy was well tolerated, and led to clinical benefit in 3 of 7 patients, including reversal of ICI-refractoriness in one patient. This trial provides proof of concept for aNK-based therapy in MCC and supports an upcoming registrational trial (NCT03853317) using cryopreserved NK cells (not requiring on-site expansion) plus N-803 plus avelumab in patients with advanced MCC refractory to treatment with ICIs.

Conclusion
aNK (with/without N-803) therapy was well tolerated, and led to clinical benefit in 3 of 7 patients, including reversal of ICI-refractoriness in one patient. This trial provides proof of concept for aNK-based therapy in MCC and supports an upcoming registrational trial (NCT03853317) using cryopreserved NK cells (not requiring on-site expansion) plus N-803 plus avelumab in patients with advanced MCC refractory to treatment with ICIs.

Correspondence: Alexander Shoushtari (shoushta@mskcc.org)

Background
Many patients (pts) with advanced melanoma experience disease progression despite receiving immune checkpoint inhibitors (ICI). Resistance to ICIs may be due to an immunosuppressive tumor microenvironment. Oncolytic viruses have the unique ability to both prime and boost immune responses. ONCOS-102 is a granulocyte-macrophage colony stimulating factor (GM-CSF) expressing oncolytic adenovirus (AdS5/D24-GMCSF). A prior phase I study demonstrated both innate and adaptive immune responses in various solid tumors.

A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma
Alexander Shoushtari, MD, Anthony Olszanski, MD, RPh, Thomas Hornyk, MD, Jedd Wolchok, MD, PhD, Sylvia Vethus, Karianne Risberg Handeland, Ilkaz Kunyk, PhD, Magnus J aden,"md, MD, M dm.
1Memorial Sloan Kettering Cancer Center, New York, NY, United States ; 2Fox Chase Cancer Center, Philadelphia, PA, United States ; 3University of Maryland, Baltimore, MD, United States ; 4Targovax ASA, Oslo, Norway
Correspondence: Alexander Shoushtari (shoushta@mskcc.org)
The aim of this study is to assess the safety, clinical and immune responses in pts with advanced melanoma who have progression despite prior PD-1 blockade.

Methods
Eligible pts had advanced or unresectable melanoma progressing after PD-1 blockade. Pts received 3 intra tumoral injections of ONCOS-102 at 3x1011 viral particles on days 1, 4 and 8 followed by pembrolizumab (2mg/kg or 200mg flat dose) on day 22 and then every 3 weeks until week 27. Biopsies were performed at baseline, Week 3 and Week 9. Primary objective was safety of the treatment. Secondary objectives: Objective Response Rate (defined as CR or PR), Clinical Benefit Rate (CR defined as PR, CR or SD) by RECIST1.1 at 27 weeks, and changes in immune cell subsets.

Results
9 pts were enrolled. Median age 73 years (40-87), 4/9 female, AJCC stage III (6 pts) and stage IV (3 pts). All pts had prior anti-PD1. 4 pts had previous anti-CTLA4, 3 T-VEC, 2 BRAFi/MEKi, 1 IL-2 and 1 TLR9 agonist. RECIST1.1 confirmed responses were seen in 3/9 pts (33%) with one CR and two PR. CBR was also 33%. The most common AEs were chills and fever associated with adenovirus replication. There were no Dose Limiting Toxicities. 5 SAEs were seen in 3 pts, including one pt with infectious colitis related to ONCOS-102. Intramuscular injection of pembrolizumab and PD1+nCD8+ T-cells was seen in all pts. Multiplex IHC in 7 paired tumor biopsies confirmed lesonal infiltration of CD8+ T-cells in all pts and PD1+nCD8+ T-cells in 6/7 pts. IFNγ ELISPOT revealed 2 patients with de novo tumor specific T-cells (MAGE-A1, NY-ESO-1) and 2 patients with MAGE-A1 and/or NY-ESO-1 at baseline that increased during the study.

Conclusions
ONCOS-102 combined with pembrolizumab is tolerable and appears to induce systemic and lesional immune activation that can lead to objective responses in anti-PD1 refractory melanomas. An expansion cohort is currently enrolling pts to receive up to 24 weeks of ONCOS-102 injections.

Trial Registration
ClinicalTrials.gov NCT02879669

Ethics Approval
This study was approved by the IRBs of Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center and the University of Maryland Greenebaum Comprehensive Cancer Center.

O21
Safety and clinical activity of avelumab (MSB0010718C), an anti-programmed death-ligand 1 (PD-L1) antibody, in recurrent thymic epithelial tumors (TETs)

Arun Rajan, MD1,2, Haobin Chen1, Chen Zhao, MD1, Shannon Swift1, Andrew Mammen1, Alessandra Brofferio1, Emerson Padernos1, Eva Szabo1, MD1, Udayan Guha1, Raffiti Hassan1, MD1, Seth Steinberg1, Yo-Ting Tsai1, Renee Donahue, PhD1, Jeffrey Schlom1, James Gulley, MD, PhD2, FACCP
1National Cancer Institute, Bethesda, MD, United States; 2National Institutes of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, United States; 3National Heart, Lung, and Blood Institute, Bethesda, MD, United States

Correspondence: Arun Rajan (rajanam@mail.nih.gov)

Background
TETs (composed of thymomas and thymic carcinomas) are PD-L1-expressing tumors with low tumor mutation burden, and particularly with thymomas, defective immune tolerance that increases the risk of paraneoplastic autoimmune. We have previously demonstrated activity of avelumab with an increased incidence of skeletal and cardiac muscle inflammation in a small cohort of thymoma patients. The present study aims to confirm the safety and activity of avelumab and evaluate cyclosorpin A (CsA) for secondary prophylaxis against immune myositis and isolated troponin elevation.

Methods
Patients with recurrent TETs and no active autoimmune disease were eligible and received avelumab 10 mg/kg intravenously q2weeks. Primary objectives were evaluation of safety (by CTCAE v4.0) and response rate (by RECIST v1.1). Patients developing non-life-threatening immune-related adverse events (irAEs) resumed avelumab after appropriate management. CsA was used for secondary prophylaxis against musculoskeletal irAEs at the lowest effective dose. Immune activation was assessed by flow cytometry and ELISA. This study is approved by the NCI Institutional Review Board and registered in clinicaltrials.gov (NCT03076554).

Results
Twenty-three subjects (12 thymoma, 11 thymic carcinoma; 10 female; median age 56 yrs) were enrolled between April 2017 and October 2018. Twenty-two subjects were evaluable for response. Among thymoma patients: partial response: 2 (17%), stable disease: 10 (83%). Among thymic carcinoma patients: partial response: 2 (20%), stable disease: 6 (60%), progressive disease: 2 (20%). After a median potential follow-up of 18.6 months, median progression-free survival for thymoma patients was 6.4 months (95% CI: 3.7 months – not estimable) and 14.7 months (95% CI: 1.3 months – not estimable) for patients with thymic carcinoma. irAEs occurred in 12 (52%) patients (thymoma 58%, thymic carcinoma 45%). Most common irAEs of any grade included myositis (17%), sicca syndrome (13%), myocarditis and thyroiditis (9% each). Avelumab rechallenge with CsA secondary prophylaxis was feasible in 3 of 4 (75%) patients with myositis with no further issues. irAEs caused treatment discontinuation in 3 (13%) patients. No treatment-related deaths occurred. All patients had high pre-treatment soluble PD-L1 levels compared with healthy donors. Low baseline B-cell counts correlated with clinical response and occurrence of some irAEs.

Conclusions
Avelumab is safe and active in TET patients. CsA can prevent recurrence of immune myositis. This is the first reported use of CsA for this indication with implications on the feasibility of immunotherapy for patients with thymoma and/or underlying autoimmunity. This trial is being amended to increase accrual ceiling with a phase II design.

Acknowledgements
This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

Trial Registration
ClinicalTrials.gov ID: NCT03076554

Ethics Approval
This study is approved by the NCI Institutional Review Board and registered in clinicaltrials.gov (NCT03076554).

Clinical Trial In Progress

O22
Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastoma

Daniela Bota1, David Piccioni, MD, PhD2, Renato LaRocca, MD3, Christopher Durma, MD4, Robert Aiken, MD5, Santosh Kesari, MD, PhD5, Jose Carrillo, MD5, Thomas Taylor, PhD3, Candace Hsieh5, Gabriel Nistor5, Robert Dillman, MD, FACCP
1University of California Irvine, Orange, CA, United States; 2University of California San Diego, San Diego, CA, United States; 3Norton Hospital, Louisville, KY, United States; 4Hagosp Hospital, Newport Beach, CA, United States; 5Rutgers University, NewBrunswick, NJ, United States; 6John Wayne Cancer Institute, Santa Monica, CA, United States; 7Avita Biomedical, Inc., Irvine, CA, United States

Correspondence: Robert Dillman (bob@avitaBiomedical.com)

Background
Despite advances in surgery, radiation therapy, and chemotherapy, glioblastoma (GBM) remains a highly lethal disease, and has been relatively refractory to anti-checkpoint therapy, presumably because of limited host anti-tumor immune responses. Treatment with an effective vaccine could increase immune responses and improve survival.

Methods
This phase II trial was approved by the Western IRB. AV-GBM-1, patient-specific dendritic cell vaccines loaded with autologous tumor
Sitravatinib in combination with nivolumab demonstrates clinical activity in platinum-experienced patients with urothelial carcinoma (UC) who progressed on prior immune checkpoint inhibitor (CPI) therapy after completion of standard optimal therapy which includes maximum safe surgical resection followed by concurrent treatment with radiation therapy and temozolomide chemotherapy. Key eligibility criteria are a diagnosis of primary GBM, age 70 or less at the time of tumor harvest, successful establishment of a short-term cancer cell line, successful leukapheresis collection of monocytes, and a Karnofsky Performance Status of 70 or greater at the time of enrollment, which takes place just prior to starting chemoradiation. Tumor is collected at the time of surgery from which a short-term cell line is derived. Dendritic cells are produced by incubating peripheral blood monocytes with GM-CSF and IL-4. The antigen source is a lysate of irradiated tumor cells from the cell culture. After completion of concurrent chemoradiation, vaccine doses admixed with GM-CSF are injected subcutaneously at week 1, 2, 3, 8, 12, 16, 20, and 24 for up to eight doses. The objective is to achieve a 75% survival rate 15 months from enrollment, which would be a 50% increase over results achieved with standard therapy alone.

Results

Cell line success rate for submitted GBM samples is 39/41 with 3 in progress. A satisfactory leukapheresis product has been obtained for 34/35 patients, but was repeated for 4. 30 of a planned 55 patients have been enrolled for intent-to-treat. 24 have started treatment; 3 have completed all 8 doses, 3 discontinued early for disease progression, 18 are currently in treatment. 121 doses have been administered in total. Proteomic analysis of blood samples obtained at baseline and at the time of each vaccine injection, has demonstrated Th1, Th2, and Th17 immune responses in 7/8 patients. No significant toxicity directly attributed to the vaccine has been reported.

Conclusions

Although logistically complex, this patient-specific vaccine approach is feasible. Furthermore, the vaccine has been well-tolerated and has induced immune responses in nearly all patients analyzed to date.

Trial Registration

ClinicalTrials.Gov. NCT03400917

Ethics Approval

The study was approved the Western Institutional Review Board, approval number 20182582

Background

Sitravatinib is a spectrum-selective TKI that targets TAM receptors (Tyrro3, Axl, MerTK), split family receptors (VEGFR2 and c-Kit) and c-Met. Inhibition of these receptor tyrosine kinases may enhance anti-tumor activity by reducing Type 2 tumor-associated macrophages, regulatory T cells and myeloid derived suppressor cells and enhancing a T cell-mediated anti-tumor immune response. Given these pleiotropic immune-enhancing effects, we hypothesized that the combination of sitravatinib with nivolumab will restore or enhance CPI clinical activity in pts with immunotherapy-resistant UC.

Methods

Study 516-003 objectives include evaluation of safety and efficacy in patients (pts) with advanced or metastatic UC. Cohort 1 includes UC pts who have disease progression on or after CPI and were previously treated with platinum-based chemotherapy. Sitravatinib is administered orally, daily, in 28-day cycles; nivolumab is administered intravenously, either 240 mg every 2 weeks or 480 mg every 4 weeks. A target sample size of 7 pts with futility based on the Predictive Probability Design (PPD) is used, with the option to expand if clinically active. Other objectives include pharmacokinetics (PK) and correlative biomarkers.

Results

The 516-003 study met its prespecified measure of clinical activity in Cohort 1 with 3 confirmed responses in the first 17 evaluable patients. A 14.7% estimated 1-year duration of response, warranting expansion of enrollment, which is ongoing. As of 26 July 2019, Cohort 1 has enrolled 25 pts with 21/25 having had > 1 on-study tumor assessment and 13/25 having had > 2 on-study tumor assessments. Sixteen out of 21 pts have demonstrated tumor reductions. Six out of 21 pts have achieved a partial response (PR): 3 confirmed (including 1 unconfirmed Complete Response on 2nd tumor assessment) and 3 unconfirmed. Clinical benefit rate (CBR), defined as confirmed response or SD on > 2 tumor assessments with treatment duration > 14 wks, was observed in 9/13 pts. Among pts with reported adverse events (AEs), treatment-related AEs (>20% of pts; all grades in decreasing frequency) included fatigue, diarrhea, decreased appetite, dysphonia, increased alanine aminotransferase, nausea, increased lipase, palmar-plantar erythrodysesthesia syndrome (PPE), increased aspartate aminotransferase, hypertension, dysgeusia, proteinuria, and vomiting. Grade 3 treatment-related AEs in > 1 pt included hypertension, fatigue, diarrhea, increased lipase, and PPE. There were no Grade 4 or 5 treatment-related AEs. Updated safety, PK and efficacy data will be presented.

Conclusions

The combination of sitravatinib with nivolumab is clinically active with manageable side effects in pts with advanced or metastatic UC who progressed on CPI and were previously treated with platinum-based chemotherapy.

Ethics Approval

The study was centrally approved by WIRB, IRB tracking number 20181442.

O24

Phase II trial of concurrent Nivolumab and radiation therapy in chemotherapy ineligible muscle invasive bladder cancer (NUTRA trial)

Saby George, MD, FACP,1 Lance Heilbrun,2 Jordan Maier, MD,2 Brenda Dickow,1 Michael Kuettel, MD,2 Arthur Fraizer, MD,3 Stacey Suisham, RN BSN OCN CCRP,2 Prahlad Parajula, PhD,3 Nitin Vaishampayan, MD,1 Ulka Vaishampayan, MD4

1Wayne State University and Barbara Ann K, Detroit, MI, United States; 2Roswell Park, Buffalo, NY, United States; 3Wayne State University, Detroit, MI, United States; 4Karmanos Cancer Center, Detroit, MI, United States

Correspondence: Ulka Vaishampayan (vaishamu@karmanos.org)


Background

Concurrent chemotherapy and radiation is a bladder sparing strategy for management of muscle invasive bladder cancer (MIBC). However many patients are not candidates for chemotherapy due to comorbid conditions, performance status, or having received prior chemotherapy
with progression. We are conducting a study in a chemotherapy ineligibile patient population with the primary objective of comparing the 12-month rate of progression-free (PFS) survival achieved with the combination of nivolumab, a programmed death (PD-1) inhibitor, and radiation therapy in localized/locally advanced urethelial cancer patients, to a historical control reference rate.

Methods

Eligible patients have MIBC, are not candidates for standard chemoradiation strategy due to any of the following: performance status of 2, creatinine clearance < 60ml/min, cardiac disease, neuropathy, or intolerance to previous treatment. Creatinine clearance >40ml/min, normal marrow and liver function were required. The primary endpoint is progression free survival rate at 12 months. Nivolumab is started within 3 days of radiation therapy and is administered at the dose of 240 mg intravenously every 2 weeks for a maximum of 6 months. Radiation therapy is per standard of care for bladder cancer. Imaging and cystoscopy and biopsy evaluation is required at months 3, 6 and 12 and then annually until progression.

Results

14 evaluable patients; median age 71 years- (range 54 to 95 years) 12 males and 2 females, 3 African American and 11 Caucasian have been enrolled. 11 patients have completed radiation therapy. 3 patients had prior intravesical therapy and 2 patients had prior systemic chemotherapy with cisplatin and gemcitabine. 2 patients were clinical T3 (T4) and one patient had pelvic LN pathy. The regimen was well tolerated with Nivolumab and radiation therapy. No severe treatment related adverse events were noted. 5 patients needed steroids due to immune mediated adverse events. 8 patients are evaluable after one assessment and 3 patients demonstrated complete remission. PDL-1 expression is being tested. Preliminary immune evaluation results indicate an improvement in CD4:CD8 ratio, natural killer (NK) cell expansion as well as enhanced expression of T cell and NK cell activation markers.

Conclusions

Concurrent nivolumab and radiation therapy is tolerable and showed promising efficacy in an elderly population with multiple comorbidities. Immune correlates data will be available for the treated patients and will be reported.

Trial Registration

The Clinical trials.gov no NCT03421652

Ethics Approval

The study was approved by Wayne State University's Ethics Board, approval number 083417MP2F

O26

A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis

Matthew Krebs, MD PhD 1, Paal Brunsvig, MD PhD 2, Åslaug Helland 2, Nuria Villosas Segara 1, Santiago Ponce AIX, MD 2, Enric Carcereny Costa 2, Manuel Domíne Gomez, MD, PhD 2, Jose Manuel Trigo Perez 2, Edune Arriola 3, Rosario García Campeol 1, James Spicer, MD, PhD 10, Jonathan Thompson, MD MS 11, Ana Laura Ortega Granados 12, Robert Holt, PhD 13, James Lorenès, PhD 13, Muhammad Shoaib, MD 13, Abdul Siddiqui 13, Emmett Schmidt, MD PhD 14, Michael Chisamore, PhD 14, Enriqueta Felip, MD PhD 15

1Christie NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom; 2Oslo University Hospital, Oslo, Norway; 3Hospital Clinic, Barcelona, Spain; 4Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 5Catalan Institute of Oncology, Badalona, Spain; 6Hospital Universitari, Madrid, Spain; 7Hospital Virgen de la Victoria, Málaga, Spain; 8Hospital del Mar, Barcelona, Spain; 9University Hospital A Coruña, A Coruña, Spain; 10King’s College London, Guy’s Hospital, London, United Kingdom; 11Medical College of Wisconsin, Milwaukee, WI, United States; 12 Complejo Hospitalario de Jaén, Jaén, Spain; 13BerGenBio ASA, Oslo, United Kingdom; 14Meck & Co., Inc, Kenilworth, NJ, United States; 15Hospital Universitari Vall d’Hebron, Barcelona, Spain

Correspondence: Matthew Krebs (matthew.krebs@christie.nhs.uk)


Background

AXL is an RTK implicated in EMT, immune suppression and resistance to anti-PD1 therapy. Bemcentinib (BGB324), a first-in-class, oral, selective and potent AXL kinase inhibitor, enhances anti-PD1 efficacy in pre-clinical models.

Methods

This is a PhII single-arm, 2-stage study with bemcentinib (200mg/d) and pembrolizumab (200 mg/g3wk) for previously-treated, 10-naive patients with Stage IV lung adenocarcinoma. Primary endpoint was ORR according to RECIST 1.1 with pre-defined minimum requirement of 18% RR in the first Stage (n=24) to proceed to Stage 2. Secondary endpoints included DCR, PFS, OS and safety. Updated biomarker analysis and correlations with clinical endpoints will be presented, including quantification of tumor and immune cell AXL, PD-L1 protein expression, and genetic and transcriptome analysis.
Results
Enrolment for both stages is complete. As of July 2019, 50 patients have been dosed with the combination. Median age 65 years (range: 39-82), 60% male. All patients received one prior line of platinum-based chemotherapy or an approved EGFR/ALK-directed therapy. AXL status was available for 33 patients: 19 AXL-positive, 14 AXL-negative. PD-L1 status was available for 42 patients: 4 TPS >50%, 16 TPS 1-49%, and 22 TPS <1%.

Most common TEAEs (occurring in >25% of patients) were asthenia/fatigue (54%, 18% grade 3+), transaminase increases (46%, 20% grade 3+), diarrhea (32%, no grades 3+) and decreased appetite (28%, no grade 3+). All cases of transaminase increase were reversible and managed with concomitant administration of systemic corticosteroids and interruption of study treatments, or Grade 1 (mild) events.

To date, 43 patients were radiologically evaluable, with 10 PRs observed (ORR 23%). 17 AXL-positive patients were radiologically evaluable, with 6 responses observed (35%), as opposed to 2 (15%) in the 13 radiologically evaluable AXL-negative patients. Of the 10 responders, 4 had a TPS 50% (1 AXL-positive); 2 did not have a PD-L1 status available (1 AXL-positive, 1 AXL-negative).

In Stage 1, mPFS was 4.0 months overall (95% CI 1.9 –NR) and 5.9 months in AXL-positive pts (n=10; 3.0 - NR). mPFS for the entire cohort continues to mature and will be reported at the meeting.

Conclusions
Promising clinical activity has been seen, particularly in pts with AXL-positive disease and including patients with PD-L1-negative tumors. Overall, bemcentinib in combination with pembrolizumab was well tolerated. Updated results will be reported at the meeting, including PFS for all Cohort A patients as well as further biomarker data.

Acknowledgements
The authors would like to thank all patients and their caretakers for participating in this trial.

Trial Registration
NCT03184571

References

Ethics Approval
This study was approved by all relevant institutions, including London Bridge Research Ethics Committee (UK), REC-South East (Norway), Drug Research Ethics Committee of the University Hospital Clinic of Barcelona (Spain), MCW/FH Institutional Review Board #4, Medical College of Wisconsin (USA).

O27
Clinical response to Tumor Infiltrating Lymphocytes (TIL) in stage 4 Non-small Cell Lung Cancer (NSCLC) correlates with Neoantigen-Specificity: a phase I trial
Chao Wang, PhD1, Jamie Teer1, Jiqiang Yao, PhD1, Aradon Galindo Carmen M1, David Noyes1, Eric Tolosa1, John Mullinax, MD1, Ana Landin, Juanelle Gray1, Tawee Tanvyetpanon1, Andreas Salts1, Linda Kelley, PhD1, Bin Fang, PhD1, John Koomen, PhD1, Amor Sarnaik, MD1, Sungjune Kim, MD, PhD1, Shari Pilon-Thomas, PhD1, Jose Conejo-Garcia, MD, PhD1, Scott Antonia, MD PhD1, Eric Haura, MD1, Ben Creelan, MD, MS1
1 Moffitt Cancer Center, Tampa, FL, United States; 2Duke University, Durham, NC, United States

Correspondence
Eric Haura (Eric.Haura@moffitt.org), Ben Creelan (Ben.Creelan@moffitt.org)


Background
Neoantigens are generated by non-synonymous somatic mutations and could be recognized by self T cells and elicit neoantigen specific T cell responses[1]. Scientists have shown that adoptive transfer of tumor infiltrating lymphocytes could induce durable remissions for patients with epithelial cancers[2,3]. We hypothesized that TIL therapy may induce remissions in anti-PD1-refractory patients. Therefore, we initiated a phase I trial to evaluate the safety and preliminary activity of TIL therapy in anti-PD1-refractory non-small cell lung cancer (NSCLC) patients and characterize the corresponding neoantigen specific T cells.

Methods
Eligible patients received TIL harvest, followed by 4 cycles of nivolumab, with 2 serial CT scans. Patients with enlarging or new tumors proceeded to receive lymphodepletion with cyclophosphamide/fludarabine (Cy/Flu), TIL infusion and IL-2. Tumors from these patients were resected, morselized and tested using whole exome sequencing and RNA sequencing. Tumor fragments were cultured and only reactive ones were pooled and expanded for TIL infusion. Predicted neoantigen epitopes were prioritized using customized algorithms and synthesized for validation assays. Reactive neoantigens were selected using ELISA/ELISpot assay and neoantigen specific T cells were identified according to their TCRβ sequences.

Results
Of 15 patients enrolled to date, 14 had successful TIL expansion. Of 12 patients who received TIL therapy, 3 have achieved a confirmed partial response (PR). The median overall survival (OS) for all enrolled patients has not yet been reached. We have discovered neoantigen-specific T cells and followed the number of neoantigen specific T cells using TCRβ sequencing. Neoantigen specific T cell clonotypes increased significantly after TIL therapy, and were retained at a relatively high level for a long time. However, some neoantigen recognition was lost in the TIL of a new recurrent tumor, indicating acquired resistance to TIL treatment may occur in some patients. In an example, allelic editing of a neoantigen was detected in a recurrent tumor, showing that fitness pressure may be exerted upon tumor cell clones after TIL treatment.

Conclusions
Adoptive cell transfer with TIL and nivolumab for NSCLC had acceptable toxicity and durable responses in this ongoing trial. TIL therapy can increase the number of neoantigen specific T cells, which mediated antitumor effects in responders.

Acknowledgements
This work has been supported in part by the Molecular Genomics Core, Tissue Core and Flow Cytometry Core at the H. Lee Moffitt Cancer Center & Research Institute, a comprehensive cancer center designated by the National Cancer Institute and funded in part by Moffitt’s Cancer Center Support Grant (P30-CA076292). This work is funded by SU2C grant.

Trial Registration
NCT03215810

References

Ethics Approval
The study was approved by Chesapeake IRB, approval number Pro00021984.
Conclusions
Evidence of immune-modulating activity was observed in non-clinical experiments of peripheral blood and tumor tissue specimens. Modest anti-tumor activity was observed in patients with resistant/refractory mesothelioma. CA-170 was well tolerated and shows favorable clinical PK. Clinical trial information: NCT02812875.

Trial Registration
NCT02812875

Ethics Approval
This study involves human subjects and complies with the principles found in the Declaration of Helsinki. The study protocol was approved by the appropriate IRB/IEC at each institution.

O29
Phase I study of multisite stereotactic body radiotherapy plus nivolumab and urelumab or nivolumab and cabiralizumab in patients with advanced solid tumors
Corey Foster, MD, MS, Jason Luke, MD, FACP, Robyn Hseu, CCRP, MLI, Linda Janisch, Gini Fleming, MD, Steven Chmura, MD, PhD
1The University of Chicago Medicine, Chicago, IL, United States; 2University of Pittsburgh Medical Center, Pittsburgh, PA, United States
Correspondence: Steven Chmura (schmura@radonc.uchicago.edu)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):O29

Background
Stereotactic body radiotherapy (SBRT) and immune checkpoint inhibition have been combined safely with preliminary suggestion of enhanced treatment effect. Agonism of CD137 or depletion of immunosuppressive myeloid cells by anti-colony stimulating factor 1 receptor (CSF1R) antibodies have been shown in preclinical studies to enhance each therapy and overcome resistance. The safety and efficacy of SBRT plus multiple checkpoint antibodies is unknown.

Methods
This is a single-institution, phase I study of multisite SBRT to 1-4 metastases with nivolumab (nivo) (480 mg IV every 4 weeks) and non-randomized administration of either (1) urelumab (ure) (CD137 agonist, 8 mg IV every 4 weeks) or (2) cabiralizumab (cab) (anti-CSF1R, 4 mg/kg IV every 2 weeks). Key eligibility criteria include ECOG 0-1 and progression on standard therapies. The primary endpoint is dose-limiting toxicity (DLT) defined as grade 3+ according to the CTCAEv4 occurring ≥3 months from the start of treatment. The recommended organ-specific SBRT doses will be associated with a ≤33% rate of DLTs. Secondary endpoints include RECIST response, progression-free survival, and overall survival. Pre- and post-SBRT biospecimens are collected for molecular correlative studies.

Results
Fifty-one eligible patients with 21 different tumor types including primarily non-immunotherapy responsive histologies have been enrolled and treated as of May 2019. Twenty-eight patients are evaluable for DLTs at 3 months with 3 (11%) experiencing ≥1 DLT. DLTs were observed in 1/6 (17%), 1/7 (14%), and 1/6 (17%) patients receiving SBRT to metastases in the peripheral lung, central lung, and abdominal/pelvic organs, respectively, while 7 patients receiving SBRT to metastases with nivolumab (nivo) (480 mg IV every 4 weeks) and non-randomized administration of either (1) urelumab (ure) (CD137 agonist, 8 mg IV every 4 weeks) or (2) cabiralizumab (cab) (anti-CSF1R, 4 mg/kg IV every 2 weeks). Key eligibility criteria include ECOG 0-1 and progression on standard therapies. The primary endpoint is dose-limiting toxicity (DLT) defined as grade 3+ according to the CTCAEv4 occurring ≥3 months from the start of treatment. The recommended organ-specific SBRT doses will be associated with a ≤33% rate of DLTs. Secondary endpoints include RECIST response, progression-free survival, and overall survival. Pre- and post-SBRT biospecimens are collected for molecular correlative studies.

Conclusions
The safety and tolerability of SBRT together with immune checkpoint inhibitors (ICIs) in this population of refractory metastatic solid tumors was acceptable with no unexpected adverse events.

Trial Registration
ClinicalTrials.gov, NCT03431948
A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors

Background
AK104 is a tetrameric PD-1/CTLA-4 bispecific antibody, based on the Akeso Tetrabody platform [1]. A number of studies have shown that combined PD-1 and CTLA-4 blockade is associated with a higher response rate in multiple tumor types. Toxicity associated with anti-CTLA-4 agents in particular is dose limiting, thereby limiting full potential for PD-1 and CTLA-4 combination therapy. AK104 introduces novel T cell targeting mechanisms of action that may provide an improved therapeutic index and a favorable toxicity profile compared to PD-1 and CTLA-4 combination therapy.

Methods
A multicenter, Phase I, open-label dose escalation and expansion study in solid tumors (NCT03261011) began in Oct 2017, evaluating the safety, efficacy and recommended phase 2 dose of AK104 administered IV every 2 weeks (q2w). For dose escalation, pts were enrolled at dose cohorts of 0.2, 0.5, 1.0, 2.0, 4.0, 6.0 and 10.0 mg/kg. Pharmacodynamic studies examined Ki67 expression on peripheral T-cells and receptor occupancy (RO).

Results
As of 8 July 2019, 40 pts, median age 66.5 years [31-85], have received AK104 at doses of 0.2 mg/kg (n = 1), 0.5 mg/kg (n = 3), 1.0 mg/kg (n = 6), 2.0 mg/kg (n = 3), 4.0 mg/kg (n = 3), 6.0 mg/kg (n = 21) and 10.0 mg/kg q2w (n = 3). Median number of doses was 4 (1–26). Treatment-related adverse events (TRAEs) occurred in 62.5% of pts. G3 TRAEs occurred in 10% [4/40], there were no G4 TRAEs. TRAEs leading to treatment discontinuation occurred in 7.5% [3/40]. Most frequent TRAEs were rash (23%), infusion reaction (15%), fatigue (15%), nausea (13%), and pruritus (10%) (Figure 1). Of 21 evaluable pts treated at doses ≥ 2 mg/kg, ORR was 28.6% (6/21) and disease control rate (DCR) was 47.6% (10/21) (Figure 2). Six responders remain on treatment (Gastric cancer, TNBC, mesothelioma, and large-cell neuroendocrine carcinoma each and 2 MSI-H CRC). Peripheral CD4+ T-cells demonstrated dose dependent increases in Ki67 expression on peripheral T-cells and receptor occupancy (RO).

Conclusions
AK104 can be given safely in patients up to 10.0 mg/kg and has demonstrated encouraging anti-tumor activity with ORR 28.6% when dosed >2mg/kg in a mixed patient population. Enrolment is currently ongoing at 10.0 mg/kg and in dose expansion cohorts. Updated data, including PK, Ki67, RO and other biomarkers based on pair biopsies will be presented. The mechanism underlying improved safety profile of tetrameric PD-1/CTLA-4 bispecific AK104 will be discussed.

O31 Intratumoral INT230-6 injection into solid tumors kills tumors and induces immune cell infiltration leading to abscopal responses and prolonged disease control in multiple refractory cancer types

Background
INT230-6 is a novel formulation of cisplatin(CIS) and vinblastine(VIN) with an amphiphilic cell penetration enhancer(SHAO), designed specifically for intratumoral (IT) administration. Nonclinical experiments indicate that the drug rapidly diffuses into cells including into the nucleus with dispersion throughout tumors. Cell death, dendritic cell influx, antigen presentation and T-cell engagement result. INT230-6 is a novel formulation of cisplatin(CIS) and vinblastine(VIN) with an amphiphilic cell penetration enhancer(SHAO), designed specifically for intratumoral (IT) administration. Nonclinical experiments indicate that the drug rapidly diffuses into cells including into the nucleus with dispersion throughout tumors. Cell death, dendritic cell influx, antigen presentation and T-cell engagement result.

Methods
This phase 1/2 study evaluated five injections of INT230-6 into multiple superficial or deep tumors. Dose was determined by tumor volume with intrapatient dose escalation permitted. Patients were...
treated every two weeks with injections of up to 50% new fluid volume at each visit (potential for 200% additional fluid volume administered prior to the first tumor imaging assessment). Blood samples were analyzed by flow cytometry, and on study tumor samples analyzed by multiplex immunohistochemistry. Conventional CT/MRI tumor assessments were performed every 2 months.

**Results**

Thirty-eight heavily pretreated subjects (median 3 prior therapies; range 0-9) have been dosed. Median age was 59 (42-76). Fourteen different cancer types were accrued. PK analysis revealed limited exposure of CIS and VIN in blood and supports that the majority of INT230-6’s active agents are retained in the tumor (consistent with low incidence of systemic AE’s despite IT doses of INT230-6 containing twice the amount of VIN for a standard 3.5 mg/m2 IV dose). There were no DLTs. The majority of drug-related AEs were grade 1/2. The most frequent treatment-related adverse event was injection-site pain (44%). Circulating CD8+ T-cells increased above baseline in most patients, with 40% of evaluable patients having a marked >30% increase. Paired biopsies were available in 5 patients and revealed >70% reduction in viable tumor cells in 3 out of 5 cases. Injected lesions demonstrated infiltration of CD4 and CD8 T-cells and reduction in FoxP3 Tregs. Several injected lesions showed asymptomatic tumor increases on the early scans (often with decreased contrast uptake), which decreased below baseline on subsequent scans without evidence of tumor reduction already at the 2 month time point. The protocol suggested to continue treatment despite radiographic progression until clinical deterioration. Ten non injected tumors in 7 patients showed tumor shrinkage.

**Conclusions**

INT230-6 is well tolerated when administered intratumorally at doses given to date. Pharmocodynamic assessments support a notable reduction in viable cancer cells and increases in CD4/CD8 T-cell infiltrates. RECIST assessments may be compromised due to large drug-volume injections and immune cell infiltration. However, imaging suggests variable necrosis and tumor reductions in both injected and non-injected lesions.

**Trial Registration**

NCT 03058289

**Ethics Approval**

The study was approved by USC Institution’s Ethics Board, approval number HS-16-00843 as well as the other centers in the study.

---

**O33**

**Single agent anti-tumor activity in PD-1 refractory NSCLC: phase 1 data from the first-in-human trial of NC318, a Siglec-15-targeted antibody**

Anthony Tolcher1, Omid Hamid, MD 2, Jeffrey Weber, MD, PhD 3, Patricia Lofrusso, DO4, Kathryn Shantz5, Kevin Heller, MD 6, Kevin Heller, MD 7, Martin Gutierrez, MD 8

1Next Oncology, San Antonio, TX, United States; 2The Angeles Clinic, Los Angeles, CA, United States; 3NYU Langone, New York, NY, United States; 4Yale University, New Haven, CT, United States; 5NextCure, Beltsville, MD, United States; 6Hackensack University Medical Center, Hackensack, NJ, United States

**Correspondence:** Kevin Heller (k Heller@nextcure.com)


**Background**

Siglec-15 (S15) is a member of the Siglec family (Sialic acid-binding Immunoglobulin Lectins), a distinct subgroup of immunoglobulin (Ig) superfamily proteins involved in discriminating self and non-self-immune regulation [1]. Recent studies have shown that S15 mediates suppression of T cell proliferation and negatively regulates T cell function. The expression of S15 and PD-L1 are mutually exclusive in NSCLC and other cancers, which supports S15 as a potential target for the treatment of cancer patients who are refractory to PD-1 directed therapies. NC318 is a first-in-class monoclonal antibody that blocks S15-mediated immune suppression and prevents tumor growth by normalizing T cell function and restoring anti-tumor immunity in the tumor microenvironment [2].

**Methods**

NC318-01 is a multi-center, first-in-human, phase 1/2, open-label, non-randomized study to determine the safety and tolerability, define the maximum tolerated dose or pharmacologically active dose, and assess the preliminary efficacy of NC318. The phase 1 component uses a 3+3 dose escalation design to determine the recommended phase 2 dose (RP2D) of NC318. Primary endpoints include safety and tolerability. Secondary endpoints include assessment of pharmacokinetics, response rate (measured every 8 weeks), progression-free survival, and overall survival. Exploratory analyses include investigation of biomarkers associated with treatment benefit.

**Results**

As of August 2019, 43 patients have been dosed across 6 dose cohorts (8mg - 800mg Q2W). The most common tumor types enrolled included: 10 NSCLC, 7 ovarian, 6 melanoma, 3 breast, and 3 CRC. NC318 has been well tolerated with no DLTs. The most common treatment-related AEs included diarrhea (4- grade 1 and 2-grade 2), pruritus (3-grade 1 and 1-grade 2), nausea (grade 1 and 2), arthralgias (2-grade 1), elevated lipase (grade 2), and elevated amylase (grade 1). Tumor responses were evaluable in 32 patients; 11 patients have not reached their first assessment, and their efficacy data will be reported at the conference. Single agent activity has been seen in NSCLC including 1 CR (ongoing at 41 weeks), 1 PR (ongoing at 14 weeks), 1 stable disease with tumor reduction (ongoing for 26 weeks), and 2 with stable disease. NC3LORR: 2/7 or 29%, DCR: 5/7 or 71%.

**Conclusions**

NC318 has been well tolerated across multiple dose levels and has shown encouraging anti-tumor activity when administered as monotherapy. Single agent anti-tumor activity was observed in 5 of 7 NSCLC subjects refractory to PD-1 therapies.

**Acknowledgements**

We would like to thank the patients and their families for participating in this clinical trial.

**Trial Registration**

Clinical trial information: NCT03665285

**References**


**Ethics Approval**

Next Oncology’s Ethics Board, IntegReview, approved 18Sep18

Hackensack University Medical Center’s Ethics Board, WIRB, approved 4Oct2018

Angeles Clinic’s Ethics Board, WIRB, approved 11Nov18

NYU School of Medicine’s Ethics Board, approved 2Oct18

Yale University’s Ethics Board, WIRB, approved 25Apr19

---

**O33**

**Immune enrichment and functional T-cell receptor (TCR) frequencies predict response to immune checkpoint blockade (ICB) in selected amygdase (grade 1, 2, and 3), and elevated lipase (grade 3 and 4). Tumor responses were evaluable in 32 patients; 11 patients have not reached their first assessment, and their efficacy data will be reported at the conference. Single agent activity has been seen in NSCLC including 1 CR (ongoing at 41 weeks), 1 PR (ongoing at 14 weeks), 1 stable disease with tumor reduction (ongoing for 26 weeks), and 2 with stable disease. NC3LORR: 2/7 or 29%, DCR: 5/7 or 71%.

**Conclusions**

NC318 has been well tolerated across multiple dose levels and has shown encouraging anti-tumor activity when administered as monotherapy. Single agent anti-tumor activity was observed in 5 of 7 NSCLC subjects refractory to PD-1 therapies.

**Acknowledgements**

We would like to thank the patients and their families for participating in this clinical trial.

**Trial Registration**

Clinical trial information: NCT03665285

**References**


**Ethics Approval**

Next Oncology’s Ethics Board, IntegReview, approved 18Sep18

Hackensack University Medical Center’s Ethics Board, WIRB, approved 4Oct2018

Angeles Clinic’s Ethics Board, WIRB, approved 11Nov18

NYU School of Medicine’s Ethics Board, approved 2Oct18

Yale University’s Ethics Board, WIRB, approved 25Apr19

---

**O33**

**Immune enrichment and functional T-cell receptor (TCR) frequencies predict response to immune checkpoint blockade (ICB) in selected amygdase (grade 1, 2, and 3), and elevated lipase (grade 3 and 4). Tumor responses were evaluable in 32 patients; 11 patients have not reached their first assessment, and their efficacy data will be reported at the conference. Single agent activity has been seen in NSCLC including 1 CR (ongoing at 41 weeks), 1 PR (ongoing at 14 weeks), 1 stable disease with tumor reduction (ongoing for 26 weeks), and 2 with stable disease. NC3LORR: 2/7 or 29%, DCR: 5/7 or 71%.

**Conclusions**

NC318 has been well tolerated across multiple dose levels and has shown encouraging anti-tumor activity when administered as monotherapy. Single agent anti-tumor activity was observed in 5 of 7 NSCLC subjects refractory to PD-1 therapies.

**Acknowledgements**

We would like to thank the patients and their families for participating in this clinical trial.

**Trial Registration**

Clinical trial information: NCT03665285

**References**

Background
Metastatic sarcomas represent a significant therapeutic challenge considering the few systemic treatment options and suboptimal survival. Tumor mutational burden (TMB), tumor-infiltrating lymphocytes, and PD-L1 expression have been identified as biomarkers of response to ICB in certain cancers; however, their role in sarcoma remains limited. We conducted a Phase-II trial (NCT02815995) in pre-treated patients with metastatic sarcoma (mixed histologies) using durvalumab (anti-PD-L1) in combination with tremelimumab (anti-CTLA-4), and identified measures of diversity in the TCR in responders through molecular profiling.

Methods
We obtained tumor biopsies at baseline and after 6 weeks of treatment and performed whole-exome, TCR and RNA-sequencing, along with multiplexed-immunofluorescence (miF). Preliminary analysis was conducted using alveolar soft par sarcoma (n=9) and synovial sarcoma (n=5) cohorts, comprised of 7 samples derived from responders and 7 samples from non-responders. TMB was calculated using mutations filtered against matched peripheral blood. TCR sequencing was conducted using high template producing samples. Differentially expressed genes (DEG) were assessed between responders and non-responders using baseline samples with adequate tumor purity. Further immune deconvolution was conducted using MCP-counter in baseline and on-treatment samples. miF was conducted on a panel of T-cell and myeloid cell markers.

Results
TMB was not found to be predictive of response within these patients. Transcriptomic profiling through targeted immune gene assessment using MCP-counter revealed higher CD8 T-cell (p=0.0053) and NK-cell proportions (p=0.0086) in responders. Correspondingly, tumor shrinkage was found to be correlated with activated cytotoxic CD8+ T cell density by miF at baseline. The most significantly-enriched DEGs in responders at baseline included CCL20, CXCL10, CXCL11 and BTLA (p

Conclusions
Together, these results highlight the potential significance for multi-lineage immune cell enrichment containing high-frequency functional oligoclonal TCRs as prognostic and predictive factors for response to ICB in sarcoma.

Trial Registration
NCT02815995

Ethics Approval
The study was approved by MD Anderson’s Ethics Board, protocol number 2015-1071.

References
Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 trial

Adi Diab, MD, Igor Puzanov, MD, MSCI, FACCP, Michele Maio, MD, PhD, Brendan Curti, MD, Mehmet Bilen, MD, Lewis, MD, Scott Tykodi, MD, PD, Gregory Daniels, MD, PhD, Alexander Spira, MD, PhD, FACCP, Chantale Bernatchez, Salah Eddine Benteibel, Michael Wong, MD, PhD, FRCP, James Larkin, MD, Ewa Kalinka, PhD, MD, Sunny Xue, Sue Currie, Ute Hoch, PhD, Wei Lin, Mary Tagliaferri, MD, Stina Singel, Michael Hurwitz, MD, PhD1

1. MD Anderson Cancer Center, Houston, TX, United States; 2. Roswell Park Cancer Institute, Buffalo, NY, United States; 3. Agency Ospedaliera Universitaria Senese, Siena, Italy; 4. Providence Portland Medical Center, Portland, OR, United States; 5. Terny University Hospital, Atlanta, GA, United States; 6. University of Colorado, Denver, Aurora, CO; 7. Seattle Cancer Care Alliance, Seattle, WA, United States; 8. University of California, San Diego, La Jolla, CA, United States; 9. Virginia Cancer Specialists, Fairfax, VA, United States; 10. The Royal Marsden, London, United Kingdom; 11. Polish Mothers Memorial Hospital, Lodz, Poland; 12. Nektar Therapeutics, San Francisco, CA, United States; 13. Yale School of Medicine, New Haven, CT, United States.

Correspondence: Adi Diab (AdiDiab@mdanderson.org)

Background

Although checkpoint inhibitor (CI) therapy has emerged as an effective treatment option for various cancers, there is an unmet need for therapies to produce more durable and deeper responses in metastatic melanoma. Safety and clinical activity of bempegaldesleukin (BEMPEG/NKTR-214), a CD-122 preferential IL-2 pathway agonist, plus anti-PD1 CI nivolumab (NIVO), was evaluated in PIVOT-02 (NCT02983045), a multicenter phase 1/2 study in multiple solid tumor settings. At SITC2018, PIVOT-02 reported encouraging preliminary clinical activity and safety data in metastatic melanoma (ORR, 53%; CR, 24%)[1,2]. We plan to report updated results in 1L metastatic melanoma patients, and the first report of PFS.

Methods

41 patients with previously untreated stage IV metastatic melanoma received ≥1 dose of BEMPEG(0.005mg/kg) + NIVO(360mg) q3w. Patients were categorized by PD-L1 status. Response was assessed every 3 cycles by RECISTv1.1. Per protocol, ORR was evaluated in the efficacy-evaluable population (≥1 post-baseline scan) by independent central radiology review (N=38; 3 patients, non-efficacy-evaluable:1 unrelated treatment-emergent AE, 2 patient decisions). Baseline immunohistochemistry (IHC) analysis for PD-L1 was performed (using Dako PD-L1 IHC 28-8 pharmDx) and defined as PD-L1 negative.

Results

At a median follow-up of 12.7 months, 38 patients were evaluable for efficacy. Table 1 shows BEMPEG plus NIVO was associated with clinical activity in patients with PD-L1 status. Confirmed ORR was 53% (20/38), and 34% (13/38) achieved a complete response. 42% (16/38) had 100% reduction in target lesions. Median time to response was 2 months, and median time to complete response was 7 months. Median duration of response was not reached (range: 11-mo-NS). BEMPEG plus NIVO was well tolerated, with TRAEs similar to those previously reported, with 14.6%(6) patients experiencing a ≥Grade 3 TRAE, and 9.4%(4) discontinuing treatment due to any TRAE. As of July 10, 2019, all 10 patients reported on treatment on March 29th, 2019 remain on treatment or achieved maximum response. At time of presentation, updated clinical results, including PFS, with ~18 months of follow-up will be reported.

Conclusions

BEMPEG plus NIVO is associated with robust clinical activity in 1L metastatic melanoma, as demonstrated by a high rate of durable responses that deepened over time. Based on these data, the FDA granted Breakthrough Therapy Designation for this combination therapy for patients with untreated unresectable or metastatic melanoma, and a Phase 3 trial evaluating the combination of BEMPEG plus NIVO vs NIVO alone in this setting is currently enrolling (NCT03635983).

Trial Registration

NCT02983045

References


Ethics Approval

The study was approved by each individual institution’s Ethics Board.

Table 1 (abstract O35).

<table>
<thead>
<tr>
<th>Clinical Response</th>
<th>Number of Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmed ORR (CR+PR)</td>
<td>53.84%</td>
</tr>
<tr>
<td>ORR (CR+PR+SD)</td>
<td>86.42%</td>
</tr>
<tr>
<td>ORR in PD-L1 negative (n=14)</td>
<td>6 (42%)</td>
</tr>
<tr>
<td>ORR (PD-L1 negative)</td>
<td>7 (50%)</td>
</tr>
<tr>
<td>ORR (PD-L1 unknown)</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>ORR (PD-L1 positive)</td>
<td>3 (19%)</td>
</tr>
<tr>
<td>ORR (PD-L1 positive)</td>
<td>3 (19%)</td>
</tr>
<tr>
<td>ORR (PD-L1 unknown)</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>ORR (PD-L1 negative)</td>
<td>2 (13%)</td>
</tr>
</tbody>
</table>

*Data as of March 29, 2019. cut-off date.

A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors

Thomas Eigentler, Dr, Juergen Krauss, Jutta Schreiber, Dr, Carsten Welshaupt, Patrick Terheyden, Lucie Heinzerling, Peter Mohr, Benjamin Weide, MD, Sebastian Ochsentheiter, Juergen Becker, MD, PhD, Franz-Georg Bauernfeind, Dr, Peter Brossart, Fatma Funkner, Regina Heidenreich, Sarah-Katherina Kays, Anke Muth, Tobias Seibel, Birgit Scheel, Oliver Schoenborn-Kellenberger, Claudia Stosnach, Angelika Daehling, Tanja Strack, Roman Korolikewicz, Ulrike Gnad-Vogt, MD, Ulrike Gnad-Vogt, MD, Ulrike Gnad-Vogt, MD, Universitätsklinikum Tübingen, Tübingen, Germany; NCT Heidelberg, Heidelberg, Germany, Universitätsklinikum Muenster, Muenster, Germany, Universitätsklinikum Schleswig Holstein, Luebeck, Germany, Universitätsklinikum Erlangen, Elte Kliniken,Stade, Germany, Universitätsklinikum Tübingen, Tübingen, Germany, Charite, Universitätsmedizin Berlin, Berlin, Germany, Translational Skin Cancer Research, Essen, Germany, Universitätsklinikum Bonn, Bonn, Germany, CureVac AG, Tübingen, Germany, CureVac AG, Frankfurt, Germany.

Correspondence: Ulrike Gnad-Vogt (Ulrike.Gnad-Vogt@curevac.com)

Background

CV8102 comprises a non-coding RNA complexed with a cationic peptide as a cancer vaccine that is intratumorally injected. CV8102 stimulates an immune response in antitumor immunity and therapy combinations.

O36
synergism with PD-1 blockade was shown in preclinical models (see abstract by Meister et al.). The ongoing phase I trial is investigating IT CV8102 either as a single agent or in combination with systemic anti-PD-1 antibodies in patients (pts) with advanced melanoma (MEL), squamous cell carcinoma of the skin (cSCC) and head and neck (hnSCC) and adenoid cystic carcinoma (ACC).

Methods

Pts with MEL, cSCC, hnSCC or ACC not amenable to curative therapy are eligible for single agent CV8102. Pts with MEL or hnSCC indicated for anti-PD-1 therapy or stable/slowly progressing disease after ≥12 weeks of anti-PD-1 are eligible for the combination therapy. Eight CV8102 IT injections are being administered over 12 weeks into superficial injectable lesions, while patients benefiting from the single agent therapy may receive further treatments. In an initial dose escalation part the maximum tolerated and recommended single agent/combination-doses (MTD, RD/RCR) will be defined. Tumor response according to RECIST 1.1 and immune responses in the peripheral blood and tumor tissue (optional) are being assessed. After determination of the RD/RCR, expansion cohorts are planned in several indications.

Results

As of July 01, 2019, 18 pts have been treated with single agent CV8102 (25-300 μg) and 10 pts have received CV8102 (25-200 μg) in combination with anti-PD-1 antibodies. No dose limiting toxicities occurred so far and the majority of treatment emergent AEs were mild to moderate injection site reactions and flu-like symptoms. After single agent CV8102 treatment one MEL pt achieved a complete response of injected and non-injected lesions and seven pts stable disease including two pts showing regressions of non-injected lymph node lesions (1 hnSCC and 1 MEL pt). Dose escalation is continuing and updated safety, efficacy and immune response data of the single agent and combination cohorts will be presented.

Conclusions

IT CV8102 single-agent and in combination with systemic anti-PD-1 antibodies appears well tolerated to date and showed evidence of single agent activity with shrinkage of injected and non-injected lesions. Updated results will be presented.

Trial Registration

NCT03291002

References


Ethics Approval

The study was approved by the Central Ethics Committee in Tuebingen, Germany under 785/2016AGM1

Consent

Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal

Combination Immunotherapies

O37

PD1 blockade augments adoptive T cell therapy via endogenous T cells rather than direct enhancement of transferred T cells

John Davies, PhD, Farah Karimipour, BS, Ling Zhang, PhD, Carylinda Sema, Christian Hinrichs, MD, NIH/NCI, Bethesda, MD, United States

Correspondence: Christian Hinrichs (hinrichs@nih.gov)


Background

The use of adoptive T cell therapy (ACT) has yielded promising clinical results, but improvements are needed. Transferred T cells experience prolonged antigen exposure during ACT and efficacy might improve if combined with PD1 axis blockade. However, limited data combining ACT with PD1 axis blockade has been published.

Methods

To assess whether ACT was improved with the combination of PD1 axis blockade, antigen-tagged retroviral constructs were used to generate B16-OVA and B16-gp33 tumors. These tumors were targeted by OT-I and P14 TCR transgenic T cells, respectively. After implanted tumors became palpable, mice underwent total body irradiation lymphodepletion and were subsequently treated with T cells and/or anti-PD1 antibody.

Results

Two independent T cell models demonstrated that ACT combined with anti-PD1 showed improved treatment compared to either therapy alone. To isolate the role of transferred T cells, mice lacking adaptive immunity (Rag1-1KO) were utilized as tumor-bearing hosts. The efficacy of anti-PD1 as a monotherapy and the added benefit when combined with ACT were abolished in Rag1-1KO hosts. These data were corroborated in mice specifically devoid of alpha-beta T cells (Trac-KO) as well as in mice containing T cells with a restricted TCR repertoire (irrelevant TCR transgenic). Antibody blockade has the confounding property of neutralizing PD1 systemically, altering signaling of the PD1 axis on both transferred cells and endogenous cells. The intrinsic role of the PD1 pathway on transferred T cells was further interrogated by engineering T cells with PD1-targeting miRNA or over-expression of PD1 without the cytoplasmic signaling domain. Both methods of intrinsic disruption of the PD1 pathway provided no added benefit to ACT in tumor-bearing wild-type animals. Another method of demonstrating that anti-PD1 activity was acting via endogenous T cells was utilizing PD1-KO T cells for ACT. PD1-KO T cell transfer combined with anti-PD1 conferred an added treatment benefit compared to either therapy alone. Moreover, endogenous T cells in the tumor increased in number after anti-PD1 treatment, while transferred T cells remained constant. Lastly, the efficacy of anti-PD1 therapy was lost when treating less immunogenic B16 tumors that were engineered with ubiquitin-tagged antigen constructs, rather than RFP-antigen constructs. This finding demonstrated that PD1-sensitive endogenous T cells were targeting antigens within RFP.

Conclusions

These data demonstrate that blocking the PD1 axis does not directly benefit adoptively transferred T cells. Rather, the benefit of anti-PD1 is dependent on the presence of endogenous T cells specific for immunogenic tumor antigens.

O38

A single-dose immunotherapy that remodels the tumor microenvironment for subsequent curative responses to checkpoint blockade

Chensu Wang, PhD1, Ang Cui2, Ayush Thomas1, Simon Liang1, Maurice Bukvanya3, Heijyun Suh4, K. Dane Wittrup, PhD1, Nir Hacohen, PhD2, Darrell Irvine, PhD1

1Massachusetts Institute of Technology, Cambridge, MA, United States; 2Broad Institute of MIT and Harvard, Cambridge, MA, United States

Correspondence: Darrell Irvine (djirvine@mit.edu)


Background

Given that immune checkpoint blockade (ICB) therapy only benefits a subset of cancer patients, much effort is currently being invested in the search for combination treatments that could increase the “visibility” of tumors to the immune system in order to sensitize them to ICB therapy[1]. We previously reported an efficacious immunotherapy termed AIPV [2], containing a tumor-targeting antibody, half-life-extended IL-2, anti-PD-1 and a lymph-node-targeting vaccine. Here we show that a minimalist “priming” therapy derived from AIPV, administered once, rapidly remodels the tumor microenvironment and initiates an immune attack that leads to tumor eradication upon subsequent ICB therapy in multiple mouse tumor models.


Methods
To define the minimal AIPV-derived “priming” therapy, we explored all possible sub-combinations of the four components of AIPV and verified the result in a several mouse tumor models. To be broadly relevant for clinical translation, we substituted the tumor-specific antibody in AIPV to a pan-tumor-targeting antibody surrogate 2SF-Fc, which recognizes integrins that are overexpressed by many human and murine tumors. We further analyzed tumor antigen release, tumor antigen uptake by dendritic cells (DCs), CD8+ T cell activation by DCs in tumor-draining lymph nodes (TDLNs), and the number of immune infiltrates in therapy-primed B16F10 tumors.

Results
We identified AIP as the minimally required combination to prime responsiveness to ICB treatment, which successfully cured more than 75% of large established syngeneic mouse tumors, including aggressive B16F10 melanoma and lung cancer models that harbor low tumor mutational burden and fail to respond to ICB therapy alone. In mechanistic studies, we found that compared to untreated and ICB-treated tumors, AIP-primed tumors showed higher levels of tumor cell death, which triggered more cross-presenting DCs to take up tumor antigens and activate CD8+ T cells in TDLNs, preceding a later wave of T cell infiltration. Moreover, the therapeutic benefit resulted from not only effector T cells but also innate immune cells, especially NK cells and macrophages that contributed to the initial tumor cell killing. Intriguingly, we found that NK cells secreted XCL1 and FLT3L to recruit and maintain cross-presenting DCs in the tumor, and depletion of NK cells completely abolished AIP-induced increases in the number of intratumoral cross-presenting DCs and activated T cells.

Conclusions
In summary, we identified a minimalist “priming” therapy that successfully synergizes with subsequent ICB treatment. Mechanistic studies indicate that the engagement of innate immune cells to initiate the “cancer-immunity-cycle” and expand cross-presenting DCs is important to the success of this combination therapy.

Acknowledgements
We thank the Koch Institute Swanson Biotechnology Center for technical support, specifically the applied therapeutics & whole animal imaging core facility, histology, microscopy and flow cytometry core facility.

References
2. Moynihan KD, Opel CF, Saeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakha K, Zhang MH, Rothschilds AM. Eradication of large established tumors in mice by combination immunotherapy that shields T epitope in HER2, impairing its antitumor effects. Also, we have shown that Etanercept (E), an inhibitor of soluble and transmembrane TNFα (sTNFα, tTNFα), downregulated MUC4 expression and sensitized de novo T-resistant BC xenografts to T [1]. The aim of this work was to study the participation of MUC4 on T resistance in vivo, on T-mediated antitumor innate immune response, and to evaluate the role of sTNFα on MUC4 expression.

Methods
We used the T-resistant JIMT-1 cell line transduced with a doxycycline (Dox)-inducible MUC4 shRNA construct (JIMT-shMUC4). To block TNFα, we used E or the dominant negative-TNFα protein INB03 (DN). Nude mice bearing JIMT-1-shMUC4 tumors (~50 mm3), were randomly assigned to the experimental (+Dox 2mg/ml in drinking water) or control group (–Dox). Both groups were treated with IgG, T, E (all 5 mg/kg), DN (10 mg/kg), T+E or T+DN i.p. twice a week and tumor volume was monitored routinely. MUC4 expression was determined by Western Blot in tumor extracts. Tumor-infiltrating immune cells were evaluated by immunofluorescence and analyzed by flow cytometry.

Results
In control groups, only T+E and T+DN administrations were able to inhibit tumor growth (72% and 75%, respectively, 
P

Conclusions
This is the first report to show that sTNFα is responsible for MUC4 regulation and that MUC4 is the major player in TNFα-induced T resistance in vivo. In addition, MUC4 favors an immunosuppressive tumor microenvironment. We propose that patients with HER2+ and MUC4+ tumors should be treated with T and TNFα-blocking agents to avoid resistance.

References

Ethics Approval
The study was approved by IACUC from Instituto de Biologia y Medicina Experimental’s Ethics Board, approval number 25/2017.

O40
Immunobiology and clinical activity of CPI-006, an anti-CD73 antibody with immunomodulating properties in a phase 1/1b trial in advanced cancers
Jason Luke, MD, FACOP,1 Jaime Merchan2, Lauren Harshman, MD,3 Thomas Marron, PhD4, John Powderly, MD, CPI5, Minal Barve6, Patricia LoRusso, DO,7 Melissa Johnson8, Andrew Horaton, PhD,9 Rachel Gittelman, PhD10, Brian Munnene9, Joseph Buggy11, Stephen Willingham12, PhD, Emily Piccione, PhD,3 Mehrdad Mobasher13, Richard Miller, MD9
1UPMC, Pittsburgh, PA, United States; 2University of Miami, Miami, FL, United States; 3Dana-Farber Cancer Institute, Boston, MA, United States; 4Stanford School of Medicine at Mount Sinai, New York, NY, United States; 5Cancer BioOncology Institute, Huntersville, NC, United States; 6Mary Crowley Cancer Research Center, Dallas, TX, United States; 7Yale University, New Haven, CT, United States; 8Sarah Cannon Research Institute, Nashville, TN, United States; 9Corvus Pharmaceuticals Inc, Burlingame, CA, United States; 10Adaptive Biotechnologies, Seattle, WA, United States

Correspondence: Richard Miller (rmiller@corvuspharma.com)

Background
CPI-006, a humanized IgG1 Fc gamma receptor binding-deficient anti-CD73 antibody blocks CD73 enzyme activity and has adenosine
independent, immunomodulatory activity including activation of lymphocytes (expression of CD69, CD83, CD25), effects on T and B cell trafficking, and increases in expression of markers on antigen presenting cells (CD86, HLA-DR)[1]. We report immunologic, safety and preliminary efficacy data from a Phase 1/1b study, with CPI-006 monotherapy and combination with ciforadenant, an adenosine-A2A receptor (A2AR) antagonist (NCT03454451).

Methods

Dose escalation/expansion design with CPI-006 monotherapy (IV, q21 days) and combination with ciforadenant (100mg oral BID). Eligibility included patients with cancers progressed on standard therapies. Blood was evaluated for lymphocyte subsets and IgH sequencing was performed to assess B cell receptor (BCR) clonality; tumor biopsies evaluated by immunohistochemistry.

Results

25 patients with median 4 prior therapies enrolled (15 monotherapy, doses 1mg/kg to 18mg/kg; 10 combination, 1mg/kg to 12mg/kg). No DLT was observed and MTD not reached. Most common adverse events were Gr 1/2 nausea, fatigue and infusion reactions. PBMC CD73 occupancy by CPI-006 for ≥21 days was seen at ≥6mg/kg (occupancy dose; OD, N=12 patients) and blockade of enzyme activity of CD73 in tumor was achieved at 12mg/kg. In blood of all 11 evaluable patients treated at ≥OD, there was reduction in circulating CD73+ B cells (median −64%) at 0.5 hr with partial recovery by day 21. Returning B cells demonstrated upregulated HLA-DR with the proportion of memory B cells expanded (median +40% in CD27+, IgD−). No change in serum immunoglobulins was seen. Circulating T, NK cells and monocytes were reduced at 0.5 hr but recovered after 24 hrs. Memory CD4 T cell numbers in blood increased >20% in 5 of 10 patients tested with three of those patients showing reduction in tumor. Tumor regression was observed in 4 of 6 evaluable patients at ≥OD (Figure 1) including best overall response of 28% and 21% in 2 patients with RCC and −18% in mCRPC. BCR analysis showed that treatment induced the generation and expansion of new B cell clones in blood of 2 of 3 patients studied including one of the responding RCC patients.

Conclusions

CPI-006 is an anti-CD73 antibody with immunomodulatory activity. Activation markers and changes in circulating lymphocytes are consistent with trafficking to nodal sites and sensitization of T and B cells. Preliminary evidence of anti-tumor activity has been observed without enrichment for tumor CD73 expression or adenosine gene signature.

References


Ethics Approval

The study was approved by Western IRB, approval number 1-1066703-1.

O41

Vasoactive intestinal peptide: a novel checkpoint pathway in pancreatic ductal adenocarcinoma

Sruthi Ravindranathan, PhD, Shuhua Wang, MD, Brandon Ware, Mohammad Zaidi, MD, MS, Jingru Zhu, Rohan Dhansaria, BS, Susan Thomas, PhD, BS, Yiwen Li, MS, Bassel El-rayes, MD, Gregory Lesinski, PhD, MPH, Edmund Walker, MD, PhD, FACP

Emory University, Atlanta, GA, United States

Correspondence: Sruthi Ravindranathan (sravin5@emory.edu)


Background

Pancreatic ductal adenocarcinoma (PDAC) largely fails to respond to FDA-approved immunotherapy, with a 5-year survival rate of only 5-7% [1]. Intriguingly, according to the cancer genome atlas (TCGA), human pancreatic cancers have exceptionally high levels of vasoactive intestinal peptide (VIP) mRNA expression in the tumor (Figure 1A). VIP is an immunosuppressive neuropeptide which when added to activated T cells decreases their proliferation and polarizes them towards the Th2 phenotype [2]. Thus, we hypothesized that VIP plays a crucial role in immune paralysis associated with PDAC and that pharmacologically inhibiting VIP signaling could enhance treatment response in PDAC tumors.

Methods

Levels of VIP in cell culture supernatant and serum of human or mouse blood was detected using VIP specific enzyme immunoassay. Subcutaneous or orthotopic mouse PDAC models were generated by injecting 1 million murine PDAC cells, MTS or luciferase transfected KPC (KPCLuc), near the flank or on a matrix gel into the tail of pancreas of immunocompetent C57BL/6 mice, respectively. Peptide VIP antagonists, ANT-00 or ANT-08 (more potent version) were subcutaneously administered every day to inhibit VIP signaling in-vivo followed by intraperitoneal administration of anti-PD1 or rat IgG2a (isotype) every 3 days for a duration of 10 days. Tumor growth was monitored by measurements with Vernier calipers or via IVIS imaging and in some cases confirmed with 9.4T MRI imaging. Immunological differences between the treatment groups were determined via flow cytometry and/or immunofluorescence staining of spleen or tumor.

Results

Our results show that peripheral blood of untreated human pancreatic cancer patients have significantly higher levels of VIP when compared to healthy volunteers (Figure 1B). Similarly, mouse PDAC cell lines also produce significantly high levels of VIP both in-vitro and in-vivo (Figure 1C&D). Treatment with ANT-00+anti-PD1 in subcutaneous MTS and KPC models, resulted in significant improvement in median survival that was associated with increased CD8+ T cell infiltration into the TME (Figure 2). The treatment strategy also resulted in significantly reduced tumor burden in the orthotopic mouse models of PDAC (Figure 3). Additionally, splenocytes from ANT-08+anti-PD1 treated mice with orthotopic PDAC tumors had more IFN gamma-secreting CD8+ T cells and lower numbers of myeloid derived suppressor cells and plasmacytoid dendritic cells, when compared to control group (Figure 4).

Conclusions

Expression of high levels of VIP is a targetable mechanism of immune escape in PDAC. Inhibiting VIP signaling along with checkpoint blockade significantly improves treatment response in murine PDAC models.

Acknowledgements

Emory Core Laboratories: Center for Systems Imaging and Research Pathology Core for their expertise in mouse MRI imaging and mouse tissue sectioning and staining, respectively.
References

Immune Cell Biology

O42
Transcriptional dissection reveals antitumor role of T follicular helper cells in head and neck cancer
Anthony Cillo, PhD, Dario Vignali, PhD
University of Pittsburgh, Pittsburgh, PA, United States

Correspondence: Dario Vignali (dvignali@pitt.edu)

Background
Head and neck squamous cell carcinoma (HNSCC) is caused by either infection with human papillomavirus (HPV+) or tobacco use (HPV-). Immunotherapy for metastatic or recurrent head and neck squamous cell carcinoma (HNSCC) is FDA-approved regardless of HPV status, but only ~15-20% of patients achieve a clinical response [1-2]. Many targets for CD8+ T cells are being investigated for clinical efficacy [3], but the potential of other cell types to enhance antitumor immunity has yet to be fully realized.

Methods
Single-cell RNAseq (scRNAseq) libraries (10X Genomics, 3’ v2) were generated by sorting CD45+ cells (i.e. all immune populations) from peripheral blood mononuclear cells (PBMC) and tumor infiltrating leukocytes (TIL) from immunotherapy naïve HNSCC patients. CD45+ cells from healthy donor PBMC and tonsil tissues from sleep apnea patients undergoing tonsillectomy were also used for scRNAseq. Clustering, differential gene expression analysis, and gene set enrichment analysis were used for scRNAseq analysis. Seven-color immunofluorescence (IF) was performed on the same tissues used for scRNAseq. A Kolmogorov-Smirnov test was used to determine enrichment scores from bulk mRNAseq from The Cancer Genome Atlas (TCGA), and log-rank tests were used for survival analyses.

Results
We identified 132,302 single cells from 6 healthy donor PBMC, 5 tonsils, 18 paired PBMC/TIL from HPV- patients, and 9 paired PBMC/TIL from HPV+ patients. Interestingly, B cells, CD4+ Tconv, and myeloid cells had divergent transcriptional profiles between HPV- and HPV+ TIL, while CD8+ T cells and CD4+ Treg were relatively similar. In HPV+ HNSCC, CD4+ Tconv expressed a T follicular helper (TFH) signature (including co-expression of CXCR5, PDCD1, ICOS and ASCL2), while those in HPV- HNSCC predominantly had an effector-memory signature. We next used the TFH signature derived from scRNAseq to generate a TFH enrichment score for HNSCC patients in TCGA. This analysis revealed better progression-free survival (PFS) in patients with a high versus low score for HNSCC patients in TCGA. This analysis revealed better progression-free survival (PFS) in patients with a high versus low TFH signature (hazard ratio=0.39; p=0.0098). In multivariate analysis, controlling for 9 covariates, high TFH signatures remained significantly associated with better PFS (hazard ratio=0.041, p=0.002). Consistent with the scRNAseq data, IF analysis revealed co-localization of CD4+ Tconv and B cells in tertiary lymphoid structures, suggesting a functional role for TFH in HNSCC.

Conclusions
Our “top-down” single-cell transcriptional analysis of immune cells in HNSCC reveals an appreciable hierarchy of immune heterogeneity. Immunotherapeutics should be tailored to unique properties of the tumor microenvironment, such as boosting the function of CD4+ TFH in HPV+ HNSCC.

Acknowledgements
We thank the Hillman Cancer Center Flow Cytometry Core for assistance with cell sorting; the University of Pittsburgh Health Science Genomics Research Core for assistance with sequencing; the University of Pittsburgh Center for Research Computing for computational resources; and the University of Colorado Denver Human Immune Monitoring Shared Resource for assistance with IF imaging. We thank the University of Pittsburgh Cancer Immunology Training Program (T32 CA082084) and the Hillman Postdoctoral Fellowship for Innovative Cancer Research for funding support.

References

Ethics Approval
This study was approved by the local Institutional Review Board under protocol UPCI 99-069, and patients provided informed consent.


Intratumoral CD163+ DC amplify the type 1 immune response of CD4+CD161+ T cells in HPV16-associated cancers and are associated with better survival

Chantal Duurland, PhD, Saskia Santegoets, Nikki Loof, Vanessa van Ham, Illina Ehsan, Marij Welters, PhD, Sjaerd van der Burg

Leiden University Medical Center, Leiden, Netherlands

Correspondence: Chantal Duurland (c.duurland@lumc.nl)

Background
High-risk human papilloma virus type 16 (HPV16) induces the majority of cervical and oropharyngeal cancers. Patients with HPV16+ oropharyngeal squamous cell carcinoma (OPSCC) and an intratumoral type 1 T cell response against the viral oncoproteins E6 and E7 (immune response positive [IR+]) have a much better prognosis after (chemo)radiotherapy than HPV16- OPSCC. Analysis of the tumor microenvironment (TME) revealed that HPV16+IR+ OPSCC were highly infiltrated by CD4+CD161+ T cells with an effector memory phenotype and their numbers correlated with improved survival. To understand how CD4+CD161+ T cells contribute to better survival, the aim of this study is to examine the regulation and role of CD4+CD161+ T cells in HPV16+ cancers.

Methods
The TME was analysed by multiplexed immunofluorescence on archived formalin-fixed paraffin-embedded tumor tissue, and flow cytometry on cryopreserved tumor infiltrating lymphocytes obtained from freshly isolated tumor tissue. DC subtypes were sorted from healthy individuals. HPV16-specific CD4+ T cell clones with or without CD161 expression were derived from OPSCC and cervical cancer patients. Proliferation and cytokine production were analysed by tritium-thymidine incorporation, flow cytometry and/or ELISA.

Results
Analysis of myeloid cell populations in the TME revealed a dense infiltration with a fairly unknown population of CD14-CD33-CD163+ myeloid cells and cells numbers correlated with a strong T cell infiltrate and improved survival. A more in-depth analysis of these cells by flow cytometry and multiplexed immunofluorescence demonstrated that these cells represent a genuine DC population. In an allogetic setting, blood-derived CD163- and CD163+ DC stimulated memory T cell proliferation, but IFNγ was mainly produced by CD161+ T cells. Interestingly, activated CD163+ DC produced higher levels of IL-12 and IL-18 than their CD161- counterparts. These cytokines are known inducers of a type 1 immune response and blockade of IL-12 and IL-18 impaired IFNγ production by T cells stimulated with these DC. Furthermore, IFNγ-production by cognate antigen-stimulated patient-derived HPV16-specific CD4+ T cells clones was enhanced by the addition of IL-12 and IL-18. Notably, under suboptimal antigen conditions, HPV16-specific CD4+CD161+ T cells produced more IFNγ in response to IL-12 and IL-18 than their CD4+CD161- counterparts.

Conclusions
In conclusion, intratumoral CD163+ DC contribute to a stronger anti-tumor response through the production of IL-12 and IL-18 which amplifies especially the type 1 response of CD4+CD161+ T cells as these cells are more sensitive to IL-12 and IL-18 than their CD161- counterparts.

Ethics Approval
Deidentified specimens were retrieved from a prospective lymphoma biobank at the Mayo Clinic, Rochester (IRB# 118-01).

O45
Overexpression of CD200 is a stem cell-specific mechanism of T cell evasion in AML
Shelley Herbrich, MS, Gheath Alatrash, DO, PhD, Richard Davis, MD, Michael Curran, PhD, Marina Konopleva, MD, PhD
The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Correspondence: Marina Konopleva (mkonopleva@mdanderson.org)

Background
Acute myeloid leukemia (AML) stem cells (LSC) are capable of surviving current standard chemotherapy and the likely source of deadly, relapsed disease. To identify potential immunotherapeutic targets, we sourced multiple large, publicly available datasets and identified CD200 as a potential stem-cell specific immune checkpoint in AML. CD200 has been shown to have an immunosuppressive effect on macrophages [1] and NK cells [2] and correlates with a high prevalence of FOXP3+ regulatory T cells [3]. Additionally, CD200 has been implicated as a poor prognostic marker in AML [4]. To date, we have screened 40 primary AML patient samples by flow cytometry, 95% of which are positive for CD200.
1. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, of the AML cells. However by RNAseq, CD200+ cells significantly
CD200 overexpression did not affect the proliferation rate or viability
Results
ment and overall survival of the CD200+/- OCI-AML3 cells.
humanized-PBMC mouse model in which we tracked the engraft-
intracellular cytokine production. Finally, we established a
normal PBMCs were cultured with the CD200+ or CD200- leukemia
in vitro, we performed a series of mixed lymphocyte reactions where
gene expression. To examine the immune function of CD200 in AML
Methods
al, we generated a CD200
To study the functional role of CD200 in AML, we generated a CD200
overexpression did not affect the proliferation rate or viability of the AML cells. However by RNAseq, CD200+ cells significantly
downregulated genes involved in inflammatory response and those
regulated by NF-kb in response to TNFα; indicating a potential intrin-
sic role in suppressing the immune microenvironment of AML LSCs.
In vitro, healthy PBMCs significantly reduced the production of in-
flammatory cytokines (including TNFα and IFNγ; Fig1 A,B) and cyto-
toxic enzymes (including GzmA, GzmB, Perforin, and sFAS ligand; Fig1 C,D) in the presence of AML cell-bound CD200. Interestingly, this did not translate into direct AML cell killing in this system. In vivo, OCI-AML3 CD200+/- cells showed no difference in engraftment, pro-
gression, and overall survival in immunodeficient NSG mice. How-
ever, when mice were humanized using healthy PBMCs (Fig 1E), CD200+ leukemia progressed rapidly, escaping elimination by T cells, compared to CD200- control leukemic cells (Fig 1F).
Conclusions
We have identified CD200 as a putative stem cell-specific immuno-
modulatory target that aids in establishing an immunosuppressive
microenvironment and allows cells to escape immune detection and destruction resulting in disease progression. These findings indicate a utility of CD200 as a novel immune checkpoint target for the develop-
ment of therapeutic strategies in AML.
References
6. Ethics Approval
All animal studies were approved by the MD Anderson Cancer Center Institutional Animal Care and Use Committee (Houston, Texas, USA) under protocol 00001146-RN0/3.

O46
Characterization of tumor infiltrating and post HSCT NK and T cells in human cancer patients
Sean Judge, MD, MS1, Cordelia Dunaj1, Ian Sturgill2, Kevin Stoffel, MS1, Patrice Chevallier3, Christelle Retière4, Arta Monjazeb1, Robert Carter, MD, MAS, FACSc1, William Murphy, PhD2
1University of California, Davis, Sacramento, CA, United States ; 2INSERM, Nantes University, Nantes, France ; 3University of California, Sacramento, CA
Correspondence: Robert Carter (rcarter@ucdavis.edu), William Murphy (wmjmurphy@ucdavis.edu)
Background
To expand the promise of immunotherapy, anti-PD-1 checkpoint in-
hibition is being applied to non-T cell-based strategies, including NK cells. Given that expression of PD-1 by NK cells remains controversial, we set out to characterize the phenotype and function of tumor infiltrating NK (and T) populations, including PD-1 and TIGIT, in human cancer patients.
Methods
We evaluated peripheral blood and tumor specimens from sarcoma and colon cancer patients and blood from post-allogeneic, T cell re-
plete HSCT patients with diverse hematologic malignancies. We also
assessed intra-tumoral lymphocytes from subcutaneous tumor-
bearing mice (CT26 colon, 4T1 mammary, B16 melanoma, and 3LL lung) with paired mouse splenocyte populations to validate findings from human specimens. Immune phenotype and function were ana-
lyzed by flow cytometry. Cell types were quantified, including expres-
sion of PD-1 and TIGIT.
Results
Within human tumors, T cells (CD3+CD56-) consistently outnumbered NK cells (CD3+CD56+) within soft tissue sarcomas (2.6 x 10^5± 3.9 x 10^5 vs 5.5 x 10^4±8.5 x 10^4 per million live cells), but not within colorectal cancer (2.1 x 10^5 vs 3.6 x 10^5). Intra-tumoral NK and T cells had higher expression of CD69 compared to blood (60% and 22% vs
Conclusions
NK cells represent a minor fraction of infiltrating lymphocytes across murine tumor types, whereas NK cell frequencies are variable in hu-
man tumors with minimal infiltration in sarcomas but high infiltration in colon cancer. Across human and mouse tumors (and HSCT pa-
patients), PD-1 expression on NK cells is negligible indicating that NK cells are unlikely to be a direct mediator of checkpoint blockade therapy. In contrast, TIGIT shows substantial expression on human intra-tumoral NK and T cells, suggesting key immunoregulatory func-
tion in the tumor microenvironment and the potential for thera-
petic targeting.
Ethics Approval
Collection of human blood and tumor specimens was approved by the
Institutional Review Board at the University of California, Davis or
Ethics Review Board of the Nantes University Hospital, and complied with all ethical regulations.

O47
IL-35+ B cells regulates anti-tumor immune response in pancreatic cancer
Bhalchandra Mirlekar, PhD, Yuiliya Pylayeva-Gupta
Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
Correspondence: Yuiliya Pylayeva-Gupta (ypylap1@email.unc.edu)
Background
Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy and the leading cause of cancer-related death with a dismal 5-year survival rate of 7%. Unfortunately, recent efforts towards treatment of pancreatic cancer with immunotherapy have not seen successful. A major barrier for immunotherapeutic approaches in PDA is marked immunosuppression within pancreatic tumor milieu [1,2]. Understanding the mechanisms that drive immunosuppression may help
to improve the efficacy of current immunotherapies. Therefore, the comprehensive aim of this research is to reveal cellular and molecular mechanisms by which immune cells promote the growth of tumor cells and thereby facilitate the progression of cancer.

Methods

We employed spontaneous and orthotopic mouse models of PDA which summarizes human pancreatic cancer [3,4]. We achieved this goal by using mouse model with a B cell-specific genetic loss of IL-35 combined with orthotopic PDA modeling. Additionally, we assessed the effect of anti-IL-35 blockade in combination with immune checkpoint blockade therapy as a pharmacological approach to provide additional invigoration for T cell-mediated killing of pancreatic cancer cells.

Results

Our analysis reveals a specialized subset of B cells, termed regulatory B cells, which promote pancreatic tumorigenesis through production of the cytokine IL-35 (encoded by subunits p35 and Ebi3) which has been previously implicated in suppression of T cell driven autoimmune diseases [5,6]. Our results demonstrate that IL-35, but not IL-10, potentiates PDA growth. This correlates with induction of regulatory T cells and suppression of effector T cells, suggesting that IL-35 controls endogenous anti-tumor immune responses [7]. While IL-35 is expressed by several immune cell types in PDA, we show that IL-35 expression specifically in B cells is essential for suppression of anti-tumor immunity. Importantly, while PDA is typically resistant to anti-PD-1 immunotherapy, we demonstrate robust synergistic reduction in tumor growth when B cell specific IL-35 deficiency is combined with anti-PD-1. Finally, we have identified an IL-35+ B cell subset in PDA patients and demonstrate that the presence of IL-35+ cells in tumor samples predicts increased occurrence of dysfunctional CD8+ T cells.

Conclusions

PDA is resistant to immune-checkpoint therapy therefore understanding the mechanism of function of IL-35+ B cells in PDA provide us with novel therapeutic targets that could be used to synergize with existing immunotherapeutic approaches and provide a path to clinical translation. In addition to expanding our basic knowledge of tumor immunology, this research has direct relevance for the design of immune based treatment therapies against patients with pancreatic cancer.

References


Ethics Approval

All mouse protocols were reviewed and approved by the Institutional Animal Care and Use Committee of the University of North Carolina at Chapel Hill (NIH/PHS Animal welfare assurance number: D16-00255 and study approval number: 17-064). Animals were maintained in a specific pathogen-free facility.

O48

Characterizing the anti-tumor immune response to an array of tumor cell lines expressing unique neoantigens

Christopher Copeland, Kim Nguyen, BA, Stefani Spranger, PhD

Massachusetts Institute of Technology, Cambridge, MA, United States

Correspondence: Stefani Spranger (spranger@mit.edu)


Background

Recent clinical studies have provided evidence that therapeutic vaccinations against mutationally derived neoantigens can enhance anti-tumor immunity and provide long-term protection. The efficacy of these therapies varies and recent work suggests that the affinity and sequence motifs of the neoantigens can be critical determinants of the magnitude of the induced immune response. However, systemic in vivo studies have thus far been hampered by the lack of appropriate neoantigen-expressing tumor mouse models.

Methods

Using a curated list of neoantigens previously identified [1-4] we have established an array of lung cancer cell lines expressing a single neoantigen, with neglectable additional mutational burden. The chosen neoantigens have varying predicted binding affinities to MHC molecules (NetMHC and Syppeithi). Each line was used to establish a subcutaneous tumor in immunocompetent or immune-deficient mice. Tumors were harvested at day 9 and day 28 and subjected to flow cytometry analysis to phenotype T cell populations. ELISpot assays were performed using splenocytes harvested from mice to determine the frequency of neoantigen-specific T cells in the periphery following peptide vaccination or tumor implantation. Cross-reactivity to the wildtype peptide sequence was also assessed. Mice were also prophylactically vaccinated with peptides derived from the neoantigen sequences before tumor implantation to study differences in therapeutic efficacies.

Results

Peptide vaccination alone was sufficient to induce expansion of neoantigen-specific T cells in the spleen for each neoantigen, though the T cell frequency and cross-reactivity to the non-mutated peptide varied depending on the peptide. The immune response of naïve mice to implanted tumors also varied depending on the peptide, while all tumor cell lines were able to grow with similar kinetics in immunocompetent mice. There was no correlation between response induced by peptide vaccination and response induced by tumor implantation by IFN-gamma ELISpot assays. A trend between anti-tumor immune response and peptide: MHC affinity could be observed however no correlation between affinity and therapeutic efficacy could be detected.

Conclusions

Using our reductionist syngeneic mouse model and using for the first time true neoantigens rather than model antigens our results suggest that therapeutic peptide vaccination may not be sufficient to drive tumor control and elimination even with predicted high-affinity peptide-MHC complexes. Instead, it may be the case that potentiating the anti-tumor immune response with checkpoint blockade antibody treatment will segregate high-affinity peptide-MHC complexes as responders and the remaining complexes as non-responders.

References

O49 Chronic activation under hypoxia drives T cell differentiation to exhaustion
Nicole Scharping, PhD, Yiyang Wang, Ashley Menk, MS, Greg Delgoffe, PhD
University of Pittsburgh, Pittsburgh, PA, United States
Correspondence: Greg Delgoffe (delgoffeg@upmc.edu)

Background
CD8+ tumor-infiltrating T lymphocytes (TIL) progressively succumb to a dysfunctional state known as exhaustion, characterized by poor effector function and sustained co-inhibitory marker expression, but the factors causing this hyporesponsive phenotype remain unclear. We have previously demonstrated that exhausted TIL also exhibit progressive loss of mitochondrial function, due in part to repression of the transcriptional co-activator PGC1α, resulting in suppressed mitochondrial fusion and biogenesis. Enforcing PGC1α expression in tumor-specific T cells not only led to increased mitochondria, but improved T cell functionality, decreased tumor burden, and increased survival in mouse B16 melanoma. We then hypothesized that T cell exhaustion may be driven by metabolic insufficiency and led us to explore the mechanism driving T cell exhaustion.

Methods
We developed models to identify how tumor-derived signals – hypoxia and chronic T cell receptor activation – induce metabolic insufficiency and T cell exhaustion in vitro and in vivo.

Results
Using several complementary systems, we found T cells experiencing chronic activation or hypoxia alone in vitro could carry out similar or superior effector functions, but experiencing both chronic activation and hypoxia simultaneously generated profound, persistent T cell dysfunction. This dysfunction was characterized by high co-inhibitory and TOX expression, loss of IFNγ production, and decreased mitochondrial oxygen consumption. Terminally exhausted TIL have high expression of the transcriptional repressor Blimp1, which we found to be driven by chronic activation and caused potent repression of PGC1α transcription. This repression resulted in dysfunctional mitochondria and excessive mitochondrial reactive oxygen species (ROS). Inducing mitochondrial ROS alone was sufficient to cause T cell exhaustion, which could be prevented by mitigating ROS with antioxidant co-culture. Consequently, by reducing tumor hypoxia in vivo, we can slow the differentiation to T cell exhaustion, allowing for a greater abundance of functional T cells in the TME and improving responses to checkpoint blockade immunotherapy.

Conclusions
Our findings support a model in which chronic activation fundamentally alters how T cells respond to hypoxic conditions, exposing a mechanism of T cell exhaustion in cancer. These data reveal potential metabolic avenues to rescue exhausted T cells and improve immunotherapy.

Ethics Approval
The study was approved by Institutional Animal Care and Use Committee of the University of Pittsburgh, approval number 17071235.

O50 PD1+ T regulatory cells in metastatic cancer patients co-express CD93 and exhibit augmented suppressive function due to decreased survival
Richard Wu, MD, PhD1, Christopher Chuckran, BS2, Ashwin Somasundaram, MD3, Rajeev Dhupar, MD4, Katie Nason, MD4, Adam Soloff, PhD5, Michael Lotze, MD6, Caleb Lampenfeld, BS7, Sheryl Kunning8, Tulia Bruno, PhD9, Dario Vignali, PhD9
1University of Pittsburgh Medical Center, Pittsburgh, PA, United States; 2University of Pittsburgh, Pittsburgh, PA, United States; 3UPMC Cancer Center, Pittsburgh, PA, United States
Correspondence: Tulia Bruno (tbruno@pitt.edu), Dario Vignali (dvignali@pitt.edu)

Background
While T regulatory cells (Tregs) maintain normal immune homeostasis, they are also potent suppressors of the anti-tumor immune response within the tumor microenvironment (TME). Tregs are associated with poor clinical response in a subset of melanoma and gastric cancer patients treated with anti-PD1 immunotherapy [1]. Currently, it is not known how inhibitory receptors (IRs) impact the survival or suppressive function of tumor-infiltrating Tregs in metastatic cancer patients [2, 3].

Methods
Using high-dimensional spectral cytometry (Cytek®), we have undertaken a comprehensive characterization of Treg phenotype and function from metastatic melanoma (n = 10) and malignant pleural effusions (MPE) (n = 27). We analyzed the differences in multiple inhibitory and stimulatory receptors, membrane-bound purinergic receptors (CD39, CD73), as well as differences in proliferation (Ki-67) and survival (Bcl-2) between Treg subsets. Since PD1 and CD39 were two of the highest-expressing inhibitory and purinergic receptors on Tregs in MPEs, we sorted these populations and utilized an allogeneic microsuppression assay to determine the differences in suppressive function between PD1+CD39+, PD1-CD39+, and PD1-CD39- Treg subsets.

Results
Our results indicate that Tregs in metastatic cancer patients express significantly higher levels of PD1, CD39, and ICOS, compared to Tregs from patient or healthy donor peripheral blood. We found PD1+ Tregs co-expressed CD39 and ICOS, and expressed higher levels of proliferation (Ki-67) with lower levels of the anti-apoptotic protein Bcl-2, compared to PD1- Tregs. After sorting MPE Tregs by PD1 expression, we observed that the PD1- subset was the most suppressive, while PD1+ subset was the least suppressive. We also found that the anti-PD1 blockade with nivolumab enhanced the suppression of the sorted PD1+ Tregs, while having no significant impact on the sorted PD1- Tregs.

Conclusions
Our study indicates that PD1 and CD39-expressing Tregs are enriched in the TME and seem to be more dysfunctional, likely due to local tumor factors such as chronic TCR stimulation, adenosine receptor signaling (known drivers of PD1), or hypoxia (a known driver of CD39). PD1+ Tregs, though co-expressing the activation marker ICOS and membrane-bound CD39, nevertheless lose suppressive function due to susceptibility to apoptosis. Thus, the relative ratios of PD1+ vs. PD1- Tregs in the TME may influence the response of metastatic cancer patients to immunotherapy.

Acknowledgements
Funding support from the UPMC Cancer Therapeutics T32 Training Program (PI: Dr. Edward Chu)

References

Ethics Approval
The study was approved by the UPMC Cancer Center’s Institutional Review Board.

O51 Sir2 inhibition enhances anti-tumor immunity by promoting T cell metabolism
Imene Hamaidi, PhD1, Lin Zhang, MD PhD2, Nayoung Kim, PhD3, Min-Hsuan Wang4, Cristina Iclozan, PhD1, Bin Fang, PhD4, Min Liu, PhD1, John Koornen, PhD1, Anders Berglund, PhD1, Sean Yadav1, Jiqiang Yao, PhD4, Ben Creelan, MD, MS5, Scott Antonia, MD PhD6, Sungjune Kim, MD PhD1
1Moffitt Cancer Center, Tampa, FL, United States; 2Tianjin Medical University Cancer Institute, Tianjin, China; 3Rosetta Exosome Inc., Seoul, Korea, Democratic People’s Republic; 4Duke University School of Medicine, Durham, NC, United States
Correspondence: Sungjune Kim (Sungjune.Kim@moffitt.org)

Background
Despite an unprecedented success with immune checkpoint inhibitors and adoptive cell therapies, the majority of patients remain refractory to
immunotherapy. Strategies to overcome immune barriers include manipulation of immune metabolism. There is a growing consensus that metabolism is a key driver of T cell functions with a direct impact on anti-tumor immunity. Sirt2 is an (NAD+)-dependent histone deacetylase with conflicting reports on its tumor suppressor or oncogenic roles. In the immune system, Sirt2 appears to primarily function as a suppressor of inflammation but its role in T cell biology has not been previously explored.

Methods
Sirt2 expression in human and murine T cells was assessed by flow cytometry and Western blot (WB). The role of Sirt2 in anti-tumor immunity was assessed by in vivo B16F10 tumor challenge, ex vivo cell proliferation (CFSE labeling), IFN-Y ELISpot assay, granzyme B expression and LDH cytotoxicity assay in Wild-type and Sirt2 knockout mice. Phenotypic profiling of peripheral T cells from B16F10 challenged mice was conducted by flow cytometry. Sirt2 interactome and acetylation were identified via mass spectrometry (MS) and immunoprecipitation/WB analyses. T cells metabolism was assessed by seahorse extracellular flux analyzer and metabolomic MS analyses. Pharmacologic inhibition of Sirt2 in human T cells was achieved using AGK2, a Sirt2 selective inhibitor.

Results
Upregulation of Sirt2 expression in human tumor-infiltrating lymphocytes (TILs) compared to peripheral blood mononuclear cells (PBMCs) from patients enrolled into a phase I clinical trial of Nivolumab and TILs in advanced non-small-cell lung cancer (NSCLC) correlated with a poor clinical response to treatment, suggesting Sirt2 deficiency in tumor-infiltrating T cell phenotype ex vivo with improved capacity to reject tumor challenge in vivo. Sirt2 was found to directly interact with key glycolytic enzymes including PFKP, GAPDH, enolase and aldolase during T cell activation, to modify their acetylation status and enzymatic activity. Consistently, Sirt2-/- T cells exhibited a hypermetabolic status with a profound upregulation of glycolysis and enhanced proliferation and effector activity in mice. More importantly, pharmacologic inhibition of Sirt2 with AGK2 conferred human TILs with superior metabolic fitness and enhanced effector functions.

Conclusions
We demonstrate that Sirt2 is a metabolic immune checkpoint and its abrogation enhances the metabolic and functional fitness of tumor reactive T cells to augment cancer immunotherapy.

Acknowledgements
This work was supported in part by K08 CA194273, ACS IRG-17-173-22, NCI Cancer Center Support Grant (P30-CA076292) and the Moffitt Foundation.

Ethics Approval
Human studies for collection and expansion of TILs received Institutional Review Board (IRB) approval: #MCC18541 and #MCC19122. Tumor biopsies were procured through Moffitt Cancer Center Hospital. All subjects provided informed consent.

For animal studies, all procedures were approved and performed in accordance with guidelines provided by the Institutional Animal Care and Use Committee: #M500004728 and #R500005143.

OS2
ADT-mediated IL-8 promotes myeloid infiltration and prostate cancer progression
Zoila Lopez Bujanda, MS1, Michael Haffner, MD1, Matthew Chaimowitz2, Nivedita Chowdhury1, Nicholas Venturini2, Aleksandar Obredovic1, Corey Hansen2, Joanna Jakłow1, Karen Sfanos1, Charles Bierberich1, Paula Hurley1, Mark Selby3, Alan Korman4, Angela Christiano, PhD2, Angelo De Marzo1, Charles Drake, MD, PhD2
1Johns Hopkins University, New York, NY, United States; 2Columbia University, New York, NY, United States; 3University of Maryland Baltimore County, Baltimore, MD, United States; 4Bristol-Myers Squibb, Redwood City, CA, United States
Correspondence: Charles Drake (cjd213@cumc.columbia.edu)

Background
Immunotherapy is a treatment for many types of cancer, primarily due to deep and durable clinical responses mediated by immune checkpoint blockade (ICB).1,2 Prostate cancer is a notable exception in that it is generally unresponsive to ICB. The standard treatment for advanced prostate cancer (androgen-deprivation therapy; ADT) is initially effective, but over time patients eventually develop castration-resistant prostate cancer (CRPC). Recently, the myeloid-derived suppressor cell (MDSC) subset that most closely relates to neutrophils, called polymorphonuclear (PMN)-MDSCs, were correlated with decreased overall survival (OS), increased levels of IL-8 (also known as CXCL8), immune resistance, and prostate cancer progression from localized to metastatic disease3, 4, 5.

Methods
We evaluated the differential expression profile of tumor epithelial cells isolated from castration-sensitive (CS) and ADT-treated MCRedAL tumor bearing mice. The effect of the two transcription factor affected by ADT treatment (p65 subunit of NF-κB and AR) was evaluated by Chip-Seq and Chip-PCR experiments on CS LNCaP cells. Their respective effects on the promoter activity of interleukine-8 (IL-8) was further evaluated by lucferase assays. ADT-mediated IL-8 and Cxcl15 expression in tumor cells was confirmed by RNA-ISH and qPCR in murine and human prostate cancer samples, respectively. Intratumoral infiltration of PMN-MDSCs was evaluated in vitro by transwell assays and in vivo by flow cytometry in a set of murine and human cell lines and xenograft models. Tumor outgrowth of an immunocompetent model of prostate cancer after receiving Cxcr2 blockade in combination with ICB + ADT was evaluated and compared to ICB + ADT alone. Finally, polyfunctional CD8 T cells were evaluated by intracellular staining of TNFα, INFγ, Granzyme B, and IL-2 cytokines.

Results
ADT regulated gene expression of both IL-8 and its potential mouse homologue (Cxc115). These chemokines drove subsequent intra-tumoral infiltration with PMN-MDSCs, promoting tumor progression. PMN-MDSC infiltration was abrogated when IL-8 was deleted from prostate cancer epithelial cells using CRISPR/Cas9, or when PMN-MDSC migration was blocked with antibodies against the IL-8 receptor CXCR2. Blocking PMN-MDSC infiltration in combination with anti-CTLA-4 delayed the onset of castration resistance and increased the density of polyfunctional CD8 T cells in tumors.

Conclusions
Taken together, our findings establish ADT-mediated IL-8 secretion and subsequent PMN-MDSC infiltration as a key suppressive mechanism in the progression of prostate cancer. Targeting of the IL-8/CXCR2 axis around the time of ADT, in combination with ICB, represents a novel therapeutic approach to delay prostate cancer progression to advanced disease.

References

OS3
Altered T-cell clonotype composition is strongly associated with differential functional orientation of colon cancer microenvironment
Jessica Roelands1, Peter Kuppen2, Lisa Mathew3, Amany Awad4, Francesco Marincola, MD2, Darawan Rinchait, PhD3, Davide Bedognetti, MD, PhD3, Wouter Hendrickx, PhD1
1Sidra Medical Research Center, Doha, Qatar; 2Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands; 3Sidra Medicine, Doha, Qatar
Correspondence: Wouter Hendrickx (whendrickx@sidra.org)

Background
Dysregulated T cell clonotypes in colorectal cancer (CRC) have been associated with different immune microenvironments and clinical outcomes. However, the relationship between T cell clonotypes and immune microenvironment in CRC has not been comprehensively elucidated.

Methods
Malignant tissue samples from 10 CRC patients were analyzed by single-cell sequencing using the Chromium platform (10X Genomics). Immune repertoire and immune microenvironment data were matched with TCGA datasets. Clonal contraction of TCR clonotypes was calculated using the MaSTR algorithm.

Results
The analysis revealed a significant number of clonal expansions in CRC compared to normal tissue. These expansions were associated with an enrichment of T cell functions in the tumor microenvironment, such as CD8+ T cell infiltration and activation. The clonal composition was also correlated with the clinical outcomes of the patients, with patients having more expansive clonotypes having worse survival.

Conclusions
These findings suggest that the clonal composition of T cells in CRC is not random, but rather reflects the immune microenvironment. This may have implications for the design of immunotherapeutic strategies in CRC.
Background
An active immune microenvironment characterized by high levels of tumor-infiltrating lymphocytes and cytotoxic activity has been associated with better prognosis of colorectal cancer patients [1]. In addition to cytotoxicity, characteristics of immune-mediated tumor rejection include expression of chemokine-receptor ligands, activation of interferon-stimulated genes and upregulation of immune regulatory genes [2]. The Immunological Constant of Rejection (ICR) gene signature summarizes these aspects and can be used to define tumor immune phenotypes [2-5]. It is increasingly clear that the composition of the T-cell repertoire, defined by T-cell clonality, contains additional valuable information. A high T-cell clonality implies expansion of specific T-cell clones. Until now, the relation between an active immune microenvironment and T-cell clonality in colon cancer remains unexplored. Here, we profiled the T-cell receptor (TCR) of primary colon cancer samples and investigated its relation to the immune contexture.

Methods
118 primary colon cancer samples were analyzed for their TCR profile. RNA and DNA were isolated from fresh frozen tissue samples of a cohort of colon cancer patients collected over the last decade at Leiden University Medical Center, the Netherlands. T-cell repertoire profiling of samples was performed using Adaptive immunoSEQ. This assay specifically amplifies and sequences the complementary determining region 3 (CDR3) of the TCR-beta locus. Both the TCR and RNASeq was performed using Illumina sequencing at Sidra Medicine. ICR score was calculated as previously described [2-5].

Results
Our multi-modal approach allowed us to investigate the association between T-cell clonality and cancer immune phenotypes. We here report, for the first time, a significant positive correlation between an active Th1 immune phenotype and a higher TCR clonality in colon cancer. T-cell clonality strongly correlated with the expression of the ICR signature (R=0.62, p=4.4e-14) [2-4], and less with T-cell enrichment estimates. Importantly, the clonality of T-cells was highest in tumor pathologic stage I compared with later stages of disease. In-depth analysis of the clonal structure of T-cell clonotypes and correlation with outcome is currently ongoing.

Conclusions
We here demonstrated that an active immune tumor microenvironment in colon cancer is positively associated with a more clonal T-cell repertoire. This observation suggests that specific T-cell clones are expanded in colon cancer with a Th1 polarized immune response.

Acknowledgements
This research has been supported by Qatar Foundation, Qatar National Research Fund (grant numbers: JSPRO7-010-3-005 and NPRP-10-0126-170262 awarded to WH and DB, respectively).

References

Ethics Approval
Sidra Medicine IRB approval: #R1602002725.
associations between rare variants and immune response traits were found.

Conclusions
We demonstrated that intratumoral immune disposition is partially under germline control through systematic pan-cancer analysis. Germline variants associated with differential immune response might be used to stratify patients based on likelihood of treatment response and to prioritize targets for development of novel therapies.

References

Methods
Here we developed a transplantable mouse tumor model that expresses a well-characterized viral epitope, GP33, coupled to a mCherry marker.

Results
Using this new model, we documented antigen cross-presentation by tumor-infiltrating myeloid cells as a key factor that drives suppression of CD8 T cell in tumors. Specifically, we show that tumor microenvironment (TME)-mediated suppression of CD8 T cell poly-functionality occurs even in the absence of direct antigen-presentation by tumor cells, suggesting that antigen cross-presentation is sufficient to enforce the establishment of this dysfunctional state. More importantly, age-related changes in tumor microenvironment had a significant impact on the differentiation of tumor-specific CD8 T cells. Transplanting MHCI-deficient tumor cells in young or adult mice, we report a striking skewing of tumor-specific effector CD8 T cells towards a TCF7lowGzmBhi terminally differentiated state in peripheral lymphoid organs. This phenotype was associated with increased levels of antigen cross-presentation by tumor-infiltrating myeloid cells in young hosts. Consistent with our mouse findings, analysis of immune infiltrates from human pediatric solid tumors revealed a strong correlation between the expression of PDL1 on myeloid cells and enrichment of CD8 TILs with an exhaustion phenotype (PD1hiTim3+).

Conclusions
Collectively we report how the “immature/young” microenvironment of an actively developing tissue/individual contributes in the generation of an immune response skewed towards a terminally differentiated state with limited plasticity, thus narrowing the window for immunotherapeutic interventions.

Acknowledgements
This study was supported by the DBSTP Garwood Fellowship (SJCRH) to AM, and funding from ALSAC (American Lebanese Syrian Associated Charities) to BY.

Trial Registration
ClinicalTrials.gov Identifier: NCT01050296 (Molecular Analysis of Solid Tumors (MAST))

Ethics Approval
MAST protocol was approved by the St. Jude Children’s Research Hospital institutional review board (IRB), approval # XP09-234
Animal protocols were approved on an annual term by the Institutional Animal Care and Use Committee (IACUC) at St. Jude Children’s Research Hospital.

O55
Antigen-cross presentation promotes the development of terminally differentiated CD8 T cells in young individuals
Ardiana Moustaki1, Shanta Alli, PhD 1, Anthony Zamora 1, Jeremy Crawford1, Paul Thomas1, Shannon Boi1, Natalie McDonald2, Alberto Pappo1, Michael Dyer1, Elizabeth Stewart1, Sara Federico1, Ben Youngblood1
1St Jude Children’s Research Hospital, Memphis, TN, United States ; 2UTHSC, Memphis, TN, United States
Correspondence: Ben Youngblood
(benjamin.youngblood@stjude.org)

Background
Recent advances in T cell-based immunotherapies have revolutionized treatment strategies for several types of cancers, however, approaches that rely on endogenous T cell responses have had limited success in pediatric populations, attributed primarily to the low mutational burden of these tumors. Here we characterized CD8 T cells isolated from a wide range of pediatric solid tumor types and observed enrichment of cells with an antigen-experienced phenotype (high PD1 expression). The limited ability of immune checkpoint blockade therapy (ICB) to trigger anti-tumor responses in pediatric populations, despite the presence of activated CD8 T cells in these tumors, prompted us to explore alternative mechanisms restricting the endogenous T cell response.

O56
Expression of ART1, an extracellular mono ADP-ribosylase, promotes lung cancer growth and dissemination by limiting tumor infiltration of P2X7R+ CD8+ T cells and CD103+ dendritic cells
Erik Wennerberg, PhD, Clarey Hung, Amanda Valeta, Timothy McGraw, Sandra Demaria, MD, Brendon Stiles, MD
Well Cornell Medicine, New York, NY, United States
Correspondence: Erik Wennerberg
(erw2010@med.cornell.edu)

Background
NAD+ released from stressed and dying cells acts as a proinflammatory mediator [1]. In the presence of mono-ADP-ribosyltransferases (ARTs), extracellular NAD+ can serve as substrate for ADP-ribosylation of P2X7-receptors (P2X7Rs) expressed on immune cells, including CD8+ T cells and CD103+ dendritic cells (DCs) which are essential for immune-mediated tumor rejection, resulting in NAD-induced cell death (NICD) [2]. NICD of P2X7R-expressing tissue-resident lymphocytes was recently described as an important regulator of tissue homeostasis [3]. However, involvement of ART-mediated NICD in cancer and its implications for anti-tumor immunity remain uninvestigated. We hypothesized that ART1-expression in non-small cell lung cancer (NSCLC) would limit immune-mediated tumor control by eliminating tumor-infiltrating P2X7R+ immune cells.
Methods

Human NSCLC tumor samples and matched adjacent normal tissue (n=40) were analyzed for ART1 expression by qPCR. In addition, a lung adenocarcinoma tissue microarray (TMA) (n=493) was scored for ART1 expression. The KP1 cell line was derived from lung tumors of KRASG12D/PS3/- mice. KP1-shART1 cells with doxycycline (DOX)-inducible knockdown of ART1 were generated by lentiviral constructs. In an orthotopic lung tumor model, C57BL/6 mice were intravenously injected with KP1-shART1 cells, fed DOX-water ad libitum and sacrificed after 14 days. Lung tumor nodules were enumerated from H&E-stained FFPE lung sections. Alternatively, lung-derived cell suspensions were analyzed for infiltration of T cells and DCs by flow cytometry.

Results

ART1 expression in human NSCLC tissue was >2-fold higher compared to normal tissue. TMA analysis revealed that 55% of tumors strongly expressed ART1. ART1-knockdown by DOX-treatment resulted in a 75% decrease in lung metastatic nodules compared to DOX-untreated mice (p<0.001). P2X7R was highly expressed on CD8+ T cells and CD103+ DCs from KP1-shART-bearing lungs. Importantly, ART1-knockdown significantly increased the percentage of CD8+ T cells (23.8% in DOX+ vs 12.9% in DOX-; p<0.05) and CD103+ DCs (20.7% in DOX+ vs 12.7% in DOX-; p<0.05) among total T cells and DCs respectively. In vitro, we confirmed that P2X7R+ CD8+ T cells were selectively susceptible to ADP-ribosylation and NOD compared with P2X7R- CD8+ T cells. In line with our hypothesis that ART1 expression counteracts immune-mediated tumor control, ART1-knockdown significantly delayed growth of subcutaneous tumors in wild type mice while it had markedly reduced differential effect on tumor progression in nude or CD8-depleted mice.

Conclusions

Our findings indicate that ART1 tumor expression constitutes a barrier to immune-mediated control of NSCLC tumors. This warrants further studies to determine whether targeted ART1-blockade can potentiate the response to immunotherapy of ART1-expressing NSCLC.

Acknowledgements

This work was supported by a Department of Defense, Breast Cancer Research Program Breakthrough Fellowship Award (WB1XWH-17-1-0029) and grants from the Lung Cancer Research Foundation (Free to Breathe) and the Graham Foundation of the American Association for Thoracic Surgery. Funding also provided by the Meyer Cancer Center, Pre-SPORE funding mechanism, “Using Radiotherapy to jump-start cancer response to immunotherapy.”

References

2. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in tumor-reactive T cell responses and eliminate regressor tumors. Functional assays with sorted antigen-presenting cells from regressor tumors in Batf3-/- mice indicated that the CD11c+ DC compartment was uniquely able to activate T cells, and specific depletion of CD11c+ cells ablated T cell responses. We found that these DC required sensing of type I interferons to mediate anti-tumor immunity but were independent of cytosolic dsDNA sensing via the cGAS-STING pathway. Single-cell RNA sequencing of myeloid cells identified a novel DC subset characterized by interferon stimulated genes (ISG). ISG+ DC highly express the cytosolic dsDNA sensors, Rig-I and MDA5, suggesting sensing of tumor-derived dsDNA. T cells primed by ISG+ DC in Batf3-/- mice induced protective systemic immunity against progressor tumors.

Conclusions

We identified a novel DC subset characterized by an ISG signature that can activate T cells through means independent of canonical cross-presentation, leading to systemic immunity. Engaging these cells provides a therapeutic opportunity to boost anti-tumor immune responses.

References


O57

Novel dsRNA-sensing dendritic cells enhance anti-tumor immunity

Ellen Duong, SCB, Stefani Spranger, PhD
Massachusetts Institute of Technology, Cambridge, MA, United States

Correspondence: Stefani Spranger (spranger@mit.edu)

Background

Myeloid cells can profoundly shape the landscape of tumor-infiltrating T cells. For example, tumor-resident cross-presenting CD103+ dendritic cells (DC1) recruit effector T cells into the tumor microenvironment (TME) and provide local T cell stimulation [1-2]. Boosting DC numbers or function enhances responses to checkpoint blockade therapy, suggesting that DC may contribute to the reactivation of exhausted or dysfunctional T cells or even prevent their induction [3]. Elucidating the DC subsets that associate with productive T cell responses in the TME will open new therapeutic opportunities to enhance anti-tumor immunity.

Methods

To identify DC subsets that correlate with functional T cell responses, we compared the myeloid infiltrate of an acutely cleared regressor tumor with that of a progressively growing tumor, an approach that was previously used to phenotype dysfunctional T cells in the TME [4]. Murine syngeneic tumor lines expressing SIY were implanted in wild-type, Rag2-/-, Batf3-/-, Clec9a-/-, CD11c-DTR bone marrow chimera, Ifnart-/-, and Sting-/- mice. Flow immuno-phenotyping was used to profile the myeloid compartment, and ELISPot was performed to quantify antigen-specific T cells. To assess function, sorted myeloid cells were co-cultured with T cells to evaluate their ability to induce T cell proliferation. Single cell RNA-sequencing was performed to profile the immune infiltrate of the regressor tumor.

Results

Compared to regressor tumors, regressor tumors showed a higher number of CD103+ DC with cell surface markers that phenotypically resembled canonical cross-presenting DC1. Yet, Batf3-/- and Clec9a-/- mice, which lack functional DC1, were still able to mount tumor-reactive T cell responses and eliminate regressor tumors. Functional assays with sorted antigen-presenting cells from regressor tumors in Batf3-/- mice indicated that the CD11c+ DC compartment was uniquely able to activate T cells, and specific depletion of CD11c+ cells ablated T cell responses. We found that these DC required sensing of type I interferons to mediate anti-tumor immunity but were independent of cytosolic dsDNA sensing via the cGAS-STING pathway. Single-cell RNA sequencing of myeloid cells identified a novel DC subset characterized by interferon stimulated genes (ISG). ISG+ DC highly express the cytosolic dsDNA sensors, Rig-I and MDA5, suggesting sensing of tumor-derived dsDNA. T cells primed by ISG+ DC in Batf3-/- mice induced protective systemic immunity against progressor tumors.

Conclusions

We identified a novel DC subset characterized by an ISG signature that can activate T cells through means independent of canonical cross-presentation, leading to systemic immunity. Engaging these cells provides a therapeutic opportunity to boost anti-tumor immune responses.
Background
Growing evidence indicates the importance of microbiota in cancer therapy, and bacteria are established to be capable of modulating anti-tumor efficacy [1]. Here, we study Mucosal-associated invariant T (MAIT) cells, a group of innate-like T cells expressing a semi-invariant TCR and recognizing riboflavin metabolites produced by many species of bacteria [2,3]. We explore whether these cells could recognize bacterial antigens in the tumors and whether this response could be microbiome-modulated.

Methods
We use mass-cytometry to deeply profile MAIT cells in human colorectal (CRC), lung (NSCLC) and kidney (RCC) cancers. Focusing particularly on colorectal cancer, we investigate the relationship between MAIT cells and the tumor microbiome by estimating the microbial composition in each bulk tumor using whole genome sequencing data.

Results
We observe that tumor-infiltrating MAIT cells from CRC are highly enriched for CD39 expression (Figure 1), a marker recently reported to distinguish between bystander and tumor-specific T cells [4], and show that in vitro, CD39 expression is induced in a TCR-dependent manner (Figure 2). We further show a distinct phenotype for MAIT cells from tumor, adjacent tissue and PBMC of CRC patients (Figure 3). Particularly, CD39+ tumor-infiltrating MAIT cells are characterized by an exhaustive phenotype profile as compared to the CD39- subset, with higher expression of the inhibitory receptors CTLA-4 and PD-1 (Figure 4). They are also more proliferative, less apoptotic and polyfunctional than the CD39- MAIT cells. Unexpectedly, we identify a subset of CD39+ MAIT cells expressing CD4 and Foxp3 within the tumors capable of producing pro-inflammatory cytokines. By sequencing CRC tumors, we observe a positive correlation between CD39+ MAIT cell frequency and tumor bacterial load, suggesting a microbiome-influenced tumor microenvironment in shaping the MAIT cell phenotype. This hypothesis is supported by a higher CD39 expression observed on tumor-infiltrating MAIT cells from CRC as compared to NSCLC and RCC, known to be less infiltrated by bacteria (Figure 5). Among the identified bacterial strains, we show that Fusobacteria nucleatum is able to activate MAIT cells in vitro in a TCR-specific way (Figure 6).

Conclusions
Our results show unique features of MAIT cells in tumors with evidence of being influenced by TCR-mediated signals, and highlight a bacterial strain that could potentially shape MAIT cell response in CRC. This work will not only provide new understanding in innate-like T cell responses in tumors, but also pave the way for manipulating these cells for cancer prevention and therapeutics.

References

Ethics Approval
The use of human samples from CRC and NSCLC patients was approved by the appropriate institutional research boards, A*STAR and the Singapore Immunology Network, Singapore. The RCC samples were provided by Northwest Biotrust, under a NWBiospecimens protocol, Seattle. The analysis was performed according to the IRB file/approval number NHS #6007-1061.
Background

Tumor infiltrating T-cells have a clear prognostic benefit in many tumor types. Immuno-biomarkers have independently improved prognostication in various cancer types, with tumor-infiltrating lymphocytes (TILs) more accurately predicting patient survival than currently employed methods [1-4]. Recent studies have highlighted similar observations in breast cancer, lung cancer, and melanoma [5-7]. These observations raise the question of whether the level of T-cell infiltration into renal tumors predicts patient outcomes, and more fundamentally, why some patients mount a strong immune response to their tumors and others do not.

Methods

Tumor tissue was collected from renal cell carcinoma (RCC) patients undergoing surgery at Emory University Hospital. Minimum follow up time was 24 months. Intraoperative tumor samples were analyzed by flow cytometry, immunofluorescence, and immunohistochemistry.

Results

The proportion of CD8 TILs, measured by flow cytometry, varied widely in RCC patients (Fig 1A). A greater proportion of tumor CD8 T-cells was associated with improved progression-free survival (PFS) (Fig 1B), and this association was particularly strong in patients with advanced disease.

In examining the phenotype and function of these TILs, the presence of a stem-like CD8 T-cell—both proliferates and differentiates—was found to be required for the generation of a strong anti-tumor T-cell response. Without stem-like T-cells, the anti-tumor response deteriorates, and patient PFS declines. The presence of dendritic cells in the tumor correlates with T-cell infiltration, and quantitative immunofluorescence revealed that stem-like CD8 T-cells reside in areas of high antigen presenting cell (APC) density (Fig 1C). Tumors lacking in TILs also lack APC density, suggesting that an APC niche is necessary to support the T-cell response. Furthermore, T-cell dense tumors harbor increased vascular and stromal cells, suggesting a potential role for non-hematopoietic cells in the tumor microenvironment in supporting the anti-tumor immune response.

Interestingly, PD-L1 status did not correlate with T-cell infiltration (Fig 1D), and there was no difference in progression free survival between patients with PD-L1+/- tumors (Fig 1E), suggesting that the described immune infiltration and organization may be a prevailing factor in predicting patient outcomes.
Conclusions
CD8 T-cell infiltration in RCC predicts PFS, particularly in patients with advanced disease. Improved prognostication is a critical goal for these patients, so these findings represent an opportunity to inform future development of prognostic tools and of reduction/intensification of therapy. T-cell infiltration is maintained by a population of stem-like T-cells, which require a supportive niche inside the tumor. Without this niche, the immune response declines, resulting in disease progression.

Acknowledgements
This work was supported by funding from the Prostate Cancer Foundation, Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Across America, and NCI grant 1-R00-CA197891. We would like to acknowledge The Yerkes NHP Genomics Core which is supported in part by Swim Ac...
between B16 melanoma and Mps. These hybrids retained nuclear IRF3 translocation but failed to express IFN-β indicating a dominant-negative mechanism. Sequencing revealed no mutations in the IFN-β promoter. However, ATAC-sequencing indicated the IFN-β promoter remained epigenetically closed after STING pathway activation in B16 tumor cells, unlike Mps controls. NF-κB is an innate immune pathway proposed to control IFN-β locus accessibility. We found B16 tumor cells and hybrids were defective in NF-κB nuclear translocation, unlike Mps controls. Furthermore, tumor cells expressed normal levels of most NF-κB factors but over expressed the negative regulator IkBα. Combined treatment with cycloheximide and a STING agonist caused IkBα degradation and tumor cell-intrinsic IFN-β expression.

Conclusions

We find tumor cells fail to express IFN-β downstream of STING pathway activation. This is likely due to a dominant-negative inhibitor of NF-κB signaling, such as IkBα, which causes the IFN-β locus to remain epigenetically repressed in tumor cells and prevents IRF3 binding. We hypothesize restoring NF-κB signaling in tumor cells will enable tumor cell-intrinsic IFN-β expression and promote tumor rejection in vivo. Therapies based on identifying and reversing tumor-specific defects in IFN-β expression represent a strategy to induce tumor site-specific innate immune activation.

Immuno-Conjugates and Chimeric Molecules

O61

Myeloid cell-targeted miR-146a mimic alleviates NF-κB-driven cytokine storm without interfering with CD19-specific CAR T cell activity against B cell lymphoma

Marcin Kortylewski, PhD1, Yu-Lin Su2, Xiuli Wang, PhD3, Mati Mann3, Dayson Moreira, PhD2, Zhuoran Zhnag2, Ching Ouyang2, Piotr Swiderski2, Stephen Forman, MD4, David Baltimore, PhD5, Ling Li2, Guido Marcuccio2, Mark Boldin6

1Beckman Research Institute, City of Hope, Duarte, CA, United States; 2City of Hope, Duarte, CA, United States; 3Caltech, Pasadena, CA, United States; 4University of Minnesota, Minneapolis, MN, United States; 5Fate Therapeutics, San Diego, United States; 6University of California-San Diego, La Jolla, CA, United States; 7Karolinska, Stockholm, Sweden

Correspondence: Marcin Kortylewski (mkortylewski@coh.org)


Background

NF-κB is a key regulator of inflammation, myeloproliferation and cancer progression, with an important role in leukemogenesis. Despite therapeutic potential, targeting NF-κB proved challenging. However, in non-malignant myeloid cells NF-κB activity is tightly regulated through many molecular mechanisms, including miRNA.

Methods

Here, we describe an original approach to NF-κB inhibition using miR146a, which targets upstream regulators of NF-κB signaling. We generated a myeloid cell-targeted NF-κB inhibitor by tethering a chemically-modified miR146a mimic oligonucleotide to a scavenger receptor (SR/Toll-like receptor 9 (TLR9) ligand (C-miR146a).

Results

Unlike an unconjugated miR-146a molecule, C-miR146a was rapidly internalized and delivered to cytoplasm of target myeloid cells such as macrophages or myeloid leukemia cells. C-miR146a reduced protein levels of classic miR-146a targets, IRAK1 and TRAF6, thereby efficiently blocking NF-κB activation in target cells. Intravenous injections of C-miR146a mimic to miR-146-deficient mice prevented excessive NF-κB activation in myeloid cells, thereby alleviating myeloproliferation and exaggerated inflammatory responses to bacterial challenge. The NF-κB-driven release of IL-1 and IL-6 from monocytes is known to be responsible for cytokine release syndrome (CRS), which can occur in response to bacterial infections, antibody-based therapies and relatively frequently as a serious adverse effect of chimeric antigen receptor (CAR) T-cell therapies. While low expression of miR146a has not yet been implicated in CRS, C-miR146a treatments did reduce pro-inflammatory activity of human monocytes, at the level of IL-1 and IL-6 production, induced by the CD19-specific but not by the naive CAR T cells in vitro. Repeated systemic administration of C-miR146a oligonucleotide alleviated human monocyte-dependent CRS in xenotransplanted B-cell lymphoma model without impeding the on-target therapeutic effects of CAR T-cells against lymphoma cells.

Conclusions

Our results demonstrate potential of using myeloid cell-targeted miR146a mimics for treatment of inflammatory diseases and prevention of potential side effects of immunotherapies. The SRTLR9-targeted miR-146a mimic design provides an outline for the development of miRNA therapeutics for a variety of myeloid cell-related diseases.

Acknowledgements

This work was supported in part by the National Cancer Institute/NIH awards R01CA213131 (to M.K.), Lymphoma SPORE P50CA107399 (to S.F.) and P30CA035572 (to the COH).
administered or in the future, secreted by the engineered iNK cell itself.

References

Ethics Approval
The study was approved by the University of Minnesota’s IRB, approval number 0709M00134

Immunotherapy Toxicities

O63
Gastric toxicity associated with PD-1 blockade therapy revealed by Multiplexed Ion Beam Imaging
Selena Ferrian, PhD\(^1\), Theodore Nowicki, MD, PhD\(^2\), David Dawson\(^3\), Alex Baranski\(^2\), John Glaspy, MD\(^4\), Antoni Ribas, MD, PhD\(^5\), Michael Angelo, MD, PhD\(^6\)
\(^1\)Stanford University, Palo Alto, CA, United States; \(^2\)Stanford University, Palo Alto, CA, United States; \(^3\)University of California Los Angeles, Los Angeles, CA, United States

Correspondence: Michael Angelo (mangel0@stanford.edu)

Background
Immune checkpoint blockade utilizing PD-1 inhibition is an effective approach for the treatment of a wide variety of cancer subtypes (1–3). However, these therapies can be associated with a diverse array of autoimmune side effects, which can affect multiple sites throughout the body (4–8). While lower gastrointestinal (GI) side effects are more common, upper gastrointestinal adverse events are rarely reported (7–9). IFN-γ is the signature cytokine generated by CD4+ Th1 and CD8+ T effector cells, but its exact role in regulating epithelial cell changes is unknown. Epithelial cells are also a source of cytokines that may regulate gastritis, including IFN-γ, IL-1b, IL-6, and IL-33 (10). This is the first comprehensive multiplexed histopathological study of a case nivolumab-associated gastroenteritis reported in the literature.

Methods
To elucidate the immunology underlying this condition, we leveraged the ability of Multiplexed Ion Beam Imaging by Time-Of-Flight (MIIII-TOF) to identify the presence and proportion of infiltrating immune cells from a single section of biopsy specimen. This approach circumvents limitations imposed by insufficient tissue for thorough histological and molecular profiling. Using MIIII-TOF we analyzed formalin-fixed, paraffin-embedded (FFPE) human gastric tissue with twenty-seven labels simultaneously.

Results
Our analysis revealed a gastritis characterized by severe mucosal injury, interferon gamma (IFN-γ)-producing gastric epithelial cells, and mixed inflammation that included CD8 and CD4 T cell infiltrates lacking or with reduced expression of granzyme B and FoxP3, respectively (Figure 1).

Conclusions
Taken together, the salient features in this case study of PD-1 associated gastritis include lamina propria expansion by mononuclear inflammation, epithelial injury from crypt apoptosis, intraepithelial lymphocytic and neutrophilic inflammation, and expression of IFN-γ by epithelial cells, in conjunction with clinical resolution of symptoms upon cessation of nivolumab therapy, are consistent with anti-PD-1-induced gastritis. Prolonged PD-1 blockade may induce gastric epithelial cells to overproduce IFN-γ, which we speculate concomitantly downregulates T-cell activity in gastric-mediated activation and immunopathology. Understanding the landscape in regard to immune cell infiltrates and their interactions with mucosal epithelia may shed light on the underlying mechanisms of anti-PD-1 induced gastritis, further informing future clinical applications of immunotherapeutic agents.

Acknowledgements
MA and S.C.B. are supported by the NIH 1-DPS-OD019822, 1R01AG06287-01, 1R01AGOS7915-01; and 1U24CA24309-01; TSN by K12HD00850, the Tower Cancer Research Foundation, and the Hyundai Hope on Wheels Award. This collaboration was enabled by the Parker Institute for Cancer Immunotherapy.

References

Ethics Approval
This study was deemed exempt under Stanford IRB-39053.

Methods
We performed a multicenter, retrospective study of patients with documented IBD who received immune checkpoint inhibitor therapy between January 2010 and February 2019. Backward selection and multivariate logistic regression were conducted to assess risk of gastrointestinal adverse events.

Results
Of the 102 included patients, 17 received therapy targeting cytotoxic T-lymphocyte antigen-4 and 85 received monotherapy targeting programmed death-1 or its ligand. Half the patients had Crohn’s disease and half had ulcerative colitis (Table 1). The median time from last active IBD episode to immunotherapy initiation was 5 years (interquartile range, 3–12). Forty-three patients were not receiving treatment for IBD. Gastrointestinal adverse events occurred in 42 patients (41%) after a median of 62 days (interquartile range, 33–123), a rate higher than that of similar patients without underlying IBD who were treated at centers participating in the study (11%; P<0.001). Gastrointestinal events among patients with IBD included grade 3 or 4 diarrhea in 21 patients (21%). Four patients experienced colonic perforation, 2 of whom required surgery (Table 2). No gastrointestinal adverse event-related deaths were recorded. Anti-cytotoxic T-lymphocyte antigen-4 therapy was associated with increased risk of gastrointestinal adverse events on univariate but not multivariate analysis (respectively, odds ratio, 3.19; 95% confidence interval, 1.8–9.48; P=0.037 and odds ratio, 4.72; 95% confidence interval, 0.95–23.53; P=0.058) (Table 3).

Conclusions
Preexisting IBD increases the risk of severe gastrointestinal adverse events in patients treated with immune checkpoint inhibitors.

Ethics Approval
This study was approved by MD Anderson Cancer Center Institutional Review Board with IRB # PA17-0329.

Consent
Written informed consent was waived given retrospective study.

Table 1 (abstract 064). See text for description

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of IBD – no. (%)</td>
<td></td>
</tr>
<tr>
<td>Crohn’s disease</td>
<td>49 (49)</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>49 (49)</td>
</tr>
<tr>
<td>Unclassified</td>
<td>4 (4)</td>
</tr>
<tr>
<td>Median time from IBD diagnosis to immunotherapy initiation – yr (IQR)</td>
<td>10 (6–13)</td>
</tr>
<tr>
<td>Median time from last active IBD episode to immunotherapy initiation – yr (IQR)</td>
<td>5 (3–12)</td>
</tr>
<tr>
<td>IBD treatment at time of immunotherapy initiation – no. (%)</td>
<td></td>
</tr>
<tr>
<td>Mesalamine</td>
<td>37 (37)</td>
</tr>
<tr>
<td>Immunosuppressive*</td>
<td>22 (22)</td>
</tr>
<tr>
<td>None</td>
<td>43 (42)</td>
</tr>
<tr>
<td>Severity of endoscopic findings of IBD before immunotherapy initiation (N = 48) – no. (%)</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>29 (60)</td>
</tr>
<tr>
<td>Mild</td>
<td>12 (25)</td>
</tr>
<tr>
<td>Moderate</td>
<td>5 (10)</td>
</tr>
<tr>
<td>Severe</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Complications from IBD* – no. (%)</td>
<td></td>
</tr>
<tr>
<td>Surgery the IBD – no. (%)</td>
<td>22 (22)</td>
</tr>
<tr>
<td>Extraintestinal manifestations – no. (%)</td>
<td>10 (10)</td>
</tr>
<tr>
<td>Extent of IBD (N = 42) – no. (%)</td>
<td></td>
</tr>
<tr>
<td>Small bowel</td>
<td>17 (20)</td>
</tr>
<tr>
<td>Colon</td>
<td>16 (19)</td>
</tr>
<tr>
<td>Both</td>
<td>10 (12)</td>
</tr>
</tbody>
</table>

*IBD indicates inflammatory bowel disease and IQR indicates interquartile range.

**Immunosuppressive therapy includes steroids, vedolizumab, methotrexate, salazosulfapyridine, and methotrexate.

**Complications of IBD include colonic strictures, fistula, perforation, and gastrointestinal cancer

Fig. 1 (abstract 063). Immune and non-immune cells landscape

O64
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease
Hamzah Abu-Sbeih, MD 1, David Faleck 2, Biagio Ricciuti, MD 3, Robin Mendelsohn 4, Abdul Rafeh Nqash, MD 5, Justine Cohen, DO 6, MacLean Sellars 6, Aanika Balaji 7, Nick Powell 9, Sai-Ching Yeung, MD, PhD 1, Elad Sharon, MD, MPH 16, Michael Dougan, MD, PhD 3, Yinghong Wang, MD, PhD 1
1Univ of Texas MD Anderson Cancer Center, Houston, TX, United States; 2Memorial Sloan Kettering Cancer Center, New York, NY, United States; 3Dana-Farber Cancer Institute, Boston, MA, United States; 4Memorial Sloan Kettering Cancer Center, New York, NY, United States; 5East Carolina Univ, Greenville, NC, United States; 6Massachusetts General Hospital, Boston, MA; 7Johns Hopkins University, Baltimore, MD, United States; 8Sheba Medical Center, Ramat Gan, Israel; 9King’s College London, London, United Kingdom; 10Vanderbilt University, Nashville, TN, United States; 11Imperial College London, London, United Kingdom; 12Ohio State University, Columbus, OH, United States; 13Yale University, New Haven, CT; 14Bologna University, Brookline, MA, United States; 15The Ohio State University, Columbus, United States; 16National Cancer Institute, Bethesda, MD, United States

Correspondence: Yinghong Wang (YWang59@mdanderson.org)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):O64

Background
The risk of immune checkpoint inhibitor therapy-related gastrointestinal adverse events in cancer patients with inflammatory bowel disease (IBD) has not been well described. We characterized gastrointestinal adverse events in patients with underlying IBD who received immune checkpoint inhibitors.
Artificial intelligence-powered retrospective analysis of PD-L1 expression in nivolumab trials of advanced non-small cell lung cancer

Vipul Baxi, MS 1, Vipul Baxi, MS 1, Andrew Beck, MD, PhD 2, Dimple Pandya1, George Lee, PhD 1, Cyrus Hedvat, MD, PhD 1, Aditya Khosla 2, Dayong Wang 2, Hunter Elliott 2, Harsha Pokkalla 2, Abhik Lahiri 2, Benjamin Glass2, Jennifer Kerner 2, Ilan Wapinski 2, Scott Chasalow 1, Han Chang, PhD1, Robin Edwards, PhD2, Michael Montalto1

1Bristol-Myers Squibb, Princeton, NJ, United States; 2PathAI, Inc, Boston, MA, United States

Correspondence: Vipul Baxi (Vipul.Baxi@bms.com)


**Background**

Immune-cell PD-L1 expression is an emerging biomarker of response to immunotherapy, but manual pathology assessment is challenging. We developed and validated an artificial intelligence (AI)-powered image analysis algorithm to quantify PD-L1 expression on tumor cells and immune cells, including expression on macrophages and lymphocytes. Statistical analyses assessed concordance between manual and AI-evaluated PD-L1 expression on different cell types and their relationship to efficacy of nivolumab monotherapy in patients with advanced non-small cell lung cancer.

**Methods**

PD-L1 expression on tumor cells, macrophages, and lymphocytes was evaluated using the PD-L1 IHC 28-8 pharmDx assay (Dako, Agilent Technologies Co) and on digital whole-slide images using the PathAI platform (not intended for diagnostic use). Deep-learning models were trained with 250,000+ image annotations to detect and classify cells. Model performance was assessed on annotated frames consisting of 150x150-micron-sized sub-regions extracted from a validation image dataset against a consensus across 5 pathologists as reference. Locked algorithms were applied to PD-L1-stained images from clinical trials of nivolumab (CheckMate 017 [n = 167], CheckMate 026 [n = 502], and CheckMate 057 [n = 410]) [1-3] in an exploratory post-hoc analysis.

**Results**

In the frame-based validation of images selected across trials, AI-powered and manual quantification of PD-L1 was correlated (Pearson coefficients were 0.93, 0.79, 0.84, and 0.83 for PD-L1 on tumor cells, macrophages, lymphocytes, and total immune cells, respectively). Both approaches yielded similar associations between PD-L1 on tumor cells and progression-free survival, with log2(HR) and P values of −0.57 (P=0.033) for AI-based and −0.50 (P=0.025) for manual in CheckMate 017; −0.30 (P=0.070) and −0.27 (P=0.176) in CheckMate 026; −0.56 (P=0.001) and −0.62 (P=0.002) in CheckMate 057. Similar associations with response were observed for tumor cell scoring and AI-powered quantitation of PD-L1 on immune cells. Composite PD-L1 expression on tumor cells plus macrophages did not show a stronger association with response compared with tumor cells alone. C-index values for PD-L1 expression on tumor cells vs tumor cells plus macrophages were 0.610 and 0.586 in CheckMate 017; 0.587 and 0.591 in CheckMate 057; and 0.522 and 0.527 in CheckMate 026.

**Conclusions**

AI-powered analysis provides a robust, scalable approach to quantify PD-L1 expression and is concordant with manual assessment. The model warrants further exploration of PD-L1 expression patterns and their association with response across tumor types.

**Acknowledgements**

Bristol-Myers Squibb and PathAI, Inc. Professional medical writing and editorial assistance were provided by Katerina Pipili, PhD, and Jay Rathi, MA, of Spark Medica Inc, funded by Bristol-Myers Squibb.

**Trial Registration**

NCT01642004, NCT02041533, NCT01673867

**References**


**Ethics Approval**

The protocol was approved by site institutional review boards or independent ethics committees and conducted according to Good...
Clinical Practice guidelines, per the International Conference on Harmonisation. Patients provided written informed consent based on Declaration of Helsinki principles.

Microbiome and Other Environmental Factors

O66 Patient-derived microbiota germ-free mouse model for identifying mechanisms of checkpoint blockade efficacy modulation
Vyara Matson, PhD, Jessica Fessler, BS, Yuanyuan Zha, PhD, Thomas Gajewski, MD, PhD
University of Chicago, Chicago, IL, United States

Correspondence: Thomas Gajewski
tgajewski@medicine.bsd.uchicago.edu

Background
Checkpoint blockade immunotherapy is having a major impact on cancer outcomes. However, a sizable subset of patients still fails to benefit. Along with tumor- and host-intrinsic factors, the gut microbiota has emerged as an important variable leading to inter-patient heterogeneity in responsiveness to PD-1 blockade (1-3). Here, we seek deeper understanding of the underlying mechanisms.

Methods
Stool samples were collected from 42 metastatic melanoma patients prior to immunotherapy and microbial composition was found to be associated with responsiveness to anti-PD-1 (1). Reconstitution of germ-free (GF) mice with patient microbiota provides a model for understanding mechanistic details and also for testing therapeutic interventions. GF mice were colonized by oral gavage with stool from 11 responding and 6 non-responding patients and efficacy of anti-PD-L1 against B16.SIY melanoma was evaluated. For a more physiologic system, we generated stable colonies of mice naturally colonized from birth with responder or non-responder patient microbiota through breeding. Interventions were explored to convert non-responder mice into responders, including oral antibiotics (vancomycin, ampicillin, metronidazole, and neomycin) and/or fecal microbiota transfer (FMT) from responders. Fecal 16S rDNA was sequenced to identify microbiome alterations associated with conversion from non-responder to responder phenotype.

Results
Transfer of fecal material from patients to GF mice recapitulated the efficacy of PD-1/PD-L1 blockade in over 72% of cases, pointing to mechanistic involvement of gut commensals. The responder microbiota conferred increased BATF3-lineage dendritic cells in the mesenteric lymph nodes and peripheral lymphoid tissues, increased activation of anti-tumor T cells, increased infiltration of tumor antigen-specific CD8+ T cells in the tumor, and higher circulating levels of IFN-γ, IL-12p70, and CXCL5. Antibiotic pre-treatment of non-responder mice partially improved anti-PD-L1 efficacy, suggesting depletion of immune-inhibiting bacteria. Responder FMT also partially improved tumor control, and a combination of antibiotics + FMT completely rescued the anti-PD-L1 efficacy. In contrast, antibiotic pre-treatment + administration of non-responder FMT interfered with immunotherapy efficacy. FMT-induced alterations in microbiome composition are informing ongoing efforts to isolate and culture specific immunomodulatory strains.

Conclusions
Gut microbiota modulation shows promise as a potential strategy for improving outcomes with checkpoint blockade therapy. Our results support the existence of both immune-potentiating and immune-inhibiting gut bacteria, and suggest that the effect of oral antibiotics depends on the initial composition of the gut microbiota.

References

O67 Variation in the commensal urinary microbiome is associated with response to Bacillus Calmette-Guérin (BCG) immunotherapy in early stage urothelial bladder cancer
Randy Sweis, MD1, Randy Sweis, MD1, Ciro Andolfi1, Jeffrey Bloodworth1, Shay Golan, MD2, Nimrod Barashi2, Elle Hill1, Ryan Wernitz3, Thomas Gajewski, MD, PhD1, Gary Steinberg, MD4
1University of Chicago, Chicago, IL, United States; 2Rabin Medical Center, Chicago, IL, United States; 3University of Illinois, Chicago, IL, United States; 4New York University, Chicago, IL, United States

Correspondence: Randy Sweis (rsweis@uchicago.edu)

Background
Intravesical bacillus Calmette-Guérin (BCG) immunotherapy is the standard of care for non-muscle invasive bladder cancer (NMIBC) with high-risk features. Its mechanism of action is pleotropic and involves innate immune activation, enhancement of antigen presentation, and stimulation of cytokine secretion resulting in an adaptive immune response. Despite the efficacy of BCG, up to 50% of patients have recurrent or progressive disease within 5 years. Recent data have indicated that the commensal gut microbiota impacts immunotherapy responsiveness for some advanced cancers. We hypothesized that a commensal urinary microbiome could influence responsiveness to BCG immunotherapy in urothelial bladder cancer.

Methods
Patients presenting with a new bladder tumor were enrolled prior to transurethral resection and BCG immunotherapy. Urine samples for microbiome assessment were collected by sterile catheterization to minimize urethral or skin contamination. The microbial composition for each sample was determined using the 16S rRNA gene sequencing-based method and shotgun sequencing. Data were organized by Operational Taxonomic Units (OTUs) and analyzed according to clinical outcome. Urine cytokine analysis (Invitrogen ProcartaPlex immunoassay) was also performed on available samples.

Results
We enrolled 31 patients with a median age of 69 years (46-87). The median follow-up was 12 months, and 10 (32%) patients experienced disease recurrence. In the overall population, Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria, and Tenericutes accounted for > 99% of the detected phyla. Distance matrix calculation indicated a significant difference between patients with and without recurrence (P = 0.007). The abundance of Proteobacteria was higher in patients with recurrence (P = 0.035), with stronger differences observed for specific taxa, such as the Gammaproteobacteria class (P = 0.0025) and the Enterobacteriaceae family (P = 0.001). Firmicutes, in particular Lactobacillales, were more abundant in patients without recurrence (P = 0.049). Cytokine concentrations were measured in urine from a subset of 13 patients, including 6 patients with recurrence. Changes in urinary IFN-γ and TNF-α levels after 6 weekly doses of BCG were calculated, and no differences were observed between patients with and without recurrence (both P > 0.10). (Figure 1).

Conclusions
In this study, we uncovered a correlation between the composition of the urinary microbiome and clinical responsiveness to BCG immunotherapy in patients with bladder cancer. Further studies to confirm these results are ongoing.

Ethics Approval
This study was approved by the University of Chicago institutional review board (IRB approval #161317).
Results

PD-L1. Tumor growth was assessed, and longitudinal microbiome diversity and enrichment of Ruminococaceae that is associated with dysbiotic gastrointestinal diseases such as C. difficile, the optimal donor (HD) was then performed into germ-free mice. Mice [5]. FMT of CR donors with Type-1 signature versus a known NR and unknown.

Methods

We characterized the gut microbiome in metastatic melanoma patients for FMT to enhance responses to ICB in cancer patients remain unknown. Importantly, not all CRs demonstrated a Type-1-like signature (60%, 21 of 35 CRs) nor did healthy controls (43%, 83 of 194). Functional metagenomics revealed differential metabolic capabilities in CR compared to other response categories. Mouse studies demonstrated reduced tumor growth in both CR-FMT and HD-FMT mice vs. NR-FMT mice and CR-FMT outperformed HD-FMT. Immune profiling of human and mouse specimens are being conducted and will be integrated with GM analysis.

Conclusions

Together, these study reveals differences in comparing healthy vs CR microbiome and functional profiles and provide important information about potential donor selection in FMT trials in immunotherapy, warranting additional studies and translational research.

References


Ethics Approval

The study was approved by the University of Texas MD Anderson Cancer Center and the Protocol Number: PA15-0232.

O69

Helicobacter hepaticus remodels the tumor immune microenvironment and reduces colorectal tumor burden

Abigail Overacre-Delgoffe, PhD, Hannah Burringer, Ansen Burr, Timothy Hand, PhD
University of Pittsburgh, Pittsburgh, PA, United States

Correspondence: Timothy Hand (timothy.hand@chp.edu)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):O69

Background

Immunotherapy has revolutionized patient treatment in numerous cancers. However, the vast majority of advanced colorectal cancer (CRC) patients are non-responsive and the 5-year survival rate is poor. While select microbes have been associated with progression and immunotherapy responsiveness in other cancers such as melanoma, fundamental mechanistic questions remain, including how the microbiota shapes anti-tumor immunity and therapeutic response in CRC. Our hypothesis is that the intestinal microbiota that live on mucosal surfaces or within colorectal tumors shift immune balance, in part through increased antigen presentation and CD4+ T cell help, resulting in a stronger anti-tumor immune response and tumor reduction.

Methods

We utilized the AOM-DSS mouse model to establish colitis-associated CRC. Once tumors were developed (7 weeks), we colonized half of the mice with Helicobacter hepaticus (Hhep) and assessed tumor number 5 weeks later. We isolated lymphocytes from the lamina propria, colonic epithelium, mesenteric lymph node, and tumor for flow cytometry analyses and performed 16S FISH and confocal microscopy of tissue sections to visualize Hhep or immune infiltrate. Lastly, we used 16S sequencing to determine how Hhep colonization affected other populations within the host microbiome.

Consent

Written informed consent was obtained from all patients on this study.

Fig. 1 (abstract O67). Variation in the urinary microbiome of BCG-treated patients.
Results
We found that modulating the microbiome of AOM-DSS tumor-bearing mice through the addition of a single bacteria, Hhep, reduces tumor burden, in some cases leading to complete tumor clearance, and significantly enhances survival. Hhep colonization restructures the tumor microenvironment (TME) through increased infiltration of migratory dendritic cells and Tconv within the tumor core and decreased Tregs. In addition, colonization leads to a substantial increase in organized tertiary lymphoid structures surrounding the tumor and a decrease in T cell exhaustion. FISH revealed that Hhep colonizes the mucosa around the tumor but was also found within the tumor itself, which we believe drives Hhep-specific CD4+ T cell infiltration, providing vital signals to cross-presenting DCs and tumor-specific T cells.

Conclusions
We have observed a complete remodeling of the TME after the addition of a single bacteria, Hhep, leading to enhanced anti-tumor immunity and increased survival in CRC. While overall rates of CRC prevalence in the US have declined, incidence among young adults has been steadily rising. Dysbiosis in CRC patients has been previously reported, and whether this has a direct effect on the anti-tumor immune response remains unknown. These studies have the potential to improve our understanding of how microbiota-specific T cells shape tumor progression as well as potentially uncover novel mechanisms of resistance to immunotherapy in CRC.

Ethics Approval
IACUC #16099226

Novel Single-Agent Immunotherapies

O70
CD122-selective IL-2 complexes treat ovarian carcinomas, possibly by dysregulating Treg differentiation and reducing suppression, and promoting T cell stem cells
Yilun Deng, MD, PhD1, Justin Dreger,1 Xinyue Zhang,2 Ryan Reyes,1 Jenny Mendez,1 Myrna Garcia,1 Alvaro Padron,1 Harshita Gupta, PhD1, Tyler Curiel, MD1
1UT Health San Antonio, San Antonio, TX, United States; 2Sun Yat-Sen University, Guangzhou, China
Correspondence: Tyler Curiel (curielt@uthscsa.edu)
Journal for Immunotherapy of Cancer 2019, 7(Suppl 1):O70

Background
Ovarian cancer (OC) responds poorly to immunotherapies. Regulatory T cells (Treg) engage IL-2 by high affinity CD25 for differentiation and function [1], and anti-tumor effector T cells (Teff) use intermediate affinity CD122. We studied IL-2 complexes (IL-2c) that selectively activate CD122 (Teff) over CD25 (Tregs). A CD8+CXCR5+TCF-1+ T cell population reportedly improves immune checkpoint blockade efficacy [2, 3], but IL-2c effects on TCSC are unreported.

Methods
Orthotopic ID8agg-luc mouse OC burden was measured by in vivo imaging. Tumor, ascites and draining lymph nodes (TDLN) were analyzed by flow cytometry and tSNE. IL-2c was complexed using 1.5 μg/mouse IL-2 and 7.5 μg/mouse αIL-2 (clone JES6-5H4) before i.p. injection every other day starting at Day 7 for 4 doses. antiPD-L1 was given at 100μg/mouse every 3 days starting from Day 11 for 4 doses. FoxP3-IREs-RFP (FIR) mice [4] were used to sort live Treg cells.

Results
IL-2c but not antiPD-L1 potently inhibits ID8agg (Figure 1). IL-2c surprisingly increased asctes Treg numbers but decreased Treg functional markers (CD25, CTLA-4, granzymeB) and suppressive function (Figure 2). TDLN Tregs were unaffected. TSNEx showed great similarity of TDLN Tregs treated with isotype and IL-2c while asctes Tregs after IL-2c showed skewed differentiation (e.g., increased T-bet, IFN-gamma) (Figure 3) which decreases suppression [5, 6]. In B16 melanoma, antiPD-L1 induced CD8+TCF-1+CXCR5+PD-1+ TCSC as reported, while adding IL-2c augmented expansion further (Figure 4). In ID8agg, IL-2c alone induced CD8+TCF-1hi TCSC (Figure 5). However, TSNEx revealed that these TCSC differed from those in B16, including distinct IL-2c versus antiPD-L1 induced TCSC. In ID8agg, antiPD-L1-induced TCSC are mostly CXCR5+ and PD1+ while IL-2c-induced TCSC are PD1- (Figure 6), distinct from B16, and express CCR2 and CXCR3.

Conclusions
We define two novel IL-2c effects: inducing novel TCSC and blunting Treg suppression through differentiation skewing. Current work tests if effects are related and help efficacy, and mechanisms for IL-2c Treg effects. We also show that elicited TCSC differ by treatment and tumor, requiring additional investigations.

Acknowledgements
This work is supported by CPRIT Research Training Award (RP 170345) to YD, RO1 CA205965 and Clayton Foundation for Biomedical Research Grant to TC

References

Ethics Approval
All animal work was done under UTHSA Institutional Animal Care and Use Committee approved studies, approved protocol numbers: 20120071AR, 20170035AR, 20140039AR, in compliance with the Guide for the Care and Use of Laboratory Animals (published by National Research Council of the National Academies), Animal Welfare Act (AWA) (published by USDA), Public Health Service Policy on Humane Care and Use of Laboratory Animals (published by NIH) and US Government Principles for Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training.

Fig. 1 (abstract 070). See text for description
O71
AMV564, a novel bivalent, bispecific T-cell engager, targets myeloid-derived suppressor cells
Sterling Eckard, PhD1, Leah Gehrs2, Victoria Smith1, Jeanmarie Guenot1, John DiPersio2, Sheng Wei, MD3, Michael Rettig2
1Amphivena Therapeutics, Inc., South San Francisco, CA, United States; 2Washington University School of Medicine, St. Louis, MO, United States; 3Moffitt Cancer Center, Tampa, FL, United States
Correspondence: Victoria Smith (vsmith@amphivena.com)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):O71

Background
Overcoming the suppressive tumor microenvironment is a major challenge in immune therapy, and the critical effectors of the suppressive tumor microenvironment are the myeloid-derived suppressor cells (MDSCs). MDSCs elicit a range of suppressive functions that inhibit normal T cell responses and cause unresponsiveness to immune checkpoint blockade. A dominant function of MDSCs is the suppression of T cell activity in a variety of manners that are path-ology and context dependent. AMV564, a bivalent, bispecific antibody that engages both CD3 and CD33 for selective depletion of MDSCs and leukemic blasts, is currently in clinical development in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Here we report ex vivo and translational clinical data that sup-port our proposal to evaluate AMV564 as a selective agent to deplete MDSCs in solid tumors.

Methods
Flow cytometry was used to phenotype AML and MDS patient blasts, T cells, and MDSCs in freshly isolated whole blood or bone marrow aspirates. Additionally, reactive oxygen species (ROS) were detected by flow cytometry using the cell permeant dye 2′,7′-dichlorofluorescin diacetate. The numbers of blasts, lymphocytes, neutrophils, and monocytes were evaluated using patient hematology panels.

Results
Treatment ex vivo of patient-derived bone marrow mononuclear cells results in selective depletion of MDSCs (p < 0.01) and a decrease in the production of ROS (Figure 1). AMV564 induces a significant increase of activated T cells only in the presence of CD33+ target cells, with >2-fold increase in the proliferation of CD4+ and CD8+ T cells. The increase in proliferation is dose-dependent and accompanied by a significant increase in IFNγ production. In the AML clinical trial, rapid depletion of both monocytic and granulocytic MDSCs is apparent with no impact on circulating neutrophil or monocyte populations (Figure 2), and with concomitant T cell redistribution consistent with T cell activation.

Conclusions
Treatment with AMV564 selectively depletes MDSCs in a dose-dependent fashion both ex vivo and in patients. The ability of AMV564 to deplete MDSCs while activating T cells should lower the threshold necessary for a patient to respond to immunotherapy, and these results indicate potential for benefit in solid tumor indications where elevated MDSCs are associated with poor outcomes including inadequate response to immunotherapy.

Ethics Approval
This study was approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) at each participating institution.
Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers

Fan Zhang, PhD, Neha Parayath, PhD, Michael Coon, MS, Sirkka Stephan, PhD, Matthias Stephan, MD, PhD
Fred Hutchinson Cancer Research Center, Seattle, WA, United States

Correspondence: Matthias Stephan (mstephan@fredhutch.org)

Background
Tumor-associated macrophages (TAMs) usually perform immunosuppressive and tumor-promoting functions, expressing what is known as an 'M2' phenotype. Reprogramming these TAMs toward an 'M1' phenotype could thwart their pro-cancer activities and unleash anti-tumor immunity, but efforts to date have proven nonspecific, eliciting systemic inflammation. Here, we describe an in vitro-transcribed mRNA encoding an M1-polarizing transcription factor, interferon regulatory factor 5 (IRF5). This mRNA can be delivered through targeted nanoparticles (NPs) to reprogram TAMs without causing systemic toxicity (Figure 1).

Methods
We first validated that IRF5-NPs can introduce mRNA expression and modify macrophage phenotype in vitro, using RT-PCR and targeted gene sequencing. In our in vivo studies, we evaluated the therapeutic efficacy of IRF5-NPs in three animal models. We then determined the mechanisms associated with the therapeutic efficacy by analyzing immune cell populations (flowcytometry), cytokines release (FACS, Luminex), T-cells infiltration (immunofluorescence), and IRF5 mRNA biodistribution (RT-PCR).

Results
Our study on bone marrow-derived macrophages showed IRF5-NPs can induce immediate, transient, robust mRNA expression, and imprint a pro-inflammatory M1-like macrophage. Specifically, IRF5-NPs induced a macrophage gene profile that was similar to the signature M1 phenotype (Figure 2); signature M2 phenotype genes were strongly downregulated (e.g., Serpinb2 and Ccl11, 87-fold and 115-fold, respectively) while key M1-differentiation genes were upregulated (e.g., Ccl5, 190-fold). Infusions of IRF5-NPs reprogrammed the immuno-suppressive TAMs to induce anti-tumor immunity in models of ovarian cancer, melanoma, and glioblastoma. For example, in an ID8 syngeneic mouse model of ovarian cancer, nine doses of intraperitoneal IRF5-NPs regressed tumor growth and significantly extended mouse median survival for more than two folds (Figure 3). IRF5-NPs reduced the percentage of immune-suppressive TAMs to induce anti-tumor immunity in models of ovarian cancer, melanoma, and glioblastoma. A biodistribution and histology-based study further established that these nanoreagents were safe for repeated dosing.

Conclusions
Thus, we have developed a novel strategy to genetically reprogramming TAMs, using NPs that carry mRNAs encode for transcriptional factor, IRF5. This new immunotherapy can safely obviate suppressive tumors without systemically disrupting immune homeostasis. Our next step is to clinically translate this technology as a new approach to treating ovarian cancer patients who were not responsive to other therapies (Figure 1).

Acknowledgements
The presenting author Fan Zhang was supported by a Research Scholar Grant, BRF1800015 from American Brain Tumor Association.
Other

O73

Designed improvement to T-cell immunotherapy by integrated single cell profiling.

Irfan Bandey, PhD1, Jay RT. Adolacion, PhD1, Gabrielle Romain, PhD1, Melissa Martinez, PhD1, An Xingyue, PhD1, Arash Saeedi1, Rasindu Rajanayake1, Ivan Liadi, PhD1, Harjeet Singh, PhD1, Laurence Cooper, MD, PhD1, Navin Varadarajan, PhD1

1University of Houston, Houston, TX, United States; 2University of Texas MD Anderson Cancer Center, Houston, TX, United States

Correspondence: Navin Varadarajan (nvaradarajan@uh.edu)


Background

CD19 specific CAR T-cells have shown promising results against B cell lymphoid malignancies. However, data from these trials have revealed suboptimal responses in some patients. Therefore, besides the need for developing new improved CAR T-cells for the treatment of liquid/solid tumors, a more fundamental insight into the dynamic functionality of CAR T-cells especially at single cell and molecular level is warranted [1-9].

Methods

Timing assays, RNAseq, phenotyping, cytokine secretion, cytotoxicity assay and mouse xenograft studies.

Results

We were functionally able to categorize CD19-specific CAR T-cells (19-28z) into serial, mono and no-killers. Integrated single-cell functional and transcriptional profiling demonstrated that at the single-cell level, killer T cells showed differential upregulation of transcripts including FASLG, CD2, CD27, HAVCR2, TNFRSF9, and TGFB1 with concomitant upregulation of LEF1, RORA, TCF7, CD69, IL2RA and GZMA transcripts in non-killer T cells. Since the abundances of the cytotoxic proteins were not different between these two subsets of cells, we utilized kinetic modeling of the contact time distributions between the T cells and tumors, and lysosome polarization experiments. These data revealed that the inability of CAR T-cells to kill is due to failures at multiple steps including those involved in lysosomal polarization and degranulation. Since CD137 and TIM3 (HAVCR2) were differentially expressed on killers, we sought to quantify the levels of these proteins using flow cytometry. These experiments revealed that upon interaction with NALM-6, 19-28z T-cells showed significant increase in protein expression of TIM3 and CD137, and these were, higher in degranulating subset (CD107a+) compared to CD107a- cells, indicating induction of CD137 expression in killer T cells upon incubation with target cells. Long-term killing experiments (48-72h) demonstrated that addition of exogenous CD137L enabled sustained killing, confirming that CD137 expression is inducible in killer CAR T cells and receptor ligation promotes sustained killing. RNA-sequencing of CD137+ cells illustrated a specific enrichment of glycolysis, mitochondrial biogenesis and proliferative pathways. Based on these results, we explored the effects of overexpression of co-stimulatory molecule 4-1BBL in 19-28z T-cells. Our mouse xenograft studies show that genetically engineered 19-28z-41BBL T-cells demonstrate better tumor regression in tumor models, at lower doses compared to 19-28z T-cell.
Conclusions
We have demonstrated that the failure of CAR T cells to kill is related to the failure in multiple steps leading to degranulation. Our data also shows that CD137 is inducible receptor within killer 19-28z T cells and that triggering upon induction can lead to sustained responses in vitro and in vivo.

Acknowledgements
Tiejuan Mi Research Investigator Division of Pediatrics, University of Texas MD Anderson Cancer Center, for helping us with imaging and injection of CAR T cells in mice.

References

Tumor and Stromal Cell Biology
O74
Fibroblast activation protein is expressed by human and murine leukocytes and nonspecific inhibition of FAP enhances anti-PD-1 therapy in murine models of PDAC
Louis Weiner, MD, Allison Fitzgerald, Shangzi Wang, PhD
Georgetown University, Washington, DC, United States
Correspondence: Allison Fitzgerald (ao546@georgetown.edu)
Journal for Immunotherapy of Cancer 2019, 7(Suppl 1):074

Background
Immunotherapy has been largely ineffective in pancreatic cancer, partially due to the dense stromal fibrosis surrounding the tumor that creates an immunosuppressive microenvironment. The main cellular components of this fibrosis, activated pancreatic stellate cells (aPSCs), are marked by elevated expression of fibroblast activation protein (FAP). Here we investigate the relationship between aPSCs, human natural killer (NK) cells and FAP.

Methods
To assess the relationship between aPSCs and NK cells we used a novel in vitro co-culturing system that utilizes primary donor-derived PSCs and human NK cell lines, NK92, NKL, YT and KHYYG-1. We tested the ability of NK cells to kill aPSCs using CytoToxGlo and Annexin V assays. We monitored FAP expression using rt-qPCR, western blot and FAP activity assays.

To assess the effects of FAP inhibition we used a non-specific FAP inhibitor, talabostat, in vivo. Forty female C57BL/6 mice were injected subcutaneously with 1×105 syngeneic MT3-2D cells (Kras+/G12D, p53+/-R172H derived from a PDAC KPC GEMM model [1]). Once tumors reached 40-50 mm3, ten mice per group were given either 30 μg of talabostat per mouse daily by oral gavage, 200 μg of anti-PD-1 per mouse twice a week by i.p., both, or neither. Control mice were treated with PBS. Treatment was terminated after 4 weeks and the mice were monitored, with tumor measurements occurring weekly. Experiment was repeated with 15 mice per group and tumors were collected for flow immunophenotyping and mRNA expression analysis. Blood was collected weekly to monitor cytokine levels.

Results
We demonstrate that the human NK cell line (NK92) is activated by and kills aPSCs (Figure 1). Upon direct contact with PSCs, PSCs down-regulate FAP expression and NK92 cells upregulate FAP. We further demonstrated that FAP is expressed in a variety of human and murine leukocyte cell lines as well as healthy-donor derived NK cells (Figure 2). The addition of a nonspecific FAP inhibitor, Talabostat, enhanced anti-PD-1 therapy efficacy in murine models of PDAC. Cytokine analysis demonstrated that talabostat treatment enhanced NK activating cytokines. Flow cytometry immunophenotyping showed that combination treatment reduced T cell infiltration but increased NK cell infiltration.

Conclusions
This is the first report of FAP expression in multiple human and murine leukocyte lineages. It further suggests that talabostat, a non-specific FAP inhibitor, can enhance NK activating cytokine production and that talabostat enhances anti-PD-1 efficacy through increased recruitment of NK cells to the tumor (Figure 3).

Acknowledgements
This work was funded by: P30 CAS1008 (LMW), R01 CA50633 (LMW), F30 CA239441 (AO), GSR Nanostriag Grant (AO)

References
Selective induction of S100a8/a9 heterodimer protein in pancreatic cancer in response to immune selection pressure
Louis Weiner, MD, Reham Ajina, MS
Georgetown University, Washington, DC, United States
Correspondence: Louis Weiner (weinerl@georgetown.edu)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):O75

Background
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths worldwide. Host immunity plays a critical role in pancreatic cancer development and progression. However, there is no FDA approved immunotherapy for pancreatic cancer yet. The aim of this study was to investigate the effects of immune selection pressure on pancreatic cancer immunoevasion. S100a8/a9, which belong to the S100 calcium-binding protein family, has been shown to enhance the progression and metastasis of many cancer entities [1], including PDAC [2,3]. While the downstream effects of S100a8/a9 have been extensively studied, the role of immune selection pressure in the regulation of S100a8/a9 expression has never been reported.

Methods
1 X105 mT3-2D murine pancreatic cancer cells (Kras+/G12D, p53+/-/R172H) [4] were injected subcutaneously into syngeneic C57BL/6J (WT), B6.CB17-Prkdcscid/SzJ (SCID) and T cell-depleted WT mice (10 mice/group). T cell depletion was performed using anti-CD4 (GK 1.5 BioXCell) anti-CD8 (2.43 BioXCell), with a dose of 200ug/mouse, twice weekly. Tumor growth was monitored over time, and 1 cm3 tumors were then harvested and processed for global proteomics profiling using NanoUPLC-MS/MS mass spectrometry (10 tumors/group were combined as one sample with two technical replicates), and transcriptomics profiling using NanoString nCounter (5 samples/group). The results were validated by immunohistochemistry (IHC) and Western blotting. T cell infiltration was evaluated using IHC (5-7 samples/group) and flow cytometry (8 samples/group).

Results
mT3-2D tumors engrafted in WT mice grow more slowly as compared with SCID and T cell-depleted tumors. While this observation indicates that the reduced mT3-2D tumor growth rate in WT mice is T cell dependent, it suggests that PDAC can develop immunoevasion mechanisms. T cells moderately infiltrate WT tumors (Among all CD45+ immune cells, 4% are CD4 T cells and 2% are CD8 T cells). Global proteomics profiling determined that S100a8 and S100a9 are selectively induced in WT tumors compared to SCID tumors. Similarly, NanoString nCounter analysis shows that S100a8 is significantly higher in WT tumors compared with SCID tumors (p-value of Kruskal-Wallis test is 0.0091). The induction of S100a8 and S100a9 was further validated by IHC (p-value of Mann Whitney test is 0.0424 and 0.0043, respectively). Interestingly, Western blotting analysis indicates that the S100a8/a9 heterodimer but not S100a8 and S100a9 monomers is selectively expressed in WT tumors.

Conclusions
Using the mT3-2D model, T cell immunity incompletely controls PDAC tumor growth. Our data shows that S100a8/a9 heterodimer is selectively induced in response to T cell selection pressure, suggesting its role in PDAC immunoevasion.

References
Interferon-gamma mediated T cell exhaustion generates distinct tumor microenvironments in synchronous melanoma via PD-1/PD-L1 axis

Peter Prieto, MD, MPH1, Shuyang Qin, BS1, Alyssa Williams1, Booyeon Han, BS2, Rachel Jewel1,1, Katherine Jackson, MD1, Alexander Chacon, MD1, Edward Engleth III, BS1, Brian Belt, JD1, Goran Micevic, MD, PhD2, David Linehan, MD2, Scott Gerber, PhD1, Alexandre Reuben1

1Department of Dermatology at Yale University for kindly gifting us with the YUMMER cell line.

Acknowledgements

We would like to thank Dr. Marcus Bosenberg from the Department of Dermatology at Yale University for kindly gifting us with the YUMMER 1.7 murine melanoma cell line.

References


Ethics Approval

Animal experiments were approved by the University Committee on Animal Resources and performed in accordance with University of Rochester approved guidelines.

O76

Clinicopathological and genomic correlates of PD-L1 expression in nonsquamous non-small cell lung cancer

Giuseppe Lamberti, MD1, Liam Strauss2, Yvonne Li2, Biagio Ricciuti, MD1, Gonzalo Recondo, MD1, Renato Umertore, Andrew Chemnitz, Matthew Meyerson, MD, PhD2, Mark Awad, MD PhD1

1Dana-Farber Cancer Institute, Brookline, MA, United States; 2Broad Institute of MIT and Harvard, Boston, MA, United States

Correspondence: Mark Awad (Mark_Awad@DFCI.harvard.edu)

Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):O76

Background

Programmed death-ligand 1 (PD-L1) expression, reported as tumor proportion score (TPS), is the only clinically-available biomarker of response to immune-checkpoint inhibitors in non-small cell lung cancer (NSCLC), but factors associated with PD-L1 expression are not well understood. We aimed to identify clinical and genomic correlates of PD-L1 expression in nonsquamous NSCLC.

Methods

We retrospectively collected clinicopathologic and genomic data from patients with nonsquamous NSCLC whose tumors underwent PD-L1 assessment and targeted next generation sequencing by OncoPanel at the Dana-Farber Cancer Institute. Samples were grouped into three PD-L1 TPS categories: negative (TPS <1%), low (TPS 1-49%) and high (TPS ≥50%). Only genomic alterations with oncogenic potential according to OncoKB were included in the analysis. Permutation testing was performed to correct for mutation enrichment accounting for differences in tumor mutation burden (TMB) among groups. Genomic mutations, copy number gains/losses, and chromosomal arm-level gains/losses were compared among PD-L1 expression groups. A q-value <0.25 was considered significant after correction for multiple comparisons.

Results

We identified 909 non-squamous NSCLCs with PD-L1 negative (N=304, 34.4%), low (N=326, 35.9%), and high (N=279, 30.7%) expression. Tumors in the PD-L1 high group were more likely to arise in smokers compared to those in the PD-L1 low and PD-L1 negative groups (86% vs 79% vs 78%, respectively; p=0.04) and to be diagnosed at advanced stage IIIb-IV disease (76% vs 67% vs 61%, respectively; p<0.001) (Table 1). The median TMB was higher in the PD-L1 high than in the PD-L1 low and PD-L1 negative groups (median 12.2 vs 10.6 vs 10.6 mutations/megabase, respectively; p=0.001). Compared to PD-L1 TPS ≥50% tumors, those with TPS <1% were more likely to have mutations in STK11 (19% vs 5%; q=0.001), EGFR (23% vs 12%; q=0.003), and CTNNB1 (4% vs <1%; q=0.036) (Figure1). The most significantly enriched gene copy losses associated with PD-L1 negativity occurred at the 9p24.1 locus, which encodes for the CD274 (PD-L1), PDCD1LG2 (PD-L2), and JAK2 genes (q<0.001). Gene amplification in CD274 and PDCD1LG2 were enriched in tumors with high PD-L1 expression (q<0.25). Chromosome 9p arm loss was significantly more frequent in
PD-L1 negative samples than in PD-L1 high tumors (23% vs 8%; q= 0.04).

Conclusions

High PD-L1 expression in non-squamous NSCLC is associated with smoking status, advanced stage at diagnosis, and high TMB. PD-L1 negative tumors are enriched in mutations in STK11, EGFR and CTNNB1 and copy loss of CD274, PDCD1LG2 and JAK2.

Ethics Approval

The study was approved by Dana-Farber Cancer Institute’s Ethics Board, approval number DF/HCC #02-180.

Table 1 (abstract 077). Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>PD-L1 &lt;1%</th>
<th>PD-L1 1-49%</th>
<th>PD-L1 ≥50%</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (N/100)</td>
<td>104 (13%)</td>
<td>326 (40%)</td>
<td>279 (35%)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male (N/556)</td>
<td>125 (14%)</td>
<td>130 (40%)</td>
<td>105 (30%)</td>
<td>0.09</td>
</tr>
<tr>
<td>Female (N/548)</td>
<td>179 (33%)</td>
<td>196 (35%)</td>
<td>174 (35%)</td>
<td></td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td>Median (range)</td>
<td>66 (15-84)</td>
<td>61 (12-80)</td>
<td>65 (29-92)</td>
</tr>
<tr>
<td>Smoking status</td>
<td>Never (N/189)</td>
<td>68 (10%)</td>
<td>68 (11%)</td>
<td>69 (11%)</td>
</tr>
<tr>
<td>Current/Former (N/724)</td>
<td>42 (12%)</td>
<td>75 (10%)</td>
<td>73 (12%)</td>
<td></td>
</tr>
<tr>
<td>Pack-years</td>
<td>Median (ICR)</td>
<td>20 (1.2-44)</td>
<td>20 (1.3-57)</td>
<td>27 (1.4-48)</td>
</tr>
<tr>
<td>ECOG</td>
<td>0-1</td>
<td>220 (64%)</td>
<td>255 (69%)</td>
<td>212 (62%)</td>
</tr>
<tr>
<td>2</td>
<td>40 (14%)</td>
<td>60 (16%)</td>
<td>42 (13%)</td>
<td></td>
</tr>
<tr>
<td>Histology</td>
<td>Adenocarcinoma (N/83)</td>
<td>287 (34%)</td>
<td>311 (39%)</td>
<td>253 (31%)</td>
</tr>
<tr>
<td>Others (N/58)</td>
<td>17 (3%)</td>
<td>15 (3%)</td>
<td>26 (5%)</td>
<td></td>
</tr>
<tr>
<td>Stage at diagnosis</td>
<td>iBAK (N=297)</td>
<td>120 (41%)</td>
<td>109 (37%)</td>
<td>119 (24%)</td>
</tr>
<tr>
<td></td>
<td>iBAK (N=1122)</td>
<td>104 (16%)</td>
<td>217 (18%)</td>
<td>211 (19%)</td>
</tr>
<tr>
<td>Bearing tumor site</td>
<td>Primary</td>
<td>180 (19%)</td>
<td>198 (19%)</td>
<td>199 (20%)</td>
</tr>
<tr>
<td>Metastasis</td>
<td>156 (13%)</td>
<td>178 (19%)</td>
<td>153 (16%)</td>
<td></td>
</tr>
<tr>
<td>Tissue of origin</td>
<td>Lung</td>
<td>252 (29%)</td>
<td>104 (29%)</td>
<td>140 (40%)</td>
</tr>
<tr>
<td>Lymph node</td>
<td>57 (18%)</td>
<td>61 (19%)</td>
<td>57 (20%)</td>
<td></td>
</tr>
<tr>
<td>Pleural/pericardia</td>
<td>24 (8%)</td>
<td>34 (10%)</td>
<td>32 (11%)</td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>14 (5%)</td>
<td>15 (5%)</td>
<td>12 (4%)</td>
<td>0.55</td>
</tr>
<tr>
<td>Liver</td>
<td>16 (6%)</td>
<td>14 (6%)</td>
<td>10 (6%)</td>
<td></td>
</tr>
<tr>
<td>Boas</td>
<td>26 (9%)</td>
<td>17 (9%)</td>
<td>21 (7%)</td>
<td></td>
</tr>
<tr>
<td>Adrenal gland</td>
<td>7 (2%)</td>
<td>9 (2%)</td>
<td>2 (1%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>6 (2%)</td>
<td>12 (4%)</td>
<td>15 (5%)</td>
<td></td>
</tr>
<tr>
<td>TMB (Mut/MB)</td>
<td>Median (ICR)</td>
<td>10.6 (7.3-14.5)</td>
<td>10.0 (6.8-15.2)</td>
<td>12.2 (8.4-18.2)</td>
</tr>
</tbody>
</table>

Results

Out of 309 total mutations initially identified in 4T1 cancer cells, six peptides able to bind H2Ld or H2Kd in vitro were tested in vaccination experiments, together with two I-Ad-predicted binders. Two MHC-I and one MHC-II neoepitopes were immunogenic, as assessed by IFNγ/TNFα response after T cell re-stimulation. These three neoepitopes were encoded by genes up-regulated by RT. Although a vaccine based on these three neoepitopes was not sufficient to inhibit tumor growth, a significant growth delay was seen when vaccination was combined with tumor-targeted RT. TCR repertoire analysis of these tumors revealed significant vaccination-related differences in the frequency of T cell clones, independent of clones specific for the dominant AH1 epitope (derived from the gp70 shared tumor antigen). In addition, in vivo killing experiments demonstrated a potent cytolytic activity of T cells from vaccinated mice towards one of these neoepitopes. Further analyses are ongoing to understand the contribution of these neoantigens to T cell-mediated tumor rejection after targeted RT.

Conclusions

These data provide initial proof-of-principle evidence that RT can expose existing neoantigens to the immune system.

References

O79 Mapping the spatial architecture of acute myeloid leukemia in the bone marrow microenvironment by multiplexed ion beam imaging
Xavier Rovira-Clave, PhD1, Suzan Jiang, PhD2, Yunhao Bai, BS3, Bokai Zhu, Marc Bosse, PhD4, Michael Angelo, MD, PhD5, Yara Banz, MD, PhD6, Christian Schürch, MD, PhD7, Garry Nolan, PhD8
1Stanford University, Stanford, CA, United States; 2University of Bern, Bern, Switzerland
Correspondence: Christian Schürch (schurch@stanford.edu), Garry Nolan, PhD (gnolan@stanford.edu)
Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):O79

Background
Acute myeloid leukemia (AML) is an aggressive blood cancer that originates from malignantly transformed hematopoietic stem cells in the bone marrow (BM). Many AML patients respond to induction chemotherapy but the majority eventually relapse and succumb to the disease within five years of diagnosis. Multi-parameter single-cell technologies have revealed a high intra- and inter-tumor heterogeneity in AML, and this heterogeneity is in part related to treatment failure and the outgrowth of drug-resistant clones. Therefore, a deeper understanding of the molecular and cellular events that promote heterogeneity and lead to AML relapse is needed.

Emerging evidence indicates that the BM microenvironment plays a crucial role in the pathobiology of AML [1]. This is especially relevant for immunotherapy, which aims to elicit an in situ immune response to eradicate tumors. So far, little is understood about the architecture and spatial composition of the AML BM microenvironment, and how this influences disease initiation, progression, immune responses, and outcome.

Methods
We created a tissue microarray (TMA) with formalin-fixed, paraffin-embedded (FFPE) BM samples from 119 AML patients comprising all subtypes of the French-American-British classification. Using an AML-specific metal-conjugated antibody panel, we analyzed the spatial distribution of more than 40 parameters simultaneously by multiplexed ion beam imaging (MIBI) (Figure 1) [2,3].

Results
The application of MIBI to study the BM microenvironment identified common immune cell subsets and malignant blasts with immunoprofiles matching the known subtypes of human AML. Unsupervised clustering detected numerous cellular clusters that corresponded to immune and leukemic cell types. Computational deconstruction of these cell clusters and their spatial distribution revealed distinct cellular neighborhoods (CNs, patches of tissue where every cell has a similar surrounding) that were either unique to or shared among specific AML subtypes. Leukemic cells and reactive immune cells expressing checkpoint and activation markers were differentially distributed among the CNs. In addition, CNs with enrichment of stem-like leukemic cells were identified.

Conclusions
MIBI enables high-throughput, highly multiplexed analysis of FFPE BM. Mapping the architecture of the BM microenvironment in AML will advance our understanding of this devastating disease and likely provide important information to guide future immunotherapies.

Acknowledgements
We thank Matt Newgren for excellent technical support on the MIBI instrument. S.J. was supported by a Stanford Dean’s Fellowship and the Leukemia & Lymphoma Society Career Development Program. X.R.C. was supported by a long-term EMBO fellowship. B.K. was supported by a Stanford Graduate Student Fellowship. C.M.S. was supported by an Advanced Postdoc Mobility Fellowship from the Swiss National Science Foundation (P300PB_171189 and P400PM_183915), and an International Award for Research in Leukemia from the Lady Tata Memorial Trust, London, UK. This work was further supported by grants from the FDA, the NIH, the Parker Institute for Cancer Immunotherapy, the Bill and Melinda Gates Foundation, and a Rachford and Carlota A. Harris Endowed Professorship to G.P.N.

Ethics Approval
The study was approved by the Cantonal Ethics Committee of Bern and was carried out according to national and international guidelines, in accordance with the ethical principles of the Declaration of Helsinki using Good Clinical Practice [4].

References

O80 Atlas of clinically-distinct cell states and cellular ecosystems across human solid tumors
Bogdan Luca, Ash Alizadeh, Max Diehn, Aaron Newman, Andrew Gentles, PhD, Chloé Steen
Stanford University, Stanford, CA, United States
Correspondence: Aaron Newman (amnewman@stanford.edu), Andrew Gentles (andrewg@stanford.edu)

Background
Tumors are complex ecosystems of malignant, immune, andstromal elements whose dynamic interactions underlie patient survival and response to therapy. A comprehensive understanding of the diversity of cellular states within the tumor microenvironment (TME), and their patterns of co-occurrence, could reveal new diagnostic tools for improved disease management, as well as novel targets for therapeutic intervention.

Methods
We applied CIBERSORTx, a recently described “digital cytometry” framework [1], to compute cell type-specific gene expression profiles of cancer cells and 11 major immune and stromal cell types from thousands of solid tumor transcriptomes profiled by The Cancer Genome Atlas (TCGA). We then devised and applied a novel machine learning framework to identify distinct transcriptional states for each cell type, validate them in scRNA-seq data, and uncover co-occurrence patterns between them in order to define tumor cellular ecosystems. We systematically profiled these states across nearly 17,000 solid tumor samples from TCGA, PRECOG [2], in situ transcriptomics arrays, and other publicly available resources, to determined their associations with genomic features, clinical outcomes, and spatial organization.

Results
By dissecting cellular heterogeneity across thousands of tumor samples, we defined robust transcriptional states of 12 cell types,
including epithelial, fibroblast, endothelial, and 9 immune subsets. These states included both known and novel cellular phenotypes, nearly all of which could be validated in published scRNA-seq tumor atlases. For example, we recapitulated the transcriptional profiles of M1 and M2 polarized macrophages, along with 7 other macrophage states, of which several were strongly associated with overall survival. We found that specific cell states often co-occur in distinct cellular communities with characteristic patterns of ligand-receptor interactions, genomic features, clinical outcomes, and spatial organization. Further analysis of these communities unveiled unique cellular ecosystems that span most solid tumor types. One such “ecotype” defined a normal-like state that was strongly enriched in non-malignant samples. Others delineated novel pro- and anti-tumor inflammatory environments involving specific fibroblast, endothelial, and immune cell transcriptional programs.

Conclusions
Large-scale deconvolution of cell type-specific transcriptomes across thousands of solid tumors revealed a comprehensive atlas of cellular states in the TME. The majority were present across multiple tumor types. We found that specific cell states tend to co-occur in a pan-cancer manner, defining robust tumor cellular ecosystems with specific biological features and clinical outcomes. Overall, our results provide a high resolution portrait of cellular heterogeneity in the TME of multiple solid tumor types, with implications for novel diagnostics and immunotherapeutic targets.

References


Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.